(lp0
(dp1
S'line'
p2
S'We have shown previously that HTLV-1 basic leucine zipper (HBZ), a viral regulatory protein encoded by the human retrovirus, human T-cell leukemia virus, type 1 (HTLV-1) cooperates with JunD to enhance hTERT transcription in adult T-cell leukemia (ATL) cells.\n'
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I186
sS'uniprot'
p8
VP17535
p9
sS'lengthInChars'
p10
I4
sS'name'
p11
VJunD
p12
sS'lengthInWords'
p13
I1
sa(dp14
g7
I30
sg8
VP30740
p15
sg10
I33
sg11
VHTLV-1 basic leucine zipper (HBZ)
p16
sg13
I5
sa(dp17
g7
I202
sg8
S''
p18
sg10
I5
sg11
VhTERT
p19
sg13
I1
sasS'diseases'
p20
(lp21
(dp22
g7
I131
sS'cui'
p23
VC0023492
p24
sg10
I15
sg11
VT-cell leukemia
p25
sg13
I2
sa(dp26
g7
I248
sg23
VC0023492
p27
sg10
I3
sg11
VATL
p28
sg13
I1
sa(dp29
g7
I225
sg23
VC0023492
p30
sg10
I21
sg11
Vadult T-cell leukemia
p31
sg13
I3
sasa(dp32
g2
S'Previously, we have shown that an AP-1 family member, FRA-2, is constitutively expressed in adult T-cell leukemia/lymphoma (ATL) and, together with JUND, upregulates CCR4 and promotes ATL cell growth.\n'
p33
sg4
(lp34
(dp35
g7
I166
sg8
VP51679
p36
sg10
I4
sg11
VCCR4
p37
sg13
I1
sa(dp38
g7
I34
sg8
VP01100
p39
sg10
I18
sg11
VAP-1 family member
p40
sg13
I3
sa(dp41
g7
I54
sg8
VP15408
p42
sg10
I5
sg11
VFRA-2
p43
sg13
I1
sasg20
(lp44
(dp45
g7
I124
sg23
VC0023493
p46
sg10
I3
sg11
VATL
p47
sg13
I1
sa(dp48
g7
I54
sg23
VC1858361
p49
sg10
I3
sg11
VFRA
p50
sg13
I1
sa(dp51
g7
I92
sg23
VC0023493
p52
sg10
I30
sg11
Vadult T-cell leukemia/lymphoma
p53
sg13
I3
sa(dp54
g7
I124
sg23
VC0023493
p55
sg10
I3
sg11
VATL
p56
sg13
I1
sasa(dp57
g2
S'Delta9 -THCA increased mitochondrial mass in neuroblastoma N2a cells and prevented cytotoxicity induced by serum deprivation in STHdhQ111/Q111 cells and by mutHtt-q94 in N2a cells.\n'
p58
sg4
(lp59
sg20
(lp60
(dp61
g7
I45
sg23
VC0027819
p62
sg10
I13
sg11
Vneuroblastoma
p63
sg13
I1
sa(dp64
g7
I83
sg23
VC0596402
p65
sg10
I12
sg11
Vcytotoxicity
p66
sg13
I1
sasa(dp67
g2
S'In this study, we performed a comprehensive, unbiased analysis of secretory pathways and identified an unconventional lysosomal pathway as an important mechanism for mHtt secretion in mouse neuroblastoma and striatal cell lines, as well as in primary neurons.\n'
p68
sg4
(lp69
sg20
(lp70
(dp71
g7
I184
sg23
VC1524043
p72
sg10
I19
sg11
Vmouse neuroblastoma
p73
sg13
I2
sasa(dp74
g2
S'Using the flow cytometry method of pulse-shape analysis (PulSA) to sort neuroblastoma (Neuro2a) cells enriched with mutant or wild-type Htt into different aggregation states, we clarified which transcriptional signatures were specifically attributable to cells before versus after inclusion assembly.\n'
p75
sg4
(lp76
(dp77
g7
I136
sg8
VP31645
p78
sg10
I3
sg11
VHtt
p79
sg13
I1
sasg20
(lp80
(dp81
g7
I72
sg23
VC0027819
p82
sg10
I13
sg11
Vneuroblastoma
p83
sg13
I1
sa(dp84
g7
I116
sg23
VC0596988
p85
sg10
I6
sg11
Vmutant
p86
sg13
I1
sasa(dp87
g2
S'We have previously shown that dopamine-induced oxidative stress triggers apoptotic cell death in dopaminergic neuroblastoma SH-SY5Y cells hyper-expressing the mutant polyQ Huntingtin (polyQ-Htt) protein.\n'
p88
sg4
(lp89
(dp90
g7
I159
sg8
VP42858
p91
sg10
I23
sg11
Vmutant polyQ Huntingtin
p92
sg13
I3
sa(dp93
g7
I184
sg8
VP31645
p94
sg10
I9
sg11
VpolyQ-Htt
p95
sg13
I1
sasg20
(lp96
(dp97
g7
I159
sg23
VC0596988
p98
sg10
I6
sg11
Vmutant
p99
sg13
I1
sa(dp100
g7
I47
sg23
VC0242606
p101
sg10
I16
sg11
Voxidative stress
p102
sg13
I2
sa(dp103
g7
I110
sg23
VC0027819
p104
sg10
I13
sg11
Vneuroblastoma
p105
sg13
I1
sasa(dp106
g2
S'Here we show that the hyper-expression of mutant (&gt;113/150) polyQ Htt is per se toxic to dopaminergic human neuroblastoma SH-SY5Y cells, and that DA exacerbates this toxicity leading to apoptosis and secondary necrosis.\n'
p107
sg4
(lp108
(dp109
g7
I92
sg8
g18
sg10
I40
sg11
Vdopaminergic human neuroblastoma SH-SY5Y
p110
sg13
I4
sa(dp111
g7
I69
sg8
VP31645
p112
sg10
I3
sg11
VHtt
p113
sg13
I1
sasg20
(lp114
(dp115
g7
I42
sg23
VC0596988
p116
sg10
I6
sg11
Vmutant
p117
sg13
I1
sa(dp118
g7
I111
sg23
VC0027819
p119
sg10
I13
sg11
Vneuroblastoma
p120
sg13
I1
sasa(dp121
g2
S'Lentiviral-mediated expression of Exp-Htt caused cell death and aggregate formation in human neuroblastoma SH-SY5Y and rat primary striatal cultures.\n'
p122
sg4
(lp123
(dp124
g7
I87
sg8
g18
sg10
I27
sg11
Vhuman neuroblastoma SH-SY5Y
p125
sg13
I3
sa(dp126
g7
I34
sg8
g18
sg10
I7
sg11
VExp-Htt
p127
sg13
I1
sasg20
(lp128
(dp129
g7
I93
sg23
VC0027819
p130
sg10
I13
sg11
Vneuroblastoma
p131
sg13
I1
sasa(dp132
g2
S'We now report that adeno-associated virus (AAV)-mediated expression of CaM-peptide in differentiated neuroblastoma SH-SY5Y cells, stably expressing an N-terminal fragment of huntingtin containing 148 glutamine repeats, significantly decreases the amount of TG-modified huntingtin and attenuates cytotoxicity.\n'
p133
sg4
(lp134
(dp135
g7
I71
sg8
VP01768
p136
sg10
I11
sg11
VCaM-peptide
p137
sg13
I1
sasg20
(lp138
(dp139
g7
I295
sg23
VC0596402
p140
sg10
I12
sg11
Vcytotoxicity
p141
sg13
I1
sa(dp142
g7
I71
sg23
VC1861821
p143
sg10
I3
sg11
VCaM
p144
sg13
I1
sa(dp145
g7
I101
sg23
VC0027819
p146
sg10
I13
sg11
Vneuroblastoma
p147
sg13
I1
sasa(dp148
g2
S"This meta-analysis demonstrates that within the Caucasian population, the NLRP1 rs12150220 polymorphism may correlate with a decreased risk of vitiligo-associated autoimmune diseases, especially autoimmune Addison's disease, type 1 diabetes, or systemic lupus erythematosus.\n"
p149
sg4
(lp150
(dp151
g7
I74
sg8
g18
sg10
I16
sg11
VNLRP1 rs12150220
p152
sg13
I2
sasg20
(lp153
(dp154
g7
I163
sg23
VC0004364
p155
sg10
I19
sg11
Vautoimmune diseases
p156
sg13
I2
sa(dp157
g7
I225
sg23
VC0011854
p158
sg10
I15
sg11
Vtype 1 diabetes
p159
sg13
I3
sa(dp160
g7
I143
sg23
VC0042900
p161
sg10
I8
sg11
Vvitiligo
p162
sg13
I1
sa(dp163
g7
I245
sg23
VC0024141
p164
sg10
I28
sg11
Vsystemic lupus erythematosus
p165
sg13
I3
sa(dp166
g7
I195
sg23
VC0271737
p167
sg10
I28
sg11
Vautoimmune Addison's disease
p168
sg13
I3
sasa(dp169
g2
S"Gene variants known to contribute to Autoimmune Addison's disease (AAD) susceptibility include those at the MHC, MICA, CIITA, CTLA4, PTPN22, CYP27B1, NLRP-1 and CD274 loci.\n"
p170
sg4
(lp171
(dp172
g7
I108
sg8
VP13747
p173
sg10
I3
sg11
VMHC
p174
sg13
I1
sa(dp175
g7
I161
sg8
g18
sg10
I10
sg11
VCD274 loci
p176
sg13
I2
sa(dp177
g7
I126
sg8
VP16410
p178
sg10
I5
sg11
VCTLA4
p179
sg13
I1
sa(dp180
g7
I141
sg8
g18
sg10
I7
sg11
VCYP27B1
p181
sg13
I1
sa(dp182
g7
I150
sg8
g18
sg10
I6
sg11
VNLRP-1
p183
sg13
I1
sa(dp184
g7
I119
sg8
VP33076
p185
sg10
I5
sg11
VCIITA
p186
sg13
I1
sa(dp187
g7
I133
sg8
g18
sg10
I6
sg11
VPTPN22
p188
sg13
I1
sasg20
(lp189
(dp190
g7
I67
sg23
VC0271737
p191
sg10
I3
sg11
VAAD
p192
sg13
I1
sa(dp193
g7
I37
sg23
VC0271737
p194
sg10
I28
sg11
VAutoimmune Addison's disease
p195
sg13
I3
sa(dp196
g7
I113
sg23
VC0700319
p197
sg10
I4
sg11
VMICA
p198
sg13
I1
sasa(dp199
g2
S'NLRP1 is genetically associated with risk of several autoimmune diseases including generalized vitiligo, Addison disease, type 1 diabetes, rheumatoid arthritis, and others.\n'
p200
sg4
(lp201
(dp202
g7
I0
sg8
g18
sg10
I5
sg11
VNLRP1
p203
sg13
I1
sasg20
(lp204
(dp205
g7
I83
sg23
VC1304470
p206
sg10
I20
sg11
Vgeneralized vitiligo
p207
sg13
I2
sa(dp208
g7
I122
sg23
VC0011854
p209
sg10
I15
sg11
Vtype 1 diabetes
p210
sg13
I3
sa(dp211
g7
I53
sg23
VC0004364
p212
sg10
I19
sg11
Vautoimmune diseases
p213
sg13
I2
sa(dp214
g7
I105
sg23
VC0266273
p215
sg10
I15
sg11
VAddison disease
p216
sg13
I2
sa(dp217
g7
I139
sg23
VC0003873
p218
sg10
I20
sg11
Vrheumatoid arthritis
p219
sg13
I2
sasa(dp220
g2
S"Investigating large patient cohorts from six different autoimmune diseases, that is autoimmune Addison's disease (n=333), type 1 diabetes (n=1086), multiple sclerosis (n=502), rheumatoid arthritis (n=945), systemic lupus erythematosus (n=156) and juvenile idiopathic arthritis (n=505), against 3273 healthy controls, we analyzed four single nucleotide polymorphisms (SNPs) in NALP1.\n"
p221
sg4
(lp222
(dp223
g7
I376
sg8
g18
sg10
I5
sg11
VNALP1
p224
sg13
I1
sasg20
(lp225
(dp226
g7
I122
sg23
VC0011854
p227
sg10
I15
sg11
Vtype 1 diabetes
p228
sg13
I3
sa(dp229
g7
I148
sg23
VC0026769
p230
sg10
I18
sg11
Vmultiple sclerosis
p231
sg13
I2
sa(dp232
g7
I176
sg23
VC0003873
p233
sg10
I20
sg11
Vrheumatoid arthritis
p234
sg13
I2
sa(dp235
g7
I206
sg23
VC0024141
p236
sg10
I28
sg11
Vsystemic lupus erythematosus
p237
sg13
I3
sa(dp238
g7
I55
sg23
VC0004364
p239
sg10
I19
sg11
Vautoimmune diseases
p240
sg13
I2
sa(dp241
g7
I247
sg23
VC0553662
p242
sg10
I29
sg11
Vjuvenile idiopathic arthritis
p243
sg13
I3
sa(dp244
g7
I84
sg23
VC0271737
p245
sg10
I28
sg11
Vautoimmune Addison's disease
p246
sg13
I3
sasa(dp247
g2
S'Many studies have suggested that SNPs in XRCC4 could be implicated in altering the risk of prostate cancer (PCa).\n'
p248
sg4
(lp249
(dp250
g7
I41
sg8
g18
sg10
I5
sg11
VXRCC4
p251
sg13
I1
sasg20
(lp252
(dp253
g7
I91
sg23
VC0600139
p254
sg10
I15
sg11
Vprostate cancer
p255
sg13
I2
sa(dp256
g7
I108
sg23
VC0268398
p257
sg10
I3
sg11
VPCa
p258
sg13
I1
sasa(dp259
g2
S'Our data suggest that the XRCC4 promoter -652G&gt;T polymorphism is functional and may influence genetic susceptibility to prostate cancer.\n'
p260
sg4
(lp261
(dp262
g7
I26
sg8
g18
sg10
I20
sg11
VXRCC4 promoter -652G
p263
sg13
I3
sasg20
(lp264
(dp265
g7
I123
sg23
VC0600139
p266
sg10
I15
sg11
Vprostate cancer
p267
sg13
I2
sasa(dp268
g2
S'In this case-control study, several novel polymorphic variants of XRCC4, including C-1622T (rs7727691), G-1394T (rs6869366), C-571T (rs2075686) and intron3 DIP (rs28360071), were investigated, and the correlation of these variants to prostate cancer susceptibility in a Taiwanese population was observed.\n'
p269
sg4
(lp270
(dp271
g7
I66
sg8
g18
sg10
I5
sg11
VXRCC4
p272
sg13
I1
sa(dp273
g7
I234
sg8
g18
sg10
I30
sg11
Vprostate cancer susceptibility
p274
sg13
I3
sasg20
(lp275
(dp276
g7
I156
sg23
VC0238378
p277
sg10
I3
sg11
VDIP
p278
sg13
I1
sa(dp279
g7
I234
sg23
VC0600139
p280
sg10
I15
sg11
Vprostate cancer
p281
sg13
I2
sasa(dp282
g2
S'The G-1394T variant of XRCC4 proved, after analysis of the frequencies of each variant in the prostate cancer and control groups, to be a significant single nucleotide polymorphism (SNP) in prostate carcinogenesis.\n'
p283
sg4
(lp284
(dp285
g7
I23
sg8
g18
sg10
I5
sg11
VXRCC4
p286
sg13
I1
sa(dp287
g7
I4
sg8
VP26640
p288
sg10
I15
sg11
VG-1394T variant
p289
sg13
I2
sasg20
(lp290
(dp291
g7
I94
sg23
VC0600139
p292
sg10
I15
sg11
Vprostate cancer
p293
sg13
I2
sa(dp294
g7
I199
sg23
VC0596263
p295
sg10
I14
sg11
Vcarcinogenesis
p296
sg13
I1
sasa(dp297
g2
S'Our data clearly indicate that the heterogeneous G of G-1394T increases the risk of suceptibility to prostate cancer (P=0.0106), while no difference in distribution of XRCC4 C-1622T (rs7727691), C-571T (rs2075686) or intron3 DIP (rs28360071) between the prostate cancer and control groups was found.\n'
p298
sg4
(lp299
(dp300
g7
I168
sg8
g18
sg10
I13
sg11
VXRCC4 C-1622T
p301
sg13
I2
sasg20
(lp302
(dp303
g7
I225
sg23
VC0238378
p304
sg10
I3
sg11
VDIP
p305
sg13
I1
sa(dp306
g7
I101
sg23
VC0600139
p307
sg10
I15
sg11
Vprostate cancer
p308
sg13
I2
sa(dp309
g7
I101
sg23
VC0600139
p310
sg10
I15
sg11
Vprostate cancer
p311
sg13
I2
sasa(dp312
g2
S'To reveal the relationship between XRCC4 and bladder cancer, seven polymorphic variants of XRCC4, including C-1622T (rs7727691), G-1394T (rs6869366), G-652T (rs2075685), C-571T (rs2075686), intron3 DIP (rs28360071), S247A (rs3734091) and intron7 DIP (rs28360317) were investigated and analyzed for their association with bladder cancer susceptibility.\n'
p313
sg4
(lp314
(dp315
g7
I35
sg8
g18
sg10
I5
sg11
VXRCC4
p316
sg13
I1
sa(dp317
g7
I35
sg8
g18
sg10
I5
sg11
VXRCC4
p318
sg13
I1
sasg20
(lp319
(dp320
g7
I45
sg23
VC0699885
p321
sg10
I14
sg11
Vbladder cancer
p322
sg13
I2
sa(dp323
g7
I198
sg23
VC0238378
p324
sg10
I3
sg11
VDIP
p325
sg13
I1
sa(dp326
g7
I198
sg23
VC0238378
p327
sg10
I3
sg11
VDIP
p328
sg13
I1
sa(dp329
g7
I45
sg23
VC0699885
p330
sg10
I14
sg11
Vbladder cancer
p331
sg13
I2
sasa(dp332
g2
S'It was found that XRCC4 G-1394T is a significant SNP in bladder carcinogenesis after analyzing the frequencies of each variant in both bladder cancer and control groups.\n'
p333
sg4
(lp334
(dp335
g7
I18
sg8
g18
sg10
I7
sg11
VXRCC4 G
p336
sg13
I2
sasg20
(lp337
(dp338
g7
I135
sg23
VC0699885
p339
sg10
I14
sg11
Vbladder cancer
p340
sg13
I2
sa(dp341
g7
I64
sg23
VC0596263
p342
sg10
I14
sg11
Vcarcinogenesis
p343
sg13
I1
sasa(dp344
g2
S'These findings suggest that the G allele of XRCC4 G-1394T may be involved in bladder carcinogenesis and useful in early detection of bladder cancer.\n'
p345
sg4
(lp346
(dp347
g7
I44
sg8
g18
sg10
I7
sg11
VXRCC4 G
p348
sg13
I2
sasg20
(lp349
(dp350
g7
I85
sg23
VC0596263
p351
sg10
I14
sg11
Vcarcinogenesis
p352
sg13
I1
sa(dp353
g7
I133
sg23
VC0699885
p354
sg10
I14
sg11
Vbladder cancer
p355
sg13
I2
sasa(dp356
g2
S'FERM domain containing 7 (FRMD7) is a member of the four-point-one, ezrin, radixin, moesin (FERM) family of proteins, and has been reported to cause X-linked idiopathic congenital nystagmus (ICN), a disease which affects ocular motor control.\n'
p357
sg4
(lp358
(dp359
g7
I68
sg8
VP15311
p360
sg10
I5
sg11
Vezrin
p361
sg13
I1
sa(dp362
g7
I75
sg8
VP35241
p363
sg10
I7
sg11
Vradixin
p364
sg13
I1
sa(dp365
g7
I84
sg8
VP26038
p366
sg10
I6
sg11
Vmoesin
p367
sg13
I1
sa(dp368
g7
I0
sg8
g18
sg10
I24
sg11
VFERM domain containing 7
p369
sg13
I4
sa(dp370
g7
I26
sg8
g18
sg10
I5
sg11
VFRMD7
p371
sg13
I1
sasg20
(lp372
(dp373
g7
I0
sg23
VC0238394
p374
sg10
I4
sg11
VFERM
p375
sg13
I1
sa(dp376
g7
I0
sg23
VC0238394
p377
sg10
I4
sg11
VFERM
p378
sg13
I1
sa(dp379
g7
I169
sg23
VC0700501
p380
sg10
I20
sg11
Vcongenital nystagmus
p381
sg13
I2
sasa(dp382
g2
S'The CD40-CD40L pathway is a promising treatment target for autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and lupus nephritis.\n'
p383
sg4
(lp384
(dp385
g7
I9
sg8
VP29965
p386
sg10
I5
sg11
VCD40L
p387
sg13
I1
sa(dp388
g7
I4
sg8
VP25942
p389
sg10
I4
sg11
VCD40
p390
sg13
I1
sasg20
(lp391
(dp392
g7
I87
sg23
VC0003873
p393
sg10
I20
sg11
Vrheumatoid arthritis
p394
sg13
I2
sa(dp395
g7
I59
sg23
VC0004364
p396
sg10
I19
sg11
Vautoimmune diseases
p397
sg13
I2
sa(dp398
g7
I142
sg23
VC0024143
p399
sg10
I15
sg11
Vlupus nephritis
p400
sg13
I2
sa(dp401
g7
I109
sg23
VC0024141
p402
sg10
I28
sg11
Vsystemic lupus erythematosus
p403
sg13
I3
sasa(dp404
g2
S'The inflammatory CD40-CD40L pathway is implicated in various autoimmune diseases, but the activity status of this pathway in various stages of rheumatoid arthritis (RA) progression is unknown.\n'
p405
sg4
(lp406
(dp407
g7
I22
sg8
VP29965
p408
sg10
I5
sg11
VCD40L
p409
sg13
I1
sa(dp410
g7
I17
sg8
VP25942
p411
sg10
I4
sg11
VCD40
p412
sg13
I1
sasg20
(lp413
(dp414
g7
I165
sg23
VC0003873
p415
sg10
I2
sg11
VRA
p416
sg13
I1
sa(dp417
g7
I61
sg23
VC0004364
p418
sg10
I19
sg11
Vautoimmune diseases
p419
sg13
I2
sa(dp420
g7
I143
sg23
VC0003873
p421
sg10
I20
sg11
Vrheumatoid arthritis
p422
sg13
I2
sasa(dp423
g2
S'In this study, we used gene signatures of CD40L stimulation derived from human immature dendritic cells and naive B cells to assess the expression of CD40-downstream genes in synovial tissues from anti-citrullinated protein Ab-positive arthralgia, undifferentiated arthritis (UA), early RA, and established RA cohorts in comparison with healthy donors.\n'
p424
sg4
(lp425
(dp426
g7
I42
sg8
VP25942
p427
sg10
I4
sg11
VCD40
p428
sg13
I1
sa(dp429
g7
I42
sg8
VP29965
p430
sg10
I5
sg11
VCD40L
p431
sg13
I1
sasg20
(lp432
(dp433
g7
I236
sg23
VC0003862
p434
sg10
I10
sg11
Varthralgia
p435
sg13
I1
sa(dp436
g7
I265
sg23
VC0003864
p437
sg10
I9
sg11
Varthritis
p438
sg13
I1
sasa(dp439
g2
S'This study explored the association between single nucleotide polymorphisms (SNPs) in the CD40 gene, rs4810485 G &gt; T and rs1883832 C &gt; T, as well as disease susceptibility and severity in knee osteoarthritis (KOA) in the Chinese Han population.\n'
p440
sg4
(lp441
(dp442
g7
I90
sg8
VP25942
p443
sg10
I9
sg11
VCD40 gene
p444
sg13
I2
sasg20
(lp445
(dp446
g7
I215
sg23
VC0409959
p447
sg10
I3
sg11
VKOA
p448
sg13
I1
sa(dp449
g7
I194
sg23
VC0409959
p450
sg10
I19
sg11
Vknee osteoarthritis
p451
sg13
I2
sasa(dp452
g2
S'The CD40 pathway is involved in the development and pathogenesis of autoimmune diseases, including rheumatoid arthritis (RA).\n'
p453
sg4
(lp454
(dp455
g7
I4
sg8
VP25942
p456
sg10
I4
sg11
VCD40
p457
sg13
I1
sasg20
(lp458
(dp459
g7
I121
sg23
VC0003873
p460
sg10
I2
sg11
VRA
p461
sg13
I1
sa(dp462
g7
I52
sg23
VC0699748
p463
sg10
I12
sg11
Vpathogenesis
p464
sg13
I1
sa(dp465
g7
I68
sg23
VC0004364
p466
sg10
I19
sg11
Vautoimmune diseases
p467
sg13
I2
sa(dp468
g7
I99
sg23
VC0003873
p469
sg10
I20
sg11
Vrheumatoid arthritis
p470
sg13
I2
sasa(dp471
g2
S'Significantly shorter postoperative overall survival was observed in HCC patients with high let-7c expression.The results suggest that aberrant expression of let-7a/7b/7c/7e occurs in benign liver diseases and HCC.\n'
p472
sg4
(lp473
sg20
(lp474
(dp475
g7
I191
sg23
VC0023895
p476
sg10
I14
sg11
Vliver diseases
p477
sg13
I2
sa(dp478
g7
I69
sg23
VC2239176
p479
sg10
I3
sg11
VHCC
p480
sg13
I1
sa(dp481
g7
I69
sg23
VC2239176
p482
sg10
I3
sg11
VHCC
p483
sg13
I1
sasa(dp484
g2
S'For this reason, the expression levels of 24 miRNA (let-7c, miR-92a-3p, 423-5p, 150-5p, 223-3p, 125b-5p, 342-3p, miR-206, 122-5p, 375, 223-5p, 10a-5p, 23b-5p, 99a-5p, 23a-5p, 10a-3p, 122-3p, 125b-1-3p, 23b-3p, 125b-2-3p, 23a-3p, 92a-1-5p, 92a-2-5p, 99a-3p) were analyzed in plasma of patients with chronic hepatitis B, HBV-positive cirrhosis and HBV-positive HCC and compared with control group samples.\n'
p485
sg4
(lp486
(dp487
g7
I60
sg8
g18
sg10
I10
sg11
VmiR-92a-3p
p488
sg13
I1
sasg20
(lp489
(dp490
g7
I359
sg23
VC2239176
p491
sg10
I3
sg11
VHCC
p492
sg13
I1
sa(dp493
g7
I319
sg23
VC0019163
p494
sg10
I3
sg11
VHBV
p495
sg13
I1
sa(dp496
g7
I319
sg23
VC0019163
p497
sg10
I3
sg11
VHBV
p498
sg13
I1
sa(dp499
g7
I298
sg23
VC0524909
p500
sg10
I19
sg11
Vchronic hepatitis B
p501
sg13
I3
sa(dp502
g7
I332
sg23
VC0023890
p503
sg10
I9
sg11
Vcirrhosis
p504
sg13
I1
sasa(dp505
g2
S'There was no correlation between let-7c miRNA levels and other clinicopathological factors, such as patient age, sex, hepatitis B virus status, Alfa-fetoprotein  levels, tumour size, tumour number, the presence of cirrhosis, liver envelope invasion or portal vein thrombosis.\n'
p506
sg4
(lp507
(dp508
g7
I231
sg8
g18
sg10
I8
sg11
Venvelope
p509
sg13
I1
sa(dp510
g7
I118
sg8
VP07332
p511
sg10
I42
sg11
Vhepatitis B virus status, Alfa-fetoprotein
p512
sg13
I5
sasg20
(lp513
(dp514
g7
I214
sg23
VC0023890
p515
sg10
I16
sg11
Vcirrhosis, liver
p516
sg13
I2
sa(dp517
g7
I170
sg23
VC0027651
p518
sg10
I6
sg11
Vtumour
p519
sg13
I1
sa(dp520
g7
I252
sg23
VC0155773
p521
sg10
I22
sg11
Vportal vein thrombosis
p522
sg13
I3
sa(dp523
g7
I170
sg23
VC0027651
p524
sg10
I6
sg11
Vtumour
p525
sg13
I1
sa(dp526
g7
I240
sg23
VC2699153
p527
sg10
I8
sg11
Vinvasion
p528
sg13
I1
sa(dp529
g7
I118
sg23
VC0019163
p530
sg10
I11
sg11
Vhepatitis B
p531
sg13
I2
sasa(dp532
g2
S'A set of 12 miRNAs (including miR-21, miR-221/222, miR-34a, miR-519a, miR-93, miR-96, and let-7c) was linked to disease progression from normal liver through cirrhosis to full-blown HCC.\n'
p533
sg4
(lp534
(dp535
g7
I51
sg8
g18
sg10
I7
sg11
VmiR-34a
p536
sg13
I1
sa(dp537
g7
I78
sg8
g18
sg10
I6
sg11
VmiR-96
p538
sg13
I1
sa(dp539
g7
I60
sg8
g18
sg10
I8
sg11
VmiR-519a
p540
sg13
I1
sa(dp541
g7
I70
sg8
g18
sg10
I6
sg11
VmiR-93
p542
sg13
I1
sasg20
(lp543
(dp544
g7
I112
sg23
VC0242656
p545
sg10
I19
sg11
Vdisease progression
p546
sg13
I2
sa(dp547
g7
I158
sg23
VC0023890
p548
sg10
I9
sg11
Vcirrhosis
p549
sg13
I1
sa(dp550
g7
I182
sg23
VC2239176
p551
sg10
I3
sg11
VHCC
p552
sg13
I1
sasa(dp553
g2
S'So far, participation in the epileptogenesis and maintenance of epilepsy was proved for 5-HT1A, 5-HT2C, 5-HT3, 5-HT4 and 5-HT7 receptors as well as 5-HTT serotonin transporter.\n'
p554
sg4
(lp555
(dp556
g7
I88
sg8
VP08908
p557
sg10
I21
sg11
V5-HT1A, 5-HT2C, 5-HT3
p558
sg13
I3
sa(dp559
g7
I111
sg8
VP34969
p560
sg10
I25
sg11
V5-HT4 and 5-HT7 receptors
p561
sg13
I4
sa(dp562
g7
I148
sg8
VP31645
p563
sg10
I27
sg11
V5-HTT serotonin transporter
p564
sg13
I3
sasg20
(lp565
(dp566
g7
I64
sg23
VC0014544
p567
sg10
I8
sg11
Vepilepsy
p568
sg13
I1
sasa(dp569
g2
S'The use of 5-HT4 receptor agonists may be an alternative strategy to achieve prokinesia during a migraine attack, although this issue still needs to be fully addressed by controlled studies.\n'
p570
sg4
(lp571
(dp572
g7
I11
sg8
g18
sg10
I14
sg11
V5-HT4 receptor
p573
sg13
I2
sasg20
(lp574
(dp575
g7
I97
sg23
VC0149931
p576
sg10
I8
sg11
Vmigraine
p577
sg13
I1
sasa(dp578
g2
S'Some of these drugs are also used therapeutically in the treatment of migraine (eg, sumatriptan, which is a 5-HT1 receptor agonist), vascular disorders (5-HT2 antagonists), and nausea and vomiting (5-HT3 antagonists, eg, dolasetron, granisetron, ondansetron, and tropisetron), and have been investigated in gastrointestinal motility disorders (5-HT4 antagonists) and behavioral psychopathologies (5-HT1 agonists and 5-HT2-4 antagonists).\n'
p579
sg4
(lp580
(dp581
g7
I108
sg8
g18
sg10
I14
sg11
V5-HT1 receptor
p582
sg13
I2
sasg20
(lp583
(dp584
g7
I133
sg23
VC0042373
p585
sg10
I18
sg11
Vvascular disorders
p586
sg13
I2
sa(dp587
g7
I70
sg23
VC0149931
p588
sg10
I8
sg11
Vmigraine
p589
sg13
I1
sa(dp590
g7
I177
sg23
VC0027498
p591
sg10
I19
sg11
Vnausea and vomiting
p592
sg13
I3
sasa(dp593
g2
S'However, the impact of TIGIT on melanoma-specific cytotoxic T lymphocytes in the effector phase remains unclear.\n'
p594
sg4
(lp595
(dp596
g7
I23
sg8
g18
sg10
I5
sg11
VTIGIT
p597
sg13
I1
sasg20
(lp598
(dp599
g7
I32
sg23
VC0025202
p600
sg10
I8
sg11
Vmelanoma
p601
sg13
I1
sasa(dp602
g2
S'In this study, we demonstrated that melanoma cells control antimelanoma cytotoxic T lymphocyte responses via the TIGIT-CD155 interaction in the effector phase.\n'
p603
sg4
(lp604
(dp605
g7
I119
sg8
VP15151
p606
sg10
I5
sg11
VCD155
p607
sg13
I1
sa(dp608
g7
I113
sg8
g18
sg10
I5
sg11
VTIGIT
p609
sg13
I1
sasg20
(lp610
(dp611
g7
I36
sg23
VC0025202
p612
sg10
I8
sg11
Vmelanoma
p613
sg13
I1
sasa(dp614
g2
S'We then demonstrated that CD155 on melanoma cells suppressed cytokine release from melanoma-specific cytotoxic T lymphocytes via interaction with TIGIT.\n'
p615
sg4
(lp616
(dp617
g7
I146
sg8
g18
sg10
I5
sg11
VTIGIT
p618
sg13
I1
sa(dp619
g7
I26
sg8
VP15151
p620
sg10
I5
sg11
VCD155
p621
sg13
I1
sasg20
(lp622
(dp623
g7
I35
sg23
VC0025202
p624
sg10
I8
sg11
Vmelanoma
p625
sg13
I1
sa(dp626
g7
I35
sg23
VC0025202
p627
sg10
I8
sg11
Vmelanoma
p628
sg13
I1
sasa(dp629
g2
S'This suggested that antimelanoma cytotoxic T lymphocyte responses are controlled not only by an imbalance in CD226 (an activating molecule that binds to CD155) and TIGIT expression on T cells but also by the expression levels of CD155 on melanoma cells.\n'
p630
sg4
(lp631
(dp632
g7
I153
sg8
VP15151
p633
sg10
I5
sg11
VCD155
p634
sg13
I1
sa(dp635
g7
I153
sg8
VP15151
p636
sg10
I5
sg11
VCD155
p637
sg13
I1
sa(dp638
g7
I109
sg8
g18
sg10
I5
sg11
VCD226
p639
sg13
I1
sa(dp640
g7
I164
sg8
g18
sg10
I5
sg11
VTIGIT
p641
sg13
I1
sasg20
(lp642
(dp643
g7
I24
sg23
VC0025202
p644
sg10
I8
sg11
Vmelanoma
p645
sg13
I1
sa(dp646
g7
I96
sg23
VC1397014
p647
sg10
I9
sg11
Vimbalance
p648
sg13
I1
sasa(dp649
g2
S'In addition, the co-blockade of TIGIT and PD-1 signals synergistically elicited a response of tumor-infiltrating lymphocytes on autologous melanoma cells.\n'
p650
sg4
(lp651
(dp652
g7
I32
sg8
g18
sg10
I5
sg11
VTIGIT
p653
sg13
I1
sa(dp654
g7
I42
sg8
VP18621
p655
sg10
I4
sg11
VPD-1
p656
sg13
I1
sasg20
(lp657
(dp658
g7
I100
sg23
VC0332448
p659
sg10
I12
sg11
Vinfiltrating
p660
sg13
I1
sa(dp661
g7
I94
sg23
VC0027651
p662
sg10
I5
sg11
Vtumor
p663
sg13
I1
sa(dp664
g7
I139
sg23
VC0025202
p665
sg10
I8
sg11
Vmelanoma
p666
sg13
I1
sasa(dp667
g2
S'These results suggest that the CD155-TIGIT interaction should be blocked for enhancement of antimelanoma immune responses.\n'
p668
sg4
(lp669
(dp670
g7
I31
sg8
VP15151
p671
sg10
I5
sg11
VCD155
p672
sg13
I1
sa(dp673
g7
I37
sg8
g18
sg10
I5
sg11
VTIGIT
p674
sg13
I1
sasg20
(lp675
sa(dp676
g2
S'describe a novel immunosuppressive mechanism in melanoma that is triggered by the interaction between CD155 (expressed by melanomas) and T-cell Ig and ITIM domain (TIGIT) (expressed by tumor infiltrating lymphocytes).\n'
p677
sg4
(lp678
(dp679
g7
I164
sg8
g18
sg10
I5
sg11
VTIGIT
p680
sg13
I1
sa(dp681
g7
I102
sg8
VP15151
p682
sg10
I5
sg11
VCD155
p683
sg13
I1
sasg20
(lp684
(dp685
g7
I191
sg23
VC0332448
p686
sg10
I12
sg11
Vinfiltrating
p687
sg13
I1
sa(dp688
g7
I122
sg23
VC0025202
p689
sg10
I9
sg11
Vmelanomas
p690
sg13
I1
sa(dp691
g7
I185
sg23
VC0027651
p692
sg10
I5
sg11
Vtumor
p693
sg13
I1
sa(dp694
g7
I48
sg23
VC0025202
p695
sg10
I8
sg11
Vmelanoma
p696
sg13
I1
sasa(dp697
g2
S'However, the impact of TIGIT on melanoma specific CTLs in the effector phase remains still unclear.\n'
p698
sg4
(lp699
(dp700
g7
I23
sg8
g18
sg10
I5
sg11
VTIGIT
p701
sg13
I1
sasg20
(lp702
(dp703
g7
I32
sg23
VC0025202
p704
sg10
I8
sg11
Vmelanoma
p705
sg13
I1
sasa(dp706
g2
S'In this study, we demonstrated that melanoma cells control anti-melanoma CTL responses via the TIGIT-CD155 interaction in the effector phase.\n'
p707
sg4
(lp708
(dp709
g7
I95
sg8
g18
sg10
I5
sg11
VTIGIT
p710
sg13
I1
sa(dp711
g7
I101
sg8
VP15151
p712
sg10
I5
sg11
VCD155
p713
sg13
I1
sasg20
(lp714
(dp715
g7
I36
sg23
VC0025202
p716
sg10
I8
sg11
Vmelanoma
p717
sg13
I1
sa(dp718
g7
I36
sg23
VC0025202
p719
sg10
I8
sg11
Vmelanoma
p720
sg13
I1
sasa(dp721
g2
S'We then demonstrated that CD155 on melanoma cells suppressed cytokine release from melanoma-specific CTLs via interaction with TIGIT.\n'
p722
sg4
(lp723
(dp724
g7
I127
sg8
g18
sg10
I5
sg11
VTIGIT
p725
sg13
I1
sa(dp726
g7
I26
sg8
VP15151
p727
sg10
I5
sg11
VCD155
p728
sg13
I1
sasg20
(lp729
(dp730
g7
I35
sg23
VC0025202
p731
sg10
I8
sg11
Vmelanoma
p732
sg13
I1
sa(dp733
g7
I35
sg23
VC0025202
p734
sg10
I8
sg11
Vmelanoma
p735
sg13
I1
sasa(dp736
g2
S'This suggested that anti-melanoma CTL responses are controlled not only by an imbalance in CD226 (an activating molecule binds to CD155) and TIGIT expression on T cells but also by the expression levels of CD155 on melanoma cells.\n'
p737
sg4
(lp738
(dp739
g7
I130
sg8
VP15151
p740
sg10
I5
sg11
VCD155
p741
sg13
I1
sa(dp742
g7
I91
sg8
g18
sg10
I5
sg11
VCD226
p743
sg13
I1
sa(dp744
g7
I141
sg8
g18
sg10
I5
sg11
VTIGIT
p745
sg13
I1
sa(dp746
g7
I130
sg8
VP15151
p747
sg10
I5
sg11
VCD155
p748
sg13
I1
sasg20
(lp749
(dp750
g7
I25
sg23
VC0025202
p751
sg10
I8
sg11
Vmelanoma
p752
sg13
I1
sa(dp753
g7
I25
sg23
VC0025202
p754
sg10
I8
sg11
Vmelanoma
p755
sg13
I1
sa(dp756
g7
I78
sg23
VC1397014
p757
sg10
I9
sg11
Vimbalance
p758
sg13
I1
sasa(dp759
g2
S'In addition, co-blockade of TIGIT and PD-1 signals synergistically elicited a response of tumor-infiltrating lymphocytes (TILs) on autologous melanoma cells.\n'
p760
sg4
(lp761
(dp762
g7
I38
sg8
VP18621
p763
sg10
I4
sg11
VPD-1
p764
sg13
I1
sa(dp765
g7
I90
sg8
VP01765
p766
sg10
I30
sg11
Vtumor-infiltrating lymphocytes
p767
sg13
I2
sa(dp768
g7
I28
sg8
g18
sg10
I5
sg11
VTIGIT
p769
sg13
I1
sa(dp770
g7
I122
sg8
VP01765
p771
sg10
I4
sg11
VTILs
p772
sg13
I1
sasg20
(lp773
(dp774
g7
I90
sg23
VC0027651
p775
sg10
I5
sg11
Vtumor
p776
sg13
I1
sa(dp777
g7
I96
sg23
VC0332448
p778
sg10
I12
sg11
Vinfiltrating
p779
sg13
I1
sa(dp780
g7
I142
sg23
VC0025202
p781
sg10
I8
sg11
Vmelanoma
p782
sg13
I1
sasa(dp783
g2
S'These results suggest that the CD155-TIGIT interaction should be blocked for enhancement of anti-melanoma immune responses.Journal of Investigative Dermatology accepted article preview online, 12 October 2015. doi:10.1038/jid.2015.404.\n'
p784
sg4
(lp785
(dp786
g7
I31
sg8
VP15151
p787
sg10
I5
sg11
VCD155
p788
sg13
I1
sa(dp789
g7
I37
sg8
g18
sg10
I5
sg11
VTIGIT
p790
sg13
I1
sasg20
(lp791
(dp792
g7
I97
sg23
VC0025202
p793
sg10
I8
sg11
Vmelanoma
p794
sg13
I1
sasa(dp795
g2
S'Here, we determined that TIGIT is upregulated on tumor antigen-specific (TA-specific) CD8+ T cells and CD8+ tumor-infiltrating lymphocytes (TILs) from patients with melanoma, and these TIGIT-expressing CD8+ T cells often coexpress the inhibitory receptor PD-1.\n'
p796
sg4
(lp797
(dp798
g7
I86
sg8
VP01732
p799
sg10
I4
sg11
VCD8+
p800
sg13
I1
sa(dp801
g7
I86
sg8
VP01732
p802
sg10
I4
sg11
VCD8+
p803
sg13
I1
sa(dp804
g7
I25
sg8
g18
sg10
I5
sg11
VTIGIT
p805
sg13
I1
sa(dp806
g7
I25
sg8
g18
sg10
I5
sg11
VTIGIT
p807
sg13
I1
sa(dp808
g7
I86
sg8
VP01732
p809
sg10
I4
sg11
VCD8+
p810
sg13
I1
sa(dp811
g7
I255
sg8
VP18621
p812
sg10
I4
sg11
VPD-1
p813
sg13
I1
sasg20
(lp814
(dp815
g7
I49
sg23
VC0027651
p816
sg10
I5
sg11
Vtumor
p817
sg13
I1
sa(dp818
g7
I165
sg23
VC0025202
p819
sg10
I8
sg11
Vmelanoma
p820
sg13
I1
sa(dp821
g7
I49
sg23
VC0027651
p822
sg10
I5
sg11
Vtumor
p823
sg13
I1
sa(dp824
g7
I114
sg23
VC0332448
p825
sg10
I12
sg11
Vinfiltrating
p826
sg13
I1
sasa(dp827
g2
S'Moreover, CD8+ TILs from patients exhibited downregulation of the costimulatory molecule CD226, which competes with TIGIT for the same ligand, supporting a TIGIT/CD226 imbalance in metastatic melanoma.\n'
p828
sg4
(lp829
(dp830
g7
I116
sg8
g18
sg10
I5
sg11
VTIGIT
p831
sg13
I1
sa(dp832
g7
I10
sg8
VP01732
p833
sg10
I9
sg11
VCD8+ TILs
p834
sg13
I2
sa(dp835
g7
I116
sg8
g18
sg10
I5
sg11
VTIGIT
p836
sg13
I1
sa(dp837
g7
I89
sg8
g18
sg10
I5
sg11
VCD226
p838
sg13
I1
sa(dp839
g7
I89
sg8
g18
sg10
I5
sg11
VCD226
p840
sg13
I1
sasg20
(lp841
(dp842
g7
I181
sg23
VC0278883
p843
sg10
I19
sg11
Vmetastatic melanoma
p844
sg13
I2
sa(dp845
g7
I168
sg23
VC1397014
p846
sg10
I9
sg11
Vimbalance
p847
sg13
I1
sasa(dp848
g2
S'Collectively, our results show that TIGIT and PD-1 regulate the expansion and function of TA-specific CD8+ T cells and CD8+ TILs in melanoma patients and suggest that dual TIGIT and PD-1 blockade should be further explored to elicit potent antitumor CD8+ T cell responses in patients with advanced melanoma.\n'
p849
sg4
(lp850
(dp851
g7
I102
sg8
VP01732
p852
sg10
I4
sg11
VCD8+
p853
sg13
I1
sa(dp854
g7
I119
sg8
VP01732
p855
sg10
I9
sg11
VCD8+ TILs
p856
sg13
I2
sa(dp857
g7
I36
sg8
g18
sg10
I5
sg11
VTIGIT
p858
sg13
I1
sa(dp859
g7
I46
sg8
VP18621
p860
sg10
I4
sg11
VPD-1
p861
sg13
I1
sa(dp862
g7
I36
sg8
g18
sg10
I5
sg11
VTIGIT
p863
sg13
I1
sa(dp864
g7
I102
sg8
VP01732
p865
sg10
I4
sg11
VCD8+
p866
sg13
I1
sa(dp867
g7
I46
sg8
VP18621
p868
sg10
I4
sg11
VPD-1
p869
sg13
I1
sasg20
(lp870
(dp871
g7
I132
sg23
VC0025202
p872
sg10
I8
sg11
Vmelanoma
p873
sg13
I1
sa(dp874
g7
I132
sg23
VC0025202
p875
sg10
I8
sg11
Vmelanoma
p876
sg13
I1
sasa(dp877
g2
S'Four patients with clinically and genetically confirmed Prader-Willi syndrome (PWS) underwent nocturnal polysomnograpy (PSG), multiple sleep latency test (MSLT), human leukocyte antigens (HLA) typing and estimation of cerebrospinal fluid (CSF) hypocretin-1 (Hcrt-1) level to investigate if a role of hypothalamic dysfunction and sleep disturbance might be functionally connected through the hypocretin (orexin) system.\n'
p878
sg4
(lp879
(dp880
g7
I258
sg8
VP50336
p881
sg10
I6
sg11
VHcrt-1
p882
sg13
I1
sa(dp883
g7
I188
sg8
VP30486
p884
sg10
I3
sg11
VHLA
p885
sg13
I1
sa(dp886
g7
I244
sg8
VP50336
p887
sg10
I10
sg11
Vhypocretin
p888
sg13
I1
sa(dp889
g7
I162
sg8
VP05534
p890
sg10
I24
sg11
Vhuman leukocyte antigens
p891
sg13
I3
sa(dp892
g7
I403
sg8
g18
sg10
I6
sg11
Vorexin
p893
sg13
I1
sa(dp894
g7
I244
sg8
g18
sg10
I12
sg11
Vhypocretin-1
p895
sg13
I1
sasg20
(lp896
(dp897
g7
I56
sg23
VC0032897
p898
sg10
I21
sg11
VPrader-Willi syndrome
p899
sg13
I2
sa(dp900
g7
I79
sg23
VC0032897
p901
sg10
I3
sg11
VPWS
p902
sg13
I1
sa(dp903
g7
I300
sg23
VC0751230
p904
sg10
I24
sg11
Vhypothalamic dysfunction
p905
sg13
I2
sa(dp906
g7
I329
sg23
VC0700201
p907
sg10
I17
sg11
Vsleep disturbance
p908
sg13
I2
sasa(dp909
g2
S'The deficiency of CSF Hcrt-1 level correlated in PWS patients with their EDS severity.\n'
p910
sg4
(lp911
(dp912
g7
I18
sg8
VP04141
p913
sg10
I10
sg11
VCSF Hcrt-1
p914
sg13
I2
sasg20
(lp915
(dp916
g7
I49
sg23
VC0032897
p917
sg10
I3
sg11
VPWS
p918
sg13
I1
sa(dp919
g7
I73
sg23
VC0013720
p920
sg10
I3
sg11
VEDS
p921
sg13
I1
sasa(dp922
g2
S'A four-generation kindred (14 affected and 10 unaffected members) from Missouri, U.S.A. in which spondyloepimetaphyseal dysplasia (SEMD) had been inherited as an autosomal dominant disorder was investigated for linkage to 13 candidate loci: COL2AI, COL9AI, COL9A2, COL9A3, COL10A1, COL11A1, COL11A2, PSACH, FGFR3, decorin, CRTL1, COMP, and PTHRP.\n'
p923
sg4
(lp924
(dp925
g7
I314
sg8
VP07585
p926
sg10
I7
sg11
Vdecorin
p927
sg13
I1
sa(dp928
g7
I257
sg8
g18
sg10
I6
sg11
VCOL9A2
p929
sg13
I1
sa(dp930
g7
I323
sg8
VP10915
p931
sg10
I5
sg11
VCRTL1
p932
sg13
I1
sa(dp933
g7
I307
sg8
VP22607
p934
sg10
I5
sg11
VFGFR3
p935
sg13
I1
sa(dp936
g7
I330
sg8
VP49747
p937
sg10
I4
sg11
VCOMP
p938
sg13
I1
sa(dp939
g7
I300
sg8
VP49747
p940
sg10
I5
sg11
VPSACH
p941
sg13
I1
sa(dp942
g7
I265
sg8
g18
sg10
I6
sg11
VCOL9A3
p943
sg13
I1
sa(dp944
g7
I340
sg8
VP12272
p945
sg10
I5
sg11
VPTHRP
p946
sg13
I1
sa(dp947
g7
I273
sg8
g18
sg10
I7
sg11
VCOL10A1
p948
sg13
I1
sa(dp949
g7
I282
sg8
VP12107
p950
sg10
I7
sg11
VCOL11A1
p951
sg13
I1
sasg20
(lp952
(dp953
g7
I120
sg23
VC0334044
p954
sg10
I9
sg11
Vdysplasia
p955
sg13
I1
sa(dp956
g7
I300
sg23
VC0410538
p957
sg10
I5
sg11
VPSACH
p958
sg13
I1
sasa(dp959
g2
S'Linkage to 2 cartilage-specific candidate genes, type II collagen (COL2A1) and proteoglycan link protein genes (CRTL1), was tested in 9 autosomal dominant families with pseudoachondroplasia.\n'
p960
sg4
(lp961
(dp962
g7
I49
sg8
VP27037
p963
sg10
I16
sg11
Vtype II collagen
p964
sg13
I3
sa(dp965
g7
I112
sg8
VP10915
p966
sg10
I5
sg11
VCRTL1
p967
sg13
I1
sasg20
(lp968
(dp969
g7
I169
sg23
VC0410538
p970
sg10
I20
sg11
Vpseudoachondroplasia
p971
sg13
I1
sasa(dp972
g2
S'In the last years, mutations in four genes (NFU1, BOLA3, ISCA2 and IBA57) have been related to a new group of multiple mitochondrial dysfunction syndromes characterized by lactic acidosis, hyperglycinemia, multiple defects of the respiratory chain complexes, and impairment of four lipoic acid-dependent enzymes: Alfa-ketoglutarate dehydrogenase complex, pyruvic dehydrogenase, branched-chain Alfa-keto acid dehydrogenase complex and the H protein of the glycine cleavage system.\n'
p973
sg4
(lp974
(dp975
g7
I355
sg8
VP49366
p976
sg10
I21
sg11
Vpyruvic dehydrogenase
p977
sg13
I2
sa(dp978
g7
I57
sg8
g18
sg10
I5
sg11
VISCA2
p979
sg13
I1
sa(dp980
g7
I44
sg8
g18
sg10
I4
sg11
VNFU1
p981
sg13
I1
sa(dp982
g7
I438
sg8
g18
sg10
I9
sg11
VH protein
p983
sg13
I2
sa(dp984
g7
I50
sg8
g18
sg10
I5
sg11
VBOLA3
p985
sg13
I1
sa(dp986
g7
I313
sg8
VP49366
p987
sg10
I40
sg11
VAlfa-ketoglutarate dehydrogenase complex
p988
sg13
I3
sa(dp989
g7
I378
sg8
VP49366
p990
sg10
I51
sg11
Vbranched-chain Alfa-keto acid dehydrogenase complex
p991
sg13
I5
sasg20
(lp992
(dp993
g7
I172
sg23
VC0001125
p994
sg10
I15
sg11
Vlactic acidosis
p995
sg13
I2
sa(dp996
g7
I263
sg23
VC0684336
p997
sg10
I10
sg11
Vimpairment
p998
sg13
I1
sa(dp999
g7
I145
sg23
VC0039082
p1000
sg10
I9
sg11
Vsyndromes
p1001
sg13
I1
sa(dp1002
g7
I189
sg23
VC0268559
p1003
sg10
I15
sg11
Vhyperglycinemia
p1004
sg13
I1
sasa(dp1005
g2
S'Variation in the reports suggesting both functional dependency and independency of TLR-2 on its heterodimeric partner TLR-6 in response to ligands exists, thus this study was postulated to observe the expression pattern of TLR-6 in synovial tissue and lymphoid organs after inducing septic arthritis by S. aureus in Swiss albino mouse model and the instigated cytokine profile could affirm its plausible role in SA.\n'
p1006
sg4
(lp1007
(dp1008
g7
I118
sg8
g18
sg10
I5
sg11
VTLR-6
p1009
sg13
I1
sa(dp1010
g7
I83
sg8
g18
sg10
I5
sg11
VTLR-2
p1011
sg13
I1
sasg20
(lp1012
(dp1013
g7
I322
sg23
VC0001916
p1014
sg10
I6
sg11
Valbino
p1015
sg13
I1
sa(dp1016
g7
I283
sg23
VC1692886
p1017
sg10
I16
sg11
Vseptic arthritis
p1018
sg13
I2
sasa(dp1019
g2
S'Our findings suggest the pro-inflammatory and catabolic role of TLR-2 mediated by the NF-KB pathway in septic arthritis.\n'
p1020
sg4
(lp1021
(dp1022
g7
I64
sg8
g18
sg10
I5
sg11
VTLR-2
p1023
sg13
I1
sasg20
(lp1024
(dp1025
g7
I103
sg23
VC1692886
p1026
sg10
I16
sg11
Vseptic arthritis
p1027
sg13
I2
sasa(dp1028
g2
S'Finally, in primary breast tumors, PR-A expression was correlated negatively with miR-92a-3p expression and positively with miR-26b-5p expression.\n'
p1029
sg4
(lp1030
(dp1031
g7
I82
sg8
g18
sg10
I10
sg11
VmiR-92a-3p
p1032
sg13
I1
sa(dp1033
g7
I124
sg8
g18
sg10
I10
sg11
VmiR-26b-5p
p1034
sg13
I1
sasg20
(lp1035
(dp1036
g7
I20
sg23
VC1458155
p1037
sg10
I13
sg11
Vbreast tumors
p1038
sg13
I2
sasa(dp1039
g2
S'Thus, upregulation of hsa-miR-26b-5p and downregulation of TRPS1 in radiation-associated breast cancer tissue samples suggests these molecules representing radiation markers in breast cancer.\n'
p1040
sg4
(lp1041
(dp1042
g7
I59
sg8
g18
sg10
I5
sg11
VTRPS1
p1043
sg13
I1
sa(dp1044
g7
I22
sg8
g18
sg10
I14
sg11
Vhsa-miR-26b-5p
p1045
sg13
I1
sasg20
(lp1046
(dp1047
g7
I59
sg23
VC0432233
p1048
sg10
I5
sg11
VTRPS1
p1049
sg13
I1
sa(dp1050
g7
I89
sg23
VC0678222
p1051
sg10
I13
sg11
Vbreast cancer
p1052
sg13
I2
sa(dp1053
g7
I22
sg23
VC0393754
p1054
sg10
I3
sg11
Vhsa
p1055
sg13
I1
sa(dp1056
g7
I89
sg23
VC0678222
p1057
sg10
I13
sg11
Vbreast cancer
p1058
sg13
I2
sasa(dp1059
g2
S'The aim of this study was to identify miRNAs that regulate PR in breast cancer.We mapped potential miRNA binding sites for miR-181a, miR-23a and miR-26b on PR mRNA and demonstrated a direct regulation of PR by these three miRNAs by in-vitro Luciferase binding assays.\n'
p1060
sg4
(lp1061
(dp1062
g7
I133
sg8
g18
sg10
I7
sg11
VmiR-23a
p1063
sg13
I1
sa(dp1064
g7
I123
sg8
g18
sg10
I8
sg11
VmiR-181a
p1065
sg13
I1
sa(dp1066
g7
I145
sg8
g18
sg10
I7
sg11
VmiR-26b
p1067
sg13
I1
sasg20
(lp1068
(dp1069
g7
I65
sg23
VC0678222
p1070
sg10
I13
sg11
Vbreast cancer
p1071
sg13
I2
sasa(dp1072
g2
S'A significant reciprocal correlation between PR mRNA and the miRNA levels were identified suggesting a role for miR-181a, miR-23a and miR-26b in PR regulation in breast cancer.\n'
p1073
sg4
(lp1074
(dp1075
g7
I112
sg8
g18
sg10
I8
sg11
VmiR-181a
p1076
sg13
I1
sa(dp1077
g7
I134
sg8
g18
sg10
I7
sg11
VmiR-26b
p1078
sg13
I1
sa(dp1079
g7
I122
sg8
g18
sg10
I7
sg11
VmiR-23a
p1080
sg13
I1
sasg20
(lp1081
(dp1082
g7
I162
sg23
VC0678222
p1083
sg10
I13
sg11
Vbreast cancer
p1084
sg13
I2
sasa(dp1085
g2
S'Furthermore, miR-181a and miR-26b were found to be over-expressed in most tumor tissues supporting their role in ER-positive breast cancer development.\n'
p1086
sg4
(lp1087
(dp1088
g7
I26
sg8
g18
sg10
I7
sg11
VmiR-26b
p1089
sg13
I1
sa(dp1090
g7
I13
sg8
g18
sg10
I8
sg11
VmiR-181a
p1091
sg13
I1
sasg20
(lp1092
(dp1093
g7
I125
sg23
VC0678222
p1094
sg10
I13
sg11
Vbreast cancer
p1095
sg13
I2
sa(dp1096
g7
I74
sg23
VC0027651
p1097
sg10
I5
sg11
Vtumor
p1098
sg13
I1
sasa(dp1099
g2
S'We conclude that miR-181a, miR-23a and miR-26b act as negative regulators of PR expression in ER-positive breast cancer.\n'
p1100
sg4
(lp1101
(dp1102
g7
I39
sg8
g18
sg10
I7
sg11
VmiR-26b
p1103
sg13
I1
sa(dp1104
g7
I27
sg8
g18
sg10
I7
sg11
VmiR-23a
p1105
sg13
I1
sa(dp1106
g7
I17
sg8
g18
sg10
I8
sg11
VmiR-181a
p1107
sg13
I1
sasg20
(lp1108
(dp1109
g7
I106
sg23
VC0678222
p1110
sg10
I13
sg11
Vbreast cancer
p1111
sg13
I2
sasa(dp1112
g2
S'MicroRNA-26b (miR-26b) has been reported to be down-regulated in a wide range of malignant tumors, However, the mechanism by which miR-26b is implicated in breast cancer tumorigenesis is incompletely understood.\n'
p1113
sg4
(lp1114
(dp1115
g7
I14
sg8
g18
sg10
I7
sg11
VmiR-26b
p1116
sg13
I1
sa(dp1117
g7
I0
sg8
g18
sg10
I12
sg11
VMicroRNA-26b
p1118
sg13
I1
sa(dp1119
g7
I14
sg8
g18
sg10
I7
sg11
VmiR-26b
p1120
sg13
I1
sasg20
(lp1121
(dp1122
g7
I156
sg23
VC0678222
p1123
sg10
I13
sg11
Vbreast cancer
p1124
sg13
I2
sa(dp1125
g7
I81
sg23
VC0006826
p1126
sg10
I16
sg11
Vmalignant tumors
p1127
sg13
I2
sa(dp1128
g7
I170
sg23
VC0007621
p1129
sg10
I13
sg11
Vtumorigenesis
p1130
sg13
I1
sasa(dp1131
g2
S'This study was undertaken to evaluate the expression pattern of miR-26b and characterize its biological role in human breast cancer.\n'
p1132
sg4
(lp1133
(dp1134
g7
I64
sg8
g18
sg10
I7
sg11
VmiR-26b
p1135
sg13
I1
sasg20
(lp1136
(dp1137
g7
I118
sg23
VC0678222
p1138
sg10
I13
sg11
Vbreast cancer
p1139
sg13
I2
sasa(dp1140
g2
S'Reverse transcription-polymerase chain reaction (RT-PCR) was used to quantify the expression levels of miR-26b in breast cancer and adjacent non-cancerous breast tissues.\n'
p1141
sg4
(lp1142
(dp1143
g7
I103
sg8
g18
sg10
I7
sg11
VmiR-26b
p1144
sg13
I1
sasg20
(lp1145
(dp1146
g7
I114
sg23
VC0678222
p1147
sg10
I13
sg11
Vbreast cancer
p1148
sg13
I2
sasa(dp1149
g2
S'Here, we found that miR-26b expression was relatively downregulated in breast cancer specimens (P&lt;0.01).\n'
p1150
sg4
(lp1151
(dp1152
g7
I20
sg8
g18
sg10
I7
sg11
VmiR-26b
p1153
sg13
I1
sasg20
(lp1154
(dp1155
g7
I71
sg23
VC0678222
p1156
sg10
I13
sg11
Vbreast cancer
p1157
sg13
I2
sasa(dp1158
g2
S'These findings suggest that miR-26b exerts a tumor suppressive role in breast cancer and the miR-26b-mediated growth inhibition is achieved through suppression of a new target gene CDK8.\n'
p1159
sg4
(lp1160
(dp1161
g7
I181
sg8
VP49336
p1162
sg10
I4
sg11
VCDK8
p1163
sg13
I1
sa(dp1164
g7
I28
sg8
g18
sg10
I7
sg11
VmiR-26b
p1165
sg13
I1
sa(dp1166
g7
I28
sg8
g18
sg10
I7
sg11
VmiR-26b
p1167
sg13
I1
sasg20
(lp1168
(dp1169
g7
I45
sg23
VC0027651
p1170
sg10
I5
sg11
Vtumor
p1171
sg13
I1
sa(dp1172
g7
I148
sg23
VC0221103
p1173
sg10
I11
sg11
Vsuppression
p1174
sg13
I1
sa(dp1175
g7
I71
sg23
VC0678222
p1176
sg10
I13
sg11
Vbreast cancer
p1177
sg13
I2
sasa(dp1178
g2
S'The expression of miR-26a or miR-26b was modulated in ER+ breast cancer cells (MCF-7 and T47D) and tumor cell growth in vitro and an in vivo xenograft model was determined.\n'
p1179
sg4
(lp1180
(dp1181
g7
I29
sg8
g18
sg10
I7
sg11
VmiR-26b
p1182
sg13
I1
sa(dp1183
g7
I18
sg8
g18
sg10
I7
sg11
VmiR-26a
p1184
sg13
I1
sasg20
(lp1185
(dp1186
g7
I58
sg23
VC0678222
p1187
sg10
I13
sg11
Vbreast cancer
p1188
sg13
I2
sa(dp1189
g7
I99
sg23
VC0027651
p1190
sg10
I5
sg11
Vtumor
p1191
sg13
I1
sasa(dp1192
g2
S'Estrogen reduced the expression of miR-26a and miR-26b in ER+ breast cancer cells.\n'
p1193
sg4
(lp1194
(dp1195
g7
I35
sg8
g18
sg10
I7
sg11
VmiR-26a
p1196
sg13
I1
sa(dp1197
g7
I47
sg8
g18
sg10
I7
sg11
VmiR-26b
p1198
sg13
I1
sasg20
(lp1199
(dp1200
g7
I62
sg23
VC0678222
p1201
sg10
I13
sg11
Vbreast cancer
p1202
sg13
I2
sasa(dp1203
g2
S'Forced expression of miR-26a or miR-26b significantly inhibited the estrogen stimulated growth of ER+ breast cancer cells and tumor growth in xenograft models, whereas miR-26a/b depletion increased the growth of ER+ breast cancer cells in the absence of estrogen treatment.\n'
p1204
sg4
(lp1205
(dp1206
g7
I32
sg8
g18
sg10
I7
sg11
VmiR-26b
p1207
sg13
I1
sa(dp1208
g7
I168
sg8
g18
sg10
I9
sg11
VmiR-26a/b
p1209
sg13
I1
sa(dp1210
g7
I21
sg8
g18
sg10
I7
sg11
VmiR-26a
p1211
sg13
I1
sasg20
(lp1212
(dp1213
g7
I126
sg23
VC0598934
p1214
sg10
I12
sg11
Vtumor growth
p1215
sg13
I2
sa(dp1216
g7
I102
sg23
VC0678222
p1217
sg10
I13
sg11
Vbreast cancer
p1218
sg13
I2
sa(dp1219
g7
I102
sg23
VC0678222
p1220
sg10
I13
sg11
Vbreast cancer
p1221
sg13
I2
sasa(dp1222
g2
S'The expression of microRNAs (miRs) that regulate (miR-29a, miR-29b, miR-29c, miR-148a and miR-148b) or are predicted to regulate DNMT3b (miR-26a, miR-26b, miR-203 and miR-222) were evaluated among 70 primary breast cancers (36 luminal A-like, 13 luminal B-like, 5 HER2-enriched, 16 basal-like) and 18 normal mammoplasty tissues.\n'
p1223
sg4
(lp1224
(dp1225
g7
I77
sg8
g18
sg10
I8
sg11
VmiR-148a
p1226
sg13
I1
sa(dp1227
g7
I146
sg8
g18
sg10
I7
sg11
VmiR-26b
p1228
sg13
I1
sa(dp1229
g7
I167
sg8
g18
sg10
I7
sg11
VmiR-222
p1230
sg13
I1
sa(dp1231
g7
I90
sg8
g18
sg10
I8
sg11
VmiR-148b
p1232
sg13
I1
sa(dp1233
g7
I264
sg8
VP04626
p1234
sg10
I4
sg11
VHER2
p1235
sg13
I1
sa(dp1236
g7
I155
sg8
g18
sg10
I7
sg11
VmiR-203
p1237
sg13
I1
sa(dp1238
g7
I137
sg8
g18
sg10
I7
sg11
VmiR-26a
p1239
sg13
I1
sa(dp1240
g7
I59
sg8
g18
sg10
I7
sg11
VmiR-29b
p1241
sg13
I1
sa(dp1242
g7
I129
sg8
g18
sg10
I6
sg11
VDNMT3b
p1243
sg13
I1
sa(dp1244
g7
I68
sg8
g18
sg10
I7
sg11
VmiR-29c
p1245
sg13
I1
sa(dp1246
g7
I50
sg8
g18
sg10
I7
sg11
VmiR-29a
p1247
sg13
I1
sasg20
(lp1248
(dp1249
g7
I208
sg23
VC0006142
p1250
sg10
I14
sg11
Vbreast cancers
p1251
sg13
I2
sasa(dp1252
g2
S'We report microRNAs that are differentially expressed between breast normal fibroblasts and CAFs of oestrogen receptor-positive cancers, and explore the influences of one of these, miR-26b, on breast cancer biology.\n'
p1253
sg4
(lp1254
(dp1255
g7
I100
sg8
VP03372
p1256
sg10
I18
sg11
Voestrogen receptor
p1257
sg13
I2
sa(dp1258
g7
I181
sg8
g18
sg10
I7
sg11
VmiR-26b
p1259
sg13
I1
sasg20
(lp1260
(dp1261
g7
I92
sg23
VC0795907
p1262
sg10
I4
sg11
VCAFs
p1263
sg13
I1
sa(dp1264
g7
I128
sg23
VC0006826
p1265
sg10
I7
sg11
Vcancers
p1266
sg13
I1
sa(dp1267
g7
I193
sg23
VC0678222
p1268
sg10
I13
sg11
Vbreast cancer
p1269
sg13
I2
sasa(dp1270
g2
S'Using qPCR, miR-26b was confirmed as down-regulated in fibroblasts from 15 of 18 further breast cancers.\n'
p1271
sg4
(lp1272
(dp1273
g7
I12
sg8
g18
sg10
I7
sg11
VmiR-26b
p1274
sg13
I1
sasg20
(lp1275
(dp1276
g7
I89
sg23
VC0006142
p1277
sg10
I14
sg11
Vbreast cancers
p1278
sg13
I2
sasa(dp1279
g2
S'Furthermore, in co-culture with MCF7 breast cancer epithelial cells, fibroblasts with reduced miR-26b expression enhanced both MCF7 migration in trans-well assays and MCF7 invasion from three-dimensional spheroids by up to five-fold.\n'
p1280
sg4
(lp1281
(dp1282
g7
I94
sg8
g18
sg10
I7
sg11
VmiR-26b
p1283
sg13
I1
sasg20
(lp1284
(dp1285
g7
I37
sg23
VC0678222
p1286
sg10
I13
sg11
Vbreast cancer
p1287
sg13
I2
sa(dp1288
g7
I172
sg23
VC2699153
p1289
sg10
I8
sg11
Vinvasion
p1290
sg13
I1
sasa(dp1291
g2
S'In addition, three novel miR-26b targets were identified (TNKS1BP1, CPSF7, COL12A1) and the expression of each in cancer stroma was shown to be significantly associated with breast cancer recurrence.\n'
p1292
sg4
(lp1293
(dp1294
g7
I58
sg8
g18
sg10
I8
sg11
VTNKS1BP1
p1295
sg13
I1
sa(dp1296
g7
I25
sg8
g18
sg10
I15
sg11
VmiR-26b targets
p1297
sg13
I2
sa(dp1298
g7
I68
sg8
g18
sg10
I5
sg11
VCPSF7
p1299
sg13
I1
sa(dp1300
g7
I75
sg8
g18
sg10
I7
sg11
VCOL12A1
p1301
sg13
I1
sasg20
(lp1302
(dp1303
g7
I181
sg23
VC0920420
p1304
sg10
I17
sg11
Vcancer recurrence
p1305
sg13
I2
sa(dp1306
g7
I114
sg23
VC0006826
p1307
sg10
I6
sg11
Vcancer
p1308
sg13
I1
sasa(dp1309
g2
S'Compared with 55 (33.3%) individuals in whom OSAS was not confirmed, OSAS patients had prolonged CLT (+12.8%), associated with higher PAI-1 antigen (+18.1%) (after adjustment for age, diabetes, and body mass index; both P &lt; 0.01) and similar levels of TAFIa, plasmin, or antiplasmin.\n'
p1310
sg4
(lp1311
(dp1312
g7
I134
sg8
VP05121
p1313
sg10
I13
sg11
VPAI-1 antigen
p1314
sg13
I2
sa(dp1315
g7
I262
sg8
VP00747
p1316
sg10
I7
sg11
Vplasmin
p1317
sg13
I1
sasg20
(lp1318
(dp1319
g7
I184
sg23
VC0011849
p1320
sg10
I8
sg11
Vdiabetes
p1321
sg13
I1
sa(dp1322
g7
I45
sg23
VC0520679
p1323
sg10
I4
sg11
VOSAS
p1324
sg13
I1
sa(dp1325
g7
I45
sg23
VC0520679
p1326
sg10
I4
sg11
VOSAS
p1327
sg13
I1
sasa(dp1328
g2
S'These factors include genetic polymorphisms in plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor, diabetes mellitus, metabolic syndrome, hyperglycemia, obesity, depression, binge alcohol consumption, anti-Parkinsonian medications, oral hormone therapy, pregnancy, and cancer.\n'
p1329
sg4
(lp1330
(dp1331
g7
I47
sg8
VP00747
p1332
sg10
I33
sg11
Vplasminogen activator inhibitor-1
p1333
sg13
I3
sa(dp1334
g7
I85
sg8
VP00734
p1335
sg10
I8
sg11
Vthrombin
p1336
sg13
I1
sasg20
(lp1337
(dp1338
g7
I169
sg23
VC0020456
p1339
sg10
I13
sg11
Vhyperglycemia
p1340
sg13
I1
sa(dp1341
g7
I193
sg23
VC0011581
p1342
sg10
I10
sg11
Vdepression
p1343
sg13
I1
sa(dp1344
g7
I205
sg23
VC0596170
p1345
sg10
I5
sg11
Vbinge
p1346
sg13
I1
sa(dp1347
g7
I184
sg23
VC0028754
p1348
sg10
I7
sg11
Vobesity
p1349
sg13
I1
sa(dp1350
g7
I130
sg23
VC0011849
p1351
sg10
I17
sg11
Vdiabetes mellitus
p1352
sg13
I2
sa(dp1353
g7
I300
sg23
VC0006826
p1354
sg10
I6
sg11
Vcancer
p1355
sg13
I1
sa(dp1356
g7
I149
sg23
VC0524620
p1357
sg10
I18
sg11
Vmetabolic syndrome
p1358
sg13
I2
sasa(dp1359
g2
S'An important inhibitor of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), participates in hypofibrinolysis in diabetes mellitus and may be involved in diabetic macrovascular disease.\n'
p1360
sg4
(lp1361
(dp1362
g7
I85
sg8
VP15169
p1363
sg10
I4
sg11
VTAFI
p1364
sg13
I1
sa(dp1365
g7
I40
sg8
VP15169
p1366
sg10
I43
sg11
Vthrombin-activatable fibrinolysis inhibitor
p1367
sg13
I3
sasg20
(lp1368
(dp1369
g7
I128
sg23
VC0011849
p1370
sg10
I17
sg11
Vdiabetes mellitus
p1371
sg13
I2
sa(dp1372
g7
I178
sg23
VC2609253
p1373
sg10
I21
sg11
Vmacrovascular disease
p1374
sg13
I2
sasa(dp1375
g2
S'The present study was designed to determine whether TAFI polymorphisms (505G/A and 1040C/T) and TAFI levels are correlated with the development of type 2 diabetes mellitus (T2DM) and macrovascular diseases (MVDs).\n'
p1376
sg4
(lp1377
(dp1378
g7
I52
sg8
VP15169
p1379
sg10
I4
sg11
VTAFI
p1380
sg13
I1
sa(dp1381
g7
I52
sg8
VP15169
p1382
sg10
I4
sg11
VTAFI
p1383
sg13
I1
sasg20
(lp1384
(dp1385
g7
I173
sg23
VC0011860
p1386
sg10
I4
sg11
VT2DM
p1387
sg13
I1
sa(dp1388
g7
I147
sg23
VC0011860
p1389
sg10
I24
sg11
Vtype 2 diabetes mellitus
p1390
sg13
I4
sasa(dp1391
g2
S'This study was designed to investigate the association between TAFI levels in relation to metabolic control, microvascular complications and lipid profile in a cohort of Egyptian children and adolescents with type 1 diabetes mellitus (T1DM).\n'
p1392
sg4
(lp1393
(dp1394
g7
I63
sg8
VP15169
p1395
sg10
I4
sg11
VTAFI
p1396
sg13
I1
sasg20
(lp1397
(dp1398
g7
I235
sg23
VC0011854
p1399
sg10
I4
sg11
VT1DM
p1400
sg13
I1
sa(dp1401
g7
I209
sg23
VC0011854
p1402
sg10
I24
sg11
Vtype 1 diabetes mellitus
p1403
sg13
I4
sasa(dp1404
g2
S'This suggests the possibility of TAFI participating in the mechanism of hypofibrinolysis, hence occurrence of microvascular complications in diabetes.\n'
p1405
sg4
(lp1406
(dp1407
g7
I33
sg8
VP15169
p1408
sg10
I4
sg11
VTAFI
p1409
sg13
I1
sasg20
(lp1410
(dp1411
g7
I141
sg23
VC0011849
p1412
sg10
I8
sg11
Vdiabetes
p1413
sg13
I1
sasa(dp1414
g2
S'We aimed to investigate TAFI in type 2 diabetes mellitus patients with MetS.\n'
p1415
sg4
(lp1416
(dp1417
g7
I71
sg8
VP41162
p1418
sg10
I4
sg11
VMetS
p1419
sg13
I1
sa(dp1420
g7
I24
sg8
VP15169
p1421
sg10
I4
sg11
VTAFI
p1422
sg13
I1
sasg20
(lp1423
(dp1424
g7
I32
sg23
VC0011860
p1425
sg10
I24
sg11
Vtype 2 diabetes mellitus
p1426
sg13
I4
sasa(dp1427
g2
S"In this study we aimed to assess the circulating levels of TAFI antigen, 'a fibrinolytic parameter' in women with gestational diabetes (GDM).\n"
p1428
sg4
(lp1429
(dp1430
g7
I59
sg8
VP15169
p1431
sg10
I4
sg11
VTAFI
p1432
sg13
I1
sasg20
(lp1433
(dp1434
g7
I114
sg23
VC0085207
p1435
sg10
I20
sg11
Vgestational diabetes
p1436
sg13
I2
sa(dp1437
g7
I136
sg23
VC0085207
p1438
sg10
I3
sg11
VGDM
p1439
sg13
I1
sasa(dp1440
g2
S'We studied the clinical effects of percutaneous radiofrequency ablation (RFCA) combined with trans-catheter arterial chemoembolization (TACE) in the treatment of breast cancer with liver metastasis.\n'
p1441
sg4
(lp1442
sg20
(lp1443
(dp1444
g7
I162
sg23
VC0678222
p1445
sg10
I13
sg11
Vbreast cancer
p1446
sg13
I2
sa(dp1447
g7
I181
sg23
VC0494165
p1448
sg10
I16
sg11
Vliver metastasis
p1449
sg13
I2
sasa(dp1450
g2
S'Therefore, RFCA combined with TACE in the treatment of breast cancer with liver metastasis is safe and effective.\n'
p1451
sg4
(lp1452
sg20
(lp1453
(dp1454
g7
I74
sg23
VC0494165
p1455
sg10
I16
sg11
Vliver metastasis
p1456
sg13
I2
sa(dp1457
g7
I55
sg23
VC0678222
p1458
sg10
I13
sg11
Vbreast cancer
p1459
sg13
I2
sasa(dp1460
g2
S'There is limited data on the impact of transarterial chemoembolisation (TACE) on survival in patients of breast cancer with liver metastasis (BCLM).\n'
p1461
sg4
(lp1462
sg20
(lp1463
(dp1464
g7
I105
sg23
VC0678222
p1465
sg10
I13
sg11
Vbreast cancer
p1466
sg13
I2
sa(dp1467
g7
I124
sg23
VC0494165
p1468
sg10
I16
sg11
Vliver metastasis
p1469
sg13
I2
sasa(dp1470
g2
S'The identification of specific effects of these endocrine disruptors on ADAM10 and ADAM17 will help to provide a better understanding of their roles in cell signaling and proinflammatory processes, and provide new potential targets for treatment of reproductive or inflammatory diseases such as asthma or breast cancer that are promoted by xenoestrogens.\n'
p1471
sg4
(lp1472
(dp1473
g7
I72
sg8
g18
sg10
I6
sg11
VADAM10
p1474
sg13
I1
sa(dp1475
g7
I83
sg8
VP78536
p1476
sg10
I6
sg11
VADAM17
p1477
sg13
I1
sasg20
(lp1478
(dp1479
g7
I295
sg23
VC0004096
p1480
sg10
I6
sg11
Vasthma
p1481
sg13
I1
sa(dp1482
g7
I305
sg23
VC0678222
p1483
sg10
I13
sg11
Vbreast cancer
p1484
sg13
I2
sasa(dp1485
g2
S'ADAM10 and ADAM17 have been shown to contribute to the acquired drug resistance of HER2-positive breast cancer in response to trastuzumab.\n'
p1486
sg4
(lp1487
(dp1488
g7
I0
sg8
g18
sg10
I6
sg11
VADAM10
p1489
sg13
I1
sa(dp1490
g7
I11
sg8
VP78536
p1491
sg10
I6
sg11
VADAM17
p1492
sg13
I1
sa(dp1493
g7
I83
sg8
VP04626
p1494
sg10
I4
sg11
VHER2
p1495
sg13
I1
sasg20
(lp1496
(dp1497
g7
I97
sg23
VC0678222
p1498
sg10
I13
sg11
Vbreast cancer
p1499
sg13
I2
sasa(dp1500
g2
S'The ADAM (adisintegrin and metalloproteinase) proteases are involved in ectodomain cleavage of transmembrane proteins, and ADAM17 is known to cleave Nectin-4 in breast cancer.\n'
p1501
sg4
(lp1502
(dp1503
g7
I149
sg8
g18
sg10
I8
sg11
VNectin-4
p1504
sg13
I1
sa(dp1505
g7
I123
sg8
VP78536
p1506
sg10
I6
sg11
VADAM17
p1507
sg13
I1
sa(dp1508
g7
I10
sg8
VP52888
p1509
sg10
I34
sg11
Vadisintegrin and metalloproteinase
p1510
sg13
I3
sa(dp1511
g7
I4
sg8
VP52888
p1512
sg10
I4
sg11
VADAM
p1513
sg13
I1
sasg20
(lp1514
(dp1515
g7
I161
sg23
VC0678222
p1516
sg10
I13
sg11
Vbreast cancer
p1517
sg13
I2
sasa(dp1518
g2
S'Here we report for the first time that DATS inhibits the expression of ADAM10 and ADAM17 in estrogen-independent MDA-MB-231 and estrogen-dependent MCF-7 breast cancer cells, and in Harvey-ras (H-Ras) transformed MCF10A-H-Ras breast epithelial cells.\n'
p1519
sg4
(lp1520
(dp1521
g7
I181
sg8
VP01112
p1522
sg10
I10
sg11
VHarvey-ras
p1523
sg13
I1
sa(dp1524
g7
I212
sg8
VP01112
p1525
sg10
I12
sg11
VMCF10A-H-Ras
p1526
sg13
I1
sa(dp1527
g7
I82
sg8
VP78536
p1528
sg10
I6
sg11
VADAM17
p1529
sg13
I1
sa(dp1530
g7
I193
sg8
VP01112
p1531
sg10
I5
sg11
VH-Ras
p1532
sg13
I1
sa(dp1533
g7
I71
sg8
g18
sg10
I6
sg11
VADAM10
p1534
sg13
I1
sasg20
(lp1535
(dp1536
g7
I39
sg23
VC0002395
p1537
sg10
I4
sg11
VDATS
p1538
sg13
I1
sa(dp1539
g7
I153
sg23
VC0678222
p1540
sg10
I13
sg11
Vbreast cancer
p1541
sg13
I2
sasa(dp1542
g2
S'As described here, we demonstrate that the cell surface protease a disintegrin and metalloproteinase 17 (ADAM17) is expressed by macrophages in mammary tumors and contributes to regulating the expression of pro-inflammatory mediators, including inflammatory cytokines and the inflammatory mediator cyclooxygenase-2 (Cox-2).\n'
p1543
sg4
(lp1544
(dp1545
g7
I316
sg8
VP35354
p1546
sg10
I5
sg11
VCox-2
p1547
sg13
I1
sa(dp1548
g7
I289
sg8
VP35354
p1549
sg10
I25
sg11
Vmediator cyclooxygenase-2
p1550
sg13
I2
sa(dp1551
g7
I105
sg8
VP78536
p1552
sg10
I6
sg11
VADAM17
p1553
sg13
I1
sa(dp1554
g7
I65
sg8
VP78536
p1555
sg10
I38
sg11
Va disintegrin and metalloproteinase 17
p1556
sg13
I5
sasg20
(lp1557
(dp1558
g7
I144
sg23
VC0024667
p1559
sg10
I14
sg11
Vmammary tumors
p1560
sg13
I2
sasa(dp1561
g2
S'Furthermore, we demonstrate that ADAM17 is expressed on leukocytes, including macrophages, within polyoma middle T (PyMT)-derived mammary tumors.\n'
p1562
sg4
(lp1563
(dp1564
g7
I33
sg8
VP78536
p1565
sg10
I6
sg11
VADAM17
p1566
sg13
I1
sasg20
(lp1567
(dp1568
g7
I130
sg23
VC0024667
p1569
sg10
I14
sg11
Vmammary tumors
p1570
sg13
I2
sasa(dp1571
g2
S'Genetic deletion of ADAM17 in leukocytes resulted in decreased onset of mammary tumor growth, which was associated with reduced expression of the Cox-2 within the tumor.\n'
p1572
sg4
(lp1573
(dp1574
g7
I20
sg8
VP78536
p1575
sg10
I6
sg11
VADAM17
p1576
sg13
I1
sa(dp1577
g7
I146
sg8
VP35354
p1578
sg10
I5
sg11
VCox-2
p1579
sg13
I1
sasg20
(lp1580
(dp1581
g7
I80
sg23
VC0027651
p1582
sg10
I5
sg11
Vtumor
p1583
sg13
I1
sa(dp1584
g7
I72
sg23
VC1458155
p1585
sg10
I13
sg11
Vmammary tumor
p1586
sg13
I2
sasa(dp1587
g2
S'These findings demonstrate that ADAM17 regulates key inflammatory mediators in macrophages and that leukocyte-specific ADAM17 is an important promoter of mammary tumor initiation.\n'
p1588
sg4
(lp1589
(dp1590
g7
I32
sg8
VP78536
p1591
sg10
I6
sg11
VADAM17
p1592
sg13
I1
sa(dp1593
g7
I32
sg8
VP78536
p1594
sg10
I6
sg11
VADAM17
p1595
sg13
I1
sasg20
(lp1596
(dp1597
g7
I162
sg23
VC0598935
p1598
sg10
I16
sg11
Vtumor initiation
p1599
sg13
I2
sasa(dp1600
g2
S'Substantial evidence has demonstrated that an obvious increased in ADAM17 cell surface expression has been discovered in breast cancer and was shown to be associated with mammary tumorigenesis, invasiveness, and drug resistance.\n'
p1601
sg4
(lp1602
(dp1603
g7
I67
sg8
VP78536
p1604
sg10
I19
sg11
VADAM17 cell surface
p1605
sg13
I3
sasg20
(lp1606
(dp1607
g7
I121
sg23
VC0678222
p1608
sg10
I13
sg11
Vbreast cancer
p1609
sg13
I2
sa(dp1610
g7
I171
sg23
VC1512981
p1611
sg10
I21
sg11
Vmammary tumorigenesis
p1612
sg13
I2
sasa(dp1613
g2
S'Over the last decades, it has received more than its share of attention that ADAM17 plays a potential role in breast cancer, including cell proliferation, invasion, angiogenesis, apoptosis, and trastuzumab resistance.\n'
p1614
sg4
(lp1615
(dp1616
g7
I77
sg8
VP78536
p1617
sg10
I6
sg11
VADAM17
p1618
sg13
I1
sasg20
(lp1619
(dp1620
g7
I155
sg23
VC2699153
p1621
sg10
I8
sg11
Vinvasion
p1622
sg13
I1
sa(dp1623
g7
I140
sg23
VC0334094
p1624
sg10
I13
sg11
Vproliferation
p1625
sg13
I1
sa(dp1626
g7
I110
sg23
VC0678222
p1627
sg10
I13
sg11
Vbreast cancer
p1628
sg13
I2
sasa(dp1629
g2
S'In our review, we discuss the mechanisms through which ADAM17 acts on breast cancer tumorigenesis and progression.\n'
p1630
sg4
(lp1631
(dp1632
g7
I55
sg8
VP78536
p1633
sg10
I6
sg11
VADAM17
p1634
sg13
I1
sasg20
(lp1635
(dp1636
g7
I84
sg23
VC0007621
p1637
sg10
I13
sg11
Vtumorigenesis
p1638
sg13
I1
sa(dp1639
g7
I70
sg23
VC0678222
p1640
sg10
I13
sg11
Vbreast cancer
p1641
sg13
I2
sasa(dp1642
g2
S'Thus, this will provide further impetus for exploiting ADAM17 as a new target for breast cancer treatment.\n'
p1643
sg4
(lp1644
(dp1645
g7
I55
sg8
VP78536
p1646
sg10
I6
sg11
VADAM17
p1647
sg13
I1
sasg20
(lp1648
(dp1649
g7
I82
sg23
VC0678222
p1650
sg10
I13
sg11
Vbreast cancer
p1651
sg13
I2
sasa(dp1652
g2
S'We investigated the ability of Abs blocking Tim-1 or Tim-3 ligand-binding activity to prevent and treat murine experimental allergic conjunctivitis (EC), a Th2-mediated disease.\n'
p1653
sg4
(lp1654
(dp1655
g7
I44
sg8
VP60174
p1656
sg10
I5
sg11
VTim-1
p1657
sg13
I1
sasg20
(lp1658
(dp1659
g7
I35
sg23
VC0233660
p1660
sg10
I8
sg11
Vblocking
p1661
sg13
I1
sa(dp1662
g7
I124
sg23
VC0009766
p1663
sg10
I23
sg11
Vallergic conjunctivitis
p1664
sg13
I2
sasa(dp1665
g2
S'Thus, treatment with anti-Tim-1 or anti-Tim-3 Ab can suppress both the induction and progression of EC, which could indicate potential preventive and/or therapeutic approaches for allergic diseases such as allergic conjunctivitis.\n'
p1666
sg4
(lp1667
(dp1668
g7
I35
sg8
VP60174
p1669
sg10
I13
sg11
Vanti-Tim-3 Ab
p1670
sg13
I2
sa(dp1671
g7
I21
sg8
VP60174
p1672
sg10
I10
sg11
Vanti-Tim-1
p1673
sg13
I1
sasg20
(lp1674
(dp1675
g7
I206
sg23
VC0009766
p1676
sg10
I23
sg11
Vallergic conjunctivitis
p1677
sg13
I2
sasa(dp1678
g2
S'In sum, the crucial role of MEK2 in MDA-MB-231 cell viability and the unknown relationship between MEK2 and MKK3/MKK6-p38 axis here revealed may open new therapeutic strategies for aggressive breast cancer.\n'
p1679
sg4
(lp1680
(dp1681
g7
I118
sg8
VP46108
p1682
sg10
I3
sg11
Vp38
p1683
sg13
I1
sa(dp1684
g7
I113
sg8
VP52564
p1685
sg10
I4
sg11
VMKK6
p1686
sg13
I1
sa(dp1687
g7
I108
sg8
VP46734
p1688
sg10
I4
sg11
VMKK3
p1689
sg13
I1
sa(dp1690
g7
I28
sg8
VP36507
p1691
sg10
I4
sg11
VMEK2
p1692
sg13
I1
sa(dp1693
g7
I28
sg8
VP36507
p1694
sg10
I4
sg11
VMEK2
p1695
sg13
I1
sasg20
(lp1696
(dp1697
g7
I181
sg23
VC0001807
p1698
sg10
I10
sg11
Vaggressive
p1699
sg13
I1
sa(dp1700
g7
I192
sg23
VC0678222
p1701
sg10
I13
sg11
Vbreast cancer
p1702
sg13
I2
sasa(dp1703
g2
S'Mitogen-activated protein kinase kinase 3 (MKK3), has been reported as a novel tumor suppressor in breast cancer.\n'
p1704
sg4
(lp1705
(dp1706
g7
I0
sg8
VP46734
p1707
sg10
I41
sg11
VMitogen-activated protein kinase kinase 3
p1708
sg13
I5
sa(dp1709
g7
I43
sg8
VP46734
p1710
sg10
I4
sg11
VMKK3
p1711
sg13
I1
sasg20
(lp1712
(dp1713
g7
I79
sg23
VC0027651
p1714
sg10
I5
sg11
Vtumor
p1715
sg13
I1
sa(dp1716
g7
I99
sg23
VC0678222
p1717
sg10
I13
sg11
Vbreast cancer
p1718
sg13
I2
sasa(dp1719
g2
S'Here, we show that the mitogen-activated protein kinase (MAPK) MKK3 suppresses the growth of breast cancer, in which it varies in copy number.\n'
p1720
sg4
(lp1721
(dp1722
g7
I63
sg8
VP46734
p1723
sg10
I4
sg11
VMKK3
p1724
sg13
I1
sa(dp1725
g7
I57
sg8
VP53779
p1726
sg10
I4
sg11
VMAPK
p1727
sg13
I1
sa(dp1728
g7
I23
sg8
VP53779
p1729
sg10
I32
sg11
Vmitogen-activated protein kinase
p1730
sg13
I3
sasg20
(lp1731
(dp1732
g7
I93
sg23
VC0678222
p1733
sg10
I13
sg11
Vbreast cancer
p1734
sg13
I2
sasa(dp1735
g2
S'A pervasive loss of MKK3 gene copy number in patients with breast cancer is associated with an impairment of MKK3 expression and protein level in malignant tissues.\n'
p1736
sg4
(lp1737
(dp1738
g7
I20
sg8
VP46734
p1739
sg10
I9
sg11
VMKK3 gene
p1740
sg13
I2
sa(dp1741
g7
I20
sg8
VP46734
p1742
sg10
I4
sg11
VMKK3
p1743
sg13
I1
sasg20
(lp1744
(dp1745
g7
I59
sg23
VC0678222
p1746
sg10
I13
sg11
Vbreast cancer
p1747
sg13
I2
sa(dp1748
g7
I95
sg23
VC0684336
p1749
sg10
I10
sg11
Vimpairment
p1750
sg13
I1
sasa(dp1751
g2
S'To assess the functional role of MKK3 in breast cancer, we showed in an animal model that MKK3 activity is required for suppression of tumor growth.\n'
p1752
sg4
(lp1753
(dp1754
g7
I33
sg8
VP46734
p1755
sg10
I4
sg11
VMKK3
p1756
sg13
I1
sa(dp1757
g7
I33
sg8
VP46734
p1758
sg10
I4
sg11
VMKK3
p1759
sg13
I1
sasg20
(lp1760
(dp1761
g7
I120
sg23
VC0221103
p1762
sg10
I11
sg11
Vsuppression
p1763
sg13
I1
sa(dp1764
g7
I41
sg23
VC0678222
p1765
sg10
I13
sg11
Vbreast cancer
p1766
sg13
I2
sa(dp1767
g7
I135
sg23
VC0598934
p1768
sg10
I12
sg11
Vtumor growth
p1769
sg13
I2
sasa(dp1770
g2
S'This study aimed to elucidate the expression of MerTK and AxlTK on glomeruli and analyze their clinical significance in lupus nephritis (LN) patients.\n'
p1771
sg4
(lp1772
(dp1773
g7
I48
sg8
g18
sg10
I5
sg11
VMerTK
p1774
sg13
I1
sasg20
(lp1775
(dp1776
g7
I137
sg23
VC0024143
p1777
sg10
I2
sg11
VLN
p1778
sg13
I1
sa(dp1779
g7
I120
sg23
VC0024143
p1780
sg10
I15
sg11
Vlupus nephritis
p1781
sg13
I2
sasa(dp1782
g2
S'To investigate the distinct functions of Axl and Mer in lupus nephritis, we compared the severity of nephrotoxic serum glomerulonephritis in wild-type (WT), Axl-knockout (KO), Mer-KO, and Axl/Mer-KO mice.\n'
p1783
sg4
(lp1784
(dp1785
g7
I49
sg8
VP29973
p1786
sg10
I3
sg11
VMer
p1787
sg13
I1
sa(dp1788
g7
I41
sg8
VP30530
p1789
sg10
I3
sg11
VAxl
p1790
sg13
I1
sa(dp1791
g7
I41
sg8
VP30530
p1792
sg10
I3
sg11
VAxl
p1793
sg13
I1
sa(dp1794
g7
I176
sg8
VP29973
p1795
sg10
I6
sg11
VMer-KO
p1796
sg13
I1
sa(dp1797
g7
I49
sg8
VP29973
p1798
sg10
I3
sg11
VMer
p1799
sg13
I1
sa(dp1800
g7
I41
sg8
VP30530
p1801
sg10
I3
sg11
VAxl
p1802
sg13
I1
sasg20
(lp1803
(dp1804
g7
I56
sg23
VC0024143
p1805
sg10
I15
sg11
Vlupus nephritis
p1806
sg13
I2
sa(dp1807
g7
I119
sg23
VC0017658
p1808
sg10
I18
sg11
Vglomerulonephritis
p1809
sg13
I1
sasa(dp1810
g2
S'Whereas AXL, ferritin, and sTNFRII were significantly elevated in patients with active lupus nephritis (LN) relative to SLE patients who were quiescent, other molecules such as OPN, sTNFRI, sTNFRII, IGFBP2, SIGLEC5, FAS, and MMP10 exhibited the capacity to distinguish SLE from healthy controls with ROC AUC exceeding 90%, all with p &lt; 0.001 significance.\n'
p1811
sg4
(lp1812
(dp1813
g7
I13
sg8
VP02794
p1814
sg10
I8
sg11
Vferritin
p1815
sg13
I1
sa(dp1816
g7
I225
sg8
VP09238
p1817
sg10
I5
sg11
VMMP10
p1818
sg13
I1
sa(dp1819
g7
I207
sg8
g18
sg10
I7
sg11
VSIGLEC5
p1820
sg13
I1
sa(dp1821
g7
I177
sg8
VP10451
p1822
sg10
I3
sg11
VOPN
p1823
sg13
I1
sa(dp1824
g7
I216
sg8
VP48023
p1825
sg10
I3
sg11
VFAS
p1826
sg13
I1
sa(dp1827
g7
I199
sg8
VP18065
p1828
sg10
I6
sg11
VIGFBP2
p1829
sg13
I1
sa(dp1830
g7
I8
sg8
VP30530
p1831
sg10
I3
sg11
VAXL
p1832
sg13
I1
sasg20
(lp1833
(dp1834
g7
I120
sg23
VC0014060
p1835
sg10
I3
sg11
VSLE
p1836
sg13
I1
sa(dp1837
g7
I120
sg23
VC0014060
p1838
sg10
I3
sg11
VSLE
p1839
sg13
I1
sa(dp1840
g7
I87
sg23
VC0024143
p1841
sg10
I15
sg11
Vlupus nephritis
p1842
sg13
I2
sa(dp1843
g7
I104
sg23
VC0024143
p1844
sg10
I2
sg11
VLN
p1845
sg13
I1
sa(dp1846
g7
I216
sg23
VC0015923
p1847
sg10
I3
sg11
VFAS
p1848
sg13
I1
sasa(dp1849
g2
S'The specificity of Axl and IGFBP-2 for concurrent active lupus nephritis was higher than anti-dsDNA or C3.\n'
p1850
sg4
(lp1851
(dp1852
g7
I27
sg8
VP18065
p1853
sg10
I7
sg11
VIGFBP-2
p1854
sg13
I1
sa(dp1855
g7
I19
sg8
VP30530
p1856
sg10
I3
sg11
VAxl
p1857
sg13
I1
sasg20
(lp1858
(dp1859
g7
I57
sg23
VC0024143
p1860
sg10
I15
sg11
Vlupus nephritis
p1861
sg13
I2
sasa(dp1862
g2
S'The performance of Axl and IGFBP-2 in lupus nephritis should be further explored in a longitudinal cohort of SLE patients.\n'
p1863
sg4
(lp1864
(dp1865
g7
I27
sg8
VP18065
p1866
sg10
I7
sg11
VIGFBP-2
p1867
sg13
I1
sa(dp1868
g7
I19
sg8
VP30530
p1869
sg10
I3
sg11
VAxl
p1870
sg13
I1
sasg20
(lp1871
(dp1872
g7
I109
sg23
VC0014060
p1873
sg10
I3
sg11
VSLE
p1874
sg13
I1
sa(dp1875
g7
I38
sg23
VC0024143
p1876
sg10
I15
sg11
Vlupus nephritis
p1877
sg13
I2
sasa(dp1878
g2
S'Dysfunction of the microRNA (miRNA)-processing enzyme DICER1 and Alu RNA accumulation are linked to the pathogenesis of age-related macular degeneration (AMD).\n'
p1879
sg4
(lp1880
(dp1881
g7
I54
sg8
g18
sg10
I6
sg11
VDICER1
p1882
sg13
I1
sasg20
(lp1883
(dp1884
g7
I120
sg23
VC0242383
p1885
sg10
I32
sg11
Vage-related macular degeneration
p1886
sg13
I3
sa(dp1887
g7
I104
sg23
VC0699748
p1888
sg10
I12
sg11
Vpathogenesis
p1889
sg13
I1
sa(dp1890
g7
I154
sg23
VC0242383
p1891
sg10
I3
sg11
VAMD
p1892
sg13
I1
sasa(dp1893
g2
S'DICER1 was recently shown to have another function of silencing the toxicity of Alu RNAs in retinal pigment epithelium (RPE) cells, which are involved in the pathogenesis of age related macular degeneration.\n'
p1894
sg4
(lp1895
(dp1896
g7
I0
sg8
g18
sg10
I6
sg11
VDICER1
p1897
sg13
I1
sasg20
(lp1898
(dp1899
g7
I158
sg23
VC0699748
p1900
sg10
I12
sg11
Vpathogenesis
p1901
sg13
I1
sa(dp1902
g7
I174
sg23
VC0242383
p1903
sg10
I32
sg11
Vage related macular degeneration
p1904
sg13
I4
sasa(dp1905
g2
S'Regarding medulloepithelioma, we have learned of the common associated features of neovascular glaucoma, retrolenticular neoplastic or vascular cyclitic membrane, intralesional cysts, response to radiotherapy, and association with Dicer-1 mutation.\n'
p1906
sg4
(lp1907
sg20
(lp1908
(dp1909
g7
I83
sg23
VC0017609
p1910
sg10
I20
sg11
Vneovascular glaucoma
p1911
sg13
I2
sa(dp1912
g7
I144
sg23
VC0948286
p1913
sg10
I17
sg11
Vcyclitic membrane
p1914
sg13
I2
sa(dp1915
g7
I177
sg23
VC0010709
p1916
sg10
I5
sg11
Vcysts
p1917
sg13
I1
sa(dp1918
g7
I10
sg23
VC0334596
p1919
sg10
I18
sg11
Vmedulloepithelioma
p1920
sg13
I1
sasa(dp1921
g2
S'Loss of FlnA and Fmn2 impairs proliferation, thereby generating multiple embryonic phenotypes, including microcephaly.\n'
p1922
sg4
(lp1923
(dp1924
g7
I17
sg8
g18
sg10
I4
sg11
VFmn2
p1925
sg13
I1
sa(dp1926
g7
I8
sg8
VP21333
p1927
sg10
I4
sg11
VFlnA
p1928
sg13
I1
sasg20
(lp1929
(dp1930
g7
I30
sg23
VC0334094
p1931
sg10
I13
sg11
Vproliferation
p1932
sg13
I1
sa(dp1933
g7
I105
sg23
VC0025958
p1934
sg10
I12
sg11
Vmicrocephaly
p1935
sg13
I1
sasa(dp1936
g2
S'Human disorders involving the actin-binding Filamin A (FLNA) and vesicle trafficking Brefeldin-associated guanine exchange factor 2 (BIG2 is encoded by the ARFGEF2 gene) proteins are implicated in these various developmental processes, resulting in a malformation of cortical development called periventricular heterotopia (nodules along the ventricular lining) and microcephaly (small brain).\n'
p1937
sg4
(lp1938
(dp1939
g7
I133
sg8
g18
sg10
I4
sg11
VBIG2
p1940
sg13
I1
sa(dp1941
g7
I156
sg8
g18
sg10
I12
sg11
VARFGEF2 gene
p1942
sg13
I2
sa(dp1943
g7
I30
sg8
VP21333
p1944
sg10
I23
sg11
Vactin-binding Filamin A
p1945
sg13
I3
sa(dp1946
g7
I55
sg8
VP21333
p1947
sg10
I4
sg11
VFLNA
p1948
sg13
I1
sa(dp1949
g7
I85
sg8
g18
sg10
I46
sg11
VBrefeldin-associated guanine exchange factor 2
p1950
sg13
I5
sasg20
(lp1951
(dp1952
g7
I366
sg23
VC0025958
p1953
sg10
I12
sg11
Vmicrocephaly
p1954
sg13
I1
sa(dp1955
g7
I65
sg23
VC0333262
p1956
sg10
I7
sg11
Vvesicle
p1957
sg13
I1
sa(dp1958
g7
I324
sg23
VC0028259
p1959
sg10
I7
sg11
Vnodules
p1960
sg13
I1
sa(dp1961
g7
I295
sg23
VC2678104
p1962
sg10
I27
sg11
Vperiventricular heterotopia
p1963
sg13
I2
sa(dp1964
g7
I251
sg23
VC0000768
p1965
sg10
I12
sg11
Vmalformation
p1966
sg13
I1
sasa(dp1967
g2
S'The presence of periventricular heterotopia, acquired microcephaly and suspected recessive inheritance led to mutation analysis of ARFGEF2 in two affected siblings and their healthy consanguineous parents, after mutations in FLNA had been ruled out.\n'
p1968
sg4
(lp1969
(dp1970
g7
I225
sg8
VP21333
p1971
sg10
I4
sg11
VFLNA
p1972
sg13
I1
sa(dp1973
g7
I131
sg8
g18
sg10
I7
sg11
VARFGEF2
p1974
sg13
I1
sasg20
(lp1975
(dp1976
g7
I54
sg23
VC0025958
p1977
sg10
I12
sg11
Vmicrocephaly
p1978
sg13
I1
sa(dp1979
g7
I16
sg23
VC2678104
p1980
sg10
I27
sg11
Vperiventricular heterotopia
p1981
sg13
I2
sasa(dp1982
g2
S'Mutations in FLNA (Xq28) and ARFGEF2 (20q13) are responsible for X-linked bilateral PH and a rare autosomal recessive form of PH with microcephaly.\n'
p1983
sg4
(lp1984
sg20
(lp1985
(dp1986
g7
I134
sg23
VC0025958
p1987
sg10
I12
sg11
Vmicrocephaly
p1988
sg13
I1
sasa(dp1989
g2
S'Within an analysis cohort of 532 samples, the following were classified correctly: 89 of 89 trisomy 21 cases (sensitivity 100%, 95% [confidence interval] CI 95.9-100), 35 of 36 trisomy 18 cases (sensitivity 97.2%, 95% CI 85.5-99.9), 11 of 14 trisomy 13 cases (sensitivity 78.6%, 95% CI 49.2-95.3), [corrected] 232 of 233 females (sensitivity 99.6%, 95% CI 97.6 to more than 99.9), 184 of 184 males (sensitivity 100%, 95% CI 98.0-100), and 15 of 16 monosomy X cases (sensitivity 93.8%, 95% CI 69.8-99.8).\n'
p1990
sg4
(lp1991
sg20
(lp1992
(dp1993
g7
I92
sg23
VC0013080
p1994
sg10
I10
sg11
Vtrisomy 21
p1995
sg13
I2
sa(dp1996
g7
I177
sg23
VC0152096
p1997
sg10
I10
sg11
Vtrisomy 18
p1998
sg13
I2
sa(dp1999
g7
I242
sg23
VC0152095
p2000
sg10
I10
sg11
Vtrisomy 13
p2001
sg13
I2
sa(dp2002
g7
I448
sg23
VC0041408
p2003
sg10
I10
sg11
Vmonosomy X
p2004
sg13
I2
sasa(dp2005
g2
S'Because HuMIF is reported to be elevated in prostate cancer and inflammation plays an important role in the initiation and progression of cancers, we have explored a role for TvMIF in prostate cancer.\n'
p2006
sg4
(lp2007
sg20
(lp2008
(dp2009
g7
I138
sg23
VC0006826
p2010
sg10
I7
sg11
Vcancers
p2011
sg13
I1
sa(dp2012
g7
I44
sg23
VC0600139
p2013
sg10
I15
sg11
Vprostate cancer
p2014
sg13
I2
sa(dp2015
g7
I64
sg23
VC0021368
p2016
sg10
I12
sg11
Vinflammation
p2017
sg13
I1
sa(dp2018
g7
I44
sg23
VC0600139
p2019
sg10
I15
sg11
Vprostate cancer
p2020
sg13
I2
sasa(dp2021
g2
S'TvMIF increases the in vitro growth and invasion through Matrigel of benign and prostate cancer cells.\n'
p2022
sg4
(lp2023
sg20
(lp2024
(dp2025
g7
I40
sg23
VC2699153
p2026
sg10
I8
sg11
Vinvasion
p2027
sg13
I1
sa(dp2028
g7
I80
sg23
VC0600139
p2029
sg10
I15
sg11
Vprostate cancer
p2030
sg13
I2
sasa(dp2031
g2
S'Together, these data indicate that chronic T. vaginalis infections may result in TvMIF-driven inflammation and cell proliferation, thus triggering pathways that contribute to the promotion and progression of prostate cancer.\n'
p2032
sg4
(lp2033
sg20
(lp2034
(dp2035
g7
I46
sg23
VC0750103
p2036
sg10
I9
sg11
Vvaginalis
p2037
sg13
I1
sa(dp2038
g7
I116
sg23
VC0334094
p2039
sg10
I13
sg11
Vproliferation
p2040
sg13
I1
sa(dp2041
g7
I193
sg23
VC1739135
p2042
sg10
I30
sg11
Vprogression of prostate cancer
p2043
sg13
I4
sa(dp2044
g7
I56
sg23
VC0021311
p2045
sg10
I10
sg11
Vinfections
p2046
sg13
I1
sa(dp2047
g7
I94
sg23
VC0021368
p2048
sg10
I12
sg11
Vinflammation
p2049
sg13
I1
sasa(dp2050
g2
S'Circulating MIF levels are elevated in several types of human cancer including prostate cancer.\n'
p2051
sg4
(lp2052
(dp2053
g7
I12
sg8
VP05109
p2054
sg10
I3
sg11
VMIF
p2055
sg13
I1
sasg20
(lp2056
(dp2057
g7
I62
sg23
VC0006826
p2058
sg10
I6
sg11
Vcancer
p2059
sg13
I1
sa(dp2060
g7
I79
sg23
VC0600139
p2061
sg10
I15
sg11
Vprostate cancer
p2062
sg13
I2
sasa(dp2063
g2
S'Recently described fully human anti-MIF antibodies were tested in vitro and in vivo for their ability to influence growth rate and invasion of the human PC3 prostate cancer cell line.\n'
p2064
sg4
(lp2065
(dp2066
g7
I31
sg8
VP05109
p2067
sg10
I19
sg11
Vanti-MIF antibodies
p2068
sg13
I2
sa(dp2069
g7
I147
sg8
VP42025
p2070
sg10
I9
sg11
Vhuman PC3
p2071
sg13
I2
sasg20
(lp2072
(dp2073
g7
I131
sg23
VC2699153
p2074
sg10
I8
sg11
Vinvasion
p2075
sg13
I1
sa(dp2076
g7
I157
sg23
VC0600139
p2077
sg10
I15
sg11
Vprostate cancer
p2078
sg13
I2
sasa(dp2079
g2
S'in Endocrine-Related Cancer demonstrates a link between macrophage migration inhibitory factor and neuroendocrine differentiation in prostate cancer.\n'
p2080
sg4
(lp2081
sg20
(lp2082
(dp2083
g7
I133
sg23
VC0600139
p2084
sg10
I15
sg11
Vprostate cancer
p2085
sg13
I2
sa(dp2086
g7
I21
sg23
VC0006826
p2087
sg10
I6
sg11
VCancer
p2088
sg13
I1
sasa(dp2089
g2
S'Macrophage migration inhibitory factor (MIF) is a protein that is overexpressed in many tumors, such as colon and prostate cancer, melanoma, and glioblastoma multiforme (GBM).\n'
p2090
sg4
(lp2091
sg20
(lp2092
(dp2093
g7
I88
sg23
VC0027651
p2094
sg10
I6
sg11
Vtumors
p2095
sg13
I1
sa(dp2096
g7
I170
sg23
VC1621958
p2097
sg10
I3
sg11
VGBM
p2098
sg13
I1
sa(dp2099
g7
I145
sg23
VC1621958
p2100
sg10
I23
sg11
Vglioblastoma multiforme
p2101
sg13
I2
sa(dp2102
g7
I131
sg23
VC0025202
p2103
sg10
I8
sg11
Vmelanoma
p2104
sg13
I1
sa(dp2105
g7
I114
sg23
VC0600139
p2106
sg10
I15
sg11
Vprostate cancer
p2107
sg13
I2
sasa(dp2108
g2
S'Consistent with HBP1-mediated repression of MIF, low levels of HBP1 expression were associated with high levels of MIF expression in prostate cancer samples.\n'
p2109
sg4
(lp2110
(dp2111
g7
I16
sg8
g18
sg10
I4
sg11
VHBP1
p2112
sg13
I1
sa(dp2113
g7
I44
sg8
VP05109
p2114
sg10
I3
sg11
VMIF
p2115
sg13
I1
sa(dp2116
g7
I44
sg8
VP05109
p2117
sg10
I3
sg11
VMIF
p2118
sg13
I1
sa(dp2119
g7
I16
sg8
g18
sg10
I4
sg11
VHBP1
p2120
sg13
I1
sasg20
(lp2121
(dp2122
g7
I133
sg23
VC0600139
p2123
sg10
I15
sg11
Vprostate cancer
p2124
sg13
I2
sasa(dp2125
g2
S'Our study showed that miR-548d-3p/TP53BP2 pathway is critically involved in the proliferation and apoptosis of breast cancer cells and may be new therapeutic target of breast cancer cells.\n'
p2126
sg4
(lp2127
(dp2128
g7
I22
sg8
g18
sg10
I11
sg11
VmiR-548d-3p
p2129
sg13
I1
sa(dp2130
g7
I34
sg8
g18
sg10
I7
sg11
VTP53BP2
p2131
sg13
I1
sasg20
(lp2132
(dp2133
g7
I111
sg23
VC0678222
p2134
sg10
I13
sg11
Vbreast cancer
p2135
sg13
I2
sa(dp2136
g7
I80
sg23
VC0334094
p2137
sg10
I13
sg11
Vproliferation
p2138
sg13
I1
sa(dp2139
g7
I111
sg23
VC0678222
p2140
sg10
I13
sg11
Vbreast cancer
p2141
sg13
I2
sasa(dp2142
g2
S'Reduced ASPP2 expression results in EMT, and is associated with poor survival in hepatocellular carcinoma and breast cancer patients.\n'
p2143
sg4
(lp2144
(dp2145
g7
I8
sg8
g18
sg10
I5
sg11
VASPP2
p2146
sg13
I1
sa(dp2147
g7
I36
sg8
g18
sg10
I3
sg11
VEMT
p2148
sg13
I1
sasg20
(lp2149
(dp2150
g7
I81
sg23
VC1512411
p2151
sg10
I24
sg11
Vhepatocellular carcinoma
p2152
sg13
I2
sa(dp2153
g7
I110
sg23
VC0678222
p2154
sg10
I13
sg11
Vbreast cancer
p2155
sg13
I2
sasa(dp2156
g2
S'Clinical and experimental data indicate roles for cytokines IL-13, TNFAlfa, circulating cardiotrophin-like cytokine factor 1 (member of the IL-6 family), circulating hemopexin, radical oxygen species, and the soluble urokinase-type plasminogen activator receptor (suPAR) in the development of nephrotic syndrome.\n'
p2157
sg4
(lp2158
(dp2159
g7
I140
sg8
VP05231
p2160
sg10
I11
sg11
VIL-6 family
p2161
sg13
I2
sa(dp2162
g7
I107
sg8
VP13236
p2163
sg10
I17
sg11
Vcytokine factor 1
p2164
sg13
I3
sa(dp2165
g7
I50
sg8
VP35225
p2166
sg10
I15
sg11
Vcytokines IL-13
p2167
sg13
I2
sa(dp2168
g7
I166
sg8
VP02790
p2169
sg10
I9
sg11
Vhemopexin
p2170
sg13
I1
sa(dp2171
g7
I264
sg8
VP00747
p2172
sg10
I5
sg11
VsuPAR
p2173
sg13
I1
sa(dp2174
g7
I209
sg8
VP00747
p2175
sg10
I53
sg11
Vsoluble urokinase-type plasminogen activator receptor
p2176
sg13
I5
sasg20
(lp2177
(dp2178
g7
I293
sg23
VC0027726
p2179
sg10
I18
sg11
Vnephrotic syndrome
p2180
sg13
I2
sasa(dp2181
g2
S'Other potential permeability factors include hemopexin and vascular permeability factor in minimal change nephrotic syndrome (MCNS) and soluble urokinase receptor in FSGS.\n'
p2182
sg4
(lp2183
(dp2184
g7
I59
sg8
g18
sg10
I28
sg11
Vvascular permeability factor
p2185
sg13
I3
sa(dp2186
g7
I45
sg8
VP02790
p2187
sg10
I9
sg11
Vhemopexin
p2188
sg13
I1
sa(dp2189
g7
I136
sg8
VP35558
p2190
sg10
I26
sg11
Vsoluble urokinase receptor
p2191
sg13
I3
sasg20
(lp2192
(dp2193
g7
I91
sg23
VC1704321
p2194
sg10
I33
sg11
Vminimal change nephrotic syndrome
p2195
sg13
I4
sa(dp2196
g7
I126
sg23
VC1704321
p2197
sg10
I4
sg11
VMCNS
p2198
sg13
I1
sasa(dp2199
g2
S'When infused into rats, hemopexin induces reversible proteinuria, and activated hemopexin is increased in children with minimal change nephrotic syndrome.\n'
p2200
sg4
(lp2201
(dp2202
g7
I24
sg8
VP02790
p2203
sg10
I9
sg11
Vhemopexin
p2204
sg13
I1
sa(dp2205
g7
I24
sg8
VP02790
p2206
sg10
I9
sg11
Vhemopexin
p2207
sg13
I1
sasg20
(lp2208
(dp2209
g7
I120
sg23
VC1704321
p2210
sg10
I33
sg11
Vminimal change nephrotic syndrome
p2211
sg13
I4
sasa(dp2212
g2
S'Since an active isoform of plasma hemopexin (Hx) has been proposed to be a potential effector molecule in minimal change disease (MCD), we tested plasma and urine samples from subjects with MCD in relapse (n = 18) or in remission (n = 23) (after treatment with prednisolone) for presence or activity of Hx.\n'
p2213
sg4
(lp2214
(dp2215
g7
I27
sg8
VP02790
p2216
sg10
I16
sg11
Vplasma hemopexin
p2217
sg13
I2
sasg20
(lp2218
(dp2219
g7
I197
sg23
VC0277556
p2220
sg10
I7
sg11
Vrelapse
p2221
sg13
I1
sa(dp2222
g7
I130
sg23
VC1636149
p2223
sg10
I3
sg11
VMCD
p2224
sg13
I1
sa(dp2225
g7
I106
sg23
VC1704320
p2226
sg10
I22
sg11
Vminimal change disease
p2227
sg13
I3
sa(dp2228
g7
I130
sg23
VC1636149
p2229
sg10
I3
sg11
VMCD
p2230
sg13
I1
sa(dp2231
g7
I220
sg23
VC0687702
p2232
sg10
I9
sg11
Vremission
p2233
sg13
I1
sasa(dp2234
g2
S'Previous studies into the relevance of a putative circulating factor in the pathogenesis of minimal change nephrotic syndrome have opened the possibility that plasma hemopexin might be an important effector molecule in this disorder.\n'
p2235
sg4
(lp2236
(dp2237
g7
I159
sg8
VP02790
p2238
sg10
I16
sg11
Vplasma hemopexin
p2239
sg13
I2
sasg20
(lp2240
(dp2241
g7
I76
sg23
VC0699748
p2242
sg10
I12
sg11
Vpathogenesis
p2243
sg13
I1
sa(dp2244
g7
I92
sg23
VC1704321
p2245
sg10
I33
sg11
Vminimal change nephrotic syndrome
p2246
sg13
I4
sasa(dp2247
g2
S'It is concluded that the hemopexin molecule as such can potentially act as a toxic protease, leading in the rat to proteinuria and glomerular alterations characteristic for minimal change nephrotic syndrome.\n'
p2248
sg4
(lp2249
(dp2250
g7
I25
sg8
VP02790
p2251
sg10
I9
sg11
Vhemopexin
p2252
sg13
I1
sasg20
(lp2253
(dp2254
g7
I173
sg23
VC1704321
p2255
sg10
I33
sg11
Vminimal change nephrotic syndrome
p2256
sg13
I4
sasa(dp2257
g2
S'Since this ecto-enzyme appears to be able to regulate plasma hemopexin, which latter molecule plays a role in the pathogenesis of corticosteroid responsive nephrotic syndrome, the question was raised whether glucocorticoids are potentially able to downregulate ecto-apyrase activity of these cells.\n'
p2258
sg4
(lp2259
(dp2260
g7
I54
sg8
VP02790
p2261
sg10
I16
sg11
Vplasma hemopexin
p2262
sg13
I2
sa(dp2263
g7
I266
sg8
VP49961
p2264
sg10
I7
sg11
Vapyrase
p2265
sg13
I1
sa(dp2266
g7
I11
sg8
g18
sg10
I11
sg11
Vecto-enzyme
p2267
sg13
I1
sasg20
(lp2268
(dp2269
g7
I114
sg23
VC0699748
p2270
sg10
I12
sg11
Vpathogenesis
p2271
sg13
I1
sa(dp2272
g7
I156
sg23
VC0027726
p2273
sg10
I18
sg11
Vnephrotic syndrome
p2274
sg13
I2
sasa(dp2275
g2
S'The aims of the present study were to determine whether the changes in density and location of CD68-positive and CD206-positive macrophages contribute to progression of hepatocellular carcinoma (HCC) and to evaluate prognostic values of these cells in post-surgical patients.\n'
p2276
sg4
(lp2277
(dp2278
g7
I95
sg8
VP34810
p2279
sg10
I4
sg11
VCD68
p2280
sg13
I1
sa(dp2281
g7
I113
sg8
VP22897
p2282
sg10
I5
sg11
VCD206
p2283
sg13
I1
sasg20
(lp2284
(dp2285
g7
I169
sg23
VC2239176
p2286
sg10
I24
sg11
Vhepatocellular carcinoma
p2287
sg13
I2
sa(dp2288
g7
I195
sg23
VC2239176
p2289
sg10
I3
sg11
VHCC
p2290
sg13
I1
sasa(dp2291
g2
S'Fibrolamellar carcinoma is a unique type of hepatocellular carcinoma with a distinctive predilection for young patients without underlying liver disease, characteristic large neoplastic cells with intervening, dense fibrosis, co-expression of keratin 7 and CD68 and activation of protein kinase A (most often by formation of DNAJB1-PRKACA).\n'
p2292
sg4
(lp2293
(dp2294
g7
I257
sg8
VP34810
p2295
sg10
I4
sg11
VCD68
p2296
sg13
I1
sa(dp2297
g7
I280
sg8
VP17612
p2298
sg10
I16
sg11
Vprotein kinase A
p2299
sg13
I3
sa(dp2300
g7
I325
sg8
VP25685
p2301
sg10
I13
sg11
VDNAJB1-PRKACA
p2302
sg13
I1
sa(dp2303
g7
I243
sg8
VP08729
p2304
sg10
I9
sg11
Vkeratin 7
p2305
sg13
I2
sasg20
(lp2306
(dp2307
g7
I139
sg23
VC0023895
p2308
sg10
I13
sg11
Vliver disease
p2309
sg13
I2
sa(dp2310
g7
I44
sg23
VC1512411
p2311
sg10
I24
sg11
Vhepatocellular carcinoma
p2312
sg13
I2
sa(dp2313
g7
I0
sg23
VC0334287
p2314
sg10
I23
sg11
VFibrolamellar carcinoma
p2315
sg13
I2
sa(dp2316
g7
I216
sg23
VC0016059
p2317
sg10
I8
sg11
Vfibrosis
p2318
sg13
I1
sasa(dp2319
g2
S'Moreover, the accumulation of CD169(+) macrophages in tumour tissues was negatively associated with disease progression and predicted favourable survival in hepatocellular carcinoma patients, which was in contrast to the trend observed for total CD68(+) macrophages.\n'
p2320
sg4
(lp2321
(dp2322
g7
I246
sg8
VP34810
p2323
sg10
I4
sg11
VCD68
p2324
sg13
I1
sa(dp2325
g7
I30
sg8
g18
sg10
I8
sg11
VCD169(+)
p2326
sg13
I1
sasg20
(lp2327
(dp2328
g7
I157
sg23
VC1512411
p2329
sg10
I24
sg11
Vhepatocellular carcinoma
p2330
sg13
I2
sa(dp2331
g7
I54
sg23
VC0027651
p2332
sg10
I6
sg11
Vtumour
p2333
sg13
I1
sa(dp2334
g7
I100
sg23
VC0242656
p2335
sg10
I19
sg11
Vdisease progression
p2336
sg13
I2
sasa(dp2337
g2
S'To gain insight into the biochemical basis of Sotos syndrome, we tested the ability of each NSD1 PHD domain to bind histone H3 when methylated at regulatory sites Lys4, Lys9, Lys27, Lys36, and Lys79, and histone H4 at regulatory Lys20, and determined whether Sotos point mutations disrupted methylation site-specific binding.\n'
p2338
sg4
(lp2339
(dp2340
g7
I204
sg8
VP62805
p2341
sg10
I10
sg11
Vhistone H4
p2342
sg13
I2
sa(dp2343
g7
I116
sg8
g18
sg10
I10
sg11
Vhistone H3
p2344
sg13
I2
sa(dp2345
g7
I97
sg8
VP20941
p2346
sg10
I10
sg11
VPHD domain
p2347
sg13
I2
sa(dp2348
g7
I92
sg8
g18
sg10
I4
sg11
VNSD1
p2349
sg13
I1
sa(dp2350
g7
I46
sg8
g18
sg10
I5
sg11
VSotos
p2351
sg13
I1
sasg20
(lp2352
(dp2353
g7
I46
sg23
VC0175695
p2354
sg10
I14
sg11
VSotos syndrome
p2355
sg13
I2
sasa(dp2356
g2
S'This study identified various genes like FN1 which is central in our analysis, NEUROD6, RELN, TGFBetaR2, NLRP1, SCRT1, CSNK2B, SCN1B, CABP1, KIF5A and antisense RNAs like AQP4-AS1 and KIRREL3-AS2 providing important insight into the understanding of the pathophysiology or genomic basis of drug refractory epilepsy due to MTS.\n'
p2357
sg4
(lp2358
(dp2359
g7
I88
sg8
VP78509
p2360
sg10
I4
sg11
VRELN
p2361
sg13
I1
sa(dp2362
g7
I94
sg8
VP37173
p2363
sg10
I9
sg11
VTGFBetaR2
p2364
sg13
I1
sa(dp2365
g7
I171
sg8
VP55087
p2366
sg10
I4
sg11
VAQP4
p2367
sg13
I1
sa(dp2368
g7
I141
sg8
g18
sg10
I5
sg11
VKIF5A
p2369
sg13
I1
sa(dp2370
g7
I184
sg8
g18
sg10
I11
sg11
VKIRREL3-AS2
p2371
sg13
I1
sa(dp2372
g7
I176
sg8
g18
sg10
I3
sg11
VAS1
p2373
sg13
I1
sa(dp2374
g7
I119
sg8
VP67870
p2375
sg10
I6
sg11
VCSNK2B
p2376
sg13
I1
sa(dp2377
g7
I79
sg8
g18
sg10
I7
sg11
VNEUROD6
p2378
sg13
I1
sa(dp2379
g7
I127
sg8
g18
sg10
I5
sg11
VSCN1B
p2380
sg13
I1
sa(dp2381
g7
I105
sg8
g18
sg10
I5
sg11
VNLRP1
p2382
sg13
I1
sa(dp2383
g7
I112
sg8
g18
sg10
I5
sg11
VSCRT1
p2384
sg13
I1
sa(dp2385
g7
I134
sg8
g18
sg10
I5
sg11
VCABP1
p2386
sg13
I1
sasg20
(lp2387
(dp2388
g7
I176
sg23
VC1846534
p2389
sg10
I3
sg11
VAS1
p2390
sg13
I1
sa(dp2391
g7
I295
sg23
VC1096063
p2392
sg10
I19
sg11
Vrefractory epilepsy
p2393
sg13
I2
sa(dp2394
g7
I322
sg23
VC0796074
p2395
sg10
I3
sg11
VMTS
p2396
sg13
I1
sasa(dp2397
g2
S'Additionally, C1QB, C1S, CFI, SCN3B and FN1 may be potential therapeutic targets for epilepsy.\n'
p2398
sg4
(lp2399
(dp2400
g7
I30
sg8
g18
sg10
I5
sg11
VSCN3B
p2401
sg13
I1
sa(dp2402
g7
I25
sg8
VP05156
p2403
sg10
I3
sg11
VCFI
p2404
sg13
I1
sa(dp2405
g7
I14
sg8
VP02746
p2406
sg10
I4
sg11
VC1QB
p2407
sg13
I1
sasg20
(lp2408
(dp2409
g7
I85
sg23
VC0014544
p2410
sg10
I8
sg11
Vepilepsy
p2411
sg13
I1
sasa(dp2412
g2
S'Our previous studies showed the diagnostic potential of miR-451 as a serological marker for inflammatory breast cancer (IBC), miR-337- 5p and miR-30b for non-inflammatory breast cancer (non-IBC).\n'
p2413
sg4
(lp2414
(dp2415
g7
I126
sg8
g18
sg10
I11
sg11
VmiR-337- 5p
p2416
sg13
I2
sa(dp2417
g7
I142
sg8
g18
sg10
I7
sg11
VmiR-30b
p2418
sg13
I1
sasg20
(lp2419
(dp2420
g7
I120
sg23
VC0278601
p2421
sg10
I3
sg11
VIBC
p2422
sg13
I1
sa(dp2423
g7
I92
sg23
VC0278601
p2424
sg10
I26
sg11
Vinflammatory breast cancer
p2425
sg13
I3
sa(dp2426
g7
I120
sg23
VC0278601
p2427
sg10
I3
sg11
VIBC
p2428
sg13
I1
sa(dp2429
g7
I92
sg23
VC0278601
p2430
sg10
I26
sg11
Vinflammatory breast cancer
p2431
sg13
I3
sasa(dp2432
g2
S'Mechanistically, we demonstrated that the nucleotide T deletion created an illegitimate binding NPM1 for miR-337-5p, which was widely expressed in different acute myeloid leukemia subtypes and inhibited NPM1 expression.\n'
p2433
sg4
(lp2434
(dp2435
g7
I105
sg8
g18
sg10
I10
sg11
VmiR-337-5p
p2436
sg13
I1
sasg20
(lp2437
(dp2438
g7
I157
sg23
VC0023467
p2439
sg10
I22
sg11
Vacute myeloid leukemia
p2440
sg13
I3
sasa(dp2441
g2
S'Recent findings suggesting that Abelson helper integration site 1 (AHI1) is involved in non-syndromic retinal disease have been debated, as the functional significance of identified missense variants was uncertain.\n'
p2442
sg4
(lp2443
(dp2444
g7
I67
sg8
g18
sg10
I4
sg11
VAHI1
p2445
sg13
I1
sa(dp2446
g7
I32
sg8
g18
sg10
I33
sg11
VAbelson helper integration site 1
p2447
sg13
I5
sasg20
(lp2448
(dp2449
g7
I102
sg23
VC0035309
p2450
sg10
I15
sg11
Vretinal disease
p2451
sg13
I2
sasa(dp2452
g2
S'We assessed whether AHI1 variants cause non-syndromic retinitis pigmentosa (RP).\n'
p2453
sg4
(lp2454
(dp2455
g7
I20
sg8
g18
sg10
I13
sg11
VAHI1 variants
p2456
sg13
I2
sasg20
(lp2457
(dp2458
g7
I76
sg23
VC0035334
p2459
sg10
I2
sg11
VRP
p2460
sg13
I1
sa(dp2461
g7
I54
sg23
VC0035334
p2462
sg10
I20
sg11
Vretinitis pigmentosa
p2463
sg13
I2
sasa(dp2464
g2
S'An electroretinogram showed mixed retinal dystrophy and an AHI1 homozygous missense c.1981T&gt;C mutation was identified (parents are carriers).\n'
p2465
sg4
(lp2466
(dp2467
g7
I59
sg8
g18
sg10
I4
sg11
VAHI1
p2468
sg13
I1
sasg20
(lp2469
(dp2470
g7
I34
sg23
VC0854723
p2471
sg10
I17
sg11
Vretinal dystrophy
p2472
sg13
I2
sasa(dp2473
g2
S'Three cases are reported, including the identification of AHI1 as a novel candidate gene for nonsyndromic retinitis pigmentosa.\n'
p2474
sg4
(lp2475
(dp2476
g7
I58
sg8
g18
sg10
I4
sg11
VAHI1
p2477
sg13
I1
sasg20
(lp2478
(dp2479
g7
I106
sg23
VC0035334
p2480
sg10
I20
sg11
Vretinitis pigmentosa
p2481
sg13
I2
sasa(dp2482
g2
S'Mutations in AHI1 are the most common genetic cause of JSRD, with developmental hindbrain anomalies and retinal degeneration being prominent features.\n'
p2483
sg4
(lp2484
(dp2485
g7
I13
sg8
g18
sg10
I4
sg11
VAHI1
p2486
sg13
I1
sasg20
(lp2487
(dp2488
g7
I104
sg23
VC0035304
p2489
sg10
I20
sg11
Vretinal degeneration
p2490
sg13
I2
sasa(dp2491
g2
S'Moreover, AHI1 screening in five other patients with CEP290-related disease and neurological involvement revealed a second novel missense variant, p.His758Pro, in one LCA patient with mild mental retardation and autism.\n'
p2492
sg4
(lp2493
(dp2494
g7
I10
sg8
g18
sg10
I4
sg11
VAHI1
p2495
sg13
I1
sasg20
(lp2496
(dp2497
g7
I184
sg23
VC0026106
p2498
sg10
I23
sg11
Vmild mental retardation
p2499
sg13
I3
sa(dp2500
g7
I212
sg23
VC0004352
p2501
sg10
I6
sg11
Vautism
p2502
sg13
I1
sa(dp2503
g7
I167
sg23
VC0339527
p2504
sg10
I3
sg11
VLCA
p2505
sg13
I1
sasa(dp2506
g2
S'The retinal degeneration observed in Ahi1(-/-) mice recapitulates aspects of the retinal phenotype observed in patients with JBTS and suggests the importance of Ahi1 in photoreceptor function.\n'
p2507
sg4
(lp2508
(dp2509
g7
I37
sg8
g18
sg10
I4
sg11
VAhi1
p2510
sg13
I1
sa(dp2511
g7
I37
sg8
g18
sg10
I4
sg11
VAhi1
p2512
sg13
I1
sasg20
(lp2513
(dp2514
g7
I4
sg23
VC0035304
p2515
sg10
I20
sg11
Vretinal degeneration
p2516
sg13
I2
sa(dp2517
g7
I125
sg23
VC0431399
p2518
sg10
I4
sg11
VJBTS
p2519
sg13
I1
sasa(dp2520
g2
S'It was discovered that enhanced HSPC111 expression paralleled the upregulation of c-Myc and was directly regulated by c-Myc in breast cancer cells.\n'
p2521
sg4
(lp2522
(dp2523
g7
I32
sg8
g18
sg10
I7
sg11
VHSPC111
p2524
sg13
I1
sa(dp2525
g7
I82
sg8
VP12524
p2526
sg10
I5
sg11
Vc-Myc
p2527
sg13
I1
sa(dp2528
g7
I82
sg8
VP12524
p2529
sg10
I5
sg11
Vc-Myc
p2530
sg13
I1
sasg20
(lp2531
(dp2532
g7
I127
sg23
VC0678222
p2533
sg10
I13
sg11
Vbreast cancer
p2534
sg13
I2
sasa(dp2535
g2
S'Finally, overall survival analysis revealed that concomitant upregulation of HSPC111 and RTCD1 correlated with the worst prognosis in a breast cancer cohort.\n'
p2536
sg4
(lp2537
(dp2538
g7
I77
sg8
g18
sg10
I7
sg11
VHSPC111
p2539
sg13
I1
sa(dp2540
g7
I89
sg8
g18
sg10
I5
sg11
VRTCD1
p2541
sg13
I1
sasg20
(lp2542
(dp2543
g7
I136
sg23
VC0678222
p2544
sg10
I13
sg11
Vbreast cancer
p2545
sg13
I2
sasa(dp2546
g2
S'Inhibition of HSPC111-dependent ribosomal biosynthesis and protein synthesis is a promising therapeutic strategy to diminish breast cancer tumor progression.\n'
p2547
sg4
(lp2548
(dp2549
g7
I14
sg8
g18
sg10
I7
sg11
VHSPC111
p2550
sg13
I1
sasg20
(lp2551
(dp2552
g7
I139
sg23
VC0178874
p2553
sg10
I17
sg11
Vtumor progression
p2554
sg13
I2
sa(dp2555
g7
I125
sg23
VC0678222
p2556
sg10
I13
sg11
Vbreast cancer
p2557
sg13
I2
sasa(dp2558
g2
S'Importantly, high expression of NOP16 was associated with poor clinical outcome in breast cancer patients.\n'
p2559
sg4
(lp2560
(dp2561
g7
I32
sg8
g18
sg10
I5
sg11
VNOP16
p2562
sg13
I1
sasg20
(lp2563
(dp2564
g7
I83
sg23
VC0678222
p2565
sg10
I13
sg11
Vbreast cancer
p2566
sg13
I2
sasa(dp2567
g2
S'In summary, the regulation of expression and localization of NOP16 varies in tumor environments with high versus low MYC levels and demonstrate the importance of stratifying clinical breast cancers based on MYC levels.\n'
p2568
sg4
(lp2569
(dp2570
g7
I61
sg8
g18
sg10
I5
sg11
VNOP16
p2571
sg13
I1
sa(dp2572
g7
I117
sg8
VP12524
p2573
sg10
I3
sg11
VMYC
p2574
sg13
I1
sa(dp2575
g7
I117
sg8
VP12524
p2576
sg10
I3
sg11
VMYC
p2577
sg13
I1
sasg20
(lp2578
(dp2579
g7
I183
sg23
VC0006142
p2580
sg10
I14
sg11
Vbreast cancers
p2581
sg13
I2
sa(dp2582
g7
I77
sg23
VC0027651
p2583
sg10
I5
sg11
Vtumor
p2584
sg13
I1
sasa(dp2585
g2
S'HSPC111 mRNA and protein were over-expressed in breast cancer cell lines and primary breast carcinomas, and this was positively correlated with MYC mRNA levels.\n'
p2586
sg4
(lp2587
(dp2588
g7
I144
sg8
VP12524
p2589
sg10
I8
sg11
VMYC mRNA
p2590
sg13
I2
sa(dp2591
g7
I0
sg8
g18
sg10
I12
sg11
VHSPC111 mRNA
p2592
sg13
I2
sasg20
(lp2593
(dp2594
g7
I48
sg23
VC0678222
p2595
sg10
I13
sg11
Vbreast cancer
p2596
sg13
I2
sa(dp2597
g7
I85
sg23
VC0678222
p2598
sg10
I17
sg11
Vbreast carcinomas
p2599
sg13
I2
sasa(dp2600
g2
S'These data identify HSPC111 as an estrogen and c-Myc target gene that is over-expressed in breast cancer and is associated with an adverse patient outcome.\n'
p2601
sg4
(lp2602
(dp2603
g7
I47
sg8
VP12524
p2604
sg10
I17
sg11
Vc-Myc target gene
p2605
sg13
I3
sasg20
(lp2606
(dp2607
g7
I91
sg23
VC0678222
p2608
sg10
I13
sg11
Vbreast cancer
p2609
sg13
I2
sasa(dp2610
g2
S'Thus formation of Smad3/Smad4/CDK9 complex drives renal fibrosis during ureteral obstruction.\n'
p2611
sg4
(lp2612
(dp2613
g7
I30
sg8
VP50750
p2614
sg10
I4
sg11
VCDK9
p2615
sg13
I1
sa(dp2616
g7
I24
sg8
g18
sg10
I5
sg11
VSmad4
p2617
sg13
I1
sasg20
(lp2618
(dp2619
g7
I72
sg23
VC0041956
p2620
sg10
I20
sg11
Vureteral obstruction
p2621
sg13
I2
sa(dp2622
g7
I50
sg23
VC0151650
p2623
sg10
I14
sg11
Vrenal fibrosis
p2624
sg13
I2
sasa(dp2625
g2
S'We found that mice with specific deletion of Smad4 in Tbx18-expressing ureteral mesenchyme exhibited hydroureter and hydronephrosis at embryonic day (E) 16.5, and the mutant mesenchymal cells failed to differentiate into SMCs with increased apoptosis and decreased proliferation.\n'
p2626
sg4
(lp2627
(dp2628
g7
I54
sg8
g18
sg10
I5
sg11
VTbx18
p2629
sg13
I1
sa(dp2630
g7
I45
sg8
g18
sg10
I5
sg11
VSmad4
p2631
sg13
I1
sasg20
(lp2632
(dp2633
g7
I117
sg23
VC0020295
p2634
sg10
I14
sg11
Vhydronephrosis
p2635
sg13
I1
sa(dp2636
g7
I265
sg23
VC0334094
p2637
sg10
I13
sg11
Vproliferation
p2638
sg13
I1
sa(dp2639
g7
I101
sg23
VC0521620
p2640
sg10
I11
sg11
Vhydroureter
p2641
sg13
I1
sa(dp2642
g7
I167
sg23
VC0596988
p2643
sg10
I6
sg11
Vmutant
p2644
sg13
I1
sasa(dp2645
g2
S'Here we studied the roles of Smad4 to regulate TGF-Beta signaling in a mouse model of unilateral ureteral obstruction using conditional Smad4 knockout mice and in isolated Smad4 mutant macrophages and fibroblasts.\n'
p2646
sg4
(lp2647
(dp2648
g7
I29
sg8
g18
sg10
I5
sg11
VSmad4
p2649
sg13
I1
sa(dp2650
g7
I172
sg8
g18
sg10
I12
sg11
VSmad4 mutant
p2651
sg13
I2
sa(dp2652
g7
I47
sg8
VP18075
p2653
sg10
I8
sg11
VTGF-Beta
p2654
sg13
I1
sa(dp2655
g7
I136
sg8
g18
sg10
I14
sg11
VSmad4 knockout
p2656
sg13
I2
sasg20
(lp2657
(dp2658
g7
I97
sg23
VC0041956
p2659
sg10
I20
sg11
Vureteral obstruction
p2660
sg13
I2
sa(dp2661
g7
I178
sg23
VC0596988
p2662
sg10
I6
sg11
Vmutant
p2663
sg13
I1
sasa(dp2664
g2
S'Ovarian juvenile granulosa cell tumor has an interesting association with multiple enchondromatosis (Ollier disease and Maffucci syndrome) and should be considered a leading diagnosis when an ovarian mass is found in young patients with these conditions.\n'
p2665
sg4
(lp2666
sg20
(lp2667
(dp2668
g7
I83
sg23
VC0014084
p2669
sg10
I16
sg11
Venchondromatosis
p2670
sg13
I1
sa(dp2671
g7
I120
sg23
VC0024454
p2672
sg10
I17
sg11
VMaffucci syndrome
p2673
sg13
I2
sa(dp2674
g7
I8
sg23
VC0334403
p2675
sg10
I29
sg11
Vjuvenile granulosa cell tumor
p2676
sg13
I4
sa(dp2677
g7
I101
sg23
VC0014084
p2678
sg10
I14
sg11
VOllier disease
p2679
sg13
I2
sasa(dp2680
g2
S'It is important to recognize that when the female patient presents with enchondromatosis and a large unilateral multilocular-solid ovarian mass, the specific diagnosis of granulosa cell tumor can be made with high accuracy.\n'
p2681
sg4
(lp2682
sg20
(lp2683
(dp2684
g7
I171
sg23
VC0018206
p2685
sg10
I20
sg11
Vgranulosa cell tumor
p2686
sg13
I3
sa(dp2687
g7
I72
sg23
VC0014084
p2688
sg10
I16
sg11
Venchondromatosis
p2689
sg13
I1
sasa(dp2690
g2
S"A 15-year-old girl developed a juvenile granulosa cell tumor associated with Maffucci's syndrome (enchondromatosis + hemangiomas).\n"
p2691
sg4
(lp2692
sg20
(lp2693
(dp2694
g7
I98
sg23
VC0014084
p2695
sg10
I16
sg11
Venchondromatosis
p2696
sg13
I1
sa(dp2697
g7
I31
sg23
VC0334403
p2698
sg10
I29
sg11
Vjuvenile granulosa cell tumor
p2699
sg13
I4
sa(dp2700
g7
I117
sg23
VC0018916
p2701
sg10
I11
sg11
Vhemangiomas
p2702
sg13
I1
sa(dp2703
g7
I77
sg23
VC0024454
p2704
sg10
I19
sg11
VMaffucci's syndrome
p2705
sg13
I2
sasa(dp2706
g2
S"A review of the literature showed 10 previous cases of juvenile granulosa cell tumor associated with enchondromatosis, two associated with Maffucci's syndrome, and the rest with Ollier's disease (enchondromatosis).\n"
p2707
sg4
(lp2708
sg20
(lp2709
(dp2710
g7
I101
sg23
VC0014084
p2711
sg10
I16
sg11
Venchondromatosis
p2712
sg13
I1
sa(dp2713
g7
I139
sg23
VC0024454
p2714
sg10
I19
sg11
VMaffucci's syndrome
p2715
sg13
I2
sa(dp2716
g7
I101
sg23
VC0014084
p2717
sg10
I16
sg11
Venchondromatosis
p2718
sg13
I1
sa(dp2719
g7
I178
sg23
VC0014084
p2720
sg10
I16
sg11
VOllier's disease
p2721
sg13
I2
sa(dp2722
g7
I55
sg23
VC0334403
p2723
sg10
I29
sg11
Vjuvenile granulosa cell tumor
p2724
sg13
I4
sasa(dp2725
g2
S'Ovarian juvenile granulosa cell tumor may occur not infrequently in female patients with enchondromatosis in the first or second decades, in contrast to the widely recognized sarcomatous changes of enchondromas that usually occur after the second decade.\n'
p2726
sg4
(lp2727
sg20
(lp2728
(dp2729
g7
I89
sg23
VC0014084
p2730
sg10
I16
sg11
Venchondromatosis
p2731
sg13
I1
sa(dp2732
g7
I8
sg23
VC0334403
p2733
sg10
I29
sg11
Vjuvenile granulosa cell tumor
p2734
sg13
I4
sa(dp2735
g7
I198
sg23
VC1704356
p2736
sg10
I12
sg11
Venchondromas
p2737
sg13
I1
sasa(dp2738
g2
S"Immunohistological staining was performed for S100A2, S100A4, S100A6, S100A7, and MMP9 in 101 cases of various types of epidermal tumors, viz., squamous cell carcinoma (SCC), Bowen's disease (BD), actinic keratosis (AK), basal cell carcinoma (BCC), keratoacanthoma (KA), and seborrheic keratosis (SK).\n"
p2739
sg4
(lp2740
(dp2741
g7
I82
sg8
VP14780
p2742
sg10
I4
sg11
VMMP9
p2743
sg13
I1
sa(dp2744
g7
I70
sg8
VP31151
p2745
sg10
I6
sg11
VS100A7
p2746
sg13
I1
sa(dp2747
g7
I46
sg8
VP29034
p2748
sg10
I6
sg11
VS100A2
p2749
sg13
I1
sa(dp2750
g7
I62
sg8
VP06703
p2751
sg10
I6
sg11
VS100A6
p2752
sg13
I1
sa(dp2753
g7
I54
sg8
VP26447
p2754
sg10
I6
sg11
VS100A4
p2755
sg13
I1
sasg20
(lp2756
(dp2757
g7
I144
sg23
VC0007137
p2758
sg10
I23
sg11
Vsquamous cell carcinoma
p2759
sg13
I3
sa(dp2760
g7
I297
sg23
VC0022603
p2761
sg10
I2
sg11
VSK
p2762
sg13
I1
sa(dp2763
g7
I197
sg23
VC0022602
p2764
sg10
I17
sg11
Vactinic keratosis
p2765
sg13
I2
sa(dp2766
g7
I266
sg23
VC0022572
p2767
sg10
I2
sg11
VKA
p2768
sg13
I1
sa(dp2769
g7
I221
sg23
VC0007117
p2770
sg10
I20
sg11
Vbasal cell carcinoma
p2771
sg13
I3
sa(dp2772
g7
I249
sg23
VC0022572
p2773
sg10
I15
sg11
Vkeratoacanthoma
p2774
sg13
I1
sa(dp2775
g7
I275
sg23
VC0022603
p2776
sg10
I20
sg11
Vseborrheic keratosis
p2777
sg13
I2
sa(dp2778
g7
I216
sg23
VC0022602
p2779
sg10
I2
sg11
VAK
p2780
sg13
I1
sa(dp2781
g7
I130
sg23
VC0027651
p2782
sg10
I6
sg11
Vtumors
p2783
sg13
I1
sa(dp2784
g7
I175
sg23
VC0006079
p2785
sg10
I15
sg11
VBowen's disease
p2786
sg13
I2
sa(dp2787
g7
I192
sg23
VC0006079
p2788
sg10
I2
sg11
VBD
p2789
sg13
I1
sa(dp2790
g7
I243
sg23
VC0007117
p2791
sg10
I3
sg11
VBCC
p2792
sg13
I1
sa(dp2793
g7
I169
sg23
VC0007137
p2794
sg10
I3
sg11
VSCC
p2795
sg13
I1
sasa(dp2796
g2
S'Varying types of skin appendage tumors and most peripheral cells in tumor nests of basal cell carcinoma and squamous cell carcinoma showed positive S100A2 immunoreactivity in neoplastic cells.\n'
p2797
sg4
(lp2798
(dp2799
g7
I148
sg8
VP29034
p2800
sg10
I6
sg11
VS100A2
p2801
sg13
I1
sasg20
(lp2802
(dp2803
g7
I108
sg23
VC0007137
p2804
sg10
I23
sg11
Vsquamous cell carcinoma
p2805
sg13
I3
sa(dp2806
g7
I32
sg23
VC0027651
p2807
sg10
I6
sg11
Vtumors
p2808
sg13
I1
sa(dp2809
g7
I32
sg23
VC0027651
p2810
sg10
I5
sg11
Vtumor
p2811
sg13
I1
sa(dp2812
g7
I83
sg23
VC0007117
p2813
sg10
I20
sg11
Vbasal cell carcinoma
p2814
sg13
I3
sasa(dp2815
g2
S'Varying types of skin appendage tumours and most peripheral cells in tumour nests of basal cell carcinoma and squamous cell carcinoma showed positive S100A2 immunoreactivity in neoplastic cells corresponding to basal cells but were nonreactive or faintly reactive for other S100 proteins.\n'
p2816
sg4
(lp2817
(dp2818
g7
I150
sg8
VP29034
p2819
sg10
I6
sg11
VS100A2
p2820
sg13
I1
sa(dp2821
g7
I274
sg8
VP04271
p2822
sg10
I13
sg11
VS100 proteins
p2823
sg13
I2
sasg20
(lp2824
(dp2825
g7
I32
sg23
VC0027651
p2826
sg10
I7
sg11
Vtumours
p2827
sg13
I1
sa(dp2828
g7
I85
sg23
VC0007117
p2829
sg10
I20
sg11
Vbasal cell carcinoma
p2830
sg13
I3
sa(dp2831
g7
I32
sg23
VC0027651
p2832
sg10
I6
sg11
Vtumour
p2833
sg13
I1
sa(dp2834
g7
I110
sg23
VC0007137
p2835
sg10
I23
sg11
Vsquamous cell carcinoma
p2836
sg13
I3
sasa(dp2837
g2
S'Paraffin-embedded tissue of normal skin adjacent to 26 naevi, 39 primary cutaneous melanomas and 14 cutaneous melanoma metastases was incubated with polyclonal antibodies against the recombinant human S100 proteins (S100A1, S100A2, S100A3, S100A4, S100A6, S100B) using the alkaline phosphatase anti-alkaline phosphatase method.\n'
p2838
sg4
(lp2839
(dp2840
g7
I183
sg8
VP04271
p2841
sg10
I31
sg11
Vrecombinant human S100 proteins
p2842
sg13
I4
sa(dp2843
g7
I216
sg8
VP23297
p2844
sg10
I6
sg11
VS100A1
p2845
sg13
I1
sa(dp2846
g7
I240
sg8
VP26447
p2847
sg10
I6
sg11
VS100A4
p2848
sg13
I1
sa(dp2849
g7
I232
sg8
VP33764
p2850
sg10
I6
sg11
VS100A3
p2851
sg13
I1
sa(dp2852
g7
I256
sg8
VP04271
p2853
sg10
I5
sg11
VS100B
p2854
sg13
I1
sa(dp2855
g7
I248
sg8
VP06703
p2856
sg10
I6
sg11
VS100A6
p2857
sg13
I1
sa(dp2858
g7
I273
sg8
VP10696
p2859
sg10
I46
sg11
Valkaline phosphatase anti-alkaline phosphatase
p2860
sg13
I4
sa(dp2861
g7
I224
sg8
VP29034
p2862
sg10
I6
sg11
VS100A2
p2863
sg13
I1
sasg20
(lp2864
(dp2865
g7
I73
sg23
VC0025202
p2866
sg10
I18
sg11
Vcutaneous melanoma
p2867
sg13
I2
sa(dp2868
g7
I119
sg23
VC0027627
p2869
sg10
I10
sg11
Vmetastases
p2870
sg13
I1
sa(dp2871
g7
I83
sg23
VC0025202
p2872
sg10
I9
sg11
Vmelanomas
p2873
sg13
I1
sasa(dp2874
g2
S'Four of 39 primary cutaneous melanomas were positive for S100A2, whereas none of the metastases or naevi showed any immunoreactivity.\n'
p2875
sg4
(lp2876
(dp2877
g7
I57
sg8
VP29034
p2878
sg10
I6
sg11
VS100A2
p2879
sg13
I1
sasg20
(lp2880
(dp2881
g7
I85
sg23
VC0027627
p2882
sg10
I10
sg11
Vmetastases
p2883
sg13
I1
sa(dp2884
g7
I29
sg23
VC0025202
p2885
sg10
I9
sg11
Vmelanomas
p2886
sg13
I1
sasa(dp2887
g2
S'The purpose of this study was to examine the expression of 4 newly available polyclonal antibodies against the human recombinant Ca(2+)-binding S100 proteins, S100A1, S100A2, S100A4 and S100A6, in cutaneous melanoma and to correlate these findings with the standard S100 staining as well as with the metastatic potential of the primary.\n'
p2888
sg4
(lp2889
(dp2890
g7
I144
sg8
VP04271
p2891
sg10
I13
sg11
VS100 proteins
p2892
sg13
I2
sa(dp2893
g7
I186
sg8
VP06703
p2894
sg10
I6
sg11
VS100A6
p2895
sg13
I1
sa(dp2896
g7
I159
sg8
VP23297
p2897
sg10
I6
sg11
VS100A1
p2898
sg13
I1
sa(dp2899
g7
I175
sg8
VP26447
p2900
sg10
I6
sg11
VS100A4
p2901
sg13
I1
sa(dp2902
g7
I167
sg8
VP29034
p2903
sg10
I6
sg11
VS100A2
p2904
sg13
I1
sasg20
(lp2905
(dp2906
g7
I197
sg23
VC0025202
p2907
sg10
I18
sg11
Vcutaneous melanoma
p2908
sg13
I2
sasa(dp2909
g2
S'To investigate the pattern and regulatory properties of biglycan expression in human adipose tissues in the context of obesity and its related diseases, we recruited 21 non-diabetic obese women, 11 type 2 diabetic obese women, and 59 normal-weight women.\n'
p2910
sg4
(lp2911
sg20
(lp2912
(dp2913
g7
I182
sg23
VC0028754
p2914
sg10
I5
sg11
Vobese
p2915
sg13
I1
sa(dp2916
g7
I119
sg23
VC0028754
p2917
sg10
I7
sg11
Vobesity
p2918
sg13
I1
sa(dp2919
g7
I182
sg23
VC0028754
p2920
sg10
I5
sg11
Vobese
p2921
sg13
I1
sasa(dp2922
g2
S'Biglycan, a small leucine rich proteoglycan ECM protein, is up-regulated in obesity and has recently been recognized as a pro-inflammatory molecule.\n'
p2923
sg4
(lp2924
(dp2925
g7
I12
sg8
VP30740
p2926
sg10
I43
sg11
Vsmall leucine rich proteoglycan ECM protein
p2927
sg13
I6
sasg20
(lp2928
(dp2929
g7
I76
sg23
VC0028754
p2930
sg10
I7
sg11
Vobesity
p2931
sg13
I1
sasa(dp2932
g2
S'In the present study, we characterized biglycan expression in various adipose depots in wild-type mice fed a low fat diet (LFD) or obesity-inducing high fat diet (HFD).\n'
p2933
sg4
(lp2934
sg20
(lp2935
(dp2936
g7
I131
sg23
VC0028754
p2937
sg10
I7
sg11
Vobesity
p2938
sg13
I1
sasa(dp2939
g2
S'Collectively, our data suggest that the small leucine-rich proteoglycan family proteins biglycan and decorin may play a role in the development of obesity and T2D, possibly by facilitating expansion of adipose tissue mass.\n'
p2940
sg4
(lp2941
(dp2942
g7
I88
sg8
VP21810
p2943
sg10
I8
sg11
Vbiglycan
p2944
sg13
I1
sa(dp2945
g7
I40
sg8
VP30740
p2946
sg10
I47
sg11
Vsmall leucine-rich proteoglycan family proteins
p2947
sg13
I5
sa(dp2948
g7
I101
sg8
VP07585
p2949
sg10
I7
sg11
Vdecorin
p2950
sg13
I1
sasg20
(lp2951
(dp2952
g7
I147
sg23
VC0028754
p2953
sg10
I7
sg11
Vobesity
p2954
sg13
I1
sa(dp2955
g7
I159
sg23
VC0011860
p2956
sg10
I3
sg11
VT2D
p2957
sg13
I1
sasa(dp2958
g2
S'Therefore, we determined the effect of chronic inflammation induced by obesity and acute inflammation by lipopolysaccharide (LPS) challenge on ECM genes including biglycan (BGN), collagen 1A1 (COL1A1) and COL6A1, major ECM genes in adipose tissue.\n'
p2959
sg4
(lp2960
(dp2961
g7
I143
sg8
g18
sg10
I9
sg11
VECM genes
p2962
sg13
I2
sa(dp2963
g7
I163
sg8
VP21810
p2964
sg10
I28
sg11
Vbiglycan (BGN), collagen 1A1
p2965
sg13
I4
sa(dp2966
g7
I213
sg8
g18
sg10
I15
sg11
Vmajor ECM genes
p2967
sg13
I3
sa(dp2968
g7
I205
sg8
VP12109
p2969
sg10
I6
sg11
VCOL6A1
p2970
sg13
I1
sasg20
(lp2971
(dp2972
g7
I71
sg23
VC0028754
p2973
sg10
I7
sg11
Vobesity
p2974
sg13
I1
sa(dp2975
g7
I39
sg23
VC0021376
p2976
sg10
I20
sg11
Vchronic inflammation
p2977
sg13
I2
sa(dp2978
g7
I105
sg23
VC0175697
p2979
sg10
I18
sg11
Vlipopolysaccharide
p2980
sg13
I1
sa(dp2981
g7
I125
sg23
VC0175697
p2982
sg10
I3
sg11
VLPS
p2983
sg13
I1
sa(dp2984
g7
I47
sg23
VC0021368
p2985
sg10
I12
sg11
Vinflammation
p2986
sg13
I1
sasa(dp2987
g2
S'Considerable efforts have been made to characterize RGS4 as a potential candidate gene for schizophrenia.\n'
p2988
sg4
(lp2989
(dp2990
g7
I52
sg8
VP49798
p2991
sg10
I4
sg11
VRGS4
p2992
sg13
I1
sasg20
(lp2993
(dp2994
g7
I91
sg23
VC0036341
p2995
sg10
I13
sg11
Vschizophrenia
p2996
sg13
I1
sasa(dp2997
g2
S'While these lines of investigations have yielded partially inconsistent findings, they provide a perspective on RGS4 as an important part of a larger biological system contributing to schizophrenia risk.\n'
p2998
sg4
(lp2999
(dp3000
g7
I112
sg8
VP49798
p3001
sg10
I4
sg11
VRGS4
p3002
sg13
I1
sasg20
(lp3003
(dp3004
g7
I184
sg23
VC0036341
p3005
sg10
I13
sg11
Vschizophrenia
p3006
sg13
I1
sasa(dp3007
g2
S"This gene-based review aims to provide a comprehensive overview of published data from different experimental modalities and discusses the current knowledge of RGS4's systems-biological impact on the schizophrenia pathology.\n"
p3008
sg4
(lp3009
(dp3010
g7
I160
sg8
VP49798
p3011
sg10
I4
sg11
VRGS4
p3012
sg13
I1
sasg20
(lp3013
(dp3014
g7
I200
sg23
VC0036341
p3015
sg10
I13
sg11
Vschizophrenia
p3016
sg13
I1
sa(dp3017
g7
I214
sg23
VC0677042
p3018
sg10
I9
sg11
Vpathology
p3019
sg13
I1
sasa(dp3020
g2
S'The Regulator of G protein signaling 4 (RGS4) gene is a candidate susceptibility gene for schizophrenia (SCZ).\n'
p3021
sg4
(lp3022
(dp3023
g7
I4
sg8
VP49798
p3024
sg10
I34
sg11
VRegulator of G protein signaling 4
p3025
sg13
I6
sa(dp3026
g7
I40
sg8
VP49798
p3027
sg10
I4
sg11
VRGS4
p3028
sg13
I1
sasg20
(lp3029
(dp3030
g7
I105
sg23
VC0036341
p3031
sg10
I3
sg11
VSCZ
p3032
sg13
I1
sa(dp3033
g7
I90
sg23
VC0036341
p3034
sg10
I13
sg11
Vschizophrenia
p3035
sg13
I1
sasa(dp3036
g2
S'We genotyped SNP1 (rs10917670), rs2661347, SNP4 (rs951436), SNP7 (rs951439), SNP18 (rs2661319), and rs10799897 (SNP9897) and tested the methylation status of CpG islands of the RGS4 gene in the postmortem DLPFC samples obtained from subjects with SCZ and bipolar disorder as well as healthy controls.\n'
p3037
sg4
(lp3038
(dp3039
g7
I177
sg8
VP49798
p3040
sg10
I9
sg11
VRGS4 gene
p3041
sg13
I2
sasg20
(lp3042
(dp3043
g7
I255
sg23
VC0005586
p3044
sg10
I16
sg11
Vbipolar disorder
p3045
sg13
I2
sasa(dp3046
g2
S'The aim of the present study was to investigate the association between the variation in the regulator of G-protein signaling 4 (RGS4) gene, a putative candidate gene for psychosis previously associated with schizophrenia endophenotypes, and psychotic-like experiences (PLEs).\n'
p3047
sg4
(lp3048
(dp3049
g7
I106
sg8
VP49798
p3050
sg10
I33
sg11
VG-protein signaling 4 (RGS4) gene
p3051
sg13
I5
sasg20
(lp3052
(dp3053
g7
I208
sg23
VC0036341
p3054
sg10
I13
sg11
Vschizophrenia
p3055
sg13
I1
sa(dp3056
g7
I242
sg23
VC0033975
p3057
sg10
I9
sg11
Vpsychotic
p3058
sg13
I1
sa(dp3059
g7
I171
sg23
VC0033975
p3060
sg10
I9
sg11
Vpsychosis
p3061
sg13
I1
sasa(dp3062
g2
S'Thus, lower levels of RGS4 would enhance GPCR-mediated reductions in NMDAR activity and could contribute to NMDAR hypofunction in schizophrenia.\n'
p3063
sg4
(lp3064
(dp3065
g7
I22
sg8
VP49798
p3066
sg10
I4
sg11
VRGS4
p3067
sg13
I1
sa(dp3068
g7
I41
sg8
g18
sg10
I4
sg11
VGPCR
p3069
sg13
I1
sasg20
(lp3070
(dp3071
g7
I114
sg23
VC0679221
p3072
sg10
I12
sg11
Vhypofunction
p3073
sg13
I1
sa(dp3074
g7
I130
sg23
VC0036341
p3075
sg10
I13
sg11
Vschizophrenia
p3076
sg13
I1
sasa(dp3077
g2
S'In this study, we quantified RGS4 mRNA and protein levels at several levels of resolution in the DLPFC from subjects with schizophrenia and matched healthy comparison subjects.\n'
p3078
sg4
(lp3079
(dp3080
g7
I29
sg8
VP49798
p3081
sg10
I9
sg11
VRGS4 mRNA
p3082
sg13
I2
sasg20
(lp3083
(dp3084
g7
I122
sg23
VC0036341
p3085
sg10
I13
sg11
Vschizophrenia
p3086
sg13
I1
sasa(dp3087
g2
S'RGS4 mRNA and protein levels were significantly lower in schizophrenia subjects and were positively correlated across all subjects.\n'
p3088
sg4
(lp3089
(dp3090
g7
I0
sg8
VP49798
p3091
sg10
I9
sg11
VRGS4 mRNA
p3092
sg13
I2
sasg20
(lp3093
(dp3094
g7
I57
sg23
VC0036341
p3095
sg10
I13
sg11
Vschizophrenia
p3096
sg13
I1
sasa(dp3097
g2
S'The RGS4 mRNA deficit was present in pyramidal neurons of DLPFC layers 3 and 5 of the schizophrenia subjects.\n'
p3098
sg4
(lp3099
(dp3100
g7
I4
sg8
VP49798
p3101
sg10
I9
sg11
VRGS4 mRNA
p3102
sg13
I2
sasg20
(lp3103
(dp3104
g7
I14
sg23
VC0162429
p3105
sg10
I7
sg11
Vdeficit
p3106
sg13
I1
sa(dp3107
g7
I86
sg23
VC0036341
p3108
sg10
I13
sg11
Vschizophrenia
p3109
sg13
I1
sasa(dp3110
g2
S'In contrast, levels of miR16 were significantly higher in the DLPFC of schizophrenia subjects, and higher miR16 levels predicted lower RGS4 mRNA levels.\n'
p3111
sg4
(lp3112
(dp3113
g7
I23
sg8
g18
sg10
I5
sg11
VmiR16
p3114
sg13
I1
sa(dp3115
g7
I135
sg8
VP49798
p3116
sg10
I9
sg11
VRGS4 mRNA
p3117
sg13
I2
sasg20
(lp3118
(dp3119
g7
I71
sg23
VC0036341
p3120
sg10
I13
sg11
Vschizophrenia
p3121
sg13
I1
sasa(dp3122
g2
S'These findings provide convergent evidence of lower RGS4 mRNA and protein levels in schizophrenia that may result from increased expression of miR16.\n'
p3123
sg4
(lp3124
(dp3125
g7
I52
sg8
VP49798
p3126
sg10
I9
sg11
VRGS4 mRNA
p3127
sg13
I2
sa(dp3128
g7
I143
sg8
g18
sg10
I5
sg11
VmiR16
p3129
sg13
I1
sasg20
(lp3130
(dp3131
g7
I84
sg23
VC0036341
p3132
sg10
I13
sg11
Vschizophrenia
p3133
sg13
I1
sasa(dp3134
g2
S'Given the role of RGS4 in regulating GPCRs, and consequently the strength of NMDAR signaling, these findings could contribute to the molecular substrate for NMDAR hypofunction in DLPFC pyramidal cells in schizophrenia.\n'
p3135
sg4
(lp3136
(dp3137
g7
I18
sg8
VP49798
p3138
sg10
I4
sg11
VRGS4
p3139
sg13
I1
sa(dp3140
g7
I37
sg8
g18
sg10
I5
sg11
VGPCRs
p3141
sg13
I1
sasg20
(lp3142
(dp3143
g7
I163
sg23
VC0679221
p3144
sg10
I12
sg11
Vhypofunction
p3145
sg13
I1
sa(dp3146
g7
I204
sg23
VC0036341
p3147
sg10
I13
sg11
Vschizophrenia
p3148
sg13
I1
sasa(dp3149
g2
S'Olanzapine coadministered with PCP normalized 34% of the 146 PCP-induced probe set expression changes, and a network of 17 olanzapine-normalized genes was identified enriched in schizophrenia candidate genes containing RGS4, SYN1 and AKT as nodes.\n'
p3150
sg4
(lp3151
(dp3152
g7
I234
sg8
g18
sg10
I3
sg11
VAKT
p3153
sg13
I1
sa(dp3154
g7
I225
sg8
VP17600
p3155
sg10
I4
sg11
VSYN1
p3156
sg13
I1
sa(dp3157
g7
I219
sg8
VP49798
p3158
sg10
I4
sg11
VRGS4
p3159
sg13
I1
sasg20
(lp3160
(dp3161
g7
I178
sg23
VC0036341
p3162
sg10
I13
sg11
Vschizophrenia
p3163
sg13
I1
sa(dp3164
g7
I31
sg23
VC2919094
p3165
sg10
I3
sg11
VPCP
p3166
sg13
I1
sa(dp3167
g7
I31
sg23
VC2919094
p3168
sg10
I3
sg11
VPCP
p3169
sg13
I1
sasa(dp3170
g2
S'In the present study we investigated the possible association of polymorphisms from five candidate genes RGS4, SLC6A3, PIP4K2A, BDNF, PI4KA with response to antipsychotic in variably ill schizophrenia patients.\n'
p3171
sg4
(lp3172
(dp3173
g7
I111
sg8
g18
sg10
I6
sg11
VSLC6A3
p3174
sg13
I1
sa(dp3175
g7
I105
sg8
VP49798
p3176
sg10
I4
sg11
VRGS4
p3177
sg13
I1
sa(dp3178
g7
I134
sg8
VP42356
p3179
sg10
I5
sg11
VPI4KA
p3180
sg13
I1
sa(dp3181
g7
I119
sg8
VP48426
p3182
sg10
I7
sg11
VPIP4K2A
p3183
sg13
I1
sasg20
(lp3184
(dp3185
g7
I183
sg23
VC0231218
p3186
sg10
I3
sg11
Vill
p3187
sg13
I1
sa(dp3188
g7
I187
sg23
VC0036341
p3189
sg10
I13
sg11
Vschizophrenia
p3190
sg13
I1
sasa(dp3191
g2
S'Using data from the Osteoarthritis Initiative, we quantified daily walking as average steps/day from an accelerometer (Actigraph GTM1) worn for &gt;10 hours/day over one week.\n'
p3192
sg4
(lp3193
sg20
(lp3194
(dp3195
g7
I20
sg23
VC0029408
p3196
sg10
I14
sg11
VOsteoarthritis
p3197
sg13
I1
sasa(dp3198
g2
S'We aimed to quantify CNVs in glutathione S-transferase M1 (GSTM1) gene and determine its genetic contribution in Tunisian rheumatoid arthritis (RA) and its subsets through an innovative technique for quantification.\n'
p3199
sg4
(lp3200
(dp3201
g7
I29
sg8
VP09488
p3202
sg10
I28
sg11
Vglutathione S-transferase M1
p3203
sg13
I3
sa(dp3204
g7
I59
sg8
VP09488
p3205
sg10
I5
sg11
VGSTM1
p3206
sg13
I1
sasg20
(lp3207
(dp3208
g7
I122
sg23
VC0003873
p3209
sg10
I20
sg11
Vrheumatoid arthritis
p3210
sg13
I2
sa(dp3211
g7
I144
sg23
VC0003873
p3212
sg10
I2
sg11
VRA
p3213
sg13
I1
sasa(dp3214
g2
S'This study aimed to determine whether Glutathione S-transferase M1 (GSTM1), P1 (GSTT1), NFKB1 polymorphisms confer susceptibility to systemic lupus erythematosus (SLE).\n'
p3215
sg4
(lp3216
(dp3217
g7
I88
sg8
VP19838
p3218
sg10
I5
sg11
VNFKB1
p3219
sg13
I1
sa(dp3220
g7
I80
sg8
VP30711
p3221
sg10
I5
sg11
VGSTT1
p3222
sg13
I1
sa(dp3223
g7
I38
sg8
VP09488
p3224
sg10
I28
sg11
VGlutathione S-transferase M1
p3225
sg13
I3
sa(dp3226
g7
I68
sg8
VP09488
p3227
sg10
I5
sg11
VGSTM1
p3228
sg13
I1
sa(dp3229
g7
I76
sg8
VP14222
p3230
sg10
I2
sg11
VP1
p3231
sg13
I1
sasg20
(lp3232
(dp3233
g7
I133
sg23
VC0024141
p3234
sg10
I28
sg11
Vsystemic lupus erythematosus
p3235
sg13
I3
sa(dp3236
g7
I163
sg23
VC0024141
p3237
sg10
I3
sg11
VSLE
p3238
sg13
I1
sasa(dp3239
g2
S'Previous studies have suggested that the null polymorphism of the glutathione S-transferases M1/T1 (GSTM1/T1) gene may be associated with the risk of developing systemic lupus erythematosus (SLE).\n'
p3240
sg4
(lp3241
(dp3242
g7
I100
sg8
VP09488
p3243
sg10
I5
sg11
VGSTM1
p3244
sg13
I1
sa(dp3245
g7
I66
sg8
VP09211
p3246
sg10
I29
sg11
Vglutathione S-transferases M1
p3247
sg13
I3
sasg20
(lp3248
(dp3249
g7
I191
sg23
VC0024141
p3250
sg10
I3
sg11
VSLE
p3251
sg13
I1
sa(dp3252
g7
I161
sg23
VC0024141
p3253
sg10
I28
sg11
Vsystemic lupus erythematosus
p3254
sg13
I3
sasa(dp3255
g2
S'More recently, IGFBP-6 was found to promote the migration of rhabdomyosarcoma (RMS) cells in an IGF-independent manner, and MAPK pathways were involved in this process.\n'
p3256
sg4
(lp3257
(dp3258
g7
I124
sg8
VP53779
p3259
sg10
I4
sg11
VMAPK
p3260
sg13
I1
sa(dp3261
g7
I15
sg8
VP01344
p3262
sg10
I3
sg11
VIGF
p3263
sg13
I1
sa(dp3264
g7
I15
sg8
VP24592
p3265
sg10
I7
sg11
VIGFBP-6
p3266
sg13
I1
sasg20
(lp3267
(dp3268
g7
I79
sg23
VC0035412
p3269
sg10
I3
sg11
VRMS
p3270
sg13
I1
sa(dp3271
g7
I61
sg23
VC0035412
p3272
sg10
I16
sg11
Vrhabdomyosarcoma
p3273
sg13
I1
sasa(dp3274
g2
S'Although RD rhabdomyosarcoma cells express IGF-II, we previously showed that mIGFBP-6 promoted migration through an IGF-independent, p38-dependent pathway.\n'
p3275
sg4
(lp3276
(dp3277
g7
I43
sg8
VP01344
p3278
sg10
I6
sg11
VIGF-II
p3279
sg13
I1
sa(dp3280
g7
I43
sg8
VP01344
p3281
sg10
I3
sg11
VIGF
p3282
sg13
I1
sa(dp3283
g7
I133
sg8
VP46108
p3284
sg10
I3
sg11
Vp38
p3285
sg13
I1
sasg20
(lp3286
(dp3287
g7
I12
sg23
VC0035412
p3288
sg10
I16
sg11
Vrhabdomyosarcoma
p3289
sg13
I1
sasa(dp3290
g2
S'We further studied the role of MAP kinases in IGFBP-6-induced migration of Rh30 rhabdomyosarcoma cells, which also express IGF-II.\n'
p3291
sg4
(lp3292
(dp3293
g7
I123
sg8
VP01344
p3294
sg10
I6
sg11
VIGF-II
p3295
sg13
I1
sa(dp3296
g7
I46
sg8
VP24592
p3297
sg10
I7
sg11
VIGFBP-6
p3298
sg13
I1
sa(dp3299
g7
I31
sg8
g18
sg10
I11
sg11
VMAP kinases
p3300
sg13
I2
sasg20
(lp3301
(dp3302
g7
I80
sg23
VC0035412
p3303
sg10
I16
sg11
Vrhabdomyosarcoma
p3304
sg13
I1
sasa(dp3305
g2
S'These results indicate that IGFBP-6 promotes Rh30 rhabdomyosarcoma chemotaxis in an IGF-independent manner, and that MAPK signaling pathways and their cross-talk play an important role in this process.\n'
p3306
sg4
(lp3307
(dp3308
g7
I28
sg8
VP01344
p3309
sg10
I3
sg11
VIGF
p3310
sg13
I1
sa(dp3311
g7
I28
sg8
VP24592
p3312
sg10
I7
sg11
VIGFBP-6
p3313
sg13
I1
sa(dp3314
g7
I117
sg8
VP53779
p3315
sg10
I4
sg11
VMAPK
p3316
sg13
I1
sa(dp3317
g7
I45
sg8
g18
sg10
I32
sg11
VRh30 rhabdomyosarcoma chemotaxis
p3318
sg13
I3
sasg20
(lp3319
(dp3320
g7
I50
sg23
VC0035412
p3321
sg10
I16
sg11
Vrhabdomyosarcoma
p3322
sg13
I1
sasa(dp3323
g2
S'We report here that both exogenous and endogenous IGFBP-6 could be imported into the nuclei of rhabdomyosarcoma and HEK-293 cells.\n'
p3324
sg4
(lp3325
(dp3326
g7
I50
sg8
VP24592
p3327
sg10
I7
sg11
VIGFBP-6
p3328
sg13
I1
sasg20
(lp3329
(dp3330
g7
I95
sg23
VC0035412
p3331
sg10
I16
sg11
Vrhabdomyosarcoma
p3332
sg13
I1
sasa(dp3333
g2
S'Wild-type and mutant IGFBP-6, as well as IGF-II, induced cell migration in RD rhabdomyosarcoma and LIM 1215 colon cancer cells.\n'
p3334
sg4
(lp3335
(dp3336
g7
I14
sg8
g18
sg10
I14
sg11
Vmutant IGFBP-6
p3337
sg13
I2
sa(dp3338
g7
I41
sg8
VP01344
p3339
sg10
I6
sg11
VIGF-II
p3340
sg13
I1
sa(dp3341
g7
I99
sg8
g18
sg10
I3
sg11
VLIM
p3342
sg13
I1
sa(dp3343
g7
I75
sg8
g18
sg10
I19
sg11
VRD rhabdomyosarcoma
p3344
sg13
I2
sasg20
(lp3345
(dp3346
g7
I78
sg23
VC0035412
p3347
sg10
I16
sg11
Vrhabdomyosarcoma
p3348
sg13
I1
sa(dp3349
g7
I14
sg23
VC0596988
p3350
sg10
I6
sg11
Vmutant
p3351
sg13
I1
sa(dp3352
g7
I108
sg23
VC0699790
p3353
sg10
I12
sg11
Vcolon cancer
p3354
sg13
I2
sasa(dp3355
g2
S'IGFBP-6 inhibits growth of a number of IGF-II-dependent cancers, including rhabdomyosarcoma, neuroblastoma and colon cancer.\n'
p3356
sg4
(lp3357
(dp3358
g7
I0
sg8
VP24592
p3359
sg10
I7
sg11
VIGFBP-6
p3360
sg13
I1
sa(dp3361
g7
I39
sg8
VP01344
p3362
sg10
I6
sg11
VIGF-II
p3363
sg13
I1
sasg20
(lp3364
(dp3365
g7
I111
sg23
VC0699790
p3366
sg10
I12
sg11
Vcolon cancer
p3367
sg13
I2
sa(dp3368
g7
I56
sg23
VC0006826
p3369
sg10
I7
sg11
Vcancers
p3370
sg13
I1
sa(dp3371
g7
I75
sg23
VC0035412
p3372
sg10
I16
sg11
Vrhabdomyosarcoma
p3373
sg13
I1
sa(dp3374
g7
I93
sg23
VC0027819
p3375
sg10
I13
sg11
Vneuroblastoma
p3376
sg13
I1
sasa(dp3377
g2
S'Treatment of Rh30 rhabdomyosarcoma cells with insulin-like growth factor binding protein-6 (IGFBP-6; 1000 ng/ml), which binds insulin-like growth factor-II with high affinity, inhibited growth in vitro (p &lt; 0.001).\n'
p3378
sg4
(lp3379
(dp3380
g7
I92
sg8
VP24592
p3381
sg10
I7
sg11
VIGFBP-6
p3382
sg13
I1
sa(dp3383
g7
I46
sg8
VP01308
p3384
sg10
I44
sg11
Vinsulin-like growth factor binding protein-6
p3385
sg13
I5
sa(dp3386
g7
I126
sg8
VP01308
p3387
sg10
I29
sg11
Vinsulin-like growth factor-II
p3388
sg13
I3
sasg20
(lp3389
(dp3390
g7
I18
sg23
VC0035412
p3391
sg10
I16
sg11
Vrhabdomyosarcoma
p3392
sg13
I1
sasa(dp3393
g2
S'CCI-779 thus acts additively with IGFBP-6 to reduce rhabdomyosarcoma growth both in vitro and in vivo.\n'
p3394
sg4
(lp3395
(dp3396
g7
I34
sg8
VP24592
p3397
sg10
I7
sg11
VIGFBP-6
p3398
sg13
I1
sasg20
(lp3399
(dp3400
g7
I52
sg23
VC0035412
p3401
sg10
I16
sg11
Vrhabdomyosarcoma
p3402
sg13
I1
sasa(dp3403
g2
S'Rhabdomyosarcoma cell lines overexpress insulin-like growth factor-II (IGF-II), an autocrine growth factor that is inhibited by insulin-like growth factor binding protein-6 (IGFBP-6).\n'
p3404
sg4
(lp3405
(dp3406
g7
I40
sg8
VP01308
p3407
sg10
I29
sg11
Vinsulin-like growth factor-II
p3408
sg13
I3
sa(dp3409
g7
I174
sg8
VP24592
p3410
sg10
I7
sg11
VIGFBP-6
p3411
sg13
I1
sa(dp3412
g7
I128
sg8
VP01308
p3413
sg10
I44
sg11
Vinsulin-like growth factor binding protein-6
p3414
sg13
I5
sa(dp3415
g7
I71
sg8
VP01344
p3416
sg10
I6
sg11
VIGF-II
p3417
sg13
I1
sasg20
(lp3418
(dp3419
g7
I0
sg23
VC0035412
p3420
sg10
I16
sg11
VRhabdomyosarcoma
p3421
sg13
I1
sasa(dp3422
g2
S'IGFBP-6 is associated with myoblast quiescence, and expression in rhabdomyosarcoma cells is low.\n'
p3423
sg4
(lp3424
(dp3425
g7
I0
sg8
VP24592
p3426
sg10
I7
sg11
VIGFBP-6
p3427
sg13
I1
sasg20
(lp3428
(dp3429
g7
I66
sg23
VC0035412
p3430
sg10
I16
sg11
Vrhabdomyosarcoma
p3431
sg13
I1
sasa(dp3432
g2
S'The effect of IGFBP-6 on 2 rhabdomyosarcoma cell lines, RD and Rh30, was studied.\n'
p3433
sg4
(lp3434
(dp3435
g7
I14
sg8
VP24592
p3436
sg10
I7
sg11
VIGFBP-6
p3437
sg13
I1
sasg20
(lp3438
(dp3439
g7
I27
sg23
VC0035412
p3440
sg10
I16
sg11
Vrhabdomyosarcoma
p3441
sg13
I1
sasa(dp3442
g2
S'IGFBP-6 therefore inhibits proliferation and promotes apoptosis of rhabdomyosarcoma in vitro and dramatically inhibits xenograft growth in vivo, at least in part by inhibiting IGF-II.\n'
p3443
sg4
(lp3444
(dp3445
g7
I0
sg8
VP24592
p3446
sg10
I7
sg11
VIGFBP-6
p3447
sg13
I1
sa(dp3448
g7
I176
sg8
VP01344
p3449
sg10
I6
sg11
VIGF-II
p3450
sg13
I1
sasg20
(lp3451
(dp3452
g7
I67
sg23
VC0035412
p3453
sg10
I16
sg11
Vrhabdomyosarcoma
p3454
sg13
I1
sa(dp3455
g7
I27
sg23
VC0334094
p3456
sg10
I13
sg11
Vproliferation
p3457
sg13
I1
sasa(dp3458
g2
S'Low expression of IGFBP-6 may therefore contribute to rhabdomyosarcoma growth and metastasis.\n'
p3459
sg4
(lp3460
(dp3461
g7
I18
sg8
VP24592
p3462
sg10
I7
sg11
VIGFBP-6
p3463
sg13
I1
sasg20
(lp3464
(dp3465
g7
I82
sg23
VC0027627
p3466
sg10
I10
sg11
Vmetastasis
p3467
sg13
I1
sa(dp3468
g7
I54
sg23
VC0035412
p3469
sg10
I16
sg11
Vrhabdomyosarcoma
p3470
sg13
I1
sasa(dp3471
g2
S'These loci, chosen for their location on HSA 1, are antithrombin 3 (AT3), renin (REN), complement component receptor 2 (CR2), phosphofructokinase muscle type (PFKM), Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog (FGR), alpha fucosidase (FUCA1), G-protein beta 1 subunit (GNB1), alpha 1A amylase, (AMY1), the neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS), and alpha skeletal actin (ACTA1).\n'
p3472
sg4
(lp3473
(dp3474
g7
I407
sg8
VP68133
p3475
sg10
I5
sg11
VACTA1
p3476
sg13
I1
sa(dp3477
g7
I294
sg8
VP04746
p3478
sg10
I16
sg11
Valpha 1A amylase
p3479
sg13
I3
sa(dp3480
g7
I374
sg8
VP01111
p3481
sg10
I4
sg11
VNRAS
p3482
sg13
I1
sa(dp3483
g7
I74
sg8
VP00797
p3484
sg10
I71
sg11
Vrenin (REN), complement component receptor 2 (CR2), phosphofructokinase
p3485
sg13
I8
sa(dp3486
g7
I253
sg8
VP04066
p3487
sg10
I5
sg11
VFUCA1
p3488
sg13
I1
sa(dp3489
g7
I261
sg8
g18
sg10
I24
sg11
VG-protein beta 1 subunit
p3490
sg13
I4
sa(dp3491
g7
I385
sg8
VP21817
p3492
sg10
I20
sg11
Valpha skeletal actin
p3493
sg13
I3
sa(dp3494
g7
I229
sg8
VP09769
p3495
sg10
I3
sg11
VFGR
p3496
sg13
I1
sa(dp3497
g7
I52
sg8
VP05546
p3498
sg10
I14
sg11
Vantithrombin 3
p3499
sg13
I2
sa(dp3500
g7
I41
sg8
g18
sg10
I5
sg11
VHSA 1
p3501
sg13
I2
sa(dp3502
g7
I287
sg8
VP62873
p3503
sg10
I4
sg11
VGNB1
p3504
sg13
I1
sa(dp3505
g7
I235
sg8
VP04066
p3506
sg10
I16
sg11
Valpha fucosidase
p3507
sg13
I2
sa(dp3508
g7
I68
sg8
VP05546
p3509
sg10
I3
sg11
VAT3
p3510
sg13
I1
sa(dp3511
g7
I313
sg8
VP04745
p3512
sg10
I4
sg11
VAMY1
p3513
sg13
I1
sasg20
(lp3514
(dp3515
g7
I189
sg23
VC1261473
p3516
sg10
I7
sg11
Vsarcoma
p3517
sg13
I1
sa(dp3518
g7
I324
sg23
VC0027819
p3519
sg10
I13
sg11
Vneuroblastoma
p3520
sg13
I1
sa(dp3521
g7
I41
sg23
VC0393754
p3522
sg10
I3
sg11
VHSA
p3523
sg13
I1
sasa(dp3524
g2
S'Using multiplex bead array and enzyme-linked immunosorbent assay, CXCL1, CXCL8, CXCL10, CXCL13, CCL20, CCL22, neurofilament light chain (NFL), neurofilament heavy chain, glial fibrillary acidic protein, chitinase-3-like-1, matrix metalloproteinase-9 and osteopontin were analysed in CSF from 41 patients with CIS or relapsing-remitting MS and 22 healthy controls.\n'
p3525
sg4
(lp3526
(dp3527
g7
I103
sg8
g18
sg10
I5
sg11
VCCL22
p3528
sg13
I1
sa(dp3529
g7
I80
sg8
VP02778
p3530
sg10
I6
sg11
VCXCL10
p3531
sg13
I1
sa(dp3532
g7
I143
sg8
VP12036
p3533
sg10
I25
sg11
Vneurofilament heavy chain
p3534
sg13
I3
sa(dp3535
g7
I223
sg8
VP14780
p3536
sg10
I26
sg11
Vmatrix metalloproteinase-9
p3537
sg13
I2
sa(dp3538
g7
I88
sg8
g18
sg10
I6
sg11
VCXCL13
p3539
sg13
I1
sa(dp3540
g7
I66
sg8
VP09341
p3541
sg10
I5
sg11
VCXCL1
p3542
sg13
I1
sa(dp3543
g7
I170
sg8
VP05230
p3544
sg10
I31
sg11
Vglial fibrillary acidic protein
p3545
sg13
I4
sa(dp3546
g7
I254
sg8
VP10451
p3547
sg10
I11
sg11
Vosteopontin
p3548
sg13
I1
sa(dp3549
g7
I203
sg8
g18
sg10
I18
sg11
Vchitinase-3-like-1
p3550
sg13
I1
sa(dp3551
g7
I110
sg8
g18
sg10
I25
sg11
Vneurofilament light chain
p3552
sg13
I3
sa(dp3553
g7
I137
sg8
VP07196
p3554
sg10
I3
sg11
VNFL
p3555
sg13
I1
sa(dp3556
g7
I96
sg8
VP78556
p3557
sg10
I5
sg11
VCCL20
p3558
sg13
I1
sasg20
(lp3559
(dp3560
g7
I309
sg23
VC0007099
p3561
sg10
I3
sg11
VCIS
p3562
sg13
I1
sasa(dp3563
g2
S'Increased levels of CCL22, CXCL10 and sCD40L characterized relapsing-remitting MS patients with the presence of gadolinium-enhancing lesions; decreased CCL2 and increased CXCL1 and CCL5 were typical of relapsing-remitting MS patients irrespectively of the presence of gadolinium-enhancing lesions.\n'
p3564
sg4
(lp3565
(dp3566
g7
I20
sg8
g18
sg10
I5
sg11
VCCL22
p3567
sg13
I1
sa(dp3568
g7
I181
sg8
VP13501
p3569
sg10
I4
sg11
VCCL5
p3570
sg13
I1
sa(dp3571
g7
I27
sg8
VP02778
p3572
sg10
I6
sg11
VCXCL10
p3573
sg13
I1
sa(dp3574
g7
I27
sg8
VP09341
p3575
sg10
I5
sg11
VCXCL1
p3576
sg13
I1
sasg20
(lp3577
sa(dp3578
g2
S'The CCL22 levels were also significantly higher in women with RRMS and PRMS patterns in comparison to healthy women (P &lt; 0.05 and P &lt; 0.01, respectively).\n'
p3579
sg4
(lp3580
(dp3581
g7
I4
sg8
g18
sg10
I5
sg11
VCCL22
p3582
sg13
I1
sasg20
(lp3583
sa(dp3584
g2
S'To study the prevalence of Hashimoto thyroiditis (HT), anti-thyroid autoantibodies (anti-thyroglobulin or TgAb and thyroperoxidase or TPOAb) in systemic lupus erythematosus (SLE) patients.\n'
p3585
sg4
(lp3586
(dp3587
g7
I115
sg8
VP40225
p3588
sg10
I15
sg11
Vthyroperoxidase
p3589
sg13
I1
sa(dp3590
g7
I84
sg8
g18
sg10
I18
sg11
Vanti-thyroglobulin
p3591
sg13
I1
sasg20
(lp3592
(dp3593
g7
I144
sg23
VC0024141
p3594
sg10
I28
sg11
Vsystemic lupus erythematosus
p3595
sg13
I3
sa(dp3596
g7
I50
sg23
VC0920350
p3597
sg10
I2
sg11
VHT
p3598
sg13
I1
sa(dp3599
g7
I27
sg23
VC0920350
p3600
sg10
I21
sg11
VHashimoto thyroiditis
p3601
sg13
I2
sa(dp3602
g7
I174
sg23
VC0024141
p3603
sg10
I3
sg11
VSLE
p3604
sg13
I1
sasa(dp3605
g2
S'The present study indicated that APH1B, JAM3, FBLN2, CSAD and PSTPIP2 may have important roles in the progression of atherosclerosis in females and may be potential biomarkers for early diagnosis and prognosis as well as treatment targets for this disease.\n'
p3606
sg4
(lp3607
(dp3608
g7
I62
sg8
g18
sg10
I7
sg11
VPSTPIP2
p3609
sg13
I1
sa(dp3610
g7
I33
sg8
g18
sg10
I5
sg11
VAPH1B
p3611
sg13
I1
sa(dp3612
g7
I53
sg8
g18
sg10
I4
sg11
VCSAD
p3613
sg13
I1
sa(dp3614
g7
I46
sg8
VP98095
p3615
sg10
I5
sg11
VFBLN2
p3616
sg13
I1
sa(dp3617
g7
I40
sg8
g18
sg10
I4
sg11
VJAM3
p3618
sg13
I1
sasg20
(lp3619
(dp3620
g7
I117
sg23
VC0004153
p3621
sg10
I15
sg11
Vatherosclerosis
p3622
sg13
I1
sasa(dp3623
g2
S'APH1A and APH1B, a subunit of the Gamma-secretase complex, also modulated ABeta42/ABeta40 ratio without any alterations in Epsilon-cleavage, a result in contrast to what has been observed with PS1 and APP FAD mutations.\n'
p3624
sg4
(lp3625
(dp3626
g7
I201
sg8
VP51587
p3627
sg10
I7
sg11
VAPP FAD
p3628
sg13
I2
sa(dp3629
g7
I10
sg8
g18
sg10
I5
sg11
VAPH1B
p3630
sg13
I1
sa(dp3631
g7
I0
sg8
g18
sg10
I5
sg11
VAPH1A
p3632
sg13
I1
sa(dp3633
g7
I193
sg8
VP49768
p3634
sg10
I3
sg11
VPS1
p3635
sg13
I1
sasg20
(lp3636
sa(dp3637
g2
S"Parkinson's disease (n = 86) and control (n = 161) DNA were genotyped for 19 regulatory region tagging single-nucleotide polymorphisms (SNPs) within nine genes (APP, ADAM10, BACE1, BACE2, PSEN1, PSEN2, PEN2, NCSTN, and APH1B) involved in the cleavage of APP.\n"
p3638
sg4
(lp3639
(dp3640
g7
I174
sg8
VP56817
p3641
sg10
I5
sg11
VBACE1
p3642
sg13
I1
sa(dp3643
g7
I181
sg8
g18
sg10
I5
sg11
VBACE2
p3644
sg13
I1
sa(dp3645
g7
I188
sg8
VP49768
p3646
sg10
I5
sg11
VPSEN1
p3647
sg13
I1
sa(dp3648
g7
I202
sg8
g18
sg10
I4
sg11
VPEN2
p3649
sg13
I1
sa(dp3650
g7
I161
sg8
g18
sg10
I3
sg11
VAPP
p3651
sg13
I1
sa(dp3652
g7
I208
sg8
g18
sg10
I5
sg11
VNCSTN
p3653
sg13
I1
sa(dp3654
g7
I161
sg8
g18
sg10
I3
sg11
VAPP
p3655
sg13
I1
sa(dp3656
g7
I166
sg8
g18
sg10
I6
sg11
VADAM10
p3657
sg13
I1
sa(dp3658
g7
I195
sg8
VP49810
p3659
sg10
I5
sg11
VPSEN2
p3660
sg13
I1
sa(dp3661
g7
I219
sg8
g18
sg10
I5
sg11
VAPH1B
p3662
sg13
I1
sasg20
(lp3663
(dp3664
g7
I0
sg23
VC0030567
p3665
sg10
I19
sg11
VParkinson's disease
p3666
sg13
I2
sasa(dp3667
g2
S'Neuregulin 1 (NRG1) and the Gamma-secretase subunit APH1B have been previously implicated as genetic risk factors for schizophrenia and schizophrenia relevant deficits have been observed in rodent models with loss of function mutations in either gene.\n'
p3668
sg4
(lp3669
(dp3670
g7
I14
sg8
VP04196
p3671
sg10
I4
sg11
VNRG1
p3672
sg13
I1
sa(dp3673
g7
I28
sg8
g18
sg10
I29
sg11
VGamma-secretase subunit APH1B
p3674
sg13
I3
sa(dp3675
g7
I0
sg8
VP04196
p3676
sg10
I12
sg11
VNeuregulin 1
p3677
sg13
I2
sasg20
(lp3678
(dp3679
g7
I118
sg23
VC0036341
p3680
sg10
I13
sg11
Vschizophrenia
p3681
sg13
I1
sa(dp3682
g7
I118
sg23
VC0036341
p3683
sg10
I13
sg11
Vschizophrenia
p3684
sg13
I1
sasa(dp3685
g2
S'In conclusion, our study sheds light on the physiological role of Aph1b-Gamma-secretase in brain and provides a new mechanistic perspective on the relevance of NRG1 processing in schizophrenia.\n'
p3686
sg4
(lp3687
(dp3688
g7
I66
sg8
g18
sg10
I21
sg11
VAph1b-Gamma-secretase
p3689
sg13
I1
sasg20
(lp3690
(dp3691
g7
I179
sg23
VC0036341
p3692
sg10
I13
sg11
Vschizophrenia
p3693
sg13
I1
sasa(dp3694
g2
S'Here, we for the first time determined mRNA expression levels of presenilin-1, presenilin-2, Aph1a, Aph1b, PEN-2, and nicastrin in a set of breast cancer tissue samples (N = 55) by quantitative real-time PCR in order to clarify the clinical significance of the expression of different Gamma-secretase complex components in breast cancer.\n'
p3695
sg4
(lp3696
(dp3697
g7
I100
sg8
g18
sg10
I5
sg11
VAph1b
p3698
sg13
I1
sa(dp3699
g7
I107
sg8
g18
sg10
I5
sg11
VPEN-2
p3700
sg13
I1
sa(dp3701
g7
I93
sg8
g18
sg10
I5
sg11
VAph1a
p3702
sg13
I1
sa(dp3703
g7
I118
sg8
g18
sg10
I9
sg11
Vnicastrin
p3704
sg13
I1
sa(dp3705
g7
I65
sg8
VP49768
p3706
sg10
I26
sg11
Vpresenilin-1, presenilin-2
p3707
sg13
I2
sasg20
(lp3708
(dp3709
g7
I140
sg23
VC0678222
p3710
sg10
I13
sg11
Vbreast cancer
p3711
sg13
I2
sa(dp3712
g7
I140
sg23
VC0678222
p3713
sg10
I13
sg11
Vbreast cancer
p3714
sg13
I2
sasa(dp3715
g2
S'Results suggest that distinct neuropeptides are able to reduce the number of lymphocytes at inflammatory sites during existing eosinophilia by inhibiting eosinophil IL-16 release, thus attenuating the pro-inflammatory action of lymphocytes and monocytes.\n'
p3716
sg4
(lp3717
(dp3718
g7
I165
sg8
g18
sg10
I5
sg11
VIL-16
p3719
sg13
I1
sasg20
(lp3720
(dp3721
g7
I127
sg23
VC0014457
p3722
sg10
I12
sg11
Veosinophilia
p3723
sg13
I1
sasa(dp3724
g2
S'Although release of sensory neuropeptides is involved in most conditions of airway hyperresponsiveness, increased bronchial resistance, and lung eosinophilia, the role of these nervous system-derived mediators in pulmonary diseases may be underestimated.\n'
p3725
sg4
(lp3726
sg20
(lp3727
(dp3728
g7
I213
sg23
VC0024115
p3729
sg10
I18
sg11
Vpulmonary diseases
p3730
sg13
I2
sa(dp3731
g7
I145
sg23
VC0014457
p3732
sg10
I12
sg11
Veosinophilia
p3733
sg13
I1
sa(dp3734
g7
I177
sg23
VC0027769
p3735
sg10
I7
sg11
Vnervous
p3736
sg13
I1
sasa(dp3737
g2
S'In this study, the role of neuropeptides in the IL-5-induced airway hyperresponsiveness and eosinophilia in the guinea pig was examined using selective neurokinin receptor antagonists.\n'
p3738
sg4
(lp3739
(dp3740
g7
I48
sg8
VP05113
p3741
sg10
I4
sg11
VIL-5
p3742
sg13
I1
sa(dp3743
g7
I152
sg8
g18
sg10
I19
sg11
Vneurokinin receptor
p3744
sg13
I2
sasg20
(lp3745
(dp3746
g7
I92
sg23
VC0014457
p3747
sg10
I12
sg11
Veosinophilia
p3748
sg13
I1
sasa(dp3749
g2
S'To determine if PPEF-2 alone or in combination with PPEF-1 plays a role in rhodopsin dephosphorylation and to determine if retinal degeneration accompanies mutation of PPEF-1 and/or PPEF-2, we have produced mice carrying targeted disruptions in the PPEF-1 and PPEF-2 genes.\n'
p3750
sg4
(lp3751
(dp3752
g7
I16
sg8
g18
sg10
I6
sg11
VPPEF-2
p3753
sg13
I1
sa(dp3754
g7
I260
sg8
g18
sg10
I12
sg11
VPPEF-2 genes
p3755
sg13
I2
sa(dp3756
g7
I75
sg8
VP08100
p3757
sg10
I9
sg11
Vrhodopsin
p3758
sg13
I1
sa(dp3759
g7
I16
sg8
g18
sg10
I6
sg11
VPPEF-2
p3760
sg13
I1
sa(dp3761
g7
I52
sg8
g18
sg10
I6
sg11
VPPEF-1
p3762
sg13
I1
sa(dp3763
g7
I52
sg8
g18
sg10
I6
sg11
VPPEF-1
p3764
sg13
I1
sa(dp3765
g7
I52
sg8
g18
sg10
I6
sg11
VPPEF-1
p3766
sg13
I1
sasg20
(lp3767
(dp3768
g7
I123
sg23
VC0035304
p3769
sg10
I20
sg11
Vretinal degeneration
p3770
sg13
I2
sasa(dp3771
g2
S'These data indicate that, in contrast to loss of rdgC function in Drosophila, elimination of PPEF function does not cause retinal degeneration in vertebrates.\n'
p3772
sg4
(lp3773
(dp3774
g7
I93
sg8
g18
sg10
I4
sg11
VPPEF
p3775
sg13
I1
sasg20
(lp3776
(dp3777
g7
I122
sg23
VC0035304
p3778
sg10
I20
sg11
Vretinal degeneration
p3779
sg13
I2
sasa(dp3780
g2
S'Unexpectedly this large deletion abolishes exons of three adjacent genes: serine-threonine phosphatase gene (PPEF-1)/serine-threonine protein phosphatase gene (PP7), retinoschisis gene (RS1), and serine-threonine kinase gene (STK9).\n'
p3781
sg4
(lp3782
(dp3783
g7
I226
sg8
g18
sg10
I4
sg11
VSTK9
p3784
sg13
I1
sa(dp3785
g7
I186
sg8
VP63244
p3786
sg10
I3
sg11
VRS1
p3787
sg13
I1
sa(dp3788
g7
I74
sg8
VP53041
p3789
sg10
I33
sg11
Vserine-threonine phosphatase gene
p3790
sg13
I3
sa(dp3791
g7
I196
sg8
g18
sg10
I28
sg11
Vserine-threonine kinase gene
p3792
sg13
I3
sa(dp3793
g7
I160
sg8
g18
sg10
I3
sg11
VPP7
p3794
sg13
I1
sasg20
(lp3795
(dp3796
g7
I166
sg23
VC0152439
p3797
sg10
I13
sg11
Vretinoschisis
p3798
sg13
I1
sasa(dp3799
g2
S'Despite these two unique deletions, which either lead to severely defective transcription or total absence of the retinoschisin and PPEF-1 protein, all the patients have a typical retinoschisis phenotype.\n'
p3800
sg4
(lp3801
(dp3802
g7
I114
sg8
g18
sg10
I13
sg11
Vretinoschisin
p3803
sg13
I1
sa(dp3804
g7
I132
sg8
g18
sg10
I14
sg11
VPPEF-1 protein
p3805
sg13
I2
sasg20
(lp3806
(dp3807
g7
I180
sg23
VC0152439
p3808
sg10
I13
sg11
Vretinoschisis
p3809
sg13
I1
sasa(dp3810
g2
S'This region of PP7 is similar to the Drosophila retinal degeneration C gene product (rdgC), and PP7 and rdgC share 42.1% identity.\n'
p3811
sg4
(lp3812
(dp3813
g7
I15
sg8
g18
sg10
I3
sg11
VPP7
p3814
sg13
I1
sa(dp3815
g7
I15
sg8
g18
sg10
I3
sg11
VPP7
p3816
sg13
I1
sasg20
(lp3817
(dp3818
g7
I48
sg23
VC0035304
p3819
sg10
I20
sg11
Vretinal degeneration
p3820
sg13
I2
sasa(dp3821
g2
S'Ataxia-telangiectasia mutated kinase (ATM) is a serine/threonine kinase.\n'
p3822
sg4
(lp3823
(dp3824
g7
I48
sg8
VP42345
p3825
sg10
I23
sg11
Vserine/threonine kinase
p3826
sg13
I2
sa(dp3827
g7
I38
sg8
g18
sg10
I3
sg11
VATM
p3828
sg13
I1
sa(dp3829
g7
I0
sg8
g18
sg10
I36
sg11
VAtaxia-telangiectasia mutated kinase
p3830
sg13
I3
sasg20
(lp3831
(dp3832
g7
I0
sg23
VC0004135
p3833
sg10
I21
sg11
VAtaxia-telangiectasia
p3834
sg13
I1
sasa(dp3835
g2
S'Mutations in the ATM gene cause a rare autosomal multisystemic disease known as Ataxia-telangiectasia (AT).\n'
p3836
sg4
(lp3837
(dp3838
g7
I80
sg8
g18
sg10
I21
sg11
VAtaxia-telangiectasia
p3839
sg13
I1
sa(dp3840
g7
I17
sg8
g18
sg10
I8
sg11
VATM gene
p3841
sg13
I2
sa(dp3842
g7
I17
sg8
g18
sg10
I2
sg11
VAT
p3843
sg13
I1
sasg20
(lp3844
(dp3845
g7
I80
sg23
VC0004135
p3846
sg10
I21
sg11
VAtaxia-telangiectasia
p3847
sg13
I1
sa(dp3848
g7
I17
sg23
VC0004135
p3849
sg10
I2
sg11
VAT
p3850
sg13
I1
sasa(dp3851
g2
S'This review summarizes the role of ATM in the heart, specifically in cardiac remodeling following Beta-adrenergic receptor stimulation and myocardial infarction.\n'
p3852
sg4
(lp3853
(dp3854
g7
I98
sg8
g18
sg10
I24
sg11
VBeta-adrenergic receptor
p3855
sg13
I2
sa(dp3856
g7
I35
sg8
g18
sg10
I3
sg11
VATM
p3857
sg13
I1
sasg20
(lp3858
(dp3859
g7
I139
sg23
VC0027051
p3860
sg10
I21
sg11
Vmyocardial infarction
p3861
sg13
I2
sasa(dp3862
g2
S'Identification of the gene defective in this syndrome, ataxia-telangiectasia mutated gene (ATM), and further characterization of the disorder together with a greater insight into the function of the ATM protein have expanded our knowledge about the molecular pathogenesis of this disease.\n'
p3863
sg4
(lp3864
(dp3865
g7
I91
sg8
g18
sg10
I3
sg11
VATM
p3866
sg13
I1
sa(dp3867
g7
I199
sg8
g18
sg10
I11
sg11
VATM protein
p3868
sg13
I2
sa(dp3869
g7
I55
sg8
g18
sg10
I34
sg11
Vataxia-telangiectasia mutated gene
p3870
sg13
I3
sasg20
(lp3871
(dp3872
g7
I45
sg23
VC0039082
p3873
sg10
I8
sg11
Vsyndrome
p3874
sg13
I1
sa(dp3875
g7
I259
sg23
VC0699748
p3876
sg10
I12
sg11
Vpathogenesis
p3877
sg13
I1
sa(dp3878
g7
I55
sg23
VC0004135
p3879
sg10
I21
sg11
Vataxia-telangiectasia
p3880
sg13
I1
sasa(dp3881
g2
S'PcG-related target genes involved in DNA damage were identified, including p53, Ataxia telangiectasia mutated (ATM) and Forkhead box O3 (FOXO3).\n'
p3882
sg4
(lp3883
(dp3884
g7
I0
sg8
VP01893
p3885
sg10
I24
sg11
VPcG-related target genes
p3886
sg13
I3
sa(dp3887
g7
I137
sg8
g18
sg10
I5
sg11
VFOXO3
p3888
sg13
I1
sa(dp3889
g7
I75
sg8
VP42771
p3890
sg10
I3
sg11
Vp53
p3891
sg13
I1
sa(dp3892
g7
I80
sg8
g18
sg10
I55
sg11
VAtaxia telangiectasia mutated (ATM) and Forkhead box O3
p3893
sg13
I8
sasg20
(lp3894
(dp3895
g7
I80
sg23
VC0004135
p3896
sg10
I21
sg11
VAtaxia telangiectasia
p3897
sg13
I2
sa(dp3898
g7
I37
sg23
VC0012860
p3899
sg10
I10
sg11
VDNA damage
p3900
sg13
I2
sasa(dp3901
g2
S'Ataxia telangiectasia mutated (ATM) gene mutations may confer increased sensitivity to ionizing radiation and increased risk of late toxicity for cancer patients.\n'
p3902
sg4
(lp3903
(dp3904
g7
I7
sg8
g18
sg10
I43
sg11
Vtelangiectasia mutated (ATM) gene mutations
p3905
sg13
I5
sasg20
(lp3906
(dp3907
g7
I0
sg23
VC0004135
p3908
sg10
I21
sg11
VAtaxia telangiectasia
p3909
sg13
I2
sa(dp3910
g7
I146
sg23
VC0006826
p3911
sg10
I6
sg11
Vcancer
p3912
sg13
I1
sasa(dp3913
g2
S'Mutations in the ataxia telangiectasia mutated gene seem to play an important role in normal cell function and in cardiovascular remodeling.\n'
p3914
sg4
(lp3915
sg20
(lp3916
(dp3917
g7
I17
sg23
VC0004135
p3918
sg10
I21
sg11
Vataxia telangiectasia
p3919
sg13
I2
sasa(dp3920
g2
S'The ataxia-telangiectasia mutated proteins (ATM) pathway is considered an important factor in the DNA damage response of tumor formation, but its function in the development of PAH remains unknown.\n'
p3921
sg4
(lp3922
(dp3923
g7
I44
sg8
g18
sg10
I3
sg11
VATM
p3924
sg13
I1
sa(dp3925
g7
I4
sg8
g18
sg10
I38
sg11
Vataxia-telangiectasia mutated proteins
p3926
sg13
I3
sasg20
(lp3927
(dp3928
g7
I4
sg23
VC0004135
p3929
sg10
I21
sg11
Vataxia-telangiectasia
p3930
sg13
I1
sa(dp3931
g7
I98
sg23
VC0012860
p3932
sg10
I10
sg11
VDNA damage
p3933
sg13
I2
sa(dp3934
g7
I121
sg23
VC0027651
p3935
sg10
I5
sg11
Vtumor
p3936
sg13
I1
sa(dp3937
g7
I177
sg23
VC0152171
p3938
sg10
I3
sg11
VPAH
p3939
sg13
I1
sasa(dp3940
g2
S'Recent evidence indicates that ataxia telangiectasia mutated (ATM) is a cytoplasmic protein that involves in insulin signaling pathways.\n'
p3941
sg4
(lp3942
(dp3943
g7
I62
sg8
g18
sg10
I3
sg11
VATM
p3944
sg13
I1
sa(dp3945
g7
I31
sg8
g18
sg10
I29
sg11
Vataxia telangiectasia mutated
p3946
sg13
I3
sa(dp3947
g7
I109
sg8
VP01308
p3948
sg10
I7
sg11
Vinsulin
p3949
sg13
I1
sasg20
(lp3950
(dp3951
g7
I31
sg23
VC0004135
p3952
sg10
I21
sg11
Vataxia telangiectasia
p3953
sg13
I2
sasa(dp3954
g2
S'Ataxia telangiectasia (AT) is a progressive multisystem autosomal recessive disorder caused by mutations in the AT-mutated (ATM) gene.\n'
p3955
sg4
(lp3956
sg20
(lp3957
(dp3958
g7
I0
sg23
VC0004135
p3959
sg10
I21
sg11
VAtaxia telangiectasia
p3960
sg13
I2
sa(dp3961
g7
I23
sg23
VC0004135
p3962
sg10
I2
sg11
VAT
p3963
sg13
I1
sa(dp3964
g7
I23
sg23
VC0004135
p3965
sg10
I2
sg11
VAT
p3966
sg13
I1
sasa(dp3967
g2
S'Senescence-related genes (ie, p21, p53, and ataxia telangiectasia mutated [ATM]) were shown to be elevated after myocardial infarction (MI) in both mouse and human hearts.\n'
p3968
sg4
(lp3969
(dp3970
g7
I35
sg8
VP42771
p3971
sg10
I3
sg11
Vp53
p3972
sg13
I1
sa(dp3973
g7
I30
sg8
VP42857
p3974
sg10
I3
sg11
Vp21
p3975
sg13
I1
sasg20
(lp3976
(dp3977
g7
I44
sg23
VC0004135
p3978
sg10
I21
sg11
Vataxia telangiectasia
p3979
sg13
I2
sa(dp3980
g7
I113
sg23
VC0027051
p3981
sg10
I21
sg11
Vmyocardial infarction
p3982
sg13
I2
sa(dp3983
g7
I136
sg23
VC0027051
p3984
sg10
I2
sg11
VMI
p3985
sg13
I1
sasa(dp3986
g2
S'Results showed that splenic granulocytic (G-)MDSCs were significantly expanded by increasing the expression of CCR1 (CC chemokine receptor 1) in diseased MRL/lpr lupus mice and in high-disease-activity SLE patients.\n'
p3987
sg4
(lp3988
(dp3989
g7
I111
sg8
VP32246
p3990
sg10
I4
sg11
VCCR1
p3991
sg13
I1
sa(dp3992
g7
I120
sg8
VP61073
p3993
sg10
I20
sg11
Vchemokine receptor 1
p3994
sg13
I3
sasg20
(lp3995
(dp3996
g7
I202
sg23
VC0014060
p3997
sg10
I3
sg11
VSLE
p3998
sg13
I1
sa(dp3999
g7
I162
sg23
VC0024131
p4000
sg10
I5
sg11
Vlupus
p4001
sg13
I1
sasa(dp4002
g2
S'Our results support a central role for G9a- and EZH2-mediated histone hypermethylation and a model of bidirectional, mutually reinforcing, and interdependent crosstalk between histone hypermethylation and DNA methylation in COX-2 epigenetic silencing in IPF.-Coward, W. R., Feghali-Bostwick, C. A., Jenkins, G., Knox, A. J., Pang, L. A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis.\n'
p4003
sg4
(lp4004
(dp4005
g7
I397
sg8
VP35354
p4006
sg10
I16
sg11
Vcyclooxygenase-2
p4007
sg13
I1
sa(dp4008
g7
I48
sg8
g18
sg10
I4
sg11
VEZH2
p4009
sg13
I1
sa(dp4010
g7
I48
sg8
g18
sg10
I4
sg11
VEZH2
p4011
sg13
I1
sa(dp4012
g7
I62
sg8
VP62805
p4013
sg10
I7
sg11
Vhistone
p4014
sg13
I1
sa(dp4015
g7
I62
sg8
VP62805
p4016
sg10
I7
sg11
Vhistone
p4017
sg13
I1
sasg20
(lp4018
(dp4019
g7
I417
sg23
VC3161101
p4020
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p4021
sg13
I3
sasa(dp4022
g2
S'We investigated whether KIF6 Trp719Arg genotypes affect cardiovascular outcomes and efficacy of statin therapy in patients with type 2 diabetes mellitus undergoing hemodialysis.\n'
p4023
sg4
(lp4024
(dp4025
g7
I24
sg8
g18
sg10
I24
sg11
VKIF6 Trp719Arg genotypes
p4026
sg13
I3
sasg20
(lp4027
(dp4028
g7
I128
sg23
VC0011860
p4029
sg10
I24
sg11
Vtype 2 diabetes mellitus
p4030
sg13
I4
sasa(dp4031
g2
S'In patients with type 2 diabetes mellitus on hemodialysis, KIF6 Trp719Arg genotypes were not associated with adverse cardiovascular outcomes during follow-up or with the efficacy of atorvastatin therapy.\n'
p4032
sg4
(lp4033
(dp4034
g7
I59
sg8
g18
sg10
I24
sg11
VKIF6 Trp719Arg genotypes
p4035
sg13
I3
sasg20
(lp4036
(dp4037
g7
I17
sg23
VC0011860
p4038
sg10
I24
sg11
Vtype 2 diabetes mellitus
p4039
sg13
I4
sasa(dp4040
g2
S'When compared with BMI- and blood pressure-matched control subjects, subjects with diabetes were associated with concentric LV remodeling, higher MTG, impaired myocardial energetics, and impaired systolic strain indicating a subtle contractile dysfunction.\n'
p4041
sg4
(lp4042
sg20
(lp4043
(dp4044
g7
I83
sg23
VC0011849
p4045
sg10
I8
sg11
Vdiabetes
p4046
sg13
I1
sa(dp4047
g7
I151
sg23
VC0684336
p4048
sg10
I8
sg11
Vimpaired
p4049
sg13
I1
sa(dp4050
g7
I151
sg23
VC0684336
p4051
sg10
I8
sg11
Vimpaired
p4052
sg13
I1
sasa(dp4053
g2
S'Because cardiac steatosis is modifiable, strategies aimed at reducing MTG may be beneficial in reversing concentric remodeling and improving contractile function in the hearts of patients with diabetes.\n'
p4054
sg4
(lp4055
sg20
(lp4056
(dp4057
g7
I193
sg23
VC0011849
p4058
sg10
I8
sg11
Vdiabetes
p4059
sg13
I1
sa(dp4060
g7
I16
sg23
VC0152254
p4061
sg10
I9
sg11
Vsteatosis
p4062
sg13
I1
sasa(dp4063
g2
S'MTG content and hypertriglyceridemia were determinants of the frontal plane QRS and WC and hyperglycemia were predictors of the QRS voltage.\n'
p4064
sg4
(lp4065
sg20
(lp4066
(dp4067
g7
I91
sg23
VC0020456
p4068
sg10
I13
sg11
Vhyperglycemia
p4069
sg13
I1
sasa(dp4070
g2
S'Excessive myocardial triglyceride (MTG) content in obesity and type 2 diabetes is associated with impaired cardiac function.\n'
p4071
sg4
(lp4072
sg20
(lp4073
(dp4074
g7
I98
sg23
VC0684336
p4075
sg10
I8
sg11
Vimpaired
p4076
sg13
I1
sa(dp4077
g7
I63
sg23
VC0011860
p4078
sg10
I15
sg11
Vtype 2 diabetes
p4079
sg13
I3
sa(dp4080
g7
I51
sg23
VC0028754
p4081
sg10
I7
sg11
Vobesity
p4082
sg13
I1
sasa(dp4083
g2
S'This was a nested sub-study of a randomised placebo-controlled trial of the effect of 6 months of treatment with rosiglitazone added to existing therapy on myocardial triglyceride (mTG) content in patients with type 2 diabetes (T2D) and prevalent cardiovascular disease (CVD) or at least one additional risk factor.\n'
p4084
sg4
(lp4085
(dp4086
g7
I181
sg8
VP35030
p4087
sg10
I3
sg11
VmTG
p4088
sg13
I1
sa(dp4089
g7
I156
sg8
VP35030
p4090
sg10
I23
sg11
Vmyocardial triglyceride
p4091
sg13
I2
sasg20
(lp4092
(dp4093
g7
I271
sg23
VC0007222
p4094
sg10
I3
sg11
VCVD
p4095
sg13
I1
sa(dp4096
g7
I228
sg23
VC0011860
p4097
sg10
I3
sg11
VT2D
p4098
sg13
I1
sa(dp4099
g7
I211
sg23
VC0011860
p4100
sg10
I15
sg11
Vtype 2 diabetes
p4101
sg13
I3
sa(dp4102
g7
I247
sg23
VC0007222
p4103
sg10
I22
sg11
Vcardiovascular disease
p4104
sg13
I2
sasa(dp4105
g2
S'Compared with placebo, treatment with rosiglitazone for 6 months had no discernible effect on mTG or left ventricular function in this population with long-standing diabetes and CVD.\n'
p4106
sg4
(lp4107
(dp4108
g7
I94
sg8
VP35030
p4109
sg10
I3
sg11
VmTG
p4110
sg13
I1
sasg20
(lp4111
(dp4112
g7
I165
sg23
VC0011849
p4113
sg10
I8
sg11
Vdiabetes
p4114
sg13
I1
sa(dp4115
g7
I178
sg23
VC0007222
p4116
sg10
I3
sg11
VCVD
p4117
sg13
I1
sasa(dp4118
g2
S'In animal models and in men with type 2 diabetes mellitus, impaired cardiac function is associated with myocardial triglyceride (MTG) accumulation.\n'
p4119
sg4
(lp4120
sg20
(lp4121
(dp4122
g7
I59
sg23
VC0684336
p4123
sg10
I8
sg11
Vimpaired
p4124
sg13
I1
sa(dp4125
g7
I33
sg23
VC0011860
p4126
sg10
I24
sg11
Vtype 2 diabetes mellitus
p4127
sg13
I4
sasa(dp4128
g2
S'Therefore, we examined the relationship between circulating glucocorticoid levels, hepatic IFN-gamma expression, and hepatic T cell glucocorticoid receptor (GR) expression in a rat model of cholangitis to provide insight into the possible mechanism underlying hepatic T cell glucocorticoid resistance in cholangitic diseases.\n'
p4129
sg4
(lp4130
(dp4131
g7
I157
sg8
VP00390
p4132
sg10
I2
sg11
VGR
p4133
sg13
I1
sa(dp4134
g7
I91
sg8
VP01579
p4135
sg10
I9
sg11
VIFN-gamma
p4136
sg13
I1
sa(dp4137
g7
I125
sg8
VP04150
p4138
sg10
I30
sg11
VT cell glucocorticoid receptor
p4139
sg13
I4
sasg20
(lp4140
(dp4141
g7
I190
sg23
VC0008311
p4142
sg10
I11
sg11
Vcholangitis
p4143
sg13
I1
sa(dp4144
g7
I275
sg23
VC1841971
p4145
sg10
I25
sg11
Vglucocorticoid resistance
p4146
sg13
I2
sasa(dp4147
g2
S'Our results suggest that tau hyperphosphorylation and the sustained over-activated mTOR signalling under hyperglycemia may be due to the suppression of Cav-1.\n'
p4148
sg4
(lp4149
(dp4150
g7
I83
sg8
VP42345
p4151
sg10
I4
sg11
VmTOR
p4152
sg13
I1
sa(dp4153
g7
I152
sg8
VP35218
p4154
sg10
I5
sg11
VCav-1
p4155
sg13
I1
sasg20
(lp4156
(dp4157
g7
I137
sg23
VC0221103
p4158
sg10
I11
sg11
Vsuppression
p4159
sg13
I1
sa(dp4160
g7
I105
sg23
VC0020456
p4161
sg10
I13
sg11
Vhyperglycemia
p4162
sg13
I1
sasa(dp4163
g2
S'Therefore, Cav-1 is a potential therapeutic target for diabetes-induced cognitive dysfunction.\n'
p4164
sg4
(lp4165
(dp4166
g7
I11
sg8
VP35218
p4167
sg10
I5
sg11
VCav-1
p4168
sg13
I1
sasg20
(lp4169
(dp4170
g7
I72
sg23
VC0338656
p4171
sg10
I21
sg11
Vcognitive dysfunction
p4172
sg13
I2
sa(dp4173
g7
I55
sg23
VC0011849
p4174
sg10
I8
sg11
Vdiabetes
p4175
sg13
I1
sasa(dp4176
g2
S'These results point to intestinal epithelial cell CAV1 as a potential therapeutic target to lower circulating FFAs and LDL cholesterol, as high levels are associated with development of type II diabetes and cardiovascular disease.\n'
p4177
sg4
(lp4178
(dp4179
g7
I34
sg8
VP12830
p4180
sg10
I20
sg11
Vepithelial cell CAV1
p4181
sg13
I3
sasg20
(lp4182
(dp4183
g7
I207
sg23
VC0007222
p4184
sg10
I22
sg11
Vcardiovascular disease
p4185
sg13
I2
sa(dp4186
g7
I186
sg23
VC0011860
p4187
sg10
I16
sg11
Vtype II diabetes
p4188
sg13
I3
sasa(dp4189
g2
S'On the basis of its role in vascular inflammation and in metabolic disorders, we hypothesised that the TNF superfamily (TNFSF) member 14 (LIGHT/TNFSF14) could be involved in the pathogenesis of type 2 diabetes mellitus.\n'
p4190
sg4
(lp4191
(dp4192
g7
I138
sg8
g18
sg10
I5
sg11
VLIGHT
p4193
sg13
I1
sa(dp4194
g7
I144
sg8
g18
sg10
I7
sg11
VTNFSF14
p4195
sg13
I1
sa(dp4196
g7
I103
sg8
VP01375
p4197
sg10
I33
sg11
VTNF superfamily (TNFSF) member 14
p4198
sg13
I5
sasg20
(lp4199
(dp4200
g7
I194
sg23
VC0011860
p4201
sg10
I24
sg11
Vtype 2 diabetes mellitus
p4202
sg13
I4
sa(dp4203
g7
I57
sg23
VC0025517
p4204
sg10
I19
sg11
Vmetabolic disorders
p4205
sg13
I2
sa(dp4206
g7
I178
sg23
VC0699748
p4207
sg10
I12
sg11
Vpathogenesis
p4208
sg13
I1
sa(dp4209
g7
I28
sg23
VC0947751
p4210
sg10
I21
sg11
Vvascular inflammation
p4211
sg13
I2
sasa(dp4212
g2
S'QR, RR (Q192R) and GC, CC (-909G/C) genotypes and L-C-A-R-G, L-T-A-R-G, L-T-G-Q-C haplotypes showed significant association with type 2 diabetes.\n'
p4213
sg4
(lp4214
(dp4215
g7
I50
sg8
VP04180
p4216
sg10
I9
sg11
VL-C-A-R-G
p4217
sg13
I1
sasg20
(lp4218
(dp4219
g7
I129
sg23
VC0011860
p4220
sg10
I15
sg11
Vtype 2 diabetes
p4221
sg13
I3
sasa(dp4222
g2
S'QR, RR, GC, CC genotypes and L-C-A-R-G, L-T-A-R-G, L-T-G-Q-C haplotypes are commoner in diabetics as compared to controls and may be related to genetic susceptibility to type 2 diabetes.\n'
p4223
sg4
(lp4224
(dp4225
g7
I29
sg8
VP04180
p4226
sg10
I9
sg11
VL-C-A-R-G
p4227
sg13
I1
sasg20
(lp4228
(dp4229
g7
I170
sg23
VC0011860
p4230
sg10
I15
sg11
Vtype 2 diabetes
p4231
sg13
I3
sasa(dp4232
g2
S'Blockade of TNFSF14 signaling caused a substantial reduction in the expression of lymphotoxin beta receptor (LTbetaR)-controlled migration factors within the islets and disrupts organization of tertiary structures, leading to prevention of diabetes.\n'
p4233
sg4
(lp4234
(dp4235
g7
I109
sg8
VP05107
p4236
sg10
I7
sg11
VLTbetaR
p4237
sg13
I1
sa(dp4238
g7
I82
sg8
g18
sg10
I25
sg11
Vlymphotoxin beta receptor
p4239
sg13
I3
sa(dp4240
g7
I12
sg8
g18
sg10
I7
sg11
VTNFSF14
p4241
sg13
I1
sasg20
(lp4242
(dp4243
g7
I240
sg23
VC0011849
p4244
sg10
I8
sg11
Vdiabetes
p4245
sg13
I1
sasa(dp4246
g2
S'Consistently, enhancing LTbetaR signaling by transgenic expression of TNFSF14 in the islets of NOD mice rapidly promoted de novo formation of local TLO, resulting in diabetes, even in the absence of draining lymph nodes (LN).\n'
p4247
sg4
(lp4248
(dp4249
g7
I70
sg8
g18
sg10
I7
sg11
VTNFSF14
p4250
sg13
I1
sa(dp4251
g7
I24
sg8
VP05107
p4252
sg10
I7
sg11
VLTbetaR
p4253
sg13
I1
sasg20
(lp4254
(dp4255
g7
I95
sg23
VC0751781
p4256
sg10
I3
sg11
VNOD
p4257
sg13
I1
sa(dp4258
g7
I166
sg23
VC0011849
p4259
sg10
I8
sg11
Vdiabetes
p4260
sg13
I1
sasa(dp4261
g2
S'Thus, the TNFSF14-LTbetaR pathway appears to be critical in the development and maintenance of TLO for the onset of diabetes.\n'
p4262
sg4
(lp4263
(dp4264
g7
I10
sg8
g18
sg10
I7
sg11
VTNFSF14
p4265
sg13
I1
sa(dp4266
g7
I18
sg8
VP05107
p4267
sg10
I7
sg11
VLTbetaR
p4268
sg13
I1
sasg20
(lp4269
(dp4270
g7
I116
sg23
VC0011849
p4271
sg10
I8
sg11
Vdiabetes
p4272
sg13
I1
sasa(dp4273
g2
S'In this study, we demonstrate that islet TNF-alpha receptor 1 (p55) influences the expression of LIGHT (TNFSF-14), a TNF family member with both cytolytic and costimulatory properties, on BDC2.5 T cells and the expression of its receptor HVEM (TNFRSF-14) by islets, indicating a role for LIGHT-HVEM interactions in autoimmune diabetes.\n'
p4274
sg4
(lp4275
(dp4276
g7
I117
sg8
VP01375
p4277
sg10
I17
sg11
VTNF family member
p4278
sg13
I3
sa(dp4279
g7
I97
sg8
g18
sg10
I5
sg11
VLIGHT
p4280
sg13
I1
sa(dp4281
g7
I35
sg8
VP01375
p4282
sg10
I26
sg11
Vislet TNF-alpha receptor 1
p4283
sg13
I4
sa(dp4284
g7
I104
sg8
VP32970
p4285
sg10
I8
sg11
VTNFSF-14
p4286
sg13
I1
sa(dp4287
g7
I238
sg8
g18
sg10
I4
sg11
VHVEM
p4288
sg13
I1
sa(dp4289
g7
I63
sg8
VP11308
p4290
sg10
I3
sg11
Vp55
p4291
sg13
I1
sa(dp4292
g7
I97
sg8
g18
sg10
I5
sg11
VLIGHT
p4293
sg13
I1
sa(dp4294
g7
I238
sg8
g18
sg10
I4
sg11
VHVEM
p4295
sg13
I1
sa(dp4296
g7
I244
sg8
VP05107
p4297
sg10
I9
sg11
VTNFRSF-14
p4298
sg13
I1
sasg20
(lp4299
(dp4300
g7
I315
sg23
VC0205734
p4301
sg10
I19
sg11
Vautoimmune diabetes
p4302
sg13
I2
sasa(dp4303
g2
S'Incidence of cervical cancer was around 10 per 100 000 women (age-standardised, world population, ASW) in the 1950s, 30 per 100 000 in the 1960s, and in the 1980s around 60 per 100 000.\n'
p4304
sg4
(lp4305
sg20
(lp4306
(dp4307
g7
I13
sg23
VC0302592
p4308
sg10
I15
sg11
Vcervical cancer
p4309
sg13
I2
sasa(dp4310
g2
S'The incidence of cervical cancer is highest in Greenland (25 per 100,000, age standardized, World Standard Population, ASW) and lowest in Finland (4 per 100,000 ASW) and rates in the other Nordic countries vary between 7 and 11 per 100,000 ASW.\n'
p4311
sg4
(lp4312
sg20
(lp4313
(dp4314
g7
I17
sg23
VC0302592
p4315
sg10
I15
sg11
Vcervical cancer
p4316
sg13
I2
sasa(dp4317
g2
S'The dissociation of the approximately 3500-kDa hexagonal bilayer (HBL) hemoglobin (Hb) of Lumbricus terrestris upon exposure to Gdm salts, urea and the heteropolytungstates [SiW11O39]8- (SiW), [NaSb9W21O86]18- (SbW) and [BaAs4W40O140]27- (AsW) at neutral pH was followed by gel filtration, SDS-polyacrylamide gel electrophoresis, and scanning transmission electron microscopy.\n'
p4318
sg4
(lp4319
(dp4320
g7
I47
sg8
VP09382
p4321
sg10
I17
sg11
Vhexagonal bilayer
p4322
sg13
I2
sa(dp4323
g7
I66
sg8
VP09382
p4324
sg10
I3
sg11
VHBL
p4325
sg13
I1
sa(dp4326
g7
I83
sg8
g18
sg10
I2
sg11
VHb
p4327
sg13
I1
sa(dp4328
g7
I71
sg8
g18
sg10
I10
sg11
Vhemoglobin
p4329
sg13
I1
sasg20
(lp4330
(dp4331
g7
I290
sg23
VC0272170
p4332
sg10
I3
sg11
VSDS
p4333
sg13
I1
sa(dp4334
g7
I128
sg23
VC0085207
p4335
sg10
I3
sg11
VGdm
p4336
sg13
I1
sa(dp4337
g7
I4
sg23
VC0086168
p4338
sg10
I12
sg11
Vdissociation
p4339
sg13
I1
sasa(dp4340
g2
S'The XPO1/CRM1 inhibitor selinexor (KPT-330), is currently being evaluated in multiple clinical trials as an anticancer agent.\n'
p4341
sg4
(lp4342
(dp4343
g7
I4
sg8
g18
sg10
I4
sg11
VXPO1
p4344
sg13
I1
sa(dp4345
g7
I9
sg8
g18
sg10
I4
sg11
VCRM1
p4346
sg13
I1
sasg20
(lp4347
sa(dp4348
g2
S'XPO1 participates in the nuclear export of FoxO-1, which we previously found to be decreased in platinum-resistant ovarian carcinoma.\n'
p4349
sg4
(lp4350
(dp4351
g7
I0
sg8
g18
sg10
I4
sg11
VXPO1
p4352
sg13
I1
sasg20
(lp4353
(dp4354
g7
I115
sg23
VC0029925
p4355
sg10
I17
sg11
Vovarian carcinoma
p4356
sg13
I2
sasa(dp4357
g2
S'Eventually, a prospective lncRNA-miRNA-mRNA regulatory network of LINC00968, three miRNAs (miR-9, miR-22 and miR-4536) and two genes (polo-like kinase 1 and exportin-1) was obtained following validation in the Cancer Genome Atlas database.\n'
p4358
sg4
(lp4359
(dp4360
g7
I91
sg8
g18
sg10
I5
sg11
VmiR-9
p4361
sg13
I1
sa(dp4362
g7
I98
sg8
g18
sg10
I6
sg11
VmiR-22
p4363
sg13
I1
sa(dp4364
g7
I109
sg8
g18
sg10
I8
sg11
VmiR-4536
p4365
sg13
I1
sa(dp4366
g7
I157
sg8
g18
sg10
I10
sg11
Vexportin-1
p4367
sg13
I1
sa(dp4368
g7
I134
sg8
VP53350
p4369
sg10
I18
sg11
Vpolo-like kinase 1
p4370
sg13
I3
sasg20
(lp4371
(dp4372
g7
I210
sg23
VC0006826
p4373
sg10
I6
sg11
VCancer
p4374
sg13
I1
sasa(dp4375
g2
S'The aim of this study was to explore the potential utility of chromosome region maintenance 1 (CRM1) inhibitor leptomycin B (LMB) in combination with gefitinib to overcome primary and acquired gefitinib resistance in NSCLC cells.\n'
p4376
sg4
(lp4377
(dp4378
g7
I62
sg8
g18
sg10
I31
sg11
Vchromosome region maintenance 1
p4379
sg13
I4
sa(dp4380
g7
I95
sg8
g18
sg10
I4
sg11
VCRM1
p4381
sg13
I1
sasg20
(lp4382
(dp4383
g7
I217
sg23
VC0007131
p4384
sg10
I5
sg11
VNSCLC
p4385
sg13
I1
sasa(dp4386
g2
S'Previously, we found that p27kip1 nuclear-cytoplasmic translocation confers proliferation potential to cholangiocarcinoma cell line QBC939 and this process is mediated by crm-1.\n'
p4387
sg4
(lp4388
(dp4389
g7
I26
sg8
VP46527
p4390
sg10
I7
sg11
Vp27kip1
p4391
sg13
I1
sasg20
(lp4392
(dp4393
g7
I76
sg23
VC0334094
p4394
sg10
I13
sg11
Vproliferation
p4395
sg13
I1
sa(dp4396
g7
I54
sg23
VC0040715
p4397
sg10
I13
sg11
Vtranslocation
p4398
sg13
I1
sa(dp4399
g7
I103
sg23
VC0206698
p4400
sg10
I18
sg11
Vcholangiocarcinoma
p4401
sg13
I1
sasa(dp4402
g2
S'Exportin-1 (XPO1) is the key mediator of nuclear export of many tumor suppressor proteins and is overexpressed in human cancers.\n'
p4403
sg4
(lp4404
(dp4405
g7
I0
sg8
g18
sg10
I10
sg11
VExportin-1
p4406
sg13
I1
sa(dp4407
g7
I12
sg8
g18
sg10
I4
sg11
VXPO1
p4408
sg13
I1
sasg20
(lp4409
(dp4410
g7
I64
sg23
VC0027651
p4411
sg10
I5
sg11
Vtumor
p4412
sg13
I1
sa(dp4413
g7
I120
sg23
VC0006826
p4414
sg10
I7
sg11
Vcancers
p4415
sg13
I1
sasa(dp4416
g2
S'Silencing of XPO1 by either shRNA or selinexor significantly reduced cellular growth and induced cell cycle arrest, apoptosis of ATC cells by altering the protein expression of cancer-related genes.\n'
p4417
sg4
(lp4418
(dp4419
g7
I13
sg8
g18
sg10
I4
sg11
VXPO1
p4420
sg13
I1
sasg20
(lp4421
(dp4422
g7
I177
sg23
VC0006826
p4423
sg10
I6
sg11
Vcancer
p4424
sg13
I1
sasa(dp4425
g2
S'Exportin 1 (XPO1) mediates nuclear export of many cellular factors known to play critical roles in malignant processes, and selinexor (KPT-330) is the first XPO1-selective inhibitor of nuclear export compound in advanced clinical development phase for cancer treatment.\n'
p4426
sg4
(lp4427
(dp4428
g7
I0
sg8
g18
sg10
I10
sg11
VExportin 1
p4429
sg13
I2
sa(dp4430
g7
I12
sg8
g18
sg10
I4
sg11
VXPO1
p4431
sg13
I1
sa(dp4432
g7
I12
sg8
g18
sg10
I4
sg11
VXPO1
p4433
sg13
I1
sasg20
(lp4434
(dp4435
g7
I252
sg23
VC0006826
p4436
sg10
I6
sg11
Vcancer
p4437
sg13
I1
sasa(dp4438
g2
S'By using a combination of array comparative genomic hybridization and a candidate gene approach, we identified nuclear factor I/X (NFIX) deletions or nonsense mutation in three sporadic cases of a Sotos-like overgrowth syndrome with advanced bone age, macrocephaly, developmental delay, scoliosis, and unusual facies.\n'
p4439
sg4
(lp4440
(dp4441
g7
I197
sg8
g18
sg10
I10
sg11
VSotos-like
p4442
sg13
I1
sa(dp4443
g7
I131
sg8
VP01160
p4444
sg10
I4
sg11
VNFIX
p4445
sg13
I1
sa(dp4446
g7
I111
sg8
VP01160
p4447
sg10
I18
sg11
Vnuclear factor I/X
p4448
sg13
I3
sasg20
(lp4449
(dp4450
g7
I266
sg23
VC0424605
p4451
sg10
I19
sg11
Vdevelopmental delay
p4452
sg13
I2
sa(dp4453
g7
I150
sg23
VC0544885
p4454
sg10
I17
sg11
Vnonsense mutation
p4455
sg13
I2
sa(dp4456
g7
I287
sg23
VC0700208
p4457
sg10
I9
sg11
Vscoliosis
p4458
sg13
I1
sa(dp4459
g7
I252
sg23
VC0221355
p4460
sg10
I12
sg11
Vmacrocephaly
p4461
sg13
I1
sa(dp4462
g7
I208
sg23
VC2986703
p4463
sg10
I19
sg11
Vovergrowth syndrome
p4464
sg13
I2
sasa(dp4465
g2
S'These features prompted us to consider NFIX as a candidate gene for Marshall-Smith syndrome (MSS), a severe malformation syndrome characterized by failure to thrive, respiratory insufficiency, accelerated osseous maturation, kyphoscoliosis, osteopenia, and unusual facies.\n'
p4466
sg4
(lp4467
sg20
(lp4468
(dp4469
g7
I68
sg23
VC0265211
p4470
sg10
I23
sg11
VMarshall-Smith syndrome
p4471
sg13
I2
sa(dp4472
g7
I225
sg23
VC0600033
p4473
sg10
I14
sg11
Vkyphoscoliosis
p4474
sg13
I1
sa(dp4475
g7
I147
sg23
VC0015544
p4476
sg10
I17
sg11
Vfailure to thrive
p4477
sg13
I3
sa(dp4478
g7
I83
sg23
VC0039082
p4479
sg10
I8
sg11
Vsyndrome
p4480
sg13
I1
sa(dp4481
g7
I166
sg23
VC0035229
p4482
sg10
I25
sg11
Vrespiratory insufficiency
p4483
sg13
I2
sa(dp4484
g7
I108
sg23
VC0000768
p4485
sg10
I12
sg11
Vmalformation
p4486
sg13
I1
sa(dp4487
g7
I93
sg23
VC0024814
p4488
sg10
I3
sg11
VMSS
p4489
sg13
I1
sa(dp4490
g7
I241
sg23
VC0029453
p4491
sg10
I10
sg11
Vosteopenia
p4492
sg13
I1
sasa(dp4493
g2
S'Here we show that Plasmodium DNA induces autoreactive responses against erythrocytes by activating a population of B cells expressing CD11c and the transcription factor T-bet, which become major producers of autoantibodies that promote malarial anaemia.\n'
p4494
sg4
(lp4495
(dp4496
g7
I169
sg8
g18
sg10
I5
sg11
VT-bet
p4497
sg13
I1
sa(dp4498
g7
I134
sg8
VP20702
p4499
sg10
I5
sg11
VCD11c
p4500
sg13
I1
sasg20
(lp4501
(dp4502
g7
I245
sg23
VC0002871
p4503
sg10
I7
sg11
Vanaemia
p4504
sg13
I1
sasa(dp4505
g2
S'Genetic polymorphisms in grainyhead-like 2 (GRHL2) variants were examined for their suspected association with sudden sensorineural hearing loss (SSHL).\n'
p4506
sg4
(lp4507
(dp4508
g7
I25
sg8
g18
sg10
I17
sg11
Vgrainyhead-like 2
p4509
sg13
I2
sa(dp4510
g7
I44
sg8
g18
sg10
I5
sg11
VGRHL2
p4511
sg13
I1
sasg20
(lp4512
(dp4513
g7
I146
sg23
VC0018784
p4514
sg10
I4
sg11
VSSHL
p4515
sg13
I1
sa(dp4516
g7
I118
sg23
VC0018784
p4517
sg10
I26
sg11
Vsensorineural hearing loss
p4518
sg13
I3
sasa(dp4519
g2
S'More than 10 years ago, a c.1609_1610insC mutation in the grainyhead-like 2 (GRHL2) gene was identified in a large family with nonsyndromic sensorineural hearing loss, so far presenting the only evidence for GRHL2 being an autosomal-dominant deafness gene (DFNA28).\n'
p4520
sg4
(lp4521
(dp4522
g7
I58
sg8
g18
sg10
I17
sg11
Vgrainyhead-like 2
p4523
sg13
I2
sa(dp4524
g7
I257
sg8
g18
sg10
I6
sg11
VDFNA28
p4525
sg13
I1
sa(dp4526
g7
I77
sg8
g18
sg10
I5
sg11
VGRHL2
p4527
sg13
I1
sa(dp4528
g7
I77
sg8
g18
sg10
I5
sg11
VGRHL2
p4529
sg13
I1
sasg20
(lp4530
(dp4531
g7
I257
sg23
VC1837640
p4532
sg10
I6
sg11
VDFNA28
p4533
sg13
I1
sa(dp4534
g7
I140
sg23
VC0018784
p4535
sg10
I26
sg11
Vsensorineural hearing loss
p4536
sg13
I3
sa(dp4537
g7
I242
sg23
VC0011053
p4538
sg10
I8
sg11
Vdeafness
p4539
sg13
I1
sasa(dp4540
g2
S'Among type 2 diabetics, 5 of the 10 trials reported incidence of diabetic retinopathy and 3 trials reported progression of retinopathy; one of the 10 trials reported a combined outcome of incidence and progression during a 4- to 5-year follow-up period.\n'
p4541
sg4
(lp4542
sg20
(lp4543
(dp4544
g7
I65
sg23
VC0011884
p4545
sg10
I20
sg11
Vdiabetic retinopathy
p4546
sg13
I2
sa(dp4547
g7
I74
sg23
VC0035309
p4548
sg10
I11
sg11
Vretinopathy
p4549
sg13
I1
sasa(dp4550
g2
S'One trial in which type 2 diabetics participated had reported no primary (or secondary) outcome targeted for this review.The evidence from these trials supported a benefit of more intensive blood pressure control intervention with respect to 4- to 5-year incidence of diabetic retinopathy (estimated risk ratio (RR) 0.80; 95% confidence interval (CI) 0.71 to 0.92) and the combined outcome of incidence and progression (estimated RR 0.78; 95% CI 0.63 to 0.97).\n'
p4551
sg4
(lp4552
sg20
(lp4553
(dp4554
g7
I268
sg23
VC0011884
p4555
sg10
I20
sg11
Vdiabetic retinopathy
p4556
sg13
I2
sasa(dp4557
g2
S'The available evidence provided less support for a benefit with respect to 4- to 5-year progression of diabetic retinopathy (point estimate was closer to 1 than point estimates for incidence and combined incidence and progression, and the CI overlapped 1; estimated RR 0.88; 95% CI 0.73 to 1.05).\n'
p4558
sg4
(lp4559
sg20
(lp4560
(dp4561
g7
I103
sg23
VC0011884
p4562
sg10
I20
sg11
Vdiabetic retinopathy
p4563
sg13
I2
sasa(dp4564
g2
S'Patients with TIA and those with ischemic stroke had similar prevalences of nondiabetic retinopathy (26.9% versus 29.5%; OR, 0.8; 95% CI, 0.5 to 1.6), diabetic retinopathy (55.5% versus 50.0%; OR, 1.3; 95% CI, 0.4 to 3.6), focal arteriolar narrowing (15.6% versus 18.4%; OR, 0.8; 95% CI, 0.4 to 1.5), and arteriovenous nicking (23.0% versus 17.8%; OR, 1.4; 95% CI, 0.7 to 2.7).\n'
p4565
sg4
(lp4566
sg20
(lp4567
(dp4568
g7
I14
sg23
VC0917805
p4569
sg10
I3
sg11
VTIA
p4570
sg13
I1
sa(dp4571
g7
I79
sg23
VC0011884
p4572
sg10
I20
sg11
Vdiabetic retinopathy
p4573
sg13
I2
sa(dp4574
g7
I88
sg23
VC0035309
p4575
sg10
I11
sg11
Vretinopathy
p4576
sg13
I1
sa(dp4577
g7
I33
sg23
VC3272363
p4578
sg10
I15
sg11
Vischemic stroke
p4579
sg13
I2
sasa(dp4580
g2
S'E2f1, Hsfy2, and Nfyb may be therapeutic targets for colon cancer.\n'
p4581
sg4
(lp4582
(dp4583
g7
I0
sg8
g18
sg10
I4
sg11
VE2f1
p4584
sg13
I1
sa(dp4585
g7
I17
sg8
VP25208
p4586
sg10
I4
sg11
VNfyb
p4587
sg13
I1
sa(dp4588
g7
I6
sg8
g18
sg10
I5
sg11
VHsfy2
p4589
sg13
I1
sasg20
(lp4590
(dp4591
g7
I53
sg23
VC0699790
p4592
sg10
I12
sg11
Vcolon cancer
p4593
sg13
I2
sasa(dp4594
g2
S'Ezh2 and its TFs such as E2f1, Hsfy2, and Nfyb may be the potential therapeutic targets for anticancer agents development.\n'
p4595
sg4
(lp4596
(dp4597
g7
I31
sg8
g18
sg10
I5
sg11
VHsfy2
p4598
sg13
I1
sa(dp4599
g7
I42
sg8
VP25208
p4600
sg10
I4
sg11
VNfyb
p4601
sg13
I1
sa(dp4602
g7
I0
sg8
g18
sg10
I4
sg11
VEzh2
p4603
sg13
I1
sa(dp4604
g7
I25
sg8
g18
sg10
I4
sg11
VE2f1
p4605
sg13
I1
sasg20
(lp4606
sa(dp4607
g2
S'Further analysis identified nine transcription factors, these being GATA3, MZF1, GATA1, GATA2, SRY, REL, NFYB, NFYC, and NFYA, which could interact with HMGB3 to regulate target gene expression and consequently regulate gastric cancer cell proliferation, migration and invasion.\n'
p4608
sg4
(lp4609
(dp4610
g7
I121
sg8
VP67809
p4611
sg10
I4
sg11
VNFYA
p4612
sg13
I1
sa(dp4613
g7
I153
sg8
g18
sg10
I5
sg11
VHMGB3
p4614
sg13
I1
sa(dp4615
g7
I88
sg8
VP23769
p4616
sg10
I5
sg11
VGATA2
p4617
sg13
I1
sa(dp4618
g7
I68
sg8
VP23771
p4619
sg10
I5
sg11
VGATA3
p4620
sg13
I1
sa(dp4621
g7
I81
sg8
VP15976
p4622
sg10
I5
sg11
VGATA1
p4623
sg13
I1
sa(dp4624
g7
I105
sg8
VP25208
p4625
sg10
I4
sg11
VNFYB
p4626
sg13
I1
sa(dp4627
g7
I75
sg8
VP28698
p4628
sg10
I4
sg11
VMZF1
p4629
sg13
I1
sa(dp4630
g7
I95
sg8
g18
sg10
I3
sg11
VSRY
p4631
sg13
I1
sa(dp4632
g7
I100
sg8
g18
sg10
I3
sg11
VREL
p4633
sg13
I1
sasg20
(lp4634
(dp4635
g7
I220
sg23
VC0024623
p4636
sg10
I14
sg11
Vgastric cancer
p4637
sg13
I2
sa(dp4638
g7
I269
sg23
VC2699153
p4639
sg10
I8
sg11
Vinvasion
p4640
sg13
I1
sa(dp4641
g7
I240
sg23
VC0334094
p4642
sg10
I13
sg11
Vproliferation
p4643
sg13
I1
sasa(dp4644
g2
S'We evaluated possible changes in the expression of interleukin (IL)-10 family cytokines (IL26, IL-28A, IL28B, IL29), their receptor subunits (IL20RB, IL22RA2, IL28RA), and genes potentially related to functioning of melanocytes (MDM1, IFNA1, IFNB1, IFNG, and ICAM1) in the case of vitiligo.\n'
p4645
sg4
(lp4646
(dp4647
g7
I229
sg8
g18
sg10
I4
sg11
VMDM1
p4648
sg13
I1
sa(dp4649
g7
I242
sg8
VP01574
p4650
sg10
I5
sg11
VIFNB1
p4651
sg13
I1
sa(dp4652
g7
I110
sg8
g18
sg10
I4
sg11
VIL29
p4653
sg13
I1
sa(dp4654
g7
I235
sg8
VP01562
p4655
sg10
I5
sg11
VIFNA1
p4656
sg13
I1
sa(dp4657
g7
I150
sg8
g18
sg10
I7
sg11
VIL22RA2
p4658
sg13
I1
sa(dp4659
g7
I51
sg8
VP60568
p4660
sg10
I36
sg11
Vinterleukin (IL)-10 family cytokines
p4661
sg13
I4
sa(dp4662
g7
I103
sg8
g18
sg10
I5
sg11
VIL28B
p4663
sg13
I1
sa(dp4664
g7
I259
sg8
VP05362
p4665
sg10
I5
sg11
VICAM1
p4666
sg13
I1
sa(dp4667
g7
I159
sg8
g18
sg10
I6
sg11
VIL28RA
p4668
sg13
I1
sa(dp4669
g7
I89
sg8
g18
sg10
I4
sg11
VIL26
p4670
sg13
I1
sa(dp4671
g7
I142
sg8
g18
sg10
I6
sg11
VIL20RB
p4672
sg13
I1
sa(dp4673
g7
I249
sg8
VP01579
p4674
sg10
I4
sg11
VIFNG
p4675
sg13
I1
sasg20
(lp4676
(dp4677
g7
I281
sg23
VC0042900
p4678
sg10
I8
sg11
Vvitiligo
p4679
sg13
I1
sasa(dp4680
g2
S'We describe a male infant with intra-uterine growth retardation and multiple congenital anomalies including prominent forehead, broad nasal bridge, hypertelorism, small upturned nose, flat philtrum, micrognathia, cleft hard palate, low-set and posteriorly rotated ears, short neck, micropenis, hypoplastic scrotum with prominent raphe and undescended testes, malformed lower extremities with contractures, bony protruberance of left thigh, bilateral absence of the fibula, bilateral equinovarus deformity with missing 4th toe on the right foot and short second fingers, congenital heart defect, renal anomalies, brain malformation, and bilateral choanal atresia.\n'
p4681
sg4
(lp4682
sg20
(lp4683
(dp4684
g7
I184
sg23
VC1142533
p4685
sg10
I13
sg11
Vflat philtrum
p4686
sg13
I2
sa(dp4687
g7
I68
sg23
VC0000772
p4688
sg10
I29
sg11
Vmultiple congenital anomalies
p4689
sg13
I3
sa(dp4690
g7
I282
sg23
VC0266435
p4691
sg10
I10
sg11
Vmicropenis
p4692
sg13
I1
sa(dp4693
g7
I612
sg23
VC0266449
p4694
sg10
I18
sg11
Vbrain malformation
p4695
sg13
I2
sa(dp4696
g7
I570
sg23
VC0018798
p4697
sg10
I23
sg11
Vcongenital heart defect
p4698
sg13
I3
sa(dp4699
g7
I294
sg23
VC0431659
p4700
sg10
I19
sg11
Vhypoplastic scrotum
p4701
sg13
I2
sa(dp4702
g7
I213
sg23
VC0432090
p4703
sg10
I17
sg11
Vcleft hard palate
p4704
sg13
I3
sa(dp4705
g7
I148
sg23
VC0020534
p4706
sg10
I13
sg11
Vhypertelorism
p4707
sg13
I1
sa(dp4708
g7
I199
sg23
VC0025990
p4709
sg10
I12
sg11
Vmicrognathia
p4710
sg13
I1
sa(dp4711
g7
I244
sg23
VC0431478
p4712
sg10
I24
sg11
Vposteriorly rotated ears
p4713
sg13
I3
sa(dp4714
g7
I595
sg23
VC0266292
p4715
sg10
I15
sg11
Vrenal anomalies
p4716
sg13
I2
sa(dp4717
g7
I646
sg23
VC0008297
p4718
sg10
I15
sg11
Vchoanal atresia
p4719
sg13
I2
sa(dp4720
g7
I45
sg23
VC0151686
p4721
sg10
I18
sg11
Vgrowth retardation
p4722
sg13
I2
sa(dp4723
g7
I339
sg23
VC0010417
p4724
sg10
I18
sg11
Vundescended testes
p4725
sg13
I2
sa(dp4726
g7
I483
sg23
VC0009081
p4727
sg10
I21
sg11
Vequinovarus deformity
p4728
sg13
I2
sa(dp4729
g7
I392
sg23
VC0009917
p4730
sg10
I12
sg11
Vcontractures
p4731
sg13
I1
sasa(dp4732
g2
S"Copy number variants thought to be associated with risk for schizophrenia and related disorders also occur in affected individuals in Palau, specifically 15q11.2 and 1q21.1 deletions, partial duplication of IL1RAPL1 (Xp21.3), and chromosome X duplications (Klinefelter's syndrome).\n"
p4733
sg4
(lp4734
(dp4735
g7
I207
sg8
g18
sg10
I8
sg11
VIL1RAPL1
p4736
sg13
I1
sasg20
(lp4737
(dp4738
g7
I192
sg23
VC1705960
p4739
sg10
I11
sg11
Vduplication
p4740
sg13
I1
sa(dp4741
g7
I257
sg23
VC0022735
p4742
sg10
I22
sg11
VKlinefelter's syndrome
p4743
sg13
I2
sa(dp4744
g7
I60
sg23
VC0036341
p4745
sg10
I13
sg11
Vschizophrenia
p4746
sg13
I1
sasa(dp4747
g2
S'Nine miRNAs (miR-30a, miR-30c, miR-31, miR-126, miR-140, miR-146b, miR-200c, miR-206, and miR-335) known to be tumor suppressive miRNAs in breast cancer were investigated in Genomic Data Common data portal miRNA-Seq dataset and The Cancer Genome Atlas (TCGA) (n = 1052).\n'
p4748
sg4
(lp4749
(dp4750
g7
I39
sg8
g18
sg10
I7
sg11
VmiR-126
p4751
sg13
I1
sa(dp4752
g7
I67
sg8
g18
sg10
I8
sg11
VmiR-200c
p4753
sg13
I1
sa(dp4754
g7
I31
sg8
g18
sg10
I6
sg11
VmiR-31
p4755
sg13
I1
sa(dp4756
g7
I57
sg8
g18
sg10
I8
sg11
VmiR-146b
p4757
sg13
I1
sa(dp4758
g7
I48
sg8
g18
sg10
I7
sg11
VmiR-140
p4759
sg13
I1
sa(dp4760
g7
I13
sg8
g18
sg10
I7
sg11
VmiR-30a
p4761
sg13
I1
sa(dp4762
g7
I22
sg8
g18
sg10
I7
sg11
VmiR-30c
p4763
sg13
I1
sa(dp4764
g7
I77
sg8
g18
sg10
I7
sg11
VmiR-206
p4765
sg13
I1
sasg20
(lp4766
(dp4767
g7
I111
sg23
VC0027651
p4768
sg10
I5
sg11
Vtumor
p4769
sg13
I1
sa(dp4770
g7
I232
sg23
VC0006826
p4771
sg10
I6
sg11
VCancer
p4772
sg13
I1
sa(dp4773
g7
I139
sg23
VC0678222
p4774
sg10
I13
sg11
Vbreast cancer
p4775
sg13
I2
sasa(dp4776
g2
S'The aim of this study was to validate the potential role of miR-31 and BRCA1-associated protein-1 (BAP1) on regulating epithelial-mesenchymal transition (EMT) in cervical cancer.\n'
p4777
sg4
(lp4778
(dp4779
g7
I71
sg8
g18
sg10
I26
sg11
VBRCA1-associated protein-1
p4780
sg13
I2
sa(dp4781
g7
I60
sg8
g18
sg10
I6
sg11
VmiR-31
p4782
sg13
I1
sa(dp4783
g7
I99
sg8
g18
sg10
I4
sg11
VBAP1
p4784
sg13
I1
sasg20
(lp4785
(dp4786
g7
I142
sg23
VC0599156
p4787
sg10
I10
sg11
Vtransition
p4788
sg13
I1
sa(dp4789
g7
I162
sg23
VC0302592
p4790
sg10
I15
sg11
Vcervical cancer
p4791
sg13
I2
sasa(dp4792
g2
S'In the present study, qRT-PCR assay revealed that the expression of miR-31 was upregulated in human cervical cancer cells and clinical tissues.\n'
p4793
sg4
(lp4794
sg20
(lp4795
(dp4796
g7
I100
sg23
VC0302592
p4797
sg10
I15
sg11
Vcervical cancer
p4798
sg13
I2
sasa(dp4799
g2
S'Furthermore, the results revealed that miR-31 promoted proliferation and EMT in cervical cancer cells and accelerated the development of tumor growth in vivo xenograft experiment by inhibiting BAP1 expression.\n'
p4800
sg4
(lp4801
(dp4802
g7
I193
sg8
g18
sg10
I4
sg11
VBAP1
p4803
sg13
I1
sasg20
(lp4804
(dp4805
g7
I55
sg23
VC0334094
p4806
sg10
I13
sg11
Vproliferation
p4807
sg13
I1
sa(dp4808
g7
I80
sg23
VC0302592
p4809
sg10
I15
sg11
Vcervical cancer
p4810
sg13
I2
sa(dp4811
g7
I137
sg23
VC0598934
p4812
sg10
I12
sg11
Vtumor growth
p4813
sg13
I2
sasa(dp4814
g2
S'Overall, these results highlight an important role of miR-31 functioning as an oncomir which could promote EMT in cervical cancer via downregulating BAP1 expression.\n'
p4815
sg4
(lp4816
(dp4817
g7
I54
sg8
g18
sg10
I6
sg11
VmiR-31
p4818
sg13
I1
sa(dp4819
g7
I149
sg8
g18
sg10
I4
sg11
VBAP1
p4820
sg13
I1
sa(dp4821
g7
I107
sg8
g18
sg10
I3
sg11
VEMT
p4822
sg13
I1
sasg20
(lp4823
(dp4824
g7
I114
sg23
VC0302592
p4825
sg10
I15
sg11
Vcervical cancer
p4826
sg13
I2
sasa(dp4827
g2
S'Thus, downregulation of miR-31 could be a novel approach for the molecular treatment of cervical cancers and other malignancies.\n'
p4828
sg4
(lp4829
(dp4830
g7
I24
sg8
g18
sg10
I6
sg11
VmiR-31
p4831
sg13
I1
sasg20
(lp4832
(dp4833
g7
I115
sg23
VC0006826
p4834
sg10
I12
sg11
Vmalignancies
p4835
sg13
I1
sa(dp4836
g7
I88
sg23
VC0007847
p4837
sg10
I16
sg11
Vcervical cancers
p4838
sg13
I2
sasa(dp4839
g2
S'We have previously identified that miR-31 may play suppressive roles in Alfa2Delta1+ hepatocellular carcinoma (HCC) TICs.\n'
p4840
sg4
(lp4841
sg20
(lp4842
(dp4843
g7
I111
sg23
VC2239176
p4844
sg10
I3
sg11
VHCC
p4845
sg13
I1
sa(dp4846
g7
I116
sg23
VC0278076
p4847
sg10
I4
sg11
VTICs
p4848
sg13
I1
sa(dp4849
g7
I85
sg23
VC2239176
p4850
sg10
I24
sg11
Vhepatocellular carcinoma
p4851
sg13
I2
sasa(dp4852
g2
S'However, the levels of miR-31, miR-155, miR-16, and miR-181a have not been explored in AS, but were verified to play vital roles in other immunological diseases.\n'
p4853
sg4
(lp4854
(dp4855
g7
I23
sg8
g18
sg10
I6
sg11
VmiR-31
p4856
sg13
I1
sa(dp4857
g7
I40
sg8
g18
sg10
I6
sg11
VmiR-16
p4858
sg13
I1
sa(dp4859
g7
I31
sg8
g18
sg10
I7
sg11
VmiR-155
p4860
sg13
I1
sa(dp4861
g7
I52
sg8
g18
sg10
I8
sg11
VmiR-181a
p4862
sg13
I1
sasg20
(lp4863
(dp4864
g7
I138
sg23
VC0021053
p4865
sg10
I22
sg11
Vimmunological diseases
p4866
sg13
I2
sasa(dp4867
g2
S'Furthermore, miR-31, miR-155, miR-16 and miR-181a may be associated with AS disease activity.\n'
p4868
sg4
(lp4869
(dp4870
g7
I30
sg8
g18
sg10
I6
sg11
VmiR-16
p4871
sg13
I1
sa(dp4872
g7
I21
sg8
g18
sg10
I7
sg11
VmiR-155
p4873
sg13
I1
sa(dp4874
g7
I13
sg8
g18
sg10
I6
sg11
VmiR-31
p4875
sg13
I1
sa(dp4876
g7
I41
sg8
g18
sg10
I8
sg11
VmiR-181a
p4877
sg13
I1
sasg20
(lp4878
sa(dp4879
g2
S'However, whether miR-31 plays as an oncogene in esophageal squamous cell carcinoma (ESCC) and the potential target molecules are still unclear.\n'
p4880
sg4
(lp4881
sg20
(lp4882
(dp4883
g7
I48
sg23
VC0279626
p4884
sg10
I34
sg11
Vesophageal squamous cell carcinoma
p4885
sg13
I4
sa(dp4886
g7
I84
sg23
VC0279626
p4887
sg10
I4
sg11
VESCC
p4888
sg13
I1
sasa(dp4889
g2
S'Within the top five of the miRNAs screened, we validated miRNA-31 (miR-31) and miR-135b as up-regulated, while miR-193a-3p was down-regulated in BRAF-mutated cancer.\n'
p4890
sg4
(lp4891
(dp4892
g7
I111
sg8
g18
sg10
I11
sg11
VmiR-193a-3p
p4893
sg13
I1
sa(dp4894
g7
I145
sg8
VP15056
p4895
sg10
I4
sg11
VBRAF
p4896
sg13
I1
sasg20
(lp4897
(dp4898
g7
I158
sg23
VC0006826
p4899
sg10
I6
sg11
Vcancer
p4900
sg13
I1
sasa(dp4901
g2
S'Here we show that miR-31 is highly expressed in MaSC-enriched mammary basal cell population and in mammary tumors, and is regulated by NF-KB signaling.\n'
p4902
sg4
(lp4903
(dp4904
g7
I18
sg8
g18
sg10
I6
sg11
VmiR-31
p4905
sg13
I1
sasg20
(lp4906
(dp4907
g7
I99
sg23
VC0024667
p4908
sg10
I14
sg11
Vmammary tumors
p4909
sg13
I2
sasa(dp4910
g2
S'Loss of miR-31 compromises mammary tumor growth, reduces the number of cancer stem cells, as well as decreases tumor-initiating ability and metastasis to the lung, supporting its pro-oncogenic function.\n'
p4911
sg4
(lp4912
sg20
(lp4913
(dp4914
g7
I140
sg23
VC0153676
p4915
sg10
I22
sg11
Vmetastasis to the lung
p4916
sg13
I4
sa(dp4917
g7
I71
sg23
VC0006826
p4918
sg10
I6
sg11
Vcancer
p4919
sg13
I1
sa(dp4920
g7
I35
sg23
VC0027651
p4921
sg10
I5
sg11
Vtumor
p4922
sg13
I1
sa(dp4923
g7
I27
sg23
VC1458155
p4924
sg10
I13
sg11
Vmammary tumor
p4925
sg13
I2
sasa(dp4926
g2
S'The present study examined the effects of a GABA(C) receptor antagonist on the light-evoked responses of retinal ganglion cells (RGCs) in a rat model of retinitis pigmentosa.\n'
p4927
sg4
(lp4928
(dp4929
g7
I44
sg8
g18
sg10
I16
sg11
VGABA(C) receptor
p4930
sg13
I2
sasg20
(lp4931
(dp4932
g7
I113
sg23
VC1258666
p4933
sg10
I8
sg11
Vganglion
p4934
sg13
I1
sa(dp4935
g7
I153
sg23
VC0035334
p4936
sg10
I20
sg11
Vretinitis pigmentosa
p4937
sg13
I2
sasa(dp4938
g2
S'In conclusion, GABA(C) receptors may be novel targets for therapeutic interventions aimed at increasing light responsiveness in patients with retinitis pigmentosa or other diseases involving degeneration of photoreceptors.\n'
p4939
sg4
(lp4940
(dp4941
g7
I15
sg8
g18
sg10
I17
sg11
VGABA(C) receptors
p4942
sg13
I2
sasg20
(lp4943
(dp4944
g7
I191
sg23
VC0011164
p4945
sg10
I12
sg11
Vdegeneration
p4946
sg13
I1
sa(dp4947
g7
I142
sg23
VC0035334
p4948
sg10
I20
sg11
Vretinitis pigmentosa
p4949
sg13
I2
sasa(dp4950
g2
S'rho(1) GABA(C) receptor antagonists inhibit myopia in chick but the site of this effect is not known.\n'
p4951
sg4
(lp4952
(dp4953
g7
I0
sg8
VP08100
p4954
sg10
I23
sg11
Vrho(1) GABA(C) receptor
p4955
sg13
I3
sasg20
(lp4956
(dp4957
g7
I44
sg23
VC0027092
p4958
sg10
I6
sg11
Vmyopia
p4959
sg13
I1
sasa(dp4960
g2
S'GABA(C) receptors play a role in myopia, memory-related disorders and circadian rhythms signifying a need to develop potent and selective agents for this class of receptors.\n'
p4961
sg4
(lp4962
sg20
(lp4963
(dp4964
g7
I33
sg23
VC0027092
p4965
sg10
I6
sg11
Vmyopia
p4966
sg13
I1
sasa(dp4967
g2
S'Doses only 10 times greater than required to inhibit recombinant GABA(C) receptors caused the antimyopia effects.\n'
p4968
sg4
(lp4969
(dp4970
g7
I53
sg8
g18
sg10
I29
sg11
Vrecombinant GABA(C) receptors
p4971
sg13
I3
sasg20
(lp4972
sa(dp4973
g2
S'In situ maturation of adventitial dendritic cells (DC) with expression of CD83 has been proposed as an early event in the pathogenesis of giant cell arteritis (GCA), preceding the appearance of an inflammatory infiltrate.\n'
p4974
sg4
(lp4975
(dp4976
g7
I74
sg8
g18
sg10
I4
sg11
VCD83
p4977
sg13
I1
sasg20
(lp4978
(dp4979
g7
I138
sg23
VC0039483
p4980
sg10
I20
sg11
Vgiant cell arteritis
p4981
sg13
I3
sa(dp4982
g7
I160
sg23
VC0039483
p4983
sg10
I3
sg11
VGCA
p4984
sg13
I1
sa(dp4985
g7
I210
sg23
VC0332448
p4986
sg10
I10
sg11
Vinfiltrate
p4987
sg13
I1
sa(dp4988
g7
I122
sg23
VC0699748
p4989
sg10
I12
sg11
Vpathogenesis
p4990
sg13
I1
sasa(dp4991
g2
S'The aim of this study was to evaluate the added value of anti-CD83 staining of temporal artery biopsy (TAB) specimens in patients with biopsy-negative temporal arteritis.\n'
p4992
sg4
(lp4993
(dp4994
g7
I57
sg8
g18
sg10
I9
sg11
Vanti-CD83
p4995
sg13
I1
sasg20
(lp4996
(dp4997
g7
I151
sg23
VC1956391
p4998
sg10
I18
sg11
Vtemporal arteritis
p4999
sg13
I2
sasa(dp5000
g2
S'We identified 7 potentially pleiotropic loci, that is rs3759579 (MARK3), rs2178950 (TRPS1), rs1473 (PUM1), rs9825174 (XXYLT1), rs2047937 (ZNF423), rs17277372 (DNM3), and rs335170 (PRDM6), associated with osteoporosis and obesity.\n'
p5001
sg4
(lp5002
(dp5003
g7
I138
sg8
g18
sg10
I6
sg11
VZNF423
p5004
sg13
I1
sa(dp5005
g7
I84
sg8
g18
sg10
I5
sg11
VTRPS1
p5006
sg13
I1
sa(dp5007
g7
I180
sg8
g18
sg10
I5
sg11
VPRDM6
p5008
sg13
I1
sa(dp5009
g7
I100
sg8
g18
sg10
I4
sg11
VPUM1
p5010
sg13
I1
sa(dp5011
g7
I65
sg8
VP27448
p5012
sg10
I5
sg11
VMARK3
p5013
sg13
I1
sasg20
(lp5014
(dp5015
g7
I204
sg23
VC0029456
p5016
sg10
I12
sg11
Vosteoporosis
p5017
sg13
I1
sa(dp5018
g7
I84
sg23
VC0432233
p5019
sg10
I5
sg11
VTRPS1
p5020
sg13
I1
sa(dp5021
g7
I221
sg23
VC0028754
p5022
sg10
I7
sg11
Vobesity
p5023
sg13
I1
sasa(dp5024
g2
S'Dynamin 3 (DNM3) is candidate tumor suppressor against hepatocellular carcinoma (HCC).\n'
p5025
sg4
(lp5026
(dp5027
g7
I0
sg8
VP50570
p5028
sg10
I9
sg11
VDynamin 3
p5029
sg13
I2
sa(dp5030
g7
I11
sg8
VP50570
p5031
sg10
I4
sg11
VDNM3
p5032
sg13
I1
sasg20
(lp5033
(dp5034
g7
I55
sg23
VC2239176
p5035
sg10
I24
sg11
Vhepatocellular carcinoma
p5036
sg13
I2
sa(dp5037
g7
I81
sg23
VC2239176
p5038
sg10
I3
sg11
VHCC
p5039
sg13
I1
sa(dp5040
g7
I30
sg23
VC0027651
p5041
sg10
I5
sg11
Vtumor
p5042
sg13
I1
sasa(dp5043
g2
S'Dynamin 1 and 2 both enhance cancer cell proliferation, tumor invasion and metastasis, whereas dynamin 3 has tumor suppression role.\n'
p5044
sg4
(lp5045
(dp5046
g7
I0
sg8
g18
sg10
I9
sg11
VDynamin 1
p5047
sg13
I2
sasg20
(lp5048
(dp5049
g7
I29
sg23
VC0006826
p5050
sg10
I6
sg11
Vcancer
p5051
sg13
I1
sa(dp5052
g7
I41
sg23
VC0334094
p5053
sg10
I13
sg11
Vproliferation
p5054
sg13
I1
sa(dp5055
g7
I62
sg23
VC2699153
p5056
sg10
I8
sg11
Vinvasion
p5057
sg13
I1
sa(dp5058
g7
I56
sg23
VC0027651
p5059
sg10
I5
sg11
Vtumor
p5060
sg13
I1
sa(dp5061
g7
I75
sg23
VC0027627
p5062
sg10
I10
sg11
Vmetastasis
p5063
sg13
I1
sa(dp5064
g7
I56
sg23
VC0027651
p5065
sg10
I5
sg11
Vtumor
p5066
sg13
I1
sa(dp5067
g7
I115
sg23
VC0221103
p5068
sg10
I11
sg11
Vsuppression
p5069
sg13
I1
sasa(dp5070
g2
S'In conclusion, DNM3 may be involved in risk to OCD.\n'
p5071
sg4
(lp5072
sg20
(lp5073
(dp5074
g7
I47
sg23
VC0028768
p5075
sg10
I3
sg11
VOCD
p5076
sg13
I1
sasa(dp5077
g2
S'Loss of CD26 (&gt;=80% CD4(+) T cells) and/or CD7 (&gt;=40% CD4(+) T cells) and combination of altered expression of STAT4, TWIST1, and DNM3 or PLS3 could distinguish, respectively, 83% and 98% of patients with Sezary syndrome from patients with erythrodermic inflammatory dermatoses with 100% specificity.\n'
p5078
sg4
(lp5079
(dp5080
g7
I23
sg8
VP01730
p5081
sg10
I3
sg11
VCD4
p5082
sg13
I1
sa(dp5083
g7
I46
sg8
VP09564
p5084
sg10
I3
sg11
VCD7
p5085
sg13
I1
sa(dp5086
g7
I124
sg8
g18
sg10
I6
sg11
VTWIST1
p5087
sg13
I1
sa(dp5088
g7
I8
sg8
VP27487
p5089
sg10
I4
sg11
VCD26
p5090
sg13
I1
sa(dp5091
g7
I144
sg8
VP13797
p5092
sg10
I4
sg11
VPLS3
p5093
sg13
I1
sa(dp5094
g7
I117
sg8
g18
sg10
I5
sg11
VSTAT4
p5095
sg13
I1
sa(dp5096
g7
I23
sg8
VP01730
p5097
sg10
I3
sg11
VCD4
p5098
sg13
I1
sasg20
(lp5099
(dp5100
g7
I211
sg23
VC0036920
p5101
sg10
I15
sg11
VSezary syndrome
p5102
sg13
I2
sa(dp5103
g7
I273
sg23
VC0037274
p5104
sg10
I10
sg11
Vdermatoses
p5105
sg13
I1
sasa(dp5106
g2
S'Zyxin is upregulated in human breast cancer and positively correlates with histological stages and metastasis.\n'
p5107
sg4
(lp5108
(dp5109
g7
I0
sg8
g18
sg10
I5
sg11
VZyxin
p5110
sg13
I1
sasg20
(lp5111
(dp5112
g7
I30
sg23
VC0678222
p5113
sg10
I13
sg11
Vbreast cancer
p5114
sg13
I2
sa(dp5115
g7
I99
sg23
VC0027627
p5116
sg10
I10
sg11
Vmetastasis
p5117
sg13
I1
sasa(dp5118
g2
S'We have previously shown that short-term feeding [20 to 25 day induction period (IP)] normal rats a sucrose-rich diet (SRD) results in an increase of plasma (P), liver (L), and heart (H) triacylglycerol (TG) levels, accompanied by a drop in plasma postheparin total (T-TGL) and hepatic (H-TGL) triglyceride lipases activities, IV glucose intolerance (low Kg) and hyperinsulin responses both in vivo and in vitro, suggesting that a state of insulin resistance had developed.\n'
p5119
sg4
(lp5120
(dp5121
g7
I307
sg8
VP04118
p5122
sg10
I7
sg11
Vlipases
p5123
sg13
I1
sa(dp5124
g7
I368
sg8
VP01308
p5125
sg10
I7
sg11
Vinsulin
p5126
sg13
I1
sasg20
(lp5127
(dp5128
g7
I330
sg23
VC0271650
p5129
sg10
I19
sg11
Vglucose intolerance
p5130
sg13
I2
sa(dp5131
g7
I440
sg23
VC0021655
p5132
sg10
I18
sg11
Vinsulin resistance
p5133
sg13
I2
sasa(dp5134
g2
S'The aim of this study was the analysis of the umbilical cord serum sP-selectin levels in pregnancies complicated by severe preeclampsia with and without intrauterine growth restriction and in normotensive pregnancies.\n'
p5135
sg4
(lp5136
(dp5137
g7
I56
sg8
g18
sg10
I22
sg11
Vcord serum sP-selectin
p5138
sg13
I3
sasg20
(lp5139
(dp5140
g7
I116
sg23
VC0341950
p5141
sg10
I19
sg11
Vsevere preeclampsia
p5142
sg13
I2
sa(dp5143
g7
I56
sg23
VC0035334
p5144
sg10
I4
sg11
Vcord
p5145
sg13
I1
sa(dp5146
g7
I153
sg23
VC0015934
p5147
sg10
I31
sg11
Vintrauterine growth restriction
p5148
sg13
I3
sasa(dp5149
g2
S'Severe preeclampsia was associated with the highest levels of P-selectin (&gt;57 ng/mL) (OR = 3.4 [1.2 to 9.7]).\n'
p5150
sg4
(lp5151
(dp5152
g7
I62
sg8
VP16109
p5153
sg10
I10
sg11
VP-selectin
p5154
sg13
I1
sasg20
(lp5155
(dp5156
g7
I0
sg23
VC0341950
p5157
sg10
I19
sg11
VSevere preeclampsia
p5158
sg13
I2
sasa(dp5159
g2
S'The aim of this study was the comparative analysis of the sP-selectin in pregnancies complicated by severe preeclampsia with intrauterine normal growth and small-for-gestational-age foetus.\n'
p5160
sg4
(lp5161
sg20
(lp5162
(dp5163
g7
I100
sg23
VC0341950
p5164
sg10
I19
sg11
Vsevere preeclampsia
p5165
sg13
I2
sasa(dp5166
g2
S'Pregnant women with severe preeclampsia had higher maternal serum sP-selectin levels than the normotensive controls.\n'
p5167
sg4
(lp5168
sg20
(lp5169
(dp5170
g7
I20
sg23
VC0341950
p5171
sg10
I19
sg11
Vsevere preeclampsia
p5172
sg13
I2
sasa(dp5173
g2
S'Our findings indicate an association between the increased levels of sP-selectin and severe preeclampsia.\n'
p5174
sg4
(lp5175
sg20
(lp5176
(dp5177
g7
I85
sg23
VC0341950
p5178
sg10
I19
sg11
Vsevere preeclampsia
p5179
sg13
I2
sasa(dp5180
g2
S'To investigate the association of functional E and P selectin polymorphisms with severe preeclampsia.\n'
p5181
sg4
(lp5182
(dp5183
g7
I51
sg8
VP16109
p5184
sg10
I10
sg11
VP selectin
p5185
sg13
I2
sa(dp5186
g7
I34
sg8
VP04733
p5187
sg10
I12
sg11
Vfunctional E
p5188
sg13
I2
sasg20
(lp5189
(dp5190
g7
I81
sg23
VC0341950
p5191
sg10
I19
sg11
Vsevere preeclampsia
p5192
sg13
I2
sasa(dp5193
g2
S'P-selectin Thr715Pro and E-selectin Serl28Arg polymorphism were determined with the polymerase chain reaction in 126 women with severe preeclampsia and in 106 healthy pregnant women.\n'
p5194
sg4
(lp5195
(dp5196
g7
I25
sg8
VP16581
p5197
sg10
I20
sg11
VE-selectin Serl28Arg
p5198
sg13
I2
sa(dp5199
g7
I0
sg8
VP16109
p5200
sg10
I20
sg11
VP-selectin Thr715Pro
p5201
sg13
I2
sasg20
(lp5202
(dp5203
g7
I128
sg23
VC0341950
p5204
sg10
I19
sg11
Vsevere preeclampsia
p5205
sg13
I2
sasa(dp5206
g2
S'P-selectin is a marker of endothelium activation in patients with severe pre-eclampsia.\n'
p5207
sg4
(lp5208
(dp5209
g7
I0
sg8
VP16109
p5210
sg10
I10
sg11
VP-selectin
p5211
sg13
I1
sasg20
(lp5212
(dp5213
g7
I66
sg23
VC0341950
p5214
sg10
I20
sg11
Vsevere pre-eclampsia
p5215
sg13
I2
sasa(dp5216
g2
S'Serum P-selectin concentrations were consistently and significantly higher in the severe preeclampsia group than in the mild preeclampsia, healthy pregnancy, and non-pregnant control groups (P&lt;0.0001, for all).\n'
p5217
sg4
(lp5218
(dp5219
g7
I0
sg8
VP16109
p5220
sg10
I16
sg11
VSerum P-selectin
p5221
sg13
I2
sasg20
(lp5222
(dp5223
g7
I89
sg23
VC0032914
p5224
sg10
I12
sg11
Vpreeclampsia
p5225
sg13
I1
sa(dp5226
g7
I82
sg23
VC0341950
p5227
sg10
I19
sg11
Vsevere preeclampsia
p5228
sg13
I2
sasa(dp5229
g2
S'The present study suggests that P-selectin may be an additional risk marker for preeclampsia, and may be useful in distinguishing women with mild and severe preeclampsia and normal pregnancy.\n'
p5230
sg4
(lp5231
(dp5232
g7
I32
sg8
VP16109
p5233
sg10
I10
sg11
VP-selectin
p5234
sg13
I1
sasg20
(lp5235
(dp5236
g7
I150
sg23
VC0341950
p5237
sg10
I19
sg11
Vsevere preeclampsia
p5238
sg13
I2
sa(dp5239
g7
I80
sg23
VC0032914
p5240
sg10
I12
sg11
Vpreeclampsia
p5241
sg13
I1
sasa(dp5242
g2
S'Herein, we investigated the role of a long noncoding RNA named MIR4697 host gene (MIR4697HG) in the cell growth and metastasis of ovarian cancer.\n'
p5243
sg4
(lp5244
sg20
(lp5245
(dp5246
g7
I116
sg23
VC0027627
p5247
sg10
I10
sg11
Vmetastasis
p5248
sg13
I1
sa(dp5249
g7
I130
sg23
VC1140680
p5250
sg10
I14
sg11
Vovarian cancer
p5251
sg13
I2
sasa(dp5252
g2
S'MIR4697HG was differentially expressed in ovarian cancer cell lines, with the highest levels in OVCAR3 and SKOV3 cells.\n'
p5253
sg4
(lp5254
sg20
(lp5255
(dp5256
g7
I42
sg23
VC1140680
p5257
sg10
I14
sg11
Vovarian cancer
p5258
sg13
I2
sasa(dp5259
g2
S'Consistently, in a xenograft model of ovarian cancer, MIR4697HG depletion also significantly restricted tumor volumes and weights.\n'
p5260
sg4
(lp5261
sg20
(lp5262
(dp5263
g7
I38
sg23
VC1140680
p5264
sg10
I14
sg11
Vovarian cancer
p5265
sg13
I2
sa(dp5266
g7
I104
sg23
VC0027651
p5267
sg10
I5
sg11
Vtumor
p5268
sg13
I1
sasa(dp5269
g2
S'These data suggested that MIR4697HG promoted ovarian cancer growth and metastasis.\n'
p5270
sg4
(lp5271
sg20
(lp5272
(dp5273
g7
I71
sg23
VC0027627
p5274
sg10
I10
sg11
Vmetastasis
p5275
sg13
I1
sa(dp5276
g7
I45
sg23
VC1140680
p5277
sg10
I14
sg11
Vovarian cancer
p5278
sg13
I2
sasa(dp5279
g2
S'The aggressive role of MIR4697HG in ovarian cancer may be related to the ERK and AKT signaling pathways.\n'
p5280
sg4
(lp5281
(dp5282
g7
I73
sg8
VP29323
p5283
sg10
I3
sg11
VERK
p5284
sg13
I1
sa(dp5285
g7
I81
sg8
g18
sg10
I3
sg11
VAKT
p5286
sg13
I1
sasg20
(lp5287
(dp5288
g7
I36
sg23
VC1140680
p5289
sg10
I14
sg11
Vovarian cancer
p5290
sg13
I2
sa(dp5291
g7
I4
sg23
VC0001807
p5292
sg10
I10
sg11
Vaggressive
p5293
sg13
I1
sasa(dp5294
g2
S'Papillotubular-type invasive ductal carcinoma (INF Beta, ly3, v0, g+, f+, s+, nuclear grade 3 [atypia 3+mitosis 3]) was diagnosed histopathologically.\n'
p5295
sg4
(lp5296
(dp5297
g7
I57
sg8
VP10966
p5298
sg10
I3
sg11
Vly3
p5299
sg13
I1
sa(dp5300
g7
I47
sg8
VP27352
p5301
sg10
I8
sg11
VINF Beta
p5302
sg13
I2
sasg20
(lp5303
(dp5304
g7
I20
sg23
VC1134719
p5305
sg10
I25
sg11
Vinvasive ductal carcinoma
p5306
sg13
I3
sasa(dp5307
g2
S'Histopathological diagnosis was M, type 1, 75 x 35 mm, papillary&gt;moderately-differentiated tubular adenocarcinoma [pT2 (MP), ly3, v0, pN2, Stage IIB].\n'
p5308
sg4
(lp5309
(dp5310
g7
I128
sg8
VP10966
p5311
sg10
I3
sg11
Vly3
p5312
sg13
I1
sasg20
(lp5313
(dp5314
g7
I94
sg23
VC0205645
p5315
sg10
I22
sg11
Vtubular adenocarcinoma
p5316
sg13
I2
sasa(dp5317
g2
S'Transverse colectomy (Cur A) was performed, histopathological examination indicated signet-ring cell carcinoma of the transverse colon, and the lesion was diagnosed as type 4, SS, ly3, v0, n1 (+), Stage III a. Postoperative adjuvant chemotherapy was recommended, but the patient was psychologically unstable and strongly rejected chemotherapy.\n'
p5318
sg4
(lp5319
(dp5320
g7
I180
sg8
VP10966
p5321
sg10
I3
sg11
Vly3
p5322
sg13
I1
sasg20
(lp5323
(dp5324
g7
I84
sg23
VC0206696
p5325
sg10
I26
sg11
Vsignet-ring cell carcinoma
p5326
sg13
I3
sasa(dp5327
g2
S'Histological examination showed papillotublar carcinoma, f, T3, ly3, v2, N2 (24/34), histological grade III, ER (-), PgR (-), HER2 (3+).\n'
p5328
sg4
(lp5329
(dp5330
g7
I64
sg8
VP10966
p5331
sg10
I3
sg11
Vly3
p5332
sg13
I1
sa(dp5333
g7
I126
sg8
VP04626
p5334
sg10
I4
sg11
VHER2
p5335
sg13
I1
sa(dp5336
g7
I117
sg8
VP06401
p5337
sg10
I7
sg11
VPgR (-)
p5338
sg13
I2
sasg20
(lp5339
(dp5340
g7
I46
sg23
VC0007097
p5341
sg10
I9
sg11
Vcarcinoma
p5342
sg13
I1
sasa(dp5343
g2
S'Pathological findings included poorly-differentiated adenocarcinoma, si (bladder), n 4, P 0, ly 3, v 3, H 0, M(-), Stage IV.\n'
p5344
sg4
(lp5345
sg20
(lp5346
(dp5347
g7
I53
sg23
VC0001418
p5348
sg10
I14
sg11
Vadenocarcinoma
p5349
sg13
I1
sasa(dp5350
g2
S'Medians (10 % and 90 % quantiles) were: age at surgery 48.4 months (23.6; 76.0), refraction (spherical equivalent)2.25 dpt (0.25; 5.50), posterior fixation 5.5 mm + 13.0 mm (12.5; 13.0) from limbus, recession 5.0 mm (4.0; 5.0), inferior oblique recession in 29 children (27 bilateral), preoperative squint angles at 5 m S/A 29 (20; 40), at 0.3 m S/A 35 (24; 45), postoperative at 5 m S 0 (-6; 10), A 2 (-6; 11), at 0.3 m S 1 (-5; 12), A 3.5 (-5; 13), S &lt;= 5 in 70.2 % at 5 m and 60.3 % at 0.3 m, consecutive exotropia 6-10 and &gt; 10 in 7.0 and 3.5 % at 5 m and 8.6 and 1.7 % at 0.3 m, residual esotropia 6-10 and &gt; 10 in 10.5 and 8.8 % at 5 m and 13.8 and 15.5 % at 0.3 m. Seven children (11.5 %) were re-operated for esotropia, four for exotropia (6.6 %).\n'
p5351
sg4
(lp5352
sg20
(lp5353
(dp5354
g7
I511
sg23
VC0015310
p5355
sg10
I9
sg11
Vexotropia
p5356
sg13
I1
sa(dp5357
g7
I299
sg23
VC0038379
p5358
sg10
I6
sg11
Vsquint
p5359
sg13
I1
sa(dp5360
g7
I199
sg23
VC0333047
p5361
sg10
I9
sg11
Vrecession
p5362
sg13
I1
sa(dp5363
g7
I590
sg23
VC0339626
p5364
sg10
I18
sg11
Vresidual esotropia
p5365
sg13
I2
sa(dp5366
g7
I599
sg23
VC0014877
p5367
sg10
I9
sg11
Vesotropia
p5368
sg13
I1
sa(dp5369
g7
I499
sg23
VC0339637
p5370
sg10
I21
sg11
Vconsecutive exotropia
p5371
sg13
I2
sa(dp5372
g7
I199
sg23
VC0333047
p5373
sg10
I9
sg11
Vrecession
p5374
sg13
I1
sasa(dp5375
g2
S'In unilateral ptosis, esotropia was 21.4 % (n = 12), in bilateral ptosis, exotropia 19 % (n = 4), as well as astigmatism &gt; or = 3 dpt 26.2 % (n = 11).\n'
p5376
sg4
(lp5377
sg20
(lp5378
(dp5379
g7
I109
sg23
VC0004106
p5380
sg10
I11
sg11
Vastigmatism
p5381
sg13
I1
sa(dp5382
g7
I74
sg23
VC0015310
p5383
sg10
I9
sg11
Vexotropia
p5384
sg13
I1
sa(dp5385
g7
I22
sg23
VC0014877
p5386
sg10
I9
sg11
Vesotropia
p5387
sg13
I1
sa(dp5388
g7
I14
sg23
VC0005745
p5389
sg10
I6
sg11
Vptosis
p5390
sg13
I1
sa(dp5391
g7
I14
sg23
VC0005745
p5392
sg10
I6
sg11
Vptosis
p5393
sg13
I1
sasa(dp5394
g2
S'We and others have subsequently shown that periostin is highly expressed in chronic inflammatory diseases-asthma, atopic dermatitis, eosinophilc chronic sinusitis/chronic rhinosinusitis with nasal polyp, and allergic conjunctivitis-and that periostin plays important roles in the pathogenesis of these diseases.\n'
p5395
sg4
(lp5396
(dp5397
g7
I43
sg8
g18
sg10
I9
sg11
Vperiostin
p5398
sg13
I1
sasg20
(lp5399
(dp5400
g7
I114
sg23
VC0011615
p5401
sg10
I17
sg11
Vatopic dermatitis
p5402
sg13
I2
sa(dp5403
g7
I280
sg23
VC0699748
p5404
sg10
I12
sg11
Vpathogenesis
p5405
sg13
I1
sa(dp5406
g7
I145
sg23
VC0149516
p5407
sg10
I17
sg11
Vchronic sinusitis
p5408
sg13
I2
sa(dp5409
g7
I208
sg23
VC0009766
p5410
sg10
I23
sg11
Vallergic conjunctivitis
p5411
sg13
I2
sa(dp5412
g7
I163
sg23
VC0149516
p5413
sg10
I22
sg11
Vchronic rhinosinusitis
p5414
sg13
I2
sa(dp5415
g7
I191
sg23
VC0027430
p5416
sg10
I11
sg11
Vnasal polyp
p5417
sg13
I2
sasa(dp5418
g2
S'High serum periostin levels (&gt;= 95 ng/mL) at enrollment, the highest treatment step, higher ICS daily doses, a history of admission due to asthma exacerbation, comorbid or a history of sinusitis, and ex-smoking were associated with a decline in FEV1 of 30 mL or greater per year.\n'
p5419
sg4
(lp5420
(dp5421
g7
I95
sg8
g18
sg10
I3
sg11
VICS
p5422
sg13
I1
sasg20
(lp5423
(dp5424
g7
I142
sg23
VC0004096
p5425
sg10
I6
sg11
Vasthma
p5426
sg13
I1
sa(dp5427
g7
I188
sg23
VC0037199
p5428
sg10
I9
sg11
Vsinusitis
p5429
sg13
I1
sa(dp5430
g7
I95
sg23
VC0022521
p5431
sg10
I3
sg11
VICS
p5432
sg13
I1
sasa(dp5433
g2
S'The following study tested the association of the 140A/G polymorphism of lactoferine (LF) encoding gene and the -33C/G polymorphism of osteoblast-specific factor-2 (OSF-2) encoding gene with a risk of chronic rhinosinusitis with nasal polyps in a Polish population.\n'
p5434
sg4
(lp5435
(dp5436
g7
I165
sg8
g18
sg10
I5
sg11
VOSF-2
p5437
sg13
I1
sa(dp5438
g7
I135
sg8
g18
sg10
I28
sg11
Vosteoblast-specific factor-2
p5439
sg13
I2
sasg20
(lp5440
(dp5441
g7
I201
sg23
VC0149516
p5442
sg10
I22
sg11
Vchronic rhinosinusitis
p5443
sg13
I2
sa(dp5444
g7
I229
sg23
VC0027430
p5445
sg10
I12
sg11
Vnasal polyps
p5446
sg13
I2
sasa(dp5447
g2
S'We reported that the 140A/G LF (OR 4.78; 95% CI 3.07-7.24), the -33C/G OSF-2 OR 3.48; 95% CI 2.19-5.52) and the -33G/G OSF-2 (OR 16.45; 95% CI 6.71-40.30) genotypes were associated with an increased risk of chronic rhinosinusitis with nasal polyps among analyzed group of patients.\n'
p5448
sg4
(lp5449
sg20
(lp5450
(dp5451
g7
I235
sg23
VC0027430
p5452
sg10
I12
sg11
Vnasal polyps
p5453
sg13
I2
sa(dp5454
g7
I207
sg23
VC0149516
p5455
sg10
I22
sg11
Vchronic rhinosinusitis
p5456
sg13
I2
sasa(dp5457
g2
S'Moreover, the group of patients without allergy or asthma indicated the association of the -33C/G (OR 3.72; 95% CI 2.24-6.19 and OR 15.11; 95% CI 5.91-38.6) and -33G/G (OR 3.73; 95% CI 2.24-6.19 and OR 14.07; 95% CI 5.47-36.16) genotypes of the OSF-2 as wells as 140A/G (OR 3.89; 95% CI 2.40-6.31 and OR 3.62; 95% CI 2.45-5.34) genotype of OSF-2 with an increased risk of chronic rhinosinusitis with nasal polyps.\n'
p5458
sg4
(lp5459
(dp5460
g7
I245
sg8
g18
sg10
I5
sg11
VOSF-2
p5461
sg13
I1
sa(dp5462
g7
I245
sg8
g18
sg10
I5
sg11
VOSF-2
p5463
sg13
I1
sasg20
(lp5464
(dp5465
g7
I51
sg23
VC0004096
p5466
sg10
I6
sg11
Vasthma
p5467
sg13
I1
sa(dp5468
g7
I400
sg23
VC0027430
p5469
sg10
I12
sg11
Vnasal polyps
p5470
sg13
I2
sa(dp5471
g7
I372
sg23
VC0149516
p5472
sg10
I22
sg11
Vchronic rhinosinusitis
p5473
sg13
I2
sa(dp5474
g7
I40
sg23
VC0020517
p5475
sg10
I7
sg11
Vallergy
p5476
sg13
I1
sasa(dp5477
g2
S'Finally, it was also found that the selected group of patients with allergy or asthma indicated a very strong association of the -33C/G (OR 2.40; 95% CI 1.23-4.69 and OR 2.40; 95% CI 1.23-4.69, respectively) and -33G/G (OR 16.01; 95% CI 5.77-44.41 and OR 17.90; 95% CI 6.53-49.05, respectively) genotypes of the OSF-2 as wells as 140A/G (OR 3.22; 95% CI 1.74-6.11 and OR 3.25; 95% CI 1.75-6.04, respectively) genotypes with an increased risk of chronic rhinosinusitis with nasal polyps.\n'
p5478
sg4
(lp5479
(dp5480
g7
I312
sg8
g18
sg10
I5
sg11
VOSF-2
p5481
sg13
I1
sasg20
(lp5482
(dp5483
g7
I68
sg23
VC0020517
p5484
sg10
I7
sg11
Vallergy
p5485
sg13
I1
sa(dp5486
g7
I473
sg23
VC0027430
p5487
sg10
I12
sg11
Vnasal polyps
p5488
sg13
I2
sa(dp5489
g7
I79
sg23
VC0004096
p5490
sg10
I6
sg11
Vasthma
p5491
sg13
I1
sa(dp5492
g7
I445
sg23
VC0149516
p5493
sg10
I22
sg11
Vchronic rhinosinusitis
p5494
sg13
I2
sasa(dp5495
g2
S"Thus, our results suggest that LF and OSF-2 gene polymorphisms may have deep impact on the risk of rhinosinusitis nasal polyps' formation which may also depend on asthma or allergy.\n"
p5496
sg4
(lp5497
sg20
(lp5498
(dp5499
g7
I114
sg23
VC0027430
p5500
sg10
I12
sg11
Vnasal polyps
p5501
sg13
I2
sa(dp5502
g7
I163
sg23
VC0004096
p5503
sg10
I6
sg11
Vasthma
p5504
sg13
I1
sa(dp5505
g7
I173
sg23
VC0020517
p5506
sg10
I7
sg11
Vallergy
p5507
sg13
I1
sa(dp5508
g7
I99
sg23
VC0948780
p5509
sg10
I14
sg11
Vrhinosinusitis
p5510
sg13
I1
sasa(dp5511
g2
S'Our results showed that the 140A/G polymorphism of LF gene and the -33C/G polymorphism of the OSF-2 gene may be associated with the risk of chronic rhinosinusitis with nasal polyps in a Polish population.\n'
p5512
sg4
(lp5513
(dp5514
g7
I94
sg8
g18
sg10
I10
sg11
VOSF-2 gene
p5515
sg13
I2
sasg20
(lp5516
(dp5517
g7
I168
sg23
VC0027430
p5518
sg10
I12
sg11
Vnasal polyps
p5519
sg13
I2
sa(dp5520
g7
I140
sg23
VC0149516
p5521
sg10
I22
sg11
Vchronic rhinosinusitis
p5522
sg13
I2
sasa(dp5523
g2
S'Eight genes were common to both treatments and were confirmed by Northern blot analysis: BRCA1, BIRC2/CIAP1, CENP-E, DDB1, MRE11A, RAD54/ATRX, Wip1 and XPF/ERCC4.\n'
p5524
sg4
(lp5525
(dp5526
g7
I96
sg8
g18
sg10
I5
sg11
VBIRC2
p5527
sg13
I1
sa(dp5528
g7
I123
sg8
VP49959
p5529
sg10
I6
sg11
VMRE11A
p5530
sg13
I1
sa(dp5531
g7
I117
sg8
g18
sg10
I4
sg11
VDDB1
p5532
sg13
I1
sa(dp5533
g7
I143
sg8
g18
sg10
I4
sg11
VWip1
p5534
sg13
I1
sa(dp5535
g7
I102
sg8
g18
sg10
I5
sg11
VCIAP1
p5536
sg13
I1
sa(dp5537
g7
I152
sg8
g18
sg10
I3
sg11
VXPF
p5538
sg13
I1
sa(dp5539
g7
I89
sg8
VP38398
p5540
sg10
I5
sg11
VBRCA1
p5541
sg13
I1
sa(dp5542
g7
I156
sg8
g18
sg10
I5
sg11
VERCC4
p5543
sg13
I1
sa(dp5544
g7
I131
sg8
g18
sg10
I5
sg11
VRAD54
p5545
sg13
I1
sa(dp5546
g7
I109
sg8
g18
sg10
I6
sg11
VCENP-E
p5547
sg13
I1
sasg20
(lp5548
(dp5549
g7
I152
sg23
VC0268140
p5550
sg10
I3
sg11
VXPF
p5551
sg13
I1
sa(dp5552
g7
I137
sg23
VC1845055
p5553
sg10
I4
sg11
VATRX
p5554
sg13
I1
sasa(dp5555
g2
S'Chondroadherin, a member of the leucine-rich repeat family, has previously been demonstrated to be fragmented in some juveniles with idiopathic scoliosis.\n'
p5556
sg4
(lp5557
(dp5558
g7
I0
sg8
g18
sg10
I14
sg11
VChondroadherin
p5559
sg13
I1
sa(dp5560
g7
I32
sg8
VP30740
p5561
sg10
I26
sg11
Vleucine-rich repeat family
p5562
sg13
I3
sasg20
(lp5563
(dp5564
g7
I133
sg23
VC0595995
p5565
sg10
I20
sg11
Vidiopathic scoliosis
p5566
sg13
I2
sasa(dp5567
g2
S'A protein such as CHAD that can influence both cell metabolism and ECM organization could influence disc pathology in scoliosis.\n'
p5568
sg4
(lp5569
sg20
(lp5570
(dp5571
g7
I118
sg23
VC0700208
p5572
sg10
I9
sg11
Vscoliosis
p5573
sg13
I1
sa(dp5574
g7
I105
sg23
VC0677042
p5575
sg10
I9
sg11
Vpathology
p5576
sg13
I1
sasa(dp5577
g2
S'In addition, proteolytic degradation of CHAD occurred in some patients with scoliosis, but not in normal IVDs.\n'
p5578
sg4
(lp5579
(dp5580
g7
I40
sg8
g18
sg10
I4
sg11
VCHAD
p5581
sg13
I1
sasg20
(lp5582
(dp5583
g7
I76
sg23
VC0700208
p5584
sg10
I9
sg11
Vscoliosis
p5585
sg13
I1
sasa(dp5586
g2
S'Surprisingly, the binding molecule of Aa bacteria to the Aa_Mab was Aa chaperonin 60 or HSP60, a protein that is not only responsible for maintaining cellular proteins conformation, but also functions as a potent virulence factor prompting bone resorption in periodontitis and as a putative pathogenic factor in atherosclerosis.\n'
p5587
sg4
(lp5588
(dp5589
g7
I68
sg8
VP10809
p5590
sg10
I16
sg11
VAa chaperonin 60
p5591
sg13
I3
sa(dp5592
g7
I88
sg8
VP10809
p5593
sg10
I5
sg11
VHSP60
p5594
sg13
I1
sasg20
(lp5595
(dp5596
g7
I312
sg23
VC0004153
p5597
sg10
I15
sg11
Vatherosclerosis
p5598
sg13
I1
sa(dp5599
g7
I259
sg23
VC0031099
p5600
sg10
I13
sg11
Vperiodontitis
p5601
sg13
I1
sasa(dp5602
g2
S'When age, sex, smoking habit, and the number of teeth were considered in multivariate logistic regressions, Aa and Pg IgG, Hsp65-IgA, CuOx-LDL-IgG and -IgM, and MDA-LDL-IgG antibody levels were associated with periodontitis, whereas Hsp60-IgG2 antibody levels were inversely associated.\n'
p5603
sg4
(lp5604
(dp5605
g7
I233
sg8
VP10809
p5606
sg10
I19
sg11
VHsp60-IgG2 antibody
p5607
sg13
I2
sa(dp5608
g7
I123
sg8
VP10809
p5609
sg10
I9
sg11
VHsp65-IgA
p5610
sg13
I1
sa(dp5611
g7
I152
sg8
VP29965
p5612
sg10
I3
sg11
VIgM
p5613
sg13
I1
sasg20
(lp5614
(dp5615
g7
I95
sg23
VC0684320
p5616
sg10
I11
sg11
Vregressions
p5617
sg13
I1
sa(dp5618
g7
I210
sg23
VC0031099
p5619
sg10
I13
sg11
Vperiodontitis
p5620
sg13
I1
sasa(dp5621
g2
S'In all cases the lesional mast cells expressed SERPINB6, and, in diffuse cutaneous mastocytosis and mastocytoma, SERPINB6 was expressed by a substantially higher number of mast cells when compared with tryptase.\n'
p5622
sg4
(lp5623
(dp5624
g7
I47
sg8
VP35237
p5625
sg10
I8
sg11
VSERPINB6
p5626
sg13
I1
sa(dp5627
g7
I47
sg8
VP35237
p5628
sg10
I8
sg11
VSERPINB6
p5629
sg13
I1
sasg20
(lp5630
(dp5631
g7
I65
sg23
VC0024901
p5632
sg10
I30
sg11
Vdiffuse cutaneous mastocytosis
p5633
sg13
I3
sa(dp5634
g7
I100
sg23
VC0334664
p5635
sg10
I11
sg11
Vmastocytoma
p5636
sg13
I1
sasa(dp5637
g2
S"In Kimura's disease characterized by blood and tissue eosinophilia, OKT4-positive T cells from the patients spontaneously produce an ECF (LDECF-HES; pI 6) without any additional stimulation.\n"
p5638
sg4
(lp5639
(dp5640
g7
I144
sg8
g18
sg10
I3
sg11
VHES
p5641
sg13
I1
sa(dp5642
g7
I149
sg8
VP35237
p5643
sg10
I4
sg11
VpI 6
p5644
sg13
I2
sasg20
(lp5645
(dp5646
g7
I3
sg23
VC0033838
p5647
sg10
I16
sg11
VKimura's disease
p5648
sg13
I2
sa(dp5649
g7
I54
sg23
VC0014457
p5650
sg10
I12
sg11
Veosinophilia
p5651
sg13
I1
sa(dp5652
g7
I144
sg23
VC0206141
p5653
sg10
I3
sg11
VHES
p5654
sg13
I1
sasa(dp5655
g2
S'In contrast, PBD-RCDP is associated with defects in the PEX7 gene alone.\n'
p5656
sg4
(lp5657
(dp5658
g7
I13
sg8
g18
sg10
I8
sg11
VPBD-RCDP
p5659
sg13
I1
sa(dp5660
g7
I56
sg8
g18
sg10
I9
sg11
VPEX7 gene
p5661
sg13
I2
sasg20
(lp5662
(dp5663
g7
I13
sg23
VC1832200
p5664
sg10
I3
sg11
VPBD
p5665
sg13
I1
sasa(dp5666
g2
S'Mutations in PEX7 cause rhizomelic chondrodysplasia punctata (RCDP), a distinct peroxisome biogenesis disorder.\n'
p5667
sg4
(lp5668
(dp5669
g7
I13
sg8
g18
sg10
I4
sg11
VPEX7
p5670
sg13
I1
sasg20
(lp5671
(dp5672
g7
I24
sg23
VC0282529
p5673
sg10
I36
sg11
Vrhizomelic chondrodysplasia punctata
p5674
sg13
I3
sa(dp5675
g7
I62
sg23
VC0282529
p5676
sg10
I4
sg11
VRCDP
p5677
sg13
I1
sasa(dp5678
g2
S'PEX7 mutations cause the peroxisome biogenesis disorder (PBD) rhizomelic chondrodysplasia punctata (RCDP).\n'
p5679
sg4
(lp5680
(dp5681
g7
I0
sg8
g18
sg10
I4
sg11
VPEX7
p5682
sg13
I1
sasg20
(lp5683
(dp5684
g7
I57
sg23
VC1832200
p5685
sg10
I3
sg11
VPBD
p5686
sg13
I1
sa(dp5687
g7
I25
sg23
VC1832200
p5688
sg10
I30
sg11
Vperoxisome biogenesis disorder
p5689
sg13
I3
sa(dp5690
g7
I62
sg23
VC0282529
p5691
sg10
I36
sg11
Vrhizomelic chondrodysplasia punctata
p5692
sg13
I3
sa(dp5693
g7
I100
sg23
VC0282529
p5694
sg10
I4
sg11
VRCDP
p5695
sg13
I1
sasa(dp5696
g2
S'Background Increased expression of vitronectin (VN) by smooth muscle cells (SMCs) promotes neointima formation after vascular injury, and may contribute to chronic vascular diseases, such as atherosclerosis.\n'
p5697
sg4
(lp5698
(dp5699
g7
I48
sg8
VP04004
p5700
sg10
I2
sg11
VVN
p5701
sg13
I1
sa(dp5702
g7
I35
sg8
VP04004
p5703
sg10
I11
sg11
Vvitronectin
p5704
sg13
I1
sasg20
(lp5705
(dp5706
g7
I164
sg23
VC0042373
p5707
sg10
I17
sg11
Vvascular diseases
p5708
sg13
I2
sa(dp5709
g7
I91
sg23
VC2936381
p5710
sg10
I19
sg11
Vneointima formation
p5711
sg13
I2
sa(dp5712
g7
I191
sg23
VC0004153
p5713
sg10
I15
sg11
Vatherosclerosis
p5714
sg13
I1
sasa(dp5715
g2
S'Protein-Protein interaction analysis evidenced a network among differentially expressed proteins in which vitronectin seems to represent a potentially pivotal node among fibrinolysis, complement dependent immune responses and inflammation in accordance with a number of in vitro and in vivo evidences for a contributory role of these proteins to the development of diabetic atherosclerosis.\n'
p5716
sg4
(lp5717
(dp5718
g7
I106
sg8
VP04004
p5719
sg10
I11
sg11
Vvitronectin
p5720
sg13
I1
sasg20
(lp5721
(dp5722
g7
I226
sg23
VC0021368
p5723
sg10
I12
sg11
Vinflammation
p5724
sg13
I1
sa(dp5725
g7
I374
sg23
VC0004153
p5726
sg10
I15
sg11
Vatherosclerosis
p5727
sg13
I1
sasa(dp5728
g2
S'From AlfavBeta3, the hormone directs transcription of specific vascular growth factor genes, regulates growth factor receptor/growth factor interactions and stimulates endothelial cell migration to a vitronectin cue; these actions are implicated experimentally in tumor-relevant angiogenesis and angioproliferative pulmonary hypertension.\n'
p5729
sg4
(lp5730
(dp5731
g7
I200
sg8
VP04004
p5732
sg10
I15
sg11
Vvitronectin cue
p5733
sg13
I2
sa(dp5734
g7
I72
sg8
g18
sg10
I13
sg11
Vgrowth factor
p5735
sg13
I2
sa(dp5736
g7
I63
sg8
g18
sg10
I28
sg11
Vvascular growth factor genes
p5737
sg13
I4
sa(dp5738
g7
I103
sg8
g18
sg10
I22
sg11
Vgrowth factor receptor
p5739
sg13
I3
sasg20
(lp5740
(dp5741
g7
I264
sg23
VC0027651
p5742
sg10
I5
sg11
Vtumor
p5743
sg13
I1
sa(dp5744
g7
I315
sg23
VC0020542
p5745
sg10
I22
sg11
Vpulmonary hypertension
p5746
sg13
I2
sasa(dp5747
g2
S'Vitronectin (VN), malondialdehyde (MDA) and high-sensitivity C-reactive rotein (hs-CRP) are cooperative agents involved in the atherosclerosis process.\n'
p5748
sg4
(lp5749
(dp5750
g7
I61
sg8
g18
sg10
I17
sg11
VC-reactive rotein
p5751
sg13
I2
sa(dp5752
g7
I80
sg8
VP02741
p5753
sg10
I6
sg11
Vhs-CRP
p5754
sg13
I1
sa(dp5755
g7
I13
sg8
VP04004
p5756
sg10
I2
sg11
VVN
p5757
sg13
I1
sa(dp5758
g7
I0
sg8
VP04004
p5759
sg10
I11
sg11
VVitronectin
p5760
sg13
I1
sasg20
(lp5761
(dp5762
g7
I127
sg23
VC0004153
p5763
sg10
I15
sg11
Vatherosclerosis
p5764
sg13
I1
sasa(dp5765
g2
S'The aim of this study was to prepare an anti-NYD-SP8 rabbit polyclonal antibody and investigate the expression of NYD-SP8 in human nasopharyngeal carcinoma cell lines and nasopharyngeal carcinoma tissues.\n'
p5766
sg4
(lp5767
(dp5768
g7
I45
sg8
g18
sg10
I7
sg11
VNYD-SP8
p5769
sg13
I1
sasg20
(lp5770
(dp5771
g7
I131
sg23
VC2931822
p5772
sg10
I24
sg11
Vnasopharyngeal carcinoma
p5773
sg13
I2
sa(dp5774
g7
I131
sg23
VC2931822
p5775
sg10
I24
sg11
Vnasopharyngeal carcinoma
p5776
sg13
I2
sasa(dp5777
g2
S'With this antibody, the NYD-SP8 expression in four nasopharyngeal carcinoma cell lines, CNE1, CNE2, 5-8F and 6-10B, was examined by Western blot and its expression in clinical tissues was also assessed by immunohistochemistry.\n'
p5778
sg4
(lp5779
(dp5780
g7
I88
sg8
g18
sg10
I4
sg11
VCNE1
p5781
sg13
I1
sa(dp5782
g7
I24
sg8
g18
sg10
I7
sg11
VNYD-SP8
p5783
sg13
I1
sasg20
(lp5784
(dp5785
g7
I51
sg23
VC2931822
p5786
sg10
I24
sg11
Vnasopharyngeal carcinoma
p5787
sg13
I2
sasa(dp5788
g2
S'Immunohistochemistry demonstrated overexpression of NYD-SP8 in nasopharyngeal carcinoma tissue while the expression in normal nasopharyngeal tissue was negligible.\n'
p5789
sg4
(lp5790
(dp5791
g7
I52
sg8
g18
sg10
I7
sg11
VNYD-SP8
p5792
sg13
I1
sasg20
(lp5793
(dp5794
g7
I63
sg23
VC2931822
p5795
sg10
I24
sg11
Vnasopharyngeal carcinoma
p5796
sg13
I2
sasa(dp5797
g2
S'The different NYD-SP8 expression in various nasopharyngeal carcinoma cell lines indicated its complicated functions at different biological stages.\n'
p5798
sg4
(lp5799
(dp5800
g7
I14
sg8
g18
sg10
I7
sg11
VNYD-SP8
p5801
sg13
I1
sasg20
(lp5802
(dp5803
g7
I44
sg23
VC2931822
p5804
sg10
I24
sg11
Vnasopharyngeal carcinoma
p5805
sg13
I2
sasa(dp5806
g2
S'The overexpression of NYD-SP8 in clinical nasopharyngeal carcinoma tissue indicated that it could play an important role in nasopharyngeal carcinoma carcinogenesis.\n'
p5807
sg4
(lp5808
(dp5809
g7
I22
sg8
g18
sg10
I7
sg11
VNYD-SP8
p5810
sg13
I1
sasg20
(lp5811
(dp5812
g7
I42
sg23
VC2931822
p5813
sg10
I24
sg11
Vnasopharyngeal carcinoma
p5814
sg13
I2
sa(dp5815
g7
I42
sg23
VC2931822
p5816
sg10
I24
sg11
Vnasopharyngeal carcinoma
p5817
sg13
I2
sa(dp5818
g7
I149
sg23
VC0596263
p5819
sg10
I14
sg11
Vcarcinogenesis
p5820
sg13
I1
sasa(dp5821
g2
S'Here, we report on a new pedigree with a germline ETV6 mutation in which the index patient and his father developed high hyperdiploid (HeH) ALL and polycythemia vera at age 13 and 51, respectively.\n'
p5822
sg4
(lp5823
(dp5824
g7
I50
sg8
VP41212
p5825
sg10
I4
sg11
VETV6
p5826
sg13
I1
sasg20
(lp5827
(dp5828
g7
I148
sg23
VC0032463
p5829
sg10
I17
sg11
Vpolycythemia vera
p5830
sg13
I2
sasa(dp5831
g2
S'Genetic studies on consanguineous families with primary microcephaly have identified 15 (MCPH) causative genes that include MCPH1, WDR62, CDK5RAP2, CASC5, ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6, CENPE, SASS6 MFSD2A ANKLE2 and CIT (Khan et al.\n'
p5832
sg4
(lp5833
(dp5834
g7
I204
sg8
g18
sg10
I4
sg11
VCDK6
p5835
sg13
I1
sa(dp5836
g7
I198
sg8
VP78364
p5837
sg10
I4
sg11
VPHC1
p5838
sg13
I1
sa(dp5839
g7
I124
sg8
g18
sg10
I5
sg11
VMCPH1
p5840
sg13
I1
sa(dp5841
g7
I168
sg8
g18
sg10
I4
sg11
VSTIL
p5842
sg13
I1
sa(dp5843
g7
I182
sg8
g18
sg10
I6
sg11
VCEP152
p5844
sg13
I1
sa(dp5845
g7
I210
sg8
g18
sg10
I5
sg11
VCENPE
p5846
sg13
I1
sa(dp5847
g7
I230
sg8
g18
sg10
I6
sg11
VANKLE2
p5848
sg13
I1
sa(dp5849
g7
I217
sg8
g18
sg10
I12
sg11
VSASS6 MFSD2A
p5850
sg13
I2
sa(dp5851
g7
I174
sg8
g18
sg10
I6
sg11
VCEP135
p5852
sg13
I1
sa(dp5853
g7
I241
sg8
g18
sg10
I3
sg11
VCIT
p5854
sg13
I1
sa(dp5855
g7
I131
sg8
g18
sg10
I5
sg11
VWDR62
p5856
sg13
I1
sa(dp5857
g7
I161
sg8
g18
sg10
I5
sg11
VCENPJ
p5858
sg13
I1
sa(dp5859
g7
I190
sg8
g18
sg10
I6
sg11
VZNF335
p5860
sg13
I1
sa(dp5861
g7
I148
sg8
g18
sg10
I5
sg11
VCASC5
p5862
sg13
I1
sasg20
(lp5863
(dp5864
g7
I48
sg23
VC0431350
p5865
sg10
I20
sg11
Vprimary microcephaly
p5866
sg13
I2
sa(dp5867
g7
I124
sg23
VC1855081
p5868
sg10
I5
sg11
VMCPH1
p5869
sg13
I1
sasa(dp5870
g2
S'Results highlight a vast viral versus human peptide commonality that, in particular, involves centriolar and centrosomal components canonically cataloged as microcephaly proteins, i.e., C2CD3, CASC5, CP131, GCP4, KIF2A, STIL, and TBG.\n'
p5871
sg4
(lp5872
(dp5873
g7
I213
sg8
g18
sg10
I5
sg11
VKIF2A
p5874
sg13
I1
sa(dp5875
g7
I230
sg8
VP05543
p5876
sg10
I3
sg11
VTBG
p5877
sg13
I1
sa(dp5878
g7
I207
sg8
g18
sg10
I4
sg11
VGCP4
p5879
sg13
I1
sa(dp5880
g7
I193
sg8
g18
sg10
I5
sg11
VCASC5
p5881
sg13
I1
sa(dp5882
g7
I220
sg8
g18
sg10
I4
sg11
VSTIL
p5883
sg13
I1
sa(dp5884
g7
I186
sg8
g18
sg10
I5
sg11
VC2CD3
p5885
sg13
I1
sasg20
(lp5886
(dp5887
g7
I157
sg23
VC0025958
p5888
sg10
I12
sg11
Vmicrocephaly
p5889
sg13
I1
sasa(dp5890
g2
S'This study confirms the involvement of CASC5 in autosomal recessive microcephaly and supports the hypothesis of a founder effect of the c.6125G&gt;A mutation.\n'
p5891
sg4
(lp5892
(dp5893
g7
I39
sg8
g18
sg10
I5
sg11
VCASC5
p5894
sg13
I1
sasg20
(lp5895
(dp5896
g7
I114
sg23
VC0263541
p5897
sg10
I7
sg11
Vfounder
p5898
sg13
I1
sa(dp5899
g7
I68
sg23
VC0025958
p5900
sg10
I12
sg11
Vmicrocephaly
p5901
sg13
I1
sasa(dp5902
g2
S'CASC5, a gene encoding a protein important for kinetochore formation and proper chromosome segregation during mitosis, has been suggested to be associated with primary microcephaly-4 (MCPH4).\n'
p5903
sg4
(lp5904
(dp5905
g7
I0
sg8
g18
sg10
I5
sg11
VCASC5
p5906
sg13
I1
sasg20
(lp5907
(dp5908
g7
I184
sg23
VC1858516
p5909
sg10
I5
sg11
VMCPH4
p5910
sg13
I1
sa(dp5911
g7
I160
sg23
VC0431350
p5912
sg10
I20
sg11
Vprimary microcephaly
p5913
sg13
I2
sa(dp5914
g7
I168
sg23
VC1858516
p5915
sg10
I14
sg11
Vmicrocephaly-4
p5916
sg13
I1
sasa(dp5917
g2
S'Our findings substantiate the proposed role of CASC5 for primary microcephaly and suggest that it also might be relevant for genome stability.\n'
p5918
sg4
(lp5919
(dp5920
g7
I47
sg8
g18
sg10
I5
sg11
VCASC5
p5921
sg13
I1
sasg20
(lp5922
(dp5923
g7
I57
sg23
VC0431350
p5924
sg10
I20
sg11
Vprimary microcephaly
p5925
sg13
I2
sasa(dp5926
g2
S'These results suggest SPARC might function as a tumor suppressor inhibiting angiogenesis and lymphangiogenesis in ovarian cancer by reducing the expression of VEGF-C and VEGF-D.\n'
p5927
sg4
(lp5928
(dp5929
g7
I22
sg8
VP09486
p5930
sg10
I5
sg11
VSPARC
p5931
sg13
I1
sa(dp5932
g7
I170
sg8
g18
sg10
I6
sg11
VVEGF-D
p5933
sg13
I1
sa(dp5934
g7
I159
sg8
VP49767
p5935
sg10
I6
sg11
VVEGF-C
p5936
sg13
I1
sasg20
(lp5937
(dp5938
g7
I114
sg23
VC1140680
p5939
sg10
I14
sg11
Vovarian cancer
p5940
sg13
I2
sa(dp5941
g7
I48
sg23
VC0027651
p5942
sg10
I5
sg11
Vtumor
p5943
sg13
I1
sasa(dp5944
g2
S'Together, these results provide a unique mechanism by which AR can either increase or decrease ccRCC metastasis at different sites and may help us to develop combined therapies using anti-AR and anti-VEGF-C compounds to better suppress ccRCC progression.The incidence of renal cell carcinoma is higher in males than in females due to the different androgen receptor signaling but the molecular mechanisms behind this gender bias are unclear.\n'
p5945
sg4
(lp5946
(dp5947
g7
I348
sg8
VP10275
p5948
sg10
I17
sg11
Vandrogen receptor
p5949
sg13
I2
sasg20
(lp5950
(dp5951
g7
I101
sg23
VC0027627
p5952
sg10
I10
sg11
Vmetastasis
p5953
sg13
I1
sa(dp5954
g7
I271
sg23
VC0007134
p5955
sg10
I20
sg11
Vrenal cell carcinoma
p5956
sg13
I3
sasa(dp5957
g2
S'The present findings demonstrated that VEGF-C mRNA expression in tumor tissues, blood and urine of bladder cancer patients was upregulated.\n'
p5958
sg4
(lp5959
(dp5960
g7
I39
sg8
VP49767
p5961
sg10
I11
sg11
VVEGF-C mRNA
p5962
sg13
I2
sasg20
(lp5963
(dp5964
g7
I65
sg23
VC0027651
p5965
sg10
I5
sg11
Vtumor
p5966
sg13
I1
sa(dp5967
g7
I99
sg23
VC0699885
p5968
sg10
I14
sg11
Vbladder cancer
p5969
sg13
I2
sasa(dp5970
g2
S'VEGF-C protein expression in bladder cancer tissues was also enhanced.\n'
p5971
sg4
(lp5972
(dp5973
g7
I5
sg8
g18
sg10
I9
sg11
VC protein
p5974
sg13
I2
sasg20
(lp5975
(dp5976
g7
I29
sg23
VC0699885
p5977
sg10
I14
sg11
Vbladder cancer
p5978
sg13
I2
sasa(dp5979
g2
S'VEGF-C protein content in blood and urine from bladder cancer patients was elevated, consistent with the results for VEGF-C mRNA.\n'
p5980
sg4
(lp5981
(dp5982
g7
I5
sg8
g18
sg10
I9
sg11
VC protein
p5983
sg13
I2
sa(dp5984
g7
I117
sg8
VP49767
p5985
sg10
I11
sg11
VVEGF-C mRNA
p5986
sg13
I2
sasg20
(lp5987
(dp5988
g7
I47
sg23
VC0699885
p5989
sg10
I14
sg11
Vbladder cancer
p5990
sg13
I2
sasa(dp5991
g2
S'Therefore, the results of the present study indicate that the expression of VEGF-C mRNA and protein is upregulated in tumor tissues, blood and urine from patients with bladder cancer, while that of miR-186 is downregulated in these samples.\n'
p5992
sg4
(lp5993
(dp5994
g7
I198
sg8
g18
sg10
I7
sg11
VmiR-186
p5995
sg13
I1
sa(dp5996
g7
I76
sg8
VP49767
p5997
sg10
I11
sg11
VVEGF-C mRNA
p5998
sg13
I2
sasg20
(lp5999
(dp6000
g7
I118
sg23
VC0027651
p6001
sg10
I5
sg11
Vtumor
p6002
sg13
I1
sa(dp6003
g7
I168
sg23
VC0699885
p6004
sg10
I14
sg11
Vbladder cancer
p6005
sg13
I2
sasa(dp6006
g2
S'miR-186 potentially regulates the invasion and metastasis of bladder cancer via VEGF-C, and may become a gene marker for bladder cancer in the future.\n'
p6007
sg4
(lp6008
(dp6009
g7
I80
sg8
VP49767
p6010
sg10
I6
sg11
VVEGF-C
p6011
sg13
I1
sa(dp6012
g7
I0
sg8
g18
sg10
I7
sg11
VmiR-186
p6013
sg13
I1
sasg20
(lp6014
(dp6015
g7
I47
sg23
VC0027627
p6016
sg10
I10
sg11
Vmetastasis
p6017
sg13
I1
sa(dp6018
g7
I61
sg23
VC0699885
p6019
sg10
I14
sg11
Vbladder cancer
p6020
sg13
I2
sa(dp6021
g7
I61
sg23
VC0699885
p6022
sg10
I14
sg11
Vbladder cancer
p6023
sg13
I2
sa(dp6024
g7
I34
sg23
VC2699153
p6025
sg10
I8
sg11
Vinvasion
p6026
sg13
I1
sasa(dp6027
g2
S'Specifically, DENND1B, LYN, MRPL30, POC1B, PRKCB, RP4-655J12.3, HIBADH, and TMBIM4 were identified from the T2DM-control study, and BCAT1, BMP2K, CSRNP2, MYNN, NCKAP5L, SAP30BP, SLC35B4, SP1, BAP1, GRB14, HSP90AB1, ITGA5, and TOMM5 were identified from the obesity-control study.\n'
p6028
sg4
(lp6029
(dp6030
g7
I215
sg8
VP08648
p6031
sg10
I5
sg11
VITGA5
p6032
sg13
I1
sa(dp6033
g7
I28
sg8
g18
sg10
I6
sg11
VMRPL30
p6034
sg13
I1
sa(dp6035
g7
I187
sg8
VP08047
p6036
sg10
I3
sg11
VSP1
p6037
sg13
I1
sa(dp6038
g7
I160
sg8
g18
sg10
I7
sg11
VNCKAP5L
p6039
sg13
I1
sa(dp6040
g7
I198
sg8
g18
sg10
I5
sg11
VGRB14
p6041
sg13
I1
sa(dp6042
g7
I192
sg8
g18
sg10
I4
sg11
VBAP1
p6043
sg13
I1
sa(dp6044
g7
I178
sg8
g18
sg10
I7
sg11
VSLC35B4
p6045
sg13
I1
sa(dp6046
g7
I23
sg8
VP07948
p6047
sg10
I3
sg11
VLYN
p6048
sg13
I1
sa(dp6049
g7
I226
sg8
g18
sg10
I5
sg11
VTOMM5
p6050
sg13
I1
sa(dp6051
g7
I146
sg8
g18
sg10
I6
sg11
VCSRNP2
p6052
sg13
I1
sa(dp6053
g7
I169
sg8
g18
sg10
I7
sg11
VSAP30BP
p6054
sg13
I1
sa(dp6055
g7
I205
sg8
VP08238
p6056
sg10
I8
sg11
VHSP90AB1
p6057
sg13
I1
sa(dp6058
g7
I132
sg8
VP54687
p6059
sg10
I5
sg11
VBCAT1
p6060
sg13
I1
sa(dp6061
g7
I36
sg8
g18
sg10
I5
sg11
VPOC1B
p6062
sg13
I1
sa(dp6063
g7
I50
sg8
VP29973
p6064
sg10
I12
sg11
VRP4-655J12.3
p6065
sg13
I1
sa(dp6066
g7
I139
sg8
g18
sg10
I5
sg11
VBMP2K
p6067
sg13
I1
sa(dp6068
g7
I76
sg8
g18
sg10
I6
sg11
VTMBIM4
p6069
sg13
I1
sasg20
(lp6070
(dp6071
g7
I257
sg23
VC0028754
p6072
sg10
I7
sg11
Vobesity
p6073
sg13
I1
sa(dp6074
g7
I50
sg23
VC3151001
p6075
sg10
I3
sg11
VRP4
p6076
sg13
I1
sasa(dp6077
g2
S'Given BMP2 as a potential regulator involved in myopia development, we investigate whether gene BMP2-inducible kinase (BMP2K, BIKe), whose expression is up-regulated during BMP2-induced osteoblast differentiation, contributes to susceptibility of high myopia.\n'
p6078
sg4
(lp6079
(dp6080
g7
I96
sg8
VP12643
p6081
sg10
I21
sg11
VBMP2-inducible kinase
p6082
sg13
I2
sa(dp6083
g7
I119
sg8
g18
sg10
I5
sg11
VBMP2K
p6084
sg13
I1
sa(dp6085
g7
I6
sg8
VP12643
p6086
sg10
I4
sg11
VBMP2
p6087
sg13
I1
sa(dp6088
g7
I126
sg8
g18
sg10
I4
sg11
VBIKe
p6089
sg13
I1
sa(dp6090
g7
I6
sg8
VP12643
p6091
sg10
I4
sg11
VBMP2
p6092
sg13
I1
sasg20
(lp6093
(dp6094
g7
I247
sg23
VC0271183
p6095
sg10
I11
sg11
Vhigh myopia
p6096
sg13
I2
sa(dp6097
g7
I48
sg23
VC0027092
p6098
sg10
I6
sg11
Vmyopia
p6099
sg13
I1
sasa(dp6100
g2
S'Participants grouped into high myopia had a spherical equivalent greater than -6.00 D, compared with a control group of spherical equivalent less than -0.5 D. Genotyping of polymorphisms 1379 G/A (rs2288255) and 3171 C/G (rs12507099), corresponding with 405 Gly/Ser and 1002 Thr/Ser variation in the BMP2K gene were determined by PCR-restriction fragment length polymorphism and associative study performed by comparing high myopic subjects and healthy controls.\n'
p6101
sg4
(lp6102
(dp6103
g7
I300
sg8
g18
sg10
I10
sg11
VBMP2K gene
p6104
sg13
I2
sasg20
(lp6105
(dp6106
g7
I26
sg23
VC0271183
p6107
sg10
I11
sg11
Vhigh myopia
p6108
sg13
I2
sasa(dp6109
g2
S'These data suggest that BMP2K gene 1379 G/A variant is strongly correlated with high myopia and may contribute to a genetic risk factor for high degrees of myopic pathogenesis.\n'
p6110
sg4
(lp6111
(dp6112
g7
I24
sg8
g18
sg10
I10
sg11
VBMP2K gene
p6113
sg13
I2
sasg20
(lp6114
(dp6115
g7
I80
sg23
VC0271183
p6116
sg10
I11
sg11
Vhigh myopia
p6117
sg13
I2
sa(dp6118
g7
I163
sg23
VC0699748
p6119
sg10
I12
sg11
Vpathogenesis
p6120
sg13
I1
sasa(dp6121
g2
S'A destructive arthropathy is much more common when generalized osteoarthritis (GOA) and articular chondrocalcinosis (ACC) coexist than in GOA alone.\n'
p6122
sg4
(lp6123
sg20
(lp6124
(dp6125
g7
I79
sg23
VC1384584
p6126
sg10
I3
sg11
VGOA
p6127
sg13
I1
sa(dp6128
g7
I117
sg23
VC0175754
p6129
sg10
I3
sg11
VACC
p6130
sg13
I1
sa(dp6131
g7
I14
sg23
VC0022408
p6132
sg10
I11
sg11
Varthropathy
p6133
sg13
I1
sa(dp6134
g7
I51
sg23
VC1384584
p6135
sg10
I26
sg11
Vgeneralized osteoarthritis
p6136
sg13
I2
sa(dp6137
g7
I79
sg23
VC1384584
p6138
sg10
I3
sg11
VGOA
p6139
sg13
I1
sa(dp6140
g7
I88
sg23
VC0175754
p6141
sg10
I27
sg11
Varticular chondrocalcinosis
p6142
sg13
I2
sasa(dp6143
g2
S'Our results indicate a melanocytic-cell-lineage-restricted expression of Pmel17/gp100 with significant transcript levels in all stages of melanoma progression, including early and amelanotic melanoma lesions, and a significantly differential expression between melanoma cells and normal melanocytes in vivo.\n'
p6144
sg4
(lp6145
(dp6146
g7
I73
sg8
VP40967
p6147
sg10
I6
sg11
VPmel17
p6148
sg13
I1
sa(dp6149
g7
I80
sg8
VP40967
p6150
sg10
I5
sg11
Vgp100
p6151
sg13
I1
sasg20
(lp6152
(dp6153
g7
I138
sg23
VC0025202
p6154
sg10
I8
sg11
Vmelanoma
p6155
sg13
I1
sa(dp6156
g7
I180
sg23
VC0206735
p6157
sg10
I19
sg11
Vamelanotic melanoma
p6158
sg13
I2
sa(dp6159
g7
I138
sg23
VC0025202
p6160
sg10
I8
sg11
Vmelanoma
p6161
sg13
I1
sasa(dp6162
g2
S'Here, in silico and manual sequence analyses revealed that a large proportion of O. tsutsugamushi strain Ikeda Anks bear a eukaryotic/poxvirus-like F-box motif, which is known to recruit host cell SCF1 ubiquitin ligase machinery.\n'
p6163
sg4
(lp6164
(dp6165
g7
I197
sg8
g18
sg10
I21
sg11
VSCF1 ubiquitin ligase
p6166
sg13
I3
sasg20
(lp6167
(dp6168
g7
I84
sg23
VC0036472
p6169
sg10
I13
sg11
Vtsutsugamushi
p6170
sg13
I1
sasa(dp6171
g2
S'These results demonstrate that O. tsutsugamushi strain Ikeda Anks can co-opt host cell polyubiquitination machinery, provide the first evidence that an O. tsutsugamushi Ank does so during infection, and advance overall understanding of microbial F-box proteins.\n'
p6172
sg4
(lp6173
(dp6174
g7
I152
sg8
g18
sg10
I20
sg11
VO. tsutsugamushi Ank
p6175
sg13
I3
sasg20
(lp6176
(dp6177
g7
I34
sg23
VC0036472
p6178
sg10
I13
sg11
Vtsutsugamushi
p6179
sg13
I1
sa(dp6180
g7
I34
sg23
VC0036472
p6181
sg10
I13
sg11
Vtsutsugamushi
p6182
sg13
I1
sa(dp6183
g7
I188
sg23
VC0009450
p6184
sg10
I9
sg11
Vinfection
p6185
sg13
I1
sasa(dp6186
g2
S'This study demonstrates that O. tsutsugamushi strain Ikeda Anks also bear F-box motifs that interact with host cell polyubiquitination machinery.\n'
p6187
sg4
(lp6188
sg20
(lp6189
(dp6190
g7
I32
sg23
VC0036472
p6191
sg10
I13
sg11
Vtsutsugamushi
p6192
sg13
I1
sasa(dp6193
g2
S'Escherichia coli expressing a functional T1SS was able to secrete chimeric hemolysin proteins bearing the C-termini of 19 of 20 O. tsutsugamushi Anks in an HlyBD-dependent manner.\n'
p6194
sg4
(lp6195
sg20
(lp6196
(dp6197
g7
I131
sg23
VC0036472
p6198
sg10
I13
sg11
Vtsutsugamushi
p6199
sg13
I1
sasa(dp6200
g2
S'Thus, O. tsutsugamushi Anks C-termini are T1SS-compatible.\n'
p6201
sg4
(lp6202
sg20
(lp6203
(dp6204
g7
I9
sg23
VC0036472
p6205
sg10
I13
sg11
Vtsutsugamushi
p6206
sg13
I1
sasa(dp6207
g2
S'This study identifies O. tsutsugamushi Anks as T1SS substrates and indicates that many display a tropism for the host cell secretory pathway.\n'
p6208
sg4
(lp6209
sg20
(lp6210
(dp6211
g7
I25
sg23
VC0036472
p6212
sg10
I13
sg11
Vtsutsugamushi
p6213
sg13
I1
sasa(dp6214
g2
S'Genes encoding proteins with eukaryotic-type ankyrin repeat domains (Anks) were identified upon genome sequencing of the C. burnetii Nine Mile reference isolate, which is associated with a case of human acute Q fever.\n'
p6215
sg4
(lp6216
(dp6217
g7
I45
sg8
VP16157
p6218
sg10
I7
sg11
Vankyrin
p6219
sg13
I1
sasg20
(lp6220
(dp6221
g7
I203
sg23
VC0519066
p6222
sg10
I13
sg11
Vacute Q fever
p6223
sg13
I3
sasa(dp6224
g2
S'To detect the protein and mRNA expression levels of forkhead box C2 (FOXC2) in visceral adipose tissues with type 2 diabetes mellitus (T2DM) as well as the polymorphism of serum FOXC2 gene, and to discuss the correlations of FOXC2 with T2DM and with relevant indices of adipose metabolism.\n'
p6225
sg4
(lp6226
(dp6227
g7
I52
sg8
g18
sg10
I15
sg11
Vforkhead box C2
p6228
sg13
I3
sa(dp6229
g7
I69
sg8
g18
sg10
I5
sg11
VFOXC2
p6230
sg13
I1
sa(dp6231
g7
I178
sg8
g18
sg10
I10
sg11
VFOXC2 gene
p6232
sg13
I2
sa(dp6233
g7
I69
sg8
g18
sg10
I5
sg11
VFOXC2
p6234
sg13
I1
sasg20
(lp6235
(dp6236
g7
I135
sg23
VC0011860
p6237
sg10
I4
sg11
VT2DM
p6238
sg13
I1
sa(dp6239
g7
I135
sg23
VC0011860
p6240
sg10
I4
sg11
VT2DM
p6241
sg13
I1
sa(dp6242
g7
I109
sg23
VC0011860
p6243
sg10
I24
sg11
Vtype 2 diabetes mellitus
p6244
sg13
I4
sasa(dp6245
g2
S'The article also shows data on the effect of treatments of differentiated podocytes with various factors associated with obesity and diabetes on the expression level of FOXC2.\n'
p6246
sg4
(lp6247
(dp6248
g7
I169
sg8
g18
sg10
I5
sg11
VFOXC2
p6249
sg13
I1
sasg20
(lp6250
(dp6251
g7
I133
sg23
VC0011849
p6252
sg10
I8
sg11
Vdiabetes
p6253
sg13
I1
sa(dp6254
g7
I121
sg23
VC0028754
p6255
sg10
I7
sg11
Vobesity
p6256
sg13
I1
sasa(dp6257
g2
S'FOXC2 has lately been implicated in diabetes and obesity as well as mitochondrial function and biogenesis and also as a regulator of mtTFA/Tfam.\n'
p6258
sg4
(lp6259
(dp6260
g7
I133
sg8
g18
sg10
I5
sg11
VmtTFA
p6261
sg13
I1
sa(dp6262
g7
I0
sg8
g18
sg10
I5
sg11
VFOXC2
p6263
sg13
I1
sa(dp6264
g7
I139
sg8
g18
sg10
I4
sg11
VTfam
p6265
sg13
I1
sasg20
(lp6266
(dp6267
g7
I49
sg23
VC0028754
p6268
sg10
I7
sg11
Vobesity
p6269
sg13
I1
sa(dp6270
g7
I36
sg23
VC0011849
p6271
sg10
I8
sg11
Vdiabetes
p6272
sg13
I1
sasa(dp6273
g2
S'In this study, the expression of FOXC2 and selected genes involved in mitochondrial function and biogenesis in healthy subjects and in a matched cohort with type 2 diabetes patients before and after treatment with rosiglitazone was determined.\n'
p6274
sg4
(lp6275
(dp6276
g7
I33
sg8
g18
sg10
I5
sg11
VFOXC2
p6277
sg13
I1
sasg20
(lp6278
(dp6279
g7
I157
sg23
VC0011860
p6280
sg10
I15
sg11
Vtype 2 diabetes
p6281
sg13
I3
sasa(dp6282
g2
S'A study of 222 candidate genes in type 2 diabetes reported association of variants in RAPGEF1, ENPP1, TP53, NRF1, SLC2A2, SLC2A4 and FOXC2 with type 2 diabetes in 4,805 Finnish individuals.\n'
p6283
sg4
(lp6284
(dp6285
g7
I95
sg8
VP22413
p6286
sg10
I5
sg11
VENPP1
p6287
sg13
I1
sa(dp6288
g7
I108
sg8
g18
sg10
I4
sg11
VNRF1
p6289
sg13
I1
sa(dp6290
g7
I133
sg8
g18
sg10
I5
sg11
VFOXC2
p6291
sg13
I1
sa(dp6292
g7
I122
sg8
VP14672
p6293
sg10
I6
sg11
VSLC2A4
p6294
sg13
I1
sa(dp6295
g7
I86
sg8
g18
sg10
I7
sg11
VRAPGEF1
p6296
sg13
I1
sa(dp6297
g7
I114
sg8
VP11168
p6298
sg10
I6
sg11
VSLC2A2
p6299
sg13
I1
sasg20
(lp6300
(dp6301
g7
I34
sg23
VC0011860
p6302
sg10
I15
sg11
Vtype 2 diabetes
p6303
sg13
I3
sa(dp6304
g7
I34
sg23
VC0011860
p6305
sg10
I15
sg11
Vtype 2 diabetes
p6306
sg13
I3
sasa(dp6307
g2
S'Lgi1, Lgi2, Vlgr1 and, we show here, TSPEAR, cause disorders with auditory features: epilepsy, which can include auditory features in humans; audiogenic seizures in animals; and/or hearing impairments in humans and mice.\n'
p6308
sg4
(lp6309
(dp6310
g7
I12
sg8
g18
sg10
I5
sg11
VVlgr1
p6311
sg13
I1
sa(dp6312
g7
I0
sg8
g18
sg10
I4
sg11
VLgi1
p6313
sg13
I1
sa(dp6314
g7
I37
sg8
g18
sg10
I6
sg11
VTSPEAR
p6315
sg13
I1
sa(dp6316
g7
I6
sg8
g18
sg10
I4
sg11
VLgi2
p6317
sg13
I1
sasg20
(lp6318
(dp6319
g7
I153
sg23
VC0036572
p6320
sg10
I8
sg11
Vseizures
p6321
sg13
I1
sa(dp6322
g7
I85
sg23
VC0014544
p6323
sg10
I8
sg11
Vepilepsy
p6324
sg13
I1
sasa(dp6325
g2
S'TRPM2 encodes a calcium channel receptor and TSPEAR encodes a peptide with repeats associated with epilepsy in the mouse.\n'
p6326
sg4
(lp6327
(dp6328
g7
I0
sg8
VP10909
p6329
sg10
I5
sg11
VTRPM2
p6330
sg13
I1
sa(dp6331
g7
I45
sg8
g18
sg10
I6
sg11
VTSPEAR
p6332
sg13
I1
sasg20
(lp6333
(dp6334
g7
I99
sg23
VC0014544
p6335
sg10
I8
sg11
Vepilepsy
p6336
sg13
I1
sasa(dp6337
g2
S'We propose the rpl32-ndhF intergenic spacer (IGS), trnV-ndhC IGS, trnL-rpl32 IGS, psbT-petB region and ndhA intron as the best candidates for future phylogenetic studies in Hydrangeeae and potentially in other Asterids.\n'
p6338
sg4
(lp6339
(dp6340
g7
I15
sg8
VP62910
p6341
sg10
I5
sg11
Vrpl32
p6342
sg13
I1
sa(dp6343
g7
I82
sg8
VP11465
p6344
sg10
I16
sg11
VpsbT-petB region
p6345
sg13
I2
sa(dp6346
g7
I66
sg8
VP62910
p6347
sg10
I14
sg11
VtrnL-rpl32 IGS
p6348
sg13
I2
sa(dp6349
g7
I51
sg8
g18
sg10
I13
sg11
VtrnV-ndhC IGS
p6350
sg13
I2
sasg20
(lp6351
(dp6352
g7
I45
sg23
VC1306856
p6353
sg10
I3
sg11
VIGS
p6354
sg13
I1
sa(dp6355
g7
I26
sg23
VC1306856
p6356
sg10
I17
sg11
Vintergenic spacer
p6357
sg13
I2
sa(dp6358
g7
I45
sg23
VC1306856
p6359
sg10
I3
sg11
VIGS
p6360
sg13
I1
sa(dp6361
g7
I45
sg23
VC1306856
p6362
sg10
I3
sg11
VIGS
p6363
sg13
I1
sasa(dp6364
g2
S'Two sarcoma cell lines were also treated with 10 ng/ml of six angiogenic growth factors (FGF1, FGF2, FGF7, FGF10, VEGF and SCF) for 24 h, and mRNA expression of endogenous FGF family members (FGF1, FGF2, FGF10, FGF11, FGF13 and FGF14) were quantitatively measured using RNase protection at various times following treatments.\n'
p6365
sg4
(lp6366
(dp6367
g7
I95
sg8
g18
sg10
I4
sg11
VFGF2
p6368
sg13
I1
sa(dp6369
g7
I218
sg8
g18
sg10
I5
sg11
VFGF13
p6370
sg13
I1
sa(dp6371
g7
I228
sg8
g18
sg10
I5
sg11
VFGF14
p6372
sg13
I1
sa(dp6373
g7
I107
sg8
g18
sg10
I5
sg11
VFGF10
p6374
sg13
I1
sa(dp6375
g7
I270
sg8
VP07998
p6376
sg10
I5
sg11
VRNase
p6377
sg13
I1
sa(dp6378
g7
I89
sg8
VP05230
p6379
sg10
I4
sg11
VFGF1
p6380
sg13
I1
sa(dp6381
g7
I62
sg8
VP19883
p6382
sg10
I25
sg11
Vangiogenic growth factors
p6383
sg13
I3
sa(dp6384
g7
I101
sg8
VP21781
p6385
sg10
I4
sg11
VFGF7
p6386
sg13
I1
sa(dp6387
g7
I95
sg8
g18
sg10
I4
sg11
VFGF2
p6388
sg13
I1
sa(dp6389
g7
I123
sg8
VP21583
p6390
sg10
I3
sg11
VSCF
p6391
sg13
I1
sa(dp6392
g7
I211
sg8
g18
sg10
I5
sg11
VFGF11
p6393
sg13
I1
sa(dp6394
g7
I89
sg8
VP05230
p6395
sg10
I4
sg11
VFGF1
p6396
sg13
I1
sa(dp6397
g7
I107
sg8
g18
sg10
I5
sg11
VFGF10
p6398
sg13
I1
sasg20
(lp6399
(dp6400
g7
I4
sg23
VC1261473
p6401
sg10
I7
sg11
Vsarcoma
p6402
sg13
I1
sasa(dp6403
g2
S"Association and possible cause-effect correlation with H. pylori infection were suggested in diseases of dermatological interest such as chronic urticaria, rosacea, Henoch-Schoenleins purpura, idiopathic thrombocytopenic purpura, cutaneous and oral lichen planus, atopic dermatitis, recurrent aphthous stomatitis, systemic sclerosis, psoriasis, Sjoegrens syndrome, Behcet's disease, pruritus, alopecia areata, primary cutaneous marginal zone B-cell lymphomas, vitiligo, chronic prurigo, multiformis, prurigo nodularis, leukocytoclastic vasculitis, prurigo pigmentosa, eczema nummulare, primary cutaneous MALT-type lymphoma, sublamina densa-type linear IgA bullous dermatosis, Sweet's syndrome, cutaneous T-cell pseudolymphoma and pemphigus vulgaris.\n"
p6404
sg4
(lp6405
(dp6406
g7
I652
sg8
VP11912
p6407
sg10
I3
sg11
VIgA
p6408
sg13
I1
sasg20
(lp6409
(dp6410
g7
I314
sg23
VC0036421
p6411
sg10
I18
sg11
Vsystemic sclerosis
p6412
sg13
I2
sa(dp6413
g7
I393
sg23
VC0002171
p6414
sg10
I15
sg11
Valopecia areata
p6415
sg13
I2
sa(dp6416
g7
I184
sg23
VC0043117
p6417
sg10
I36
sg11
Vpurpura, idiopathic thrombocytopenic
p6418
sg13
I3
sa(dp6419
g7
I568
sg23
VC0013595
p6420
sg10
I6
sg11
Veczema
p6421
sg13
I1
sa(dp6422
g7
I548
sg23
VC0406301
p6423
sg10
I18
sg11
Vprurigo pigmentosa
p6424
sg13
I2
sa(dp6425
g7
I500
sg23
VC0263353
p6426
sg10
I17
sg11
Vprurigo nodularis
p6427
sg13
I2
sa(dp6428
g7
I645
sg23
VC0406650
p6429
sg10
I29
sg11
Vlinear IgA bullous dermatosis
p6430
sg13
I4
sa(dp6431
g7
I156
sg23
VC0035854
p6432
sg10
I7
sg11
Vrosacea
p6433
sg13
I1
sa(dp6434
g7
I676
sg23
VC0085077
p6435
sg10
I16
sg11
VSweet's syndrome
p6436
sg13
I2
sa(dp6437
g7
I383
sg23
VC0033774
p6438
sg10
I8
sg11
Vpruritus
p6439
sg13
I1
sa(dp6440
g7
I65
sg23
VC0009450
p6441
sg10
I9
sg11
Vinfection
p6442
sg13
I1
sa(dp6443
g7
I355
sg23
VC0039082
p6444
sg10
I8
sg11
Vsyndrome
p6445
sg13
I1
sa(dp6446
g7
I137
sg23
VC0263338
p6447
sg10
I17
sg11
Vchronic urticaria
p6448
sg13
I2
sa(dp6449
g7
I470
sg23
VC0406299
p6450
sg10
I15
sg11
Vchronic prurigo
p6451
sg13
I2
sa(dp6452
g7
I460
sg23
VC0042900
p6453
sg10
I8
sg11
Vvitiligo
p6454
sg13
I1
sa(dp6455
g7
I184
sg23
VC0034150
p6456
sg10
I7
sg11
Vpurpura
p6457
sg13
I1
sa(dp6458
g7
I264
sg23
VC0011615
p6459
sg10
I17
sg11
Vatopic dermatitis
p6460
sg13
I2
sa(dp6461
g7
I449
sg23
VC0024299
p6462
sg10
I8
sg11
Vlymphoma
p6463
sg13
I1
sa(dp6464
g7
I283
sg23
VC2937365
p6465
sg10
I29
sg11
Vrecurrent aphthous stomatitis
p6466
sg13
I3
sa(dp6467
g7
I694
sg23
VC1290062
p6468
sg10
I31
sg11
Vcutaneous T-cell pseudolymphoma
p6469
sg13
I3
sa(dp6470
g7
I519
sg23
VC2973529
p6471
sg10
I27
sg11
Vleukocytoclastic vasculitis
p6472
sg13
I2
sa(dp6473
g7
I365
sg23
VC0004943
p6474
sg10
I16
sg11
VBehcet's disease
p6475
sg13
I2
sa(dp6476
g7
I334
sg23
VC0033860
p6477
sg10
I9
sg11
Vpsoriasis
p6478
sg13
I1
sa(dp6479
g7
I730
sg23
VC0030809
p6480
sg10
I18
sg11
Vpemphigus vulgaris
p6481
sg13
I2
sa(dp6482
g7
I442
sg23
VC0079731
p6483
sg10
I16
sg11
VB-cell lymphomas
p6484
sg13
I2
sa(dp6485
g7
I244
sg23
VC0206139
p6486
sg10
I18
sg11
Voral lichen planus
p6487
sg13
I3
sasa(dp6488
g2
S'Estimation of serum Immunoglobulins (IgG, IgM and IgA) and complements (C3 and C4) was carried out in 100 cases of alopecia areata as per method described by Mancini (1965).\n'
p6489
sg4
(lp6490
(dp6491
g7
I50
sg8
VP11912
p6492
sg10
I3
sg11
VIgA
p6493
sg13
I1
sa(dp6494
g7
I42
sg8
VP29965
p6495
sg10
I3
sg11
VIgM
p6496
sg13
I1
sa(dp6497
g7
I14
sg8
g18
sg10
I21
sg11
Vserum Immunoglobulins
p6498
sg13
I2
sasg20
(lp6499
(dp6500
g7
I115
sg23
VC0002171
p6501
sg10
I15
sg11
Valopecia areata
p6502
sg13
I2
sasa(dp6503
g2
S"Modification of dodecadeoxyribonucleotide d(pA-A-C-C-T-G-T-T-T-G-G-C) (I) with a heptanucleotide 4-(N-2-chloroethyl-N-methylamino)benzylidene (RCI) derivative d(pC-C-A-A-A-C) ARCI (II) and with similar reagent (III) bearing an additional 5'-terminal N-(2-hydroxyethyl)phenazinium residue (Phn) has been unvestigated.\n"
p6504
sg4
(lp6505
sg20
(lp6506
(dp6507
g7
I250
sg23
VC0032768
p6508
sg10
I37
sg11
VN-(2-hydroxyethyl)phenazinium residue
p6509
sg13
I2
sa(dp6510
g7
I289
sg23
VC0032768
p6511
sg10
I3
sg11
VPhn
p6512
sg13
I1
sasa(dp6513
g2
S'The aim of this study is to investigate the effect of transdermal fentanyl (TDF) as an adjuvant to paravertebral block (PVB) for pain control after breast cancer surgery.\n'
p6514
sg4
(lp6515
sg20
(lp6516
(dp6517
g7
I148
sg23
VC0678222
p6518
sg10
I13
sg11
Vbreast cancer
p6519
sg13
I2
sasa(dp6520
g2
S'qRT-PCR showed that miR-370 was down-regulated in human glioma tissue and cells.\n'
p6521
sg4
(lp6522
(dp6523
g7
I20
sg8
g18
sg10
I7
sg11
VmiR-370
p6524
sg13
I1
sasg20
(lp6525
(dp6526
g7
I56
sg23
VC0017638
p6527
sg10
I6
sg11
Vglioma
p6528
sg13
I1
sasa(dp6529
g2
S'In addition, restoration of miR-370 exerted tumor-suppressive function via inhibiting cell proliferation, migration and invasion, while promoting the apoptosis of human glioma cells.\n'
p6530
sg4
(lp6531
sg20
(lp6532
(dp6533
g7
I91
sg23
VC0334094
p6534
sg10
I13
sg11
Vproliferation
p6535
sg13
I1
sa(dp6536
g7
I44
sg23
VC0027651
p6537
sg10
I5
sg11
Vtumor
p6538
sg13
I1
sa(dp6539
g7
I120
sg23
VC2699153
p6540
sg10
I8
sg11
Vinvasion
p6541
sg13
I1
sa(dp6542
g7
I169
sg23
VC0017638
p6543
sg10
I6
sg11
Vglioma
p6544
sg13
I1
sasa(dp6545
g2
S'These results provided a comprehensive analysis of KCNQ1OT1-miR-370-CCNE2 axis in human glioma cells and might provide a novel strategy for glioma treatment.\n'
p6546
sg4
(lp6547
(dp6548
g7
I51
sg8
g18
sg10
I22
sg11
VKCNQ1OT1-miR-370-CCNE2
p6549
sg13
I1
sasg20
(lp6550
(dp6551
g7
I88
sg23
VC0017638
p6552
sg10
I6
sg11
Vglioma
p6553
sg13
I1
sa(dp6554
g7
I88
sg23
VC0017638
p6555
sg10
I6
sg11
Vglioma
p6556
sg13
I1
sasa(dp6557
g2
S'However, the role of miR-370 in melanoma remains largely unknown.\n'
p6558
sg4
(lp6559
(dp6560
g7
I21
sg8
g18
sg10
I7
sg11
VmiR-370
p6561
sg13
I1
sasg20
(lp6562
(dp6563
g7
I32
sg23
VC0025202
p6564
sg10
I8
sg11
Vmelanoma
p6565
sg13
I1
sasa(dp6566
g2
S'The present study is designed to investigate the function of miR-370 in melanoma and to explore the molecular mechanism underlying its function.\n'
p6567
sg4
(lp6568
(dp6569
g7
I61
sg8
g18
sg10
I7
sg11
VmiR-370
p6570
sg13
I1
sasg20
(lp6571
(dp6572
g7
I72
sg23
VC0025202
p6573
sg10
I8
sg11
Vmelanoma
p6574
sg13
I1
sasa(dp6575
g2
S'The expression level of miR-370 was detected in melanoma tissues and cell lines by real-time quantitative polymerase chain reaction (qRT-PCR).\n'
p6576
sg4
(lp6577
(dp6578
g7
I24
sg8
g18
sg10
I7
sg11
VmiR-370
p6579
sg13
I1
sasg20
(lp6580
(dp6581
g7
I48
sg23
VC0025202
p6582
sg10
I8
sg11
Vmelanoma
p6583
sg13
I1
sasa(dp6584
g2
S'Western blotting analysis was used to detect the influence of miR-370 on the expression of target genes, and Pearson analysis was used to calculate the correlation between the expression of targets gene and miR-370 in melanoma tissues.\n'
p6585
sg4
(lp6586
(dp6587
g7
I62
sg8
g18
sg10
I7
sg11
VmiR-370
p6588
sg13
I1
sa(dp6589
g7
I62
sg8
g18
sg10
I7
sg11
VmiR-370
p6590
sg13
I1
sasg20
(lp6591
(dp6592
g7
I218
sg23
VC0025202
p6593
sg10
I8
sg11
Vmelanoma
p6594
sg13
I1
sasa(dp6595
g2
S'Our study showed that miR-370 was upregulated in melanoma tissues compared with non-cancerous tissues (P&lt;0.01).\n'
p6596
sg4
(lp6597
(dp6598
g7
I22
sg8
g18
sg10
I7
sg11
VmiR-370
p6599
sg13
I1
sasg20
(lp6600
(dp6601
g7
I49
sg23
VC0025202
p6602
sg10
I8
sg11
Vmelanoma
p6603
sg13
I1
sasa(dp6604
g2
S'In addition, the expression of miR-370 in melanoma cell lines was also significantly higher (P&lt;0.01).\n'
p6605
sg4
(lp6606
(dp6607
g7
I31
sg8
g18
sg10
I7
sg11
VmiR-370
p6608
sg13
I1
sasg20
(lp6609
(dp6610
g7
I42
sg23
VC0025202
p6611
sg10
I8
sg11
Vmelanoma
p6612
sg13
I1
sasa(dp6613
g2
S'Enforced expression of miR-370 promotes melanoma cell proliferation, inhibits apoptosis and enhances invasion and glycolysis and led to downregulation of the PDHB protein.\n'
p6614
sg4
(lp6615
(dp6616
g7
I158
sg8
VP11177
p6617
sg10
I12
sg11
VPDHB protein
p6618
sg13
I2
sa(dp6619
g7
I23
sg8
g18
sg10
I7
sg11
VmiR-370
p6620
sg13
I1
sasg20
(lp6621
(dp6622
g7
I54
sg23
VC0334094
p6623
sg10
I13
sg11
Vproliferation
p6624
sg13
I1
sa(dp6625
g7
I101
sg23
VC2699153
p6626
sg10
I8
sg11
Vinvasion
p6627
sg13
I1
sa(dp6628
g7
I40
sg23
VC0025202
p6629
sg10
I8
sg11
Vmelanoma
p6630
sg13
I1
sasa(dp6631
g2
S'Moreover, the expression level of miR-370 in melanoma tissues showed inverse relationship with the expression level of PDHB protein.\n'
p6632
sg4
(lp6633
(dp6634
g7
I119
sg8
VP11177
p6635
sg10
I12
sg11
VPDHB protein
p6636
sg13
I2
sa(dp6637
g7
I34
sg8
g18
sg10
I7
sg11
VmiR-370
p6638
sg13
I1
sasg20
(lp6639
(dp6640
g7
I45
sg23
VC0025202
p6641
sg10
I8
sg11
Vmelanoma
p6642
sg13
I1
sasa(dp6643
g2
S'In conclusion, our findings suggested that miR-370 represents a potential oncogenic miRNA and plays an important role in melanoma progression by directly targeting PDHB.\n'
p6644
sg4
(lp6645
(dp6646
g7
I164
sg8
VP11177
p6647
sg10
I4
sg11
VPDHB
p6648
sg13
I1
sa(dp6649
g7
I43
sg8
g18
sg10
I7
sg11
VmiR-370
p6650
sg13
I1
sasg20
(lp6651
(dp6652
g7
I121
sg23
VC0025202
p6653
sg10
I8
sg11
Vmelanoma
p6654
sg13
I1
sasa(dp6655
g2
S'We identified 60 miRNAs that were significantly increased in recurrent serous ovarian carcinoma compared with primary tumor tissue, including miR-630, miR-370, and miR-575.\n'
p6656
sg4
(lp6657
(dp6658
g7
I142
sg8
g18
sg10
I7
sg11
VmiR-630
p6659
sg13
I1
sa(dp6660
g7
I151
sg8
g18
sg10
I7
sg11
VmiR-370
p6661
sg13
I1
sasg20
(lp6662
(dp6663
g7
I110
sg23
VC0677930
p6664
sg10
I13
sg11
Vprimary tumor
p6665
sg13
I2
sa(dp6666
g7
I78
sg23
VC0029925
p6667
sg10
I17
sg11
Vovarian carcinoma
p6668
sg13
I2
sasa(dp6669
g2
S'Thus, our study demonstrated a critical clinical role of an up-regulated miR-370-3p expression in glioblastoma multiforme chemotherapy sensitivity.\n'
p6670
sg4
(lp6671
(dp6672
g7
I73
sg8
g18
sg10
I10
sg11
VmiR-370-3p
p6673
sg13
I1
sasg20
(lp6674
(dp6675
g7
I98
sg23
VC1621958
p6676
sg10
I23
sg11
Vglioblastoma multiforme
p6677
sg13
I2
sasa(dp6678
g2
S'The aim of this study was to explore the expression and biological role of miR-370-3p in human gliomas.\n'
p6679
sg4
(lp6680
(dp6681
g7
I75
sg8
g18
sg10
I10
sg11
VmiR-370-3p
p6682
sg13
I1
sasg20
(lp6683
(dp6684
g7
I95
sg23
VC0017638
p6685
sg10
I7
sg11
Vgliomas
p6686
sg13
I1
sasa(dp6687
g2
S'Clinical specimens from the brains of 20 glioma patients and 10 healthy controls were obtained to quantify the expression level of miR-370-3p using quantitative real-time PCR.\n'
p6688
sg4
(lp6689
(dp6690
g7
I131
sg8
g18
sg10
I10
sg11
VmiR-370-3p
p6691
sg13
I1
sasg20
(lp6692
(dp6693
g7
I41
sg23
VC0017638
p6694
sg10
I6
sg11
Vglioma
p6695
sg13
I1
sasa(dp6696
g2
S'miR-370-3p expression was frequently found to be decreased in glioma tissues, and its expression level was negatively correlated with the malignant degree of the glioma.\n'
p6697
sg4
(lp6698
(dp6699
g7
I0
sg8
g18
sg10
I10
sg11
VmiR-370-3p
p6700
sg13
I1
sasg20
(lp6701
(dp6702
g7
I62
sg23
VC0017638
p6703
sg10
I6
sg11
Vglioma
p6704
sg13
I1
sa(dp6705
g7
I62
sg23
VC0017638
p6706
sg10
I6
sg11
Vglioma
p6707
sg13
I1
sasa(dp6708
g2
S'Finally, in 20 glioma tissues the expression of miR-370-3p was negatively correlated with both protein and mRNA levels of Beta-catenin.\n'
p6709
sg4
(lp6710
(dp6711
g7
I122
sg8
VP35222
p6712
sg10
I12
sg11
VBeta-catenin
p6713
sg13
I1
sa(dp6714
g7
I48
sg8
g18
sg10
I10
sg11
VmiR-370-3p
p6715
sg13
I1
sasg20
(lp6716
(dp6717
g7
I15
sg23
VC0017638
p6718
sg10
I6
sg11
Vglioma
p6719
sg13
I1
sasa(dp6720
g2
S'miR-370-3p suppresses glioma cell growth by directly targeting Beta-catenin, suggesting that the miR-370-3p/Beta-catenin axis may be a target for glioma therapy.\n'
p6721
sg4
(lp6722
(dp6723
g7
I0
sg8
g18
sg10
I10
sg11
VmiR-370-3p
p6724
sg13
I1
sa(dp6725
g7
I63
sg8
VP35222
p6726
sg10
I12
sg11
VBeta-catenin
p6727
sg13
I1
sa(dp6728
g7
I0
sg8
g18
sg10
I10
sg11
VmiR-370-3p
p6729
sg13
I1
sasg20
(lp6730
(dp6731
g7
I22
sg23
VC0017638
p6732
sg10
I6
sg11
Vglioma
p6733
sg13
I1
sa(dp6734
g7
I22
sg23
VC0017638
p6735
sg10
I6
sg11
Vglioma
p6736
sg13
I1
sasa(dp6737
g2
S'Three other miRNAs, miR-19b, miR-433, and miR-370 were associated with lymph node metastasis, decreased curvature, and poorly differentiated carcinoma.\n'
p6738
sg4
(lp6739
(dp6740
g7
I29
sg8
g18
sg10
I7
sg11
VmiR-433
p6741
sg13
I1
sa(dp6742
g7
I42
sg8
g18
sg10
I7
sg11
VmiR-370
p6743
sg13
I1
sa(dp6744
g7
I20
sg8
g18
sg10
I7
sg11
VmiR-19b
p6745
sg13
I1
sasg20
(lp6746
(dp6747
g7
I71
sg23
VC0686619
p6748
sg10
I21
sg11
Vlymph node metastasis
p6749
sg13
I3
sa(dp6750
g7
I119
sg23
VC0741899
p6751
sg10
I31
sg11
Vpoorly differentiated carcinoma
p6752
sg13
I3
sasa(dp6753
g2
S'A preliminary screening study suggested that down-regulation of miR-370 occurs in oral squamous cell carcinoma (OSCC) tissue.\n'
p6754
sg4
(lp6755
(dp6756
g7
I64
sg8
g18
sg10
I7
sg11
VmiR-370
p6757
sg13
I1
sasg20
(lp6758
(dp6759
g7
I87
sg23
VC0007137
p6760
sg10
I23
sg11
Vsquamous cell carcinoma
p6761
sg13
I3
sasa(dp6762
g2
S'Squamous cell carcinoma tissues with perineural invasion had lowered miR-370 expression compared with contrasting OSCC.\n'
p6763
sg4
(lp6764
(dp6765
g7
I69
sg8
g18
sg10
I7
sg11
VmiR-370
p6766
sg13
I1
sasg20
(lp6767
(dp6768
g7
I48
sg23
VC2699153
p6769
sg10
I8
sg11
Vinvasion
p6770
sg13
I1
sa(dp6771
g7
I0
sg23
VC0007137
p6772
sg10
I23
sg11
VSquamous cell carcinoma
p6773
sg13
I3
sasa(dp6774
g2
S'Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues.\n'
p6775
sg4
(lp6776
(dp6777
g7
I36
sg8
g18
sg10
I7
sg11
VmiR-30d
p6778
sg13
I1
sa(dp6779
g7
I57
sg8
g18
sg10
I7
sg11
VmiR-370
p6780
sg13
I1
sa(dp6781
g7
I27
sg8
g18
sg10
I7
sg11
VmiR-30c
p6782
sg13
I1
sa(dp6783
g7
I45
sg8
g18
sg10
I10
sg11
VmiR-30e-3p
p6784
sg13
I1
sasg20
(lp6785
(dp6786
g7
I102
sg23
VC0007097
p6787
sg10
I9
sg11
Vcarcinoma
p6788
sg13
I1
sa(dp6789
g7
I102
sg23
VC0007097
p6790
sg10
I10
sg11
Vcarcinomas
p6791
sg13
I1
sasa(dp6792
g2
S'#########(myocardial ischemia-reperfusion injury, MI/RI)##########################NOD#########3(NOD-like receptor pyrin domain containing 3, NLRP3)###################MI/RI#################, ##### NLRP3###################MI/RI#######.\n'
p6793
sg4
(lp6794
(dp6795
g7
I114
sg8
g18
sg10
I25
sg11
Vpyrin domain containing 3
p6796
sg13
I4
sasg20
(lp6797
(dp6798
g7
I82
sg23
VC0751781
p6799
sg10
I3
sg11
VNOD
p6800
sg13
I1
sa(dp6801
g7
I82
sg23
VC0751781
p6802
sg10
I3
sg11
VNOD
p6803
sg13
I1
sa(dp6804
g7
I10
sg23
VC0151744
p6805
sg10
I19
sg11
Vmyocardial ischemia
p6806
sg13
I2
sasa(dp6807
g2
S'NLR family-pyrin domain containing 3 (NLRP3) was reported to affect a renal ischemia/reperfusion (I/R) injury by exerting a direct effect on the renal tubular epithelium.\n'
p6808
sg4
(lp6809
(dp6810
g7
I0
sg8
g18
sg10
I36
sg11
VNLR family-pyrin domain containing 3
p6811
sg13
I5
sa(dp6812
g7
I38
sg8
g18
sg10
I5
sg11
VNLRP3
p6813
sg13
I1
sasg20
(lp6814
(dp6815
g7
I70
sg23
VC0920646
p6816
sg10
I14
sg11
Vrenal ischemia
p6817
sg13
I2
sasa(dp6818
g2
S'Although the nucleotide-binding oligomerization domain- (NOD-) like receptor pyrin domain containing 3 (NLRP3) inflammasome has been recently detected in the heart, its role in cardiac ischemia/reperfusion (IR) is still controversial.\n'
p6819
sg4
(lp6820
(dp6821
g7
I68
sg8
g18
sg10
I34
sg11
Vreceptor pyrin domain containing 3
p6822
sg13
I5
sasg20
(lp6823
(dp6824
g7
I177
sg23
VC0151744
p6825
sg10
I16
sg11
Vcardiac ischemia
p6826
sg13
I2
sa(dp6827
g7
I57
sg23
VC0751781
p6828
sg10
I3
sg11
VNOD
p6829
sg13
I1
sasa(dp6830
g2
S'After 2 h he died of cardiac tamponade.\n'
p6831
sg4
(lp6832
sg20
(lp6833
(dp6834
g7
I21
sg23
VC0007177
p6835
sg10
I17
sg11
Vcardiac tamponade
p6836
sg13
I2
sasa(dp6837
g2
S'Ninjurin1 is involved in the pathogenesis of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis, by mediating leukocyte extravasation, a process that depends on homotypic binding.\n'
p6838
sg4
(lp6839
(dp6840
g7
I0
sg8
g18
sg10
I9
sg11
VNinjurin1
p6841
sg13
I1
sasg20
(lp6842
(dp6843
g7
I58
sg23
VC0443146
p6844
sg10
I10
sg11
Vautoimmune
p6845
sg13
I1
sa(dp6846
g7
I150
sg23
VC0015376
p6847
sg10
I13
sg11
Vextravasation
p6848
sg13
I1
sa(dp6849
g7
I29
sg23
VC0699748
p6850
sg10
I12
sg11
Vpathogenesis
p6851
sg13
I1
sa(dp6852
g7
I107
sg23
VC0026769
p6853
sg10
I18
sg11
Vmultiple sclerosis
p6854
sg13
I2
sa(dp6855
g7
I69
sg23
VC0014070
p6856
sg10
I17
sg11
Vencephalomyelitis
p6857
sg13
I1
sasa(dp6858
g2
S'The collective data described here show that Ninj1 is required for the entry, adhesion, activation, and movement of leukocytes during tissue remodeling and might be a potential therapeutic target to regulate the adhesion and trafficking of leukocytes in inflammation and leukocyte-mediated diseases such as multiple sclerosis, diabetic retinopathy, and neuropathy.\n'
p6859
sg4
(lp6860
(dp6861
g7
I45
sg8
g18
sg10
I5
sg11
VNinj1
p6862
sg13
I1
sasg20
(lp6863
(dp6864
g7
I78
sg23
VC0001511
p6865
sg10
I8
sg11
Vadhesion
p6866
sg13
I1
sa(dp6867
g7
I353
sg23
VC0442874
p6868
sg10
I10
sg11
Vneuropathy
p6869
sg13
I1
sa(dp6870
g7
I78
sg23
VC0001511
p6871
sg10
I8
sg11
Vadhesion
p6872
sg13
I1
sa(dp6873
g7
I327
sg23
VC0011884
p6874
sg10
I20
sg11
Vdiabetic retinopathy
p6875
sg13
I2
sa(dp6876
g7
I307
sg23
VC0026769
p6877
sg10
I18
sg11
Vmultiple sclerosis
p6878
sg13
I2
sa(dp6879
g7
I254
sg23
VC0021368
p6880
sg10
I12
sg11
Vinflammation
p6881
sg13
I1
sasa(dp6882
g2
S'Abnormal expression of Cables1 has been observed in multiple types of cancers and other diseases.\n'
p6883
sg4
(lp6884
(dp6885
g7
I23
sg8
g18
sg10
I7
sg11
VCables1
p6886
sg13
I1
sasg20
(lp6887
(dp6888
g7
I70
sg23
VC0006826
p6889
sg10
I7
sg11
Vcancers
p6890
sg13
I1
sasa(dp6891
g2
S'In this review, we summarize the characteristics of Cables1 and highlight the molecular mechanisms through which Cables1 regulates the development of cancer and other diseases.\n'
p6892
sg4
(lp6893
(dp6894
g7
I52
sg8
g18
sg10
I7
sg11
VCables1
p6895
sg13
I1
sa(dp6896
g7
I52
sg8
g18
sg10
I7
sg11
VCables1
p6897
sg13
I1
sasg20
(lp6898
(dp6899
g7
I150
sg23
VC0006826
p6900
sg10
I6
sg11
Vcancer
p6901
sg13
I1
sasa(dp6902
g2
S'Finally, we discuss future challenges in demonstrating the role and potential application of Cables1 in cancer and other diseases.\n'
p6903
sg4
(lp6904
(dp6905
g7
I93
sg8
g18
sg10
I7
sg11
VCables1
p6906
sg13
I1
sasg20
(lp6907
(dp6908
g7
I104
sg23
VC0006826
p6909
sg10
I6
sg11
Vcancer
p6910
sg13
I1
sasa(dp6911
g2
S'Cables1 expression is lost frequently in human cancer but little is known about its regulation.\n'
p6912
sg4
(lp6913
(dp6914
g7
I0
sg8
g18
sg10
I7
sg11
VCables1
p6915
sg13
I1
sasg20
(lp6916
(dp6917
g7
I47
sg23
VC0006826
p6918
sg10
I6
sg11
Vcancer
p6919
sg13
I1
sasa(dp6920
g2
S'Clinically, levels of phosphorylated Cables1 and phosphorylated Akt correlated with each other in human lung cancer specimens, consistent with pathophysiologic significance.\n'
p6921
sg4
(lp6922
(dp6923
g7
I64
sg8
g18
sg10
I3
sg11
VAkt
p6924
sg13
I1
sa(dp6925
g7
I37
sg8
g18
sg10
I7
sg11
VCables1
p6926
sg13
I1
sasg20
(lp6927
(dp6928
g7
I104
sg23
VC0684249
p6929
sg10
I11
sg11
Vlung cancer
p6930
sg13
I2
sasa(dp6931
g2
S'In further support of a potential pathophysiological role of Cables1, the expression level of Cables1 is tightly associated with p21 in both cancer cell lines and human lung cancer patient tumor samples.\n'
p6932
sg4
(lp6933
(dp6934
g7
I61
sg8
g18
sg10
I7
sg11
VCables1
p6935
sg13
I1
sa(dp6936
g7
I129
sg8
VP42857
p6937
sg10
I3
sg11
Vp21
p6938
sg13
I1
sa(dp6939
g7
I61
sg8
g18
sg10
I7
sg11
VCables1
p6940
sg13
I1
sasg20
(lp6941
(dp6942
g7
I189
sg23
VC0027651
p6943
sg10
I5
sg11
Vtumor
p6944
sg13
I1
sa(dp6945
g7
I141
sg23
VC0006826
p6946
sg10
I6
sg11
Vcancer
p6947
sg13
I1
sa(dp6948
g7
I169
sg23
VC0684249
p6949
sg10
I11
sg11
Vlung cancer
p6950
sg13
I2
sasa(dp6951
g2
S'This study investigates the role of CABLES1 in an in vivo mouse model of intestinal adenocarcinoma and in human colon cancer cell culture.\n'
p6952
sg4
(lp6953
(dp6954
g7
I36
sg8
g18
sg10
I7
sg11
VCABLES1
p6955
sg13
I1
sasg20
(lp6956
(dp6957
g7
I112
sg23
VC0699790
p6958
sg10
I12
sg11
Vcolon cancer
p6959
sg13
I2
sa(dp6960
g7
I73
sg23
VC0948209
p6961
sg10
I25
sg11
Vintestinal adenocarcinoma
p6962
sg13
I2
sasa(dp6963
g2
S'Beta-catenin activity in human colon cancer cells with CABLES1 inactivation and intestinal progenitor cell function in Cables1(-/-) mice were assayed in vitro.\n'
p6964
sg4
(lp6965
(dp6966
g7
I119
sg8
g18
sg10
I7
sg11
VCables1
p6967
sg13
I1
sa(dp6968
g7
I55
sg8
g18
sg10
I7
sg11
VCABLES1
p6969
sg13
I1
sa(dp6970
g7
I0
sg8
VP35222
p6971
sg10
I12
sg11
VBeta-catenin
p6972
sg13
I1
sasg20
(lp6973
(dp6974
g7
I63
sg23
VC0544461
p6975
sg10
I12
sg11
Vinactivation
p6976
sg13
I1
sa(dp6977
g7
I31
sg23
VC0699790
p6978
sg10
I12
sg11
Vcolon cancer
p6979
sg13
I2
sasa(dp6980
g2
S'Cables1 is a tumor suppressor gene on chromosome 18q in this in vivo mouse model and likely has a similar role in human colon cancer.\n'
p6981
sg4
(lp6982
(dp6983
g7
I0
sg8
g18
sg10
I7
sg11
VCables1
p6984
sg13
I1
sasg20
(lp6985
(dp6986
g7
I120
sg23
VC0699790
p6987
sg10
I12
sg11
Vcolon cancer
p6988
sg13
I2
sa(dp6989
g7
I13
sg23
VC0027651
p6990
sg10
I5
sg11
Vtumor
p6991
sg13
I1
sasa(dp6992
g2
S'Loss of nuclear Cables 1 expression is observed in human colon, lung and endometrial cancers.\n'
p6993
sg4
(lp6994
sg20
(lp6995
(dp6996
g7
I73
sg23
VC0476089
p6997
sg10
I19
sg11
Vendometrial cancers
p6998
sg13
I2
sasa(dp6999
g2
S'Our present objective was to examine Cables 1 expression in ovarian cancer in greater detail, and determine the predominant mechanisms of Cables 1 loss.\n'
p7000
sg4
(lp7001
sg20
(lp7002
(dp7003
g7
I60
sg23
VC1140680
p7004
sg10
I14
sg11
Vovarian cancer
p7005
sg13
I2
sasa(dp7006
g2
S'Although we detected no Cables 1 mutations, there was evidence of LOH at the Cables 1 locus and epigenetic modification of the Cables 1 promoter region in a subset of ovarian carcinomas and established cancer cell lines.\n'
p7007
sg4
(lp7008
(dp7009
g7
I24
sg8
g18
sg10
I8
sg11
VCables 1
p7010
sg13
I2
sa(dp7011
g7
I127
sg8
g18
sg10
I24
sg11
VCables 1 promoter region
p7012
sg13
I4
sasg20
(lp7013
(dp7014
g7
I167
sg23
VC0029925
p7015
sg10
I18
sg11
Vovarian carcinomas
p7016
sg13
I2
sa(dp7017
g7
I202
sg23
VC0006826
p7018
sg10
I6
sg11
Vcancer
p7019
sg13
I1
sasa(dp7020
g2
S'Together these findings suggest that multiple mechanisms underlie the loss of Cables 1 expression in ovarian cancer cells, supporting the hypothesis that Cables 1 is a tumor suppressor in human ovarian cancer.\n'
p7021
sg4
(lp7022
(dp7023
g7
I78
sg8
g18
sg10
I8
sg11
VCables 1
p7024
sg13
I2
sasg20
(lp7025
(dp7026
g7
I101
sg23
VC1140680
p7027
sg10
I14
sg11
Vovarian cancer
p7028
sg13
I2
sa(dp7029
g7
I168
sg23
VC0027651
p7030
sg10
I5
sg11
Vtumor
p7031
sg13
I1
sa(dp7032
g7
I101
sg23
VC1140680
p7033
sg10
I14
sg11
Vovarian cancer
p7034
sg13
I2
sasa(dp7035
g2
S'To describe the electroclinical features of subjects who presented with a photosensitive benign myoclonic epilepsy in infancy (PBMEI).\n'
p7036
sg4
(lp7037
sg20
(lp7038
(dp7039
g7
I89
sg23
VC0751120
p7040
sg10
I36
sg11
Vbenign myoclonic epilepsy in infancy
p7041
sg13
I5
sasa(dp7042
g2
S"In the current chapter, we will demonstrate the validity of human stem cell-based models and address the utility of other stem cell-based applications for several human brain disorders with multifactorial and (epi)genetic bases, including Parkinson's disease (PD), Alzheimer's disease (AD), fragile X syndrome (FXS), Angelman syndrome (AS), Prader-Willi syndrome (PWS), and Rett syndrome (RTT).\n"
p7043
sg4
(lp7044
sg20
(lp7045
(dp7046
g7
I210
sg23
VC0267963
p7047
sg10
I3
sg11
Vepi
p7048
sg13
I1
sa(dp7049
g7
I389
sg23
VC0035372
p7050
sg10
I3
sg11
VRTT
p7051
sg13
I1
sa(dp7052
g7
I364
sg23
VC0032897
p7053
sg10
I3
sg11
VPWS
p7054
sg13
I1
sa(dp7055
g7
I291
sg23
VC0016667
p7056
sg10
I18
sg11
Vfragile X syndrome
p7057
sg13
I3
sa(dp7058
g7
I317
sg23
VC0162635
p7059
sg10
I17
sg11
VAngelman syndrome
p7060
sg13
I2
sa(dp7061
g7
I336
sg23
VC0162635
p7062
sg10
I2
sg11
VAS
p7063
sg13
I1
sa(dp7064
g7
I311
sg23
VC0016667
p7065
sg10
I3
sg11
VFXS
p7066
sg13
I1
sa(dp7067
g7
I169
sg23
VC0006111
p7068
sg10
I15
sg11
Vbrain disorders
p7069
sg13
I2
sa(dp7070
g7
I260
sg23
VC0030567
p7071
sg10
I2
sg11
VPD
p7072
sg13
I1
sa(dp7073
g7
I374
sg23
VC0035372
p7074
sg10
I13
sg11
VRett syndrome
p7075
sg13
I2
sa(dp7076
g7
I341
sg23
VC0032897
p7077
sg10
I21
sg11
VPrader-Willi syndrome
p7078
sg13
I2
sa(dp7079
g7
I286
sg23
VC1521724
p7080
sg10
I2
sg11
VAD
p7081
sg13
I1
sa(dp7082
g7
I239
sg23
VC0030567
p7083
sg10
I19
sg11
VParkinson's disease
p7084
sg13
I2
sa(dp7085
g7
I265
sg23
VC1521724
p7086
sg10
I19
sg11
VAlzheimer's disease
p7087
sg13
I2
sasa(dp7088
g2
S'We will review our current knowledge on MeCP2-related diseases, including Rett Syndrome, Angelman Syndrome, Fetal Alcohol Spectrum Disorder, Hirschsprung disease, and Cancer.\n'
p7089
sg4
(lp7090
(dp7091
g7
I40
sg8
VP51608
p7092
sg10
I5
sg11
VMeCP2
p7093
sg13
I1
sasg20
(lp7094
(dp7095
g7
I79
sg23
VC0039082
p7096
sg10
I8
sg11
VSyndrome
p7097
sg13
I1
sa(dp7098
g7
I141
sg23
VC0019569
p7099
sg10
I20
sg11
VHirschsprung disease
p7100
sg13
I2
sa(dp7101
g7
I79
sg23
VC0162635
p7102
sg10
I18
sg11
VSyndrome, Angelman
p7103
sg13
I2
sa(dp7104
g7
I167
sg23
VC0006826
p7105
sg10
I6
sg11
VCancer
p7106
sg13
I1
sa(dp7107
g7
I108
sg23
VC2985290
p7108
sg10
I31
sg11
VFetal Alcohol Spectrum Disorder
p7109
sg13
I4
sasa(dp7110
g2
S'Both types of bruxism are associated with certain epigenetically determined disorders, such as Rett syndrome (RTT), Prader-Willi syndrome (PWS), and Angelman syndrome (AS), and these associations suggest a mechanistic link between epigenetic deregulation and bruxism.\n'
p7111
sg4
(lp7112
sg20
(lp7113
(dp7114
g7
I110
sg23
VC0035372
p7115
sg10
I3
sg11
VRTT
p7116
sg13
I1
sa(dp7117
g7
I168
sg23
VC0162635
p7118
sg10
I2
sg11
VAS
p7119
sg13
I1
sa(dp7120
g7
I14
sg23
VC0006325
p7121
sg10
I7
sg11
Vbruxism
p7122
sg13
I1
sa(dp7123
g7
I95
sg23
VC0035372
p7124
sg10
I13
sg11
VRett syndrome
p7125
sg13
I2
sa(dp7126
g7
I149
sg23
VC0162635
p7127
sg10
I17
sg11
VAngelman syndrome
p7128
sg13
I2
sa(dp7129
g7
I139
sg23
VC0032897
p7130
sg10
I3
sg11
VPWS
p7131
sg13
I1
sa(dp7132
g7
I14
sg23
VC0006325
p7133
sg10
I7
sg11
Vbruxism
p7134
sg13
I1
sa(dp7135
g7
I116
sg23
VC0032897
p7136
sg10
I21
sg11
VPrader-Willi syndrome
p7137
sg13
I2
sasa(dp7138
g2
S'Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome).\n'
p7139
sg4
(lp7140
(dp7141
g7
I262
sg8
g18
sg10
I6
sg11
VSLC9A6
p7142
sg13
I1
sa(dp7143
g7
I195
sg8
VP07498
p7144
sg10
I4
sg11
VCASK
p7145
sg13
I1
sa(dp7146
g7
I201
sg8
g18
sg10
I5
sg11
VCDKL5
p7147
sg13
I1
sa(dp7148
g7
I64
sg8
VP51608
p7149
sg10
I5
sg11
VMECP2
p7150
sg13
I1
sa(dp7151
g7
I298
sg8
VP15884
p7152
sg10
I4
sg11
VTCF4
p7153
sg13
I1
sa(dp7154
g7
I208
sg8
g18
sg10
I6
sg11
VCREBBP
p7155
sg13
I1
sa(dp7156
g7
I255
sg8
VP55316
p7157
sg10
I5
sg11
VFOXG1
p7158
sg13
I1
sasg20
(lp7159
(dp7160
g7
I42
sg23
VC0162635
p7161
sg10
I17
sg11
VAngelman syndrome
p7162
sg13
I2
sa(dp7163
g7
I97
sg23
VC0035372
p7164
sg10
I13
sg11
VRett syndrome
p7165
sg13
I2
sa(dp7166
g7
I227
sg23
VC0035934
p7167
sg10
I25
sg11
VRubinstein-Taybi syndrome
p7168
sg13
I2
sa(dp7169
g7
I51
sg23
VC0039082
p7170
sg10
I8
sg11
Vsyndrome
p7171
sg13
I1
sa(dp7172
g7
I304
sg23
VC1970431
p7173
sg10
I21
sg11
VPitt-Hopkins syndrome
p7174
sg13
I2
sasa(dp7175
g2
S'Rett syndrome (RTT) and Angelman syndrome (AS) are devastating neurological disorders that share many clinical features.\n'
p7176
sg4
(lp7177
sg20
(lp7178
(dp7179
g7
I63
sg23
VC0027765
p7180
sg10
I22
sg11
Vneurological disorders
p7181
sg13
I2
sa(dp7182
g7
I0
sg23
VC0035372
p7183
sg10
I13
sg11
VRett syndrome
p7184
sg13
I2
sa(dp7185
g7
I24
sg23
VC0162635
p7186
sg10
I17
sg11
VAngelman syndrome
p7187
sg13
I2
sa(dp7188
g7
I43
sg23
VC0162635
p7189
sg10
I2
sg11
VAS
p7190
sg13
I1
sa(dp7191
g7
I15
sg23
VC0035372
p7192
sg10
I3
sg11
VRTT
p7193
sg13
I1
sasa(dp7194
g2
S'Mutations in the X-linked gene encoding Methyl-CpG-binding protein 2 (MECP2) have been associated with neurodevelopmental and neuropsychiatric disorders including Rett Syndrome, X-linked mental retardation syndrome, severe neonatal encephalopathy, and Angelman syndrome.\n'
p7195
sg4
(lp7196
(dp7197
g7
I70
sg8
VP51608
p7198
sg10
I5
sg11
VMECP2
p7199
sg13
I1
sa(dp7200
g7
I40
sg8
VP51608
p7201
sg10
I28
sg11
VMethyl-CpG-binding protein 2
p7202
sg13
I3
sasg20
(lp7203
(dp7204
g7
I163
sg23
VC0035372
p7205
sg10
I13
sg11
VRett Syndrome
p7206
sg13
I2
sa(dp7207
g7
I252
sg23
VC0162635
p7208
sg10
I17
sg11
VAngelman syndrome
p7209
sg13
I2
sa(dp7210
g7
I223
sg23
VC0235820
p7211
sg10
I23
sg11
Vneonatal encephalopathy
p7212
sg13
I2
sa(dp7213
g7
I206
sg23
VC0039082
p7214
sg10
I8
sg11
Vsyndrome
p7215
sg13
I1
sa(dp7216
g7
I178
sg23
VC1136249
p7217
sg10
I27
sg11
VX-linked mental retardation
p7218
sg13
I3
sasa(dp7219
g2
S'Methyl-CpG binding protein 2 gene (MECP2) testing is indicated for patients with numerous clinical presentations, including Rett syndrome (classic and atypical), unexplained neonatal encephalopathy, Angelman syndrome, nonspecific mental retardation, autism (females), and an X-linked family history of developmental delay.\n'
p7220
sg4
(lp7221
(dp7222
g7
I0
sg8
VP51608
p7223
sg10
I33
sg11
VMethyl-CpG binding protein 2 gene
p7224
sg13
I5
sa(dp7225
g7
I35
sg8
VP51608
p7226
sg10
I5
sg11
VMECP2
p7227
sg13
I1
sasg20
(lp7228
(dp7229
g7
I199
sg23
VC0162635
p7230
sg10
I17
sg11
VAngelman syndrome
p7231
sg13
I2
sa(dp7232
g7
I124
sg23
VC0035372
p7233
sg10
I13
sg11
VRett syndrome
p7234
sg13
I2
sa(dp7235
g7
I302
sg23
VC0424605
p7236
sg10
I19
sg11
Vdevelopmental delay
p7237
sg13
I2
sa(dp7238
g7
I250
sg23
VC0004352
p7239
sg10
I6
sg11
Vautism
p7240
sg13
I1
sa(dp7241
g7
I174
sg23
VC0235820
p7242
sg10
I23
sg11
Vneonatal encephalopathy
p7243
sg13
I2
sa(dp7244
g7
I230
sg23
VC0025362
p7245
sg10
I18
sg11
Vmental retardation
p7246
sg13
I2
sasa(dp7247
g2
S'Briefly, sequencing of exons 1 to 4 of MECP2 is recommended for patients with a Rett syndrome phenotype, unexplained neonatal encephalopathy, an Angelman syndrome phenotype (with negative 15q11-13 analysis), nonspecific mental retardation, or autism (females).\n'
p7248
sg4
(lp7249
(dp7250
g7
I39
sg8
VP51608
p7251
sg10
I5
sg11
VMECP2
p7252
sg13
I1
sasg20
(lp7253
(dp7254
g7
I145
sg23
VC0162635
p7255
sg10
I17
sg11
VAngelman syndrome
p7256
sg13
I2
sa(dp7257
g7
I243
sg23
VC0004352
p7258
sg10
I6
sg11
Vautism
p7259
sg13
I1
sa(dp7260
g7
I220
sg23
VC0025362
p7261
sg10
I18
sg11
Vmental retardation
p7262
sg13
I2
sa(dp7263
g7
I117
sg23
VC0235820
p7264
sg10
I23
sg11
Vneonatal encephalopathy
p7265
sg13
I2
sa(dp7266
g7
I80
sg23
VC0035372
p7267
sg10
I13
sg11
VRett syndrome
p7268
sg13
I2
sasa(dp7269
g2
S'Additional testing for large-scale MECP2 deletions is recommended for patients with Rett syndrome or Angelman syndrome phenotypes (with negative 15q11-13 analysis) following negative sequencing.\n'
p7270
sg4
(lp7271
(dp7272
g7
I35
sg8
VP51608
p7273
sg10
I5
sg11
VMECP2
p7274
sg13
I1
sasg20
(lp7275
(dp7276
g7
I84
sg23
VC0035372
p7277
sg10
I13
sg11
VRett syndrome
p7278
sg13
I2
sa(dp7279
g7
I101
sg23
VC0162635
p7280
sg10
I17
sg11
VAngelman syndrome
p7281
sg13
I2
sasa(dp7282
g2
S'Antibodies to porcine PDC and Mycoplasma pneumoniae (mp) antigens mpPDH-C (to be designated mpPDC-E2 chain), mpPDH-B (to be designated mpPDC-E1beta chain), mpCARDS TX and mpP1 were investigated in sera from 43 PBC patients, 19 patients with autoimmune hepatitis and 11 healthy controls by an enzyme-linked immunosorbent assay and Western blotting.\n'
p7283
sg4
(lp7284
(dp7285
g7
I171
sg8
g18
sg10
I4
sg11
VmpP1
p7286
sg13
I1
sasg20
(lp7287
(dp7288
g7
I241
sg23
VC0241910
p7289
sg10
I20
sg11
Vautoimmune hepatitis
p7290
sg13
I2
sa(dp7291
g7
I210
sg23
VC0008312
p7292
sg10
I3
sg11
VPBC
p7293
sg13
I1
sa(dp7294
g7
I30
sg23
VC0026936
p7295
sg10
I10
sg11
VMycoplasma
p7296
sg13
I1
sa(dp7297
g7
I22
sg23
VC1869117
p7298
sg10
I3
sg11
VPDC
p7299
sg13
I1
sasa(dp7300
g2
S'We studied 77 serum samples, including 24 from patients with anti-PDC-E2-positive PBC and 53 controls (16 with autoimmune hepatitis (AIH), 10 with primary sclerosing cholangitis (PSC), and 27 healthy individuals) for their reactivities at serial dilutions (1:10, 1:20 and 1:40) against Escherichia coli DH5 alpha lysate overexpressing human PDC-E2 using immunoblotting (IB).\n'
p7301
sg4
(lp7302
(dp7303
g7
I61
sg8
VP10515
p7304
sg10
I11
sg11
Vanti-PDC-E2
p7305
sg13
I1
sa(dp7306
g7
I286
sg8
VP78549
p7307
sg10
I26
sg11
VEscherichia coli DH5 alpha
p7308
sg13
I4
sa(dp7309
g7
I335
sg8
VP10515
p7310
sg10
I12
sg11
Vhuman PDC-E2
p7311
sg13
I2
sasg20
(lp7312
(dp7313
g7
I147
sg23
VC0566602
p7314
sg10
I30
sg11
Vprimary sclerosing cholangitis
p7315
sg13
I3
sa(dp7316
g7
I82
sg23
VC0008312
p7317
sg10
I3
sg11
VPBC
p7318
sg13
I1
sa(dp7319
g7
I179
sg23
VC0566602
p7320
sg10
I3
sg11
VPSC
p7321
sg13
I1
sa(dp7322
g7
I111
sg23
VC0241910
p7323
sg10
I20
sg11
Vautoimmune hepatitis
p7324
sg13
I2
sa(dp7325
g7
I66
sg23
VC1869117
p7326
sg10
I3
sg11
VPDC
p7327
sg13
I1
sa(dp7328
g7
I66
sg23
VC1869117
p7329
sg10
I3
sg11
VPDC
p7330
sg13
I1
sasa(dp7331
g2
S'Since frequency and significance of anti-PDC-E2 in patients with autoimmune hepatitis (AIH) remain obscure, we measured anti-PDC-E2 in sera from well-defined AIH cases by Western blotting using bovine heart mitochondrial protein and recombinant PDC-E2 protein as antigen sources.\n'
p7332
sg4
(lp7333
(dp7334
g7
I36
sg8
VP10515
p7335
sg10
I11
sg11
Vanti-PDC-E2
p7336
sg13
I1
sa(dp7337
g7
I36
sg8
VP10515
p7338
sg10
I11
sg11
Vanti-PDC-E2
p7339
sg13
I1
sa(dp7340
g7
I233
sg8
VP63146
p7341
sg10
I26
sg11
Vrecombinant PDC-E2 protein
p7342
sg13
I3
sasg20
(lp7343
(dp7344
g7
I87
sg23
VC0241910
p7345
sg10
I3
sg11
VAIH
p7346
sg13
I1
sa(dp7347
g7
I41
sg23
VC1869117
p7348
sg10
I3
sg11
VPDC
p7349
sg13
I1
sa(dp7350
g7
I41
sg23
VC1869117
p7351
sg10
I3
sg11
VPDC
p7352
sg13
I1
sa(dp7353
g7
I87
sg23
VC0241910
p7354
sg10
I3
sg11
VAIH
p7355
sg13
I1
sa(dp7356
g7
I65
sg23
VC0241910
p7357
sg10
I20
sg11
Vautoimmune hepatitis
p7358
sg13
I2
sa(dp7359
g7
I41
sg23
VC1869117
p7360
sg10
I3
sg11
VPDC
p7361
sg13
I1
sasa(dp7362
g2
S'A recent genome-wide association study has reported three newly identified susceptible loci (rs2842992 near the gene SOD2, rs1789110 near the gene MBP and rs722782 near the gene C8orf42) to be associated with the geographic atrophy subtype of age-related macular degeneration in European-descent population.\n'
p7363
sg4
(lp7364
(dp7365
g7
I173
sg8
g18
sg10
I12
sg11
Vgene C8orf42
p7366
sg13
I2
sa(dp7367
g7
I142
sg8
VP13727
p7368
sg10
I8
sg11
Vgene MBP
p7369
sg13
I2
sa(dp7370
g7
I117
sg8
VP04179
p7371
sg10
I4
sg11
VSOD2
p7372
sg13
I1
sasg20
(lp7373
(dp7374
g7
I243
sg23
VC0242383
p7375
sg10
I32
sg11
Vage-related macular degeneration
p7376
sg13
I3
sa(dp7377
g7
I213
sg23
VC1536085
p7378
sg10
I18
sg11
Vgeographic atrophy
p7379
sg13
I2
sasa(dp7380
g2
S'This study was undertaken to test the role of HNE-modified-histone-H2A (HNE-H2A) in systemic lupus erythematosus (SLE).\n'
p7381
sg4
(lp7382
(dp7383
g7
I46
sg8
VP08246
p7384
sg10
I3
sg11
VHNE
p7385
sg13
I1
sa(dp7386
g7
I67
sg8
VP04908
p7387
sg10
I3
sg11
VH2A
p7388
sg13
I1
sa(dp7389
g7
I67
sg8
VP04908
p7390
sg10
I3
sg11
VH2A
p7391
sg13
I1
sa(dp7392
g7
I46
sg8
VP08246
p7393
sg10
I20
sg11
VHNE-modified-histone
p7394
sg13
I1
sasg20
(lp7395
(dp7396
g7
I84
sg23
VC0024141
p7397
sg10
I28
sg11
Vsystemic lupus erythematosus
p7398
sg13
I3
sa(dp7399
g7
I114
sg23
VC0024141
p7400
sg10
I3
sg11
VSLE
p7401
sg13
I1
sasa(dp7402
g2
S'Because nitric oxide (NO)-related species have been found in inflamed joints of arthritis patients, we investigated whether nitrotyrosine is present in sera of RA patients, and whether peroxynitrite-modified H2A histone is likely to be involved in the induction and progression of RA.\n'
p7403
sg4
(lp7404
(dp7405
g7
I208
sg8
g18
sg10
I11
sg11
VH2A histone
p7406
sg13
I2
sasg20
(lp7407
(dp7408
g7
I80
sg23
VC0003864
p7409
sg10
I9
sg11
Varthritis
p7410
sg13
I1
sasa(dp7411
g2
S'Tranilast significantly reduced clinical and X-ray scores of arthritis and decreased numbers of TNF-alpha-positive mast cells and mRNA levels of TNF-alpha, chymase (mouse mast cell protease 4), tryptase (mouse mast cell protease 6), stem cell factor, interleukin-6, cathepsin-K, receptor activator of nuclear factor-kappaB, and of receptor activator of nuclear factor-kappaB-ligand, but increased interleukin-10 mRNA level in paws of arthritic mice.\n'
p7412
sg4
(lp7413
(dp7414
g7
I279
sg8
VP01160
p7415
sg10
I43
sg11
Vreceptor activator of nuclear factor-kappaB
p7416
sg13
I5
sa(dp7417
g7
I266
sg8
VP43235
p7418
sg10
I31
sg11
Vcathepsin-K, receptor activator
p7419
sg13
I3
sa(dp7420
g7
I301
sg8
VP01160
p7421
sg10
I21
sg11
Vnuclear factor-kappaB
p7422
sg13
I2
sa(dp7423
g7
I397
sg8
VP22301
p7424
sg10
I19
sg11
Vinterleukin-10 mRNA
p7425
sg13
I2
sa(dp7426
g7
I165
sg8
VP20231
p7427
sg10
I26
sg11
Vmouse mast cell protease 4
p7428
sg13
I5
sa(dp7429
g7
I96
sg8
VP01375
p7430
sg10
I9
sg11
VTNF-alpha
p7431
sg13
I1
sa(dp7432
g7
I96
sg8
VP01375
p7433
sg10
I9
sg11
VTNF-alpha
p7434
sg13
I1
sa(dp7435
g7
I233
sg8
VP21583
p7436
sg10
I16
sg11
Vstem cell factor
p7437
sg13
I3
sa(dp7438
g7
I204
sg8
VP20231
p7439
sg10
I26
sg11
Vmouse mast cell protease 6
p7440
sg13
I5
sa(dp7441
g7
I251
sg8
VP05231
p7442
sg10
I13
sg11
Vinterleukin-6
p7443
sg13
I1
sa(dp7444
g7
I156
sg8
VP23946
p7445
sg10
I7
sg11
Vchymase
p7446
sg13
I1
sasg20
(lp7447
(dp7448
g7
I61
sg23
VC0003864
p7449
sg10
I9
sg11
Varthritis
p7450
sg13
I1
sasa(dp7451
g2
S'K/BxN serum transfer-induced arthritis was also reduced by treatment with a chymase inhibitor.\n'
p7452
sg4
(lp7453
(dp7454
g7
I76
sg8
VP23946
p7455
sg10
I7
sg11
Vchymase
p7456
sg13
I1
sasg20
(lp7457
(dp7458
g7
I29
sg23
VC0003864
p7459
sg10
I9
sg11
Varthritis
p7460
sg13
I1
sasa(dp7461
g2
S'Examples include cancer growth and metastasis (urokinase-type plasminogen activator, uPA), diabetes or transplant rejection (dipeptidyl peptidase IV, DPPIV), osteoarthritis and lung injury (elastase) or heart failure (mast cell chymase).\n'
p7462
sg4
(lp7463
(dp7464
g7
I218
sg8
VP23946
p7465
sg10
I17
sg11
Vmast cell chymase
p7466
sg13
I3
sa(dp7467
g7
I150
sg8
VP27487
p7468
sg10
I5
sg11
VDPPIV
p7469
sg13
I1
sa(dp7470
g7
I85
sg8
VP00749
p7471
sg10
I3
sg11
VuPA
p7472
sg13
I1
sa(dp7473
g7
I136
sg8
g18
sg10
I12
sg11
Vpeptidase IV
p7474
sg13
I2
sa(dp7475
g7
I47
sg8
VP00747
p7476
sg10
I36
sg11
Vurokinase-type plasminogen activator
p7477
sg13
I3
sasg20
(lp7478
(dp7479
g7
I158
sg23
VC0029408
p7480
sg10
I14
sg11
Vosteoarthritis
p7481
sg13
I1
sa(dp7482
g7
I17
sg23
VC0006826
p7483
sg10
I6
sg11
Vcancer
p7484
sg13
I1
sa(dp7485
g7
I35
sg23
VC0027627
p7486
sg10
I10
sg11
Vmetastasis
p7487
sg13
I1
sa(dp7488
g7
I91
sg23
VC0011849
p7489
sg10
I8
sg11
Vdiabetes
p7490
sg13
I1
sa(dp7491
g7
I203
sg23
VC0018802
p7492
sg10
I13
sg11
Vheart failure
p7493
sg13
I2
sasa(dp7494
g2
S'Here we investigated whether mouse mast cell protease-4 (mMCP-4), a chymase present in the mast cell secretory granule, contributes to experimental arthritis.\n'
p7495
sg4
(lp7496
(dp7497
g7
I68
sg8
VP23946
p7498
sg10
I7
sg11
Vchymase
p7499
sg13
I1
sa(dp7500
g7
I57
sg8
VP20231
p7501
sg10
I6
sg11
VmMCP-4
p7502
sg13
I1
sa(dp7503
g7
I29
sg8
VP20231
p7504
sg10
I26
sg11
Vmouse mast cell protease-4
p7505
sg13
I4
sa(dp7506
g7
I91
sg8
VP00390
p7507
sg10
I27
sg11
Vmast cell secretory granule
p7508
sg13
I4
sasg20
(lp7509
(dp7510
g7
I148
sg23
VC0003864
p7511
sg10
I9
sg11
Varthritis
p7512
sg13
I1
sasa(dp7513
g2
S'The studies using chymase inhibitors have also shown the potential role of chymase in other diseases, including atopic dermatitis, tissue fibrosis and rheumatoid arthritis; a chymase inhibitor also reduced ischemic reperfusion injury in the small intestine.\n'
p7514
sg4
(lp7515
(dp7516
g7
I18
sg8
VP23946
p7517
sg10
I7
sg11
Vchymase
p7518
sg13
I1
sa(dp7519
g7
I18
sg8
VP23946
p7520
sg10
I7
sg11
Vchymase
p7521
sg13
I1
sa(dp7522
g7
I18
sg8
VP23946
p7523
sg10
I7
sg11
Vchymase
p7524
sg13
I1
sasg20
(lp7525
(dp7526
g7
I151
sg23
VC0003873
p7527
sg10
I20
sg11
Vrheumatoid arthritis
p7528
sg13
I2
sa(dp7529
g7
I112
sg23
VC0011615
p7530
sg10
I17
sg11
Vatopic dermatitis
p7531
sg13
I2
sa(dp7532
g7
I138
sg23
VC0016059
p7533
sg10
I8
sg11
Vfibrosis
p7534
sg13
I1
sasa(dp7535
g2
S'The NSpO2mean , DA4% and SB90% were significantly correlated with %DeltaTdi, PaO2 , %PImax of the predicted value and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage.\n'
p7536
sg4
(lp7537
sg20
(lp7538
(dp7539
g7
I16
sg23
VC1836756
p7540
sg10
I3
sg11
VDA4
p7541
sg13
I1
sa(dp7542
g7
I144
sg23
VC0024117
p7543
sg10
I32
sg11
VChronic Obstructive Lung Disease
p7544
sg13
I4
sasa(dp7545
g2
S'The case report describes novel data derived from miniature superficial sensors that continuously monitored the amplitude and symmetry of the chest wall tidal displacement (TDi) in a premature infant that suffered from pneumothorax.\n'
p7546
sg4
(lp7547
sg20
(lp7548
(dp7549
g7
I219
sg23
VC0032326
p7550
sg10
I12
sg11
Vpneumothorax
p7551
sg13
I1
sa(dp7552
g7
I205
sg23
VC0683278
p7553
sg10
I8
sg11
Vsuffered
p7554
sg13
I1
sasa(dp7555
g2
S'The TDi responses to changes in peak inspiratory pressure (n = 7), induction of one-lung intubation (n = 7), and slowly progressing pneumothorax (PTX) (n = 6) were monitored in parallel with conventional respiratory (SpO(2), EtCO(2), pressure and flow) and hemodynamic (HR and BP) indices.\n'
p7556
sg4
(lp7557
sg20
(lp7558
(dp7559
g7
I146
sg23
VC0032326
p7560
sg10
I3
sg11
VPTX
p7561
sg13
I1
sa(dp7562
g7
I132
sg23
VC0032326
p7563
sg10
I12
sg11
Vpneumothorax
p7564
sg13
I1
sasa(dp7565
g2
S'To gather data on this point, we computed TTdi by both methods in spontaneously breathing normal adult males (AMN) and age-matched males with chronic obstructive pulmonary disease (COPD) at rest and during treadmill exercise.\n'
p7566
sg4
(lp7567
sg20
(lp7568
(dp7569
g7
I110
sg23
VC1527231
p7570
sg10
I3
sg11
VAMN
p7571
sg13
I1
sa(dp7572
g7
I181
sg23
VC0024117
p7573
sg10
I4
sg11
VCOPD
p7574
sg13
I1
sa(dp7575
g7
I142
sg23
VC0024117
p7576
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p7577
sg13
I4
sasa(dp7578
g2
S'Human fibrosarcoma HT1080 cells retained the ability to activate both prothrombin and plasminogen, but did not express TM.\n'
p7579
sg4
(lp7580
(dp7581
g7
I86
sg8
VP00747
p7582
sg10
I11
sg11
Vplasminogen
p7583
sg13
I1
sa(dp7584
g7
I70
sg8
VP00734
p7585
sg10
I11
sg11
Vprothrombin
p7586
sg13
I1
sasg20
(lp7587
(dp7588
g7
I6
sg23
VC0016057
p7589
sg10
I12
sg11
Vfibrosarcoma
p7590
sg13
I1
sasa(dp7591
g2
S'Here, we describe the in vitro antitumor activity of some novel Pt(IV)-based agents against mouse fibrosarcoma L929 cells and human astrocytoma U251 cells.\n'
p7592
sg4
(lp7593
sg20
(lp7594
(dp7595
g7
I92
sg23
VC1522302
p7596
sg10
I18
sg11
Vmouse fibrosarcoma
p7597
sg13
I2
sa(dp7598
g7
I132
sg23
VC0004114
p7599
sg10
I11
sg11
Vastrocytoma
p7600
sg13
I1
sasa(dp7601
g2
S'The highly 1,25D up-regulated target genes CLMN, SERPINB1, EFTUD1, and KLK6were selected for further analysis and up-regulation by 1,25D was confirmed by qRT-PCR analysis in breast cancer cell lines and in a subset of human clinical samples from normal and cancer breast tissues.\n'
p7602
sg4
(lp7603
(dp7604
g7
I59
sg8
g18
sg10
I6
sg11
VEFTUD1
p7605
sg13
I1
sa(dp7606
g7
I49
sg8
VP30740
p7607
sg10
I8
sg11
VSERPINB1
p7608
sg13
I1
sa(dp7609
g7
I43
sg8
g18
sg10
I4
sg11
VCLMN
p7610
sg13
I1
sasg20
(lp7611
(dp7612
g7
I181
sg23
VC0006826
p7613
sg10
I6
sg11
Vcancer
p7614
sg13
I1
sa(dp7615
g7
I174
sg23
VC0678222
p7616
sg10
I13
sg11
Vbreast cancer
p7617
sg13
I2
sasa(dp7618
g2
S'Elevated expression levels of CLMN, SERPINB1, and KLK6 are associated with prolonged relapse-free survival for breast cancer patients.\n'
p7619
sg4
(lp7620
(dp7621
g7
I36
sg8
VP30740
p7622
sg10
I8
sg11
VSERPINB1
p7623
sg13
I1
sa(dp7624
g7
I30
sg8
g18
sg10
I4
sg11
VCLMN
p7625
sg13
I1
sa(dp7626
g7
I50
sg8
VP06870
p7627
sg10
I4
sg11
VKLK6
p7628
sg13
I1
sasg20
(lp7629
(dp7630
g7
I85
sg23
VC0277556
p7631
sg10
I7
sg11
Vrelapse
p7632
sg13
I1
sa(dp7633
g7
I111
sg23
VC0678222
p7634
sg10
I13
sg11
Vbreast cancer
p7635
sg13
I2
sasa(dp7636
g2
S'Four of these 11 genes (CYP24A1, CLMN, EFTUD1, and SERPINB1) were also identified as 1,25D responsive in human breast tumor explants, suggesting that this gene signature may prove useful as a biomarker of vitamin D exposure in breast tissue.\n'
p7637
sg4
(lp7638
(dp7639
g7
I24
sg8
g18
sg10
I7
sg11
VCYP24A1
p7640
sg13
I1
sa(dp7641
g7
I33
sg8
g18
sg10
I4
sg11
VCLMN
p7642
sg13
I1
sa(dp7643
g7
I39
sg8
g18
sg10
I6
sg11
VEFTUD1
p7644
sg13
I1
sa(dp7645
g7
I51
sg8
VP30740
p7646
sg10
I8
sg11
VSERPINB1
p7647
sg13
I1
sasg20
(lp7648
(dp7649
g7
I111
sg23
VC1458155
p7650
sg10
I12
sg11
Vbreast tumor
p7651
sg13
I2
sasa(dp7652
g2
S'We report here the identification of 14 genes that are rapidly induced by atRA (retinoic acid induced in neuroblastoma or RAINB), eight of which were previously not known to be atRA responsive (BTBD11, calmin, cyclin M2, ephrin B2, HOXD10, NEDD9, RAINB6 and tenascin R).\n'
p7653
sg4
(lp7654
(dp7655
g7
I232
sg8
VP28358
p7656
sg10
I6
sg11
VHOXD10
p7657
sg13
I1
sa(dp7658
g7
I258
sg8
g18
sg10
I10
sg11
Vtenascin R
p7659
sg13
I2
sa(dp7660
g7
I240
sg8
g18
sg10
I5
sg11
VNEDD9
p7661
sg13
I1
sa(dp7662
g7
I210
sg8
g18
sg10
I9
sg11
Vcyclin M2
p7663
sg13
I2
sa(dp7664
g7
I194
sg8
g18
sg10
I6
sg11
VBTBD11
p7665
sg13
I1
sa(dp7666
g7
I221
sg8
VP52799
p7667
sg10
I9
sg11
Vephrin B2
p7668
sg13
I2
sa(dp7669
g7
I202
sg8
g18
sg10
I6
sg11
Vcalmin
p7670
sg13
I1
sasg20
(lp7671
(dp7672
g7
I105
sg23
VC0027819
p7673
sg10
I13
sg11
Vneuroblastoma
p7674
sg13
I1
sasa(dp7675
g2
S'However, the roles of c-Src and phosphorylated-Src (p-Src) in nasopharyngeal carcinoma (NPC) progression are rarely investigated.\n'
p7676
sg4
(lp7677
(dp7678
g7
I22
sg8
VP12931
p7679
sg10
I5
sg11
Vc-Src
p7680
sg13
I1
sa(dp7681
g7
I52
sg8
VP12931
p7682
sg10
I5
sg11
Vp-Src
p7683
sg13
I1
sa(dp7684
g7
I32
sg8
VP12931
p7685
sg10
I18
sg11
Vphosphorylated-Src
p7686
sg13
I1
sasg20
(lp7687
(dp7688
g7
I62
sg23
VC2931822
p7689
sg10
I24
sg11
Vnasopharyngeal carcinoma
p7690
sg13
I2
sa(dp7691
g7
I88
sg23
VC2931822
p7692
sg10
I3
sg11
VNPC
p7693
sg13
I1
sasa(dp7694
g2
S'To investigate the influence of microRNA-378g (miR-378g) on radiosensitivity and metastasis of nasopharyngeal carcinoma cells and study how miR-378g regulated Src homology region 2 domain-containing phosphatase-1 (SHP-1) expression.\n'
p7695
sg4
(lp7696
(dp7697
g7
I47
sg8
g18
sg10
I8
sg11
VmiR-378g
p7698
sg13
I1
sa(dp7699
g7
I140
sg8
g18
sg10
I72
sg11
VmiR-378g regulated Src homology region 2 domain-containing phosphatase-1
p7700
sg13
I8
sa(dp7701
g7
I32
sg8
g18
sg10
I13
sg11
VmicroRNA-378g
p7702
sg13
I1
sa(dp7703
g7
I214
sg8
VP29350
p7704
sg10
I5
sg11
VSHP-1
p7705
sg13
I1
sasg20
(lp7706
(dp7707
g7
I81
sg23
VC0027627
p7708
sg10
I10
sg11
Vmetastasis
p7709
sg13
I1
sa(dp7710
g7
I95
sg23
VC2931822
p7711
sg10
I24
sg11
Vnasopharyngeal carcinoma
p7712
sg13
I2
sasa(dp7713
g2
S'Hence, the present study was carried out to investigate the association of ACE and CYP46A1 genes polymorphism with senile cataract cases and controls.\n'
p7714
sg4
(lp7715
(dp7716
g7
I75
sg8
VP12821
p7717
sg10
I3
sg11
VACE
p7718
sg13
I1
sa(dp7719
g7
I83
sg8
g18
sg10
I13
sg11
VCYP46A1 genes
p7720
sg13
I2
sasg20
(lp7721
(dp7722
g7
I115
sg23
VC0036646
p7723
sg10
I15
sg11
Vsenile cataract
p7724
sg13
I2
sasa(dp7725
g2
S'Frequencies of ACE ID, DD, and II genotypes in senile cataract cases were 64.07%, 4.85%, and 31.06% and controls were 61.76%, 26.47%, and 11.76%, respectively.\n'
p7726
sg4
(lp7727
(dp7728
g7
I15
sg8
VP12821
p7729
sg10
I6
sg11
VACE ID
p7730
sg13
I2
sasg20
(lp7731
(dp7732
g7
I47
sg23
VC0036646
p7733
sg10
I15
sg11
Vsenile cataract
p7734
sg13
I2
sasa(dp7735
g2
S'ACE DD and II genotypes (P &lt; 0.001,P = 0.0008) and CYP46A1 CT and TT genotypes (P = 0.003,P = 0.0003) were significantly associated with senile cataract cases compared to the controls.\n'
p7736
sg4
(lp7737
(dp7738
g7
I54
sg8
g18
sg10
I10
sg11
VCYP46A1 CT
p7739
sg13
I2
sa(dp7740
g7
I0
sg8
VP12821
p7741
sg10
I3
sg11
VACE
p7742
sg13
I1
sasg20
(lp7743
(dp7744
g7
I140
sg23
VC0036646
p7745
sg10
I15
sg11
Vsenile cataract
p7746
sg13
I2
sasa(dp7747
g2
S'Findings of this study suggest that ACE and CYP46A1 genes polymorphism may be a predictive marker for early identification of population at risk of senile cataract.\n'
p7748
sg4
(lp7749
(dp7750
g7
I44
sg8
g18
sg10
I13
sg11
VCYP46A1 genes
p7751
sg13
I2
sa(dp7752
g7
I36
sg8
VP12821
p7753
sg10
I3
sg11
VACE
p7754
sg13
I1
sasg20
(lp7755
(dp7756
g7
I148
sg23
VC0036646
p7757
sg10
I15
sg11
Vsenile cataract
p7758
sg13
I2
sasa(dp7759
g2
S'This potential role of ACE and CYP46A1 genes polymorphism as a marker of susceptibility to senile cataract needs further validation in studies involving larger number of patients from different regions.\n'
p7760
sg4
(lp7761
(dp7762
g7
I23
sg8
VP12821
p7763
sg10
I3
sg11
VACE
p7764
sg13
I1
sa(dp7765
g7
I31
sg8
g18
sg10
I13
sg11
VCYP46A1 genes
p7766
sg13
I2
sasg20
(lp7767
(dp7768
g7
I91
sg23
VC0036646
p7769
sg10
I15
sg11
Vsenile cataract
p7770
sg13
I2
sasa(dp7771
g2
S'Treatments with ACEI and ARBs reduced the incidence of the occurrence of cataract.\n'
p7772
sg4
(lp7773
sg20
(lp7774
(dp7775
g7
I73
sg23
VC0086543
p7776
sg10
I8
sg11
Vcataract
p7777
sg13
I1
sasa(dp7778
g2
S'The purpose of this study was to evaluate the effect of ACEIs on cataract formation in experimental alloxan-induced diabetes in rabbits and assess the role of the reactive function group of the ACEIs in this process.\n'
p7779
sg4
(lp7780
sg20
(lp7781
(dp7782
g7
I65
sg23
VC0086543
p7783
sg10
I8
sg11
Vcataract
p7784
sg13
I1
sa(dp7785
g7
I116
sg23
VC0011849
p7786
sg10
I8
sg11
Vdiabetes
p7787
sg13
I1
sasa(dp7788
g2
S'Six-month administration of ACEI to rabbis resulted in a delay of diabetic cataractogenesis.\n'
p7789
sg4
(lp7790
sg20
(lp7791
sa(dp7792
g2
S'ACEIs delay diabetic cataractogenesis in an experimental animal model.\n'
p7793
sg4
(lp7794
sg20
(lp7795
sa(dp7796
g2
S'Quantification of GIP1-42 and GIP3-42 in plasma from patients with type 2 diabetes was possible using this method, which included protein precipitation, Asp-N proteolysis, solid-phase extraction, nanoflow LC, and positive-ion multiple reaction monitoring cubed (MRM(3)) for GIP1-8, and MRM for GIP3-8 to achieve accurate, precise, and quantitative analysis that can be validated to support large clinical trials.\n'
p7797
sg4
(lp7798
sg20
(lp7799
(dp7800
g7
I67
sg23
VC0011860
p7801
sg10
I15
sg11
Vtype 2 diabetes
p7802
sg13
I3
sasa(dp7803
g2
S'Data mining on public domain identified that thymidylate synthetase (TYMS) and dihydrofolate reductase (DHFR) transcripts were significantly higher expressed in nasopharyngeal carcinoma (NPC).\n'
p7804
sg4
(lp7805
(dp7806
g7
I45
sg8
VP04818
p7807
sg10
I22
sg11
Vthymidylate synthetase
p7808
sg13
I2
sa(dp7809
g7
I79
sg8
VP00374
p7810
sg10
I23
sg11
Vdihydrofolate reductase
p7811
sg13
I2
sa(dp7812
g7
I69
sg8
VP04818
p7813
sg10
I4
sg11
VTYMS
p7814
sg13
I1
sa(dp7815
g7
I104
sg8
VP00374
p7816
sg10
I4
sg11
VDHFR
p7817
sg13
I1
sasg20
(lp7818
(dp7819
g7
I187
sg23
VC2931822
p7820
sg10
I3
sg11
VNPC
p7821
sg13
I1
sa(dp7822
g7
I161
sg23
VC2931822
p7823
sg10
I24
sg11
Vnasopharyngeal carcinoma
p7824
sg13
I2
sasa(dp7825
g2
S'Some genes differentially expressed between HPV-positive and HPV-negative oropharyngeal cancer (eg, TYMS, STMN1, CCND1, and RBBP4) are involved in chemotherapy or radiation sensitivity.\n'
p7826
sg4
(lp7827
(dp7828
g7
I100
sg8
VP04818
p7829
sg10
I4
sg11
VTYMS
p7830
sg13
I1
sa(dp7831
g7
I113
sg8
VP24385
p7832
sg10
I5
sg11
VCCND1
p7833
sg13
I1
sa(dp7834
g7
I124
sg8
g18
sg10
I5
sg11
VRBBP4
p7835
sg13
I1
sa(dp7836
g7
I106
sg8
VP16949
p7837
sg10
I5
sg11
VSTMN1
p7838
sg13
I1
sasg20
(lp7839
(dp7840
g7
I74
sg23
VC0153382
p7841
sg10
I20
sg11
Voropharyngeal cancer
p7842
sg13
I2
sasa(dp7843
g2
S'This case report of a NSE-producing primary hemangiosarcoma of the liver clearly outlines that a histological confirmation of an allegedly clear clinical diagnosis should always be performed because malignant tumours are capable of (co-)expressing so called tumour markers independently of their histogenesis.\n'
p7844
sg4
(lp7845
(dp7846
g7
I22
sg8
VP09104
p7847
sg10
I3
sg11
VNSE
p7848
sg13
I1
sasg20
(lp7849
(dp7850
g7
I209
sg23
VC0027651
p7851
sg10
I6
sg11
Vtumour
p7852
sg13
I1
sa(dp7853
g7
I44
sg23
VC0345907
p7854
sg10
I28
sg11
Vhemangiosarcoma of the liver
p7855
sg13
I4
sa(dp7856
g7
I199
sg23
VC0006826
p7857
sg10
I17
sg11
Vmalignant tumours
p7858
sg13
I2
sasa(dp7859
g2
S'They were characterized as follows: (1) disease onset with initial signs/symptoms due to intractable otitis media with effusion or granulation, which did not respond to ordinary treatments such as antibiotics and insertion of tympanic ventilation tubes, followed by progressive hearing loss; (2) predominantly female (73%) and older (median age: 68 years); (3) predominantly myeloperoxidase (MPO)-ANCA-positive (60%), followed by proteinase 3 (PR3)-ANCA-positive (19%) and both ANCAs-negative (16%); (4) frequently observed accompanying facial palsy (36%) and hypertrophic pachymeningitis (28%); and (5) disease often involving lung (35%) and kidney (26%) lesions.\n'
p7860
sg4
(lp7861
(dp7862
g7
I430
sg8
VP63123
p7863
sg10
I12
sg11
Vproteinase 3
p7864
sg13
I2
sa(dp7865
g7
I444
sg8
VP63123
p7866
sg10
I3
sg11
VPR3
p7867
sg13
I1
sa(dp7868
g7
I375
sg8
VP05164
p7869
sg10
I15
sg11
Vmyeloperoxidase
p7870
sg13
I1
sa(dp7871
g7
I392
sg8
VP05164
p7872
sg10
I3
sg11
VMPO
p7873
sg13
I1
sasg20
(lp7874
(dp7875
g7
I537
sg23
VC0015469
p7876
sg10
I12
sg11
Vfacial palsy
p7877
sg13
I2
sa(dp7878
g7
I101
sg23
VC0029883
p7879
sg10
I26
sg11
Votitis media with effusion
p7880
sg13
I4
sa(dp7881
g7
I278
sg23
VC0011053
p7882
sg10
I12
sg11
Vhearing loss
p7883
sg13
I2
sa(dp7884
g7
I560
sg23
VC0948402
p7885
sg10
I28
sg11
Vhypertrophic pachymeningitis
p7886
sg13
I2
sasa(dp7887
g2
S'A 69-year-old man was diagnosed with granulomatosis with polyangiitis (GPA) based on the presence of skin granuloma, refractory otitis media, renal insufficiency and myeloperoxidase-antineutrophil cytoplasmic antibody positivity and slight lung opacity.\n'
p7888
sg4
(lp7889
(dp7890
g7
I166
sg8
VP05164
p7891
sg10
I51
sg11
Vmyeloperoxidase-antineutrophil cytoplasmic antibody
p7892
sg13
I3
sasg20
(lp7893
(dp7894
g7
I37
sg23
VC0018188
p7895
sg10
I9
sg11
Vgranuloma
p7896
sg13
I1
sa(dp7897
g7
I142
sg23
VC0035078
p7898
sg10
I19
sg11
Vrenal insufficiency
p7899
sg13
I2
sa(dp7900
g7
I128
sg23
VC0029882
p7901
sg10
I12
sg11
Votitis media
p7902
sg13
I2
sa(dp7903
g7
I245
sg23
VC1265876
p7904
sg10
I7
sg11
Vopacity
p7905
sg13
I1
sa(dp7906
g7
I37
sg23
VC0521173
p7907
sg10
I14
sg11
Vgranulomatosis
p7908
sg13
I1
sasa(dp7909
g2
S'Proteinase 3-ANCA (PR3-ANCA) positive otitis media causes granulomatous formation or middle ear effusion in the middle ear, on the other hand myeloperoxidase-ANCA (MPO-ANCA) positive otitis media predominantly presents as otitis media with effusion.\n'
p7910
sg4
(lp7911
(dp7912
g7
I164
sg8
VP05164
p7913
sg10
I8
sg11
VMPO-ANCA
p7914
sg13
I1
sa(dp7915
g7
I142
sg8
VP05164
p7916
sg10
I20
sg11
Vmyeloperoxidase-ANCA
p7917
sg13
I1
sa(dp7918
g7
I0
sg8
VP63123
p7919
sg10
I12
sg11
VProteinase 3
p7920
sg13
I2
sasg20
(lp7921
(dp7922
g7
I38
sg23
VC0029882
p7923
sg10
I12
sg11
Votitis media
p7924
sg13
I2
sa(dp7925
g7
I85
sg23
VC0029883
p7926
sg10
I19
sg11
Vmiddle ear effusion
p7927
sg13
I3
sa(dp7928
g7
I38
sg23
VC0029882
p7929
sg10
I12
sg11
Votitis media
p7930
sg13
I2
sa(dp7931
g7
I222
sg23
VC0029883
p7932
sg10
I26
sg11
Votitis media with effusion
p7933
sg13
I4
sasa(dp7934
g2
S'In our cohort, MPO-GPA was most likely to affect older women and was associated with otitis media, nervous system involvement, mild renal impairment and more favorable outcome.\n'
p7935
sg4
(lp7936
(dp7937
g7
I15
sg8
VP05164
p7938
sg10
I7
sg11
VMPO-GPA
p7939
sg13
I1
sasg20
(lp7940
(dp7941
g7
I85
sg23
VC0029882
p7942
sg10
I12
sg11
Votitis media
p7943
sg13
I2
sa(dp7944
g7
I132
sg23
VC0341697
p7945
sg10
I16
sg11
Vrenal impairment
p7946
sg13
I2
sa(dp7947
g7
I99
sg23
VC0027769
p7948
sg10
I7
sg11
Vnervous
p7949
sg13
I1
sasa(dp7950
g2
S"Myeloperoxidase-ANCA-positive hypertrophic pachymeningitis was characterized by: (i) an elderly female predominance; (ii) 82% of patients diagnosed with granulomatosis with polyangiitis (previously known as Wegener's granulomatosis) according to Watts' algorithm; (iii) a high frequency of patients with lesions limited to the dura mater and upper airways, developing headaches, chronic sinusitis, otitis media or mastoiditis; (iv) a low frequency of patients with the 'classical or generalized form' of granulomatosis with polyangiitis involving the entire upper and lower airways and kidney, or progressing to generalized disease, in contrast to proteinase 3-ANCA-positive hypertrophic pachymeningitis; (v) less severe neurological damage according to the modified Rankin Scale and low disease activity according to the Birmingham Vasculitis Activity Score compared with proteinase 3-ANCA-positive hypertrophic pachymeningitis; (vi) increased levels of CXCL10, CXCL8 and interleukin 6 in cerebrospinal fluids, and increased numbers of T cells, neutrophils, eosinophils, plasma cells and monocytes/macrophages in autopsied or biopsied dura mater with pachymeningitis, suggesting TH1-predominant granulomatous lesions in hypertrophic pachymeningitis, as previously reported in pulmonary or renal lesions of granulomatosis with polyangiitis; and (vii) greater efficacy of combination therapy with prednisolone and cyclophosphamide compared with monotherapy with prednisolone.\n"
p7951
sg4
(lp7952
(dp7953
g7
I0
sg8
VP05164
p7954
sg10
I15
sg11
VMyeloperoxidase
p7955
sg13
I1
sa(dp7956
g7
I973
sg8
VP05231
p7957
sg10
I13
sg11
Vinterleukin 6
p7958
sg13
I2
sa(dp7959
g7
I648
sg8
VP63123
p7960
sg10
I12
sg11
Vproteinase 3
p7961
sg13
I2
sa(dp7962
g7
I955
sg8
VP02778
p7963
sg10
I6
sg11
VCXCL10
p7964
sg13
I1
sa(dp7965
g7
I648
sg8
VP63123
p7966
sg10
I12
sg11
Vproteinase 3
p7967
sg13
I2
sasg20
(lp7968
(dp7969
g7
I153
sg23
VC0521173
p7970
sg10
I14
sg11
Vgranulomatosis
p7971
sg13
I1
sa(dp7972
g7
I833
sg23
VC0042384
p7973
sg10
I10
sg11
VVasculitis
p7974
sg13
I1
sa(dp7975
g7
I30
sg23
VC0948402
p7976
sg10
I28
sg11
Vhypertrophic pachymeningitis
p7977
sg13
I2
sa(dp7978
g7
I30
sg23
VC0948402
p7979
sg10
I28
sg11
Vhypertrophic pachymeningitis
p7980
sg13
I2
sa(dp7981
g7
I414
sg23
VC0024904
p7982
sg10
I11
sg11
Vmastoiditis
p7983
sg13
I1
sa(dp7984
g7
I153
sg23
VC0521173
p7985
sg10
I14
sg11
Vgranulomatosis
p7986
sg13
I1
sa(dp7987
g7
I43
sg23
VC0030167
p7988
sg10
I15
sg11
Vpachymeningitis
p7989
sg13
I1
sa(dp7990
g7
I153
sg23
VC0521173
p7991
sg10
I14
sg11
Vgranulomatosis
p7992
sg13
I1
sa(dp7993
g7
I1196
sg23
VC0018188
p7994
sg10
I21
sg11
Vgranulomatous lesions
p7995
sg13
I2
sa(dp7996
g7
I207
sg23
VC0043092
p7997
sg10
I24
sg11
VWegener's granulomatosis
p7998
sg13
I2
sa(dp7999
g7
I30
sg23
VC0948402
p8000
sg10
I28
sg11
Vhypertrophic pachymeningitis
p8001
sg13
I2
sa(dp8002
g7
I387
sg23
VC0037199
p8003
sg10
I9
sg11
Vsinusitis
p8004
sg13
I1
sa(dp8005
g7
I368
sg23
VC0151293
p8006
sg10
I18
sg11
Vheadaches, chronic
p8007
sg13
I2
sa(dp8008
g7
I612
sg23
VC0849867
p8009
sg10
I19
sg11
Vgeneralized disease
p8010
sg13
I2
sa(dp8011
g7
I398
sg23
VC0029882
p8012
sg10
I12
sg11
Votitis media
p8013
sg13
I2
sa(dp8014
g7
I30
sg23
VC0948402
p8015
sg10
I28
sg11
Vhypertrophic pachymeningitis
p8016
sg13
I2
sasa(dp8017
g2
S'To quantify the levels of tissue inhibitor of metalloproteinase 4 (TIMP4) and its ratios with free metalloproteinases (MMP) in the aqueous humor of patients with primary open angle glaucoma (POAG), pseudoexfoliation syndrome (PXS) and pseudoexfoliative glaucoma (PXG) and to evaluate a possible imbalance between MMPs and TIMPs in these samples.\n'
p8018
sg4
(lp8019
(dp8020
g7
I26
sg8
g18
sg10
I39
sg11
Vtissue inhibitor of metalloproteinase 4
p8021
sg13
I5
sa(dp8022
g7
I67
sg8
g18
sg10
I5
sg11
VTIMP4
p8023
sg13
I1
sa(dp8024
g7
I119
sg8
g18
sg10
I3
sg11
VMMP
p8025
sg13
I1
sa(dp8026
g7
I99
sg8
VP39900
p8027
sg10
I18
sg11
Vmetalloproteinases
p8028
sg13
I1
sa(dp8029
g7
I322
sg8
VP01033
p8030
sg10
I5
sg11
VTIMPs
p8031
sg13
I1
sasg20
(lp8032
(dp8033
g7
I191
sg23
VC0339573
p8034
sg10
I4
sg11
VPOAG
p8035
sg13
I1
sa(dp8036
g7
I226
sg23
VC0206368
p8037
sg10
I3
sg11
VPXS
p8038
sg13
I1
sa(dp8039
g7
I181
sg23
VC0017601
p8040
sg10
I8
sg11
Vglaucoma
p8041
sg13
I1
sa(dp8042
g7
I295
sg23
VC1397014
p8043
sg10
I9
sg11
Vimbalance
p8044
sg13
I1
sa(dp8045
g7
I162
sg23
VC0339573
p8046
sg10
I27
sg11
Vprimary open angle glaucoma
p8047
sg13
I4
sa(dp8048
g7
I198
sg23
VC0206368
p8049
sg10
I26
sg11
Vpseudoexfoliation syndrome
p8050
sg13
I2
sa(dp8051
g7
I131
sg23
VC0595936
p8052
sg10
I13
sg11
Vaqueous humor
p8053
sg13
I2
sasa(dp8054
g2
S'TIMP4 was elevated in glaucoma patients(POAG: 0.95 +/- 0.49 PXG: 1.28 +/- 1.38 pg/ml.\n'
p8055
sg4
(lp8056
(dp8057
g7
I0
sg8
g18
sg10
I5
sg11
VTIMP4
p8058
sg13
I1
sasg20
(lp8059
(dp8060
g7
I40
sg23
VC0339573
p8061
sg10
I4
sg11
VPOAG
p8062
sg13
I1
sa(dp8063
g7
I22
sg23
VC0017601
p8064
sg10
I8
sg11
Vglaucoma
p8065
sg13
I1
sasa(dp8066
g2
S'TIMP4 elevation is a novel finding in glaucomatous eyes.\n'
p8067
sg4
(lp8068
(dp8069
g7
I0
sg8
g18
sg10
I5
sg11
VTIMP4
p8070
sg13
I1
sasg20
(lp8071
sa(dp8072
g2
S'Emerging evidence demonstrates that the stromal derived factor-1 (SDF-1Alfa)/CXCR4 axis is associated with tumor aggressiveness and metastasis, including glioma, the most common brain cancer.\n'
p8073
sg4
(lp8074
(dp8075
g7
I77
sg8
VP61073
p8076
sg10
I5
sg11
VCXCR4
p8077
sg13
I1
sa(dp8078
g7
I40
sg8
VP48061
p8079
sg10
I24
sg11
Vstromal derived factor-1
p8080
sg13
I3
sasg20
(lp8081
(dp8082
g7
I132
sg23
VC0027627
p8083
sg10
I10
sg11
Vmetastasis
p8084
sg13
I1
sa(dp8085
g7
I154
sg23
VC0017638
p8086
sg10
I6
sg11
Vglioma
p8087
sg13
I1
sa(dp8088
g7
I178
sg23
VC0153633
p8089
sg10
I12
sg11
Vbrain cancer
p8090
sg13
I2
sa(dp8091
g7
I113
sg23
VC0001807
p8092
sg10
I14
sg11
Vaggressiveness
p8093
sg13
I1
sa(dp8094
g7
I107
sg23
VC0027651
p8095
sg10
I5
sg11
Vtumor
p8096
sg13
I1
sasa(dp8097
g2
S'The CXCR4 chemokine and Sonic Hedgehog (SHH) morphogen pathways are well-validated therapeutic targets in cancer, including medulloblastoma.\n'
p8098
sg4
(lp8099
(dp8100
g7
I4
sg8
VP61073
p8101
sg10
I15
sg11
VCXCR4 chemokine
p8102
sg13
I2
sa(dp8103
g7
I24
sg8
g18
sg10
I14
sg11
VSonic Hedgehog
p8104
sg13
I2
sa(dp8105
g7
I40
sg8
g18
sg10
I3
sg11
VSHH
p8106
sg13
I1
sasg20
(lp8107
(dp8108
g7
I106
sg23
VC0006826
p8109
sg10
I6
sg11
Vcancer
p8110
sg13
I1
sa(dp8111
g7
I124
sg23
VC0025149
p8112
sg10
I15
sg11
Vmedulloblastoma
p8113
sg13
I1
sasa(dp8114
g2
S'Here, we discovered that dual inhibition of the SHH and CXCR4 pathways in a murine model of SHH-subtype medulloblastoma exerts potent antitumor effects.\n'
p8115
sg4
(lp8116
(dp8117
g7
I56
sg8
VP61073
p8118
sg10
I5
sg11
VCXCR4
p8119
sg13
I1
sa(dp8120
g7
I48
sg8
g18
sg10
I3
sg11
VSHH
p8121
sg13
I1
sa(dp8122
g7
I48
sg8
g18
sg10
I3
sg11
VSHH
p8123
sg13
I1
sasg20
(lp8124
(dp8125
g7
I104
sg23
VC0025149
p8126
sg10
I15
sg11
Vmedulloblastoma
p8127
sg13
I1
sasa(dp8128
g2
S'Moreover, they provide a mechanistic rationale to evaluate the combination of SHH and CXCR4 inhibitors in clinical trials for the treatment of medulloblastoma, as well as other cancers driven by SHH that coexpress high levels of CXCR4.\n'
p8129
sg4
(lp8130
(dp8131
g7
I86
sg8
VP61073
p8132
sg10
I5
sg11
VCXCR4
p8133
sg13
I1
sa(dp8134
g7
I78
sg8
g18
sg10
I3
sg11
VSHH
p8135
sg13
I1
sa(dp8136
g7
I86
sg8
VP61073
p8137
sg10
I5
sg11
VCXCR4
p8138
sg13
I1
sa(dp8139
g7
I78
sg8
g18
sg10
I3
sg11
VSHH
p8140
sg13
I1
sasg20
(lp8141
(dp8142
g7
I143
sg23
VC0025149
p8143
sg10
I15
sg11
Vmedulloblastoma
p8144
sg13
I1
sa(dp8145
g7
I177
sg23
VC0006826
p8146
sg10
I7
sg11
Vcancers
p8147
sg13
I1
sasa(dp8148
g2
S'The CXCL12/CXCR4 pathway regulates tumor cell proliferation, metastasis, angiogenesis and the tumor-microenvironment cross-talk in several solid tumors, including glioblastoma (GBM), the most common and fatal brain cancer.\n'
p8149
sg4
(lp8150
(dp8151
g7
I11
sg8
VP61073
p8152
sg10
I5
sg11
VCXCR4
p8153
sg13
I1
sa(dp8154
g7
I4
sg8
VP48061
p8155
sg10
I6
sg11
VCXCL12
p8156
sg13
I1
sasg20
(lp8157
(dp8158
g7
I163
sg23
VC0017636
p8159
sg10
I12
sg11
Vglioblastoma
p8160
sg13
I1
sa(dp8161
g7
I46
sg23
VC0334094
p8162
sg10
I13
sg11
Vproliferation
p8163
sg13
I1
sa(dp8164
g7
I61
sg23
VC0027627
p8165
sg10
I10
sg11
Vmetastasis
p8166
sg13
I1
sa(dp8167
g7
I35
sg23
VC0027651
p8168
sg10
I5
sg11
Vtumor
p8169
sg13
I1
sa(dp8170
g7
I177
sg23
VC0017636
p8171
sg10
I3
sg11
VGBM
p8172
sg13
I1
sa(dp8173
g7
I35
sg23
VC0027651
p8174
sg10
I5
sg11
Vtumor
p8175
sg13
I1
sa(dp8176
g7
I139
sg23
VC0280100
p8177
sg10
I12
sg11
Vsolid tumors
p8178
sg13
I2
sa(dp8179
g7
I209
sg23
VC0153633
p8180
sg10
I12
sg11
Vbrain cancer
p8181
sg13
I2
sasa(dp8182
g2
S'Immunohistochemical staining for CXCR4, CXCR5, CCR7, CXCL12, and CXCL13 was performed on 89 tissue samples, including cases of primary central nervous system lymphoma (PCNSL), secondary CNS lymphoma (sCNSL), and systemic DLBCL.\n'
p8183
sg4
(lp8184
(dp8185
g7
I40
sg8
VP32302
p8186
sg10
I5
sg11
VCXCR5
p8187
sg13
I1
sa(dp8188
g7
I33
sg8
VP61073
p8189
sg10
I5
sg11
VCXCR4
p8190
sg13
I1
sa(dp8191
g7
I65
sg8
g18
sg10
I6
sg11
VCXCL13
p8192
sg13
I1
sa(dp8193
g7
I53
sg8
VP48061
p8194
sg10
I6
sg11
VCXCL12
p8195
sg13
I1
sa(dp8196
g7
I47
sg8
VP32248
p8197
sg10
I4
sg11
VCCR7
p8198
sg13
I1
sasg20
(lp8199
(dp8200
g7
I186
sg23
VC0742472
p8201
sg10
I12
sg11
VCNS lymphoma
p8202
sg13
I2
sa(dp8203
g7
I168
sg23
VC0280803
p8204
sg10
I5
sg11
VPCNSL
p8205
sg13
I1
sa(dp8206
g7
I127
sg23
VC0280803
p8207
sg10
I39
sg11
Vprimary central nervous system lymphoma
p8208
sg13
I5
sasa(dp8209
g2
S'Different types of cyto-chemokines are involved in the crosstalk between hAT-MSCs and BTICs (medulloblastoma and AT/RT: CXCR4/SDF-1, CCR5/RANTES, IL6R/IL-6 and IL8R/IL8; glioblastoma: CXCR4/SDF-1, IL6R/IL-6, IL8R/IL-8 and IGF1R/IGF-1).\n'
p8210
sg4
(lp8211
(dp8212
g7
I222
sg8
VP08069
p8213
sg10
I5
sg11
VIGF1R
p8214
sg13
I1
sa(dp8215
g7
I120
sg8
VP61073
p8216
sg10
I5
sg11
VCXCR4
p8217
sg13
I1
sa(dp8218
g7
I120
sg8
VP61073
p8219
sg10
I5
sg11
VCXCR4
p8220
sg13
I1
sa(dp8221
g7
I146
sg8
VP08887
p8222
sg10
I4
sg11
VIL6R
p8223
sg13
I1
sa(dp8224
g7
I133
sg8
VP32302
p8225
sg10
I4
sg11
VCCR5
p8226
sg13
I1
sa(dp8227
g7
I228
sg8
VP01343
p8228
sg10
I5
sg11
VIGF-1
p8229
sg13
I1
sa(dp8230
g7
I73
sg8
g18
sg10
I8
sg11
VhAT-MSCs
p8231
sg13
I1
sa(dp8232
g7
I126
sg8
VP48061
p8233
sg10
I5
sg11
VSDF-1
p8234
sg13
I1
sa(dp8235
g7
I151
sg8
VP05231
p8236
sg10
I4
sg11
VIL-6
p8237
sg13
I1
sa(dp8238
g7
I138
sg8
VP13501
p8239
sg10
I6
sg11
VRANTES
p8240
sg13
I1
sa(dp8241
g7
I151
sg8
VP05231
p8242
sg10
I4
sg11
VIL-6
p8243
sg13
I1
sa(dp8244
g7
I146
sg8
VP08887
p8245
sg10
I4
sg11
VIL6R
p8246
sg13
I1
sa(dp8247
g7
I126
sg8
VP48061
p8248
sg10
I5
sg11
VSDF-1
p8249
sg13
I1
sasg20
(lp8250
(dp8251
g7
I113
sg23
VC1266184
p8252
sg10
I5
sg11
VAT/RT
p8253
sg13
I1
sa(dp8254
g7
I93
sg23
VC0025149
p8255
sg10
I15
sg11
Vmedulloblastoma
p8256
sg13
I1
sa(dp8257
g7
I170
sg23
VC0017636
p8258
sg10
I12
sg11
Vglioblastoma
p8259
sg13
I1
sasa(dp8260
g2
S'Mutations in KCNJ5, ATP1A1, ATP2B3 and CACNA1D are found in aldosterone producing adenoma (APA) and familial hyperaldosteronism (FH).\n'
p8261
sg4
(lp8262
(dp8263
g7
I13
sg8
VP48544
p8264
sg10
I5
sg11
VKCNJ5
p8265
sg13
I1
sa(dp8266
g7
I39
sg8
g18
sg10
I7
sg11
VCACNA1D
p8267
sg13
I1
sa(dp8268
g7
I20
sg8
VP05023
p8269
sg10
I6
sg11
VATP1A1
p8270
sg13
I1
sa(dp8271
g7
I28
sg8
g18
sg10
I6
sg11
VATP2B3
p8272
sg13
I1
sasg20
(lp8273
(dp8274
g7
I82
sg23
VC0001430
p8275
sg10
I7
sg11
Vadenoma
p8276
sg13
I1
sa(dp8277
g7
I109
sg23
VC0020428
p8278
sg10
I18
sg11
Vhyperaldosteronism
p8279
sg13
I1
sasa(dp8280
g2
S'Recurrent somatic mutations in KCNJ5, CACNA1D, ATP1A1, and ATP2B3 have been identified in aldosterone-producing adenomas (APAs).\n'
p8281
sg4
(lp8282
(dp8283
g7
I47
sg8
VP05023
p8284
sg10
I6
sg11
VATP1A1
p8285
sg13
I1
sa(dp8286
g7
I31
sg8
VP48544
p8287
sg10
I5
sg11
VKCNJ5
p8288
sg13
I1
sa(dp8289
g7
I38
sg8
g18
sg10
I7
sg11
VCACNA1D
p8290
sg13
I1
sa(dp8291
g7
I59
sg8
g18
sg10
I6
sg11
VATP2B3
p8292
sg13
I1
sasg20
(lp8293
(dp8294
g7
I112
sg23
VC0001430
p8295
sg10
I8
sg11
Vadenomas
p8296
sg13
I1
sa(dp8297
g7
I10
sg23
VC0544886
p8298
sg10
I17
sg11
Vsomatic mutations
p8299
sg13
I2
sasa(dp8300
g2
S'Several novel susceptibility genes have been found to be mutated in aldosterone-producing adenomas: KCNJ5, ATP1A1, ATP2B3, CTNNB1, CACNA1D, CACNA1H and ARMC5 This review describes the genes currently known to be responsible for primary aldosteronism, discusses the origin of aldosterone-producing adenomas and considers the future clinical implications based on these novel insights.\n'
p8301
sg4
(lp8302
(dp8303
g7
I123
sg8
VP35222
p8304
sg10
I6
sg11
VCTNNB1
p8305
sg13
I1
sa(dp8306
g7
I115
sg8
g18
sg10
I6
sg11
VATP2B3
p8307
sg13
I1
sa(dp8308
g7
I140
sg8
g18
sg10
I7
sg11
VCACNA1H
p8309
sg13
I1
sa(dp8310
g7
I152
sg8
g18
sg10
I5
sg11
VARMC5
p8311
sg13
I1
sa(dp8312
g7
I107
sg8
VP05023
p8313
sg10
I6
sg11
VATP1A1
p8314
sg13
I1
sa(dp8315
g7
I100
sg8
VP48544
p8316
sg10
I5
sg11
VKCNJ5
p8317
sg13
I1
sa(dp8318
g7
I131
sg8
g18
sg10
I7
sg11
VCACNA1D
p8319
sg13
I1
sasg20
(lp8320
(dp8321
g7
I90
sg23
VC0001430
p8322
sg10
I8
sg11
Vadenomas
p8323
sg13
I1
sa(dp8324
g7
I90
sg23
VC0001430
p8325
sg10
I8
sg11
Vadenomas
p8326
sg13
I1
sa(dp8327
g7
I228
sg23
VC1384514
p8328
sg10
I21
sg11
Vprimary aldosteronism
p8329
sg13
I2
sasa(dp8330
g2
S'KCNJ5, ATP1A1, ATP2B3, CACNA1D, CTNNB1, and CACNA1H mutations are causal of primary aldosteronism.\n'
p8331
sg4
(lp8332
(dp8333
g7
I32
sg8
VP35222
p8334
sg10
I6
sg11
VCTNNB1
p8335
sg13
I1
sa(dp8336
g7
I44
sg8
g18
sg10
I17
sg11
VCACNA1H mutations
p8337
sg13
I2
sa(dp8338
g7
I15
sg8
g18
sg10
I6
sg11
VATP2B3
p8339
sg13
I1
sa(dp8340
g7
I0
sg8
VP48544
p8341
sg10
I5
sg11
VKCNJ5
p8342
sg13
I1
sa(dp8343
g7
I23
sg8
g18
sg10
I7
sg11
VCACNA1D
p8344
sg13
I1
sa(dp8345
g7
I7
sg8
VP05023
p8346
sg10
I6
sg11
VATP1A1
p8347
sg13
I1
sasg20
(lp8348
(dp8349
g7
I76
sg23
VC1384514
p8350
sg10
I21
sg11
Vprimary aldosteronism
p8351
sg13
I2
sasa(dp8352
g2
S'In contrast, primary steroid-resistant nephrotic syndrome was associated with HLA-DR4 and DQ8.\n'
p8353
sg4
(lp8354
(dp8355
g7
I78
sg8
VP30486
p8356
sg10
I7
sg11
VHLA-DR4
p8357
sg13
I1
sasg20
(lp8358
(dp8359
g7
I21
sg23
VC0403397
p8360
sg10
I36
sg11
Vsteroid-resistant nephrotic syndrome
p8361
sg13
I3
sasa(dp8362
g2
S'These specific haplotypes were selected from our earlier work to include one haplotype bearing a short DQCAR allele (celiac disease and DR3,DQ2-DQCAR99) and two haplotypes bearing long DQCAR alleles (Diabetes Mellitus and DR4,DQ4-DQCAR 113 or 115 Idiopathic Nephrotic syndrome and DR7,DQ2-DQCAR 111-121).\n'
p8363
sg4
(lp8364
(dp8365
g7
I222
sg8
g18
sg10
I3
sg11
VDR4
p8366
sg13
I1
sa(dp8367
g7
I285
sg8
g18
sg10
I17
sg11
VDQ2-DQCAR 111-121
p8368
sg13
I2
sa(dp8369
g7
I281
sg8
VP13761
p8370
sg10
I3
sg11
VDR7
p8371
sg13
I1
sa(dp8372
g7
I140
sg8
g18
sg10
I11
sg11
VDQ2-DQCAR99
p8373
sg13
I1
sasg20
(lp8374
(dp8375
g7
I117
sg23
VC0007570
p8376
sg10
I14
sg11
Vceliac disease
p8377
sg13
I2
sa(dp8378
g7
I247
sg23
VC1704321
p8379
sg10
I29
sg11
VIdiopathic Nephrotic syndrome
p8380
sg13
I3
sa(dp8381
g7
I200
sg23
VC0011849
p8382
sg10
I17
sg11
VDiabetes Mellitus
p8383
sg13
I2
sasa(dp8384
g2
S'Twelve patients underwent surgery, out of which 10 had prior leukopenia, 11 thrombopenia, 9 longer prothrombin times and all had hypersplenism.\n'
p8385
sg4
(lp8386
(dp8387
g7
I99
sg8
VP00734
p8388
sg10
I11
sg11
Vprothrombin
p8389
sg13
I1
sasg20
(lp8390
(dp8391
g7
I129
sg23
VC0020532
p8392
sg10
I13
sg11
Vhypersplenism
p8393
sg13
I1
sa(dp8394
g7
I61
sg23
VC0023530
p8395
sg10
I10
sg11
Vleukopenia
p8396
sg13
I1
sasa(dp8397
g2
S'Blood investigations confirmed the neutropenia and showed elongation of prothrombin time.\n'
p8398
sg4
(lp8399
(dp8400
g7
I72
sg8
VP00734
p8401
sg10
I11
sg11
Vprothrombin
p8402
sg13
I1
sasg20
(lp8403
sa(dp8404
g2
S'In four studies, renal denervation was compared to sham procedure; one study compared a proximal ablation to a complete renal artery denervation; in the remaining, renal denervation was tested against standard or intensified antihypertensive therapy.None of the included trials was designed to look at hard clinical end points as primary outcomes.When compared to control, there was low quality evidence that renal denervation did not reduce the risk of myocardial infarction (4 studies, 742 participants; RR 1.31, 95% CI 0.45 to 3.84), ischaemic stroke (4 studies, 823 participants; RR 1.15, 95% CI 0.36 to 3.72), or unstable angina (2 studies, 201 participants; RR 0.63, 95% CI 0.08 to 5.06), and moderate quality evidence that it had no effect on 24-hour ambulatory blood pressure monitoring (ABPM) systolic BP (5 studies, 797 participants; MD 0.28 mmHg, 95% CI -3.74 to 4.29), diastolic BP (4 studies, 756 participants; MD 0.93 mmHg, 95% CI -4.50 to 6.36), office measured systolic BP (6 studies, 886 participants; MD -4.08 mmHg, 95% CI -15.26 to 7.11), or diastolic BP (5 studies, 845 participants; MD -1.30 mmHg, 95% CI -7.30 to 4.69).\n'
p8405
sg4
(lp8406
sg20
(lp8407
(dp8408
g7
I618
sg23
VC0002965
p8409
sg10
I15
sg11
Vunstable angina
p8410
sg13
I2
sa(dp8411
g7
I537
sg23
VC0948008
p8412
sg10
I16
sg11
Vischaemic stroke
p8413
sg13
I2
sa(dp8414
g7
I454
sg23
VC0027051
p8415
sg10
I21
sg11
Vmyocardial infarction
p8416
sg13
I2
sasa(dp8417
g2
S'We evaluated the effects of metformin on serum 3-O-methylglucose (3-OMG; a marker of glucose absorption) and plasma total GLP-1 concentrations during a standardized intraduodenal infusion of glucose and 3-OMG in patients with type 2 diabetes.\n'
p8418
sg4
(lp8419
(dp8420
g7
I122
sg8
VP43220
p8421
sg10
I5
sg11
VGLP-1
p8422
sg13
I1
sasg20
(lp8423
(dp8424
g7
I226
sg23
VC0011860
p8425
sg10
I15
sg11
Vtype 2 diabetes
p8426
sg13
I3
sasa(dp8427
g2
S'Dynamic positron emission tomography (PET) imaging was performed using sequential tracer injections ([(15)O]H2O, [(11)C]3-O-methylglucose [3-OMG], and [(18)F]fluorodeoxyglucose [FDG]) to quantify, respectively, skeletal muscle tissue perfusion (glucose delivery), kinetics of bidirectional glucose transport, and glucose phosphorylation to interrogate the individual contribution and interaction among these steps in muscle insulin resistance (IR) in type 2 diabetes (T2D).\n'
p8428
sg4
(lp8429
(dp8430
g7
I424
sg8
VP01308
p8431
sg10
I7
sg11
Vinsulin
p8432
sg13
I1
sasg20
(lp8433
(dp8434
g7
I424
sg23
VC0021655
p8435
sg10
I18
sg11
Vinsulin resistance
p8436
sg13
I2
sa(dp8437
g7
I468
sg23
VC0011860
p8438
sg10
I3
sg11
VT2D
p8439
sg13
I1
sa(dp8440
g7
I451
sg23
VC0011860
p8441
sg10
I15
sg11
Vtype 2 diabetes
p8442
sg13
I3
sa(dp8443
g7
I444
sg23
VC0021655
p8444
sg10
I2
sg11
VIR
p8445
sg13
I1
sasa(dp8446
g2
S'Plasma 3-OMG concentrations were significantly higher in type 2 diabetic patients than in healthy control subjects during acute hyperglycemia.\n'
p8447
sg4
(lp8448
(dp8449
g7
I0
sg8
VP23515
p8450
sg10
I12
sg11
VPlasma 3-OMG
p8451
sg13
I2
sasg20
(lp8452
(dp8453
g7
I122
sg23
VC0342301
p8454
sg10
I19
sg11
Vacute hyperglycemia
p8455
sg13
I2
sasa(dp8456
g2
S'The up-regulated miRNAs in colon cancer included has-miR-194, has-miR-215, has-miR-93, has-miR-192, has-miR-92a, has-miR-29b, and has-miR-20a (median false discovery rate&lt;5%), while the down-regulated miRNAs were has-miR-1231, has-miR-195, has-miR-143, and has-miR-145 (median false discovery rate&lt;5%).\n'
p8457
sg4
(lp8458
sg20
(lp8459
(dp8460
g7
I27
sg23
VC0699790
p8461
sg10
I12
sg11
Vcolon cancer
p8462
sg13
I2
sasa(dp8463
g2
S'The ZNF217 gene, a potential oncogene amplified and overexpressed in several cancers including colorectal cancer (CRC), acts as a transcription factor that activates or represses target genes.\n'
p8464
sg4
(lp8465
(dp8466
g7
I4
sg8
g18
sg10
I11
sg11
VZNF217 gene
p8467
sg13
I2
sasg20
(lp8468
(dp8469
g7
I95
sg23
VC1527249
p8470
sg10
I17
sg11
Vcolorectal cancer
p8471
sg13
I2
sa(dp8472
g7
I77
sg23
VC0006826
p8473
sg10
I7
sg11
Vcancers
p8474
sg13
I1
sa(dp8475
g7
I114
sg23
VC1527249
p8476
sg10
I3
sg11
VCRC
p8477
sg13
I1
sasa(dp8478
g2
S'Automated FISH analysis was performed on 13 different colon cancer samples that had been stained for CD133; each sample was scored for MYC, ZNF217 and Chromosome 6 in CD133 positive and negative glands.\n'
p8479
sg4
(lp8480
(dp8481
g7
I140
sg8
g18
sg10
I6
sg11
VZNF217
p8482
sg13
I1
sa(dp8483
g7
I101
sg8
g18
sg10
I5
sg11
VCD133
p8484
sg13
I1
sa(dp8485
g7
I135
sg8
VP12524
p8486
sg10
I3
sg11
VMYC
p8487
sg13
I1
sasg20
(lp8488
(dp8489
g7
I54
sg23
VC0699790
p8490
sg10
I12
sg11
Vcolon cancer
p8491
sg13
I2
sasa(dp8492
g2
S'Automated FISH analysis was performed on 13 different colon cancer samples that had been stained for CD133; each sample was scored for MYC, ZNF217 and Chromosome 6 in CD133 positive and negative glands.\n'
p8493
sg4
(lp8494
(dp8495
g7
I140
sg8
g18
sg10
I6
sg11
VZNF217
p8496
sg13
I1
sa(dp8497
g7
I101
sg8
g18
sg10
I5
sg11
VCD133
p8498
sg13
I1
sa(dp8499
g7
I135
sg8
VP12524
p8500
sg10
I3
sg11
VMYC
p8501
sg13
I1
sasg20
(lp8502
(dp8503
g7
I54
sg23
VC0699790
p8504
sg10
I12
sg11
Vcolon cancer
p8505
sg13
I2
sasa(dp8506
g2
S'In this study we have defined the changes in gene copy number of the candidate oncogene ZNF217 during colon cancer development and progression.\n'
p8507
sg4
(lp8508
(dp8509
g7
I79
sg8
VP35125
p8510
sg10
I15
sg11
Voncogene ZNF217
p8511
sg13
I2
sasg20
(lp8512
(dp8513
g7
I102
sg23
VC0699790
p8514
sg10
I12
sg11
Vcolon cancer
p8515
sg13
I2
sasa(dp8516
g2
S'Of the 100 colon cancers studied, 61 showed some level of amplification of ZNF217, 15 had loss of ZNF217, while 24 were diploid.\n'
p8517
sg4
(lp8518
(dp8519
g7
I75
sg8
g18
sg10
I6
sg11
VZNF217
p8520
sg13
I1
sa(dp8521
g7
I75
sg8
g18
sg10
I6
sg11
VZNF217
p8522
sg13
I1
sasg20
(lp8523
(dp8524
g7
I11
sg23
VC0007102
p8525
sg10
I13
sg11
Vcolon cancers
p8526
sg13
I2
sa(dp8527
g7
I58
sg23
VC1705759
p8528
sg10
I13
sg11
Vamplification
p8529
sg13
I1
sasa(dp8530
g2
S'In this study we have found that ZNF217 amplification is a frequent event in colon cancer and that the extent of its amplification varies markedly between tumours (range 3-13 copies).\n'
p8531
sg4
(lp8532
(dp8533
g7
I33
sg8
g18
sg10
I6
sg11
VZNF217
p8534
sg13
I1
sasg20
(lp8535
(dp8536
g7
I77
sg23
VC0699790
p8537
sg10
I12
sg11
Vcolon cancer
p8538
sg13
I2
sa(dp8539
g7
I40
sg23
VC1705759
p8540
sg10
I13
sg11
Vamplification
p8541
sg13
I1
sa(dp8542
g7
I40
sg23
VC1705759
p8543
sg10
I13
sg11
Vamplification
p8544
sg13
I1
sa(dp8545
g7
I155
sg23
VC0027651
p8546
sg10
I7
sg11
Vtumours
p8547
sg13
I1
sasa(dp8548
g2
S"The inhibition of hindpaw (non-opiate) footshock-induced analgesia (HP-FSIA) by cimetidine, the histamine H2-receptor antagonist, was characterized in rats, and the drug's presence in brain was demonstrated.\n"
p8549
sg4
(lp8550
(dp8551
g7
I96
sg8
g18
sg10
I21
sg11
Vhistamine H2-receptor
p8552
sg13
I2
sasg20
(lp8553
(dp8554
g7
I57
sg23
VC0344307
p8555
sg10
I9
sg11
Vanalgesia
p8556
sg13
I1
sasa(dp8557
g2
S'Because previous studies have suggested that activation of baroreceptors could mediate stress-induced analgesia, the effect of acute exposure to footshock on mean arterial pressure (MAP) and pain sensitivity was simultaneously determined in conscious rats receiving the histamine H2 receptor antagonist cimetidine or vehicle.\n'
p8558
sg4
(lp8559
(dp8560
g7
I270
sg8
VP25021
p8561
sg10
I21
sg11
Vhistamine H2 receptor
p8562
sg13
I3
sasg20
(lp8563
(dp8564
g7
I102
sg23
VC0344307
p8565
sg10
I9
sg11
Vanalgesia
p8566
sg13
I1
sasa(dp8567
g2
S'The action of zolantidine, a histamine H2-receptor antagonist which penetrates the brain, was characterized on the analgesia elicited by brief continuous footshock of 3 intensities.\n'
p8568
sg4
(lp8569
(dp8570
g7
I29
sg8
g18
sg10
I21
sg11
Vhistamine H2-receptor
p8571
sg13
I2
sasg20
(lp8572
(dp8573
g7
I115
sg23
VC0344307
p8574
sg10
I9
sg11
Vanalgesia
p8575
sg13
I1
sasa(dp8576
g2
S'To test this hypothesis, we analyzed the expression of 15 members of the BCL-2 protein family (Bax, Bak, Bok, Bcl-2, Bcl-xl, Bcl-w, Mcl-1, Bad, Bid, Bim, Bik, Bmf, Hrk, Noxa and Puma) in glioblastoma multiforme (GBM) tumors, the most frequent brain tumor in adults.\n'
p8577
sg4
(lp8578
(dp8579
g7
I178
sg8
g18
sg10
I4
sg11
VPuma
p8580
sg13
I1
sa(dp8581
g7
I164
sg8
g18
sg10
I3
sg11
VHrk
p8582
sg13
I1
sa(dp8583
g7
I154
sg8
g18
sg10
I3
sg11
VBik
p8584
sg13
I1
sa(dp8585
g7
I139
sg8
g18
sg10
I3
sg11
VBad
p8586
sg13
I1
sa(dp8587
g7
I125
sg8
g18
sg10
I5
sg11
VBcl-w
p8588
sg13
I1
sa(dp8589
g7
I132
sg8
VP07954
p8590
sg10
I5
sg11
VMcl-1
p8591
sg13
I1
sa(dp8592
g7
I73
sg8
VP10415
p8593
sg10
I20
sg11
VBCL-2 protein family
p8594
sg13
I3
sa(dp8595
g7
I159
sg8
g18
sg10
I3
sg11
VBmf
p8596
sg13
I1
sa(dp8597
g7
I110
sg8
VP10415
p8598
sg10
I5
sg11
VBcl-2
p8599
sg13
I1
sa(dp8600
g7
I169
sg8
g18
sg10
I4
sg11
VNoxa
p8601
sg13
I1
sa(dp8602
g7
I117
sg8
g18
sg10
I6
sg11
VBcl-xl
p8603
sg13
I1
sa(dp8604
g7
I144
sg8
VP55957
p8605
sg10
I3
sg11
VBid
p8606
sg13
I1
sa(dp8607
g7
I100
sg8
g18
sg10
I3
sg11
VBak
p8608
sg13
I1
sa(dp8609
g7
I105
sg8
g18
sg10
I3
sg11
VBok
p8610
sg13
I1
sasg20
(lp8611
(dp8612
g7
I217
sg23
VC0027651
p8613
sg10
I6
sg11
Vtumors
p8614
sg13
I1
sa(dp8615
g7
I132
sg23
VC1708350
p8616
sg10
I3
sg11
VMcl
p8617
sg13
I1
sa(dp8618
g7
I212
sg23
VC1621958
p8619
sg10
I3
sg11
VGBM
p8620
sg13
I1
sa(dp8621
g7
I187
sg23
VC1621958
p8622
sg10
I23
sg11
Vglioblastoma multiforme
p8623
sg13
I2
sa(dp8624
g7
I243
sg23
VC0006118
p8625
sg10
I11
sg11
Vbrain tumor
p8626
sg13
I2
sasa(dp8627
g2
S'We find that lung squamous cell carcinoma (SQCC), which accounts for ~20% of lung cancer, exhibits increased expression of the PI3K subunit PIK3R2, which is at low expression levels in normal tissues.\n'
p8628
sg4
(lp8629
(dp8630
g7
I127
sg8
VP42336
p8631
sg10
I19
sg11
VPI3K subunit PIK3R2
p8632
sg13
I3
sasg20
(lp8633
(dp8634
g7
I77
sg23
VC0684249
p8635
sg10
I11
sg11
Vlung cancer
p8636
sg13
I2
sa(dp8637
g7
I13
sg23
VC0149782
p8638
sg10
I28
sg11
Vlung squamous cell carcinoma
p8639
sg13
I4
sasa(dp8640
g2
S'These results validate the use PIK3R2 interfering tools for the treatment of lung squamous cell carcinoma.\n'
p8641
sg4
(lp8642
sg20
(lp8643
(dp8644
g7
I77
sg23
VC0149782
p8645
sg10
I28
sg11
Vlung squamous cell carcinoma
p8646
sg13
I4
sasa(dp8647
g2
S'Our study explored whether the microRNA-126 (miR-126)-mediated PTEN/PI3K/AKT (phosphatase and tensin homology deleted on chromosome 10/phosphatidylinositol 3-kinase regulatory subunit-Beta/AKT) signaling pathway by targeting PIK3R2 affects the proliferation, migration, and invasion of non-small-cell lung cancer (NSCLC) A549 cells.\n'
p8648
sg4
(lp8649
(dp8650
g7
I68
sg8
VP42336
p8651
sg10
I4
sg11
VPI3K
p8652
sg13
I1
sa(dp8653
g7
I135
sg8
VP42336
p8654
sg10
I53
sg11
Vphosphatidylinositol 3-kinase regulatory subunit-Beta
p8655
sg13
I4
sa(dp8656
g7
I73
sg8
g18
sg10
I3
sg11
VAKT
p8657
sg13
I1
sa(dp8658
g7
I73
sg8
g18
sg10
I3
sg11
VAKT
p8659
sg13
I1
sa(dp8660
g7
I63
sg8
VP60484
p8661
sg10
I4
sg11
VPTEN
p8662
sg13
I1
sa(dp8663
g7
I225
sg8
g18
sg10
I6
sg11
VPIK3R2
p8664
sg13
I1
sa(dp8665
g7
I94
sg8
g18
sg10
I15
sg11
Vtensin homology
p8666
sg13
I2
sasg20
(lp8667
(dp8668
g7
I314
sg23
VC0007131
p8669
sg10
I5
sg11
VNSCLC
p8670
sg13
I1
sa(dp8671
g7
I244
sg23
VC0334094
p8672
sg10
I13
sg11
Vproliferation
p8673
sg13
I1
sa(dp8674
g7
I286
sg23
VC0007131
p8675
sg10
I26
sg11
Vnon-small-cell lung cancer
p8676
sg13
I3
sa(dp8677
g7
I274
sg23
VC2699153
p8678
sg10
I8
sg11
Vinvasion
p8679
sg13
I1
sasa(dp8680
g2
S'The upregulation of miR-126 in NSCLC A549 cells can reduce the expression of the target gene PIK3R2 and influence the PTEN/PI3K/AKT signaling pathway, suppressing the proliferation, migration, and invasive abilities of A549 cells.\n'
p8681
sg4
(lp8682
(dp8683
g7
I93
sg8
g18
sg10
I6
sg11
VPIK3R2
p8684
sg13
I1
sa(dp8685
g7
I128
sg8
g18
sg10
I3
sg11
VAKT
p8686
sg13
I1
sa(dp8687
g7
I118
sg8
VP60484
p8688
sg10
I4
sg11
VPTEN
p8689
sg13
I1
sa(dp8690
g7
I123
sg8
VP42336
p8691
sg10
I4
sg11
VPI3K
p8692
sg13
I1
sasg20
(lp8693
(dp8694
g7
I31
sg23
VC0007131
p8695
sg10
I5
sg11
VNSCLC
p8696
sg13
I1
sa(dp8697
g7
I167
sg23
VC0334094
p8698
sg10
I13
sg11
Vproliferation
p8699
sg13
I1
sasa(dp8700
g2
S'Included in the duplicated region is the gene EP300, mutations and deletions of which are implicated in Rubinstein-Taybi syndrome and thyrotroph embryonic factor, which has been proposed to be related to the pituitary hypoplasia seen in one patient with a large duplication, and several other genes without clear relation to disease.\n'
p8701
sg4
(lp8702
(dp8703
g7
I41
sg8
g18
sg10
I10
sg11
Vgene EP300
p8704
sg13
I2
sasg20
(lp8705
(dp8706
g7
I262
sg23
VC1705960
p8707
sg10
I11
sg11
Vduplication
p8708
sg13
I1
sa(dp8709
g7
I104
sg23
VC0035934
p8710
sg10
I25
sg11
VRubinstein-Taybi syndrome
p8711
sg13
I2
sa(dp8712
g7
I208
sg23
VC0948740
p8713
sg10
I20
sg11
Vpituitary hypoplasia
p8714
sg13
I2
sasa(dp8715
g2
S'We describe, for the first time in literature, a RTS Caucasian girl, 14-year-old, with growth hormone (GH) deficiency, pituitary hypoplasia, Arnold Chiari malformation type 1, double syringomyelic cavity and a novel CREBBP mutation (c.3546insCC).\n'
p8716
sg4
(lp8717
(dp8718
g7
I87
sg8
VP01242
p8719
sg10
I14
sg11
Vgrowth hormone
p8720
sg13
I2
sa(dp8721
g7
I103
sg8
VP01242
p8722
sg10
I2
sg11
VGH
p8723
sg13
I1
sa(dp8724
g7
I216
sg8
g18
sg10
I6
sg11
VCREBBP
p8725
sg13
I1
sasg20
(lp8726
(dp8727
g7
I49
sg23
VC0035372
p8728
sg10
I3
sg11
VRTS
p8729
sg13
I1
sa(dp8730
g7
I141
sg23
VC0003803
p8731
sg10
I26
sg11
VArnold Chiari malformation
p8732
sg13
I3
sa(dp8733
g7
I197
sg23
VC0011334
p8734
sg10
I6
sg11
Vcavity
p8735
sg13
I1
sa(dp8736
g7
I119
sg23
VC0948740
p8737
sg10
I20
sg11
Vpituitary hypoplasia
p8738
sg13
I2
sasa(dp8739
g2
S'We hypothesize that CREBBP mutation we have identified in this patient could be responsible also for RTS atypical features as GH deficiency and pituitary hypoplasia.\n'
p8740
sg4
(lp8741
(dp8742
g7
I20
sg8
g18
sg10
I6
sg11
VCREBBP
p8743
sg13
I1
sasg20
(lp8744
(dp8745
g7
I144
sg23
VC0948740
p8746
sg10
I20
sg11
Vpituitary hypoplasia
p8747
sg13
I2
sa(dp8748
g7
I101
sg23
VC0035372
p8749
sg10
I3
sg11
VRTS
p8750
sg13
I1
sasa(dp8751
g2
S'Evaluation of cognitive performance by using P300 ERPs has not been reported in acromegaly, and the comparisons of the P300 ERPs between the patients with GH deficiency and GH excess have not been done yet.\n'
p8752
sg4
(lp8753
(dp8754
g7
I45
sg8
g18
sg10
I9
sg11
VP300 ERPs
p8755
sg13
I2
sasg20
(lp8756
(dp8757
g7
I80
sg23
VC0001206
p8758
sg10
I10
sg11
Vacromegaly
p8759
sg13
I1
sasa(dp8760
g2
S'The mean P300 amplitude of the patients with acromegaly was significantly (P=0.005) lower when compared with that of normal controls and GH deficient patients at all electrode sites.\n'
p8761
sg4
(lp8762
sg20
(lp8763
(dp8764
g7
I45
sg23
VC0001206
p8765
sg10
I10
sg11
Vacromegaly
p8766
sg13
I1
sasa(dp8767
g2
S'Using ERPs recordings, the present study indicates the prolongation of P300 latencies in patients with severe GH deficiency and reduction of P300 amplitudes in patients with acromegaly.\n'
p8768
sg4
(lp8769
sg20
(lp8770
(dp8771
g7
I174
sg23
VC0001206
p8772
sg10
I10
sg11
Vacromegaly
p8773
sg13
I1
sasa(dp8774
g2
S"The present study was designed to investigate the effects of GHD and 6 months of GHRT on cognitive function in patients with Sheehan's syndrome by using P300 latency.\n"
p8775
sg4
(lp8776
sg20
(lp8777
(dp8778
g7
I125
sg23
VC0242342
p8779
sg10
I18
sg11
VSheehan's syndrome
p8780
sg13
I2
sa(dp8781
g7
I61
sg23
VC0271561
p8782
sg10
I3
sg11
VGHD
p8783
sg13
I1
sasa(dp8784
g2
S"The present study, using P300 ERP latencies, therefore suggests an impairment of cognitive abilities due to severe GHD in patients with Sheehan's syndrome and an improvement of cognitive function after 6 months of physiological GHRT.\n"
p8785
sg4
(lp8786
sg20
(lp8787
(dp8788
g7
I136
sg23
VC0242342
p8789
sg10
I18
sg11
VSheehan's syndrome
p8790
sg13
I2
sa(dp8791
g7
I115
sg23
VC0271561
p8792
sg10
I3
sg11
VGHD
p8793
sg13
I1
sa(dp8794
g7
I67
sg23
VC0684336
p8795
sg10
I10
sg11
Vimpairment
p8796
sg13
I1
sasa(dp8797
g2
S'Abnormal laboratory findings included square wave jerks, upbeat nystagmus, and "bow tie" nystagmus by EOG, atrophy of the cerebellum and the brainstem by CT, a slight prolongation of the P300 latency, and a central diabetes insipidus pattern by water deprivation test and Carter-Robbins tests.\n'
p8798
sg4
(lp8799
sg20
(lp8800
(dp8801
g7
I64
sg23
VC0028738
p8802
sg10
I9
sg11
Vnystagmus
p8803
sg13
I1
sa(dp8804
g7
I57
sg23
VC0585545
p8805
sg10
I16
sg11
Vupbeat nystagmus
p8806
sg13
I2
sa(dp8807
g7
I50
sg23
VC0231530
p8808
sg10
I5
sg11
Vjerks
p8809
sg13
I1
sa(dp8810
g7
I207
sg23
VC0687720
p8811
sg10
I26
sg11
Vcentral diabetes insipidus
p8812
sg13
I3
sa(dp8813
g7
I107
sg23
VC0333641
p8814
sg10
I7
sg11
Vatrophy
p8815
sg13
I1
sasa(dp8816
g2
S'The expression of the VEGF-A gene proved to be higher in patients at a higher risk of acute leukemia and positively correlated with the expression levels of the VEGFR1 gene (p&lt;0.05) rather than that of the VEGFR2 gene.\n'
p8817
sg4
(lp8818
(dp8819
g7
I161
sg8
VP17948
p8820
sg10
I11
sg11
VVEGFR1 gene
p8821
sg13
I2
sa(dp8822
g7
I209
sg8
VP35968
p8823
sg10
I11
sg11
VVEGFR2 gene
p8824
sg13
I2
sasg20
(lp8825
(dp8826
g7
I86
sg23
VC0085669
p8827
sg10
I14
sg11
Vacute leukemia
p8828
sg13
I2
sasa(dp8829
g2
S'Patients with intermediate-2 or high-risk acute leukemia showed an increase in the average expression levels of VEGF-A and VEGFR1 and a reduction in VEGFR2 expression.\n'
p8830
sg4
(lp8831
(dp8832
g7
I123
sg8
VP17948
p8833
sg10
I6
sg11
VVEGFR1
p8834
sg13
I1
sa(dp8835
g7
I149
sg8
VP35968
p8836
sg10
I6
sg11
VVEGFR2
p8837
sg13
I1
sasg20
(lp8838
(dp8839
g7
I42
sg23
VC0085669
p8840
sg10
I14
sg11
Vacute leukemia
p8841
sg13
I2
sasa(dp8842
g2
S'It is concluded that the CTGF, CYR61, VEGF-C and VEGFR-2 mRNA and protein play a role in acute leukemia.\n'
p8843
sg4
(lp8844
(dp8845
g7
I38
sg8
VP49767
p8846
sg10
I6
sg11
VVEGF-C
p8847
sg13
I1
sa(dp8848
g7
I25
sg8
VP29279
p8849
sg10
I4
sg11
VCTGF
p8850
sg13
I1
sa(dp8851
g7
I31
sg8
g18
sg10
I5
sg11
VCYR61
p8852
sg13
I1
sa(dp8853
g7
I49
sg8
VP35968
p8854
sg10
I12
sg11
VVEGFR-2 mRNA
p8855
sg13
I2
sasg20
(lp8856
(dp8857
g7
I89
sg23
VC0085669
p8858
sg10
I14
sg11
Vacute leukemia
p8859
sg13
I2
sasa(dp8860
g2
S'In acute leukemia (AML/ALL), the expression of above mentioned factor was high, but except VEGFR-2.\n'
p8861
sg4
(lp8862
(dp8863
g7
I91
sg8
VP35968
p8864
sg10
I7
sg11
VVEGFR-2
p8865
sg13
I1
sasg20
(lp8866
(dp8867
g7
I19
sg23
VC0023467
p8868
sg10
I3
sg11
VAML
p8869
sg13
I1
sa(dp8870
g7
I3
sg23
VC0085669
p8871
sg10
I14
sg11
Vacute leukemia
p8872
sg13
I2
sasa(dp8873
g2
S'The expression levels of VEGF-C, VEGFR-2 mRNA in acute leukemia patients with extramedullary infiltration were higher than those in acute leukemia patients without extramedullary infiltration (p = 0.028, 0.047).\n'
p8874
sg4
(lp8875
(dp8876
g7
I33
sg8
VP35968
p8877
sg10
I12
sg11
VVEGFR-2 mRNA
p8878
sg13
I2
sa(dp8879
g7
I25
sg8
VP49767
p8880
sg10
I6
sg11
VVEGF-C
p8881
sg13
I1
sasg20
(lp8882
(dp8883
g7
I49
sg23
VC0085669
p8884
sg10
I14
sg11
Vacute leukemia
p8885
sg13
I2
sa(dp8886
g7
I93
sg23
VC0332448
p8887
sg10
I12
sg11
Vinfiltration
p8888
sg13
I1
sa(dp8889
g7
I49
sg23
VC0085669
p8890
sg10
I14
sg11
Vacute leukemia
p8891
sg13
I2
sa(dp8892
g7
I93
sg23
VC0332448
p8893
sg10
I12
sg11
Vinfiltration
p8894
sg13
I1
sasa(dp8895
g2
S'Further, corresponding to the morphological changes of nucleolus in number and size, these highly proliferating SSEA1 cells demonstrated coexpression of either D2-40 or the mesodermal marker Scl (stem cell leukemia), brachyury, and Flk-1 (vascular endothelial growth factor-2), respectively, indicative of the neoplasmtic transformation into the stromal or vascular cells.\n'
p8896
sg4
(lp8897
(dp8898
g7
I191
sg8
VP17542
p8899
sg10
I3
sg11
VScl
p8900
sg13
I1
sa(dp8901
g7
I239
sg8
g18
sg10
I36
sg11
Vvascular endothelial growth factor-2
p8902
sg13
I4
sa(dp8903
g7
I196
sg8
VP17542
p8904
sg10
I18
sg11
Vstem cell leukemia
p8905
sg13
I3
sa(dp8906
g7
I232
sg8
VP35968
p8907
sg10
I5
sg11
VFlk-1
p8908
sg13
I1
sasg20
(lp8909
(dp8910
g7
I191
sg23
VC1378511
p8911
sg10
I3
sg11
VScl
p8912
sg13
I1
sa(dp8913
g7
I196
sg23
VC1378511
p8914
sg10
I18
sg11
Vstem cell leukemia
p8915
sg13
I3
sa(dp8916
g7
I322
sg23
VC1510411
p8917
sg10
I14
sg11
Vtransformation
p8918
sg13
I1
sasa(dp8919
g2
S'Taken together, we conclude that cholesterol regulates VEGF:VEGFR-1 signaling on subsets of acute leukemias, modulating cell migration, and viability, which may be crucial for disease progression.\n'
p8920
sg4
(lp8921
(dp8922
g7
I60
sg8
VP17948
p8923
sg10
I7
sg11
VVEGFR-1
p8924
sg13
I1
sasg20
(lp8925
(dp8926
g7
I176
sg23
VC0242656
p8927
sg10
I19
sg11
Vdisease progression
p8928
sg13
I2
sa(dp8929
g7
I92
sg23
VC0085669
p8930
sg10
I15
sg11
Vacute leukemias
p8931
sg13
I2
sasa(dp8932
g2
S'Consistent with an embryologically derived hemangioblast, the neoplastic cells demonstrated coexpression of the mesodermal markers brachyury, Flk-1 (vascular endothelial growth factor-2), and stem cell leukemia (Scl).\n'
p8933
sg4
(lp8934
(dp8935
g7
I142
sg8
VP35968
p8936
sg10
I5
sg11
VFlk-1
p8937
sg13
I1
sa(dp8938
g7
I149
sg8
g18
sg10
I36
sg11
Vvascular endothelial growth factor-2
p8939
sg13
I4
sasg20
(lp8940
(dp8941
g7
I192
sg23
VC1378511
p8942
sg10
I18
sg11
Vstem cell leukemia
p8943
sg13
I3
sa(dp8944
g7
I212
sg23
VC1378511
p8945
sg10
I3
sg11
VScl
p8946
sg13
I1
sasa(dp8947
g2
S'Furthermore, an inverse correlation between the expression levels of MTA1 and RNF144A was demonstrated in publicly available breast cancer microarray datasets and the MCF10 breast cancer progression model system.\n'
p8948
sg4
(lp8949
(dp8950
g7
I78
sg8
VP50876
p8951
sg10
I7
sg11
VRNF144A
p8952
sg13
I1
sa(dp8953
g7
I69
sg8
g18
sg10
I4
sg11
VMTA1
p8954
sg13
I1
sasg20
(lp8955
(dp8956
g7
I180
sg23
VC0178874
p8957
sg10
I18
sg11
Vcancer progression
p8958
sg13
I2
sa(dp8959
g7
I125
sg23
VC0678222
p8960
sg10
I13
sg11
Vbreast cancer
p8961
sg13
I2
sasa(dp8962
g2
S'Thirty-two per cent of 51 group A strains isolated from ARF family members (29 from throat, 22 from skin) were M11 or "M41" strains which were associated with ARF during the study, while only 8% were M1, T4 (MNT or 60) or M55 strains which were associated with AGN.\n'
p8963
sg4
(lp8964
(dp8965
g7
I56
sg8
VP42771
p8966
sg10
I3
sg11
VARF
p8967
sg13
I1
sa(dp8968
g7
I56
sg8
VP42771
p8969
sg10
I18
sg11
VARF family members
p8970
sg13
I3
sasg20
(lp8971
(dp8972
g7
I56
sg23
VC0264490
p8973
sg10
I3
sg11
VARF
p8974
sg13
I1
sa(dp8975
g7
I56
sg23
VC0264490
p8976
sg10
I3
sg11
VARF
p8977
sg13
I1
sasa(dp8978
g2
S'The purpose of the present study was to investigate the effect of ginger extract on apolipoproteins (apo) A and B, hyperhomocysteinemia, cathepsin G and leptin changes, as well as cardiac fibrosis and heart muscle cell proliferation under hyperglycemic conditions in vivo.\n'
p8979
sg4
(lp8980
(dp8981
g7
I137
sg8
VP08311
p8982
sg10
I11
sg11
Vcathepsin G
p8983
sg13
I2
sa(dp8984
g7
I84
sg8
g18
sg10
I29
sg11
Vapolipoproteins (apo) A and B
p8985
sg13
I5
sa(dp8986
g7
I153
sg8
VP41159
p8987
sg10
I6
sg11
Vleptin
p8988
sg13
I1
sasg20
(lp8989
(dp8990
g7
I219
sg23
VC0334094
p8991
sg10
I13
sg11
Vproliferation
p8992
sg13
I1
sa(dp8993
g7
I180
sg23
VC1397307
p8994
sg10
I16
sg11
Vcardiac fibrosis
p8995
sg13
I2
sa(dp8996
g7
I115
sg23
VC0598608
p8997
sg10
I20
sg11
Vhyperhomocysteinemia
p8998
sg13
I1
sasa(dp8999
g2
S'Compared with the wild-type haplotype TATG, the risks of dyslipidemia with CGCC, TGCC, or CATG haplotypes (odds ratios = 2.434, 1.503, and 2.740, respectively) were significantly higher.\n'
p9000
sg4
(lp9001
sg20
(lp9002
(dp9003
g7
I57
sg23
VC0242339
p9004
sg10
I12
sg11
Vdyslipidemia
p9005
sg13
I1
sasa(dp9006
g2
S'Individuals carrying the CGCC, TGCC, or CATG haplotypes were prone to dyslipidemia.\n'
p9007
sg4
(lp9008
sg20
(lp9009
(dp9010
g7
I70
sg23
VC0242339
p9011
sg10
I12
sg11
Vdyslipidemia
p9012
sg13
I1
sasa(dp9013
g2
S"CatG is involved in the pathophysiology of several serious human diseases, such as chronic obstructive pulmonary disease (COPD), Crohn's disease, rheumatoid arthritis, cystic fibrosis and other conditions clinically manifested by excessive inflammatory reactions.\n"
p9014
sg4
(lp9015
(dp9016
g7
I0
sg8
VP08311
p9017
sg10
I4
sg11
VCatG
p9018
sg13
I1
sasg20
(lp9019
(dp9020
g7
I83
sg23
VC0024117
p9021
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p9022
sg13
I4
sa(dp9023
g7
I168
sg23
VC0010674
p9024
sg10
I15
sg11
Vcystic fibrosis
p9025
sg13
I2
sa(dp9026
g7
I146
sg23
VC0003873
p9027
sg10
I20
sg11
Vrheumatoid arthritis
p9028
sg13
I2
sa(dp9029
g7
I129
sg23
VC0010346
p9030
sg10
I15
sg11
VCrohn's disease
p9031
sg13
I2
sa(dp9032
g7
I122
sg23
VC0024117
p9033
sg10
I4
sg11
VCOPD
p9034
sg13
I1
sasa(dp9035
g2
S'Brains from scrapie-infected mice showed significantly decreased ELKS, an active zone matrix marker compared with those of age-matched control mice.\n'
p9036
sg4
(lp9037
sg20
(lp9038
(dp9039
g7
I12
sg23
VC0036457
p9040
sg10
I7
sg11
Vscrapie
p9041
sg13
I1
sasa(dp9042
g2
S'Prion diseases include Creutzfeldt-Jakob disease (CJD) in humans, bovine spongiform encephalopathy (BSE, "mad cow disease") in cattle, scrapie in sheep, and chronic wasting disease (CWD) in deer and elks.\n'
p9043
sg4
(lp9044
sg20
(lp9045
(dp9046
g7
I106
sg23
VC0085209
p9047
sg10
I15
sg11
Vmad cow disease
p9048
sg13
I3
sa(dp9049
g7
I135
sg23
VC0036457
p9050
sg10
I7
sg11
Vscrapie
p9051
sg13
I1
sa(dp9052
g7
I23
sg23
VC0022336
p9053
sg10
I25
sg11
VCreutzfeldt-Jakob disease
p9054
sg13
I2
sa(dp9055
g7
I182
sg23
VC1135993
p9056
sg10
I3
sg11
VCWD
p9057
sg13
I1
sa(dp9058
g7
I0
sg23
VC0162534
p9059
sg10
I14
sg11
VPrion diseases
p9060
sg13
I2
sa(dp9061
g7
I100
sg23
VC0085209
p9062
sg10
I3
sg11
VBSE
p9063
sg13
I1
sa(dp9064
g7
I50
sg23
VC0022336
p9065
sg10
I3
sg11
VCJD
p9066
sg13
I1
sa(dp9067
g7
I66
sg23
VC0085209
p9068
sg10
I32
sg11
Vbovine spongiform encephalopathy
p9069
sg13
I3
sa(dp9070
g7
I157
sg23
VC1135993
p9071
sg10
I23
sg11
Vchronic wasting disease
p9072
sg13
I3
sasa(dp9073
g2
S'Spongiform encephalopathies include seven neurodegenerative diseases: three in man (Creutzfeldt-Jakob disease, Gerstmann-Straeussler-Scheinker disease and kuru) and four in animals (scrapie, mink encephalopathy, bovine spongiform encephalopathy and chronic wasting disease in deer and elks).\n'
p9074
sg4
(lp9075
sg20
(lp9076
(dp9077
g7
I196
sg23
VC0085584
p9078
sg10
I14
sg11
Vencephalopathy
p9079
sg13
I1
sa(dp9080
g7
I84
sg23
VC0022336
p9081
sg10
I25
sg11
VCreutzfeldt-Jakob disease
p9082
sg13
I2
sa(dp9083
g7
I182
sg23
VC0036457
p9084
sg10
I7
sg11
Vscrapie
p9085
sg13
I1
sa(dp9086
g7
I11
sg23
VC0085584
p9087
sg10
I16
sg11
Vencephalopathies
p9088
sg13
I1
sa(dp9089
g7
I155
sg23
VC0022802
p9090
sg10
I4
sg11
Vkuru
p9091
sg13
I1
sa(dp9092
g7
I249
sg23
VC1135993
p9093
sg10
I23
sg11
Vchronic wasting disease
p9094
sg13
I3
sa(dp9095
g7
I196
sg23
VC0085209
p9096
sg10
I33
sg11
Vencephalopathy, bovine spongiform
p9097
sg13
I3
sa(dp9098
g7
I42
sg23
VC0524851
p9099
sg10
I26
sg11
Vneurodegenerative diseases
p9100
sg13
I2
sasa(dp9101
g2
S'Western blotting suggests that vinorelbine cleaves caspase-3, -9 and -8 and reduces the amount of mitochondrial cytochrome c. Caspase-8 deficiency suppresses all of these events.\n'
p9102
sg4
(lp9103
(dp9104
g7
I98
sg8
VP99999
p9105
sg10
I26
sg11
Vmitochondrial cytochrome c
p9106
sg13
I3
sa(dp9107
g7
I51
sg8
VP42574
p9108
sg10
I9
sg11
Vcaspase-3
p9109
sg13
I1
sa(dp9110
g7
I126
sg8
VP39880
p9111
sg10
I9
sg11
VCaspase-8
p9112
sg13
I1
sasg20
(lp9113
(dp9114
g7
I126
sg23
VC1846545
p9115
sg10
I20
sg11
VCaspase-8 deficiency
p9116
sg13
I2
sasa(dp9117
g2
S'Caspase-8 deficiency also inhibited the cytochrome c release induced by ER stress.\n'
p9118
sg4
(lp9119
(dp9120
g7
I40
sg8
VP99999
p9121
sg10
I12
sg11
Vcytochrome c
p9122
sg13
I2
sa(dp9123
g7
I0
sg8
VP39880
p9124
sg10
I9
sg11
VCaspase-8
p9125
sg13
I1
sasg20
(lp9126
(dp9127
g7
I0
sg23
VC1846545
p9128
sg10
I20
sg11
VCaspase-8 deficiency
p9129
sg13
I2
sasa(dp9130
g2
S'As increased serum levels and local overproduction of endothelin-1 in the airways are reported in cystic fibrosis (CF) patients, we reasoned that anti-ETAR antibodies could be prevalent in endstage CF patients prior to lung transplantation (LTx).\n'
p9131
sg4
(lp9132
(dp9133
g7
I146
sg8
VP25101
p9134
sg10
I20
sg11
Vanti-ETAR antibodies
p9135
sg13
I2
sa(dp9136
g7
I54
sg8
VP20800
p9137
sg10
I12
sg11
Vendothelin-1
p9138
sg13
I1
sasg20
(lp9139
(dp9140
g7
I115
sg23
VC0016059
p9141
sg10
I2
sg11
VCF
p9142
sg13
I1
sa(dp9143
g7
I115
sg23
VC0016059
p9144
sg10
I2
sg11
VCF
p9145
sg13
I1
sa(dp9146
g7
I98
sg23
VC0010674
p9147
sg10
I15
sg11
Vcystic fibrosis
p9148
sg13
I2
sasa(dp9149
g2
S'Cytogenetic investigations of malignant mesothelioma (MM) have revealed frequent losses in chromosomes 13 and 14, suggesting that inactivation of tumor suppressor genes (TSGs) residing in these chromosomes may contribute to mesothelial cell tumorigenesis.\n'
p9150
sg4
(lp9151
sg20
(lp9152
(dp9153
g7
I130
sg23
VC0544461
p9154
sg10
I12
sg11
Vinactivation
p9155
sg13
I1
sa(dp9156
g7
I146
sg23
VC0027651
p9157
sg10
I5
sg11
Vtumor
p9158
sg13
I1
sa(dp9159
g7
I30
sg23
VC0345967
p9160
sg10
I22
sg11
Vmalignant mesothelioma
p9161
sg13
I2
sa(dp9162
g7
I241
sg23
VC0007621
p9163
sg10
I13
sg11
Vtumorigenesis
p9164
sg13
I1
sasa(dp9165
g2
S'Mutations in the with-no-lysine kinase 1 (WNK1), WNK4, Kelch-like 3 (KLHL3), and Cullin3 (CUL3) genes were identified as being responsible for hereditary hypertensive disease pseudohypoaldosteronism type II (PHAII).\n'
p9166
sg4
(lp9167
(dp9168
g7
I42
sg8
g18
sg10
I4
sg11
VWNK1
p9169
sg13
I1
sa(dp9170
g7
I17
sg8
g18
sg10
I23
sg11
Vwith-no-lysine kinase 1
p9171
sg13
I3
sa(dp9172
g7
I69
sg8
g18
sg10
I5
sg11
VKLHL3
p9173
sg13
I1
sa(dp9174
g7
I49
sg8
g18
sg10
I4
sg11
VWNK4
p9175
sg13
I1
sa(dp9176
g7
I55
sg8
g18
sg10
I12
sg11
VKelch-like 3
p9177
sg13
I2
sa(dp9178
g7
I90
sg8
g18
sg10
I4
sg11
VCUL3
p9179
sg13
I1
sa(dp9180
g7
I81
sg8
g18
sg10
I7
sg11
VCullin3
p9181
sg13
I1
sasg20
(lp9182
(dp9183
g7
I154
sg23
VC0020538
p9184
sg10
I20
sg11
Vhypertensive disease
p9185
sg13
I2
sa(dp9186
g7
I175
sg23
VC0033805
p9187
sg10
I23
sg11
Vpseudohypoaldosteronism
p9188
sg13
I1
sasa(dp9189
g2
S'Mutations in the with-no-lysine kinase 1 (WNK1), WNK4, kelch-like 3 (KLHL3), and cullin3 (CUL3) genes are known to cause the hereditary disease pseudohypoaldosteronism type II (PHAII).\n'
p9190
sg4
(lp9191
(dp9192
g7
I42
sg8
g18
sg10
I4
sg11
VWNK1
p9193
sg13
I1
sa(dp9194
g7
I17
sg8
g18
sg10
I23
sg11
Vwith-no-lysine kinase 1
p9195
sg13
I3
sa(dp9196
g7
I69
sg8
g18
sg10
I5
sg11
VKLHL3
p9197
sg13
I1
sa(dp9198
g7
I49
sg8
g18
sg10
I4
sg11
VWNK4
p9199
sg13
I1
sa(dp9200
g7
I55
sg8
g18
sg10
I12
sg11
Vkelch-like 3
p9201
sg13
I2
sa(dp9202
g7
I90
sg8
g18
sg10
I4
sg11
VCUL3
p9203
sg13
I1
sa(dp9204
g7
I81
sg8
g18
sg10
I7
sg11
Vcullin3
p9205
sg13
I1
sasg20
(lp9206
(dp9207
g7
I144
sg23
VC0033805
p9208
sg10
I23
sg11
Vpseudohypoaldosteronism
p9209
sg13
I1
sa(dp9210
g7
I125
sg23
VC0019247
p9211
sg10
I18
sg11
Vhereditary disease
p9212
sg13
I2
sasa(dp9213
g2
S'Cullin-3 (CUL3) mutations (CUL3Delta9) were previously identified in hypertensive patients with pseudohypoaldosteronism type-II (PHAII), but the mechanism causing hypertension and whether this is driven by renal tubular or extratubular mechanisms remains unknown.\n'
p9214
sg4
(lp9215
(dp9216
g7
I10
sg8
g18
sg10
I4
sg11
VCUL3
p9217
sg13
I1
sa(dp9218
g7
I0
sg8
g18
sg10
I8
sg11
VCullin-3
p9219
sg13
I1
sasg20
(lp9220
(dp9221
g7
I163
sg23
VC0020538
p9222
sg10
I12
sg11
Vhypertension
p9223
sg13
I1
sa(dp9224
g7
I96
sg23
VC0033805
p9225
sg10
I23
sg11
Vpseudohypoaldosteronism
p9226
sg13
I1
sasa(dp9227
g2
S'Pseudohypoaldosteronism type II (PHAII) is a hereditary hypertensive disease caused by mutations in four different genes: with-no-lysine kinases (WNK) 1 and 4, Kelch-like family member 3 (KLHL3), and cullin 3 (Cul3).\n'
p9228
sg4
(lp9229
(dp9230
g7
I188
sg8
g18
sg10
I5
sg11
VKLHL3
p9231
sg13
I1
sa(dp9232
g7
I0
sg8
VP27037
p9233
sg10
I31
sg11
VPseudohypoaldosteronism type II
p9234
sg13
I3
sa(dp9235
g7
I200
sg8
g18
sg10
I8
sg11
Vcullin 3
p9236
sg13
I2
sa(dp9237
g7
I33
sg8
VP27037
p9238
sg10
I5
sg11
VPHAII
p9239
sg13
I1
sa(dp9240
g7
I210
sg8
g18
sg10
I4
sg11
VCul3
p9241
sg13
I1
sa(dp9242
g7
I127
sg8
VP20794
p9243
sg10
I31
sg11
Vno-lysine kinases (WNK) 1 and 4
p9244
sg13
I6
sa(dp9245
g7
I160
sg8
g18
sg10
I26
sg11
VKelch-like family member 3
p9246
sg13
I4
sasg20
(lp9247
(dp9248
g7
I56
sg23
VC0020538
p9249
sg10
I20
sg11
Vhypertensive disease
p9250
sg13
I2
sa(dp9251
g7
I0
sg23
VC0033805
p9252
sg10
I23
sg11
VPseudohypoaldosteronism
p9253
sg13
I1
sasa(dp9254
g2
S"Approved recombinant enzymes are also now used as therapy for myocardial infarction (alteplase, reteplase, and tenecteplase), cystic fibrosis (dornase alfa), chronic gout (pegloticase), tumor lysis syndrome (rasburicase), leukemia (L-asparaginase), some collagen-based disorders such as Dupuytren's contracture (collagenase), severe combined immunodeficiency disease (pegademase bovine), detoxification of methotrexate (glucarpidase), and vitreomacular adhesion (ocriplasmin).\n"
p9255
sg4
(lp9256
(dp9257
g7
I312
sg8
VP03956
p9258
sg10
I11
sg11
Vcollagenase
p9259
sg13
I1
sasg20
(lp9260
(dp9261
g7
I126
sg23
VC0010674
p9262
sg10
I15
sg11
Vcystic fibrosis
p9263
sg13
I2
sa(dp9264
g7
I439
sg23
VC2748203
p9265
sg10
I22
sg11
Vvitreomacular adhesion
p9266
sg13
I2
sa(dp9267
g7
I326
sg23
VC0085110
p9268
sg10
I40
sg11
Vsevere combined immunodeficiency disease
p9269
sg13
I4
sa(dp9270
g7
I222
sg23
VC0023418
p9271
sg10
I8
sg11
Vleukemia
p9272
sg13
I1
sa(dp9273
g7
I158
sg23
VC0268108
p9274
sg10
I12
sg11
Vchronic gout
p9275
sg13
I2
sa(dp9276
g7
I62
sg23
VC0027051
p9277
sg10
I21
sg11
Vmyocardial infarction
p9278
sg13
I2
sa(dp9279
g7
I186
sg23
VC0041364
p9280
sg10
I20
sg11
Vtumor lysis syndrome
p9281
sg13
I3
sa(dp9282
g7
I287
sg23
VC0013312
p9283
sg10
I23
sg11
VDupuytren's contracture
p9284
sg13
I2
sasa(dp9285
g2
S'These results suggested that the mechanical induction of uPA, tPA and uPAR upregulated PA activity, which may provide a proteolytic environment of extracellular matrix components and subsequently contribute to the cartilage degradation in TMJ osteoarthritis.\n'
p9286
sg4
(lp9287
(dp9288
g7
I57
sg8
VP00749
p9289
sg10
I3
sg11
VuPA
p9290
sg13
I1
sasg20
(lp9291
(dp9292
g7
I239
sg23
VC0039496
p9293
sg10
I3
sg11
VTMJ
p9294
sg13
I1
sa(dp9295
g7
I243
sg23
VC0029408
p9296
sg10
I14
sg11
Vosteoarthritis
p9297
sg13
I1
sasa(dp9298
g2
S'Plasma concentrations of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-Alfa), interleukin-10 (IL-10), N-terminal-proatrial natriuretic peptide (NT-proANP) and N-terminal-probrain natriuretic peptide (NT-proBNP) were assessed and echocardiographic measurements were performed in twenty-eight patients with atrial septal defect prior to, and at the first, second and sixth months post transcatheter closure.\n'
p9299
sg4
(lp9300
(dp9301
g7
I40
sg8
VP05231
p9302
sg10
I4
sg11
VIL-6
p9303
sg13
I1
sa(dp9304
g7
I76
sg8
VP01375
p9305
sg10
I8
sg11
VTNF-Alfa
p9306
sg13
I1
sa(dp9307
g7
I47
sg8
VP01375
p9308
sg10
I27
sg11
Vtumor necrosis factor-alpha
p9309
sg13
I3
sa(dp9310
g7
I103
sg8
VP22301
p9311
sg10
I5
sg11
VIL-10
p9312
sg13
I1
sa(dp9313
g7
I25
sg8
VP05231
p9314
sg10
I13
sg11
Vinterleukin-6
p9315
sg13
I1
sa(dp9316
g7
I87
sg8
VP22301
p9317
sg10
I14
sg11
Vinterleukin-10
p9318
sg13
I1
sasg20
(lp9319
(dp9320
g7
I47
sg23
VC0333516
p9321
sg10
I14
sg11
Vtumor necrosis
p9322
sg13
I2
sa(dp9323
g7
I314
sg23
VC0018817
p9324
sg10
I20
sg11
Vatrial septal defect
p9325
sg13
I3
sasa(dp9326
g2
S'SOCS3 was found significantly declined, while microRNA-221 (miR-221) obviously up-regulated in bladder cancer tissue.\n'
p9327
sg4
(lp9328
(dp9329
g7
I0
sg8
g18
sg10
I5
sg11
VSOCS3
p9330
sg13
I1
sasg20
(lp9331
(dp9332
g7
I95
sg23
VC0699885
p9333
sg10
I14
sg11
Vbladder cancer
p9334
sg13
I2
sasa(dp9335
g2
S'This study investigated the role of miR-221 in regulating SOCS3/JAK-STAT3 signaling pathway and bladder cancer cell proliferation and apoptosis.\n'
p9336
sg4
(lp9337
(dp9338
g7
I68
sg8
VP40763
p9339
sg10
I5
sg11
VSTAT3
p9340
sg13
I1
sa(dp9341
g7
I58
sg8
g18
sg10
I5
sg11
VSOCS3
p9342
sg13
I1
sa(dp9343
g7
I36
sg8
g18
sg10
I7
sg11
VmiR-221
p9344
sg13
I1
sasg20
(lp9345
(dp9346
g7
I96
sg23
VC0699885
p9347
sg10
I14
sg11
Vbladder cancer
p9348
sg13
I2
sa(dp9349
g7
I116
sg23
VC0334094
p9350
sg10
I13
sg11
Vproliferation
p9351
sg13
I1
sasa(dp9352
g2
S'Bladder cancer tumor tissue and para-carcinoma tissue were collected from patients to test miR-221 and SOCS3 expressions.\n'
p9353
sg4
(lp9354
(dp9355
g7
I91
sg8
g18
sg10
I7
sg11
VmiR-221
p9356
sg13
I1
sa(dp9357
g7
I103
sg8
g18
sg10
I5
sg11
VSOCS3
p9358
sg13
I1
sasg20
(lp9359
(dp9360
g7
I0
sg23
VC0699885
p9361
sg10
I14
sg11
VBladder cancer
p9362
sg13
I2
sa(dp9363
g7
I15
sg23
VC0027651
p9364
sg10
I5
sg11
Vtumor
p9365
sg13
I1
sa(dp9366
g7
I37
sg23
VC0007097
p9367
sg10
I9
sg11
Vcarcinoma
p9368
sg13
I1
sasa(dp9369
g2
S'MiR-221 significantly increased, while SOCS3 obviously reduced in bladder cancer tissue compared with para-carcinoma tissue.\n'
p9370
sg4
(lp9371
(dp9372
g7
I0
sg8
g18
sg10
I7
sg11
VMiR-221
p9373
sg13
I1
sa(dp9374
g7
I39
sg8
g18
sg10
I5
sg11
VSOCS3
p9375
sg13
I1
sasg20
(lp9376
(dp9377
g7
I107
sg23
VC0007097
p9378
sg10
I9
sg11
Vcarcinoma
p9379
sg13
I1
sa(dp9380
g7
I66
sg23
VC0699885
p9381
sg10
I14
sg11
Vbladder cancer
p9382
sg13
I2
sasa(dp9383
g2
S'MiR-221 elevated, while SOCS3 reduced in bladder cancer tissue.\n'
p9384
sg4
(lp9385
(dp9386
g7
I0
sg8
g18
sg10
I29
sg11
VMiR-221 elevated, while SOCS3
p9387
sg13
I4
sasg20
(lp9388
(dp9389
g7
I41
sg23
VC0699885
p9390
sg10
I14
sg11
Vbladder cancer
p9391
sg13
I2
sasa(dp9392
g2
S'In this study, we investigated the role of miR-221 in the development and progression of clear cell renal cell carcinoma (ccRCC).\n'
p9393
sg4
(lp9394
sg20
(lp9395
(dp9396
g7
I122
sg23
VC0279702
p9397
sg10
I5
sg11
VccRCC
p9398
sg13
I1
sa(dp9399
g7
I89
sg23
VC0279702
p9400
sg10
I31
sg11
Vclear cell renal cell carcinoma
p9401
sg13
I5
sasa(dp9402
g2
S'Then, we investigated the role of miR-221 to determine its potential roles on renal cancer cell proliferation, migration and invasion in vitro.\n'
p9403
sg4
(lp9404
sg20
(lp9405
(dp9406
g7
I125
sg23
VC2699153
p9407
sg10
I8
sg11
Vinvasion
p9408
sg13
I1
sa(dp9409
g7
I78
sg23
VC0740457
p9410
sg10
I12
sg11
Vrenal cancer
p9411
sg13
I2
sa(dp9412
g7
I96
sg23
VC0334094
p9413
sg10
I13
sg11
Vproliferation
p9414
sg13
I1
sasa(dp9415
g2
S'A luciferase reporter assay was conducted to confirm the target gene of miR-221 and the results were validated in renal cancer cells.\n'
p9416
sg4
(lp9417
(dp9418
g7
I72
sg8
g18
sg10
I7
sg11
VmiR-221
p9419
sg13
I1
sasg20
(lp9420
(dp9421
g7
I114
sg23
VC0740457
p9422
sg10
I12
sg11
Vrenal cancer
p9423
sg13
I2
sasa(dp9424
g2
S'Knocked-down expression of miR-221 remarkably inhibited cell proliferation, migration and invasion of renal cancer cells.\n'
p9425
sg4
(lp9426
(dp9427
g7
I27
sg8
g18
sg10
I7
sg11
VmiR-221
p9428
sg13
I1
sasg20
(lp9429
(dp9430
g7
I102
sg23
VC0740457
p9431
sg10
I12
sg11
Vrenal cancer
p9432
sg13
I2
sa(dp9433
g7
I61
sg23
VC0334094
p9434
sg10
I13
sg11
Vproliferation
p9435
sg13
I1
sa(dp9436
g7
I90
sg23
VC2699153
p9437
sg10
I8
sg11
Vinvasion
p9438
sg13
I1
sasa(dp9439
g2
S'These findings suggested that miR-221 play an oncogenic role in the renal cancer cell proliferation, migration and invasion by directly inhibiting the tumor suppressor TIMP2, indicating miR-221 act as a potential new therapeutic target for the treatment of ccRCC.\n'
p9440
sg4
(lp9441
(dp9442
g7
I168
sg8
VP16035
p9443
sg10
I5
sg11
VTIMP2
p9444
sg13
I1
sasg20
(lp9445
(dp9446
g7
I86
sg23
VC0334094
p9447
sg10
I13
sg11
Vproliferation
p9448
sg13
I1
sa(dp9449
g7
I68
sg23
VC0740457
p9450
sg10
I12
sg11
Vrenal cancer
p9451
sg13
I2
sa(dp9452
g7
I115
sg23
VC2699153
p9453
sg10
I8
sg11
Vinvasion
p9454
sg13
I1
sa(dp9455
g7
I151
sg23
VC0027651
p9456
sg10
I5
sg11
Vtumor
p9457
sg13
I1
sasa(dp9458
g2
S'miR-221, as oncogenes in several human cancers, was significantly up-regulated in bladder cancers.\n'
p9459
sg4
(lp9460
(dp9461
g7
I0
sg8
g18
sg10
I7
sg11
VmiR-221
p9462
sg13
I1
sasg20
(lp9463
(dp9464
g7
I82
sg23
VC0005684
p9465
sg10
I15
sg11
Vbladder cancers
p9466
sg13
I2
sa(dp9467
g7
I39
sg23
VC0006826
p9468
sg10
I7
sg11
Vcancers
p9469
sg13
I1
sasa(dp9470
g2
S'However, the role of miR-221 in the progression of bladder cancer metastasis remains largely unknown.\n'
p9471
sg4
(lp9472
(dp9473
g7
I21
sg8
g18
sg10
I7
sg11
VmiR-221
p9474
sg13
I1
sasg20
(lp9475
(dp9476
g7
I51
sg23
VC0699885
p9477
sg10
I14
sg11
Vbladder cancer
p9478
sg13
I2
sa(dp9479
g7
I66
sg23
VC0027627
p9480
sg10
I10
sg11
Vmetastasis
p9481
sg13
I1
sasa(dp9482
g2
S'We used qRT-PCR and western blot to accurately measure the levels of miR-221, STMN1 and EMT markers in TGFBeta1 induced EMT of bladder cancer cells.\n'
p9483
sg4
(lp9484
(dp9485
g7
I103
sg8
VP01137
p9486
sg10
I8
sg11
VTGFBeta1
p9487
sg13
I1
sa(dp9488
g7
I88
sg8
g18
sg10
I3
sg11
VEMT
p9489
sg13
I1
sa(dp9490
g7
I88
sg8
g18
sg10
I3
sg11
VEMT
p9491
sg13
I1
sa(dp9492
g7
I78
sg8
VP16949
p9493
sg10
I5
sg11
VSTMN1
p9494
sg13
I1
sa(dp9495
g7
I69
sg8
g18
sg10
I7
sg11
VmiR-221
p9496
sg13
I1
sasg20
(lp9497
(dp9498
g7
I127
sg23
VC0699885
p9499
sg10
I14
sg11
Vbladder cancer
p9500
sg13
I2
sasa(dp9501
g2
S'miR-221 inhibitors were re-introduced into bladder cancer cells to investigate its role on tumor metastasis which was measured by MTT, wound healing, transwell invasion and adherent assays.\n'
p9502
sg4
(lp9503
sg20
(lp9504
(dp9505
g7
I43
sg23
VC0699885
p9506
sg10
I14
sg11
Vbladder cancer
p9507
sg13
I2
sa(dp9508
g7
I91
sg23
VC0027627
p9509
sg10
I16
sg11
Vtumor metastasis
p9510
sg13
I2
sa(dp9511
g7
I160
sg23
VC2699153
p9512
sg10
I8
sg11
Vinvasion
p9513
sg13
I1
sasa(dp9514
g2
S'miR-221 expression was greatly increased by TGFBeta1 in bladder cancer cell.\n'
p9515
sg4
(lp9516
(dp9517
g7
I44
sg8
VP01137
p9518
sg10
I8
sg11
VTGFBeta1
p9519
sg13
I1
sasg20
(lp9520
(dp9521
g7
I56
sg23
VC0699885
p9522
sg10
I14
sg11
Vbladder cancer
p9523
sg13
I2
sasa(dp9524
g2
S'Furthermore, miR-221 expression is positively correlated with malignant potential of bladder cancer cell through promoting loss of cell adhesion and prometastatic behavior.\n'
p9525
sg4
(lp9526
sg20
(lp9527
(dp9528
g7
I85
sg23
VC0699885
p9529
sg10
I14
sg11
Vbladder cancer
p9530
sg13
I2
sa(dp9531
g7
I136
sg23
VC0001511
p9532
sg10
I8
sg11
Vadhesion
p9533
sg13
I1
sasa(dp9534
g2
S'Our study demonstrated that miR-221 facilitated TGFBeta1-induced EMT in human bladder cancer cells by targeting STMN1 and represented a promising therapeutic target in the process of metastasis.\n'
p9535
sg4
(lp9536
(dp9537
g7
I48
sg8
VP01137
p9538
sg10
I8
sg11
VTGFBeta1
p9539
sg13
I1
sa(dp9540
g7
I28
sg8
g18
sg10
I7
sg11
VmiR-221
p9541
sg13
I1
sa(dp9542
g7
I65
sg8
g18
sg10
I3
sg11
VEMT
p9543
sg13
I1
sa(dp9544
g7
I112
sg8
VP16949
p9545
sg10
I5
sg11
VSTMN1
p9546
sg13
I1
sasg20
(lp9547
(dp9548
g7
I183
sg23
VC0027627
p9549
sg10
I10
sg11
Vmetastasis
p9550
sg13
I1
sa(dp9551
g7
I78
sg23
VC0699885
p9552
sg10
I14
sg11
Vbladder cancer
p9553
sg13
I2
sasa(dp9554
g2
S'to study the expression of epidermal growth factor receptor (EGFR) in patients with seborrheic keratomas (SK) and insulin resistance (type 2 diabetes mellitus (DM2)) and in those without concomitant carbohydrate metabolic disturbances.\n'
p9555
sg4
(lp9556
(dp9557
g7
I27
sg8
VP01133
p9558
sg10
I32
sg11
Vepidermal growth factor receptor
p9559
sg13
I4
sa(dp9560
g7
I114
sg8
VP01308
p9561
sg10
I7
sg11
Vinsulin
p9562
sg13
I1
sasg20
(lp9563
(dp9564
g7
I160
sg23
VC2931689
p9565
sg10
I3
sg11
VDM2
p9566
sg13
I1
sa(dp9567
g7
I95
sg23
VC0086501
p9568
sg10
I9
sg11
Vkeratomas
p9569
sg13
I1
sa(dp9570
g7
I134
sg23
VC0011860
p9571
sg10
I24
sg11
Vtype 2 diabetes mellitus
p9572
sg13
I4
sa(dp9573
g7
I114
sg23
VC0021655
p9574
sg10
I18
sg11
Vinsulin resistance
p9575
sg13
I2
sasa(dp9576
g2
S'The increased EGFR expression revealed in patients with SK and concomitant DM2 is caused by insulin resistance and hyperinsulinemia, in which the dysregulation of insulin signal transmission into the cell leads to changes in EGF synthesis and signaling pathway that regulates cell proliferation and growth.\n'
p9577
sg4
(lp9578
(dp9579
g7
I92
sg8
VP01308
p9580
sg10
I7
sg11
Vinsulin
p9581
sg13
I1
sa(dp9582
g7
I14
sg8
VP01133
p9583
sg10
I3
sg11
VEGF
p9584
sg13
I1
sa(dp9585
g7
I92
sg8
VP01308
p9586
sg10
I7
sg11
Vinsulin
p9587
sg13
I1
sasg20
(lp9588
(dp9589
g7
I281
sg23
VC0334094
p9590
sg10
I13
sg11
Vproliferation
p9591
sg13
I1
sa(dp9592
g7
I92
sg23
VC0021655
p9593
sg10
I18
sg11
Vinsulin resistance
p9594
sg13
I2
sa(dp9595
g7
I75
sg23
VC2931689
p9596
sg10
I3
sg11
VDM2
p9597
sg13
I1
sa(dp9598
g7
I115
sg23
VC0020459
p9599
sg10
I16
sg11
Vhyperinsulinemia
p9600
sg13
I1
sasa(dp9601
g2
S'When obesity was eliminated, there was a significantly higher levels for EGF, IL-8, MCP1 and TNFAlfa and lower levels for IL-1Alfa and IL-3 in the postmenopausal group (p&lt;0.05).\n'
p9602
sg4
(lp9603
(dp9604
g7
I84
sg8
VP13500
p9605
sg10
I4
sg11
VMCP1
p9606
sg13
I1
sa(dp9607
g7
I73
sg8
VP01133
p9608
sg10
I3
sg11
VEGF
p9609
sg13
I1
sa(dp9610
g7
I135
sg8
VP08700
p9611
sg10
I4
sg11
VIL-3
p9612
sg13
I1
sasg20
(lp9613
(dp9614
g7
I5
sg23
VC0028754
p9615
sg10
I7
sg11
Vobesity
p9616
sg13
I1
sasa(dp9617
g2
S'The patient had a family history of hyperuricemia and stage IV CKD; both the patient and her affected family members had a novel mutation in the UMOD gene: c.C518G (p.P173R), located between the EGF-like domains and D8C.\n'
p9618
sg4
(lp9619
(dp9620
g7
I195
sg8
VP01133
p9621
sg10
I16
sg11
VEGF-like domains
p9622
sg13
I2
sa(dp9623
g7
I145
sg8
VP07911
p9624
sg10
I9
sg11
VUMOD gene
p9625
sg13
I2
sasg20
(lp9626
(dp9627
g7
I36
sg23
VC0740394
p9628
sg10
I13
sg11
Vhyperuricemia
p9629
sg13
I1
sa(dp9630
g7
I123
sg23
VC2985438
p9631
sg10
I14
sg11
Vnovel mutation
p9632
sg13
I2
sasa(dp9633
g2
S'To study the expression of cadherin17(CDH17) in metanephric adenoma (MA), and to explore the value of CDH17 in the diagnosis of metanephric adenoma.\n'
p9634
sg4
(lp9635
(dp9636
g7
I38
sg8
g18
sg10
I5
sg11
VCDH17
p9637
sg13
I1
sa(dp9638
g7
I38
sg8
g18
sg10
I5
sg11
VCDH17
p9639
sg13
I1
sasg20
(lp9640
(dp9641
g7
I69
sg23
VC1266045
p9642
sg10
I2
sg11
VMA
p9643
sg13
I1
sa(dp9644
g7
I48
sg23
VC1266045
p9645
sg10
I19
sg11
Vmetanephric adenoma
p9646
sg13
I2
sa(dp9647
g7
I48
sg23
VC1266045
p9648
sg10
I19
sg11
Vmetanephric adenoma
p9649
sg13
I2
sasa(dp9650
g2
S'The expression of CDH17 was also examined in other common renal epithelial tumors, including 10 cases of clear cell renal cell carcinomas (CCRCC), 10 chromophobe renal cell carcinomas (CHRCC), and 10 oncocytomas.\n'
p9651
sg4
(lp9652
(dp9653
g7
I18
sg8
g18
sg10
I5
sg11
VCDH17
p9654
sg13
I1
sasg20
(lp9655
(dp9656
g7
I116
sg23
VC0007134
p9657
sg10
I21
sg11
Vrenal cell carcinomas
p9658
sg13
I3
sa(dp9659
g7
I64
sg23
VC1368683
p9660
sg10
I17
sg11
Vepithelial tumors
p9661
sg13
I2
sa(dp9662
g7
I200
sg23
VC0949541
p9663
sg10
I11
sg11
Voncocytomas
p9664
sg13
I1
sa(dp9665
g7
I116
sg23
VC0007134
p9666
sg10
I21
sg11
Vrenal cell carcinomas
p9667
sg13
I3
sasa(dp9668
g2
S'CDH17 was negative in all cases of CCRCC, CHRCC and oncocytoma.\n'
p9669
sg4
(lp9670
(dp9671
g7
I0
sg8
g18
sg10
I5
sg11
VCDH17
p9672
sg13
I1
sasg20
(lp9673
(dp9674
g7
I52
sg23
VC0949541
p9675
sg10
I10
sg11
Voncocytoma
p9676
sg13
I1
sasa(dp9677
g2
S'Ksp-cadherin showed positive staining in 100% (7/7) of chromophobe RCCs and 33% (4/12) of oncocytomas.\n'
p9678
sg4
(lp9679
(dp9680
g7
I0
sg8
g18
sg10
I12
sg11
VKsp-cadherin
p9681
sg13
I1
sasg20
(lp9682
(dp9683
g7
I90
sg23
VC0949541
p9684
sg10
I11
sg11
Voncocytomas
p9685
sg13
I1
sa(dp9686
g7
I67
sg23
VC0007134
p9687
sg10
I4
sg11
VRCCs
p9688
sg13
I1
sasa(dp9689
g2
S'Here, we report a comprehensive analysis of sE-cadherin levels in sera from patients with CRC, colorectal adenoma, inflammatory bowel disease and familial adenomatous polyposis (FAP).\n'
p9690
sg4
(lp9691
(dp9692
g7
I44
sg8
g18
sg10
I11
sg11
VsE-cadherin
p9693
sg13
I1
sasg20
(lp9694
(dp9695
g7
I95
sg23
VC1302401
p9696
sg10
I18
sg11
Vcolorectal adenoma
p9697
sg13
I2
sa(dp9698
g7
I90
sg23
VC1527249
p9699
sg10
I3
sg11
VCRC
p9700
sg13
I1
sa(dp9701
g7
I146
sg23
VC0032580
p9702
sg10
I30
sg11
Vfamilial adenomatous polyposis
p9703
sg13
I3
sa(dp9704
g7
I178
sg23
VC0032580
p9705
sg10
I3
sg11
VFAP
p9706
sg13
I1
sa(dp9707
g7
I115
sg23
VC0021390
p9708
sg10
I26
sg11
Vinflammatory bowel disease
p9709
sg13
I3
sasa(dp9710
g2
S'In the present study, the expression of BNIP3 in pancreatic cancer tissues, the correlation with clinicopathological characteristics and prognosis and the regulation of this protein in pancreatic cancer cell lines with regard to the induction of apoptosis were investigated.\n'
p9711
sg4
(lp9712
(dp9713
g7
I40
sg8
g18
sg10
I5
sg11
VBNIP3
p9714
sg13
I1
sasg20
(lp9715
(dp9716
g7
I49
sg23
VC0235974
p9717
sg10
I17
sg11
Vpancreatic cancer
p9718
sg13
I2
sa(dp9719
g7
I49
sg23
VC0235974
p9720
sg10
I17
sg11
Vpancreatic cancer
p9721
sg13
I2
sasa(dp9722
g2
S'BNIP3 expression was significantly lower in pancreatic cancer tissues compared with normal epithelia and was associated with tumor size, clinical stage, and lymph node metastasis.\n'
p9723
sg4
(lp9724
(dp9725
g7
I0
sg8
g18
sg10
I5
sg11
VBNIP3
p9726
sg13
I1
sasg20
(lp9727
(dp9728
g7
I44
sg23
VC0235974
p9729
sg10
I17
sg11
Vpancreatic cancer
p9730
sg13
I2
sa(dp9731
g7
I157
sg23
VC0686619
p9732
sg10
I21
sg11
Vlymph node metastasis
p9733
sg13
I3
sa(dp9734
g7
I125
sg23
VC0027651
p9735
sg10
I5
sg11
Vtumor
p9736
sg13
I1
sasa(dp9737
g2
S'The restoration of BNIP3 expression in pancreatic cancer cells in vitro, caused loss of DeltaPsim, increase in ROS production, and apoptosis induction.\n'
p9738
sg4
(lp9739
(dp9740
g7
I19
sg8
g18
sg10
I5
sg11
VBNIP3
p9741
sg13
I1
sasg20
(lp9742
(dp9743
g7
I39
sg23
VC0235974
p9744
sg10
I17
sg11
Vpancreatic cancer
p9745
sg13
I2
sasa(dp9746
g2
S'The opposite effect was observed in pancreatic cancer cells, following BNIP3 silencing by RNAi.\n'
p9747
sg4
(lp9748
(dp9749
g7
I71
sg8
g18
sg10
I15
sg11
VBNIP3 silencing
p9750
sg13
I2
sasg20
(lp9751
(dp9752
g7
I36
sg23
VC0235974
p9753
sg10
I17
sg11
Vpancreatic cancer
p9754
sg13
I2
sasa(dp9755
g2
S"The absence of BNIP3 expression in pancreatic cancer cells was related to gene methylation that suppressed binding of HIF-1Alfa to the BNIP3 promoter, whereas 5-Aza-2'-deoxycytidine (Aza-dC) treatment restored BNIP3 expression and sensitized pancreatic cancer cells to BNIP3-induced apoptosis.\n"
p9756
sg4
(lp9757
(dp9758
g7
I15
sg8
g18
sg10
I5
sg11
VBNIP3
p9759
sg13
I1
sa(dp9760
g7
I15
sg8
g18
sg10
I5
sg11
VBNIP3
p9761
sg13
I1
sa(dp9762
g7
I15
sg8
g18
sg10
I5
sg11
VBNIP3
p9763
sg13
I1
sa(dp9764
g7
I135
sg8
g18
sg10
I14
sg11
VBNIP3 promoter
p9765
sg13
I2
sasg20
(lp9766
(dp9767
g7
I35
sg23
VC0235974
p9768
sg10
I17
sg11
Vpancreatic cancer
p9769
sg13
I2
sa(dp9770
g7
I35
sg23
VC0235974
p9771
sg10
I17
sg11
Vpancreatic cancer
p9772
sg13
I2
sasa(dp9773
g2
S'The findings indicated that BNIP3 was significantly downregulated in pancreatic cancer resulting in reduced apoptosis induction.\n'
p9774
sg4
(lp9775
(dp9776
g7
I28
sg8
g18
sg10
I5
sg11
VBNIP3
p9777
sg13
I1
sasg20
(lp9778
(dp9779
g7
I69
sg23
VC0235974
p9780
sg10
I17
sg11
Vpancreatic cancer
p9781
sg13
I2
sasa(dp9782
g2
S'The data suggest that BNIP3 reactivation is a potential target for therapeutic intervention against pancreatic cancer.\n'
p9783
sg4
(lp9784
(dp9785
g7
I22
sg8
g18
sg10
I5
sg11
VBNIP3
p9786
sg13
I1
sasg20
(lp9787
(dp9788
g7
I100
sg23
VC0235974
p9789
sg10
I17
sg11
Vpancreatic cancer
p9790
sg13
I2
sasa(dp9791
g2
S'This study aimed to investigate the expression and implications of the major autophagy-related molecules light chain (LC) 3A, LC3B, p62, and BNIP-3 in human thyroid carcinoma.\n'
p9792
sg4
(lp9793
(dp9794
g7
I77
sg8
g18
sg10
I47
sg11
Vautophagy-related molecules light chain (LC) 3A
p9795
sg13
I6
sa(dp9796
g7
I126
sg8
g18
sg10
I4
sg11
VLC3B
p9797
sg13
I1
sa(dp9798
g7
I141
sg8
g18
sg10
I6
sg11
VBNIP-3
p9799
sg13
I1
sa(dp9800
g7
I132
sg8
VP37198
p9801
sg10
I3
sg11
Vp62
p9802
sg13
I1
sasg20
(lp9803
(dp9804
g7
I157
sg23
VC0549473
p9805
sg10
I17
sg11
Vthyroid carcinoma
p9806
sg13
I2
sasa(dp9807
g2
S'Apoptosis, but not autophagy, that is induced via p21-activated BNIP3 expression accounts for the efficacy of ICMT inhibition in sensitive pancreatic cancer cells in both in vitro and in vivo models.\n'
p9808
sg4
(lp9809
(dp9810
g7
I64
sg8
g18
sg10
I5
sg11
VBNIP3
p9811
sg13
I1
sa(dp9812
g7
I50
sg8
VP42857
p9813
sg10
I3
sg11
Vp21
p9814
sg13
I1
sasg20
(lp9815
(dp9816
g7
I139
sg23
VC0235974
p9817
sg10
I17
sg11
Vpancreatic cancer
p9818
sg13
I2
sasa(dp9819
g2
S'Using a yeast two-hybrid screening approach, based on a thyroid cancer patients library, we showed that CDH6 directly interacts with GABARAP, BNIP3 and BNIP3L, and that through these interactions CDH6 restrains autophagy and promotes re-organization of mitochondrial network through a DRP1-mediated mechanism.\n'
p9820
sg4
(lp9821
(dp9822
g7
I152
sg8
g18
sg10
I6
sg11
VBNIP3L
p9823
sg13
I1
sa(dp9824
g7
I104
sg8
VP55285
p9825
sg10
I4
sg11
VCDH6
p9826
sg13
I1
sa(dp9827
g7
I285
sg8
VP46939
p9828
sg10
I4
sg11
VDRP1
p9829
sg13
I1
sa(dp9830
g7
I104
sg8
VP55285
p9831
sg10
I4
sg11
VCDH6
p9832
sg13
I1
sa(dp9833
g7
I133
sg8
g18
sg10
I7
sg11
VGABARAP
p9834
sg13
I1
sa(dp9835
g7
I142
sg8
g18
sg10
I5
sg11
VBNIP3
p9836
sg13
I1
sasg20
(lp9837
(dp9838
g7
I56
sg23
VC0007115
p9839
sg10
I14
sg11
Vthyroid cancer
p9840
sg13
I2
sasa(dp9841
g2
S'Furthermore, overexpression of miR-148b and -152 in pancreatic cancer cell lines (MIA PaCa-2 and AsPC-1) decreased DNMT-1 expression (53% and 59% respectively), returned DNA methylation to normal patterns and induced re-expression of tumor suppressor genes, like BNIP3 (4.7- and 3.8-fold) and SPARC (5.3- and 2.9-fold) for miR-148b and -152 respectively.\n'
p9842
sg4
(lp9843
(dp9844
g7
I31
sg8
g18
sg10
I8
sg11
VmiR-148b
p9845
sg13
I1
sa(dp9846
g7
I82
sg8
g18
sg10
I10
sg11
VMIA PaCa-2
p9847
sg13
I2
sa(dp9848
g7
I293
sg8
VP09486
p9849
sg10
I5
sg11
VSPARC
p9850
sg13
I1
sa(dp9851
g7
I115
sg8
VP26358
p9852
sg10
I6
sg11
VDNMT-1
p9853
sg13
I1
sa(dp9854
g7
I263
sg8
g18
sg10
I25
sg11
VBNIP3 (4.7- and 3.8-fold)
p9855
sg13
I4
sa(dp9856
g7
I31
sg8
g18
sg10
I8
sg11
VmiR-148b
p9857
sg13
I1
sasg20
(lp9858
(dp9859
g7
I234
sg23
VC0027651
p9860
sg10
I5
sg11
Vtumor
p9861
sg13
I1
sa(dp9862
g7
I52
sg23
VC0235974
p9863
sg10
I17
sg11
Vpancreatic cancer
p9864
sg13
I2
sa(dp9865
g7
I86
sg23
VC1836780
p9866
sg10
I4
sg11
VPaCa
p9867
sg13
I1
sasa(dp9868
g2
S'Conclusively these findings mean that miRs that are targeting DNMT-1 and modifying methylation status of tumor suppressor genes such as BNIP3 and SPARC can be applied in killing the pancreatic cancer cells and decreasing the tumorigenicity of these cells.\n'
p9869
sg4
(lp9870
(dp9871
g7
I146
sg8
VP09486
p9872
sg10
I5
sg11
VSPARC
p9873
sg13
I1
sa(dp9874
g7
I62
sg8
VP26358
p9875
sg10
I6
sg11
VDNMT-1
p9876
sg13
I1
sa(dp9877
g7
I136
sg8
g18
sg10
I5
sg11
VBNIP3
p9878
sg13
I1
sasg20
(lp9879
(dp9880
g7
I182
sg23
VC0235974
p9881
sg10
I17
sg11
Vpancreatic cancer
p9882
sg13
I2
sa(dp9883
g7
I225
sg23
VC1519697
p9884
sg10
I14
sg11
Vtumorigenicity
p9885
sg13
I1
sa(dp9886
g7
I105
sg23
VC0027651
p9887
sg10
I5
sg11
Vtumor
p9888
sg13
I1
sasa(dp9889
g2
S'The combination of gossypol and BRD4770 increased LC3-II levels and the autophagosome number in PANC-1 cells, and the compound combination appears to act in a BNIP3 (B-cell lymphoma 2 19-kDa interacting protein)-dependent manner, suggesting that these compounds act together to induce autophagy-related cell death in pancreatic cancer cells.\n'
p9890
sg4
(lp9891
(dp9892
g7
I50
sg8
g18
sg10
I6
sg11
VLC3-II
p9893
sg13
I1
sasg20
(lp9894
(dp9895
g7
I166
sg23
VC0079731
p9896
sg10
I15
sg11
VB-cell lymphoma
p9897
sg13
I2
sa(dp9898
g7
I317
sg23
VC0235974
p9899
sg10
I17
sg11
Vpancreatic cancer
p9900
sg13
I2
sasa(dp9901
g2
S'Only HS-18, a liposarcoma cell line, lacked expression of the retinoblastoma protein.\n'
p9902
sg4
(lp9903
(dp9904
g7
I62
sg8
g18
sg10
I22
sg11
Vretinoblastoma protein
p9905
sg13
I2
sasg20
(lp9906
(dp9907
g7
I14
sg23
VC0023827
p9908
sg10
I11
sg11
Vliposarcoma
p9909
sg13
I1
sa(dp9910
g7
I62
sg23
VC0035335
p9911
sg10
I14
sg11
Vretinoblastoma
p9912
sg13
I1
sasa(dp9913
g2
S'Growth inhibition assays indicated that the IC50 values for methotrexate (MTX) and 5-fluorodeoxyuridine (FdUrd) in HS-18, a liposarcoma cell line lacking retinoblastoma protein (pRB), and SaOS-2, an osteosarcoma cell line with a truncated and nonfunctional pRB, were 10- to 12-fold and 4- to 11-fold higher, respectively, than for the HT-1080 (fibrosarcoma) cell line, which has wild-type pRB.\n'
p9914
sg4
(lp9915
(dp9916
g7
I154
sg8
g18
sg10
I22
sg11
Vretinoblastoma protein
p9917
sg13
I2
sa(dp9918
g7
I178
sg8
g18
sg10
I3
sg11
VpRB
p9919
sg13
I1
sa(dp9920
g7
I178
sg8
g18
sg10
I3
sg11
VpRB
p9921
sg13
I1
sa(dp9922
g7
I178
sg8
g18
sg10
I3
sg11
VpRB
p9923
sg13
I1
sasg20
(lp9924
(dp9925
g7
I124
sg23
VC0023827
p9926
sg10
I11
sg11
Vliposarcoma
p9927
sg13
I1
sa(dp9928
g7
I154
sg23
VC0035335
p9929
sg10
I14
sg11
Vretinoblastoma
p9930
sg13
I1
sa(dp9931
g7
I344
sg23
VC0016057
p9932
sg10
I12
sg11
Vfibrosarcoma
p9933
sg13
I1
sa(dp9934
g7
I199
sg23
VC0029463
p9935
sg10
I12
sg11
Vosteosarcoma
p9936
sg13
I1
sasa(dp9937
g2
S'Failure to consider the diagnosis of secondary achalasia can lead to multiple fruitless attempts at dilatation or even inappropriate reoperations.\n'
p9938
sg4
(lp9939
sg20
(lp9940
(dp9941
g7
I100
sg23
VC0012359
p9942
sg10
I10
sg11
Vdilatation
p9943
sg13
I1
sa(dp9944
g7
I47
sg23
VC0014848
p9945
sg10
I9
sg11
Vachalasia
p9946
sg13
I1
sasa(dp9947
g2
S'Sixteen patients with stroke for more than 3 mos were randomly assigned into the experimental and control groups.\n'
p9948
sg4
(lp9949
sg20
(lp9950
(dp9951
g7
I45
sg23
VC0026987
p9952
sg10
I3
sg11
Vmos
p9953
sg13
I1
sa(dp9954
g7
I22
sg23
VC0038454
p9955
sg10
I6
sg11
Vstroke
p9956
sg13
I1
sasa(dp9957
g2
S'This cross-sectional-designed study enrolled 145 stroke patients at three different stroke duration periods (&lt;=3 mos, 3 mos to 1 yr, and &gt;1 yr) receiving inpatient or outpatient rehabilitation programs in a regional teaching hospital.\n'
p9958
sg4
(lp9959
sg20
(lp9960
(dp9961
g7
I116
sg23
VC0026987
p9962
sg10
I3
sg11
Vmos
p9963
sg13
I1
sa(dp9964
g7
I49
sg23
VC0038454
p9965
sg10
I6
sg11
Vstroke
p9966
sg13
I1
sa(dp9967
g7
I49
sg23
VC0038454
p9968
sg10
I6
sg11
Vstroke
p9969
sg13
I1
sa(dp9970
g7
I116
sg23
VC0026987
p9971
sg10
I3
sg11
Vmos
p9972
sg13
I1
sasa(dp9973
g2
S'The patients with stroke duration within 3 mos had the highest spontaneous muscle pain intensity and were most sensitive to pressure pain, with a prevalence of 48.3% of moderate to severe pain intensity (verbally reported numerical rating scale, 4-10) in the hemiparetic side.\n'
p9974
sg4
(lp9975
sg20
(lp9976
(dp9977
g7
I18
sg23
VC0038454
p9978
sg10
I6
sg11
Vstroke
p9979
sg13
I1
sa(dp9980
g7
I181
sg23
VC0278140
p9981
sg10
I11
sg11
Vsevere pain
p9982
sg13
I2
sa(dp9983
g7
I43
sg23
VC0026987
p9984
sg10
I3
sg11
Vmos
p9985
sg13
I1
sa(dp9986
g7
I75
sg23
VC0231528
p9987
sg10
I11
sg11
Vmuscle pain
p9988
sg13
I2
sasa(dp9989
g2
S'The aim of the present study was to analyze the effects of whole-body vibration on lower limb muscle architecture, muscle strength, and balance in stroke patients during a period of 3 mos.\n'
p9990
sg4
(lp9991
sg20
(lp9992
(dp9993
g7
I147
sg23
VC0038454
p9994
sg10
I6
sg11
Vstroke
p9995
sg13
I1
sa(dp9996
g7
I184
sg23
VC0026987
p9997
sg10
I3
sg11
Vmos
p9998
sg13
I1
sasa(dp9999
g2
S'Correlation and linear regression analyses of pretreatment and end-of-treatment Fugl-Meyer scores and modified Emory Functional Ambulation Profile scores from hemiparetic subjects (n = 108, &gt;3 mos post stroke) who participated in a randomized controlled trial comparing two 12-wk ambulation training treatments were generated.\n'
p10000
sg4
(lp10001
sg20
(lp10002
(dp10003
g7
I205
sg23
VC0038454
p10004
sg10
I6
sg11
Vstroke
p10005
sg13
I1
sa(dp10006
g7
I196
sg23
VC0026987
p10007
sg10
I3
sg11
Vmos
p10008
sg13
I1
sasa(dp10009
g2
S'Further, EGFL7 became upregulated in vessels of the stroke penumbra using a mouse model of reversible middle cerebral artery occlusion.\n'
p10010
sg4
(lp10011
(dp10012
g7
I9
sg8
g18
sg10
I5
sg11
VEGFL7
p10013
sg13
I1
sasg20
(lp10014
(dp10015
g7
I102
sg23
VC0740391
p10016
sg10
I32
sg11
Vmiddle cerebral artery occlusion
p10017
sg13
I4
sa(dp10018
g7
I52
sg23
VC0038454
p10019
sg10
I6
sg11
Vstroke
p10020
sg13
I1
sasa(dp10021
g2
S'Our previous research provided evidence of periostin increase in parallel with interleukin-13 (IL13) increase in the synovial fluid of patients with osteoarthritis (OA).\n'
p10022
sg4
(lp10023
(dp10024
g7
I95
sg8
VP35225
p10025
sg10
I4
sg11
VIL13
p10026
sg13
I1
sa(dp10027
g7
I79
sg8
VP35225
p10028
sg10
I14
sg11
Vinterleukin-13
p10029
sg13
I1
sasg20
(lp10030
(dp10031
g7
I165
sg23
VC0029408
p10032
sg10
I2
sg11
VOA
p10033
sg13
I1
sa(dp10034
g7
I149
sg23
VC0029408
p10035
sg10
I14
sg11
Vosteoarthritis
p10036
sg13
I1
sasa(dp10037
g2
S'Recent studies indicated that periostin is involved in the pathogenesis and progression of knee osteoarthritis (OA).\n'
p10038
sg4
(lp10039
sg20
(lp10040
(dp10041
g7
I91
sg23
VC0409959
p10042
sg10
I19
sg11
Vknee osteoarthritis
p10043
sg13
I2
sa(dp10044
g7
I59
sg23
VC0699748
p10045
sg10
I12
sg11
Vpathogenesis
p10046
sg13
I1
sasa(dp10047
g2
S'We investigated the role of periostin, an extracellular matrix protein, in the pathophysiology of osteoarthritis (OA).\n'
p10048
sg4
(lp10049
(dp10050
g7
I42
sg8
VP55082
p10051
sg10
I28
sg11
Vextracellular matrix protein
p10052
sg13
I3
sasg20
(lp10053
(dp10054
g7
I98
sg23
VC0029408
p10055
sg10
I14
sg11
Vosteoarthritis
p10056
sg13
I1
sa(dp10057
g7
I114
sg23
VC0029408
p10058
sg10
I2
sg11
VOA
p10059
sg13
I1
sasa(dp10060
g2
S'Our aim was to investigate the relationships between serum periostin (POSTN) and both prevalence and incidence/progression of knee osteoarthritis (OA) in women.\n'
p10061
sg4
(lp10062
sg20
(lp10063
(dp10064
g7
I126
sg23
VC0409959
p10065
sg10
I19
sg11
Vknee osteoarthritis
p10066
sg13
I2
sasa(dp10067
g2
S'GADD45G and SPTBN1 not only contribute to tumor progression in hepatocellular carcinoma, but also correlate with poor prognosis in esophageal squamous cell carcinoma and pancreatic cancer respectively.\n'
p10068
sg4
(lp10069
(dp10070
g7
I12
sg8
g18
sg10
I6
sg11
VSPTBN1
p10071
sg13
I1
sa(dp10072
g7
I0
sg8
g18
sg10
I7
sg11
VGADD45G
p10073
sg13
I1
sasg20
(lp10074
(dp10075
g7
I63
sg23
VC1512411
p10076
sg10
I24
sg11
Vhepatocellular carcinoma
p10077
sg13
I2
sa(dp10078
g7
I170
sg23
VC0235974
p10079
sg10
I17
sg11
Vpancreatic cancer
p10080
sg13
I2
sa(dp10081
g7
I42
sg23
VC0178874
p10082
sg10
I17
sg11
Vtumor progression
p10083
sg13
I2
sa(dp10084
g7
I131
sg23
VC0279626
p10085
sg10
I34
sg11
Vesophageal squamous cell carcinoma
p10086
sg13
I4
sasa(dp10087
g2
S'Furthermore, the adenovirus-mediated delivery of Gadd45gamma gene in anaplastic thyroid cancer resulted in the inhibition of tumor growth in vivo.\n'
p10088
sg4
(lp10089
(dp10090
g7
I49
sg8
g18
sg10
I16
sg11
VGadd45gamma gene
p10091
sg13
I2
sasg20
(lp10092
(dp10093
g7
I125
sg23
VC0598934
p10094
sg10
I12
sg11
Vtumor growth
p10095
sg13
I2
sa(dp10096
g7
I17
sg23
VC0001486
p10097
sg10
I10
sg11
Vadenovirus
p10098
sg13
I1
sa(dp10099
g7
I69
sg23
VC0238461
p10100
sg10
I25
sg11
Vanaplastic thyroid cancer
p10101
sg13
I3
sasa(dp10102
g2
S'This in vitro and in vivo activity of the adenovirus-mediated transduction of CR6/Gadd45gamma, on anaplastic thyroid cancer cell growth suppression, was reminiscent of the effects of p53.\n'
p10103
sg4
(lp10104
(dp10105
g7
I78
sg8
g18
sg10
I3
sg11
VCR6
p10106
sg13
I1
sa(dp10107
g7
I82
sg8
g18
sg10
I11
sg11
VGadd45gamma
p10108
sg13
I1
sa(dp10109
g7
I183
sg8
VP42771
p10110
sg10
I3
sg11
Vp53
p10111
sg13
I1
sasg20
(lp10112
(dp10113
g7
I129
sg23
VC0151686
p10114
sg10
I18
sg11
Vgrowth suppression
p10115
sg13
I2
sa(dp10116
g7
I98
sg23
VC0238461
p10117
sg10
I25
sg11
Vanaplastic thyroid cancer
p10118
sg13
I3
sa(dp10119
g7
I42
sg23
VC0001486
p10120
sg10
I10
sg11
Vadenovirus
p10121
sg13
I1
sasa(dp10122
g2
S'This study demonstrates that the Gadd45gamma gene has potential use as a candidate gene for gene therapy in anaplastic thyroid cancer.\n'
p10123
sg4
(lp10124
(dp10125
g7
I33
sg8
g18
sg10
I16
sg11
VGadd45gamma gene
p10126
sg13
I2
sasg20
(lp10127
(dp10128
g7
I108
sg23
VC0238461
p10129
sg10
I25
sg11
Vanaplastic thyroid cancer
p10130
sg13
I3
sasa(dp10131
g2
S'We observed perivascular and parenchymal T lymphocytes (CD8+, T-cytotoxic) with granzyme-B+ granules in FCD IIb and TSC specimens.\n'
p10132
sg4
(lp10133
(dp10134
g7
I104
sg8
g18
sg10
I7
sg11
VFCD IIb
p10135
sg13
I2
sa(dp10136
g7
I56
sg8
VP01732
p10137
sg10
I4
sg11
VCD8+
p10138
sg13
I1
sa(dp10139
g7
I116
sg8
VP55017
p10140
sg10
I3
sg11
VTSC
p10141
sg13
I1
sasg20
(lp10142
(dp10143
g7
I104
sg23
VC1562113
p10144
sg10
I3
sg11
VFCD
p10145
sg13
I1
sa(dp10146
g7
I116
sg23
VC0041341
p10147
sg10
I3
sg11
VTSC
p10148
sg13
I1
sasa(dp10149
g2
S'Toll-like receptor 9 (TLR9) is a key immunotherapy target for glioblastoma (GBM).\n'
p10150
sg4
(lp10151
(dp10152
g7
I0
sg8
g18
sg10
I20
sg11
VToll-like receptor 9
p10153
sg13
I3
sa(dp10154
g7
I22
sg8
g18
sg10
I4
sg11
VTLR9
p10155
sg13
I1
sasg20
(lp10156
(dp10157
g7
I76
sg23
VC0017636
p10158
sg10
I3
sg11
VGBM
p10159
sg13
I1
sa(dp10160
g7
I62
sg23
VC0017636
p10161
sg10
I12
sg11
Vglioblastoma
p10162
sg13
I1
sasa(dp10163
g2
S'This study explored the correlation of TLR9 expression with tumor location and survival outcomes in patients with supratentorial GBM.\n'
p10164
sg4
(lp10165
(dp10166
g7
I39
sg8
g18
sg10
I4
sg11
VTLR9
p10167
sg13
I1
sasg20
(lp10168
(dp10169
g7
I129
sg23
VC0017636
p10170
sg10
I3
sg11
VGBM
p10171
sg13
I1
sa(dp10172
g7
I60
sg23
VC0027651
p10173
sg10
I5
sg11
Vtumor
p10174
sg13
I1
sasa(dp10175
g2
S'We retrospectively identified 46 patients with supratentorial GBMs and divided them into those with high TLR9 (TRL9High) and low TLR9 (TRL9Low) levels.\n'
p10176
sg4
(lp10177
(dp10178
g7
I105
sg8
g18
sg10
I4
sg11
VTLR9
p10179
sg13
I1
sa(dp10180
g7
I105
sg8
g18
sg10
I4
sg11
VTLR9
p10181
sg13
I1
sasg20
(lp10182
sa(dp10183
g2
S'The TLR9 expression percentages for the GBM specimens were TRL9High: 72% (33/46) and TRL9Low: 28% (13/46).\n'
p10184
sg4
(lp10185
(dp10186
g7
I4
sg8
g18
sg10
I4
sg11
VTLR9
p10187
sg13
I1
sasg20
(lp10188
(dp10189
g7
I40
sg23
VC0017636
p10190
sg10
I3
sg11
VGBM
p10191
sg13
I1
sasa(dp10192
g2
S'Patients with TRL9Low supratentorial GBM tend to have longer survival than those with higher TLR9 expression.\n'
p10193
sg4
(lp10194
(dp10195
g7
I93
sg8
g18
sg10
I4
sg11
VTLR9
p10196
sg13
I1
sasg20
(lp10197
(dp10198
g7
I37
sg23
VC0017636
p10199
sg10
I3
sg11
VGBM
p10200
sg13
I1
sasa(dp10201
g2
S'The aim of this study was to assess the association and prognostic value of TLR9 and NFKBIA with clinical significance and also their impact on patient survival in human glioma.\n'
p10202
sg4
(lp10203
(dp10204
g7
I76
sg8
g18
sg10
I4
sg11
VTLR9
p10205
sg13
I1
sa(dp10206
g7
I85
sg8
VP25963
p10207
sg10
I6
sg11
VNFKBIA
p10208
sg13
I1
sasg20
(lp10209
(dp10210
g7
I170
sg23
VC0017638
p10211
sg10
I6
sg11
Vglioma
p10212
sg13
I1
sasa(dp10213
g2
S'Quantitative real-time PCR analysis showed that TLR9 mRNAs is markedly expressed in glioma tissues than in non-neoplastic tissues (mean+/-SD: 3.26+/-0.40 vs. 0.71+/-0.36, P&lt;0.001).\n'
p10214
sg4
(lp10215
(dp10216
g7
I48
sg8
g18
sg10
I10
sg11
VTLR9 mRNAs
p10217
sg13
I2
sasg20
(lp10218
(dp10219
g7
I84
sg23
VC0017638
p10220
sg10
I6
sg11
Vglioma
p10221
sg13
I1
sasa(dp10222
g2
S'There was also a significant difference between TLR9 mRNAs and high grade glioma (P&lt;0.001).NFKBIA mRNAs was significantly identified in non-neoplastic tissues compared with glioma specimens (mean+/-SD: 2.76+/-0.30 vs. 0.94+/-0.35, P&lt;0.001).\n'
p10223
sg4
(lp10224
(dp10225
g7
I94
sg8
VP25963
p10226
sg10
I12
sg11
VNFKBIA mRNAs
p10227
sg13
I2
sa(dp10228
g7
I48
sg8
g18
sg10
I10
sg11
VTLR9 mRNAs
p10229
sg13
I2
sasg20
(lp10230
(dp10231
g7
I74
sg23
VC0017638
p10232
sg10
I6
sg11
Vglioma
p10233
sg13
I1
sa(dp10234
g7
I74
sg23
VC0017638
p10235
sg10
I6
sg11
Vglioma
p10236
sg13
I1
sasa(dp10237
g2
S'Furthermore, Immunoreactivity for high expression of TLR9 was detected in 65% of cases (26/40) that was associated with high grade glioma (P=0.001).\n'
p10238
sg4
(lp10239
(dp10240
g7
I53
sg8
g18
sg10
I4
sg11
VTLR9
p10241
sg13
I1
sasg20
(lp10242
(dp10243
g7
I131
sg23
VC0017638
p10244
sg10
I6
sg11
Vglioma
p10245
sg13
I1
sasa(dp10246
g2
S'These data indicate that TLR9 and NFKBIA protein expressions act as independent predictor of survival for the diagnosis of glioma and a prognostic biomarker for those with a tumor at an advanced pathological grade.\n'
p10247
sg4
(lp10248
(dp10249
g7
I34
sg8
VP25963
p10250
sg10
I14
sg11
VNFKBIA protein
p10251
sg13
I2
sa(dp10252
g7
I25
sg8
g18
sg10
I4
sg11
VTLR9
p10253
sg13
I1
sasg20
(lp10254
(dp10255
g7
I174
sg23
VC0027651
p10256
sg10
I5
sg11
Vtumor
p10257
sg13
I1
sa(dp10258
g7
I123
sg23
VC0017638
p10259
sg10
I6
sg11
Vglioma
p10260
sg13
I1
sasa(dp10261
g2
S'Investigation of the molecular mechanisms demonstrated that CpG ODN107 + irradiation increased the levels of TLR9 and p-ERK, and decreased the level of p-mTOR in glioma cells.\n'
p10262
sg4
(lp10263
(dp10264
g7
I152
sg8
VP42345
p10265
sg10
I6
sg11
Vp-mTOR
p10266
sg13
I1
sa(dp10267
g7
I109
sg8
g18
sg10
I4
sg11
VTLR9
p10268
sg13
I1
sa(dp10269
g7
I118
sg8
VP29323
p10270
sg10
I5
sg11
Vp-ERK
p10271
sg13
I1
sasg20
(lp10272
(dp10273
g7
I162
sg23
VC0017638
p10274
sg10
I6
sg11
Vglioma
p10275
sg13
I1
sasa(dp10276
g2
S'Further, TLR9-specific siRNA could affect the expressions of p-ERK and autophagy-related proteins in glioma cells.\n'
p10277
sg4
(lp10278
(dp10279
g7
I9
sg8
g18
sg10
I19
sg11
VTLR9-specific siRNA
p10280
sg13
I2
sa(dp10281
g7
I71
sg8
VP02649
p10282
sg10
I26
sg11
Vautophagy-related proteins
p10283
sg13
I2
sa(dp10284
g7
I63
sg8
VP29323
p10285
sg10
I3
sg11
VERK
p10286
sg13
I1
sasg20
(lp10287
(dp10288
g7
I101
sg23
VC0017638
p10289
sg10
I6
sg11
Vglioma
p10290
sg13
I1
sasa(dp10291
g2
S'Taken together, CpG ODN107 combined with irradiation could induce autophagic cell death, and this effect was closely related to the TLR9-ERK-mTOR signaling pathway in glioma cells, providing new insights into the investigation mechanism of CpG ODN.\n'
p10292
sg4
(lp10293
(dp10294
g7
I137
sg8
VP29323
p10295
sg10
I3
sg11
VERK
p10296
sg13
I1
sa(dp10297
g7
I141
sg8
VP42345
p10298
sg10
I4
sg11
VmTOR
p10299
sg13
I1
sa(dp10300
g7
I132
sg8
g18
sg10
I4
sg11
VTLR9
p10301
sg13
I1
sasg20
(lp10302
(dp10303
g7
I167
sg23
VC0017638
p10304
sg10
I6
sg11
Vglioma
p10305
sg13
I1
sasa(dp10306
g2
S'Here, we show that the Toll-like receptor TLR9 is elevated in glioma stem-like cells (GSC) in which it contributes to glioma growth.\n'
p10307
sg4
(lp10308
(dp10309
g7
I42
sg8
g18
sg10
I4
sg11
VTLR9
p10310
sg13
I1
sa(dp10311
g7
I23
sg8
g18
sg10
I18
sg11
VToll-like receptor
p10312
sg13
I2
sasg20
(lp10313
(dp10314
g7
I62
sg23
VC0017638
p10315
sg10
I6
sg11
Vglioma
p10316
sg13
I1
sa(dp10317
g7
I62
sg23
VC0017638
p10318
sg10
I6
sg11
Vglioma
p10319
sg13
I1
sasa(dp10320
g2
S'Our findings identify TLR9 as a functional marker for GSC and a target for the delivery of efficacious therapeutics for glioma treatment.\n'
p10321
sg4
(lp10322
(dp10323
g7
I22
sg8
g18
sg10
I4
sg11
VTLR9
p10324
sg13
I1
sasg20
(lp10325
(dp10326
g7
I120
sg23
VC0017638
p10327
sg10
I6
sg11
Vglioma
p10328
sg13
I1
sasa(dp10329
g2
S'The aim of this study was to determine if there was an association between expression of toll-like receptor 9 (TLR9) in glioblastoma tissue and patient outcome in glioblastoma multiforme.\n'
p10330
sg4
(lp10331
(dp10332
g7
I89
sg8
g18
sg10
I20
sg11
Vtoll-like receptor 9
p10333
sg13
I3
sa(dp10334
g7
I111
sg8
g18
sg10
I4
sg11
VTLR9
p10335
sg13
I1
sasg20
(lp10336
(dp10337
g7
I120
sg23
VC0017636
p10338
sg10
I12
sg11
Vglioblastoma
p10339
sg13
I1
sa(dp10340
g7
I163
sg23
VC1621958
p10341
sg10
I23
sg11
Vglioblastoma multiforme
p10342
sg13
I2
sasa(dp10343
g2
S'Further, we characterized the direct in vitro effects of the TLR9 agonist, CpG oligodeoxynucleotide (ODN), commonly used as a vaccine adjuvant in cancer immunotherapy, on glioma cells.\n'
p10344
sg4
(lp10345
(dp10346
g7
I61
sg8
g18
sg10
I4
sg11
VTLR9
p10347
sg13
I1
sasg20
(lp10348
(dp10349
g7
I171
sg23
VC0017638
p10350
sg10
I6
sg11
Vglioma
p10351
sg13
I1
sa(dp10352
g7
I146
sg23
VC0006826
p10353
sg10
I6
sg11
Vcancer
p10354
sg13
I1
sasa(dp10355
g2
S'TLR9 expression was assessed using immunohistochemical techniques, and enzyme-linked immunosorbent assays were used to investigate the expression of other proteins in glioma cells relevant to immunotherapy.\n'
p10356
sg4
(lp10357
(dp10358
g7
I0
sg8
g18
sg10
I4
sg11
VTLR9
p10359
sg13
I1
sasg20
(lp10360
(dp10361
g7
I167
sg23
VC0017638
p10362
sg10
I6
sg11
Vglioma
p10363
sg13
I1
sasa(dp10364
g2
S'In in vitro glioma cells, there was a positive correlation between the protein levels of TLR9 and both matrix metalloproteinase (MMP)-2 and MMP-9 (p&lt;0.05), but no relationship between TLR9 levels and levels of interleukin-6, transforming growth factor-Beta2 or signal transducer and activator of transcription (STAT)-3 (p&gt;0.05).\n'
p10365
sg4
(lp10366
(dp10367
g7
I228
sg8
VP61812
p10368
sg10
I32
sg11
Vtransforming growth factor-Beta2
p10369
sg13
I3
sa(dp10370
g7
I103
sg8
g18
sg10
I32
sg11
Vmatrix metalloproteinase (MMP)-2
p10371
sg13
I3
sa(dp10372
g7
I140
sg8
VP14780
p10373
sg10
I5
sg11
VMMP-9
p10374
sg13
I1
sa(dp10375
g7
I213
sg8
VP05231
p10376
sg10
I13
sg11
Vinterleukin-6
p10377
sg13
I1
sa(dp10378
g7
I89
sg8
g18
sg10
I4
sg11
VTLR9
p10379
sg13
I1
sa(dp10380
g7
I89
sg8
g18
sg10
I4
sg11
VTLR9
p10381
sg13
I1
sa(dp10382
g7
I264
sg8
g18
sg10
I57
sg11
Vsignal transducer and activator of transcription (STAT)-3
p10383
sg13
I7
sasg20
(lp10384
(dp10385
g7
I12
sg23
VC0017638
p10386
sg10
I6
sg11
Vglioma
p10387
sg13
I1
sasa(dp10388
g2
S'Our data indicate that expression of TLR9 correlates with shorter progression-free survival and overall survival in patients with glioblastoma multiforme.\n'
p10389
sg4
(lp10390
(dp10391
g7
I37
sg8
g18
sg10
I4
sg11
VTLR9
p10392
sg13
I1
sasg20
(lp10393
(dp10394
g7
I130
sg23
VC1621958
p10395
sg10
I23
sg11
Vglioblastoma multiforme
p10396
sg13
I2
sasa(dp10397
g2
S'Our findings also indicate that caution is warranted when directly injecting the TLR9 agonist CpG ODN into glioma tissues as part of glioma immunotherapy.\n'
p10398
sg4
(lp10399
(dp10400
g7
I81
sg8
g18
sg10
I4
sg11
VTLR9
p10401
sg13
I1
sasg20
(lp10402
(dp10403
g7
I107
sg23
VC0017638
p10404
sg10
I6
sg11
Vglioma
p10405
sg13
I1
sa(dp10406
g7
I107
sg23
VC0017638
p10407
sg10
I6
sg11
Vglioma
p10408
sg13
I1
sasa(dp10409
g2
S'This study was a pilot project to assess the safety and efficacy of carboxypeptidase G2 (CPG2) rescue from high-dose (HD) methotrexate (MTX) in patients with recurrent cerebral lymphoma.\n'
p10410
sg4
(lp10411
sg20
(lp10412
(dp10413
g7
I168
sg23
VC0240803
p10414
sg10
I17
sg11
Vcerebral lymphoma
p10415
sg13
I2
sasa(dp10416
g2
S'To estimate the prevalence of the genotypes of the candidate genes ACE (I/D, rs4646994), ADRB1 (Ser49Gly, A/G, rs1801252) ADRA2B (I/D), MTHFR (C677T, Ala222Val, rs1801133), and eNOS (4b/4a) and their association with hypertension in two ethnic groups of Mountain Shoria.\n'
p10417
sg4
(lp10418
(dp10419
g7
I89
sg8
VP08588
p10420
sg10
I5
sg11
VADRB1
p10421
sg13
I1
sa(dp10422
g7
I67
sg8
VP12821
p10423
sg10
I3
sg11
VACE
p10424
sg13
I1
sa(dp10425
g7
I136
sg8
VP42898
p10426
sg10
I5
sg11
VMTHFR
p10427
sg13
I1
sa(dp10428
g7
I122
sg8
VP18089
p10429
sg10
I6
sg11
VADRA2B
p10430
sg13
I1
sasg20
(lp10431
(dp10432
g7
I217
sg23
VC0020538
p10433
sg10
I12
sg11
Vhypertension
p10434
sg13
I1
sasa(dp10435
g2
S'Hypertension was associated with the ACE DD, MTHFR CT, and ADRB1 AA genotypes in the native ethnic group and with the ACE ID genotype in the non-indigenous population.\n'
p10436
sg4
(lp10437
(dp10438
g7
I118
sg8
VP12821
p10439
sg10
I6
sg11
VACE ID
p10440
sg13
I2
sa(dp10441
g7
I45
sg8
VP42898
p10442
sg10
I8
sg11
VMTHFR CT
p10443
sg13
I2
sa(dp10444
g7
I37
sg8
VP12821
p10445
sg10
I6
sg11
VACE DD
p10446
sg13
I2
sa(dp10447
g7
I59
sg8
VP08588
p10448
sg10
I8
sg11
VADRB1 AA
p10449
sg13
I2
sasg20
(lp10450
(dp10451
g7
I0
sg23
VC0020538
p10452
sg10
I12
sg11
VHypertension
p10453
sg13
I1
sasa(dp10454
g2
S'CLLU1, located at chromosome 12q22, encodes a transcript specific to chronic lymphocytic leukemia and has potential prognostic value.\n'
p10455
sg4
(lp10456
(dp10457
g7
I0
sg8
g18
sg10
I5
sg11
VCLLU1
p10458
sg13
I1
sasg20
(lp10459
(dp10460
g7
I69
sg23
VC0023434
p10461
sg10
I28
sg11
Vchronic lymphocytic leukemia
p10462
sg13
I3
sasa(dp10463
g2
S'CLLU1 expression analysis helps to refine the prognosis of patients with chronic lymphocytic leukemia who have mutated IGHV genes.\n'
p10464
sg4
(lp10465
(dp10466
g7
I119
sg8
VP01764
p10467
sg10
I10
sg11
VIGHV genes
p10468
sg13
I2
sa(dp10469
g7
I0
sg8
g18
sg10
I5
sg11
VCLLU1
p10470
sg13
I1
sasg20
(lp10471
(dp10472
g7
I73
sg23
VC0023434
p10473
sg10
I28
sg11
Vchronic lymphocytic leukemia
p10474
sg13
I3
sasa(dp10475
g2
S'The expression levels of LPL, ZAP70, TCL1A, CLLU1 and MCL1 have recently been proposed as prognostic factors in chronic lymphocytic leukemia.\n'
p10476
sg4
(lp10477
(dp10478
g7
I25
sg8
VP06858
p10479
sg10
I3
sg11
VLPL
p10480
sg13
I1
sa(dp10481
g7
I44
sg8
g18
sg10
I5
sg11
VCLLU1
p10482
sg13
I1
sa(dp10483
g7
I30
sg8
VP43403
p10484
sg10
I5
sg11
VZAP70
p10485
sg13
I1
sa(dp10486
g7
I37
sg8
VP56279
p10487
sg10
I5
sg11
VTCL1A
p10488
sg13
I1
sasg20
(lp10489
(dp10490
g7
I112
sg23
VC0023434
p10491
sg10
I28
sg11
Vchronic lymphocytic leukemia
p10492
sg13
I3
sasa(dp10493
g2
S'To investigate the expression level of chronic lymphocytic leukemia (CLL) up-regulated gene 1 (CLLU1) mRNA in CLL and its prognostic value in CLL.\n'
p10494
sg4
(lp10495
(dp10496
g7
I69
sg8
VP04207
p10497
sg10
I3
sg11
VCLL
p10498
sg13
I1
sa(dp10499
g7
I39
sg8
VP04207
p10500
sg10
I28
sg11
Vchronic lymphocytic leukemia
p10501
sg13
I3
sa(dp10502
g7
I69
sg8
VP04207
p10503
sg10
I3
sg11
VCLL
p10504
sg13
I1
sa(dp10505
g7
I95
sg8
g18
sg10
I5
sg11
VCLLU1
p10506
sg13
I1
sasg20
(lp10507
(dp10508
g7
I69
sg23
VC0023434
p10509
sg10
I3
sg11
VCLL
p10510
sg13
I1
sa(dp10511
g7
I39
sg23
VC0023434
p10512
sg10
I28
sg11
Vchronic lymphocytic leukemia
p10513
sg13
I3
sa(dp10514
g7
I69
sg23
VC0023434
p10515
sg10
I3
sg11
VCLL
p10516
sg13
I1
sa(dp10517
g7
I69
sg23
VC0023434
p10518
sg10
I3
sg11
VCLL
p10519
sg13
I1
sasa(dp10520
g2
S'Plasminogen precursor, Apo A-IV precursor, C4A/C4B complement, C2 precursor, Vitamin D binding protein and hypothetical protein are differentially expressed in oral lichen planus patients before and after hydroxychloroquine therapy, but the results need to be validated by other biochemical technologies.\n'
p10521
sg4
(lp10522
(dp10523
g7
I77
sg8
VP02774
p10524
sg10
I25
sg11
VVitamin D binding protein
p10525
sg13
I4
sa(dp10526
g7
I0
sg8
VP00747
p10527
sg10
I21
sg11
VPlasminogen precursor
p10528
sg13
I2
sa(dp10529
g7
I47
sg8
VP04003
p10530
sg10
I3
sg11
VC4B
p10531
sg13
I1
sasg20
(lp10532
(dp10533
g7
I160
sg23
VC0206139
p10534
sg10
I18
sg11
Voral lichen planus
p10535
sg13
I3
sasa(dp10536
g2
S'In order to study if in patients with hereditary angioedema (HAE), copy number of the two genes (C4A and C4A) encoded in the central region of main histocompatibility complex (MHC) influences the diagnostically important C4 serum concentration as well as the clinical course of the disease, we determined copy number of the complement C4A and C4B genes in DNA samples of 95 HAE patients and 246 healthy controls.\n'
p10537
sg4
(lp10538
(dp10539
g7
I143
sg8
VP13747
p10540
sg10
I31
sg11
Vmain histocompatibility complex
p10541
sg13
I3
sa(dp10542
g7
I176
sg8
VP13747
p10543
sg10
I3
sg11
VMHC
p10544
sg13
I1
sa(dp10545
g7
I324
sg8
g18
sg10
I14
sg11
Vcomplement C4A
p10546
sg13
I2
sa(dp10547
g7
I343
sg8
VP04003
p10548
sg10
I9
sg11
VC4B genes
p10549
sg13
I2
sasg20
(lp10550
(dp10551
g7
I38
sg23
VC0019243
p10552
sg10
I21
sg11
Vhereditary angioedema
p10553
sg13
I2
sa(dp10554
g7
I61
sg23
VC0019243
p10555
sg10
I3
sg11
VHAE
p10556
sg13
I1
sa(dp10557
g7
I61
sg23
VC0019243
p10558
sg10
I3
sg11
VHAE
p10559
sg13
I1
sasa(dp10560
g2
S'The study aimed to investigate the impact of clopidogrel combined with proton pump inhibitors (PPI) pantoprazole treatment on the prognosis of patients with transient ischemic attack (TIA).\n'
p10561
sg4
(lp10562
sg20
(lp10563
(dp10564
g7
I184
sg23
VC0007787
p10565
sg10
I3
sg11
VTIA
p10566
sg13
I1
sa(dp10567
g7
I157
sg23
VC0007787
p10568
sg10
I25
sg11
Vtransient ischemic attack
p10569
sg13
I3
sasa(dp10570
g2
S'The statistical model showed that bruxism was a statistically significantly risk factor to implant failure (HR 3*396; 95% CI 1*314, 8*777; P = 0*012), as well as implant length, implant diameter, implant surface, bone quantity D in relation to quantity A, bone quality 4 in relation to quality 1 (Lekholm and Zarb classification), smoking and the intake of proton pump inhibitors.\n'
p10571
sg4
(lp10572
sg20
(lp10573
(dp10574
g7
I34
sg23
VC0006325
p10575
sg10
I7
sg11
Vbruxism
p10576
sg13
I1
sasa(dp10577
g2
S'The objective of this study was to quantify the relative risk of seizure associated with the use of proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) in a general population, overall and stratified by epilepsy status, and to determine the effects of demographics and comorbidities.\n'
p10578
sg4
(lp10579
(dp10580
g7
I134
sg8
g18
sg10
I20
sg11
Vhistamine-2 receptor
p10581
sg13
I2
sasg20
(lp10582
(dp10583
g7
I226
sg23
VC0014544
p10584
sg10
I8
sg11
Vepilepsy
p10585
sg13
I1
sa(dp10586
g7
I65
sg23
VC0036572
p10587
sg10
I7
sg11
Vseizure
p10588
sg13
I1
sasa(dp10589
g2
S'A viral homolog of human interleukin-6 (hIL-6) named viral interleukin-6 (vIL-6) is encoded by KSHV and expressed in KSHV-associated cancers.\n'
p10590
sg4
(lp10591
(dp10592
g7
I40
sg8
VP01771
p10593
sg10
I5
sg11
VhIL-6
p10594
sg13
I1
sa(dp10595
g7
I19
sg8
VP05231
p10596
sg10
I19
sg11
Vhuman interleukin-6
p10597
sg13
I2
sa(dp10598
g7
I74
sg8
VP01711
p10599
sg10
I5
sg11
VvIL-6
p10600
sg13
I1
sa(dp10601
g7
I53
sg8
VP05231
p10602
sg10
I19
sg11
Vviral interleukin-6
p10603
sg13
I2
sasg20
(lp10604
(dp10605
g7
I133
sg23
VC0006826
p10606
sg10
I7
sg11
Vcancers
p10607
sg13
I1
sasa(dp10608
g2
S"We also observed transcripts at the EBV vIL-10 locus exclusively in the Hodgkin's lymphoma cell line, Hs 611.T, the expression of which were uncoupled from other lytic genes.\n"
p10609
sg4
(lp10610
sg20
(lp10611
(dp10612
g7
I162
sg23
VC0024348
p10613
sg10
I5
sg11
Vlytic
p10614
sg13
I1
sa(dp10615
g7
I72
sg23
VC0019829
p10616
sg10
I18
sg11
VHodgkin's lymphoma
p10617
sg13
I2
sasa(dp10618
g2
S"EBV transcriptome analysis showed expression of vIL-10 transcripts in a Hodgkin's lymphoma that was uncoupled from lytic genes.\n"
p10619
sg4
(lp10620
(dp10621
g7
I48
sg8
VP01711
p10622
sg10
I18
sg11
VvIL-10 transcripts
p10623
sg13
I2
sasg20
(lp10624
(dp10625
g7
I115
sg23
VC0024348
p10626
sg10
I5
sg11
Vlytic
p10627
sg13
I1
sa(dp10628
g7
I72
sg23
VC0019829
p10629
sg10
I18
sg11
VHodgkin's lymphoma
p10630
sg13
I2
sasa(dp10631
g2
S'Collectively, our data indicate that HYOU1 is important for vIL-6 function and may play a role in the pathogenesis of KSHV-associated cancers.\n'
p10632
sg4
(lp10633
(dp10634
g7
I37
sg8
g18
sg10
I5
sg11
VHYOU1
p10635
sg13
I1
sa(dp10636
g7
I60
sg8
VP01711
p10637
sg10
I5
sg11
VvIL-6
p10638
sg13
I1
sasg20
(lp10639
(dp10640
g7
I134
sg23
VC0006826
p10641
sg10
I7
sg11
Vcancers
p10642
sg13
I1
sa(dp10643
g7
I102
sg23
VC0699748
p10644
sg10
I12
sg11
Vpathogenesis
p10645
sg13
I1
sasa(dp10646
g2
S'We investigated the role of activated B cells in thrombopoiesis through the production of interleukin (IL)-1beta and IL-6 in patients with essential thrombocythaemia.\n'
p10647
sg4
(lp10648
(dp10649
g7
I90
sg8
VP60568
p10650
sg10
I22
sg11
Vinterleukin (IL)-1beta
p10651
sg13
I2
sa(dp10652
g7
I117
sg8
VP05231
p10653
sg10
I4
sg11
VIL-6
p10654
sg13
I1
sasg20
(lp10655
(dp10656
g7
I139
sg23
VC0040028
p10657
sg10
I26
sg11
Vessential thrombocythaemia
p10658
sg13
I2
sasa(dp10659
g2
S'However, the number of IL-1beta/IL-6-producing B cells was significantly higher in essential thrombocythaemia patients than that in healthy controls.\n'
p10660
sg4
(lp10661
(dp10662
g7
I32
sg8
VP05231
p10663
sg10
I4
sg11
VIL-6
p10664
sg13
I1
sa(dp10665
g7
I23
sg8
VP01584
p10666
sg10
I8
sg11
VIL-1beta
p10667
sg13
I1
sasg20
(lp10668
(dp10669
g7
I83
sg23
VC0040028
p10670
sg10
I26
sg11
Vessential thrombocythaemia
p10671
sg13
I2
sasa(dp10672
g2
S'In a previous study, we found increased plasma soluble receptor for interleukin-6 (sIL-6R) levels in patients with essential thrombocythemia (ET) that could promote megakaryopoiesis through IL-6 binding and further interaction with the signal transducer gp130.\n'
p10673
sg4
(lp10674
(dp10675
g7
I84
sg8
VP05231
p10676
sg10
I4
sg11
VIL-6
p10677
sg13
I1
sa(dp10678
g7
I83
sg8
VP08887
p10679
sg10
I6
sg11
VsIL-6R
p10680
sg13
I1
sa(dp10681
g7
I40
sg8
VP35558
p10682
sg10
I23
sg11
Vplasma soluble receptor
p10683
sg13
I3
sa(dp10684
g7
I68
sg8
VP05231
p10685
sg10
I13
sg11
Vinterleukin-6
p10686
sg13
I1
sa(dp10687
g7
I236
sg8
VP40189
p10688
sg10
I23
sg11
Vsignal transducer gp130
p10689
sg13
I3
sasg20
(lp10690
(dp10691
g7
I115
sg23
VC0040028
p10692
sg10
I25
sg11
Vessential thrombocythemia
p10693
sg13
I2
sa(dp10694
g7
I83
sg23
VC0333873
p10695
sg10
I3
sg11
VsIL
p10696
sg13
I1
sa(dp10697
g7
I142
sg23
VC0040028
p10698
sg10
I2
sg11
VET
p10699
sg13
I1
sasa(dp10700
g2
S"Moreover, LSC loss leads to corneal opacity and blindness, while limbal grafting restores patients' vision.\n"
p10701
sg4
(lp10702
sg20
(lp10703
(dp10704
g7
I48
sg23
VC0456909
p10705
sg10
I9
sg11
Vblindness
p10706
sg13
I1
sa(dp10707
g7
I36
sg23
VC1265876
p10708
sg10
I7
sg11
Vopacity
p10709
sg13
I1
sasa(dp10710
g2
S'Cornea epithelial cells (CECs) undergo continuous renewal from limbal stem or progenitor cells (LSCs), and deficiency in LSCs or corneal epithelium--which turns cornea into a non-transparent, keratinized skin-like epithelium--causes corneal surface disease that leads to blindness in millions of people worldwide.\n'
p10711
sg4
(lp10712
sg20
(lp10713
(dp10714
g7
I271
sg23
VC0456909
p10715
sg10
I9
sg11
Vblindness
p10716
sg13
I1
sasa(dp10717
g2
S'Loss of WNT7A or PAX6 induces LSCs into skin-like epithelium, a critical defect tightly linked to common human corneal diseases.\n'
p10718
sg4
(lp10719
(dp10720
g7
I8
sg8
g18
sg10
I5
sg11
VWNT7A
p10721
sg13
I1
sa(dp10722
g7
I17
sg8
VP26367
p10723
sg10
I4
sg11
VPAX6
p10724
sg13
I1
sasg20
(lp10725
(dp10726
g7
I111
sg23
VC0010034
p10727
sg10
I16
sg11
Vcorneal diseases
p10728
sg13
I2
sasa(dp10729
g2
S'Corneal epithelial homeostasis and regeneration are sustained by limbal stem cells (LSCs), and LSC deficiency is a major cause of blindness worldwide.\n'
p10730
sg4
(lp10731
(dp10732
g7
I84
sg8
g18
sg10
I3
sg11
VLSC
p10733
sg13
I1
sasg20
(lp10734
(dp10735
g7
I130
sg23
VC0456909
p10736
sg10
I9
sg11
Vblindness
p10737
sg13
I1
sasa(dp10738
g2
S'Identification and prospective isolation of molecularly defined LSCs with essential functions in corneal development and repair has important implications for the treatment of corneal disease, particularly corneal blindness due to LSC deficiency.\n'
p10739
sg4
(lp10740
(dp10741
g7
I64
sg8
g18
sg10
I3
sg11
VLSC
p10742
sg13
I1
sasg20
(lp10743
(dp10744
g7
I214
sg23
VC0456909
p10745
sg10
I9
sg11
Vblindness
p10746
sg13
I1
sa(dp10747
g7
I176
sg23
VC0010034
p10748
sg10
I15
sg11
Vcorneal disease
p10749
sg13
I2
sasa(dp10750
g2
S'In rabbit total limbal stem cell deficiency (LSCD) models, the tissue-engineering graft had the potential to reconstruct the damaged ocular surface and alleviated the invasion of corneal neovascularization.\n'
p10751
sg4
(lp10752
sg20
(lp10753
(dp10754
g7
I45
sg23
VC1561989
p10755
sg10
I4
sg11
VLSCD
p10756
sg13
I1
sa(dp10757
g7
I179
sg23
VC0085109
p10758
sg10
I26
sg11
Vcorneal neovascularization
p10759
sg13
I2
sa(dp10760
g7
I16
sg23
VC1561989
p10761
sg10
I27
sg11
Vlimbal stem cell deficiency
p10762
sg13
I4
sa(dp10763
g7
I167
sg23
VC2699153
p10764
sg10
I8
sg11
Vinvasion
p10765
sg13
I1
sasa(dp10766
g2
S'Limbal Stem Cell Deficiency (LSCD) can lead to corneal opacity and vascularization, with consequent visual impairment or blindness.\n'
p10767
sg4
(lp10768
sg20
(lp10769
(dp10770
g7
I67
sg23
VC0027686
p10771
sg10
I15
sg11
Vvascularization
p10772
sg13
I1
sa(dp10773
g7
I29
sg23
VC1561989
p10774
sg10
I4
sg11
VLSCD
p10775
sg13
I1
sa(dp10776
g7
I0
sg23
VC1561989
p10777
sg10
I27
sg11
VLimbal Stem Cell Deficiency
p10778
sg13
I4
sa(dp10779
g7
I55
sg23
VC1265876
p10780
sg10
I7
sg11
Vopacity
p10781
sg13
I1
sa(dp10782
g7
I100
sg23
VC3489703
p10783
sg10
I17
sg11
Vvisual impairment
p10784
sg13
I2
sa(dp10785
g7
I121
sg23
VC0456909
p10786
sg10
I9
sg11
Vblindness
p10787
sg13
I1
sasa(dp10788
g2
S'Transcription levels of pluripotency-related (octamer binding protein 4, Nanog), osteogenesis-related (collagen type I, Runx2, alkaline phosphatase, and bone sialoprotein), and chondrogenesis-related (collagen types II and X, and aggrecan) genes were not predictive of either bone or teratoma formation.\n'
p10789
sg4
(lp10790
(dp10791
g7
I153
sg8
VP10451
p10792
sg10
I17
sg11
Vbone sialoprotein
p10793
sg13
I2
sa(dp10794
g7
I127
sg8
VP10696
p10795
sg10
I20
sg11
Valkaline phosphatase
p10796
sg13
I2
sa(dp10797
g7
I103
sg8
VP29475
p10798
sg10
I15
sg11
Vcollagen type I
p10799
sg13
I3
sa(dp10800
g7
I201
sg8
g18
sg10
I23
sg11
Vcollagen types II and X
p10801
sg13
I5
sa(dp10802
g7
I120
sg8
g18
sg10
I5
sg11
VRunx2
p10803
sg13
I1
sasg20
(lp10804
(dp10805
g7
I284
sg23
VC0039538
p10806
sg10
I8
sg11
Vteratoma
p10807
sg13
I1
sasa(dp10808
g2
S'In addition, IGF-1, PTEN, Akt1, Akt2, FoxO3 and FoxO4 gene expression levels were upregulated following WRS, and peaked after 7 h of WRS.\n'
p10809
sg4
(lp10810
(dp10811
g7
I26
sg8
VP31749
p10812
sg10
I4
sg11
VAkt1
p10813
sg13
I1
sa(dp10814
g7
I48
sg8
VP98177
p10815
sg10
I10
sg11
VFoxO4 gene
p10816
sg13
I2
sa(dp10817
g7
I20
sg8
VP60484
p10818
sg10
I4
sg11
VPTEN
p10819
sg13
I1
sa(dp10820
g7
I32
sg8
VP31751
p10821
sg10
I4
sg11
VAkt2
p10822
sg13
I1
sa(dp10823
g7
I13
sg8
VP01343
p10824
sg10
I5
sg11
VIGF-1
p10825
sg13
I1
sa(dp10826
g7
I38
sg8
g18
sg10
I5
sg11
VFoxO3
p10827
sg13
I1
sasg20
(lp10828
(dp10829
g7
I104
sg23
VC0035828
p10830
sg10
I3
sg11
VWRS
p10831
sg13
I1
sa(dp10832
g7
I104
sg23
VC0035828
p10833
sg10
I3
sg11
VWRS
p10834
sg13
I1
sasa(dp10835
g2
S'Specifically, PTEN, FoxO3a and FoxO4 were also localized in the cellular cytoplasm of lamina propria of restituted villi in the duodenal mucosa of rat subjected to WRS.\n'
p10836
sg4
(lp10837
(dp10838
g7
I20
sg8
g18
sg10
I6
sg11
VFoxO3a
p10839
sg13
I1
sa(dp10840
g7
I14
sg8
VP60484
p10841
sg10
I4
sg11
VPTEN
p10842
sg13
I1
sa(dp10843
g7
I31
sg8
VP98177
p10844
sg10
I5
sg11
VFoxO4
p10845
sg13
I1
sasg20
(lp10846
(dp10847
g7
I164
sg23
VC0035828
p10848
sg10
I3
sg11
VWRS
p10849
sg13
I1
sasa(dp10850
g2
S'In addition, messenger RNA transcript levels of IGF-1, PTEN, Akt1, Akt2, FoxO3, and FoxO4 were upregulated in the duodenal mucosa, with a peak between the 4th and 8th day after 7 h of WRS.\n'
p10851
sg4
(lp10852
(dp10853
g7
I48
sg8
VP01343
p10854
sg10
I5
sg11
VIGF-1
p10855
sg13
I1
sa(dp10856
g7
I73
sg8
g18
sg10
I5
sg11
VFoxO3
p10857
sg13
I1
sa(dp10858
g7
I61
sg8
VP31749
p10859
sg10
I4
sg11
VAkt1
p10860
sg13
I1
sa(dp10861
g7
I67
sg8
VP31751
p10862
sg10
I4
sg11
VAkt2
p10863
sg13
I1
sa(dp10864
g7
I55
sg8
VP60484
p10865
sg10
I4
sg11
VPTEN
p10866
sg13
I1
sasg20
(lp10867
(dp10868
g7
I184
sg23
VC0035828
p10869
sg10
I3
sg11
VWRS
p10870
sg13
I1
sasa(dp10871
g2
S'Moreover, in the rat gastric ulcers, the mRNA transcript levels of IGF-1, PTEN, Akt-1, Akt-2, FoxO3 and FoxO4 were upregulated in the gastric ulcer margin, with a peak between Days 4 and 8 following 7 h of WRS.\n'
p10872
sg4
(lp10873
(dp10874
g7
I87
sg8
g18
sg10
I5
sg11
VAkt-2
p10875
sg13
I1
sa(dp10876
g7
I67
sg8
VP01343
p10877
sg10
I5
sg11
VIGF-1
p10878
sg13
I1
sa(dp10879
g7
I80
sg8
g18
sg10
I5
sg11
VAkt-1
p10880
sg13
I1
sa(dp10881
g7
I74
sg8
VP60484
p10882
sg10
I4
sg11
VPTEN
p10883
sg13
I1
sasg20
(lp10884
(dp10885
g7
I206
sg23
VC0035828
p10886
sg10
I3
sg11
VWRS
p10887
sg13
I1
sa(dp10888
g7
I21
sg23
VC0038358
p10889
sg10
I14
sg11
Vgastric ulcers
p10890
sg13
I2
sa(dp10891
g7
I21
sg23
VC0038358
p10892
sg10
I13
sg11
Vgastric ulcer
p10893
sg13
I2
sasa(dp10894
g2
S'From August 2003 through February 2006, 100 drug-resistant symptomatic patients with lone atrial fibrillation underwent thoracoscopic off-pump closed-chest epicardial ablation using the FLEX 10 AFx Microwave Ablation System (Guidant, Indianapolis, IN, USA).\n'
p10895
sg4
(lp10896
(dp10897
g7
I186
sg8
VP98177
p10898
sg10
I11
sg11
VFLEX 10 AFx
p10899
sg13
I3
sasg20
(lp10900
(dp10901
g7
I85
sg23
VC0340489
p10902
sg10
I24
sg11
Vlone atrial fibrillation
p10903
sg13
I3
sasa(dp10904
g2
S'The t(4;14) (p16; q32) with fusion of the IGH (immunoglobulin heavy chain) and FGFR3 (fibroblast growth factor receptor 3) genes are rarely present in patients with chronic lymphocytic leukemia (CLL), with only two previously reported cases.\n'
p10905
sg4
(lp10906
(dp10907
g7
I42
sg8
VP01877
p10908
sg10
I3
sg11
VIGH
p10909
sg13
I1
sa(dp10910
g7
I79
sg8
VP22607
p10911
sg10
I5
sg11
VFGFR3
p10912
sg13
I1
sa(dp10913
g7
I47
sg8
VP01860
p10914
sg10
I26
sg11
Vimmunoglobulin heavy chain
p10915
sg13
I3
sa(dp10916
g7
I13
sg8
VP42771
p10917
sg10
I3
sg11
Vp16
p10918
sg13
I1
sa(dp10919
g7
I86
sg8
g18
sg10
I35
sg11
Vfibroblast growth factor receptor 3
p10920
sg13
I5
sasg20
(lp10921
(dp10922
g7
I165
sg23
VC0023434
p10923
sg10
I28
sg11
Vchronic lymphocytic leukemia
p10924
sg13
I3
sa(dp10925
g7
I195
sg23
VC0023434
p10926
sg10
I3
sg11
VCLL
p10927
sg13
I1
sasa(dp10928
g2
S'These include t(4;14) multiple myeloma associated with ectopic expression of FGFR3 and t(4;12)(p16;p13) acute myeloid leukemia associated with expression of a constitutively activated fusion tyrosine kinase, TEL-FGFR3.\n'
p10929
sg4
(lp10930
(dp10931
g7
I95
sg8
VP42771
p10932
sg10
I3
sg11
Vp16
p10933
sg13
I1
sa(dp10934
g7
I99
sg8
g18
sg10
I3
sg11
Vp13
p10935
sg13
I1
sa(dp10936
g7
I77
sg8
VP22607
p10937
sg10
I5
sg11
VFGFR3
p10938
sg13
I1
sa(dp10939
g7
I77
sg8
VP22607
p10940
sg10
I5
sg11
VFGFR3
p10941
sg13
I1
sa(dp10942
g7
I184
sg8
VP29401
p10943
sg10
I22
sg11
Vfusion tyrosine kinase
p10944
sg13
I3
sa(dp10945
g7
I208
sg8
VP41212
p10946
sg10
I3
sg11
VTEL
p10947
sg13
I1
sasg20
(lp10948
(dp10949
g7
I22
sg23
VC0026764
p10950
sg10
I16
sg11
Vmultiple myeloma
p10951
sg13
I2
sa(dp10952
g7
I104
sg23
VC0023467
p10953
sg10
I22
sg11
Vacute myeloid leukemia
p10954
sg13
I3
sasa(dp10955
g2
S'The expression levels of fgfr3 mRNA in 4 leukemic cell lines and bone marrow samples from 96 patients with leukemia and 14 controls were assayed by RT-PCR.\n'
p10956
sg4
(lp10957
(dp10958
g7
I25
sg8
VP22607
p10959
sg10
I10
sg11
Vfgfr3 mRNA
p10960
sg13
I2
sasg20
(lp10961
(dp10962
g7
I107
sg23
VC0023418
p10963
sg10
I8
sg11
Vleukemia
p10964
sg13
I1
sasa(dp10965
g2
S'AA genes with highest degree and betweenness were considered as hub genes of GCN, namely CDC20, MELK, PTTG1, CCNB2, CDC45, CCNB1, TK1 and PSMB2, which could distinguish cancer from normal controls with ALDOA.\n'
p10966
sg4
(lp10967
(dp10968
g7
I202
sg8
VP04075
p10969
sg10
I5
sg11
VALDOA
p10970
sg13
I1
sa(dp10971
g7
I96
sg8
g18
sg10
I4
sg11
VMELK
p10972
sg13
I1
sa(dp10973
g7
I0
sg8
VP01893
p10974
sg10
I8
sg11
VAA genes
p10975
sg13
I2
sa(dp10976
g7
I109
sg8
g18
sg10
I5
sg11
VCCNB2
p10977
sg13
I1
sa(dp10978
g7
I89
sg8
g18
sg10
I5
sg11
VCDC20
p10979
sg13
I1
sa(dp10980
g7
I77
sg8
VP56537
p10981
sg10
I3
sg11
VGCN
p10982
sg13
I1
sa(dp10983
g7
I138
sg8
VP49721
p10984
sg10
I5
sg11
VPSMB2
p10985
sg13
I1
sa(dp10986
g7
I130
sg8
VP04183
p10987
sg10
I3
sg11
VTK1
p10988
sg13
I1
sa(dp10989
g7
I102
sg8
g18
sg10
I5
sg11
VPTTG1
p10990
sg13
I1
sa(dp10991
g7
I116
sg8
g18
sg10
I5
sg11
VCDC45
p10992
sg13
I1
sa(dp10993
g7
I123
sg8
VP14635
p10994
sg10
I5
sg11
VCCNB1
p10995
sg13
I1
sasg20
(lp10996
(dp10997
g7
I169
sg23
VC0006826
p10998
sg10
I6
sg11
Vcancer
p10999
sg13
I1
sasa(dp11000
g2
S'Herein, we investigated whether the angiotensin II receptor-neprilysin inhibitor sacubitril/valsartan (LCZ696) would improve reduced EDH-mediated responses and whether LCZ696 would exert additional effects on endothelium-dependent and endothelium-independent vasorelaxation compared with an angiotensin II type 1 receptor blocker alone during hypertension.\n'
p11001
sg4
(lp11002
(dp11003
g7
I291
sg8
VP30556
p11004
sg10
I30
sg11
Vangiotensin II type 1 receptor
p11005
sg13
I5
sa(dp11006
g7
I36
sg8
VP08473
p11007
sg10
I34
sg11
Vangiotensin II receptor-neprilysin
p11008
sg13
I3
sasg20
(lp11009
(dp11010
g7
I343
sg23
VC0020538
p11011
sg10
I12
sg11
Vhypertension
p11012
sg13
I1
sasa(dp11013
g2
S'The efficacy and safety of sacubitril/valsartan (LCZ696), a first-in-class angiotensin receptor neprilysin inhibitor, vs. olmesartan was evaluated in elderly Asian patients (&gt;=65 years) with systolic hypertension.\n'
p11014
sg4
(lp11015
(dp11016
g7
I75
sg8
VP08473
p11017
sg10
I31
sg11
Vangiotensin receptor neprilysin
p11018
sg13
I3
sasg20
(lp11019
(dp11020
g7
I194
sg23
VC0221155
p11021
sg10
I21
sg11
Vsystolic hypertension
p11022
sg13
I2
sasa(dp11023
g2
S'Cytoplasmic AR expression (AR1 and AR2) in tumors trended higher in those with higher serum adiponectin levels and in those with diabetes mellitus, but the association was not statistically significant.\n'
p11024
sg4
(lp11025
(dp11026
g7
I86
sg8
g18
sg10
I17
sg11
Vserum adiponectin
p11027
sg13
I2
sa(dp11028
g7
I0
sg8
g18
sg10
I14
sg11
VCytoplasmic AR
p11029
sg13
I2
sasg20
(lp11030
(dp11031
g7
I129
sg23
VC0011849
p11032
sg10
I17
sg11
Vdiabetes mellitus
p11033
sg13
I2
sa(dp11034
g7
I43
sg23
VC0027651
p11035
sg10
I6
sg11
Vtumors
p11036
sg13
I1
sasa(dp11037
g2
S'Pancreatic carcinoma (n = 7), pancreatitis tissue (n = 4), normal pancreas tissue (n = 5), colonic adenocarcinoma (n = 4) and in vitro human pancreatic cancer cell lines (n = 6) were studied with the murine monoclonal antibodies (MAbs) 3DS2A, AR1-28, AR2-20, Ca19-9 and CA17-1A to determine their immunohistologic specificity and sensitivity for use as radiolabeled diagnostic imaging agents.\n'
p11038
sg4
(lp11039
(dp11040
g7
I243
sg8
g18
sg10
I6
sg11
VAR1-28
p11041
sg13
I1
sasg20
(lp11042
(dp11043
g7
I30
sg23
VC0030305
p11044
sg10
I12
sg11
Vpancreatitis
p11045
sg13
I1
sa(dp11046
g7
I91
sg23
VC0338106
p11047
sg10
I22
sg11
Vcolonic adenocarcinoma
p11048
sg13
I2
sa(dp11049
g7
I141
sg23
VC0235974
p11050
sg10
I17
sg11
Vpancreatic cancer
p11051
sg13
I2
sa(dp11052
g7
I0
sg23
VC0235974
p11053
sg10
I20
sg11
VPancreatic carcinoma
p11054
sg13
I2
sasa(dp11055
g2
S'In one subject with complete androgen insensitivity syndrome, a reduction in size of the 2.4 kilobase band hybridizing to hAR1 was noted.\n'
p11056
sg4
(lp11057
sg20
(lp11058
(dp11059
g7
I20
sg23
VC0936016
p11060
sg10
I40
sg11
Vcomplete androgen insensitivity syndrome
p11061
sg13
I4
sasa(dp11062
g2
S"Moreover, in other forms of spondyloarthropathy, a similar association has been reported: 42% of patients with spondyloarthropathy and associated asymptomatic chronic gut inflammation, who are considered likely to develop Crohn's disease and ankylosing spondylitis, are carriers of at least one CARD15 mutation, compared with only 7% of patients with normal histology.\n"
p11063
sg4
(lp11064
(dp11065
g7
I295
sg8
g18
sg10
I15
sg11
VCARD15 mutation
p11066
sg13
I2
sasg20
(lp11067
(dp11068
g7
I171
sg23
VC0021368
p11069
sg10
I12
sg11
Vinflammation
p11070
sg13
I1
sa(dp11071
g7
I222
sg23
VC0010346
p11072
sg10
I15
sg11
VCrohn's disease
p11073
sg13
I2
sa(dp11074
g7
I28
sg23
VC0949691
p11075
sg10
I19
sg11
Vspondyloarthropathy
p11076
sg13
I1
sa(dp11077
g7
I28
sg23
VC0949691
p11078
sg10
I19
sg11
Vspondyloarthropathy
p11079
sg13
I1
sa(dp11080
g7
I242
sg23
VC0038013
p11081
sg10
I22
sg11
Vankylosing spondylitis
p11082
sg13
I2
sasa(dp11083
g2
S'According the importance of genetic factors in the etiopathogenesis of both diseases (mutation in the NOD2 gene for Crohn--HLA-B27 phenotype for spondyloarthropathy) future studies are necessary to find a common alteration explaining the link between gut and joint.\n'
p11084
sg4
(lp11085
(dp11086
g7
I102
sg8
VP22301
p11087
sg10
I9
sg11
VNOD2 gene
p11088
sg13
I2
sa(dp11089
g7
I116
sg8
VP30486
p11090
sg10
I14
sg11
VCrohn--HLA-B27
p11091
sg13
I1
sasg20
(lp11092
(dp11093
g7
I145
sg23
VC0949691
p11094
sg10
I19
sg11
Vspondyloarthropathy
p11095
sg13
I1
sasa(dp11096
g2
S'A recent publication in Science identifies the cytosolic adapter molecule MAVS as being responsible for species restriction of infection with hepatitis A virus as well as linking cytosolic immune sensing in infected hepatocytes with innate effector functions and protective adaptive immunity.\n'
p11097
sg4
(lp11098
sg20
(lp11099
(dp11100
g7
I142
sg23
VC0019159
p11101
sg10
I11
sg11
Vhepatitis A
p11102
sg13
I2
sa(dp11103
g7
I127
sg23
VC0009450
p11104
sg10
I9
sg11
Vinfection
p11105
sg13
I1
sasa(dp11106
g2
S'To refine the role of MAVS subcellular localization for the induction of type I and III IFN responses in hepatocytes and its counteraction by the hepatitis C virus (HCV), we generated various functional and genetic knock-out cell systems that were reconstituted to express mitochondrial (mito) or peroxisomal (pex) MAVS, exclusively.\n'
p11107
sg4
(lp11108
(dp11109
g7
I88
sg8
VP01562
p11110
sg10
I3
sg11
VIFN
p11111
sg13
I1
sasg20
(lp11112
(dp11113
g7
I146
sg23
VC0019196
p11114
sg10
I11
sg11
Vhepatitis C
p11115
sg13
I2
sasa(dp11116
g2
S'To determine whether viral counteraction of MAVS is affected by its subcellular localization we employed infection of cells with HCV, a major causative agent of chronic liver disease with a high propensity to establish persistence.\n'
p11117
sg4
(lp11118
(dp11119
g7
I44
sg8
g18
sg10
I4
sg11
VMAVS
p11120
sg13
I1
sasg20
(lp11121
(dp11122
g7
I105
sg23
VC0009450
p11123
sg10
I9
sg11
Vinfection
p11124
sg13
I1
sa(dp11125
g7
I161
sg23
VC0341439
p11126
sg10
I21
sg11
Vchronic liver disease
p11127
sg13
I3
sasa(dp11128
g2
S'To identify components that regulate MAVS signalosome assembly on the MAM, we characterized the proteome of MAM, ER, and cytosol from cells infected with either chronic (hepatitis C) or acute (Sendai) RNA virus infections, as well as mock-infected cells.\n'
p11129
sg4
(lp11130
(dp11131
g7
I70
sg8
g18
sg10
I3
sg11
VMAM
p11132
sg13
I1
sasg20
(lp11133
(dp11134
g7
I170
sg23
VC0019196
p11135
sg10
I11
sg11
Vhepatitis C
p11136
sg13
I2
sa(dp11137
g7
I201
sg23
VC0035690
p11138
sg10
I20
sg11
VRNA virus infections
p11139
sg13
I3
sasa(dp11140
g2
S'TTC19 deficiency is a progressive neurodegenerative disease associated with isolated mitochondrial respiratory chain (MRC) complex III deficiency and loss-of-function mutations in the TT19 gene in the few patients reported so far.\n'
p11141
sg4
(lp11142
(dp11143
g7
I0
sg8
g18
sg10
I5
sg11
VTTC19
p11144
sg13
I1
sasg20
(lp11145
(dp11146
g7
I34
sg23
VC0524851
p11147
sg10
I25
sg11
Vneurodegenerative disease
p11148
sg13
I2
sa(dp11149
g7
I123
sg23
VC0342778
p11150
sg10
I22
sg11
Vcomplex III deficiency
p11151
sg13
I3
sasa(dp11152
g2
S'Mutations in TTC19 have been rarely associated with mitochondrial disease to date, being described in about ten patients with heterogeneous clinical presentations, ranging from early onset encephalomyopathy to adult forms with cerebellar ataxia.\n'
p11153
sg4
(lp11154
(dp11155
g7
I13
sg8
g18
sg10
I5
sg11
VTTC19
p11156
sg13
I1
sasg20
(lp11157
(dp11158
g7
I227
sg23
VC0007758
p11159
sg10
I17
sg11
Vcerebellar ataxia
p11160
sg13
I2
sa(dp11161
g7
I52
sg23
VC0751651
p11162
sg10
I21
sg11
Vmitochondrial disease
p11163
sg13
I2
sasa(dp11164
g2
S'TTC19 has been reported to be a causative gene of a neurodegenerative disease in Italian and Portuguese families and to be involved in the pathogenesis of mitochondrial respiratory chain complex III (cIII) deficiency.\n'
p11165
sg4
(lp11166
(dp11167
g7
I0
sg8
g18
sg10
I5
sg11
VTTC19
p11168
sg13
I1
sa(dp11169
g7
I155
sg8
VP41217
p11170
sg10
I43
sg11
Vmitochondrial respiratory chain complex III
p11171
sg13
I5
sasg20
(lp11172
(dp11173
g7
I52
sg23
VC0524851
p11174
sg10
I25
sg11
Vneurodegenerative disease
p11175
sg13
I2
sa(dp11176
g7
I139
sg23
VC0699748
p11177
sg10
I12
sg11
Vpathogenesis
p11178
sg13
I1
sasa(dp11179
g2
S'We identified a homozygous nonsense mutation in the gene encoding tetratricopeptide 19 (TTC19) in individuals from two families affected by progressive encephalopathy associated with profound cIII deficiency and accumulation of cIII-specific assembly intermediates.\n'
p11180
sg4
(lp11181
sg20
(lp11182
(dp11183
g7
I27
sg23
VC0544885
p11184
sg10
I17
sg11
Vnonsense mutation
p11185
sg13
I2
sa(dp11186
g7
I152
sg23
VC0085584
p11187
sg10
I14
sg11
Vencephalopathy
p11188
sg13
I1
sasa(dp11189
g2
S"Recent studies highlight the importance of both traditional and newly recognized interactors of mTOR, such as p70S6K, 4EBP1, GSK-3Beta, REDD1/RTP801, TSC1/TSC2, growth factors, wingless, and forkhead transcription factors, that influence Alzheimer's disease, Parkinson's disease, Huntington's disease, tuberous sclerosis, and epilepsy.\n"
p11190
sg4
(lp11191
(dp11192
g7
I125
sg8
VP49841
p11193
sg10
I9
sg11
VGSK-3Beta
p11194
sg13
I1
sa(dp11195
g7
I161
sg8
VP19883
p11196
sg10
I14
sg11
Vgrowth factors
p11197
sg13
I2
sa(dp11198
g7
I191
sg8
VP19883
p11199
sg10
I30
sg11
Vforkhead transcription factors
p11200
sg13
I3
sa(dp11201
g7
I96
sg8
VP42345
p11202
sg10
I4
sg11
VmTOR
p11203
sg13
I1
sa(dp11204
g7
I142
sg8
g18
sg10
I6
sg11
VRTP801
p11205
sg13
I1
sa(dp11206
g7
I155
sg8
VP49815
p11207
sg10
I4
sg11
VTSC2
p11208
sg13
I1
sa(dp11209
g7
I136
sg8
g18
sg10
I5
sg11
VREDD1
p11210
sg13
I1
sa(dp11211
g7
I118
sg8
g18
sg10
I5
sg11
V4EBP1
p11212
sg13
I1
sa(dp11213
g7
I150
sg8
g18
sg10
I4
sg11
VTSC1
p11214
sg13
I1
sasg20
(lp11215
(dp11216
g7
I238
sg23
VC1521724
p11217
sg10
I19
sg11
VAlzheimer's disease
p11218
sg13
I2
sa(dp11219
g7
I302
sg23
VC0041341
p11220
sg10
I18
sg11
Vtuberous sclerosis
p11221
sg13
I2
sa(dp11222
g7
I280
sg23
VC0020179
p11223
sg10
I20
sg11
VHuntington's disease
p11224
sg13
I2
sa(dp11225
g7
I155
sg23
VC1860707
p11226
sg10
I4
sg11
VTSC2
p11227
sg13
I1
sa(dp11228
g7
I259
sg23
VC0030567
p11229
sg10
I19
sg11
VParkinson's disease
p11230
sg13
I2
sa(dp11231
g7
I326
sg23
VC0014544
p11232
sg10
I8
sg11
Vepilepsy
p11233
sg13
I1
sa(dp11234
g7
I150
sg23
VC1854465
p11235
sg10
I4
sg11
VTSC1
p11236
sg13
I1
sasa(dp11237
g2
S'JARID2 is down-regulated in B-chronic lymphocytic leukemia (B-CLL) and acute monocytic leukemia (AMOL), and knockdown of JARID2 promotes leukemia cell proliferation via acceleration of the G1/S transition.\n'
p11238
sg4
(lp11239
(dp11240
g7
I0
sg8
g18
sg10
I6
sg11
VJARID2
p11241
sg13
I1
sa(dp11242
g7
I0
sg8
g18
sg10
I6
sg11
VJARID2
p11243
sg13
I1
sasg20
(lp11244
(dp11245
g7
I97
sg23
VC1318544
p11246
sg10
I4
sg11
VAMOL
p11247
sg13
I1
sa(dp11248
g7
I151
sg23
VC0334094
p11249
sg10
I13
sg11
Vproliferation
p11250
sg13
I1
sa(dp11251
g7
I194
sg23
VC0599156
p11252
sg10
I10
sg11
Vtransition
p11253
sg13
I1
sa(dp11254
g7
I71
sg23
VC1318544
p11255
sg10
I24
sg11
Vacute monocytic leukemia
p11256
sg13
I3
sa(dp11257
g7
I50
sg23
VC0023418
p11258
sg10
I8
sg11
Vleukemia
p11259
sg13
I1
sa(dp11260
g7
I62
sg23
VC0023434
p11261
sg10
I3
sg11
VCLL
p11262
sg13
I1
sa(dp11263
g7
I30
sg23
VC0023434
p11264
sg10
I28
sg11
Vchronic lymphocytic leukemia
p11265
sg13
I3
sasa(dp11266
g2
S'In addition, we demonstrated that miR-15b degraded SMURF2 and its overexpression promoted EMT in pancreatic cancer, and its expression was associated with metastasis in the disease.\n'
p11267
sg4
(lp11268
(dp11269
g7
I90
sg8
g18
sg10
I3
sg11
VEMT
p11270
sg13
I1
sa(dp11271
g7
I51
sg8
g18
sg10
I6
sg11
VSMURF2
p11272
sg13
I1
sa(dp11273
g7
I34
sg8
g18
sg10
I7
sg11
VmiR-15b
p11274
sg13
I1
sasg20
(lp11275
(dp11276
g7
I97
sg23
VC0235974
p11277
sg10
I17
sg11
Vpancreatic cancer
p11278
sg13
I2
sa(dp11279
g7
I155
sg23
VC0027627
p11280
sg10
I10
sg11
Vmetastasis
p11281
sg13
I1
sasa(dp11282
g2
S'Our results support the use of carnosic acid-rich rosemary extract as a complementary approach in colon and pancreatic cancer and indicate that GCNT3 expression may be involved in its antitumor mechanism and that miR-15b might be used as a non-invasive biomarker to monitor rosemary anticancer effect.\n'
p11283
sg4
(lp11284
(dp11285
g7
I213
sg8
g18
sg10
I7
sg11
VmiR-15b
p11286
sg13
I1
sa(dp11287
g7
I144
sg8
g18
sg10
I5
sg11
VGCNT3
p11288
sg13
I1
sasg20
(lp11289
(dp11290
g7
I108
sg23
VC0235974
p11291
sg10
I17
sg11
Vpancreatic cancer
p11292
sg13
I2
sasa(dp11293
g2
S'Eight miRNAs were significantly upregulated in most pancreatic cancer tissues and cell lines, including miR-196a, miR-190, miR-186, miR-221, miR-222, miR-200b, miR-15b, and miR-95.\n'
p11294
sg4
(lp11295
(dp11296
g7
I150
sg8
g18
sg10
I8
sg11
VmiR-200b
p11297
sg13
I1
sa(dp11298
g7
I160
sg8
g18
sg10
I7
sg11
VmiR-15b
p11299
sg13
I1
sa(dp11300
g7
I173
sg8
g18
sg10
I6
sg11
VmiR-95
p11301
sg13
I1
sa(dp11302
g7
I141
sg8
g18
sg10
I7
sg11
VmiR-222
p11303
sg13
I1
sa(dp11304
g7
I132
sg8
g18
sg10
I7
sg11
VmiR-221
p11305
sg13
I1
sa(dp11306
g7
I114
sg8
g18
sg10
I7
sg11
VmiR-190
p11307
sg13
I1
sa(dp11308
g7
I104
sg8
g18
sg10
I8
sg11
VmiR-196a
p11309
sg13
I1
sa(dp11310
g7
I123
sg8
g18
sg10
I7
sg11
VmiR-186
p11311
sg13
I1
sasg20
(lp11312
(dp11313
g7
I52
sg23
VC0235974
p11314
sg10
I17
sg11
Vpancreatic cancer
p11315
sg13
I2
sasa(dp11316
g2
S'Van den Ende-Gupta Syndrome (VDEGS) is an autosomal recessive disorder characterized by blepharophimosis, distinctive nose, hypoplastic maxilla, and skeletal abnormalities.\n'
p11317
sg4
(lp11318
sg20
(lp11319
(dp11320
g7
I29
sg23
VC1833136
p11321
sg10
I5
sg11
VVDEGS
p11322
sg13
I1
sa(dp11323
g7
I88
sg23
VC0005744
p11324
sg10
I16
sg11
Vblepharophimosis
p11325
sg13
I1
sa(dp11326
g7
I0
sg23
VC1833136
p11327
sg10
I27
sg11
VVan den Ende-Gupta Syndrome
p11328
sg13
I4
sasa(dp11329
g2
S'[2010] described a VDEGS patient with sclerocornea and cataracts with compound heterozygosity for the common 22q11.2 microdeletion and a hemizygous SCARF2 mutation.\n'
p11330
sg4
(lp11331
(dp11332
g7
I148
sg8
g18
sg10
I6
sg11
VSCARF2
p11333
sg13
I1
sasg20
(lp11334
(dp11335
g7
I38
sg23
VC1853235
p11336
sg10
I12
sg11
Vsclerocornea
p11337
sg13
I1
sa(dp11338
g7
I19
sg23
VC1833136
p11339
sg10
I5
sg11
VVDEGS
p11340
sg13
I1
sa(dp11341
g7
I55
sg23
VC0521707
p11342
sg10
I9
sg11
Vcataracts
p11343
sg13
I1
sasa(dp11344
g2
S'Because sclerocornea had been described in DiGeorge-velo-cardio-facial syndrome but not in VDEGS, they suggested that the ocular abnormalities were caused by the 22q11.2 microdeletion.\n'
p11345
sg4
(lp11346
sg20
(lp11347
(dp11348
g7
I8
sg23
VC1853235
p11349
sg10
I12
sg11
Vsclerocornea
p11350
sg13
I1
sa(dp11351
g7
I91
sg23
VC1833136
p11352
sg10
I5
sg11
VVDEGS
p11353
sg13
I1
sa(dp11354
g7
I52
sg23
VC0220704
p11355
sg10
I27
sg11
Vvelo-cardio-facial syndrome
p11356
sg13
I2
sasa(dp11357
g2
S'We report on a 23-year-old male who presented with bilateral sclerocornea and the VDGEGS phenotype who was subsequently found to be homozygous for a 17 bp deletion in exon 4 of SCARF2.\n'
p11358
sg4
(lp11359
(dp11360
g7
I177
sg8
g18
sg10
I6
sg11
VSCARF2
p11361
sg13
I1
sasg20
(lp11362
(dp11363
g7
I61
sg23
VC1853235
p11364
sg10
I12
sg11
Vsclerocornea
p11365
sg13
I1
sasa(dp11366
g2
S'The occurrence of bilateral sclerocornea in our patient together with that of Bedeschi et al., suggests that the full VDEGS phenotype may include sclerocornea resulting from homozygosity or compound heterozygosity for loss of function variants in SCARF2.\n'
p11367
sg4
(lp11368
(dp11369
g7
I247
sg8
g18
sg10
I6
sg11
VSCARF2
p11370
sg13
I1
sasg20
(lp11371
(dp11372
g7
I118
sg23
VC1833136
p11373
sg10
I5
sg11
VVDEGS
p11374
sg13
I1
sa(dp11375
g7
I28
sg23
VC1853235
p11376
sg10
I12
sg11
Vsclerocornea
p11377
sg13
I1
sa(dp11378
g7
I28
sg23
VC1853235
p11379
sg10
I12
sg11
Vsclerocornea
p11380
sg13
I1
sasa(dp11381
g2
S'Van den Ende-Gupta syndrome (VDEGS) is a congenital condition characterized by craniofacial and skeletal manifestations, specifically blepharophimosis, malar and maxillary hypoplasia, distinctive nose, arachnocamptodactyly, and long slender bones of the hands and feet.\n'
p11382
sg4
(lp11383
sg20
(lp11384
(dp11385
g7
I29
sg23
VC1833136
p11386
sg10
I5
sg11
VVDEGS
p11387
sg13
I1
sa(dp11388
g7
I52
sg23
VC0012634
p11389
sg10
I9
sg11
Vcondition
p11390
sg13
I1
sa(dp11391
g7
I162
sg23
VC0240310
p11392
sg10
I20
sg11
Vmaxillary hypoplasia
p11393
sg13
I2
sa(dp11394
g7
I0
sg23
VC1833136
p11395
sg10
I27
sg11
VVan den Ende-Gupta syndrome
p11396
sg13
I4
sa(dp11397
g7
I134
sg23
VC0005744
p11398
sg10
I16
sg11
Vblepharophimosis
p11399
sg13
I1
sasa(dp11400
g2
S'Van Den Ende-Gupta syndrome (VDEGS) is an infrequently described disorder characterized by arachnodactyly, camptodactyly, blepharophimosis, malar hypoplasia, narrow nasal bridge, convex nasal ridge, and everted lower lip.\n'
p11401
sg4
(lp11402
sg20
(lp11403
(dp11404
g7
I29
sg23
VC1833136
p11405
sg10
I5
sg11
VVDEGS
p11406
sg13
I1
sa(dp11407
g7
I146
sg23
VC0243069
p11408
sg10
I10
sg11
Vhypoplasia
p11409
sg13
I1
sa(dp11410
g7
I0
sg23
VC1833136
p11411
sg10
I27
sg11
VVan Den Ende-Gupta syndrome
p11412
sg13
I4
sa(dp11413
g7
I122
sg23
VC0005744
p11414
sg10
I16
sg11
Vblepharophimosis
p11415
sg13
I1
sa(dp11416
g7
I91
sg23
VC0003706
p11417
sg10
I14
sg11
Varachnodactyly
p11418
sg13
I1
sa(dp11419
g7
I107
sg23
VC0221369
p11420
sg10
I13
sg11
Vcamptodactyly
p11421
sg13
I1
sa(dp11422
g7
I217
sg23
VC0264511
p11423
sg10
I3
sg11
Vlip
p11424
sg13
I1
sasa(dp11425
g2
S'Van Den Ende-Gupta syndrome (VDEGS) is an extremely rare autosomal-recessive disorder characterized by distinctive craniofacial features, which include blepharophimosis, malar and/or maxillary hypoplasia, a narrow and beaked nose, and an everted lower lip.\n'
p11426
sg4
(lp11427
sg20
(lp11428
(dp11429
g7
I29
sg23
VC1833136
p11430
sg10
I5
sg11
VVDEGS
p11431
sg13
I1
sa(dp11432
g7
I152
sg23
VC0005744
p11433
sg10
I16
sg11
Vblepharophimosis
p11434
sg13
I1
sa(dp11435
g7
I252
sg23
VC0264511
p11436
sg10
I3
sg11
Vlip
p11437
sg13
I1
sa(dp11438
g7
I0
sg23
VC1833136
p11439
sg10
I27
sg11
VVan Den Ende-Gupta syndrome
p11440
sg13
I4
sa(dp11441
g7
I183
sg23
VC0240310
p11442
sg10
I20
sg11
Vmaxillary hypoplasia
p11443
sg13
I2
sasa(dp11444
g2
S'van den Ende-Gupta syndrome is characterized by craniofacial and skeletal manifestations, mainly malar and/or maxillary hypoplasia, blepharophimosis, distinctive nose, lower lip eversion, arachnodactyly, camptodactyly, and long slender bones of hands and feet.\n'
p11445
sg4
(lp11446
sg20
(lp11447
(dp11448
g7
I0
sg23
VC1833136
p11449
sg10
I27
sg11
Vvan den Ende-Gupta syndrome
p11450
sg13
I4
sa(dp11451
g7
I110
sg23
VC0240310
p11452
sg10
I20
sg11
Vmaxillary hypoplasia
p11453
sg13
I2
sa(dp11454
g7
I188
sg23
VC0003706
p11455
sg10
I14
sg11
Varachnodactyly
p11456
sg13
I1
sa(dp11457
g7
I132
sg23
VC0005744
p11458
sg10
I16
sg11
Vblepharophimosis
p11459
sg13
I1
sa(dp11460
g7
I174
sg23
VC0264511
p11461
sg10
I3
sg11
Vlip
p11462
sg13
I1
sa(dp11463
g7
I204
sg23
VC0221369
p11464
sg10
I13
sg11
Vcamptodactyly
p11465
sg13
I1
sasa(dp11466
g2
S'Here, we report on a Venezuelan child with manifestations of van den Ende-Gupta syndrome, including blepharophimosis, arachnodactyly, and congenital contractures.\n'
p11467
sg4
(lp11468
sg20
(lp11469
(dp11470
g7
I61
sg23
VC1833136
p11471
sg10
I27
sg11
Vvan den Ende-Gupta syndrome
p11472
sg13
I4
sa(dp11473
g7
I100
sg23
VC1833136
p11474
sg10
I61
sg11
Vblepharophimosis, arachnodactyly, and congenital contractures
p11475
sg13
I5
sasa(dp11476
g2
S'This is the fifth report of VDEGS, which is characterized by blepharophimosis, narrow nose with hypoplastic alae nasi, hypoplastic maxilla, everted lower lip, slender and elongated hands and feet, arachnodactyly, self-limiting joint contractures, and distinctive skeletal findings.\n'
p11477
sg4
(lp11478
sg20
(lp11479
(dp11480
g7
I28
sg23
VC1833136
p11481
sg10
I5
sg11
VVDEGS
p11482
sg13
I1
sa(dp11483
g7
I154
sg23
VC0264511
p11484
sg10
I3
sg11
Vlip
p11485
sg13
I1
sa(dp11486
g7
I197
sg23
VC0003706
p11487
sg10
I14
sg11
Varachnodactyly
p11488
sg13
I1
sa(dp11489
g7
I227
sg23
VC0009918
p11490
sg10
I18
sg11
Vjoint contractures
p11491
sg13
I2
sa(dp11492
g7
I61
sg23
VC0005744
p11493
sg10
I16
sg11
Vblepharophimosis
p11494
sg13
I1
sasa(dp11495
g2
S'It is important to distinguish VDEGS from Marden-Walker syndrome (MWS) since both syndromes include blepharophimosis, arachnodactyly, and congenital contractures.\n'
p11496
sg4
(lp11497
sg20
(lp11498
(dp11499
g7
I42
sg23
VC0796033
p11500
sg10
I22
sg11
VMarden-Walker syndrome
p11501
sg13
I2
sa(dp11502
g7
I66
sg23
VC0796033
p11503
sg10
I3
sg11
VMWS
p11504
sg13
I1
sa(dp11505
g7
I100
sg23
VC1833136
p11506
sg10
I61
sg11
Vblepharophimosis, arachnodactyly, and congenital contractures
p11507
sg13
I5
sa(dp11508
g7
I82
sg23
VC0039082
p11509
sg10
I9
sg11
Vsyndromes
p11510
sg13
I1
sa(dp11511
g7
I31
sg23
VC1833136
p11512
sg10
I5
sg11
VVDEGS
p11513
sg13
I1
sasa(dp11514
g2
S'While, congenital contractures with arachnodactyly are features commonly seen in several other delineated syndromes, such as congenital contractural arachnodactyly (CCA) syndrome, characteristic facial features (blepharophimosis, narrow nose with ocular hypertelorism, prominent ears, and everted lower lip), distinguish VDEGS from other syndromes associated with CCA, including CCA.\n'
p11515
sg4
(lp11516
sg20
(lp11517
(dp11518
g7
I165
sg23
VC0268365
p11519
sg10
I3
sg11
VCCA
p11520
sg13
I1
sa(dp11521
g7
I165
sg23
VC0268365
p11522
sg10
I3
sg11
VCCA
p11523
sg13
I1
sa(dp11524
g7
I212
sg23
VC0005744
p11525
sg10
I16
sg11
Vblepharophimosis
p11526
sg13
I1
sa(dp11527
g7
I36
sg23
VC0003706
p11528
sg10
I14
sg11
Varachnodactyly
p11529
sg13
I1
sa(dp11530
g7
I106
sg23
VC0039082
p11531
sg10
I9
sg11
Vsyndromes
p11532
sg13
I1
sa(dp11533
g7
I321
sg23
VC1833136
p11534
sg10
I5
sg11
VVDEGS
p11535
sg13
I1
sa(dp11536
g7
I165
sg23
VC0268365
p11537
sg10
I3
sg11
VCCA
p11538
sg13
I1
sa(dp11539
g7
I247
sg23
VC0020534
p11540
sg10
I20
sg11
Vocular hypertelorism
p11541
sg13
I2
sa(dp11542
g7
I106
sg23
VC0039082
p11543
sg10
I9
sg11
Vsyndromes
p11544
sg13
I1
sa(dp11545
g7
I269
sg23
VC1305420
p11546
sg10
I14
sg11
Vprominent ears
p11547
sg13
I2
sa(dp11548
g7
I125
sg23
VC0220668
p11549
sg10
I38
sg11
Vcongenital contractural arachnodactyly
p11550
sg13
I3
sa(dp11551
g7
I106
sg23
VC0039082
p11552
sg10
I8
sg11
Vsyndrome
p11553
sg13
I1
sa(dp11554
g7
I303
sg23
VC0264511
p11555
sg10
I3
sg11
Vlip
p11556
sg13
I1
sa(dp11557
g7
I7
sg23
VC0332878
p11558
sg10
I23
sg11
Vcongenital contractures
p11559
sg13
I2
sasa(dp11560
g2
S'We previously observed that mitsugumin 29 (Mg29), an important t-tubule organizing protein in skeletal muscle, was induced in the mouse heart for the first time during dilated cardiomyopathy with heart failure.\n'
p11561
sg4
(lp11562
(dp11563
g7
I63
sg8
g18
sg10
I27
sg11
Vt-tubule organizing protein
p11564
sg13
I3
sasg20
(lp11565
(dp11566
g7
I168
sg23
VC0007193
p11567
sg10
I22
sg11
Vdilated cardiomyopathy
p11568
sg13
I2
sa(dp11569
g7
I196
sg23
VC0018802
p11570
sg10
I13
sg11
Vheart failure
p11571
sg13
I2
sasa(dp11572
g2
S'CCDDs have been associated with dominant or recessive monogenic mutations in at least 7 different genes (CHN1, SALL4, HOXA1, KIF21A, PHOX2A, TUBB3, ROBO3) that cause phenotypes such as Duane retraction syndrome, congenital fibrosis of the extraocular muscles, and horizontal gaze palsy with progressive scoliosis.\n'
p11573
sg4
(lp11574
(dp11575
g7
I148
sg8
g18
sg10
I5
sg11
VROBO3
p11576
sg13
I1
sa(dp11577
g7
I105
sg8
VP15882
p11578
sg10
I4
sg11
VCHN1
p11579
sg13
I1
sa(dp11580
g7
I118
sg8
VP49639
p11581
sg10
I5
sg11
VHOXA1
p11582
sg13
I1
sa(dp11583
g7
I141
sg8
VP04350
p11584
sg10
I5
sg11
VTUBB3
p11585
sg13
I1
sa(dp11586
g7
I133
sg8
g18
sg10
I6
sg11
VPHOX2A
p11587
sg13
I1
sa(dp11588
g7
I111
sg8
g18
sg10
I5
sg11
VSALL4
p11589
sg13
I1
sasg20
(lp11590
(dp11591
g7
I185
sg23
VC0013261
p11592
sg10
I25
sg11
VDuane retraction syndrome
p11593
sg13
I3
sa(dp11594
g7
I264
sg23
VC0339651
p11595
sg10
I21
sg11
Vhorizontal gaze palsy
p11596
sg13
I3
sa(dp11597
g7
I223
sg23
VC0016059
p11598
sg10
I8
sg11
Vfibrosis
p11599
sg13
I1
sa(dp11600
g7
I303
sg23
VC0700208
p11601
sg10
I9
sg11
Vscoliosis
p11602
sg13
I1
sasa(dp11603
g2
S'The objective of this study was to investigate whether the genetic polymorphism rs12665607 of ESR1, rs10995190 of ZNF365, rs3817198 of LSP1 and rs17001868 of SGSM3/MKL1 are associated with the development of breast cancer (BC) in the Chinese women.\n'
p11604
sg4
(lp11605
(dp11606
g7
I94
sg8
VP03372
p11607
sg10
I4
sg11
VESR1
p11608
sg13
I1
sa(dp11609
g7
I114
sg8
g18
sg10
I6
sg11
VZNF365
p11610
sg13
I1
sa(dp11611
g7
I135
sg8
VP33241
p11612
sg10
I4
sg11
VLSP1
p11613
sg13
I1
sa(dp11614
g7
I164
sg8
g18
sg10
I4
sg11
VMKL1
p11615
sg13
I1
sa(dp11616
g7
I158
sg8
g18
sg10
I5
sg11
VSGSM3
p11617
sg13
I1
sasg20
(lp11618
(dp11619
g7
I223
sg23
VC0678222
p11620
sg10
I2
sg11
VBC
p11621
sg13
I1
sa(dp11622
g7
I208
sg23
VC0678222
p11623
sg10
I13
sg11
Vbreast cancer
p11624
sg13
I2
sasa(dp11625
g2
S'The objective of the present work was to investigate key genes in ovarian cancer based on mAP-KL method which comprised the maxT multiple hypothesis (m), Krzanowski and Lai (KL) cluster quality index, and affinity propagation (AP) clustering algorithm, and mutual information network (MIN) constructed by the context likelihood of relatedness (CLR) algorithm.\n'
p11626
sg4
(lp11627
sg20
(lp11628
(dp11629
g7
I66
sg23
VC1140680
p11630
sg10
I14
sg11
Vovarian cancer
p11631
sg13
I2
sasa(dp11632
g2
S'SVM model validated that the classification between normal controls and ovarian cancer patients by mAP-KL had a good performance.\n'
p11633
sg4
(lp11634
sg20
(lp11635
(dp11636
g7
I72
sg23
VC1140680
p11637
sg10
I14
sg11
Vovarian cancer
p11638
sg13
I2
sasa(dp11639
g2
S'We have obtained three key genes (C9orf16, COX5B and ACTB) for ovarian cancer on the basis of mAP-KL method and MIN analysis.\n'
p11640
sg4
(lp11641
(dp11642
g7
I53
sg8
VP63261
p11643
sg10
I4
sg11
VACTB
p11644
sg13
I1
sa(dp11645
g7
I43
sg8
VP10606
p11646
sg10
I5
sg11
VCOX5B
p11647
sg13
I1
sa(dp11648
g7
I34
sg8
g18
sg10
I7
sg11
VC9orf16
p11649
sg13
I1
sasg20
(lp11650
(dp11651
g7
I63
sg23
VC1140680
p11652
sg10
I14
sg11
Vovarian cancer
p11653
sg13
I2
sasa(dp11654
g2
S'We selected for evaluation 1327 single nucleotide polymorphisms (SNPs) showing the lowest P-values for interaction (P int) in a meta-analysis of genome-wide gene-environment interaction studies with MHT use on risk of breast cancer, 2541 SNPs in candidate genes (AKR1C4, CYP1A1-CYP1A2, CYP1B1, ESR2, PPARG, PRL, SULT1A1-SULT1A2 and TNF) and ten SNPs (AREG-rs10034692, PRDM6-rs186749, ESR1-rs12665607, ZNF365-rs10995190, 8p11.23-rs7816345, LSP1-rs3817198, IGF1-rs703556, 12q24-rs1265507, TMEM184B-rs7289126, and SGSM3-rs17001868) associated with mammographic density in genome-wide studies.\n'
p11655
sg4
(lp11656
(dp11657
g7
I278
sg8
VP05177
p11658
sg10
I6
sg11
VCYP1A2
p11659
sg13
I1
sa(dp11660
g7
I300
sg8
g18
sg10
I5
sg11
VPPARG
p11661
sg13
I1
sa(dp11662
g7
I368
sg8
g18
sg10
I14
sg11
VPRDM6-rs186749
p11663
sg13
I1
sa(dp11664
g7
I439
sg8
VP33241
p11665
sg10
I4
sg11
VLSP1
p11666
sg13
I1
sa(dp11667
g7
I384
sg8
VP03372
p11668
sg10
I4
sg11
VESR1
p11669
sg13
I1
sa(dp11670
g7
I312
sg8
VP50225
p11671
sg10
I15
sg11
VSULT1A1-SULT1A2
p11672
sg13
I1
sa(dp11673
g7
I332
sg8
VP01375
p11674
sg10
I3
sg11
VTNF
p11675
sg13
I1
sa(dp11676
g7
I351
sg8
VP15514
p11677
sg10
I15
sg11
VAREG-rs10034692
p11678
sg13
I1
sa(dp11679
g7
I487
sg8
g18
sg10
I8
sg11
VTMEM184B
p11680
sg13
I1
sa(dp11681
g7
I401
sg8
g18
sg10
I36
sg11
VZNF365-rs10995190, 8p11.23-rs7816345
p11682
sg13
I2
sa(dp11683
g7
I65
sg8
g18
sg10
I4
sg11
VSNPs
p11684
sg13
I1
sa(dp11685
g7
I511
sg8
g18
sg10
I16
sg11
VSGSM3-rs17001868
p11686
sg13
I1
sa(dp11687
g7
I455
sg8
VP01343
p11688
sg10
I4
sg11
VIGF1
p11689
sg13
I1
sa(dp11690
g7
I32
sg8
g18
sg10
I31
sg11
Vsingle nucleotide polymorphisms
p11691
sg13
I3
sa(dp11692
g7
I286
sg8
g18
sg10
I6
sg11
VCYP1B1
p11693
sg13
I1
sa(dp11694
g7
I263
sg8
VP17516
p11695
sg10
I6
sg11
VAKR1C4
p11696
sg13
I1
sa(dp11697
g7
I307
sg8
VP01236
p11698
sg10
I3
sg11
VPRL
p11699
sg13
I1
sa(dp11700
g7
I271
sg8
VP04798
p11701
sg10
I6
sg11
VCYP1A1
p11702
sg13
I1
sasg20
(lp11703
(dp11704
g7
I218
sg23
VC0678222
p11705
sg10
I13
sg11
Vbreast cancer
p11706
sg13
I2
sa(dp11707
g7
I545
sg23
VC1846502
p11708
sg10
I20
sg11
Vmammographic density
p11709
sg13
I2
sasa(dp11710
g2
S'In this study, the expression of miR-663a/miR-423-5p and TNIP2 were compared between human renal biopsy tissues from LN patients and renal cell carcinoma patients.\n'
p11711
sg4
(lp11712
(dp11713
g7
I57
sg8
g18
sg10
I5
sg11
VTNIP2
p11714
sg13
I1
sa(dp11715
g7
I42
sg8
g18
sg10
I10
sg11
VmiR-423-5p
p11716
sg13
I1
sa(dp11717
g7
I33
sg8
g18
sg10
I8
sg11
VmiR-663a
p11718
sg13
I1
sasg20
(lp11719
(dp11720
g7
I133
sg23
VC0007134
p11721
sg10
I20
sg11
Vrenal cell carcinoma
p11722
sg13
I3
sasa(dp11723
g2
S'This study aimed to investigate the effect of miR-423-5p on the sensitivity of glioma stem cells to apigenin and to explore the potential mechanism.\n'
p11724
sg4
(lp11725
(dp11726
g7
I46
sg8
g18
sg10
I10
sg11
VmiR-423-5p
p11727
sg13
I1
sasg20
(lp11728
(dp11729
g7
I79
sg23
VC0017638
p11730
sg10
I6
sg11
Vglioma
p11731
sg13
I1
sasa(dp11732
g2
S'In this study, we found miR-423-5p to be overexpressed in glioma tissues and corresponding glioma stem cells.\n'
p11733
sg4
(lp11734
(dp11735
g7
I24
sg8
g18
sg10
I10
sg11
VmiR-423-5p
p11736
sg13
I1
sasg20
(lp11737
(dp11738
g7
I58
sg23
VC0017638
p11739
sg10
I6
sg11
Vglioma
p11740
sg13
I1
sa(dp11741
g7
I58
sg23
VC0017638
p11742
sg10
I6
sg11
Vglioma
p11743
sg13
I1
sasa(dp11744
g2
S'Downregulation of miR-423-5p repressed glioma stem cell growth but did not cause apoptosis.\n'
p11745
sg4
(lp11746
(dp11747
g7
I18
sg8
g18
sg10
I10
sg11
VmiR-423-5p
p11748
sg13
I1
sasg20
(lp11749
(dp11750
g7
I39
sg23
VC0017638
p11751
sg10
I6
sg11
Vglioma
p11752
sg13
I1
sasa(dp11753
g2
S'Based on the concept of "Pharmaco-miR," this study further demonstrated that the combination of miR-423-5p knockdown and apigenin had a notable additive effect on inhibiting proliferation and promoting apoptosis in glioma stem cells.\n'
p11754
sg4
(lp11755
(dp11756
g7
I96
sg8
g18
sg10
I10
sg11
VmiR-423-5p
p11757
sg13
I1
sasg20
(lp11758
(dp11759
g7
I215
sg23
VC0017638
p11760
sg10
I6
sg11
Vglioma
p11761
sg13
I1
sa(dp11762
g7
I174
sg23
VC0334094
p11763
sg10
I13
sg11
Vproliferation
p11764
sg13
I1
sasa(dp11765
g2
S'In conclusion, this study indicates that downregulation of miR-423-5p enhances the sensitivity of glioma stem cells to apigenin through the mitochondrial pathway.\n'
p11766
sg4
(lp11767
(dp11768
g7
I59
sg8
g18
sg10
I10
sg11
VmiR-423-5p
p11769
sg13
I1
sasg20
(lp11770
(dp11771
g7
I98
sg23
VC0017638
p11772
sg10
I6
sg11
Vglioma
p11773
sg13
I1
sasa(dp11774
g2
S'Among the top, miR-21-5p, let-7b-5p, let-7a-5p, miR-424-5p, miR-423-5p, miR-21-3p, miR-199b-5p, miR-182-5p, and miR-205-5p were differentially expressed between thin and thick melanomas.\n'
p11775
sg4
(lp11776
(dp11777
g7
I48
sg8
g18
sg10
I10
sg11
VmiR-424-5p
p11778
sg13
I1
sa(dp11779
g7
I72
sg8
g18
sg10
I9
sg11
VmiR-21-3p
p11780
sg13
I1
sa(dp11781
g7
I15
sg8
g18
sg10
I9
sg11
VmiR-21-5p
p11782
sg13
I1
sa(dp11783
g7
I60
sg8
g18
sg10
I10
sg11
VmiR-423-5p
p11784
sg13
I1
sa(dp11785
g7
I112
sg8
g18
sg10
I10
sg11
VmiR-205-5p
p11786
sg13
I1
sa(dp11787
g7
I83
sg8
g18
sg10
I11
sg11
VmiR-199b-5p
p11788
sg13
I1
sa(dp11789
g7
I96
sg8
g18
sg10
I10
sg11
VmiR-182-5p
p11790
sg13
I1
sasg20
(lp11791
(dp11792
g7
I176
sg23
VC0025202
p11793
sg10
I9
sg11
Vmelanomas
p11794
sg13
I1
sasa(dp11795
g2
S'Real-time PCR was used to analyze the expression of microRNA-423-5p (miR-423-5p) in human glioma samples and normal brain tissue.\n'
p11796
sg4
(lp11797
(dp11798
g7
I52
sg8
g18
sg10
I15
sg11
VmicroRNA-423-5p
p11799
sg13
I1
sa(dp11800
g7
I69
sg8
g18
sg10
I10
sg11
VmiR-423-5p
p11801
sg13
I1
sasg20
(lp11802
(dp11803
g7
I90
sg23
VC0017638
p11804
sg10
I6
sg11
Vglioma
p11805
sg13
I1
sasa(dp11806
g2
S'Western blotting was used to determine the expression of inhibitor of growth 4 (ING-4)in glioma tissues, and a luciferase reporter assay was conducted to confirm whether ING-4 is a direct target of miR-423-5p.\n'
p11807
sg4
(lp11808
(dp11809
g7
I198
sg8
g18
sg10
I10
sg11
VmiR-423-5p
p11810
sg13
I1
sa(dp11811
g7
I80
sg8
g18
sg10
I5
sg11
VING-4
p11812
sg13
I1
sa(dp11813
g7
I80
sg8
g18
sg10
I5
sg11
VING-4
p11814
sg13
I1
sa(dp11815
g7
I57
sg8
g18
sg10
I21
sg11
Vinhibitor of growth 4
p11816
sg13
I4
sasg20
(lp11817
(dp11818
g7
I89
sg23
VC0017638
p11819
sg10
I6
sg11
Vglioma
p11820
sg13
I1
sasa(dp11821
g2
S'Western blotting was used to identify the potential signaling pathways that are affected in glioma cell growth by miR-423-5p.\n'
p11822
sg4
(lp11823
(dp11824
g7
I114
sg8
g18
sg10
I10
sg11
VmiR-423-5p
p11825
sg13
I1
sasg20
(lp11826
(dp11827
g7
I92
sg23
VC0017638
p11828
sg10
I6
sg11
Vglioma
p11829
sg13
I1
sasa(dp11830
g2
S'Xenograft tumors were examined in vivo for the carcinogenic effects of miR-423-5p in glioma tissues.\n'
p11831
sg4
(lp11832
(dp11833
g7
I71
sg8
g18
sg10
I10
sg11
VmiR-423-5p
p11834
sg13
I1
sasg20
(lp11835
(dp11836
g7
I85
sg23
VC0017638
p11837
sg10
I6
sg11
Vglioma
p11838
sg13
I1
sa(dp11839
g7
I10
sg23
VC0027651
p11840
sg10
I6
sg11
Vtumors
p11841
sg13
I1
sasa(dp11842
g2
S'We first reported that miR-423-5p expression was increased in gliomas and was a potential tumor promoter via targeting ING-4.\n'
p11843
sg4
(lp11844
(dp11845
g7
I23
sg8
g18
sg10
I10
sg11
VmiR-423-5p
p11846
sg13
I1
sasg20
(lp11847
(dp11848
g7
I62
sg23
VC0017638
p11849
sg10
I7
sg11
Vgliomas
p11850
sg13
I1
sa(dp11851
g7
I90
sg23
VC0027651
p11852
sg10
I5
sg11
Vtumor
p11853
sg13
I1
sasa(dp11854
g2
S'Furthermore, the overexpression of miR-423-5p strengthened glioma cell proliferation, angiogenesis, and invasion.\n'
p11855
sg4
(lp11856
(dp11857
g7
I35
sg8
g18
sg10
I10
sg11
VmiR-423-5p
p11858
sg13
I1
sasg20
(lp11859
(dp11860
g7
I104
sg23
VC2699153
p11861
sg10
I8
sg11
Vinvasion
p11862
sg13
I1
sa(dp11863
g7
I71
sg23
VC0334094
p11864
sg10
I13
sg11
Vproliferation
p11865
sg13
I1
sa(dp11866
g7
I59
sg23
VC0017638
p11867
sg10
I6
sg11
Vglioma
p11868
sg13
I1
sasa(dp11869
g2
S'Finally, miR-423-5p overexpression also strengthened GBM neurosphere formation and rendered glioma cells resistant to temozolomide (TMZ).\n'
p11870
sg4
(lp11871
(dp11872
g7
I9
sg8
g18
sg10
I10
sg11
VmiR-423-5p
p11873
sg13
I1
sasg20
(lp11874
(dp11875
g7
I92
sg23
VC0017638
p11876
sg10
I6
sg11
Vglioma
p11877
sg13
I1
sa(dp11878
g7
I53
sg23
VC0017636
p11879
sg10
I3
sg11
VGBM
p11880
sg13
I1
sasa(dp11881
g2
S'This study establishes that miR-423-5p functions as an oncogene in glioma tissues by suppressing ING-4 and suggests that it has therapeutic potential for glioma.\n'
p11882
sg4
(lp11883
(dp11884
g7
I28
sg8
g18
sg10
I10
sg11
VmiR-423-5p
p11885
sg13
I1
sasg20
(lp11886
(dp11887
g7
I67
sg23
VC0017638
p11888
sg10
I6
sg11
Vglioma
p11889
sg13
I1
sa(dp11890
g7
I67
sg23
VC0017638
p11891
sg10
I6
sg11
Vglioma
p11892
sg13
I1
sasa(dp11893
g2
S'Finally, we discuss the different circulating miRNAs such as miR-21, miR-20a, miR-155, miR-221, miR-210, miR-218, miR-200-family, miR-141, miR-122, miR-486-5p, miR-423-5p, miR-29a, and miR-500 for clinical diagnosis of various cancers.\n'
p11894
sg4
(lp11895
(dp11896
g7
I105
sg8
g18
sg10
I7
sg11
VmiR-218
p11897
sg13
I1
sa(dp11898
g7
I87
sg8
g18
sg10
I7
sg11
VmiR-221
p11899
sg13
I1
sa(dp11900
g7
I148
sg8
g18
sg10
I10
sg11
VmiR-486-5p
p11901
sg13
I1
sa(dp11902
g7
I160
sg8
g18
sg10
I10
sg11
VmiR-423-5p
p11903
sg13
I1
sa(dp11904
g7
I130
sg8
g18
sg10
I7
sg11
VmiR-141
p11905
sg13
I1
sa(dp11906
g7
I139
sg8
g18
sg10
I7
sg11
VmiR-122
p11907
sg13
I1
sa(dp11908
g7
I69
sg8
g18
sg10
I7
sg11
VmiR-20a
p11909
sg13
I1
sa(dp11910
g7
I78
sg8
g18
sg10
I7
sg11
VmiR-155
p11911
sg13
I1
sa(dp11912
g7
I114
sg8
g18
sg10
I14
sg11
VmiR-200-family
p11913
sg13
I1
sa(dp11914
g7
I96
sg8
g18
sg10
I7
sg11
VmiR-210
p11915
sg13
I1
sa(dp11916
g7
I172
sg8
g18
sg10
I7
sg11
VmiR-29a
p11917
sg13
I1
sasg20
(lp11918
(dp11919
g7
I227
sg23
VC0006826
p11920
sg10
I7
sg11
Vcancers
p11921
sg13
I1
sasa(dp11922
g2
S'These effects of n-3 polyunsaturated fatty acids (PUFA) on lipid metabolism may be linked to the upregulation of Fra1 and attenuated activity of c-Jun and c-Fos, thus ultimately reducing the severity of the lipid metabolism disorder and liver damage to some extent.\n'
p11923
sg4
(lp11924
(dp11925
g7
I155
sg8
VP01100
p11926
sg10
I5
sg11
Vc-Fos
p11927
sg13
I1
sa(dp11928
g7
I145
sg8
VP05412
p11929
sg10
I5
sg11
Vc-Jun
p11930
sg13
I1
sa(dp11931
g7
I113
sg8
VP15407
p11932
sg10
I4
sg11
VFra1
p11933
sg13
I1
sasg20
(lp11934
(dp11935
g7
I237
sg23
VC0151763
p11936
sg10
I12
sg11
Vliver damage
p11937
sg13
I2
sa(dp11938
g7
I207
sg23
VC0154251
p11939
sg10
I25
sg11
Vlipid metabolism disorder
p11940
sg13
I3
sasa(dp11941
g2
S'Data were analysed from the Fabry Outcome Survey (FOS; Shire; extracted August 2013) for "index patients", defined as the first patient diagnosed with Fabry disease from a family with several or no additional members registered in FOS.\n'
p11942
sg4
(lp11943
sg20
(lp11944
(dp11945
g7
I151
sg23
VC0002986
p11946
sg10
I13
sg11
VFabry disease
p11947
sg13
I2
sasa(dp11948
g2
S'After TI, the number of c-Fos-ir increased in the caudal and intermediate areas of the ICo (but not in the GCt), throughout the rostrocaudal axis of the dorsal stratum griseum periventriculare (SGPd) of the optic tectum and in the n. mesencephalicus lateralis pars dorsalis (MLd), which is part of the ascending auditory pathway.\n'
p11949
sg4
(lp11950
(dp11951
g7
I24
sg8
VP06213
p11952
sg10
I8
sg11
Vc-Fos-ir
p11953
sg13
I1
sasg20
(lp11954
(dp11955
g7
I275
sg23
VC0023522
p11956
sg10
I3
sg11
VMLd
p11957
sg13
I1
sa(dp11958
g7
I234
sg23
VC0023522
p11959
sg10
I39
sg11
Vmesencephalicus lateralis pars dorsalis
p11960
sg13
I4
sasa(dp11961
g2
S'To evaluate the utility of magnetic resonance (MR) cisternography using 3-dimensional (3D) fast asymmetric spin-echo (FASE) sequences with multiplanar reconstruction (MPR) for detection of the sites of neurovascular compression (NVC) in patients with trigeminal neuralgia.\n'
p11962
sg4
(lp11963
sg20
(lp11964
(dp11965
g7
I251
sg23
VC0040997
p11966
sg10
I20
sg11
Vtrigeminal neuralgia
p11967
sg13
I2
sasa(dp11968
g2
S'The technique of MR cisternography using 3D-FASE sequences with MPR is more accurate and useful than MRA for detection of the site of NVC in patients with trigeminal neuralgia.\n'
p11969
sg4
(lp11970
sg20
(lp11971
(dp11972
g7
I155
sg23
VC0040997
p11973
sg10
I20
sg11
Vtrigeminal neuralgia
p11974
sg13
I2
sasa(dp11975
g2
S'To evaluate three-dimensional (3D) constructive interference in steady-state (CISS) magnetic resonance (MR) imaging and MR angiography with multiplanar reconstruction (MPR) for detection of neurovascular compression (NVC) in patients with trigeminal neuralgia and to evaluate the relationship between clinical symptoms related to trigeminal branches and those related to the site of trigeminal nerve compression.\n'
p11976
sg4
(lp11977
sg20
(lp11978
(dp11979
g7
I239
sg23
VC0040997
p11980
sg10
I20
sg11
Vtrigeminal neuralgia
p11981
sg13
I2
sasa(dp11982
g2
S'3D CISS MR imaging with MPR is useful in the detection of NVC in patients with trigeminal neuralgia, compared with MR angiography.\n'
p11983
sg4
(lp11984
sg20
(lp11985
(dp11986
g7
I79
sg23
VC0040997
p11987
sg10
I20
sg11
Vtrigeminal neuralgia
p11988
sg13
I2
sasa(dp11989
g2
S'A new technique, simultaneous display of magnetic resonance angiography (MRA) and multiplanar reconstruction (MPR), was performed by a workstation to identify the involved vessels in patients with trigeminal neuralgia (TN) or hemifacial spasm (HFS), and the results were compared with those of oblique sagittal MRI technique.\n'
p11990
sg4
(lp11991
sg20
(lp11992
(dp11993
g7
I219
sg23
VC0040997
p11994
sg10
I2
sg11
VTN
p11995
sg13
I1
sa(dp11996
g7
I237
sg23
VC0037763
p11997
sg10
I5
sg11
Vspasm
p11998
sg13
I1
sa(dp11999
g7
I197
sg23
VC0040997
p12000
sg10
I20
sg11
Vtrigeminal neuralgia
p12001
sg13
I2
sasa(dp12002
g2
S'Recently, CRTC1-MAML2 fusion gene was reported in hidradenomas, with the fusion transcript being demonstrated in approximately 50% of cases.\n'
p12003
sg4
(lp12004
(dp12005
g7
I16
sg8
g18
sg10
I5
sg11
VMAML2
p12006
sg13
I1
sasg20
(lp12007
(dp12008
g7
I50
sg23
VC0206671
p12009
sg10
I12
sg11
Vhidradenomas
p12010
sg13
I1
sasa(dp12011
g2
S'We conclude that CRTC1/3-MAML2 fusion gene analysis can be a useful method for diagnosing hidradenoma.\n'
p12012
sg4
(lp12013
(dp12014
g7
I25
sg8
g18
sg10
I5
sg11
VMAML2
p12015
sg13
I1
sasg20
(lp12016
(dp12017
g7
I90
sg23
VC0206671
p12018
sg10
I11
sg11
Vhidradenoma
p12019
sg13
I1
sasa(dp12020
g2
S'Twenty-one hidradenomas from 20 patients (13 female, 7 male) ranging in age from 18 to 87years (mean, 57.75years; median, 60years) were studied for CRTC1-MAML2 and CRTC3-MAML2 fusions to find out whether there is a correlation between the particular cell type (polyhedral eosinophilic, clear, mucinous, epidermoid, and oncocytic) and presence the above alterations.\n'
p12021
sg4
(lp12022
(dp12023
g7
I154
sg8
g18
sg10
I5
sg11
VMAML2
p12024
sg13
I1
sa(dp12025
g7
I164
sg8
g18
sg10
I5
sg11
VCRTC3
p12026
sg13
I1
sa(dp12027
g7
I154
sg8
g18
sg10
I5
sg11
VMAML2
p12028
sg13
I1
sasg20
(lp12029
(dp12030
g7
I11
sg23
VC0206671
p12031
sg10
I12
sg11
Vhidradenomas
p12032
sg13
I1
sasa(dp12033
g2
S"MLL-MAML2 in secondary AML/MDS and MECT1-MAML2 in mucoepithelioid carcinoma, benign Wartin's tumor, and clear cell hidradenoma consist of the same COOH-terminal part of MAML2.\n"
p12034
sg4
(lp12035
(dp12036
g7
I35
sg8
g18
sg10
I11
sg11
VMECT1-MAML2
p12037
sg13
I1
sa(dp12038
g7
I0
sg8
g18
sg10
I9
sg11
VMLL-MAML2
p12039
sg13
I1
sa(dp12040
g7
I27
sg8
VP62258
p12041
sg10
I3
sg11
VMDS
p12042
sg13
I1
sa(dp12043
g7
I4
sg8
g18
sg10
I5
sg11
VMAML2
p12044
sg13
I1
sasg20
(lp12045
(dp12046
g7
I13
sg23
VC0280449
p12047
sg10
I13
sg11
Vsecondary AML
p12048
sg13
I2
sa(dp12049
g7
I104
sg23
VC1370701
p12050
sg10
I22
sg11
Vclear cell hidradenoma
p12051
sg13
I3
sa(dp12052
g7
I93
sg23
VC0027651
p12053
sg10
I5
sg11
Vtumor
p12054
sg13
I1
sa(dp12055
g7
I27
sg23
VC0265219
p12056
sg10
I3
sg11
VMDS
p12057
sg13
I1
sa(dp12058
g7
I66
sg23
VC0007097
p12059
sg10
I9
sg11
Vcarcinoma
p12060
sg13
I1
sasa(dp12061
g2
S'RT-PCR analysis of a clear cell hidradenoma with a t(11;19)(q21;p13) translocation revealed expression of a TORC1-MAML2 fusion transcript consisting of exon 1 of TORC1 fused to exons 2-5 of MAML2.\n'
p12062
sg4
(lp12063
(dp12064
g7
I114
sg8
g18
sg10
I5
sg11
VMAML2
p12065
sg13
I1
sa(dp12066
g7
I64
sg8
g18
sg10
I3
sg11
Vp13
p12067
sg13
I1
sa(dp12068
g7
I114
sg8
g18
sg10
I5
sg11
VMAML2
p12069
sg13
I1
sasg20
(lp12070
(dp12071
g7
I69
sg23
VC0040715
p12072
sg10
I13
sg11
Vtranslocation
p12073
sg13
I1
sa(dp12074
g7
I21
sg23
VC1370701
p12075
sg10
I22
sg11
Vclear cell hidradenoma
p12076
sg13
I3
sasa(dp12077
g2
S'PI3KGamma has emerged as a promising target for the treatment of obesity and insulin resistance; however, previous studies have indicated that PI3KGamma activity in pancreatic Beta-cells is required for normal insulin secretion in response to glucose.\n'
p12078
sg4
(lp12079
(dp12080
g7
I77
sg8
VP01308
p12081
sg10
I7
sg11
Vinsulin
p12082
sg13
I1
sa(dp12083
g7
I0
sg8
VP48736
p12084
sg10
I9
sg11
VPI3KGamma
p12085
sg13
I1
sa(dp12086
g7
I77
sg8
VP01308
p12087
sg10
I7
sg11
Vinsulin
p12088
sg13
I1
sa(dp12089
g7
I0
sg8
VP48736
p12090
sg10
I9
sg11
VPI3KGamma
p12091
sg13
I1
sasg20
(lp12092
(dp12093
g7
I65
sg23
VC0028754
p12094
sg10
I7
sg11
Vobesity
p12095
sg13
I1
sa(dp12096
g7
I77
sg23
VC0021655
p12097
sg10
I18
sg11
Vinsulin resistance
p12098
sg13
I2
sasa(dp12099
g2
S'To address this issue, we investigated the effects of PI3KGamma ablation in db/db diabetic mice, a genetic model of obesity-driven Beta-cell failure and diabetes.\n'
p12100
sg4
(lp12101
(dp12102
g7
I54
sg8
VP48736
p12103
sg10
I9
sg11
VPI3KGamma
p12104
sg13
I1
sasg20
(lp12105
(dp12106
g7
I153
sg23
VC0011849
p12107
sg10
I8
sg11
Vdiabetes
p12108
sg13
I1
sa(dp12109
g7
I116
sg23
VC0028754
p12110
sg10
I7
sg11
Vobesity
p12111
sg13
I1
sasa(dp12112
g2
S'Our results are consistent with the concept that the beneficial action of PI3KGamma ablation in obesity-driven glucose intolerance is largely a result of its leptin-dependent effects on adiposity and, to a lesser extent, the promotion of adipose tissue neutrophil recruitment and M1 polarization of gene expression.\n'
p12113
sg4
(lp12114
(dp12115
g7
I158
sg8
VP41159
p12116
sg10
I6
sg11
Vleptin
p12117
sg13
I1
sa(dp12118
g7
I74
sg8
VP48736
p12119
sg10
I9
sg11
VPI3KGamma
p12120
sg13
I1
sasg20
(lp12121
(dp12122
g7
I186
sg23
VC0028754
p12123
sg10
I9
sg11
Vadiposity
p12124
sg13
I1
sa(dp12125
g7
I111
sg23
VC0271650
p12126
sg10
I19
sg11
Vglucose intolerance
p12127
sg13
I2
sa(dp12128
g7
I96
sg23
VC0028754
p12129
sg10
I7
sg11
Vobesity
p12130
sg13
I1
sa(dp12131
g7
I264
sg23
VC0271510
p12132
sg10
I11
sg11
Vrecruitment
p12133
sg13
I1
sasa(dp12134
g2
S'PI3KGamma plays an important role in diet-induced obesity and insulin resistance.\n'
p12135
sg4
(lp12136
(dp12137
g7
I62
sg8
VP01308
p12138
sg10
I7
sg11
Vinsulin
p12139
sg13
I1
sa(dp12140
g7
I0
sg8
VP48736
p12141
sg10
I9
sg11
VPI3KGamma
p12142
sg13
I1
sasg20
(lp12143
(dp12144
g7
I62
sg23
VC0021655
p12145
sg10
I18
sg11
Vinsulin resistance
p12146
sg13
I2
sa(dp12147
g7
I50
sg23
VC0028754
p12148
sg10
I7
sg11
Vobesity
p12149
sg13
I1
sasa(dp12150
g2
S'Since subclinical inflammation is a hallmark of atherosclerosis, obesity-related insulin resistance, and pancreatic Beta-cell failure, we asked whether common genetic variation in the PI3KGamma gene (PIK3CG) contributes to body fat content/distribution, serum adipokine/cytokine concentrations, alterations in plasma lipid profiles, insulin sensitivity, insulin release, and glucose homeostasis.\n'
p12151
sg4
(lp12152
(dp12153
g7
I81
sg8
VP01308
p12154
sg10
I7
sg11
Vinsulin
p12155
sg13
I1
sa(dp12156
g7
I81
sg8
VP01308
p12157
sg10
I7
sg11
Vinsulin
p12158
sg13
I1
sa(dp12159
g7
I200
sg8
VP48736
p12160
sg10
I6
sg11
VPIK3CG
p12161
sg13
I1
sa(dp12162
g7
I184
sg8
VP48736
p12163
sg10
I14
sg11
VPI3KGamma gene
p12164
sg13
I2
sa(dp12165
g7
I81
sg8
VP01308
p12166
sg10
I7
sg11
Vinsulin
p12167
sg13
I1
sasg20
(lp12168
(dp12169
g7
I81
sg23
VC0021655
p12170
sg10
I18
sg11
Vinsulin resistance
p12171
sg13
I2
sa(dp12172
g7
I65
sg23
VC0028754
p12173
sg10
I7
sg11
Vobesity
p12174
sg13
I1
sa(dp12175
g7
I18
sg23
VC0021368
p12176
sg10
I12
sg11
Vinflammation
p12177
sg13
I1
sa(dp12178
g7
I341
sg23
VC0920563
p12179
sg10
I20
sg11
Vsensitivity, insulin
p12180
sg13
I2
sa(dp12181
g7
I48
sg23
VC0004153
p12182
sg10
I15
sg11
Vatherosclerosis
p12183
sg13
I1
sasa(dp12184
g2
S'This study provides estimates for the prevalence of DSM-5 EDs in adolescents, further support for their impact on mental health, and new evidence for an association between bulimic disorders and obesity.\n'
p12185
sg4
(lp12186
sg20
(lp12187
(dp12188
g7
I195
sg23
VC0028754
p12189
sg10
I7
sg11
Vobesity
p12190
sg13
I1
sa(dp12191
g7
I58
sg23
VC0013720
p12192
sg10
I3
sg11
VEDs
p12193
sg13
I1
sasa(dp12194
g2
S'These results suggest that combined inhibition of PI3KBeta and PI3KGamma might represent a promising treatment for obesity.\n'
p12195
sg4
(lp12196
(dp12197
g7
I50
sg8
VP42338
p12198
sg10
I8
sg11
VPI3KBeta
p12199
sg13
I1
sa(dp12200
g7
I63
sg8
VP48736
p12201
sg10
I9
sg11
VPI3KGamma
p12202
sg13
I1
sasg20
(lp12203
(dp12204
g7
I115
sg23
VC0028754
p12205
sg10
I7
sg11
Vobesity
p12206
sg13
I1
sasa(dp12207
g2
S'Furthermore, loss of miR-103 causes strong upregulation of the PI3K-Akt-mTOR pathway in vitro and its application into the ARC of the Dicer-deficient mice both reverses upregulation of Pik3cg, the mRNA encoding the catalytic subunit p110Gamma of the PI3K complex, and attenuates the hyperphagic obesity.\n'
p12208
sg4
(lp12209
(dp12210
g7
I185
sg8
VP48736
p12211
sg10
I6
sg11
VPik3cg
p12212
sg13
I1
sa(dp12213
g7
I68
sg8
g18
sg10
I3
sg11
VAkt
p12214
sg13
I1
sa(dp12215
g7
I72
sg8
VP42345
p12216
sg10
I4
sg11
VmTOR
p12217
sg13
I1
sa(dp12218
g7
I63
sg8
VP42336
p12219
sg10
I4
sg11
VPI3K
p12220
sg13
I1
sa(dp12221
g7
I21
sg8
g18
sg10
I7
sg11
VmiR-103
p12222
sg13
I1
sa(dp12223
g7
I250
sg8
VP42336
p12224
sg10
I12
sg11
VPI3K complex
p12225
sg13
I2
sasg20
(lp12226
(dp12227
g7
I123
sg23
VC0001857
p12228
sg10
I3
sg11
VARC
p12229
sg13
I1
sa(dp12230
g7
I295
sg23
VC0028754
p12231
sg10
I7
sg11
Vobesity
p12232
sg13
I1
sasa(dp12233
g2
S'Ribosomal protein S6 kinase 1 (S6K1) is a serine/threonine protein kinase that plays an important role in the PIK3/mTOR signaling pathway, and is implicated in diseases including diabetes, obesity, and cancer.\n'
p12234
sg4
(lp12235
(dp12236
g7
I110
sg8
VP48736
p12237
sg10
I4
sg11
VPIK3
p12238
sg13
I1
sa(dp12239
g7
I42
sg8
VP51812
p12240
sg10
I31
sg11
Vserine/threonine protein kinase
p12241
sg13
I3
sa(dp12242
g7
I115
sg8
VP42345
p12243
sg10
I4
sg11
VmTOR
p12244
sg13
I1
sa(dp12245
g7
I0
sg8
g18
sg10
I29
sg11
VRibosomal protein S6 kinase 1
p12246
sg13
I5
sasg20
(lp12247
(dp12248
g7
I189
sg23
VC0028754
p12249
sg10
I7
sg11
Vobesity
p12250
sg13
I1
sa(dp12251
g7
I202
sg23
VC0006826
p12252
sg10
I6
sg11
Vcancer
p12253
sg13
I1
sa(dp12254
g7
I179
sg23
VC0011849
p12255
sg10
I8
sg11
Vdiabetes
p12256
sg13
I1
sasa(dp12257
g2
S'These results illustrate the impact of TRPC3 on LV compliance and flexibility and, focusing on the TRPC3-Nox2 complex, provide a strategy for prevention of doxorubicin-induced cardiomyopathy.\n'
p12258
sg4
(lp12259
(dp12260
g7
I39
sg8
g18
sg10
I5
sg11
VTRPC3
p12261
sg13
I1
sa(dp12262
g7
I39
sg8
g18
sg10
I5
sg11
VTRPC3
p12263
sg13
I1
sa(dp12264
g7
I105
sg8
VP04839
p12265
sg10
I4
sg11
VNox2
p12266
sg13
I1
sasg20
(lp12267
(dp12268
g7
I176
sg23
VC0878544
p12269
sg10
I14
sg11
Vcardiomyopathy
p12270
sg13
I1
sasa(dp12271
g2
S'We conclude that inhibition of TRPC3 channels contributes to H-R-induced suppression of KCa channel activity, which serves as a mechanism underlying coronary endothelial dysfunction in ischemia-reperfusion (I-R) injury and renders TRPC3 a potential target for endothelial protection in I-R conditions.\n'
p12272
sg4
(lp12273
(dp12274
g7
I31
sg8
g18
sg10
I14
sg11
VTRPC3 channels
p12275
sg13
I2
sa(dp12276
g7
I88
sg8
VP07498
p12277
sg10
I11
sg11
VKCa channel
p12278
sg13
I2
sa(dp12279
g7
I31
sg8
g18
sg10
I5
sg11
VTRPC3
p12280
sg13
I1
sasg20
(lp12281
(dp12282
g7
I158
sg23
VC0856169
p12283
sg10
I23
sg11
Vendothelial dysfunction
p12284
sg13
I2
sa(dp12285
g7
I185
sg23
VC0022116
p12286
sg10
I8
sg11
Vischemia
p12287
sg13
I1
sa(dp12288
g7
I73
sg23
VC0221103
p12289
sg10
I11
sg11
Vsuppression
p12290
sg13
I1
sasa(dp12291
g2
S'However, it remains elusive whether mitochondrial TRPC3 participates in hypertension by increasing mitochondrial calcium handling and ROS production.\n'
p12292
sg4
(lp12293
(dp12294
g7
I50
sg8
g18
sg10
I5
sg11
VTRPC3
p12295
sg13
I1
sasg20
(lp12296
(dp12297
g7
I72
sg23
VC0020538
p12298
sg10
I12
sg11
Vhypertension
p12299
sg13
I1
sasa(dp12300
g2
S'More importantly, TRPC3 knockout mice exhibited significantly ameliorated hypertension through reduction of angiotensin II-induced mitochondrial ROS generation.\n'
p12301
sg4
(lp12302
(dp12303
g7
I108
sg8
VP01019
p12304
sg10
I14
sg11
Vangiotensin II
p12305
sg13
I2
sa(dp12306
g7
I18
sg8
g18
sg10
I5
sg11
VTRPC3
p12307
sg13
I1
sasg20
(lp12308
(dp12309
g7
I74
sg23
VC0020538
p12310
sg10
I12
sg11
Vhypertension
p12311
sg13
I1
sasa(dp12312
g2
S'Working in vitro with H9c2 cardiomyoblasts subjected to 9-h hypoxia followed by 6-h reoxygenation (H/R), and analyzing changes occurring in areas-at-risk (AARs) of murine hearts subjected to a 30-min ischemia followed by 24-h reperfusion (I/R) protocol, we found: (i) that blocking TRPC with SKF96365 significantly ameliorated damage induced by H/R, including development of the mitochondrial permeability transition and proapoptotic changes in Bcl2/BAX ratios; and (ii) that AAR tissues had increased TUNEL+ cells, augmented Bcl2/BAX ratios, and increased p(S240)NFATc3, p(S473)AKT, p(S9)GSK3Beta, and TRPC3 and -6 proteins, consistent with activation of a positive-feedback loop in which calcium entering through TRPCs activates calcineurin-mediated NFATc3-directed transcription of TRPC genes, leading to more Ca2+ entry.\n'
p12313
sg4
(lp12314
(dp12315
g7
I564
sg8
g18
sg10
I6
sg11
VNFATc3
p12316
sg13
I1
sa(dp12317
g7
I564
sg8
g18
sg10
I6
sg11
VNFATc3
p12318
sg13
I1
sa(dp12319
g7
I785
sg8
VP01893
p12320
sg10
I10
sg11
VTRPC genes
p12321
sg13
I2
sa(dp12322
g7
I603
sg8
g18
sg10
I5
sg11
VTRPC3
p12323
sg13
I1
sa(dp12324
g7
I445
sg8
VP10415
p12325
sg10
I4
sg11
VBcl2
p12326
sg13
I1
sa(dp12327
g7
I572
sg8
g18
sg10
I10
sg11
Vp(S473)AKT
p12328
sg13
I1
sa(dp12329
g7
I445
sg8
VP10415
p12330
sg10
I4
sg11
VBcl2
p12331
sg13
I1
sasg20
(lp12332
(dp12333
g7
I60
sg23
VC0242184
p12334
sg10
I7
sg11
Vhypoxia
p12335
sg13
I1
sa(dp12336
g7
I406
sg23
VC0599156
p12337
sg10
I10
sg11
Vtransition
p12338
sg13
I1
sa(dp12339
g7
I273
sg23
VC0233660
p12340
sg10
I8
sg11
Vblocking
p12341
sg13
I1
sa(dp12342
g7
I200
sg23
VC0022116
p12343
sg10
I8
sg11
Vischemia
p12344
sg13
I1
sasa(dp12345
g2
S'Conflicting information exists regarding changes in TRPC3/TRPC6 functional expression in hypertension.\n'
p12346
sg4
(lp12347
(dp12348
g7
I58
sg8
g18
sg10
I5
sg11
VTRPC6
p12349
sg13
I1
sa(dp12350
g7
I52
sg8
g18
sg10
I5
sg11
VTRPC3
p12351
sg13
I1
sasg20
(lp12352
(dp12353
g7
I89
sg23
VC0020538
p12354
sg10
I12
sg11
Vhypertension
p12355
sg13
I1
sasa(dp12356
g2
S'The expression profiles and biological relevance of long non-coding RNA XIST and its activator JPX in hepatocellular carcinoma (HCC) are not well elucidated.\n'
p12357
sg4
(lp12358
sg20
(lp12359
(dp12360
g7
I128
sg23
VC2239176
p12361
sg10
I3
sg11
VHCC
p12362
sg13
I1
sa(dp12363
g7
I102
sg23
VC2239176
p12364
sg10
I24
sg11
Vhepatocellular carcinoma
p12365
sg13
I2
sasa(dp12366
g2
S'Interestingly, decreased Xist expression in breast cancer samples was associated with reduced levels of Jpx RNA, an lncRNA that positively regulates Xist promoter activity.\n'
p12367
sg4
(lp12368
sg20
(lp12369
(dp12370
g7
I44
sg23
VC0678222
p12371
sg10
I13
sg11
Vbreast cancer
p12372
sg13
I2
sasa(dp12373
g2
S'ME-143 (NV-143), a synthetic isoflavone under clinical evaluation for efficacy in the management of ovarian and other forms of human cancer, blocked the activity of a cancer-specific and growth-related cell surface ECTO-NOX protein with both oxidative (hydroquinone) and protein disulfide-thiol interchange activity designated ENOX2 (tNOX) and inhibited the growth of cultured cancer cells with EC50s in the range of 20-50 nM.\n'
p12374
sg4
(lp12375
(dp12376
g7
I334
sg8
g18
sg10
I4
sg11
VtNOX
p12377
sg13
I1
sa(dp12378
g7
I279
sg8
g18
sg10
I53
sg11
Vdisulfide-thiol interchange activity designated ENOX2
p12379
sg13
I5
sasg20
(lp12380
(dp12381
g7
I133
sg23
VC0006826
p12382
sg10
I6
sg11
Vcancer
p12383
sg13
I1
sa(dp12384
g7
I133
sg23
VC0006826
p12385
sg10
I6
sg11
Vcancer
p12386
sg13
I1
sa(dp12387
g7
I133
sg23
VC0006826
p12388
sg10
I6
sg11
Vcancer
p12389
sg13
I1
sasa(dp12390
g2
S'Activities of constitutive ENOX1 (CNOX) forms of either cancer or noncancer cells were unaffected by ME-143 over the range of concentrations inhibiting ENOX2.\n'
p12391
sg4
(lp12392
(dp12393
g7
I34
sg8
g18
sg10
I4
sg11
VCNOX
p12394
sg13
I1
sa(dp12395
g7
I14
sg8
g18
sg10
I18
sg11
Vconstitutive ENOX1
p12396
sg13
I2
sa(dp12397
g7
I152
sg8
g18
sg10
I5
sg11
VENOX2
p12398
sg13
I1
sasg20
(lp12399
(dp12400
g7
I56
sg23
VC0006826
p12401
sg10
I6
sg11
Vcancer
p12402
sg13
I1
sasa(dp12403
g2
S'Taken together, the findings show that ME-143 binds to ENOX2 with an affinity 4 to 10 times greater than that reported previously for the related anticancer isoflavone, phenoxodiol.\n'
p12404
sg4
(lp12405
(dp12406
g7
I55
sg8
g18
sg10
I5
sg11
VENOX2
p12407
sg13
I1
sasg20
(lp12408
sa(dp12409
g2
S'Functional motifs previously identified by site-directed mutagenesis in a cancer-associated ENOX (tNOX or ENOX2) as adenine nucleotide or copper binding along with essential cysteines are present, but the drug-binding motif (EEMTE) sequence of ENOX2 is absent.\n'
p12410
sg4
(lp12411
(dp12412
g7
I106
sg8
g18
sg10
I5
sg11
VENOX2
p12413
sg13
I1
sa(dp12414
g7
I106
sg8
g18
sg10
I5
sg11
VENOX2
p12415
sg13
I1
sa(dp12416
g7
I98
sg8
g18
sg10
I4
sg11
VtNOX
p12417
sg13
I1
sa(dp12418
g7
I92
sg8
g18
sg10
I4
sg11
VENOX
p12419
sg13
I1
sasg20
(lp12420
(dp12421
g7
I74
sg23
VC0006826
p12422
sg10
I6
sg11
Vcancer
p12423
sg13
I1
sasa(dp12424
g2
S"In order to further elucidate the biological properties of the NU-T2-BMZ antigen, we investigated the expression of NU-T2-BMZ antigen and type VII collagen (well identified component of anchoring fibrils) in various skin tumors such as basal cell epithelioma (BCE), squamous cell carcinoma, Bowen's disease, actinic keratosis and seborrheic keratosis.\n"
p12425
sg4
(lp12426
(dp12427
g7
I63
sg8
VP14209
p12428
sg10
I17
sg11
VNU-T2-BMZ antigen
p12429
sg13
I2
sa(dp12430
g7
I138
sg8
g18
sg10
I17
sg11
Vtype VII collagen
p12431
sg13
I3
sa(dp12432
g7
I63
sg8
VP14209
p12433
sg10
I17
sg11
VNU-T2-BMZ antigen
p12434
sg13
I2
sasg20
(lp12435
(dp12436
g7
I291
sg23
VC0006079
p12437
sg10
I15
sg11
VBowen's disease
p12438
sg13
I2
sa(dp12439
g7
I236
sg23
VC0007117
p12440
sg10
I22
sg11
Vbasal cell epithelioma
p12441
sg13
I3
sa(dp12442
g7
I260
sg23
VC0007117
p12443
sg10
I3
sg11
VBCE
p12444
sg13
I1
sa(dp12445
g7
I308
sg23
VC0022602
p12446
sg10
I17
sg11
Vactinic keratosis
p12447
sg13
I2
sa(dp12448
g7
I216
sg23
VC0037286
p12449
sg10
I11
sg11
Vskin tumors
p12450
sg13
I2
sa(dp12451
g7
I266
sg23
VC0007137
p12452
sg10
I23
sg11
Vsquamous cell carcinoma
p12453
sg13
I3
sa(dp12454
g7
I330
sg23
VC0022603
p12455
sg10
I20
sg11
Vseborrheic keratosis
p12456
sg13
I2
sasa(dp12457
g2
S'Principal component analysis (PCA) in allogeneic cultures of ESRDP identified two correlation clusters, one consisting of sCD30, the Th-1 cytokine IFN-Gamma, MIP-1Alfa, RANTES, sIL-2RAlfa, MIP-1Beta, TNF-Beta, MDC, GM-CSF and IL-5, and another one consisting of CD30 and t-bet transcripts, IL-13 and proinflammatory proteins IP-10, IL-8, IL-1RAlfa and MCP-1.\n'
p12458
sg4
(lp12459
(dp12460
g7
I169
sg8
VP13501
p12461
sg10
I6
sg11
VRANTES
p12462
sg13
I1
sa(dp12463
g7
I147
sg8
VP01579
p12464
sg10
I9
sg11
VIFN-Gamma
p12465
sg13
I1
sa(dp12466
g7
I290
sg8
VP35225
p12467
sg10
I5
sg11
VIL-13
p12468
sg13
I1
sa(dp12469
g7
I200
sg8
VP01375
p12470
sg10
I8
sg11
VTNF-Beta
p12471
sg13
I1
sa(dp12472
g7
I271
sg8
g18
sg10
I17
sg11
Vt-bet transcripts
p12473
sg13
I2
sa(dp12474
g7
I325
sg8
VP02778
p12475
sg10
I5
sg11
VIP-10
p12476
sg13
I1
sa(dp12477
g7
I226
sg8
VP05113
p12478
sg10
I4
sg11
VIL-5
p12479
sg13
I1
sa(dp12480
g7
I177
sg8
VP40967
p12481
sg10
I10
sg11
VsIL-2RAlfa
p12482
sg13
I1
sa(dp12483
g7
I123
sg8
VP28908
p12484
sg10
I4
sg11
VCD30
p12485
sg13
I1
sa(dp12486
g7
I158
sg8
g18
sg10
I9
sg11
VMIP-1Alfa
p12487
sg13
I1
sa(dp12488
g7
I352
sg8
VP41597
p12489
sg10
I5
sg11
VMCP-1
p12490
sg13
I1
sa(dp12491
g7
I189
sg8
g18
sg10
I9
sg11
VMIP-1Beta
p12492
sg13
I1
sa(dp12493
g7
I210
sg8
g18
sg10
I3
sg11
VMDC
p12494
sg13
I1
sa(dp12495
g7
I215
sg8
VP04141
p12496
sg10
I6
sg11
VGM-CSF
p12497
sg13
I1
sasg20
(lp12498
(dp12499
g7
I0
sg23
VC0268398
p12500
sg10
I28
sg11
VPrincipal component analysis
p12501
sg13
I3
sa(dp12502
g7
I158
sg23
VC1851100
p12503
sg10
I3
sg11
VMIP
p12504
sg13
I1
sa(dp12505
g7
I30
sg23
VC0268398
p12506
sg10
I3
sg11
VPCA
p12507
sg13
I1
sa(dp12508
g7
I177
sg23
VC0333873
p12509
sg10
I3
sg11
VsIL
p12510
sg13
I1
sa(dp12511
g7
I158
sg23
VC1851100
p12512
sg10
I3
sg11
VMIP
p12513
sg13
I1
sasa(dp12514
g2
S'We previously showed that loss of tauCstF-64 causes male infertility because of major defects in mouse spermatogenesis.\n'
p12515
sg4
(lp12516
(dp12517
g7
I34
sg8
g18
sg10
I10
sg11
VtauCstF-64
p12518
sg13
I1
sasg20
(lp12519
(dp12520
g7
I52
sg23
VC0021364
p12521
sg10
I16
sg11
Vmale infertility
p12522
sg13
I2
sasa(dp12523
g2
S'Here we show that targeted disruption of Cstf2t in mice causes aberrant spermatogenesis, specifically disrupting meiotic and postmeiotic development, resulting in male infertility resembling oligoasthenoteratozoospermia.\n'
p12524
sg4
(lp12525
(dp12526
g7
I41
sg8
g18
sg10
I6
sg11
VCstf2t
p12527
sg13
I1
sasg20
(lp12528
(dp12529
g7
I163
sg23
VC0021364
p12530
sg10
I16
sg11
Vmale infertility
p12531
sg13
I2
sasa(dp12532
g2
S'Our results indicate that, although the infertility in Cstf2t(-/-) males is due to low sperm count, multiple genes controlling many aspects of germ-cell development depend on tauCstF-64 for their normal expression.\n'
p12533
sg4
(lp12534
sg20
(lp12535
(dp12536
g7
I40
sg23
VC0021359
p12537
sg10
I11
sg11
Vinfertility
p12538
sg13
I1
sa(dp12539
g7
I83
sg23
VC0028960
p12540
sg10
I15
sg11
Vlow sperm count
p12541
sg13
I3
sasa(dp12542
g2
S'Radiation hybrid mapping places the human tauCstF-64 gene at 10q22-q23, which is the site of a translocation that has been associated with human neurological problems and male infertility.\n'
p12543
sg4
(lp12544
sg20
(lp12545
(dp12546
g7
I171
sg23
VC0021364
p12547
sg10
I16
sg11
Vmale infertility
p12548
sg13
I2
sa(dp12549
g7
I95
sg23
VC0040715
p12550
sg10
I13
sg11
Vtranslocation
p12551
sg13
I1
sasa(dp12552
g2
S'In cervical cancer cells, KpnBeta1 downregulation results in sustained degradation of the antiapoptotic protein, Mcl-1, and elevated Noxa expression, as well as mitochondrial membrane permeabilization resulting in the release of cytochrome C and activation of associated caspases.\n'
p12553
sg4
(lp12554
(dp12555
g7
I113
sg8
VP07954
p12556
sg10
I5
sg11
VMcl-1
p12557
sg13
I1
sa(dp12558
g7
I133
sg8
g18
sg10
I4
sg11
VNoxa
p12559
sg13
I1
sa(dp12560
g7
I271
sg8
VP39880
p12561
sg10
I8
sg11
Vcaspases
p12562
sg13
I1
sa(dp12563
g7
I229
sg8
VP99999
p12564
sg10
I12
sg11
Vcytochrome C
p12565
sg13
I2
sasg20
(lp12566
(dp12567
g7
I113
sg23
VC1708350
p12568
sg10
I3
sg11
VMcl
p12569
sg13
I1
sa(dp12570
g7
I3
sg23
VC0302592
p12571
sg10
I15
sg11
Vcervical cancer
p12572
sg13
I2
sasa(dp12573
g2
S'Therefore, we have revealed that the modulation of the Mcl-1/Noxa axis by platinum compounds results in a strong sensitization of chemoresistant ovarian carcinoma cells to ABT-737, which could constitute a promising therapeutic in these cancers.\n'
p12574
sg4
(lp12575
(dp12576
g7
I55
sg8
VP07954
p12577
sg10
I5
sg11
VMcl-1
p12578
sg13
I1
sa(dp12579
g7
I61
sg8
g18
sg10
I4
sg11
VNoxa
p12580
sg13
I1
sasg20
(lp12581
(dp12582
g7
I55
sg23
VC1708350
p12583
sg10
I3
sg11
VMcl
p12584
sg13
I1
sa(dp12585
g7
I237
sg23
VC0006826
p12586
sg10
I7
sg11
Vcancers
p12587
sg13
I1
sa(dp12588
g7
I145
sg23
VC0029925
p12589
sg10
I17
sg11
Vovarian carcinoma
p12590
sg13
I2
sasa(dp12591
g2
S'In this study, we found that genetic variants of Bcl-2 proteins exist among cisplatin-sensitive and -resistant ovarian cancer cells, and the responses of NOXA and Bax to cisplatin are regulated mainly by p53.\n'
p12592
sg4
(lp12593
(dp12594
g7
I204
sg8
VP42771
p12595
sg10
I3
sg11
Vp53
p12596
sg13
I1
sa(dp12597
g7
I49
sg8
VP10415
p12598
sg10
I14
sg11
VBcl-2 proteins
p12599
sg13
I2
sa(dp12600
g7
I154
sg8
g18
sg10
I4
sg11
VNOXA
p12601
sg13
I1
sasg20
(lp12602
(dp12603
g7
I111
sg23
VC1140680
p12604
sg10
I14
sg11
Vovarian cancer
p12605
sg13
I2
sasa(dp12606
g2
S'To our knowledge, these data suggest a new mechanism by which NOXA chemosensitized ovarian cancer cells to cisplatin by inducing alterations in the Bax/Smac axis.\n'
p12607
sg4
(lp12608
(dp12609
g7
I152
sg8
g18
sg10
I4
sg11
VSmac
p12610
sg13
I1
sa(dp12611
g7
I62
sg8
g18
sg10
I4
sg11
VNOXA
p12612
sg13
I1
sasg20
(lp12613
(dp12614
g7
I83
sg23
VC1140680
p12615
sg10
I14
sg11
Vovarian cancer
p12616
sg13
I2
sasa(dp12617
g2
S'Taken together, our findings show that NOXA is potentially useful as a chemosensitizer in ovarian cancer therapy.\n'
p12618
sg4
(lp12619
(dp12620
g7
I39
sg8
g18
sg10
I4
sg11
VNOXA
p12621
sg13
I1
sasg20
(lp12622
(dp12623
g7
I90
sg23
VC1140680
p12624
sg10
I14
sg11
Vovarian cancer
p12625
sg13
I2
sasa(dp12626
g2
S'Experiments were carried out to investigate whether Noxa could, therefore, enhance the cytotoxic effect of gemcitabine in human ovarian cancer cell lines (A2780 and COC1).\n'
p12627
sg4
(lp12628
sg20
(lp12629
(dp12630
g7
I128
sg23
VC1140680
p12631
sg10
I14
sg11
Vovarian cancer
p12632
sg13
I2
sasa(dp12633
g2
S'Our data suggest that Noxa exhibited potent proapoptotic activity against human ovarian cancer cells, and the combination of Noxa and gemcitabine showed a more significant cytotoxic effect against ovarian cancer cells in comparison with either of these agents alone.\n'
p12634
sg4
(lp12635
sg20
(lp12636
(dp12637
g7
I80
sg23
VC1140680
p12638
sg10
I14
sg11
Vovarian cancer
p12639
sg13
I2
sa(dp12640
g7
I80
sg23
VC1140680
p12641
sg10
I14
sg11
Vovarian cancer
p12642
sg13
I2
sasa(dp12643
g2
S'To our knowledge, we have provided the first evidence that Noxa can enhance therapeutic responses of ovarian cancer cells to gemcitabine, and that it could be potentially useful as a chemosensitizer in ovarian cancer therapy.\n'
p12644
sg4
(lp12645
(dp12646
g7
I59
sg8
g18
sg10
I4
sg11
VNoxa
p12647
sg13
I1
sasg20
(lp12648
(dp12649
g7
I101
sg23
VC1140680
p12650
sg10
I14
sg11
Vovarian cancer
p12651
sg13
I2
sa(dp12652
g7
I101
sg23
VC1140680
p12653
sg10
I14
sg11
Vovarian cancer
p12654
sg13
I2
sasa(dp12655
g2
S'Tandem mass analysis and renal biopsy also indicated that the patient had methylmalonic acidemia (MMA) and thrombotic microangiopathy combined with focal renal cortical necrosis.\n'
p12656
sg4
(lp12657
sg20
(lp12658
(dp12659
g7
I98
sg23
VC0276096
p12660
sg10
I3
sg11
VMMA
p12661
sg13
I1
sa(dp12662
g7
I154
sg23
VC0022656
p12663
sg10
I23
sg11
Vrenal cortical necrosis
p12664
sg13
I3
sa(dp12665
g7
I74
sg23
VC0268583
p12666
sg10
I22
sg11
Vmethylmalonic acidemia
p12667
sg13
I2
sa(dp12668
g7
I107
sg23
VC2717961
p12669
sg10
I26
sg11
Vthrombotic microangiopathy
p12670
sg13
I2
sasa(dp12671
g2
S'The positive expression rates and expression levels of mRNA of FOXC2, N-cadherin, VEGF, SDF-1, Notch and LYVE-1 in cervical cancer were significantly higher than those in CIN, and those in the inflammatory tissues were the lowest, while the positive expression rate of E-cadherin in cervical cancer was lower than that in CIN, and that in the inflammatory tissues was the highest (P&lt;0.05).\n'
p12672
sg4
(lp12673
(dp12674
g7
I88
sg8
VP48061
p12675
sg10
I5
sg11
VSDF-1
p12676
sg13
I1
sa(dp12677
g7
I269
sg8
VP12830
p12678
sg10
I10
sg11
VE-cadherin
p12679
sg13
I1
sa(dp12680
g7
I63
sg8
g18
sg10
I5
sg11
VFOXC2
p12681
sg13
I1
sa(dp12682
g7
I105
sg8
g18
sg10
I6
sg11
VLYVE-1
p12683
sg13
I1
sa(dp12684
g7
I70
sg8
VP19022
p12685
sg10
I10
sg11
VN-cadherin
p12686
sg13
I1
sasg20
(lp12687
(dp12688
g7
I115
sg23
VC0302592
p12689
sg10
I15
sg11
Vcervical cancer
p12690
sg13
I2
sa(dp12691
g7
I171
sg23
VC0206708
p12692
sg10
I3
sg11
VCIN
p12693
sg13
I1
sa(dp12694
g7
I171
sg23
VC0206708
p12695
sg10
I3
sg11
VCIN
p12696
sg13
I1
sa(dp12697
g7
I115
sg23
VC0302592
p12698
sg10
I15
sg11
Vcervical cancer
p12699
sg13
I2
sasa(dp12700
g2
S'The positive expression rates of FOXC2, N-cadherin, VEGF, SDF-1, Notch and LYVE-1 in patients with cervical cancer [human papillomavirus (HPV) positive, squamous cell carcinoma, Stages III-IV, maximal diameter &gt;=3.8 cm and low differentiation] were increased, and the positive expression rate of E-cadherin was decreased (P&lt;0.05).\n'
p12701
sg4
(lp12702
(dp12703
g7
I75
sg8
g18
sg10
I6
sg11
VLYVE-1
p12704
sg13
I1
sa(dp12705
g7
I299
sg8
VP12830
p12706
sg10
I10
sg11
VE-cadherin
p12707
sg13
I1
sa(dp12708
g7
I40
sg8
VP19022
p12709
sg10
I10
sg11
VN-cadherin
p12710
sg13
I1
sa(dp12711
g7
I58
sg8
VP48061
p12712
sg10
I5
sg11
VSDF-1
p12713
sg13
I1
sa(dp12714
g7
I33
sg8
g18
sg10
I5
sg11
VFOXC2
p12715
sg13
I1
sasg20
(lp12716
(dp12717
g7
I153
sg23
VC0007137
p12718
sg10
I23
sg11
Vsquamous cell carcinoma
p12719
sg13
I3
sa(dp12720
g7
I99
sg23
VC0302592
p12721
sg10
I15
sg11
Vcervical cancer
p12722
sg13
I2
sasa(dp12723
g2
S'In this study, using the antioxidant N-acetylcysteine (NAC), we show that hypoxia-induced reactive oxygen species (ROS) in MDA-MB-468 breast cancer cells, selectively regulate hypoxia-induced increases in N-cadherin and SERPINE1, two proteins involved in cell adhesion.\n'
p12724
sg4
(lp12725
(dp12726
g7
I220
sg8
VP05121
p12727
sg10
I8
sg11
VSERPINE1
p12728
sg13
I1
sa(dp12729
g7
I205
sg8
VP19022
p12730
sg10
I10
sg11
VN-cadherin
p12731
sg13
I1
sasg20
(lp12732
(dp12733
g7
I134
sg23
VC0678222
p12734
sg10
I13
sg11
Vbreast cancer
p12735
sg13
I2
sa(dp12736
g7
I74
sg23
VC0242184
p12737
sg10
I7
sg11
Vhypoxia
p12738
sg13
I1
sa(dp12739
g7
I74
sg23
VC0242184
p12740
sg10
I7
sg11
Vhypoxia
p12741
sg13
I1
sa(dp12742
g7
I260
sg23
VC0001511
p12743
sg10
I8
sg11
Vadhesion
p12744
sg13
I1
sasa(dp12745
g2
S'Results of the present study demonstrated that CEACAM1-4S suppresses breast cancer cell invasion and migration in a manner that is dependent on the balance between matrix metalloproteinase 2/tissue inhibitor of metalloproteinase 2 and E-/N-cadherin expression.\n'
p12746
sg4
(lp12747
(dp12748
g7
I164
sg8
VP08253
p12749
sg10
I84
sg11
Vmatrix metalloproteinase 2/tissue inhibitor of metalloproteinase 2 and E-/N-cadherin
p12750
sg13
I9
sa(dp12751
g7
I47
sg8
VP13688
p12752
sg10
I10
sg11
VCEACAM1-4S
p12753
sg13
I1
sasg20
(lp12754
(dp12755
g7
I69
sg23
VC0678222
p12756
sg10
I13
sg11
Vbreast cancer
p12757
sg13
I2
sa(dp12758
g7
I83
sg23
VC2699153
p12759
sg10
I13
sg11
Vcell invasion
p12760
sg13
I2
sasa(dp12761
g2
S'Here we established a doxorubicin-resistant breast cancer cell line MCF-7/Adr, and found these cells exhibited an EMT phenotype featured by a fibroblast-like morphology, increased the capacity of migration and invasion, and underwent the changes of molecular markers of EMT including E-cadherin, N-cadherin, and vimentin.\n'
p12762
sg4
(lp12763
(dp12764
g7
I284
sg8
VP12830
p12765
sg10
I10
sg11
VE-cadherin
p12766
sg13
I1
sa(dp12767
g7
I296
sg8
VP19022
p12768
sg10
I10
sg11
VN-cadherin
p12769
sg13
I1
sa(dp12770
g7
I114
sg8
g18
sg10
I3
sg11
VEMT
p12771
sg13
I1
sasg20
(lp12772
(dp12773
g7
I210
sg23
VC2699153
p12774
sg10
I8
sg11
Vinvasion
p12775
sg13
I1
sa(dp12776
g7
I44
sg23
VC0678222
p12777
sg10
I13
sg11
Vbreast cancer
p12778
sg13
I2
sasa(dp12779
g2
S'In MRL.lpr/lpr mice, which were used to examine disease manifestations, AdTACI reduced the extent of glomerulonephritis and proteinuria and improved survival, but had little effect on T cell infiltration and interstitial nephritis.\n'
p12780
sg4
(lp12781
(dp12782
g7
I7
sg8
g18
sg10
I3
sg11
Vlpr
p12783
sg13
I1
sa(dp12784
g7
I7
sg8
g18
sg10
I3
sg11
Vlpr
p12785
sg13
I1
sasg20
(lp12786
(dp12787
g7
I191
sg23
VC0332448
p12788
sg10
I12
sg11
Vinfiltration
p12789
sg13
I1
sa(dp12790
g7
I208
sg23
VC0027707
p12791
sg10
I22
sg11
Vinterstitial nephritis
p12792
sg13
I2
sa(dp12793
g7
I101
sg23
VC0017658
p12794
sg10
I18
sg11
Vglomerulonephritis
p12795
sg13
I1
sasa(dp12796
g2
S'In patients with symptomatic pregnancy hydronephrosis, the likelihood of surgical treatment for CRP levels, WBC counts and VAS is high.\n'
p12797
sg4
(lp12798
(dp12799
g7
I96
sg8
VP02741
p12800
sg10
I3
sg11
VCRP
p12801
sg13
I1
sasg20
(lp12802
(dp12803
g7
I39
sg23
VC0020295
p12804
sg10
I14
sg11
Vhydronephrosis
p12805
sg13
I1
sasa(dp12806
g2
S'On univariate Cox analysis, clinical T stage, histology of transurethral resection of bladder tumor (TURBT) specimen, pretreatment hemoglobin, pretreatment neutrophil-to-lymphocyte ratio (NLR), pretreatment serum C-reactive protein level, pretreatment serum albumin level, presence of hydronephrosis, and presence of sarcopenia were associated with significantly worse CSS.\n'
p12807
sg4
(lp12808
(dp12809
g7
I258
sg8
VP00441
p12810
sg10
I7
sg11
Valbumin
p12811
sg13
I1
sa(dp12812
g7
I131
sg8
g18
sg10
I10
sg11
Vhemoglobin
p12813
sg13
I1
sa(dp12814
g7
I207
sg8
VP02741
p12815
sg10
I24
sg11
Vserum C-reactive protein
p12816
sg13
I3
sasg20
(lp12817
(dp12818
g7
I285
sg23
VC0020295
p12819
sg10
I14
sg11
Vhydronephrosis
p12820
sg13
I1
sa(dp12821
g7
I369
sg23
VC0265338
p12822
sg10
I3
sg11
VCSS
p12823
sg13
I1
sa(dp12824
g7
I86
sg23
VC0005695
p12825
sg10
I13
sg11
Vbladder tumor
p12826
sg13
I2
sasa(dp12827
g2
S'Stone size, previous spontaneous passage, hydronephrosis, serum C-reactive protein and white blood count can be used to predict spontaneous stone passage in patients with 4 to 10 mm distal ureteral stones.\n'
p12828
sg4
(lp12829
(dp12830
g7
I58
sg8
VP02741
p12831
sg10
I24
sg11
Vserum C-reactive protein
p12832
sg13
I3
sasg20
(lp12833
(dp12834
g7
I42
sg23
VC0020295
p12835
sg10
I14
sg11
Vhydronephrosis
p12836
sg13
I1
sasa(dp12837
g2
S'Clinicians should have high index of suspicion for retroperitoneal fibrosis when patients present with an elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) and renal insufficiency from obstructive uropathy.\n'
p12838
sg4
(lp12839
(dp12840
g7
I175
sg8
VP02741
p12841
sg10
I3
sg11
VCRP
p12842
sg13
I1
sa(dp12843
g7
I155
sg8
VP02741
p12844
sg10
I18
sg11
VC-reactive protein
p12845
sg13
I2
sasg20
(lp12846
(dp12847
g7
I184
sg23
VC0035078
p12848
sg10
I19
sg11
Vrenal insufficiency
p12849
sg13
I2
sa(dp12850
g7
I209
sg23
VC0178879
p12851
sg10
I20
sg11
Vobstructive uropathy
p12852
sg13
I2
sa(dp12853
g7
I51
sg23
VC0035357
p12854
sg10
I24
sg11
Vretroperitoneal fibrosis
p12855
sg13
I2
sasa(dp12856
g2
S'Germ line deletion of 14-3-3Epsilon led to malalignment of both the outflow tract (OFT) and atrioventricular (AV) cushions, with resulting tricuspid stenosis and atresia, mitral valve abnormalities, and perimembranous ventricular septal defects (VSDs).\n'
p12857
sg4
(lp12858
sg20
(lp12859
(dp12860
g7
I246
sg23
VC0018818
p12861
sg10
I4
sg11
VVSDs
p12862
sg13
I1
sa(dp12863
g7
I43
sg23
VC1275957
p12864
sg10
I12
sg11
Vmalalignment
p12865
sg13
I1
sa(dp12866
g7
I218
sg23
VC0018818
p12867
sg10
I26
sg11
Vventricular septal defects
p12868
sg13
I3
sa(dp12869
g7
I139
sg23
VC0040963
p12870
sg10
I18
sg11
Vtricuspid stenosis
p12871
sg13
I2
sa(dp12872
g7
I162
sg23
VC0243066
p12873
sg10
I7
sg11
Vatresia
p12874
sg13
I1
sasa(dp12875
g2
S'These data suggest that 14-3-3Epsilon, in addition to left ventricular non-compaction (LVNC), might be linked to different forms of congenital heart disease (CHD).\n'
p12876
sg4
(lp12877
sg20
(lp12878
(dp12879
g7
I158
sg23
VC0152021
p12880
sg10
I3
sg11
VCHD
p12881
sg13
I1
sa(dp12882
g7
I132
sg23
VC0152021
p12883
sg10
I24
sg11
Vcongenital heart disease
p12884
sg13
I3
sasa(dp12885
g2
S'Previous reports show that defects in TAZ, SCN5A, TPM1, YWHAE, MYH7, ACTC1 and TNNT2 are associated with LVNC.\n'
p12886
sg4
(lp12887
(dp12888
g7
I38
sg8
g18
sg10
I3
sg11
VTAZ
p12889
sg13
I1
sa(dp12890
g7
I69
sg8
VP68032
p12891
sg10
I5
sg11
VACTC1
p12892
sg13
I1
sa(dp12893
g7
I79
sg8
VP45379
p12894
sg10
I5
sg11
VTNNT2
p12895
sg13
I1
sa(dp12896
g7
I50
sg8
VP07951
p12897
sg10
I4
sg11
VTPM1
p12898
sg13
I1
sa(dp12899
g7
I56
sg8
VP62258
p12900
sg10
I5
sg11
VYWHAE
p12901
sg13
I1
sasg20
(lp12902
sa(dp12903
g2
S'It has been previously shown that LVNC is associated with defects in TAZ, DNTA, LDB3, YWHAE, MIB1, PRDM16, and sarcomeric genes.\n'
p12904
sg4
(lp12905
(dp12906
g7
I99
sg8
g18
sg10
I6
sg11
VPRDM16
p12907
sg13
I1
sa(dp12908
g7
I86
sg8
VP62258
p12909
sg10
I5
sg11
VYWHAE
p12910
sg13
I1
sasg20
(lp12911
sa(dp12912
g2
S'Therefore, we hypothesized that variants in YWHAE may contribute to the pathophysiology of LVNC in humans.\n'
p12913
sg4
(lp12914
sg20
(lp12915
sa(dp12916
g2
S'In 77 Japanese patients with LVNC, including the probands of 29 families, mutation analysis of YWHAE by direct DNA sequencing identified 7 novel variants.\n'
p12917
sg4
(lp12918
sg20
(lp12919
sa(dp12920
g2
S'One of them, c.-458G&gt;T, in the YWHAE promoter, was identified in a familial patient with LVNC and hypoplasia of the corpus callosum.\n'
p12921
sg4
(lp12922
(dp12923
g7
I34
sg8
VP62258
p12924
sg10
I14
sg11
VYWHAE promoter
p12925
sg13
I2
sasg20
(lp12926
(dp12927
g7
I101
sg23
VC0344482
p12928
sg10
I33
sg11
Vhypoplasia of the corpus callosum
p12929
sg13
I5
sasa(dp12930
g2
S'These data suggest that the -458G&gt;T YWHAE variant contributes to the abnormal myocardial morphogenesis characteristic of LVNC as well as abnormal brain development, and implicate YWHAE as a novel candidate gene in pediatric cardiomyopathies.\n'
p12931
sg4
(lp12932
sg20
(lp12933
(dp12934
g7
I227
sg23
VC0878544
p12935
sg10
I16
sg11
Vcardiomyopathies
p12936
sg13
I1
sasa(dp12937
g2
S'14-3-3Epsilon deletion did not appear to induce compensation by other 14-3-3 isoforms but led to ventricular noncompaction, with features similar to LVNC, resulting from a selective reduction in compact myocardium thickness.\n'
p12938
sg4
(lp12939
(dp12940
g7
I70
sg8
VP27348
p12941
sg10
I15
sg11
V14-3-3 isoforms
p12942
sg13
I2
sasg20
(lp12943
sa(dp12944
g2
S'These data are consistent with the long-held view that human LVNC may result from compaction arrest, and they implicate 14-3-3Epsilon as a new candidate gene in congenital human cardiomyopathies.\n'
p12945
sg4
(lp12946
sg20
(lp12947
(dp12948
g7
I178
sg23
VC0878544
p12949
sg10
I16
sg11
Vcardiomyopathies
p12950
sg13
I1
sasa(dp12951
g2
S'In LQT2 families, we identified three novel heterozygous HERG mutations (G965X, R1014PfsX39, V1038AfsX21) in the C-terminus that led to protein truncation and loss of a PKA phosphorylation site required for binding of 14-3-3epsilon.\n'
p12952
sg4
(lp12953
(dp12954
g7
I57
sg8
g18
sg10
I14
sg11
VHERG mutations
p12955
sg13
I2
sa(dp12956
g7
I3
sg8
g18
sg10
I4
sg11
VLQT2
p12957
sg13
I1
sa(dp12958
g7
I169
sg8
VP17612
p12959
sg10
I3
sg11
VPKA
p12960
sg13
I1
sasg20
(lp12961
(dp12962
g7
I3
sg23
VC3150943
p12963
sg10
I4
sg11
VLQT2
p12964
sg13
I1
sa(dp12965
g7
I136
sg23
VC1706395
p12966
sg10
I18
sg11
Vprotein truncation
p12967
sg13
I2
sasa(dp12968
g2
S'Idiopathic pulmonary fibrosis (IPF) is an incurable complex genetic disorder that is associated with sequence changes in 7 genes (MUC5B, TERT, TERC, RTEL1, PARN, SFTPC, and SFTPA2) and with variants in at least 11 novel loci.\n'
p12969
sg4
(lp12970
(dp12971
g7
I137
sg8
g18
sg10
I4
sg11
VTERT
p12972
sg13
I1
sa(dp12973
g7
I156
sg8
g18
sg10
I4
sg11
VPARN
p12974
sg13
I1
sa(dp12975
g7
I162
sg8
VP11686
p12976
sg10
I5
sg11
VSFTPC
p12977
sg13
I1
sa(dp12978
g7
I173
sg8
g18
sg10
I6
sg11
VSFTPA2
p12979
sg13
I1
sa(dp12980
g7
I149
sg8
g18
sg10
I5
sg11
VRTEL1
p12981
sg13
I1
sasg20
(lp12982
(dp12983
g7
I60
sg23
VC0019247
p12984
sg10
I16
sg11
Vgenetic disorder
p12985
sg13
I2
sa(dp12986
g7
I0
sg23
VC3161101
p12987
sg10
I29
sg11
VIdiopathic pulmonary fibrosis
p12988
sg13
I3
sa(dp12989
g7
I31
sg23
VC3161101
p12990
sg10
I3
sg11
VIPF
p12991
sg13
I1
sasa(dp12992
g2
S'The differential responses of alveolar macrophages to SP-A1 and SP-A2 highlight the importance of genotype in immune regulation and the susceptibility to lung disease and the need for development of individualized treatment options.\n'
p12993
sg4
(lp12994
(dp12995
g7
I54
sg8
g18
sg10
I5
sg11
VSP-A1
p12996
sg13
I1
sasg20
(lp12997
(dp12998
g7
I154
sg23
VC0024115
p12999
sg10
I12
sg11
Vlung disease
p13000
sg13
I2
sasa(dp13001
g2
S'Most of the individuals of the control group and influenza patients are carries of alleles and genotypes rs1965708 and rs1059046 of SFTPA2 gene, rs1130866 of SFTPB gene, that have, based on scientific literature data, shown association with severe course of influenza A(H1N1) pdm09 and other inflammatory diseases of the respiratory tract.\n'
p13002
sg4
(lp13003
(dp13004
g7
I258
sg8
g18
sg10
I11
sg11
Vinfluenza A
p13005
sg13
I2
sa(dp13006
g7
I132
sg8
g18
sg10
I6
sg11
VSFTPA2
p13007
sg13
I1
sa(dp13008
g7
I158
sg8
VP07988
p13009
sg10
I10
sg11
VSFTPB gene
p13010
sg13
I2
sasg20
(lp13011
(dp13012
g7
I49
sg23
VC0021400
p13013
sg10
I9
sg11
Vinfluenza
p13014
sg13
I1
sa(dp13015
g7
I49
sg23
VC0021400
p13016
sg10
I9
sg11
Vinfluenza
p13017
sg13
I1
sasa(dp13018
g2
S'Generally, significant differences in frequency of occurrence of unfavorable genotypes CC rs1965708, AA rs1059046 of SFTPA2 gene and CC rs1130866 of SFTPB gene in influenza patients in comparison with individuals of the control group were not detected, that gives evidence on a high (from 19 to 51%) prevalence of these genotypes in the studied population.\n'
p13019
sg4
(lp13020
(dp13021
g7
I117
sg8
g18
sg10
I11
sg11
VSFTPA2 gene
p13022
sg13
I2
sa(dp13023
g7
I149
sg8
VP07988
p13024
sg10
I10
sg11
VSFTPB gene
p13025
sg13
I2
sasg20
(lp13026
(dp13027
g7
I163
sg23
VC0021400
p13028
sg10
I9
sg11
Vinfluenza
p13029
sg13
I1
sasa(dp13030
g2
S'Allele C and genotype CC rs1965708 of SFTPA2 gene, allele A and genotype AA rs1059046 of SFTPA2 gene, allele C and genotype CC rs1130866 of SFTPB gene did not shown an association with severe course of A(H1N1) pdm09 influenza.\n'
p13031
sg4
(lp13032
(dp13033
g7
I38
sg8
g18
sg10
I11
sg11
VSFTPA2 gene
p13034
sg13
I2
sa(dp13035
g7
I38
sg8
g18
sg10
I11
sg11
VSFTPA2 gene
p13036
sg13
I2
sa(dp13037
g7
I140
sg8
VP07988
p13038
sg10
I10
sg11
VSFTPB gene
p13039
sg13
I2
sasg20
(lp13040
(dp13041
g7
I216
sg23
VC0021400
p13042
sg10
I9
sg11
Vinfluenza
p13043
sg13
I1
sasa(dp13044
g2
S'DEGs, including JUN, tumor necrosis factor (TNF), Ras homolog family member B (RHOB) and transforming growth factor Beta2 (TGFBeta2) were significantly enriched in the signaling pathway of renal cell carcinoma.\n'
p13045
sg4
(lp13046
(dp13047
g7
I44
sg8
VP01375
p13048
sg10
I3
sg11
VTNF
p13049
sg13
I1
sa(dp13050
g7
I89
sg8
VP61812
p13051
sg10
I32
sg11
Vtransforming growth factor Beta2
p13052
sg13
I4
sa(dp13053
g7
I50
sg8
VP01116
p13054
sg10
I27
sg11
VRas homolog family member B
p13055
sg13
I5
sa(dp13056
g7
I0
sg8
g18
sg10
I4
sg11
VDEGs
p13057
sg13
I1
sa(dp13058
g7
I123
sg8
VP61812
p13059
sg10
I8
sg11
VTGFBeta2
p13060
sg13
I1
sa(dp13061
g7
I16
sg8
VP05412
p13062
sg10
I3
sg11
VJUN
p13063
sg13
I1
sa(dp13064
g7
I21
sg8
VP01375
p13065
sg10
I21
sg11
Vtumor necrosis factor
p13066
sg13
I3
sa(dp13067
g7
I79
sg8
VP62745
p13068
sg10
I4
sg11
VRHOB
p13069
sg13
I1
sasg20
(lp13070
(dp13071
g7
I21
sg23
VC0333516
p13072
sg10
I14
sg11
Vtumor necrosis
p13073
sg13
I2
sa(dp13074
g7
I189
sg23
VC0007134
p13075
sg10
I20
sg11
Vrenal cell carcinoma
p13076
sg13
I3
sasa(dp13077
g2
S'In a mouse model of B16F10 melanoma, Trp2/PHM10/CpG showed significantly higher antigen-specific cytotoxic T lymphocyte activity and greater anticancer efficacy than Trp2/PHM0/CpG without PCL-PEI or a mixture of free Trp2 and CpG.\n'
p13078
sg4
(lp13079
(dp13080
g7
I37
sg8
VP49792
p13081
sg10
I4
sg11
VTrp2
p13082
sg13
I1
sa(dp13083
g7
I188
sg8
VP35916
p13084
sg10
I7
sg11
VPCL-PEI
p13085
sg13
I1
sa(dp13086
g7
I37
sg8
VP49792
p13087
sg10
I4
sg11
VTrp2
p13088
sg13
I1
sa(dp13089
g7
I37
sg8
VP49792
p13090
sg10
I4
sg11
VTrp2
p13091
sg13
I1
sasg20
(lp13092
(dp13093
g7
I27
sg23
VC0025202
p13094
sg10
I8
sg11
Vmelanoma
p13095
sg13
I1
sa(dp13096
g7
I188
sg23
VC1704423
p13097
sg10
I3
sg11
VPCL
p13098
sg13
I1
sasa(dp13099
g2
S'They also suggest that PHMs can serve as a structurally simple and highly tunable platform for co-delivery of antigen and adjuvant in cancer immunotherapy.\n'
p13100
sg4
(lp13101
sg20
(lp13102
(dp13103
g7
I134
sg23
VC0006826
p13104
sg10
I6
sg11
Vcancer
p13105
sg13
I1
sasa(dp13106
g2
S'Hydatidiform moles (HM), presenting as complete (CHM) and partial (PHM) form, are rare pregnancy disorder.\n'
p13107
sg4
(lp13108
sg20
(lp13109
(dp13110
g7
I87
sg23
VC0151864
p13111
sg10
I18
sg11
Vpregnancy disorder
p13112
sg13
I2
sa(dp13113
g7
I20
sg23
VC0020217
p13114
sg10
I2
sg11
VHM
p13115
sg13
I1
sa(dp13116
g7
I49
sg23
VC0678213
p13117
sg10
I3
sg11
VCHM
p13118
sg13
I1
sa(dp13119
g7
I0
sg23
VC0020217
p13120
sg10
I18
sg11
VHydatidiform moles
p13121
sg13
I2
sasa(dp13122
g2
S'In the CHM group, 9 (75%) input diagnoses were mola in obs, and 3 (25%) of them were signed as abortion, unlike the PHM where 126 (67%) were qualified as abortion, 35 (19%) as blighted ovum, and 26 (14%) were suggestive for molar pregnancy.\n'
p13123
sg4
(lp13124
sg20
(lp13125
(dp13126
g7
I7
sg23
VC0678213
p13127
sg10
I3
sg11
VCHM
p13128
sg13
I1
sa(dp13129
g7
I224
sg23
VC0020217
p13130
sg10
I15
sg11
Vmolar pregnancy
p13131
sg13
I2
sa(dp13132
g7
I176
sg23
VC0266648
p13133
sg10
I13
sg11
Vblighted ovum
p13134
sg13
I2
sasa(dp13135
g2
S'Sinusitis and skin infections are the most common presentation of subcutaneous PHM caused by the fungus Bipolaris spicifera.\n'
p13136
sg4
(lp13137
sg20
(lp13138
(dp13139
g7
I14
sg23
VC0037278
p13140
sg10
I15
sg11
Vskin infections
p13141
sg13
I2
sa(dp13142
g7
I0
sg23
VC0037199
p13143
sg10
I9
sg11
VSinusitis
p13144
sg13
I1
sasa(dp13145
g2
S'The present study documents a case of subcutaneous PHM caused by infection with Bipolaris spicifera in a 56-year-old Chinese man, who presented with plaque papillomatosis on the left foot.\n'
p13146
sg4
(lp13147
sg20
(lp13148
(dp13149
g7
I149
sg23
VC0011389
p13150
sg10
I6
sg11
Vplaque
p13151
sg13
I1
sa(dp13152
g7
I65
sg23
VC0009450
p13153
sg10
I9
sg11
Vinfection
p13154
sg13
I1
sa(dp13155
g7
I156
sg23
VC0205875
p13156
sg10
I14
sg11
Vpapillomatosis
p13157
sg13
I1
sasa(dp13158
g2
S'The objectives of this study were to describe the distribution of brain metastases (BM) in breast cancer patients and investigate the risk factors for perihippocampal metastases (PHM).\n'
p13159
sg4
(lp13160
sg20
(lp13161
(dp13162
g7
I72
sg23
VC0027627
p13163
sg10
I10
sg11
Vmetastases
p13164
sg13
I1
sa(dp13165
g7
I66
sg23
VC0220650
p13166
sg10
I16
sg11
Vbrain metastases
p13167
sg13
I2
sa(dp13168
g7
I84
sg23
VC0220650
p13169
sg10
I2
sg11
VBM
p13170
sg13
I1
sa(dp13171
g7
I91
sg23
VC0678222
p13172
sg10
I13
sg11
Vbreast cancer
p13173
sg13
I2
sasa(dp13174
g2
S'Breast cancer subtype (BCS) was not associated with PHM.\n'
p13175
sg4
(lp13176
sg20
(lp13177
(dp13178
g7
I0
sg23
VC0678222
p13179
sg10
I13
sg11
VBreast cancer
p13180
sg13
I2
sasa(dp13181
g2
S'Our study suggests that a low incidence of PHM may be acceptable to perform hippocampal-sparing whole-brain radiation therapy for breast cancer patients.\n'
p13182
sg4
(lp13183
sg20
(lp13184
(dp13185
g7
I130
sg23
VC0678222
p13186
sg10
I13
sg11
Vbreast cancer
p13187
sg13
I2
sasa(dp13188
g2
S'To evaluate the agreement of multichannel intraluminal impedance-pH monitoring (MII-pHM) and gastroesophageal reflux scintigraphy (GES) for the diagnosis of gastroesophageal reflux disease.\n'
p13189
sg4
(lp13190
sg20
(lp13191
(dp13192
g7
I157
sg23
VC0017168
p13193
sg10
I31
sg11
Vgastroesophageal reflux disease
p13194
sg13
I3
sa(dp13195
g7
I93
sg23
VC0017168
p13196
sg10
I23
sg11
Vgastroesophageal reflux
p13197
sg13
I2
sasa(dp13198
g2
S'Seventy-five consecutive patients with suspected gastroesophageal reflux disease (GERD) underwent 24-h combined MII-pHM recording and one hour radionuclide scintigraphy during the course of the MII-pHM study.\n'
p13199
sg4
(lp13200
sg20
(lp13201
(dp13202
g7
I49
sg23
VC0017168
p13203
sg10
I31
sg11
Vgastroesophageal reflux disease
p13204
sg13
I3
sa(dp13205
g7
I82
sg23
VC0017168
p13206
sg10
I4
sg11
VGERD
p13207
sg13
I1
sasa(dp13208
g2
S'According to diagnostic criteria, GERD was diagnosed in 34 (57.7%), 44 (73.3%), 47 (78.3%) and 51 (85%) patients by means of pHM, MII, GES and MII-pHM, respectively.\n'
p13209
sg4
(lp13210
(dp13211
g7
I135
sg8
g18
sg10
I3
sg11
VGES
p13212
sg13
I1
sasg20
(lp13213
(dp13214
g7
I34
sg23
VC0017168
p13215
sg10
I4
sg11
VGERD
p13216
sg13
I1
sasa(dp13217
g2
S'To determine the prevalence of high myopia (HM), progressive high (degenerative) myopia (PHM), and myopic choroidal neovascularization (mCNV) in the United States.\n'
p13218
sg4
(lp13219
sg20
(lp13220
(dp13221
g7
I49
sg23
VC0154778
p13222
sg10
I38
sg11
Vprogressive high (degenerative) myopia
p13223
sg13
I4
sa(dp13224
g7
I31
sg23
VC0271183
p13225
sg10
I11
sg11
Vhigh myopia
p13226
sg13
I2
sa(dp13227
g7
I44
sg23
VC0271183
p13228
sg10
I2
sg11
VHM
p13229
sg13
I1
sa(dp13230
g7
I106
sg23
VC0600518
p13231
sg10
I28
sg11
Vchoroidal neovascularization
p13232
sg13
I2
sasa(dp13233
g2
S'Streptavidin-peroxidase immunohistochemistry was used to detect the expression of OPN, p2lras, and CD44V6 in tissue samples from 96 breast cancer patients, and the multivariate Cox proportional hazards model (mCOX-PHM) was used to analyze the factors that affect prognosis.\n'
p13234
sg4
(lp13235
(dp13236
g7
I82
sg8
VP10451
p13237
sg10
I3
sg11
VOPN
p13238
sg13
I1
sa(dp13239
g7
I0
sg8
VP05164
p13240
sg10
I23
sg11
VStreptavidin-peroxidase
p13241
sg13
I1
sasg20
(lp13242
(dp13243
g7
I132
sg23
VC0678222
p13244
sg10
I13
sg11
Vbreast cancer
p13245
sg13
I2
sasa(dp13246
g2
S'To analyze the prognostic value of the polymorphisms of the thrombophilic genes: plasminogen activator inhibitor type 1 (PAI-1) (-675 4G/5G), factor XIII (FXIII) (G485T), fibrinogen (FBG) (G(-455)A), glycoprotein Ia (GPIa) (C807T), glycoprotein IIIa (GPIIIa) (T106C), and p22phox (C242T), as well as protein genes involved in the pathogenesis of endothelial dysfunction: subunits of p22phox NADH-oxidase (p22phox) (C242T), endothelial NO-synthase (eNOS) (G894T), and methylenetetrahydrofolate reductase (MTHFR) (C677T) for the development of antiphospholipid syndrome (APS) and a type of progressive lupous nephritis (LN) in patients with systemic lupus erythematosus (SLE).\n'
p13247
sg4
(lp13248
(dp13249
g7
I200
sg8
g18
sg10
I15
sg11
Vglycoprotein Ia
p13250
sg13
I2
sa(dp13251
g7
I232
sg8
VP05106
p13252
sg10
I17
sg11
Vglycoprotein IIIa
p13253
sg13
I2
sa(dp13254
g7
I171
sg8
VP22087
p13255
sg10
I10
sg11
Vfibrinogen
p13256
sg13
I1
sa(dp13257
g7
I121
sg8
VP05121
p13258
sg10
I5
sg11
VPAI-1
p13259
sg13
I1
sa(dp13260
g7
I467
sg8
VP42898
p13261
sg10
I35
sg11
Vmethylenetetrahydrofolate reductase
p13262
sg13
I2
sa(dp13263
g7
I504
sg8
VP42898
p13264
sg10
I5
sg11
VMTHFR
p13265
sg13
I1
sa(dp13266
g7
I81
sg8
VP00747
p13267
sg10
I38
sg11
Vplasminogen activator inhibitor type 1
p13268
sg13
I5
sa(dp13269
g7
I217
sg8
VP17301
p13270
sg10
I4
sg11
VGPIa
p13271
sg13
I1
sa(dp13272
g7
I272
sg8
VP13498
p13273
sg10
I7
sg11
Vp22phox
p13274
sg13
I1
sa(dp13275
g7
I272
sg8
VP13498
p13276
sg10
I7
sg11
Vp22phox
p13277
sg13
I1
sa(dp13278
g7
I383
sg8
VP13498
p13279
sg10
I20
sg11
Vp22phox NADH-oxidase
p13280
sg13
I2
sa(dp13281
g7
I183
sg8
VP22087
p13282
sg10
I3
sg11
VFBG
p13283
sg13
I1
sa(dp13284
g7
I251
sg8
VP05106
p13285
sg10
I6
sg11
VGPIIIa
p13286
sg13
I1
sa(dp13287
g7
I448
sg8
g18
sg10
I4
sg11
VeNOS
p13288
sg13
I1
sa(dp13289
g7
I142
sg8
g18
sg10
I27
sg11
Vfactor XIII (FXIII) (G485T)
p13290
sg13
I4
sa(dp13291
g7
I423
sg8
g18
sg10
I23
sg11
Vendothelial NO-synthase
p13292
sg13
I2
sasg20
(lp13293
(dp13294
g7
I346
sg23
VC0856169
p13295
sg10
I23
sg11
Vendothelial dysfunction
p13296
sg13
I2
sa(dp13297
g7
I607
sg23
VC0027697
p13298
sg10
I9
sg11
Vnephritis
p13299
sg13
I1
sa(dp13300
g7
I330
sg23
VC0699748
p13301
sg10
I12
sg11
Vpathogenesis
p13302
sg13
I1
sa(dp13303
g7
I569
sg23
VC0085409
p13304
sg10
I3
sg11
VAPS
p13305
sg13
I1
sa(dp13306
g7
I542
sg23
VC0085278
p13307
sg10
I25
sg11
Vantiphospholipid syndrome
p13308
sg13
I2
sa(dp13309
g7
I639
sg23
VC0024141
p13310
sg10
I28
sg11
Vsystemic lupus erythematosus
p13311
sg13
I3
sa(dp13312
g7
I669
sg23
VC0024141
p13313
sg10
I3
sg11
VSLE
p13314
sg13
I1
sasa(dp13315
g2
S'In HR-/HER2+ breast cancer, four genes (three i-genes BTN3A2, CD2, and TRBC1 and the p-gene MMP11) were significantly associated with distant metastasis-free survival (DMFS).\n'
p13316
sg4
(lp13317
(dp13318
g7
I71
sg8
VP01850
p13319
sg10
I5
sg11
VTRBC1
p13320
sg13
I1
sa(dp13321
g7
I62
sg8
VP06729
p13322
sg10
I3
sg11
VCD2
p13323
sg13
I1
sa(dp13324
g7
I54
sg8
VP78410
p13325
sg10
I6
sg11
VBTN3A2
p13326
sg13
I1
sa(dp13327
g7
I85
sg8
VP24347
p13328
sg10
I12
sg11
Vp-gene MMP11
p13329
sg13
I2
sasg20
(lp13330
(dp13331
g7
I142
sg23
VC0027627
p13332
sg10
I10
sg11
Vmetastasis
p13333
sg13
I1
sa(dp13334
g7
I13
sg23
VC0678222
p13335
sg10
I13
sg11
Vbreast cancer
p13336
sg13
I2
sasa(dp13337
g2
S'A new prognostic model for HR-/HER2+ breast cancer based on the expression of MMP11 and CD2 was developed and the DMFS for patients in the high-risk group according to our model was significantly lower than that for those in the low-risk group.\n'
p13338
sg4
(lp13339
(dp13340
g7
I78
sg8
VP24347
p13341
sg10
I5
sg11
VMMP11
p13342
sg13
I1
sa(dp13343
g7
I88
sg8
VP06729
p13344
sg10
I3
sg11
VCD2
p13345
sg13
I1
sasg20
(lp13346
(dp13347
g7
I37
sg23
VC0678222
p13348
sg10
I13
sg11
Vbreast cancer
p13349
sg13
I2
sasa(dp13350
g2
S'NK cells isolated from the peritoneal environment of ovarian cancer patients, known to be impaired in mediating ADCC, bind to huKS-IL2 via CD25.\n'
p13351
sg4
(lp13352
(dp13353
g7
I139
sg8
VP01589
p13354
sg10
I4
sg11
VCD25
p13355
sg13
I1
sa(dp13356
g7
I126
sg8
VP60568
p13357
sg10
I8
sg11
VhuKS-IL2
p13358
sg13
I1
sasg20
(lp13359
(dp13360
g7
I90
sg23
VC0684336
p13361
sg10
I8
sg11
Vimpaired
p13362
sg13
I1
sa(dp13363
g7
I112
sg23
VC1859972
p13364
sg10
I4
sg11
VADCC
p13365
sg13
I1
sa(dp13366
g7
I53
sg23
VC1140680
p13367
sg10
I14
sg11
Vovarian cancer
p13368
sg13
I2
sasa(dp13369
g2
S'In the present investigation, comprising 204 untreated breast cancer patients, we showed that the proportion of the total T-cell population (CD2 and CD3 positive cells) and the proportion of helper/inducer T-cells (CD4 positive) was positively linked to spread of cancer cells to axillary nodes which in turn Was strongly correlated to prognosis.\n'
p13370
sg4
(lp13371
(dp13372
g7
I215
sg8
VP01730
p13373
sg10
I3
sg11
VCD4
p13374
sg13
I1
sa(dp13375
g7
I141
sg8
VP06729
p13376
sg10
I3
sg11
VCD2
p13377
sg13
I1
sasg20
(lp13378
(dp13379
g7
I62
sg23
VC0006826
p13380
sg10
I6
sg11
Vcancer
p13381
sg13
I1
sa(dp13382
g7
I55
sg23
VC0678222
p13383
sg10
I13
sg11
Vbreast cancer
p13384
sg13
I2
sasa(dp13385
g2
S'Five FCD causal genes [solute carrier family 4, sodium borate transporter, member 11 (SLC4A11), zinc finger E-box binding homeobox 1 (ZEB1), lipoxygenase homology domains 1 (LOXHD1), collagen, type VIII, alpha 2 (COL8A2) and transcription factor 4 (TCF4)], previously reported to be implicated in the pathogenesis of FCD, were screened.\n'
p13386
sg4
(lp13387
(dp13388
g7
I96
sg8
VP37275
p13389
sg10
I76
sg11
Vzinc finger E-box binding homeobox 1 (ZEB1), lipoxygenase homology domains 1
p13390
sg13
I11
sa(dp13391
g7
I23
sg8
g18
sg10
I23
sg11
Vsolute carrier family 4
p13392
sg13
I4
sa(dp13393
g7
I249
sg8
VP15884
p13394
sg10
I4
sg11
VTCF4
p13395
sg13
I1
sa(dp13396
g7
I48
sg8
g18
sg10
I46
sg11
Vsodium borate transporter, member 11 (SLC4A11)
p13397
sg13
I6
sa(dp13398
g7
I193
sg8
VP15884
p13399
sg10
I54
sg11
Vtype VIII, alpha 2 (COL8A2) and transcription factor 4
p13400
sg13
I9
sa(dp13401
g7
I174
sg8
g18
sg10
I6
sg11
VLOXHD1
p13402
sg13
I1
sasg20
(lp13403
(dp13404
g7
I5
sg23
VC1562113
p13405
sg10
I3
sg11
VFCD
p13406
sg13
I1
sa(dp13407
g7
I301
sg23
VC0699748
p13408
sg10
I12
sg11
Vpathogenesis
p13409
sg13
I1
sa(dp13410
g7
I5
sg23
VC1562113
p13411
sg10
I3
sg11
VFCD
p13412
sg13
I1
sasa(dp13413
g2
S"A total of 27 variants [including 22 known single nucleotide polymorphisms (SNPs) from the Single Nucleotide Polymorphism Database (dbSNP) and 5 variants absent from dbSNP] were detected in this FCD pedigree across the SLC4A11, ZEB1, LOXHD1 and COL8A2 genes as follows: i) 22 known SNPs from dbSNP, including 3 coding (p.R161R, p.S213S and p.T833T) and 11 non-coding variants of SLC4A11, 2 intronic SNPs of ZEB1 from dbSNP (rs220057 and rs220060), 1 intronic SNP of LOXHD1 from dbSNP (rs16939650), and 5 SNPs of COL8A2 from dbSNP (p.A35A, p.R155Q, p.L335L, p.G495G and p.T502M); and ii) 5 variants that have not been previously reported in FCD patients and that are absent from dbSNP were identified across the ZEB1 and LOXHD1 genes; these included 3 continuous indels located at the junction of the 5'-UTR and the adjacent exon 1 of ZEB1 [Indel 1 (c.-86_-53delins gggaggggtggaggcggaggggtGGGGGGGAAGG); Indel 2 (c.-52_-46delinsGGGAGGG); and Indel 3 (c.-45_-42delinsAGGG)], and 2 intronic variants of LOXHD1 (c.5332-126C&gt;T and c.1809+155G&gt;A).\n"
p13414
sg4
(lp13415
(dp13416
g7
I228
sg8
VP37275
p13417
sg10
I4
sg11
VZEB1
p13418
sg13
I1
sa(dp13419
g7
I234
sg8
g18
sg10
I6
sg11
VLOXHD1
p13420
sg13
I1
sa(dp13421
g7
I245
sg8
VP25067
p13422
sg10
I12
sg11
VCOL8A2 genes
p13423
sg13
I2
sa(dp13424
g7
I228
sg8
VP37275
p13425
sg10
I4
sg11
VZEB1
p13426
sg13
I1
sa(dp13427
g7
I234
sg8
g18
sg10
I6
sg11
VLOXHD1
p13428
sg13
I1
sa(dp13429
g7
I245
sg8
VP25067
p13430
sg10
I6
sg11
VCOL8A2
p13431
sg13
I1
sa(dp13432
g7
I219
sg8
g18
sg10
I7
sg11
VSLC4A11
p13433
sg13
I1
sa(dp13434
g7
I720
sg8
g18
sg10
I12
sg11
VLOXHD1 genes
p13435
sg13
I2
sa(dp13436
g7
I228
sg8
VP37275
p13437
sg10
I4
sg11
VZEB1
p13438
sg13
I1
sa(dp13439
g7
I228
sg8
VP37275
p13440
sg10
I4
sg11
VZEB1
p13441
sg13
I1
sa(dp13442
g7
I234
sg8
g18
sg10
I6
sg11
VLOXHD1
p13443
sg13
I1
sasg20
(lp13444
(dp13445
g7
I195
sg23
VC1562113
p13446
sg10
I3
sg11
VFCD
p13447
sg13
I1
sa(dp13448
g7
I195
sg23
VC1562113
p13449
sg10
I3
sg11
VFCD
p13450
sg13
I1
sasa(dp13451
g2
S'Sequencing of the coding exons of TCF4 and LOXHD1 in six patients showed no variant described with FECD.\n'
p13452
sg4
(lp13453
(dp13454
g7
I43
sg8
g18
sg10
I6
sg11
VLOXHD1
p13455
sg13
I1
sa(dp13456
g7
I34
sg8
VP15884
p13457
sg10
I4
sg11
VTCF4
p13458
sg13
I1
sasg20
(lp13459
sa(dp13460
g2
S'FECD is associated with mutations of a variety of unrelated genes: SLC4A11, COL8A2, TCF8, and LOXHD1.\n'
p13461
sg4
(lp13462
(dp13463
g7
I84
sg8
VP37275
p13464
sg10
I4
sg11
VTCF8
p13465
sg13
I1
sa(dp13466
g7
I67
sg8
g18
sg10
I7
sg11
VSLC4A11
p13467
sg13
I1
sa(dp13468
g7
I76
sg8
VP25067
p13469
sg10
I6
sg11
VCOL8A2
p13470
sg13
I1
sa(dp13471
g7
I0
sg8
VP25067
p13472
sg10
I4
sg11
VFECD
p13473
sg13
I1
sa(dp13474
g7
I94
sg8
g18
sg10
I6
sg11
VLOXHD1
p13475
sg13
I1
sasg20
(lp13476
sa(dp13477
g2
S'Corneal sections of the original proband were stained for LOXHD1 and demonstrated a distinct increase in antibody punctate staining in the endothelium and Descemet membrane; punctate staining was absent from both normal corneas and FCD corneas negative for causal LOXHD1 mutations.\n'
p13478
sg4
(lp13479
(dp13480
g7
I264
sg8
g18
sg10
I16
sg11
VLOXHD1 mutations
p13481
sg13
I2
sa(dp13482
g7
I58
sg8
g18
sg10
I6
sg11
VLOXHD1
p13483
sg13
I1
sasg20
(lp13484
(dp13485
g7
I232
sg23
VC1562113
p13486
sg10
I3
sg11
VFCD
p13487
sg13
I1
sasa(dp13488
g2
S'All together, our data implicate rare alleles in LOXHD1 in the pathogenesis of FCD and highlight how different mutations in the same locus can potentially produce diverse phenotypes.\n'
p13489
sg4
(lp13490
(dp13491
g7
I49
sg8
g18
sg10
I6
sg11
VLOXHD1
p13492
sg13
I1
sasg20
(lp13493
(dp13494
g7
I79
sg23
VC1562113
p13495
sg10
I3
sg11
VFCD
p13496
sg13
I1
sa(dp13497
g7
I63
sg23
VC0699748
p13498
sg10
I12
sg11
Vpathogenesis
p13499
sg13
I1
sasa(dp13500
g2
S'However, the potential biological roles and regulatory mechanisms of CCAT1 in intrahepatic cholangiocarcinoma (ICC) remain unclear.\n'
p13501
sg4
(lp13502
sg20
(lp13503
(dp13504
g7
I78
sg23
VC0345905
p13505
sg10
I31
sg11
Vintrahepatic cholangiocarcinoma
p13506
sg13
I2
sa(dp13507
g7
I111
sg23
VC0268074
p13508
sg10
I3
sg11
VICC
p13509
sg13
I1
sasa(dp13510
g2
S'To investigate the expression of long noncoding RNA CCAT1 in cholangiocarcinoma (CCA) and to assess the CCAT1 expression as a prognostic biomarker for CCA.\n'
p13511
sg4
(lp13512
sg20
(lp13513
(dp13514
g7
I61
sg23
VC0206698
p13515
sg10
I18
sg11
Vcholangiocarcinoma
p13516
sg13
I1
sa(dp13517
g7
I52
sg23
VC0206698
p13518
sg10
I3
sg11
VCCA
p13519
sg13
I1
sa(dp13520
g7
I52
sg23
VC0206698
p13521
sg10
I3
sg11
VCCA
p13522
sg13
I1
sasa(dp13523
g2
S'Our study showed that lncRNA CCAT1, which was upregulated and associated with aggressive malignant behavior, may serve as a novel prognostic biomarker and potential therapeutic target for cholangiocarcinoma.\n'
p13524
sg4
(lp13525
sg20
(lp13526
(dp13527
g7
I188
sg23
VC0206698
p13528
sg10
I18
sg11
Vcholangiocarcinoma
p13529
sg13
I1
sa(dp13530
g7
I78
sg23
VC0001807
p13531
sg10
I10
sg11
Vaggressive
p13532
sg13
I1
sasa(dp13533
g2
S'Inner-ear hair cell differentiation requires Atoh1 function, while Eya1, Six1, and Sox2 are coexpressed in sensory progenitors and mutations in these genes cause sensorineural hearing loss.\n'
p13534
sg4
(lp13535
(dp13536
g7
I83
sg8
VP48431
p13537
sg10
I4
sg11
VSox2
p13538
sg13
I1
sa(dp13539
g7
I73
sg8
g18
sg10
I4
sg11
VSix1
p13540
sg13
I1
sa(dp13541
g7
I45
sg8
g18
sg10
I5
sg11
VAtoh1
p13542
sg13
I1
sa(dp13543
g7
I67
sg8
g18
sg10
I4
sg11
VEya1
p13544
sg13
I1
sasg20
(lp13545
(dp13546
g7
I162
sg23
VC0018784
p13547
sg10
I26
sg11
Vsensorineural hearing loss
p13548
sg13
I3
sasa(dp13549
g2
S'Mutation in SIX1 is responsible also for DFNA23, a locus for non-syndromic HI.\n'
p13550
sg4
(lp13551
(dp13552
g7
I41
sg8
g18
sg10
I6
sg11
VDFNA23
p13553
sg13
I1
sa(dp13554
g7
I12
sg8
g18
sg10
I4
sg11
VSIX1
p13555
sg13
I1
sasg20
(lp13556
(dp13557
g7
I41
sg23
VC1854594
p13558
sg10
I6
sg11
VDFNA23
p13559
sg13
I1
sasa(dp13560
g2
S'The results suggest that decreased NPY expression in the extended amygdala might be causally linked with the depression induced following type 2 diabetes and that the antidepressant action of imipramine in diabetic mice might be mediated by NPY-NPY Y1 receptor system.\n'
p13561
sg4
(lp13562
(dp13563
g7
I35
sg8
VP25929
p13564
sg10
I3
sg11
VNPY
p13565
sg13
I1
sa(dp13566
g7
I241
sg8
VP25929
p13567
sg10
I19
sg11
VNPY-NPY Y1 receptor
p13568
sg13
I3
sasg20
(lp13569
(dp13570
g7
I138
sg23
VC0011860
p13571
sg10
I15
sg11
Vtype 2 diabetes
p13572
sg13
I3
sa(dp13573
g7
I109
sg23
VC0011581
p13574
sg10
I10
sg11
Vdepression
p13575
sg13
I1
sasa(dp13576
g2
S'Numerous models of obesity and diabetes are characterized by increased central nervous system (CNS) neuropeptide Y (NPY); in fact, a single intracerebroventricular (icv) administration of NPY in lean fasted rats elevates hepatic VLDL-TG secretion and does so, in large part, via signaling through the CNS NPY Y1 receptor.\n'
p13577
sg4
(lp13578
(dp13579
g7
I301
sg8
VP25929
p13580
sg10
I19
sg11
VCNS NPY Y1 receptor
p13581
sg13
I4
sa(dp13582
g7
I116
sg8
VP25929
p13583
sg10
I3
sg11
VNPY
p13584
sg13
I1
sa(dp13585
g7
I116
sg8
VP25929
p13586
sg10
I3
sg11
VNPY
p13587
sg13
I1
sa(dp13588
g7
I100
sg8
VP01303
p13589
sg10
I14
sg11
Vneuropeptide Y
p13590
sg13
I2
sasg20
(lp13591
(dp13592
g7
I31
sg23
VC0011849
p13593
sg10
I8
sg11
Vdiabetes
p13594
sg13
I1
sa(dp13595
g7
I19
sg23
VC0028754
p13596
sg10
I7
sg11
Vobesity
p13597
sg13
I1
sa(dp13598
g7
I79
sg23
VC0027769
p13599
sg10
I7
sg11
Vnervous
p13600
sg13
I1
sasa(dp13601
g2
S'All 41 human homologs of the mutated genes were mutated in the clinical samples, and some mutations were associated with clinical outcomes, suggesting a high probability of cancer driver genes in the spontaneous tumors of the mouse model.\n'
p13602
sg4
(lp13603
sg20
(lp13604
(dp13605
g7
I173
sg23
VC0006826
p13606
sg10
I6
sg11
Vcancer
p13607
sg13
I1
sa(dp13608
g7
I212
sg23
VC0027651
p13609
sg10
I6
sg11
Vtumors
p13610
sg13
I1
sasa(dp13611
g2
S'In the present study, the expression of ICAT in 41 human cervical cancer tissues and 30 normal cervical tissues was evaluated by immunohistochemical analysis.\n'
p13612
sg4
(lp13613
(dp13614
g7
I40
sg8
g18
sg10
I4
sg11
VICAT
p13615
sg13
I1
sasg20
(lp13616
(dp13617
g7
I57
sg23
VC0302592
p13618
sg10
I15
sg11
Vcervical cancer
p13619
sg13
I2
sasa(dp13620
g2
S'The erythrocyte protein band 4.1-like5 (EPB4.1L5) regulates E-cadherin in cancer invasion and metastasis inducing epithelial-to-mesenchymal transition.\n'
p13621
sg4
(lp13622
(dp13623
g7
I60
sg8
VP12830
p13624
sg10
I10
sg11
VE-cadherin
p13625
sg13
I1
sasg20
(lp13626
(dp13627
g7
I94
sg23
VC0027627
p13628
sg10
I10
sg11
Vmetastasis
p13629
sg13
I1
sa(dp13630
g7
I74
sg23
VC0006826
p13631
sg10
I6
sg11
Vcancer
p13632
sg13
I1
sa(dp13633
g7
I81
sg23
VC2699153
p13634
sg10
I8
sg11
Vinvasion
p13635
sg13
I1
sa(dp13636
g7
I140
sg23
VC0599156
p13637
sg10
I10
sg11
Vtransition
p13638
sg13
I1
sasa(dp13639
g2
S'To detect the expression of protein 4.1 family members in mouse melanoma cell lines and evaluate their effect on cell proliferation.\n'
p13640
sg4
(lp13641
(dp13642
g7
I28
sg8
VP01031
p13643
sg10
I26
sg11
Vprotein 4.1 family members
p13644
sg13
I4
sasg20
(lp13645
(dp13646
g7
I118
sg23
VC0334094
p13647
sg10
I13
sg11
Vproliferation
p13648
sg13
I1
sa(dp13649
g7
I58
sg23
VC1522102
p13650
sg10
I14
sg11
Vmouse melanoma
p13651
sg13
I2
sasa(dp13652
g2
S'The expression plasmid vector pEGFP-N1-EPB41L3 carrying 4.1B gene sequence amplified from genomic RNA of mouse embryo fibroblasts was constructed and transiently transfected into mouse melanoma cells.\n'
p13653
sg4
(lp13654
(dp13655
g7
I30
sg8
g18
sg10
I16
sg11
VpEGFP-N1-EPB41L3
p13656
sg13
I1
sasg20
(lp13657
(dp13658
g7
I179
sg23
VC1522102
p13659
sg10
I14
sg11
Vmouse melanoma
p13660
sg13
I2
sasa(dp13661
g2
S'The eukaryotic expression vector carrying EPB41L3 sequence is capable of inhibiting the proliferation of mouse melanoma B16 and B16-F10 cells.\n'
p13662
sg4
(lp13663
(dp13664
g7
I42
sg8
g18
sg10
I16
sg11
VEPB41L3 sequence
p13665
sg13
I2
sasg20
(lp13666
(dp13667
g7
I105
sg23
VC1522102
p13668
sg10
I14
sg11
Vmouse melanoma
p13669
sg13
I2
sa(dp13670
g7
I88
sg23
VC0334094
p13671
sg10
I13
sg11
Vproliferation
p13672
sg13
I1
sasa(dp13673
g2
S'The aim of this study was to examine the association between T309G (rs2279744) and 40-bp Insertion/deletion (rs3730485) polymorphisms of the MDM2 gene and risk of uterine leiomyoma (UL).\n'
p13674
sg4
(lp13675
sg20
(lp13676
(dp13677
g7
I163
sg23
VC0042133
p13678
sg10
I17
sg11
Vuterine leiomyoma
p13679
sg13
I2
sa(dp13680
g7
I182
sg23
VC0042133
p13681
sg10
I2
sg11
VUL
p13682
sg13
I1
sasa(dp13683
g2
S'In addition, it is demonstrated that AlfavBeta3 is coexpressed with synaptophysin, a biomarker for aggressive neuroendocrine prostate cancer.\n'
p13684
sg4
(lp13685
(dp13686
g7
I68
sg8
VP08247
p13687
sg10
I13
sg11
Vsynaptophysin
p13688
sg13
I1
sasg20
(lp13689
(dp13690
g7
I99
sg23
VC0001807
p13691
sg10
I10
sg11
Vaggressive
p13692
sg13
I1
sa(dp13693
g7
I125
sg23
VC0600139
p13694
sg10
I15
sg11
Vprostate cancer
p13695
sg13
I2
sasa(dp13696
g2
S'Neurological diseases that exhibit parkinsonism and have normal dopaminergic cells in the nigrostriatal system (e.g., essential tremor, psychogenic parkinsonism, DOPA-responsive dystonia, vascular parkinsonism, drug-induced parkinsonism, manganism, brain tumor, myoclonus-dystonia (DYT11), and fragile X syndrome) might be diagnosed with SWEDDs.\n'
p13697
sg4
(lp13698
sg20
(lp13699
(dp13700
g7
I178
sg23
VC0393593
p13701
sg10
I8
sg11
Vdystonia
p13702
sg13
I1
sa(dp13703
g7
I282
sg23
VC1834570
p13704
sg10
I5
sg11
VDYT11
p13705
sg13
I1
sa(dp13706
g7
I118
sg23
VC0270736
p13707
sg10
I16
sg11
Vessential tremor
p13708
sg13
I2
sa(dp13709
g7
I211
sg23
VC0270729
p13710
sg10
I25
sg11
Vdrug-induced parkinsonism
p13711
sg13
I2
sa(dp13712
g7
I294
sg23
VC0016667
p13713
sg10
I18
sg11
Vfragile X syndrome
p13714
sg13
I3
sa(dp13715
g7
I262
sg23
VC0027066
p13716
sg10
I9
sg11
Vmyoclonus
p13717
sg13
I1
sa(dp13718
g7
I35
sg23
VC0242422
p13719
sg10
I12
sg11
Vparkinsonism
p13720
sg13
I1
sa(dp13721
g7
I188
sg23
VC0393568
p13722
sg10
I21
sg11
Vvascular parkinsonism
p13723
sg13
I2
sa(dp13724
g7
I35
sg23
VC0242422
p13725
sg10
I12
sg11
Vparkinsonism
p13726
sg13
I1
sa(dp13727
g7
I178
sg23
VC0393593
p13728
sg10
I8
sg11
Vdystonia
p13729
sg13
I1
sa(dp13730
g7
I249
sg23
VC0006118
p13731
sg10
I11
sg11
Vbrain tumor
p13732
sg13
I2
sasa(dp13733
g2
S'In this study, the efficacy of the MS pyrosequencing method at H19-DMR and LIT1-DMR at 11p15 and SGCE-DMR at 7q21 was evaluated for the genetic diagnosis of BWS (n=18) and SRS (n=20) patients.\n'
p13734
sg4
(lp13735
(dp13736
g7
I67
sg8
g18
sg10
I3
sg11
VDMR
p13737
sg13
I1
sa(dp13738
g7
I75
sg8
g18
sg10
I8
sg11
VLIT1-DMR
p13739
sg13
I1
sasg20
(lp13740
(dp13741
g7
I172
sg23
VC0175693
p13742
sg10
I3
sg11
VSRS
p13743
sg13
I1
sa(dp13744
g7
I157
sg23
VC0004903
p13745
sg10
I3
sg11
VBWS
p13746
sg13
I1
sasa(dp13747
g2
S'Raldh3 knockout notably causes choanal atresia (CA), which is responsible for respiratory distress and death of Raldh3-null mutants at birth.\n'
p13748
sg4
(lp13749
(dp13750
g7
I0
sg8
VP47895
p13751
sg10
I6
sg11
VRaldh3
p13752
sg13
I1
sa(dp13753
g7
I0
sg8
VP47895
p13754
sg10
I6
sg11
VRaldh3
p13755
sg13
I1
sasg20
(lp13756
(dp13757
g7
I78
sg23
VC0476273
p13758
sg10
I20
sg11
Vrespiratory distress
p13759
sg13
I2
sa(dp13760
g7
I48
sg23
VC0008297
p13761
sg10
I2
sg11
VCA
p13762
sg13
I1
sa(dp13763
g7
I31
sg23
VC0008297
p13764
sg10
I15
sg11
Vchoanal atresia
p13765
sg13
I2
sasa(dp13766
g2
S'Treg cells (CD4+CD25+CD127(low) ) and Teff cells (CD4+CD25-) were isolated from peripheral blood and synovial fluid obtained from JIA patients, healthy controls, and children with Lyme arthritis.\n'
p13767
sg4
(lp13768
(dp13769
g7
I12
sg8
VP01730
p13770
sg10
I14
sg11
VCD4+CD25+CD127
p13771
sg13
I1
sasg20
(lp13772
(dp13773
g7
I180
sg23
VC0242381
p13774
sg10
I14
sg11
VLyme arthritis
p13775
sg13
I2
sasa(dp13776
g2
S'The study aims to investigate the frequency of CD4(+)CD25(+)Foxp3(+)CD127(-) T regulatory cells (Tregs) and the expression of CCR4, CCR6 and/or other chemokine receptors on Tregs in peripheral blood (PB) in patients with rheumatoid arthritis, as well as in PB, draining lymph nodes (dLNs), lungs and spleens in collagen-induced arthritis (CIA) mice.\n'
p13777
sg4
(lp13778
(dp13779
g7
I132
sg8
VP51684
p13780
sg10
I4
sg11
VCCR6
p13781
sg13
I1
sa(dp13782
g7
I126
sg8
VP51679
p13783
sg10
I4
sg11
VCCR4
p13784
sg13
I1
sa(dp13785
g7
I47
sg8
VP01730
p13786
sg10
I26
sg11
VCD4(+)CD25(+)Foxp3(+)CD127
p13787
sg13
I1
sasg20
(lp13788
(dp13789
g7
I232
sg23
VC0003864
p13790
sg10
I9
sg11
Varthritis
p13791
sg13
I1
sa(dp13792
g7
I221
sg23
VC0003873
p13793
sg10
I20
sg11
Vrheumatoid arthritis
p13794
sg13
I2
sasa(dp13795
g2
S'Implications of assessing the proximal and far para-tracheal or sub-carinal nodes (para-tracheal [PTN] or sub-carinal [SCN]) associated with lower primary esophageal carcinomas (ECs) are unclear.\n'
p13796
sg4
(lp13797
sg20
(lp13798
(dp13799
g7
I166
sg23
VC0007097
p13800
sg10
I10
sg11
Vcarcinomas
p13801
sg13
I1
sasa(dp13802
g2
S'Pleiotrophin (PTN) is a secreted cytokine that is expressed in various cancer cell lines and human tumor such as colon cancer, lung cancer, gastric cancer and melanoma.\n'
p13803
sg4
(lp13804
(dp13805
g7
I0
sg8
VP21246
p13806
sg10
I12
sg11
VPleiotrophin
p13807
sg13
I1
sa(dp13808
g7
I14
sg8
VP21246
p13809
sg10
I3
sg11
VPTN
p13810
sg13
I1
sasg20
(lp13811
(dp13812
g7
I99
sg23
VC0027651
p13813
sg10
I5
sg11
Vtumor
p13814
sg13
I1
sa(dp13815
g7
I71
sg23
VC0006826
p13816
sg10
I6
sg11
Vcancer
p13817
sg13
I1
sa(dp13818
g7
I132
sg23
VC0024623
p13819
sg10
I15
sg11
Vcancer, gastric
p13820
sg13
I2
sa(dp13821
g7
I119
sg23
VC0242379
p13822
sg10
I12
sg11
Vcancer, lung
p13823
sg13
I2
sa(dp13824
g7
I71
sg23
VC0006826
p13825
sg10
I6
sg11
Vcancer
p13826
sg13
I1
sa(dp13827
g7
I159
sg23
VC0025202
p13828
sg10
I8
sg11
Vmelanoma
p13829
sg13
I1
sasa(dp13830
g2
S'Immunohistochemical expression of Cx43 was analyzed in 50 colorectal adenocarcinomas from surgically-treated patients of stage pT3N1-2 without metastases (M0) and 50 specimens of the same pTN stage from patients with synchronous liver metastases (M1).\n'
p13831
sg4
(lp13832
(dp13833
g7
I34
sg8
VP17302
p13834
sg10
I4
sg11
VCx43
p13835
sg13
I1
sasg20
(lp13836
(dp13837
g7
I143
sg23
VC0027627
p13838
sg10
I10
sg11
Vmetastases
p13839
sg13
I1
sa(dp13840
g7
I69
sg23
VC0001418
p13841
sg10
I15
sg11
Vadenocarcinomas
p13842
sg13
I1
sa(dp13843
g7
I229
sg23
VC0494165
p13844
sg10
I16
sg11
Vliver metastases
p13845
sg13
I2
sasa(dp13846
g2
S'Data were collected on the preoperative cTN stage according to the radiologist and postoperative pTN stage according to the pathologist on all patients operated on for colon cancer in Sweden 2007-2010.\n'
p13847
sg4
(lp13848
(dp13849
g7
I40
sg8
g18
sg10
I3
sg11
VcTN
p13850
sg13
I1
sasg20
(lp13851
(dp13852
g7
I168
sg23
VC0699790
p13853
sg10
I12
sg11
Vcolon cancer
p13854
sg13
I2
sasa(dp13855
g2
S'To our knowledge, this is the first study to demonstrate the utility of PTN as a surrogate marker of outcome in antiangiogenic therapy for metastatic colorectal cancer.\n'
p13856
sg4
(lp13857
(dp13858
g7
I72
sg8
VP21246
p13859
sg10
I3
sg11
VPTN
p13860
sg13
I1
sasg20
(lp13861
(dp13862
g7
I139
sg23
VC0948380
p13863
sg10
I28
sg11
Vmetastatic colorectal cancer
p13864
sg13
I3
sasa(dp13865
g2
S"To determine the roles of MBD2 and DNA methylation in human Epsilon-globin gene silencing, transgenic mice containing all sequences extending from the 5' hypersensitive site 5 (HS5) of the Beta-globin locus LCR to the human Gamma-globin gene promoter were generated.\n"
p13866
sg4
(lp13867
(dp13868
g7
I54
sg8
VP02100
p13869
sg10
I25
sg11
Vhuman Epsilon-globin gene
p13870
sg13
I3
sa(dp13871
g7
I26
sg8
g18
sg10
I4
sg11
VMBD2
p13872
sg13
I1
sasg20
(lp13873
(dp13874
g7
I154
sg23
VC2675192
p13875
sg10
I21
sg11
Vhypersensitive site 5
p13876
sg13
I3
sa(dp13877
g7
I177
sg23
VC2675192
p13878
sg10
I3
sg11
VHS5
p13879
sg13
I1
sasa(dp13880
g2
S'In the LTR-HS5-epsilonp-GFP plasmid integrated into K562 cells, mutation of the CCAAT motif in the LTR enhancer to abolish NF-Y binding inactivated the enhancer, closed down the chromatin structure of the epsilon-globin promoter, and silenced transcription of the green fluorescent protein gene.\n'
p13881
sg4
(lp13882
(dp13883
g7
I99
sg8
g18
sg10
I12
sg11
VLTR enhancer
p13884
sg13
I2
sa(dp13885
g7
I264
sg8
g18
sg10
I25
sg11
Vgreen fluorescent protein
p13886
sg13
I3
sa(dp13887
g7
I205
sg8
VP02100
p13888
sg10
I23
sg11
Vepsilon-globin promoter
p13889
sg13
I2
sa(dp13890
g7
I7
sg8
VP16452
p13891
sg10
I20
sg11
VLTR-HS5-epsilonp-GFP
p13892
sg13
I1
sasg20
(lp13893
(dp13894
g7
I11
sg23
VC2675192
p13895
sg10
I3
sg11
VHS5
p13896
sg13
I1
sasa(dp13897
g2
S'Curiously, we also observed an attenuating activity in HS5 that was specific to the epsilon-globin gene at the primitive stage and was independent of the HS5 CTCF binding site.\n'
p13898
sg4
(lp13899
(dp13900
g7
I154
sg8
VP16452
p13901
sg10
I21
sg11
VHS5 CTCF binding site
p13902
sg13
I4
sa(dp13903
g7
I84
sg8
VP02100
p13904
sg10
I19
sg11
Vepsilon-globin gene
p13905
sg13
I2
sasg20
(lp13906
(dp13907
g7
I55
sg23
VC2675192
p13908
sg10
I3
sg11
VHS5
p13909
sg13
I1
sa(dp13910
g7
I55
sg23
VC2675192
p13911
sg10
I3
sg11
VHS5
p13912
sg13
I1
sasa(dp13913
g2
S'The LTR enhancer initiates synthesis of long RNAs from the LTR promoter through the intervening HS5 site into the epsilon-globin promoter and the GFP gene.\n'
p13914
sg4
(lp13915
(dp13916
g7
I4
sg8
g18
sg10
I12
sg11
VLTR enhancer
p13917
sg13
I2
sa(dp13918
g7
I114
sg8
VP02100
p13919
sg10
I23
sg11
Vepsilon-globin promoter
p13920
sg13
I2
sasg20
(lp13921
(dp13922
g7
I96
sg23
VC2675192
p13923
sg10
I3
sg11
VHS5
p13924
sg13
I1
sasa(dp13925
g2
S'However, reversing the orientation of the LTR in plasmid (LTR)rev-HS5-epsilonp-GFP, thus reversing the direction of synthesis of LTR RNAs in the antisense direction away from the epsilon-globin promoter and GFP gene drastically reduces the level of GFP mRNA and thus LTR enhancer function.\n'
p13926
sg4
(lp13927
(dp13928
g7
I62
sg8
VP16452
p13929
sg10
I20
sg11
Vrev-HS5-epsilonp-GFP
p13930
sg13
I1
sa(dp13931
g7
I129
sg8
g18
sg10
I8
sg11
VLTR RNAs
p13932
sg13
I2
sa(dp13933
g7
I179
sg8
VP02100
p13934
sg10
I23
sg11
Vepsilon-globin promoter
p13935
sg13
I2
sa(dp13936
g7
I267
sg8
g18
sg10
I12
sg11
VLTR enhancer
p13937
sg13
I2
sasg20
(lp13938
(dp13939
g7
I66
sg23
VC2675192
p13940
sg10
I3
sg11
VHS5
p13941
sg13
I1
sasa(dp13942
g2
S'The roles of each DNase hypersensitive site (HS), and the DNA sequences between them, in the activity of the locus control region of the mammalian beta-globin gene domain were examined by placing human and rabbit restriction fragments containing the cores of HS2, HS3, HS4, and HS5, along with varying amounts of flanking DNA, upstream of a hybrid epsilon-globin-luciferase reporter gene and testing for effects on expression both prior to and after integration into the chromosomes of K562 cells, a human erythroid cell line.\n'
p13943
sg4
(lp13944
(dp13945
g7
I341
sg8
VP02100
p13946
sg10
I21
sg11
Vhybrid epsilon-globin
p13947
sg13
I2
sa(dp13948
g7
I18
sg8
VP24855
p13949
sg10
I25
sg11
VDNase hypersensitive site
p13950
sg13
I3
sasg20
(lp13951
(dp13952
g7
I269
sg23
VC2675212
p13953
sg10
I3
sg11
VHS4
p13954
sg13
I1
sa(dp13955
g7
I278
sg23
VC2675192
p13956
sg10
I3
sg11
VHS5
p13957
sg13
I1
sa(dp13958
g7
I264
sg23
VC2678338
p13959
sg10
I3
sg11
VHS3
p13960
sg13
I1
sasa(dp13961
g2
S'CUZD1 was also elevated in breast and lung cancer specimens and not in colorectal, prostate and testicular cancer specimens.\n'
p13962
sg4
(lp13963
(dp13964
g7
I0
sg8
g18
sg10
I5
sg11
VCUZD1
p13965
sg13
I1
sasg20
(lp13966
(dp13967
g7
I38
sg23
VC0684249
p13968
sg10
I11
sg11
Vlung cancer
p13969
sg13
I2
sa(dp13970
g7
I96
sg23
VC0153594
p13971
sg10
I17
sg11
Vtesticular cancer
p13972
sg13
I2
sasa(dp13973
g2
S'We validated my-cisTarget by re-analyzing the TAL1 and LMO1 enhancer mutations in T-ALL, and the TERT promoter mutation in melanoma.\n'
p13974
sg4
(lp13975
(dp13976
g7
I46
sg8
VP17542
p13977
sg10
I4
sg11
VTAL1
p13978
sg13
I1
sa(dp13979
g7
I55
sg8
VP25800
p13980
sg10
I13
sg11
VLMO1 enhancer
p13981
sg13
I2
sa(dp13982
g7
I97
sg8
g18
sg10
I13
sg11
VTERT promoter
p13983
sg13
I2
sasg20
(lp13984
(dp13985
g7
I82
sg23
VC1961099
p13986
sg10
I5
sg11
VT-ALL
p13987
sg13
I1
sa(dp13988
g7
I123
sg23
VC0025202
p13989
sg10
I8
sg11
Vmelanoma
p13990
sg13
I1
sasa(dp13991
g2
S'SIL-TAL1 rearrangement is common in T-cell acute lymphoblastic leukemia (T-ALL).\n'
p13992
sg4
(lp13993
(dp13994
g7
I0
sg8
VP40967
p13995
sg10
I8
sg11
VSIL-TAL1
p13996
sg13
I1
sasg20
(lp13997
(dp13998
g7
I73
sg23
VC1961099
p13999
sg10
I5
sg11
VT-ALL
p14000
sg13
I1
sa(dp14001
g7
I36
sg23
VC1961099
p14002
sg10
I35
sg11
VT-cell acute lymphoblastic leukemia
p14003
sg13
I4
sa(dp14004
g7
I0
sg23
VC0333873
p14005
sg10
I3
sg11
VSIL
p14006
sg13
I1
sasa(dp14007
g2
S"Their MRD were evaluated by SIL-TAL1, Wilms' tumor 1 (WT1) expression, and the leukemia-associated immunophenotype (LAIP) .\n"
p14008
sg4
(lp14009
(dp14010
g7
I32
sg8
VP17542
p14011
sg10
I4
sg11
VTAL1
p14012
sg13
I1
sa(dp14013
g7
I54
sg8
g18
sg10
I3
sg11
VWT1
p14014
sg13
I1
sa(dp14015
g7
I38
sg8
g18
sg10
I14
sg11
VWilms' tumor 1
p14016
sg13
I3
sasg20
(lp14017
(dp14018
g7
I28
sg23
VC0333873
p14019
sg10
I3
sg11
VSIL
p14020
sg13
I1
sa(dp14021
g7
I79
sg23
VC0023418
p14022
sg10
I8
sg11
Vleukemia
p14023
sg13
I1
sa(dp14024
g7
I54
sg23
VC0027708
p14025
sg10
I3
sg11
VWT1
p14026
sg13
I1
sa(dp14027
g7
I6
sg23
VC1840451
p14028
sg10
I3
sg11
VMRD
p14029
sg13
I1
sa(dp14030
g7
I38
sg23
VC0027708
p14031
sg10
I14
sg11
VWilms' tumor 1
p14032
sg13
I3
sasa(dp14033
g2
S'In this vein, overexpression of TAL1s stimulates the transcription of Beta-hemoglobin in human leukemia K562 cells and promotes erythroid differentiation of human cord blood CD34+ cells cultured in erythropoietin-containing medium.\n'
p14034
sg4
(lp14035
(dp14036
g7
I70
sg8
g18
sg10
I15
sg11
VBeta-hemoglobin
p14037
sg13
I1
sa(dp14038
g7
I198
sg8
VP01588
p14039
sg10
I14
sg11
Verythropoietin
p14040
sg13
I1
sa(dp14041
g7
I32
sg8
VP17542
p14042
sg10
I5
sg11
VTAL1s
p14043
sg13
I1
sasg20
(lp14044
(dp14045
g7
I163
sg23
VC0035334
p14046
sg10
I4
sg11
Vcord
p14047
sg13
I1
sa(dp14048
g7
I95
sg23
VC0023418
p14049
sg10
I8
sg11
Vleukemia
p14050
sg13
I1
sasa(dp14051
g2
S'SCL/TAL1 (stem cell leukemia/T-cell acute lymphoblastic leukemia [T-ALL] 1) is an essential transcription factor in normal and malignant hematopoiesis.\n'
p14052
sg4
(lp14053
(dp14054
g7
I0
sg8
VP17542
p14055
sg10
I3
sg11
VSCL
p14056
sg13
I1
sa(dp14057
g7
I4
sg8
VP17542
p14058
sg10
I4
sg11
VTAL1
p14059
sg13
I1
sasg20
(lp14060
(dp14061
g7
I10
sg23
VC1378511
p14062
sg10
I18
sg11
Vstem cell leukemia
p14063
sg13
I3
sa(dp14064
g7
I29
sg23
VC1961099
p14065
sg10
I35
sg11
VT-cell acute lymphoblastic leukemia
p14066
sg13
I4
sa(dp14067
g7
I66
sg23
VC1961099
p14068
sg10
I5
sg11
VT-ALL
p14069
sg13
I1
sasa(dp14070
g2
S'Gene expression analysis revealed that four of the five genes, HOXA9, TAL1, ATP8A2, ENG and SPARCL1, each harboring one of the five frequently hypermethylated CpG sites within its promoters, were also frequently down-regulated in lung adenocarcinoma.\n'
p14071
sg4
(lp14072
(dp14073
g7
I63
sg8
VP31269
p14074
sg10
I5
sg11
VHOXA9
p14075
sg13
I1
sa(dp14076
g7
I76
sg8
g18
sg10
I6
sg11
VATP8A2
p14077
sg13
I1
sa(dp14078
g7
I84
sg8
VP17813
p14079
sg10
I3
sg11
VENG
p14080
sg13
I1
sa(dp14081
g7
I92
sg8
g18
sg10
I7
sg11
VSPARCL1
p14082
sg13
I1
sa(dp14083
g7
I70
sg8
VP17542
p14084
sg10
I4
sg11
VTAL1
p14085
sg13
I1
sasg20
(lp14086
(dp14087
g7
I230
sg23
VC0152013
p14088
sg10
I19
sg11
Vlung adenocarcinoma
p14089
sg13
I2
sasa(dp14090
g2
S'We investigated the ability of microRNA-93 (miR-93) to influence proliferation, invasion, migration, and apoptosisofrenal cell carcinoma (RCC) cells via transforming growth factor-Beta/solvated metal atom dispersed (TGF-Beta/Smad) signaling by targeting runt-related transcription factor 3 (RUNX3).\n'
p14091
sg4
(lp14092
(dp14093
g7
I216
sg8
VP18075
p14094
sg10
I8
sg11
VTGF-Beta
p14095
sg13
I1
sa(dp14096
g7
I291
sg8
g18
sg10
I5
sg11
VRUNX3
p14097
sg13
I1
sa(dp14098
g7
I254
sg8
g18
sg10
I35
sg11
Vrunt-related transcription factor 3
p14099
sg13
I4
sasg20
(lp14100
(dp14101
g7
I254
sg23
VC0013336
p14102
sg10
I4
sg11
Vrunt
p14103
sg13
I1
sa(dp14104
g7
I65
sg23
VC0334094
p14105
sg10
I13
sg11
Vproliferation
p14106
sg13
I1
sa(dp14107
g7
I80
sg23
VC2699153
p14108
sg10
I8
sg11
Vinvasion
p14109
sg13
I1
sa(dp14110
g7
I127
sg23
VC0007097
p14111
sg10
I9
sg11
Vcarcinoma
p14112
sg13
I1
sa(dp14113
g7
I138
sg23
VC0007134
p14114
sg10
I3
sg11
VRCC
p14115
sg13
I1
sasa(dp14116
g2
S'There were significant differences in the methylation status of p14ARF, RUNX3, RARBeta, DAPK, and HPP1 between the healthy control, glandular cystitis, and bladder cancer groups (p = 0.027, p &lt; 0.001, p &lt; 0.001, p = 0.030 and p = 0.003, respectively).\n'
p14117
sg4
(lp14118
(dp14119
g7
I88
sg8
VP53355
p14120
sg10
I4
sg11
VDAPK
p14121
sg13
I1
sa(dp14122
g7
I98
sg8
g18
sg10
I4
sg11
VHPP1
p14123
sg13
I1
sa(dp14124
g7
I72
sg8
g18
sg10
I5
sg11
VRUNX3
p14125
sg13
I1
sa(dp14126
g7
I64
sg8
VP42771
p14127
sg10
I6
sg11
Vp14ARF
p14128
sg13
I1
sasg20
(lp14129
(dp14130
g7
I156
sg23
VC0699885
p14131
sg10
I14
sg11
Vbladder cancer
p14132
sg13
I2
sa(dp14133
g7
I142
sg23
VC0010692
p14134
sg10
I8
sg11
Vcystitis
p14135
sg13
I1
sasa(dp14136
g2
S'Based on the results of this study we recommend the RUNX3 and RARBeta panel as the first choice for bladder cancer detection.\n'
p14137
sg4
(lp14138
(dp14139
g7
I52
sg8
g18
sg10
I5
sg11
VRUNX3
p14140
sg13
I1
sasg20
(lp14141
(dp14142
g7
I100
sg23
VC0699885
p14143
sg10
I14
sg11
Vbladder cancer
p14144
sg13
I2
sasa(dp14145
g2
S'Promoter hypermethylation of a tumor suppressor gene, runt-related transcription factor 3 (RUNX3), may also be associated with bladder cancer genesis.\n'
p14146
sg4
(lp14147
(dp14148
g7
I54
sg8
g18
sg10
I35
sg11
Vrunt-related transcription factor 3
p14149
sg13
I4
sa(dp14150
g7
I91
sg8
g18
sg10
I5
sg11
VRUNX3
p14151
sg13
I1
sasg20
(lp14152
(dp14153
g7
I54
sg23
VC0013336
p14154
sg10
I4
sg11
Vrunt
p14155
sg13
I1
sa(dp14156
g7
I127
sg23
VC0699885
p14157
sg10
I14
sg11
Vbladder cancer
p14158
sg13
I2
sa(dp14159
g7
I31
sg23
VC0027651
p14160
sg10
I5
sg11
Vtumor
p14161
sg13
I1
sasa(dp14162
g2
S'In this study, we investigated changes of DNA methylation in LINE-1 and RUNX3 promoter in a bladder cancer cell (UM-UC-3) under oxidative stress conditions, stimulated by challenge with H2O2 for 72 h. Cells were pretreated with an antioxidant, tocopheryl acetate for 1 h to attenuate oxidative stress.\n'
p14163
sg4
(lp14164
(dp14165
g7
I72
sg8
g18
sg10
I14
sg11
VRUNX3 promoter
p14166
sg13
I2
sasg20
(lp14167
(dp14168
g7
I92
sg23
VC0699885
p14169
sg10
I14
sg11
Vbladder cancer
p14170
sg13
I2
sa(dp14171
g7
I128
sg23
VC0242606
p14172
sg10
I16
sg11
Voxidative stress
p14173
sg13
I2
sa(dp14174
g7
I128
sg23
VC0242606
p14175
sg10
I16
sg11
Voxidative stress
p14176
sg13
I2
sasa(dp14177
g2
S'In conclusion, hypomethylation of LINE-1 and hypermethylation of RUNX3 promoter in bladder cancer cell line was experimentally induced by reactive oxygen species (ROS).\n'
p14178
sg4
(lp14179
(dp14180
g7
I65
sg8
g18
sg10
I14
sg11
VRUNX3 promoter
p14181
sg13
I2
sasg20
(lp14182
(dp14183
g7
I83
sg23
VC0699885
p14184
sg10
I14
sg11
Vbladder cancer
p14185
sg13
I2
sasa(dp14186
g2
S'The RUNX3 tumor suppressor gene promoter was hypomethylated with a significant increase in proportion of the completely unmethylated haplotype after the long-term CSE treatment; whereas RUNX3 promoter hypermethylation was previously reported for bladder cancers of smokers.\n'
p14187
sg4
(lp14188
(dp14189
g7
I4
sg8
g18
sg10
I36
sg11
VRUNX3 tumor suppressor gene promoter
p14190
sg13
I5
sa(dp14191
g7
I186
sg8
g18
sg10
I14
sg11
VRUNX3 promoter
p14192
sg13
I2
sasg20
(lp14193
(dp14194
g7
I10
sg23
VC0027651
p14195
sg10
I5
sg11
Vtumor
p14196
sg13
I1
sa(dp14197
g7
I163
sg23
VC1832855
p14198
sg10
I3
sg11
VCSE
p14199
sg13
I1
sa(dp14200
g7
I246
sg23
VC0005684
p14201
sg10
I15
sg11
Vbladder cancers
p14202
sg13
I2
sasa(dp14203
g2
S'However, little is known about the role of RUNX3 in human renal cell carcinoma (RCC).\n'
p14204
sg4
(lp14205
(dp14206
g7
I43
sg8
g18
sg10
I5
sg11
VRUNX3
p14207
sg13
I1
sasg20
(lp14208
(dp14209
g7
I80
sg23
VC0007134
p14210
sg10
I3
sg11
VRCC
p14211
sg13
I1
sa(dp14212
g7
I58
sg23
VC0007134
p14213
sg10
I20
sg11
Vrenal cell carcinoma
p14214
sg13
I3
sasa(dp14215
g2
S'Two different models of brain ischemia were used to examine the evoked changes in the tyrosine phosphorylation of NMDA receptor subunits 2A and 2B (NR2A and NR2B), as well as their interactions with non-receptor tyrosine kinases (NRTKs: FAK, PYK2 Src), and PSD-95 protein.\n'
p14216
sg4
(lp14217
(dp14218
g7
I199
sg8
VP29401
p14219
sg10
I29
sg11
Vnon-receptor tyrosine kinases
p14220
sg13
I3
sa(dp14221
g7
I157
sg8
g18
sg10
I4
sg11
VNR2B
p14222
sg13
I1
sa(dp14223
g7
I148
sg8
g18
sg10
I4
sg11
VNR2A
p14224
sg13
I1
sa(dp14225
g7
I257
sg8
VP78352
p14226
sg10
I14
sg11
VPSD-95 protein
p14227
sg13
I2
sa(dp14228
g7
I114
sg8
g18
sg10
I32
sg11
VNMDA receptor subunits 2A and 2B
p14229
sg13
I6
sa(dp14230
g7
I237
sg8
g18
sg10
I3
sg11
VFAK
p14231
sg13
I1
sa(dp14232
g7
I242
sg8
g18
sg10
I8
sg11
VPYK2 Src
p14233
sg13
I2
sasg20
(lp14234
(dp14235
g7
I24
sg23
VC0007786
p14236
sg10
I14
sg11
Vbrain ischemia
p14237
sg13
I2
sasa(dp14238
g2
S'Multiple parameters were evaluated including: (1) production of GHB (Gamma-hydroxybutyrate), the biochemical hallmark of SSADHD; (2) rescue from cell death with the dual mTOR (mechanistic target of rapamycin) inhibitor, XL-765, an agent previously shown to rescue aldh5a1-/- mice from premature lethality; (3) mitochondrial number, total reactive oxygen species, and mitochondrial superoxide production, all previously documented as abnormal in aldh5a1-/- mice; (4) total ATP levels and ATP consumption; and (5) selected gene expression profiles associated with epilepsy, a prominent feature in both experimental and human SSADHD.\n'
p14239
sg4
(lp14240
(dp14241
g7
I170
sg8
VP42345
p14242
sg10
I4
sg11
VmTOR
p14243
sg13
I1
sa(dp14244
g7
I264
sg8
VP51649
p14245
sg10
I7
sg11
Valdh5a1
p14246
sg13
I1
sa(dp14247
g7
I264
sg8
VP51649
p14248
sg10
I7
sg11
Valdh5a1
p14249
sg13
I1
sa(dp14250
g7
I176
sg8
VP42345
p14251
sg10
I31
sg11
Vmechanistic target of rapamycin
p14252
sg13
I4
sasg20
(lp14253
(dp14254
g7
I562
sg23
VC0014544
p14255
sg10
I8
sg11
Vepilepsy
p14256
sg13
I1
sasa(dp14257
g2
S'The human phenotype is that of nonprogressive encephalopathy with prominent bilateral discoloration of the globi pallidi and variable seizures, the latter displayed prominently in Aldh5a1-/- mice with lethal convulsions.\n'
p14258
sg4
(lp14259
(dp14260
g7
I180
sg8
VP51649
p14261
sg10
I7
sg11
VAldh5a1
p14262
sg13
I1
sasg20
(lp14263
(dp14264
g7
I208
sg23
VC0009951
p14265
sg10
I11
sg11
Vconvulsions
p14266
sg13
I1
sa(dp14267
g7
I134
sg23
VC0036572
p14268
sg10
I8
sg11
Vseizures
p14269
sg13
I1
sa(dp14270
g7
I46
sg23
VC0085584
p14271
sg10
I14
sg11
Vencephalopathy
p14272
sg13
I1
sasa(dp14273
g2
S'Our findings indicate early GABAergic alterations in Aldh5a1-/- mice, possibly exacerbated by other metabolites, which likely induce a heightened excitatory state that may predispose neural networks to epilepsy in these animals.\n'
p14274
sg4
(lp14275
(dp14276
g7
I53
sg8
VP51649
p14277
sg10
I7
sg11
VAldh5a1
p14278
sg13
I1
sasg20
(lp14279
(dp14280
g7
I202
sg23
VC0014544
p14281
sg10
I8
sg11
Vepilepsy
p14282
sg13
I1
sasa(dp14283
g2
S'Yiqi Chutan Recipe has a certain inhibitory effect on A549 lung cancer in mice and its possible mechanism is relevant to the increase of expression of Caspase-4 and DNA-PK protein.\n'
p14284
sg4
(lp14285
(dp14286
g7
I151
sg8
VP49662
p14287
sg10
I9
sg11
VCaspase-4
p14288
sg13
I1
sa(dp14289
g7
I165
sg8
g18
sg10
I14
sg11
VDNA-PK protein
p14290
sg13
I2
sasg20
(lp14291
(dp14292
g7
I59
sg23
VC0684249
p14293
sg10
I11
sg11
Vlung cancer
p14294
sg13
I2
sasa(dp14295
g2
S'The mutations were detected in 11 gastric carcinomas (2 caspase-1 and 9 caspase-5 mutations), 6 colorectal carcinomas (2 caspase-4 and 4 caspase-5 mutations), 1 breast carcinoma (1 caspase-5 mutation), and 1 lung carcinoma (1 caspase-5 mutation).\n'
p14296
sg4
(lp14297
(dp14298
g7
I56
sg8
VP29466
p14299
sg10
I9
sg11
Vcaspase-1
p14300
sg13
I1
sa(dp14301
g7
I72
sg8
VP39880
p14302
sg10
I18
sg11
Vcaspase-5 mutation
p14303
sg13
I2
sa(dp14304
g7
I72
sg8
VP39880
p14305
sg10
I18
sg11
Vcaspase-5 mutation
p14306
sg13
I2
sa(dp14307
g7
I70
sg8
VP39880
p14308
sg10
I21
sg11
V9 caspase-5 mutations
p14309
sg13
I3
sa(dp14310
g7
I121
sg8
VP49662
p14311
sg10
I35
sg11
Vcaspase-4 and 4 caspase-5 mutations
p14312
sg13
I5
sasg20
(lp14313
(dp14314
g7
I161
sg23
VC0678222
p14315
sg10
I16
sg11
Vbreast carcinoma
p14316
sg13
I2
sa(dp14317
g7
I96
sg23
VC0009402
p14318
sg10
I21
sg11
Vcolorectal carcinomas
p14319
sg13
I2
sa(dp14320
g7
I42
sg23
VC0007097
p14321
sg10
I10
sg11
Vcarcinomas
p14322
sg13
I1
sa(dp14323
g7
I208
sg23
VC0684249
p14324
sg10
I14
sg11
Vlung carcinoma
p14325
sg13
I2
sasa(dp14326
g2
S'The observations also indicated that DHA downregulated the mRNA and protein expression level of survivin in the lung cancer cell line SPC-A-1 cells, whereas it did not affect those of caspase-4.\n'
p14327
sg4
(lp14328
(dp14329
g7
I184
sg8
VP49662
p14330
sg10
I9
sg11
Vcaspase-4
p14331
sg13
I1
sasg20
(lp14332
(dp14333
g7
I112
sg23
VC0684249
p14334
sg10
I11
sg11
Vlung cancer
p14335
sg13
I2
sasa(dp14336
g2
S'Non-parametric multipoint linkage analysis, using the GeneHunter program, provided significant evidence for a novel IGE susceptibility locus on chromosome 3q26 (Z(NPL) = 4.19 at D3S3725; P = 0.000017) and suggestive evidence for two IGE loci on chromosome 14q23 (Z(NPL) = 3.28 at D14S63; P = 0.000566), and chromosome 2q36 (Z(NPL) = 2.98 at D2S1371; P = 0.000535).\n'
p14337
sg4
(lp14338
(dp14339
g7
I116
sg8
VP01854
p14340
sg10
I18
sg11
VIGE susceptibility
p14341
sg13
I2
sasg20
(lp14342
(dp14343
g7
I116
sg23
VC0270850
p14344
sg10
I3
sg11
VIGE
p14345
sg13
I1
sa(dp14346
g7
I116
sg23
VC0270850
p14347
sg10
I3
sg11
VIGE
p14348
sg13
I1
sasa(dp14349
g2
S'A weak trend towards an excess of allele sharing (identity by descent) among family members affected by an IGE was obtained in 26 families of JME patients (Z[NPL] = 1.25 at theta = 0.000, p = 0.057).\n'
p14350
sg4
(lp14351
sg20
(lp14352
(dp14353
g7
I142
sg23
VC0270853
p14354
sg10
I3
sg11
VJME
p14355
sg13
I1
sa(dp14356
g7
I107
sg23
VC0270850
p14357
sg10
I3
sg11
VIGE
p14358
sg13
I1
sasa(dp14359
g2
S'Our results, in contrast to those of previous investigations of localization-related epilepsy, which showed an increase in IEDs after NAL administration, suggest a possible difference in the mechanism whereby SD enhances IEDs in IGE and localization-related epilepsy.\n'
p14360
sg4
(lp14361
sg20
(lp14362
(dp14363
g7
I64
sg23
VC0014547
p14364
sg10
I29
sg11
Vlocalization-related epilepsy
p14365
sg13
I2
sa(dp14366
g7
I229
sg23
VC0270850
p14367
sg10
I3
sg11
VIGE
p14368
sg13
I1
sa(dp14369
g7
I64
sg23
VC0014547
p14370
sg10
I29
sg11
Vlocalization-related epilepsy
p14371
sg13
I2
sasa(dp14372
g2
S"The defective activation of pyruvate dehydrogenase complex (PDHC) in Leigh's disease (subacute necrotizing encephalomyelopathy) could be due to deficiency of pyruvate dehydrogenase phosphate (PDHb) phosphatase (EC 3.1.3.43).\n"
p14373
sg4
(lp14374
(dp14375
g7
I60
sg8
VP29803
p14376
sg10
I4
sg11
VPDHC
p14377
sg13
I1
sa(dp14378
g7
I158
sg8
VP49366
p14379
sg10
I51
sg11
Vpyruvate dehydrogenase phosphate (PDHb) phosphatase
p14380
sg13
I5
sa(dp14381
g7
I28
sg8
VP49366
p14382
sg10
I30
sg11
Vpyruvate dehydrogenase complex
p14383
sg13
I3
sa(dp14384
g7
I211
sg8
g18
sg10
I11
sg11
VEC 3.1.3.43
p14385
sg13
I2
sasg20
(lp14386
(dp14387
g7
I69
sg23
VC0023264
p14388
sg10
I15
sg11
VLeigh's disease
p14389
sg13
I2
sa(dp14390
g7
I144
sg23
VC0034345
p14391
sg10
I36
sg11
Vdeficiency of pyruvate dehydrogenase
p14392
sg13
I4
sa(dp14393
g7
I86
sg23
VC0023264
p14394
sg10
I40
sg11
Vsubacute necrotizing encephalomyelopathy
p14395
sg13
I3
sasa(dp14396
g2
S'A-07, U-25, D-12, or R-18 melanoma xenografts were grown in dorsal window chambers and given daily treatments of sunitinib (40 mg/kg) or vehicle.\n'
p14397
sg4
(lp14398
sg20
(lp14399
(dp14400
g7
I26
sg23
VC0025202
p14401
sg10
I8
sg11
Vmelanoma
p14402
sg13
I1
sasa(dp14403
g2
S'A-07, D-12, R-18, and U-25 human melanoma cells transfected with green fluorescent protein were injected stereotactically into the right cerebral hemisphere of nude mice.\n'
p14404
sg4
(lp14405
(dp14406
g7
I65
sg8
g18
sg10
I25
sg11
Vgreen fluorescent protein
p14407
sg13
I3
sasg20
(lp14408
(dp14409
g7
I33
sg23
VC0025202
p14410
sg10
I8
sg11
Vmelanoma
p14411
sg13
I1
sasa(dp14412
g2
S'Human melanoma xenografts (D-12, R-18, and U-25) were used as models of melanoma in humans.\n'
p14413
sg4
(lp14414
sg20
(lp14415
(dp14416
g7
I6
sg23
VC0025202
p14417
sg10
I8
sg11
Vmelanoma
p14418
sg13
I1
sa(dp14419
g7
I6
sg23
VC0025202
p14420
sg10
I8
sg11
Vmelanoma
p14421
sg13
I1
sasa(dp14422
g2
S'Melanoma angiogenesis, lung colonization, and spontaneous pulmonary metastasis were inhibited in mice bearing D-12, U-25, or thrombospondin-1 overexpressing R-18 tumors, which showed high thrombospondin-1 expression and secreted large quantities of thrombospondin-1 into the blood, but not in mice bearing wild-type R-18 tumors, which were negative for thrombospondin-1.\n'
p14423
sg4
(lp14424
(dp14425
g7
I125
sg8
VP07996
p14426
sg10
I16
sg11
Vthrombospondin-1
p14427
sg13
I1
sa(dp14428
g7
I125
sg8
VP07996
p14429
sg10
I16
sg11
Vthrombospondin-1
p14430
sg13
I1
sa(dp14431
g7
I125
sg8
VP07996
p14432
sg10
I16
sg11
Vthrombospondin-1
p14433
sg13
I1
sa(dp14434
g7
I125
sg8
VP07996
p14435
sg10
I16
sg11
Vthrombospondin-1
p14436
sg13
I1
sasg20
(lp14437
(dp14438
g7
I58
sg23
VC0153676
p14439
sg10
I20
sg11
Vpulmonary metastasis
p14440
sg13
I2
sa(dp14441
g7
I0
sg23
VC0025202
p14442
sg10
I8
sg11
VMelanoma
p14443
sg13
I1
sa(dp14444
g7
I162
sg23
VC0027651
p14445
sg10
I6
sg11
Vtumors
p14446
sg13
I1
sa(dp14447
g7
I162
sg23
VC0027651
p14448
sg10
I6
sg11
Vtumors
p14449
sg13
I1
sasa(dp14450
g2
S'Three melanoma lines (A-07, R-18, and U-25) were included in the study.\n'
p14451
sg4
(lp14452
sg20
(lp14453
(dp14454
g7
I6
sg23
VC0025202
p14455
sg10
I8
sg11
Vmelanoma
p14456
sg13
I1
sasa(dp14457
g2
S'Cells from human melanoma lines (A-07, D-12, R-18, and U-25) transplanted to BALB/c nu/nu mice were used as tumor models.\n'
p14458
sg4
(lp14459
sg20
(lp14460
(dp14461
g7
I108
sg23
VC0027651
p14462
sg10
I5
sg11
Vtumor
p14463
sg13
I1
sa(dp14464
g7
I17
sg23
VC0025202
p14465
sg10
I8
sg11
Vmelanoma
p14466
sg13
I1
sasa(dp14467
g2
S'High expression of Ras protein accompanied with high RbAp46 and low RECK expression were detected in 75% (3/4) of the clinical bladder cancer tumor tissues compared to the adjacent normal parts.\n'
p14468
sg4
(lp14469
(dp14470
g7
I19
sg8
VP01116
p14471
sg10
I11
sg11
VRas protein
p14472
sg13
I2
sa(dp14473
g7
I68
sg8
g18
sg10
I4
sg11
VRECK
p14474
sg13
I1
sa(dp14475
g7
I53
sg8
g18
sg10
I6
sg11
VRbAp46
p14476
sg13
I1
sasg20
(lp14477
(dp14478
g7
I127
sg23
VC0699885
p14479
sg10
I14
sg11
Vbladder cancer
p14480
sg13
I2
sa(dp14481
g7
I142
sg23
VC0027651
p14482
sg10
I5
sg11
Vtumor
p14483
sg13
I1
sasa(dp14484
g2
S'In conclusion, our data suggests that miR-182-5p plays an important role as an oncogene by knocking down RECK and Smad4, resulting in activation of the Wnt-beta-catenin signaling pathway in bladder cancer.\n'
p14485
sg4
(lp14486
(dp14487
g7
I38
sg8
g18
sg10
I10
sg11
VmiR-182-5p
p14488
sg13
I1
sa(dp14489
g7
I105
sg8
g18
sg10
I4
sg11
VRECK
p14490
sg13
I1
sa(dp14491
g7
I114
sg8
g18
sg10
I5
sg11
VSmad4
p14492
sg13
I1
sasg20
(lp14493
(dp14494
g7
I190
sg23
VC0699885
p14495
sg10
I14
sg11
Vbladder cancer
p14496
sg13
I2
sasa(dp14497
g2
S'Data on RECK in urothelial bladder cancer are lacking and information on EMMPRIN is sparse.\n'
p14498
sg4
(lp14499
(dp14500
g7
I8
sg8
g18
sg10
I4
sg11
VRECK
p14501
sg13
I1
sasg20
(lp14502
(dp14503
g7
I27
sg23
VC0699885
p14504
sg10
I14
sg11
Vbladder cancer
p14505
sg13
I2
sasa(dp14506
g2
S'The state of urinary organs was examined in 126 patients when using for an associated radiotherapy of cervical cancer a high-dose-rate pipe apparatus "Agat-B" together with moving distant gamma-therapy.\n'
p14507
sg4
(lp14508
sg20
(lp14509
(dp14510
g7
I102
sg23
VC0302592
p14511
sg10
I15
sg11
Vcervical cancer
p14512
sg13
I2
sasa(dp14513
g2
S'Under study was the efficacy of three schedules of dose fractionation in intracavitary gamma-therapy in cervical cancer patients treated on the machine "AGAT-B".\n'
p14514
sg4
(lp14515
sg20
(lp14516
(dp14517
g7
I104
sg23
VC0302592
p14518
sg10
I15
sg11
Vcervical cancer
p14519
sg13
I2
sasa(dp14520
g2
S'Clinical appraisal is made of an associated use of radiotherapy in two groups of cervical cancer patients, subjected to intracavitary irradiation on a high-dose-rate Agat-B apparatus, depending on different dosage at point A.\n'
p14521
sg4
(lp14522
sg20
(lp14523
(dp14524
g7
I81
sg23
VC0302592
p14525
sg10
I15
sg11
Vcervical cancer
p14526
sg13
I2
sasa(dp14527
g2
S'The results of combined radiotherapy of corpus uteri cancer in 54 patients with Stages I-III of the disease using an Agat-B remote afterloading apparatus were analysed.\n'
p14528
sg4
(lp14529
(dp14530
g7
I117
sg8
VP50440
p14531
sg10
I6
sg11
VAgat-B
p14532
sg13
I1
sasg20
(lp14533
(dp14534
g7
I40
sg23
VC1883486
p14535
sg10
I19
sg11
Vcorpus uteri cancer
p14536
sg13
I3
sasa(dp14537
g2
S'Furthermore, we report that the levels of PLK2 are significantly increased in brains of Alzheimer disease and Lewy body disease patients.\n'
p14538
sg4
(lp14539
(dp14540
g7
I42
sg8
g18
sg10
I4
sg11
VPLK2
p14541
sg13
I1
sasg20
(lp14542
(dp14543
g7
I110
sg23
VC0752347
p14544
sg10
I17
sg11
VLewy body disease
p14545
sg13
I3
sa(dp14546
g7
I88
sg23
VC0002395
p14547
sg10
I17
sg11
VAlzheimer disease
p14548
sg13
I2
sasa(dp14549
g2
S'We have previously reported that Cezanne could be a prognostic biomarker for survival in hepatocellular carcinoma (HCC) patients.\n'
p14550
sg4
(lp14551
sg20
(lp14552
(dp14553
g7
I89
sg23
VC2239176
p14554
sg10
I24
sg11
Vhepatocellular carcinoma
p14555
sg13
I2
sa(dp14556
g7
I115
sg23
VC2239176
p14557
sg10
I3
sg11
VHCC
p14558
sg13
I1
sasa(dp14559
g2
S'Cezanne-1 and IGF1R expressions were evaluated in 103 patients with lung adenocarcinoma using immunohistochemical (IHC) analysis.\n'
p14560
sg4
(lp14561
(dp14562
g7
I14
sg8
VP08069
p14563
sg10
I5
sg11
VIGF1R
p14564
sg13
I1
sa(dp14565
g7
I0
sg8
g18
sg10
I9
sg11
VCezanne-1
p14566
sg13
I1
sasg20
(lp14567
(dp14568
g7
I68
sg23
VC0152013
p14569
sg10
I19
sg11
Vlung adenocarcinoma
p14570
sg13
I2
sasa(dp14571
g2
S'Our findings indicated both cezanne-1 and IGF1R expressions were negative independent predictive factors for the prognosis of lung adenocarcinoma, respectively.\n'
p14572
sg4
(lp14573
(dp14574
g7
I28
sg8
g18
sg10
I9
sg11
Vcezanne-1
p14575
sg13
I1
sa(dp14576
g7
I42
sg8
VP08069
p14577
sg10
I5
sg11
VIGF1R
p14578
sg13
I1
sasg20
(lp14579
(dp14580
g7
I126
sg23
VC0152013
p14581
sg10
I19
sg11
Vlung adenocarcinoma
p14582
sg13
I2
sasa(dp14583
g2
S'To investigate the correlation among OTUD7B and NIK expression and the clinicopathological characteristics in NSCLC patients.\n'
p14584
sg4
(lp14585
(dp14586
g7
I37
sg8
g18
sg10
I6
sg11
VOTUD7B
p14587
sg13
I1
sa(dp14588
g7
I48
sg8
g18
sg10
I3
sg11
VNIK
p14589
sg13
I1
sasg20
(lp14590
(dp14591
g7
I110
sg23
VC0007131
p14592
sg10
I5
sg11
VNSCLC
p14593
sg13
I1
sasa(dp14594
g2
S'The expression of OTUD7B and NIK were negatively correlated in NSCLC tumor samples (rs=-0.421, P&lt;0.001).\n'
p14595
sg4
(lp14596
(dp14597
g7
I18
sg8
g18
sg10
I6
sg11
VOTUD7B
p14598
sg13
I1
sa(dp14599
g7
I29
sg8
g18
sg10
I3
sg11
VNIK
p14600
sg13
I1
sasg20
(lp14601
(dp14602
g7
I69
sg23
VC0027651
p14603
sg10
I5
sg11
Vtumor
p14604
sg13
I1
sa(dp14605
g7
I63
sg23
VC0007131
p14606
sg10
I5
sg11
VNSCLC
p14607
sg13
I1
sasa(dp14608
g2
S'In addition, the high expression of OTUD7B was associated with good prognosis of NSCLC patients (log-rank=6.714, P=0.0096), and a high OTUD7B/low NIK index can predict an even better prognosis (log-rank=11.794, P=0.0006).\n'
p14609
sg4
(lp14610
(dp14611
g7
I36
sg8
g18
sg10
I6
sg11
VOTUD7B
p14612
sg13
I1
sa(dp14613
g7
I36
sg8
g18
sg10
I6
sg11
VOTUD7B
p14614
sg13
I1
sasg20
(lp14615
(dp14616
g7
I81
sg23
VC0007131
p14617
sg10
I5
sg11
VNSCLC
p14618
sg13
I1
sasa(dp14619
g2
S'Moreover, the multivariate Cox regression analysis showed that OTUD7B rather than NIK is an independent marker of overall survival in NSCLC patients(HR=1.602, 95% CI 1.009-2.544, P=0.046).\n'
p14620
sg4
(lp14621
(dp14622
g7
I82
sg8
g18
sg10
I3
sg11
VNIK
p14623
sg13
I1
sa(dp14624
g7
I63
sg8
g18
sg10
I6
sg11
VOTUD7B
p14625
sg13
I1
sasg20
(lp14626
(dp14627
g7
I134
sg23
VC0007131
p14628
sg10
I5
sg11
VNSCLC
p14629
sg13
I1
sasa(dp14630
g2
S'OTUD7B and NIK may play important roles in the development of lung cancer.\n'
p14631
sg4
(lp14632
(dp14633
g7
I0
sg8
g18
sg10
I6
sg11
VOTUD7B
p14634
sg13
I1
sa(dp14635
g7
I11
sg8
g18
sg10
I3
sg11
VNIK
p14636
sg13
I1
sasg20
(lp14637
(dp14638
g7
I62
sg23
VC0684249
p14639
sg10
I11
sg11
Vlung cancer
p14640
sg13
I2
sasa(dp14641
g2
S'The combination of OTUD7B and NIK expression may be a good index for predicting the prognosis of NSCLC.\n'
p14642
sg4
(lp14643
(dp14644
g7
I19
sg8
g18
sg10
I6
sg11
VOTUD7B
p14645
sg13
I1
sa(dp14646
g7
I30
sg8
g18
sg10
I3
sg11
VNIK
p14647
sg13
I1
sasg20
(lp14648
(dp14649
g7
I97
sg23
VC0007131
p14650
sg10
I5
sg11
VNSCLC
p14651
sg13
I1
sasa(dp14652
g2
S'The purpose of this study is to investigate the correlation of Cezanne expression with clinicopathological/prognostic value in hepatocellular carcinoma (HCC).\n'
p14653
sg4
(lp14654
sg20
(lp14655
(dp14656
g7
I127
sg23
VC2239176
p14657
sg10
I24
sg11
Vhepatocellular carcinoma
p14658
sg13
I2
sa(dp14659
g7
I153
sg23
VC2239176
p14660
sg10
I3
sg11
VHCC
p14661
sg13
I1
sasa(dp14662
g2
S'The correlation between expression of Cezanne and MMP-9, clinicopathological/prognostic value in hepatocellular carcinoma was examined.\n'
p14663
sg4
(lp14664
(dp14665
g7
I38
sg8
g18
sg10
I7
sg11
VCezanne
p14666
sg13
I1
sa(dp14667
g7
I50
sg8
VP14780
p14668
sg10
I5
sg11
VMMP-9
p14669
sg13
I1
sasg20
(lp14670
(dp14671
g7
I97
sg23
VC1512411
p14672
sg10
I24
sg11
Vhepatocellular carcinoma
p14673
sg13
I2
sasa(dp14674
g2
S'Patients who had Cezanne downregulation, in which cancer cells showed high invasiveness, had shorter TTR and poor OS.\n'
p14675
sg4
(lp14676
sg20
(lp14677
(dp14678
g7
I50
sg23
VC0006826
p14679
sg10
I6
sg11
Vcancer
p14680
sg13
I1
sasa(dp14681
g2
S'sICAM-1 level may reflect endothelial inflammatory reactions, probably harmful, in the liver and may be useful for monitoring morbidity evolution in schistosomiasis mansoni.\n'
p14682
sg4
(lp14683
sg20
(lp14684
(dp14685
g7
I149
sg23
VC0036330
p14686
sg10
I23
sg11
Vschistosomiasis mansoni
p14687
sg13
I2
sasa(dp14688
g2
S'In a case-control study based in two areas of Kenya, hepatosplenic schistosomiasis mansoni was shown to be linked with low levels of IL-5 and with correspondingly high IFN-gamma, TNF, and circulating soluble TNF receptor I (sTNFR-I), sTNFR-II, and sICAM-1.\n'
p14689
sg4
(lp14690
(dp14691
g7
I133
sg8
VP05113
p14692
sg10
I4
sg11
VIL-5
p14693
sg13
I1
sa(dp14694
g7
I179
sg8
VP01375
p14695
sg10
I3
sg11
VTNF
p14696
sg13
I1
sa(dp14697
g7
I234
sg8
g18
sg10
I8
sg11
VsTNFR-II
p14698
sg13
I1
sa(dp14699
g7
I168
sg8
VP01579
p14700
sg10
I9
sg11
VIFN-gamma
p14701
sg13
I1
sa(dp14702
g7
I224
sg8
g18
sg10
I7
sg11
VsTNFR-I
p14703
sg13
I1
sa(dp14704
g7
I200
sg8
g18
sg10
I22
sg11
Vsoluble TNF receptor I
p14705
sg13
I4
sasg20
(lp14706
(dp14707
g7
I53
sg23
VC0343968
p14708
sg10
I29
sg11
Vhepatosplenic schistosomiasis
p14709
sg13
I2
sasa(dp14710
g2
S'The aim of this study was to evaluate the expression levels of activin BetaA-subunit, myostatin, and MMP14 messenger RNAs (mRNAs) in uterine leiomyomas and the possible correlation of these factors with clinical features of the disease.\n'
p14711
sg4
(lp14712
(dp14713
g7
I86
sg8
g18
sg10
I9
sg11
Vmyostatin
p14714
sg13
I1
sa(dp14715
g7
I101
sg8
VP50281
p14716
sg10
I20
sg11
VMMP14 messenger RNAs
p14717
sg13
I3
sa(dp14718
g7
I63
sg8
VP58166
p14719
sg10
I21
sg11
Vactivin BetaA-subunit
p14720
sg13
I2
sasg20
(lp14721
(dp14722
g7
I141
sg23
VC0023267
p14723
sg10
I10
sg11
Vleiomyomas
p14724
sg13
I1
sasa(dp14725
g2
S'Matrix metalloproteinase 14 was highly expressed in uterine leiomyoma and correlated with myostatin and activin A mRNA expression.\n'
p14726
sg4
(lp14727
(dp14728
g7
I90
sg8
g18
sg10
I9
sg11
Vmyostatin
p14729
sg13
I1
sa(dp14730
g7
I104
sg8
VP08476
p14731
sg10
I14
sg11
Vactivin A mRNA
p14732
sg13
I3
sa(dp14733
g7
I0
sg8
VP50281
p14734
sg10
I27
sg11
VMatrix metalloproteinase 14
p14735
sg13
I3
sasg20
(lp14736
(dp14737
g7
I52
sg23
VC0042133
p14738
sg10
I17
sg11
Vuterine leiomyoma
p14739
sg13
I2
sasa(dp14740
g2
S'Overall, the present findings showed that MMP14 mRNA is highly expressed in uterine leiomyoma, where it correlates with the molecular expression of growth factors and is further increased in cases of intense dysmenorrhea.\n'
p14741
sg4
(lp14742
(dp14743
g7
I42
sg8
VP50281
p14744
sg10
I10
sg11
VMMP14 mRNA
p14745
sg13
I2
sasg20
(lp14746
(dp14747
g7
I208
sg23
VC0013390
p14748
sg10
I12
sg11
Vdysmenorrhea
p14749
sg13
I1
sa(dp14750
g7
I76
sg23
VC0042133
p14751
sg10
I17
sg11
Vuterine leiomyoma
p14752
sg13
I2
sasa(dp14753
g2
S'A previous study has revealed that miR-29c functions as a tumor suppressor in hepatocellular carcinoma (HCC), but the clinical significance and prognostic value of miR-29c in HCC have not been investigated.\n'
p14754
sg4
(lp14755
(dp14756
g7
I35
sg8
g18
sg10
I7
sg11
VmiR-29c
p14757
sg13
I1
sa(dp14758
g7
I35
sg8
g18
sg10
I7
sg11
VmiR-29c
p14759
sg13
I1
sasg20
(lp14760
(dp14761
g7
I104
sg23
VC2239176
p14762
sg10
I3
sg11
VHCC
p14763
sg13
I1
sa(dp14764
g7
I104
sg23
VC2239176
p14765
sg10
I3
sg11
VHCC
p14766
sg13
I1
sa(dp14767
g7
I58
sg23
VC0027651
p14768
sg10
I5
sg11
Vtumor
p14769
sg13
I1
sa(dp14770
g7
I78
sg23
VC2239176
p14771
sg10
I24
sg11
Vhepatocellular carcinoma
p14772
sg13
I2
sasa(dp14773
g2
S'We identified a miRNA classifier (Cmi) containing seven differentially expressed miRNAs (miR-29a, miR-29c, miR-133a, miR-143, miR-145, miR-192, and miR-505) that could detect hepatocellular carcinoma.\n'
p14774
sg4
(lp14775
(dp14776
g7
I148
sg8
g18
sg10
I7
sg11
VmiR-505
p14777
sg13
I1
sa(dp14778
g7
I135
sg8
g18
sg10
I7
sg11
VmiR-192
p14779
sg13
I1
sa(dp14780
g7
I126
sg8
g18
sg10
I7
sg11
VmiR-145
p14781
sg13
I1
sa(dp14782
g7
I98
sg8
g18
sg10
I7
sg11
VmiR-29c
p14783
sg13
I1
sa(dp14784
g7
I117
sg8
g18
sg10
I7
sg11
VmiR-143
p14785
sg13
I1
sa(dp14786
g7
I89
sg8
g18
sg10
I7
sg11
VmiR-29a
p14787
sg13
I1
sa(dp14788
g7
I107
sg8
g18
sg10
I8
sg11
VmiR-133a
p14789
sg13
I1
sasg20
(lp14790
(dp14791
g7
I175
sg23
VC1512411
p14792
sg10
I24
sg11
Vhepatocellular carcinoma
p14793
sg13
I2
sasa(dp14794
g2
S'Here, we show that low-dose ionizing radiation (IR) induces miR-29c expression in female mouse liver, while inhibiting its expression in HepG2, a human hepatocellular carcinoma cell line which is used as a model system in this study.\n'
p14795
sg4
(lp14796
(dp14797
g7
I60
sg8
g18
sg10
I7
sg11
VmiR-29c
p14798
sg13
I1
sasg20
(lp14799
(dp14800
g7
I152
sg23
VC1512411
p14801
sg10
I24
sg11
Vhepatocellular carcinoma
p14802
sg13
I2
sasa(dp14803
g2
S'miR-29c expression is downregulated in human hepatocellular carcinoma cells, which is inversely correlated with WIP1 expression.\n'
p14804
sg4
(lp14805
(dp14806
g7
I112
sg8
g18
sg10
I4
sg11
VWIP1
p14807
sg13
I1
sa(dp14808
g7
I0
sg8
g18
sg10
I7
sg11
VmiR-29c
p14809
sg13
I1
sasg20
(lp14810
(dp14811
g7
I45
sg23
VC1512411
p14812
sg10
I24
sg11
Vhepatocellular carcinoma
p14813
sg13
I2
sasa(dp14814
g2
S'Finally, fluorescence in situ hybridization (FISH) and immunohistochemical analyses indicate that miR-29c is downregulated in 50.6% of liver carcinoma tissues examined, whereas WIP1 is upregulated in 45.4% of these tissues.\n'
p14815
sg4
(lp14816
(dp14817
g7
I177
sg8
g18
sg10
I4
sg11
VWIP1
p14818
sg13
I1
sa(dp14819
g7
I98
sg8
g18
sg10
I7
sg11
VmiR-29c
p14820
sg13
I1
sasg20
(lp14821
(dp14822
g7
I135
sg23
VC2239176
p14823
sg10
I15
sg11
Vliver carcinoma
p14824
sg13
I2
sasa(dp14825
g2
S'Our results suggest that the IR-responsive miR-29c may function as a tumor suppressor that plays a crucial role in the development of liver carcinoma via targeting WIP1, therefore possibly representing a target molecule for therapeutic intervention for this disease.\n'
p14826
sg4
(lp14827
(dp14828
g7
I43
sg8
g18
sg10
I7
sg11
VmiR-29c
p14829
sg13
I1
sa(dp14830
g7
I164
sg8
g18
sg10
I4
sg11
VWIP1
p14831
sg13
I1
sasg20
(lp14832
(dp14833
g7
I69
sg23
VC0027651
p14834
sg10
I5
sg11
Vtumor
p14835
sg13
I1
sa(dp14836
g7
I134
sg23
VC2239176
p14837
sg10
I15
sg11
Vliver carcinoma
p14838
sg13
I2
sasa(dp14839
g2
S'Here, we report that miR-29c was significantly downregulated in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) cell lines as well as in clinical tissues compared with their corresponding controls.\n'
p14840
sg4
(lp14841
(dp14842
g7
I21
sg8
g18
sg10
I7
sg11
VmiR-29c
p14843
sg13
I1
sasg20
(lp14844
(dp14845
g7
I64
sg23
VC0019163
p14846
sg10
I17
sg11
Vhepatitis B virus
p14847
sg13
I3
sa(dp14848
g7
I83
sg23
VC0019163
p14849
sg10
I3
sg11
VHBV
p14850
sg13
I1
sa(dp14851
g7
I96
sg23
VC2239176
p14852
sg10
I24
sg11
Vhepatocellular carcinoma
p14853
sg13
I2
sa(dp14854
g7
I122
sg23
VC2239176
p14855
sg10
I3
sg11
VHCC
p14856
sg13
I1
sasa(dp14857
g2
S'Two miRNAs, miR-101, and miR-29c, were shown to be significantly down regulated in human hepatoma tissues and induced over 4-fold in HepG2 cells under TPA treatment.\n'
p14858
sg4
(lp14859
(dp14860
g7
I25
sg8
g18
sg10
I7
sg11
VmiR-29c
p14861
sg13
I1
sa(dp14862
g7
I12
sg8
g18
sg10
I7
sg11
VmiR-101
p14863
sg13
I1
sasg20
(lp14864
(dp14865
g7
I89
sg23
VC0023903
p14866
sg10
I8
sg11
Vhepatoma
p14867
sg13
I1
sasa(dp14868
g2
S"Genome-wide association studies (GWAS) and replication studies have shown conflicting associations between the NELL1, NCF4, and FAM92B genes and susceptibility for Crohn's disease (CD).\n"
p14869
sg4
(lp14870
(dp14871
g7
I128
sg8
g18
sg10
I12
sg11
VFAM92B genes
p14872
sg13
I2
sa(dp14873
g7
I118
sg8
g18
sg10
I4
sg11
VNCF4
p14874
sg13
I1
sa(dp14875
g7
I111
sg8
g18
sg10
I5
sg11
VNELL1
p14876
sg13
I1
sasg20
(lp14877
(dp14878
g7
I164
sg23
VC0010346
p14879
sg10
I15
sg11
VCrohn's disease
p14880
sg13
I2
sa(dp14881
g7
I181
sg23
VC0010346
p14882
sg10
I2
sg11
VCD
p14883
sg13
I1
sasa(dp14884
g2
S'Relative to comparison subjects, CDC42EP4, LIMK1, LIMK2, ARHGDIA, and PAK3 messenger RNA levels were significantly upregulated in subjects with schizophrenia in laminar and cellular samples.\n'
p14885
sg4
(lp14886
(dp14887
g7
I33
sg8
g18
sg10
I8
sg11
VCDC42EP4
p14888
sg13
I1
sa(dp14889
g7
I43
sg8
VP53667
p14890
sg10
I5
sg11
VLIMK1
p14891
sg13
I1
sa(dp14892
g7
I50
sg8
VP53671
p14893
sg10
I5
sg11
VLIMK2
p14894
sg13
I1
sa(dp14895
g7
I57
sg8
VP52565
p14896
sg10
I7
sg11
VARHGDIA
p14897
sg13
I1
sa(dp14898
g7
I70
sg8
VP01215
p14899
sg10
I18
sg11
VPAK3 messenger RNA
p14900
sg13
I3
sasg20
(lp14901
(dp14902
g7
I144
sg23
VC0036341
p14903
sg10
I13
sg11
Vschizophrenia
p14904
sg13
I1
sasa(dp14905
g2
S"To evaluate the T1rho (T(1rho)) MRI relaxation time in hippocampus in the brain of Alzheimer's disease (AD), mild cognitive impairment (MCI), and control, and to determine whether the T(1rho) shows any significant difference between these cohorts.\n"
p14906
sg4
(lp14907
sg20
(lp14908
(dp14909
g7
I104
sg23
VC1521724
p14910
sg10
I2
sg11
VAD
p14911
sg13
I1
sa(dp14912
g7
I109
sg23
VC1270972
p14913
sg10
I25
sg11
Vmild cognitive impairment
p14914
sg13
I3
sa(dp14915
g7
I136
sg23
VC1270972
p14916
sg10
I3
sg11
VMCI
p14917
sg13
I1
sa(dp14918
g7
I83
sg23
VC1521724
p14919
sg10
I19
sg11
VAlzheimer's disease
p14920
sg13
I2
sasa(dp14921
g2
S'Here, we analyzed 4 common single nucleotide polymorphisms (SNPs) of C4BPB and 5 SNPs of C4BPA in a group of 556 schizophrenia patients and a matched group of 610 healthy controls to see if the genes C4BPB and C4BPA, which encode C4BP, may confer a susceptibility to schizophrenia.\n'
p14922
sg4
(lp14923
(dp14924
g7
I79
sg8
VP04003
p14925
sg10
I15
sg11
V5 SNPs of C4BPA
p14926
sg13
I4
sa(dp14927
g7
I69
sg8
VP20851
p14928
sg10
I5
sg11
VC4BPB
p14929
sg13
I1
sa(dp14930
g7
I89
sg8
VP04003
p14931
sg10
I5
sg11
VC4BPA
p14932
sg13
I1
sa(dp14933
g7
I69
sg8
VP20851
p14934
sg10
I5
sg11
VC4BPB
p14935
sg13
I1
sa(dp14936
g7
I69
sg8
VP04003
p14937
sg10
I4
sg11
VC4BP
p14938
sg13
I1
sasg20
(lp14939
(dp14940
g7
I113
sg23
VC0036341
p14941
sg10
I13
sg11
Vschizophrenia
p14942
sg13
I1
sa(dp14943
g7
I113
sg23
VC0036341
p14944
sg10
I13
sg11
Vschizophrenia
p14945
sg13
I1
sasa(dp14946
g2
S'Comparing the genotype and allele frequencies of those SNPs between cases and controls, we found no association between the C4BPB/C4BPA variants and schizophrenia.\n'
p14947
sg4
(lp14948
(dp14949
g7
I124
sg8
VP20851
p14950
sg10
I5
sg11
VC4BPB
p14951
sg13
I1
sa(dp14952
g7
I130
sg8
VP04003
p14953
sg10
I5
sg11
VC4BPA
p14954
sg13
I1
sasg20
(lp14955
(dp14956
g7
I149
sg23
VC0036341
p14957
sg10
I13
sg11
Vschizophrenia
p14958
sg13
I1
sasa(dp14959
g2
S'Our results provided preliminary evidence that C4BPB/C4BPA may not confer susceptibility to schizophrenia among Han Chinese.\n'
p14960
sg4
(lp14961
(dp14962
g7
I47
sg8
VP20851
p14963
sg10
I5
sg11
VC4BPB
p14964
sg13
I1
sa(dp14965
g7
I53
sg8
VP04003
p14966
sg10
I5
sg11
VC4BPA
p14967
sg13
I1
sasg20
(lp14968
(dp14969
g7
I92
sg23
VC0036341
p14970
sg10
I13
sg11
Vschizophrenia
p14971
sg13
I1
sasa(dp14972
g2
S'The serum concentrations of various cytokines (tumor necrosis factor alpha [TNF-Alfa], interleukin-6 [IL-6], and gamma interferon [IFN-Gamma]) and chemokines (IL-8, interferon-inducible protein 10 [IP-10], monocyte chemoattractant protein 1 [MCP-1], macrophage inflammatory protein 1Alfa [MIP-1Alfa], MIP-1Beta, and eotaxin) were measured in 32 TD and 21 JSF patients.\n'
p14973
sg4
(lp14974
(dp14975
g7
I102
sg8
VP05231
p14976
sg10
I4
sg11
VIL-6
p14977
sg13
I1
sa(dp14978
g7
I119
sg8
VP01563
p14979
sg10
I10
sg11
Vinterferon
p14980
sg13
I1
sa(dp14981
g7
I206
sg8
VP14222
p14982
sg10
I81
sg11
Vmonocyte chemoattractant protein 1 [MCP-1], macrophage inflammatory protein 1Alfa
p14983
sg13
I9
sa(dp14984
g7
I47
sg8
VP01375
p14985
sg10
I27
sg11
Vtumor necrosis factor alpha
p14986
sg13
I4
sa(dp14987
g7
I316
sg8
VP51671
p14988
sg10
I7
sg11
Veotaxin
p14989
sg13
I1
sa(dp14990
g7
I87
sg8
VP05231
p14991
sg10
I13
sg11
Vinterleukin-6
p14992
sg13
I1
sa(dp14993
g7
I113
sg8
VP01579
p14994
sg10
I16
sg11
Vgamma interferon
p14995
sg13
I2
sasg20
(lp14996
(dp14997
g7
I289
sg23
VC1851100
p14998
sg10
I3
sg11
VMIP
p14999
sg13
I1
sa(dp15000
g7
I289
sg23
VC1851100
p15001
sg10
I3
sg11
VMIP
p15002
sg13
I1
sa(dp15003
g7
I47
sg23
VC0333516
p15004
sg10
I14
sg11
Vtumor necrosis
p15005
sg13
I2
sasa(dp15006
g2
S'Comparatively higher levels of other cytokines and chemokines (IL-6, IFN-Gamma, IL-8, IP-10, MCP-1, MIP-1Alfa, and MIP-1Beta) were also observed in the acute phase of JSF.\n'
p15007
sg4
(lp15008
(dp15009
g7
I115
sg8
g18
sg10
I9
sg11
VMIP-1Beta
p15010
sg13
I1
sa(dp15011
g7
I63
sg8
VP05231
p15012
sg10
I4
sg11
VIL-6
p15013
sg13
I1
sa(dp15014
g7
I69
sg8
VP01579
p15015
sg10
I9
sg11
VIFN-Gamma
p15016
sg13
I1
sa(dp15017
g7
I100
sg8
g18
sg10
I9
sg11
VMIP-1Alfa
p15018
sg13
I1
sa(dp15019
g7
I93
sg8
VP41597
p15020
sg10
I5
sg11
VMCP-1
p15021
sg13
I1
sa(dp15022
g7
I86
sg8
VP02778
p15023
sg10
I5
sg11
VIP-10
p15024
sg13
I1
sasg20
(lp15025
(dp15026
g7
I100
sg23
VC1851100
p15027
sg10
I3
sg11
VMIP
p15028
sg13
I1
sa(dp15029
g7
I100
sg23
VC1851100
p15030
sg10
I3
sg11
VMIP
p15031
sg13
I1
sasa(dp15032
g2
S'In conclusion, the data presented here indicate that steatohepatitis develops in the absence of leptin, and that TLR4 is integral to the development NASH secondary to hyperphagia.\n'
p15033
sg4
(lp15034
(dp15035
g7
I96
sg8
VP41159
p15036
sg10
I6
sg11
Vleptin
p15037
sg13
I1
sasg20
(lp15038
(dp15039
g7
I167
sg23
VC0020505
p15040
sg10
I11
sg11
Vhyperphagia
p15041
sg13
I1
sa(dp15042
g7
I53
sg23
VC2711227
p15043
sg10
I15
sg11
Vsteatohepatitis
p15044
sg13
I1
sasa(dp15045
g2
S'The aim of this study was to investigate the relationship between IL28B rs12979860 genotype, the level of TNFAlfa activation and the degree of IR in patients with chronic hepatitis C. One hundred and thirty-three nondiabetic genotype 1 HCV-infected patients with biopsy proven noncirrhotic hepatitis C were investigated for IR (using HOMA index), IL28B rs12979860 genotype and fasting circulating levels of soluble receptor 1 of TNFAlfa (sTNFR1) and adipokines: leptin, adiponectin and IL-6.\n'
p15046
sg4
(lp15047
(dp15048
g7
I407
sg8
VP35558
p15049
sg10
I18
sg11
Vsoluble receptor 1
p15050
sg13
I3
sa(dp15051
g7
I470
sg8
g18
sg10
I11
sg11
Vadiponectin
p15052
sg13
I1
sa(dp15053
g7
I486
sg8
VP05231
p15054
sg10
I4
sg11
VIL-6
p15055
sg13
I1
sa(dp15056
g7
I66
sg8
g18
sg10
I25
sg11
VIL28B rs12979860 genotype
p15057
sg13
I3
sa(dp15058
g7
I462
sg8
VP41159
p15059
sg10
I6
sg11
Vleptin
p15060
sg13
I1
sa(dp15061
g7
I66
sg8
g18
sg10
I25
sg11
VIL28B rs12979860 genotype
p15062
sg13
I3
sasg20
(lp15063
(dp15064
g7
I171
sg23
VC0019196
p15065
sg10
I11
sg11
Vhepatitis C
p15066
sg13
I2
sa(dp15067
g7
I163
sg23
VC0524910
p15068
sg10
I19
sg11
Vchronic hepatitis C
p15069
sg13
I3
sasa(dp15070
g2
S'AAH patients had higher serum resistin and plasmin activation inhibitor-1 levels, while serum leptin was decreased.\n'
p15071
sg4
(lp15072
(dp15073
g7
I43
sg8
VP00747
p15074
sg10
I7
sg11
Vplasmin
p15075
sg13
I1
sa(dp15076
g7
I62
sg8
g18
sg10
I11
sg11
Vinhibitor-1
p15077
sg13
I1
sa(dp15078
g7
I88
sg8
VP41159
p15079
sg10
I12
sg11
Vserum leptin
p15080
sg13
I2
sasg20
(lp15081
sa(dp15082
g2
S'La obesidad es uno de los mayores problemas de salud y un factor determinante del padecimiento de enfermedades prevalentes como sindrome metabolico, asma, apnea del sueno, infertilidad y diferentes tipos de cancer.\n'
p15083
sg4
(lp15084
sg20
(lp15085
(dp15086
g7
I207
sg23
VC0006826
p15087
sg10
I6
sg11
Vcancer
p15088
sg13
I1
sa(dp15089
g7
I155
sg23
VC0003578
p15090
sg10
I5
sg11
Vapnea
p15091
sg13
I1
sasa(dp15092
g2
S'Several experimental evidences pinpoint the possible role of Activin A (ActA) as a driver of cancer cachexia.\n'
p15093
sg4
(lp15094
(dp15095
g7
I61
sg8
VP08476
p15096
sg10
I9
sg11
VActivin A
p15097
sg13
I2
sa(dp15098
g7
I72
sg8
VP68133
p15099
sg10
I4
sg11
VActA
p15100
sg13
I1
sasg20
(lp15101
(dp15102
g7
I93
sg23
VC1391732
p15103
sg10
I15
sg11
Vcancer cachexia
p15104
sg13
I2
sasa(dp15105
g2
S'Supporting this hypothesis, we showed recently that human cancer cachexia is associated with high ActA levels.\n'
p15106
sg4
(lp15107
(dp15108
g7
I98
sg8
VP68133
p15109
sg10
I4
sg11
VActA
p15110
sg13
I1
sasg20
(lp15111
(dp15112
g7
I58
sg23
VC1391732
p15113
sg10
I15
sg11
Vcancer cachexia
p15114
sg13
I2
sasa(dp15115
g2
S'Moreover, ActA levels were correlated with body weight loss and skeletal muscle density, two prognostic factors in cancer patients.\n'
p15116
sg4
(lp15117
(dp15118
g7
I10
sg8
VP68133
p15119
sg10
I4
sg11
VActA
p15120
sg13
I1
sasg20
(lp15121
(dp15122
g7
I115
sg23
VC0006826
p15123
sg10
I6
sg11
Vcancer
p15124
sg13
I1
sasa(dp15125
g2
S'Our goal was therefore to investigate the value of ActA to predict survival in cancer patients.\n'
p15126
sg4
(lp15127
(dp15128
g7
I51
sg8
VP68133
p15129
sg10
I4
sg11
VActA
p15130
sg13
I1
sasg20
(lp15131
(dp15132
g7
I79
sg23
VC0006826
p15133
sg10
I6
sg11
Vcancer
p15134
sg13
I1
sasa(dp15135
g2
S'Patients with high ActA (&gt;=408 pg/mL) had lower OS than those with low levels, regardless the type of cancer (OS in colorectal cancer, 50% vs. 79%, P &lt; 0.05; and in lung cancer, 27% vs. 67%, P = 0.001).\n'
p15136
sg4
(lp15137
(dp15138
g7
I19
sg8
VP68133
p15139
sg10
I4
sg11
VActA
p15140
sg13
I1
sasg20
(lp15141
(dp15142
g7
I171
sg23
VC0684249
p15143
sg10
I11
sg11
Vlung cancer
p15144
sg13
I2
sa(dp15145
g7
I105
sg23
VC0006826
p15146
sg10
I6
sg11
Vcancer
p15147
sg13
I1
sa(dp15148
g7
I119
sg23
VC1527249
p15149
sg10
I17
sg11
Vcolorectal cancer
p15150
sg13
I2
sasa(dp15151
g2
S'The multivariable analysis confirmed the prognostic value of ActA independently of tumour stage or inflammatory markers, particularly in lung cancer.\n'
p15152
sg4
(lp15153
(dp15154
g7
I61
sg8
VP68133
p15155
sg10
I4
sg11
VActA
p15156
sg13
I1
sasg20
(lp15157
(dp15158
g7
I83
sg23
VC0027651
p15159
sg10
I6
sg11
Vtumour
p15160
sg13
I1
sa(dp15161
g7
I137
sg23
VC0684249
p15162
sg10
I11
sg11
Vlung cancer
p15163
sg13
I2
sasa(dp15164
g2
S'Our study demonstrates that high ActA level is an independent prognosis factor of survival in cancer patients.\n'
p15165
sg4
(lp15166
(dp15167
g7
I33
sg8
VP68133
p15168
sg10
I4
sg11
VActA
p15169
sg13
I1
sasg20
(lp15170
(dp15171
g7
I94
sg23
VC0006826
p15172
sg10
I6
sg11
Vcancer
p15173
sg13
I1
sasa(dp15174
g2
S'Antecedentes: La hipovitaminosis D ha sido asociada con diversas enfermedades cronicas como infecciones, enfermedades autoinmunes, enfermedad pulmonar obstructiva cronica, cancer y asma.\n'
p15175
sg4
(lp15176
sg20
(lp15177
(dp15178
g7
I172
sg23
VC0006826
p15179
sg10
I6
sg11
Vcancer
p15180
sg13
I1
sasa(dp15181
g2
S'The present study aimed to determine the levels and prognostic significance of Alfa-smooth muscle actin-positive (ASMA+) CAFs, plus HMGB1 and receptor for advanced glycation end products (RAGE) in cancer cells.\n'
p15182
sg4
(lp15183
(dp15184
g7
I132
sg8
VP09429
p15185
sg10
I18
sg11
VHMGB1 and receptor
p15186
sg13
I3
sa(dp15187
g7
I98
sg8
VP68133
p15188
sg10
I27
sg11
Vactin-positive (ASMA+) CAFs
p15189
sg13
I3
sasg20
(lp15190
(dp15191
g7
I121
sg23
VC0795907
p15192
sg10
I4
sg11
VCAFs
p15193
sg13
I1
sa(dp15194
g7
I197
sg23
VC0006826
p15195
sg10
I6
sg11
Vcancer
p15196
sg13
I1
sasa(dp15197
g2
S'The levels of ASMA (hazard ratio, 14.162; P = .010) and tumor cytoplasmic HMGB1 (hazard ratio, 0.221; P = .005) could serve as independent prognostic markers for metastatic relapse in breast cancer patients.\n'
p15198
sg4
(lp15199
(dp15200
g7
I56
sg8
g18
sg10
I23
sg11
Vtumor cytoplasmic HMGB1
p15201
sg13
I3
sasg20
(lp15202
(dp15203
g7
I184
sg23
VC0678222
p15204
sg10
I13
sg11
Vbreast cancer
p15205
sg13
I2
sa(dp15206
g7
I56
sg23
VC0027651
p15207
sg10
I5
sg11
Vtumor
p15208
sg13
I1
sa(dp15209
g7
I173
sg23
VC0277556
p15210
sg10
I7
sg11
Vrelapse
p15211
sg13
I1
sasa(dp15212
g2
S'We present for the first time, to the best of our knowledge, the potential clinical implications of the combined assessment of ASMA+ fibroblasts and cytoplasmic HMGB1 in breast cancer.\n'
p15213
sg4
(lp15214
(dp15215
g7
I149
sg8
g18
sg10
I17
sg11
Vcytoplasmic HMGB1
p15216
sg13
I2
sasg20
(lp15217
(dp15218
g7
I170
sg23
VC0678222
p15219
sg10
I13
sg11
Vbreast cancer
p15220
sg13
I2
sasa(dp15221
g2
S'Immunohistochemical staining showed that the tumor was positive for c-kit and CD34, and negative for a-SMA and S-100, so the tumor was diagnosed as GIST.\n'
p15222
sg4
(lp15223
(dp15224
g7
I111
sg8
VP04271
p15225
sg10
I5
sg11
VS-100
p15226
sg13
I1
sa(dp15227
g7
I103
sg8
g18
sg10
I3
sg11
VSMA
p15228
sg13
I1
sa(dp15229
g7
I78
sg8
VP28906
p15230
sg10
I4
sg11
VCD34
p15231
sg13
I1
sa(dp15232
g7
I68
sg8
VP10721
p15233
sg10
I5
sg11
Vc-kit
p15234
sg13
I1
sasg20
(lp15235
(dp15236
g7
I148
sg23
VC1847319
p15237
sg10
I4
sg11
VGIST
p15238
sg13
I1
sa(dp15239
g7
I45
sg23
VC0027651
p15240
sg10
I5
sg11
Vtumor
p15241
sg13
I1
sa(dp15242
g7
I103
sg23
VC0026847
p15243
sg10
I3
sg11
VSMA
p15244
sg13
I1
sa(dp15245
g7
I45
sg23
VC0027651
p15246
sg10
I5
sg11
Vtumor
p15247
sg13
I1
sasa(dp15248
g2
S"However, the role of PTTG1 in bladder cancer (BC) hasn't yet been characterized well.\n"
p15249
sg4
(lp15250
(dp15251
g7
I21
sg8
g18
sg10
I5
sg11
VPTTG1
p15252
sg13
I1
sasg20
(lp15253
(dp15254
g7
I30
sg23
VC0699885
p15255
sg10
I14
sg11
Vbladder cancer
p15256
sg13
I2
sa(dp15257
g7
I46
sg23
VC0699885
p15258
sg10
I2
sg11
VBC
p15259
sg13
I1
sasa(dp15260
g2
S'Chia seeds normalized insulin stimulated GLUT-4 transporter, the abundance of IRS-1 and pAMPK, changed the profile of fatty acid phospholipids, reduced left-ventricle collagen deposition and normalized hypertension and dyslipidemia.\n'
p15261
sg4
(lp15262
(dp15263
g7
I22
sg8
VP01308
p15264
sg10
I7
sg11
Vinsulin
p15265
sg13
I1
sa(dp15266
g7
I41
sg8
VP14672
p15267
sg10
I18
sg11
VGLUT-4 transporter
p15268
sg13
I2
sa(dp15269
g7
I78
sg8
VP35568
p15270
sg10
I5
sg11
VIRS-1
p15271
sg13
I1
sasg20
(lp15272
(dp15273
g7
I219
sg23
VC0242339
p15274
sg10
I12
sg11
Vdyslipidemia
p15275
sg13
I1
sa(dp15276
g7
I202
sg23
VC0020538
p15277
sg10
I12
sg11
Vhypertension
p15278
sg13
I1
sasa(dp15279
g2
S'Autoantibodies to Ro/SSA occur in nearly half of the patients with systemic lupus erythematosus and are associated with lymphopenia, photosensitive dermatitis, and pulmonary and renal disease, which suggests that they have an immunopathologic role.\n'
p15280
sg4
(lp15281
(dp15282
g7
I21
sg8
VP19474
p15283
sg10
I3
sg11
VSSA
p15284
sg13
I1
sasg20
(lp15285
(dp15286
g7
I133
sg23
VC0162830
p15287
sg10
I25
sg11
Vphotosensitive dermatitis
p15288
sg13
I2
sa(dp15289
g7
I120
sg23
VC0024312
p15290
sg10
I11
sg11
Vlymphopenia
p15291
sg13
I1
sa(dp15292
g7
I67
sg23
VC0024141
p15293
sg10
I28
sg11
Vsystemic lupus erythematosus
p15294
sg13
I3
sa(dp15295
g7
I178
sg23
VC0022658
p15296
sg10
I13
sg11
Vrenal disease
p15297
sg13
I2
sasa(dp15298
g2
S'These ANA-negative, Ro(SSA)-positive lupus patients generally demonstrate a prominent widespread photosensitive dermatitis and are frequently initially seen and evaluated by a dermatologist.\n'
p15299
sg4
(lp15300
(dp15301
g7
I6
sg8
g18
sg10
I3
sg11
VANA
p15302
sg13
I1
sasg20
(lp15303
(dp15304
g7
I97
sg23
VC0162830
p15305
sg10
I25
sg11
Vphotosensitive dermatitis
p15306
sg13
I2
sa(dp15307
g7
I37
sg23
VC0024131
p15308
sg10
I5
sg11
Vlupus
p15309
sg13
I1
sasa(dp15310
g2
S'Pyrazolo-pyrido-diazepine dione derivatives targeting Nox4 and Nox1 isoforms appear highly promising therapeutics for the treatment of idiopathic pulmonary fibrosis.\n'
p15311
sg4
(lp15312
(dp15313
g7
I54
sg8
g18
sg10
I4
sg11
VNox4
p15314
sg13
I1
sa(dp15315
g7
I63
sg8
g18
sg10
I13
sg11
VNox1 isoforms
p15316
sg13
I2
sasg20
(lp15317
(dp15318
g7
I135
sg23
VC3161101
p15319
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p15320
sg13
I3
sasa(dp15321
g2
S'By clamping the exposed femoral artery, we induced RIC by six 4-min cycles of ischemia and reperfusion.\n'
p15322
sg4
(lp15323
sg20
(lp15324
(dp15325
g7
I78
sg23
VC0022116
p15326
sg10
I8
sg11
Vischemia
p15327
sg13
I1
sasa(dp15328
g2
S'Six 4-min cycles of ischemia-reperfusion were performed.\n'
p15329
sg4
(lp15330
sg20
(lp15331
(dp15332
g7
I20
sg23
VC0022116
p15333
sg10
I8
sg11
Vischemia
p15334
sg13
I1
sasa(dp15335
g2
S'Furthermore, ischemic PC induced by either a single episode (one 5 min occlusion) or multiple episodes (six 4 min occlusions) of ischemia produced equivalent reductions in infarct size in A3AR(-/-)and A3AR(+/+)mice.\n'
p15336
sg4
(lp15337
(dp15338
g7
I188
sg8
VP33765
p15339
sg10
I4
sg11
VA3AR
p15340
sg13
I1
sa(dp15341
g7
I188
sg8
VP33765
p15342
sg10
I4
sg11
VA3AR
p15343
sg13
I1
sasg20
(lp15344
(dp15345
g7
I172
sg23
VC0021308
p15346
sg10
I7
sg11
Vinfarct
p15347
sg13
I1
sa(dp15348
g7
I129
sg23
VC0022116
p15349
sg10
I8
sg11
Vischemia
p15350
sg13
I1
sa(dp15351
g7
I71
sg23
VC0028778
p15352
sg10
I9
sg11
Vocclusion
p15353
sg13
I1
sa(dp15354
g7
I114
sg23
VC0028778
p15355
sg10
I10
sg11
Vocclusions
p15356
sg13
I1
sasa(dp15357
g2
S'We examined the promoter methylation status and LOH of the chromosome 3p genes, von Hippel-Lindau disease (VHL), retinoic acid receptor beta (RAR-beta), RAS association domain family 1A (RASSF1A), and fragile histidine triad (FHIT), in 37 samples of cervical squamous cell carcinoma and corresponding noncancerous tissues.\n'
p15358
sg4
(lp15359
(dp15360
g7
I187
sg8
g18
sg10
I7
sg11
VRASSF1A
p15361
sg13
I1
sa(dp15362
g7
I80
sg8
VP40337
p15363
sg10
I25
sg11
Vvon Hippel-Lindau disease
p15364
sg13
I3
sa(dp15365
g7
I107
sg8
VP40337
p15366
sg10
I3
sg11
VVHL
p15367
sg13
I1
sa(dp15368
g7
I142
sg8
VP10826
p15369
sg10
I8
sg11
VRAR-beta
p15370
sg13
I1
sa(dp15371
g7
I113
sg8
VP10826
p15372
sg10
I27
sg11
Vretinoic acid receptor beta
p15373
sg13
I4
sa(dp15374
g7
I153
sg8
g18
sg10
I32
sg11
VRAS association domain family 1A
p15375
sg13
I5
sasg20
(lp15376
(dp15377
g7
I250
sg23
VC0279671
p15378
sg10
I32
sg11
Vcervical squamous cell carcinoma
p15379
sg13
I4
sa(dp15380
g7
I80
sg23
VC0019562
p15381
sg10
I25
sg11
Vvon Hippel-Lindau disease
p15382
sg13
I3
sa(dp15383
g7
I107
sg23
VC0019562
p15384
sg10
I3
sg11
VVHL
p15385
sg13
I1
sasa(dp15386
g2
S'In comparison with the normal mucosa of the non-cancer patients, the following 14 genes displayed no tumor associated changes: breast cancer 1, early onset (BRCA1), cadherin 1, type 1, E-cadherin (epithelial) (CDH1), death-associated protein kinase 1 (DAPK1), DNA (cytosine-5-)-methyltransferase 1 (DNMT1), melanoma antigen, family A, 1 (directs expression of antigen MZ2-E) (MAGEA1), tumor suppressor candidate 3 (N33), cyclin-dependent kinase inhibitor 1A (p21, Cip1) (p21(WAF1)), cyclin-dependent kinase inhibitor 1B (p27, Kip1) (p27(KIP1)), phosphatase and tensin homolog (mutated in multiple advanced cancers 1) (PTEN), retinoic acid receptor, beta (RAR- , Ras association (RalGDS/AF-6) domain family 1 C (RASSF1C), secreted frizzled-related protein 1 (SFRP1), tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory) (TIMP3), and von Hippel-Lindau syndrome (VHL).\n'
p15387
sg4
(lp15388
(dp15389
g7
I421
sg8
VP38936
p15390
sg10
I36
sg11
Vcyclin-dependent kinase inhibitor 1A
p15391
sg13
I4
sa(dp15392
g7
I758
sg8
g18
sg10
I5
sg11
VSFRP1
p15393
sg13
I1
sa(dp15394
g7
I521
sg8
VP40305
p15395
sg10
I3
sg11
Vp27
p15396
sg13
I1
sa(dp15397
g7
I157
sg8
VP38398
p15398
sg10
I5
sg11
VBRCA1
p15399
sg13
I1
sa(dp15400
g7
I625
sg8
VP10826
p15401
sg10
I28
sg11
Vretinoic acid receptor, beta
p15402
sg13
I4
sa(dp15403
g7
I252
sg8
VP53355
p15404
sg10
I5
sg11
VDAPK1
p15405
sg13
I1
sa(dp15406
g7
I299
sg8
VP26358
p15407
sg10
I5
sg11
VDNMT1
p15408
sg13
I1
sa(dp15409
g7
I721
sg8
g18
sg10
I35
sg11
Vsecreted frizzled-related protein 1
p15410
sg13
I4
sa(dp15411
g7
I766
sg8
VP35625
p15412
sg10
I93
sg11
Vtissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory) (TIMP3)
p15413
sg13
I10
sa(dp15414
g7
I483
sg8
VP46527
p15415
sg10
I36
sg11
Vcyclin-dependent kinase inhibitor 1B
p15416
sg13
I4
sa(dp15417
g7
I307
sg8
g18
sg10
I16
sg11
Vmelanoma antigen
p15418
sg13
I2
sa(dp15419
g7
I385
sg8
g18
sg10
I34
sg11
Vtumor suppressor candidate 3 (N33)
p15420
sg13
I5
sa(dp15421
g7
I618
sg8
VP60484
p15422
sg10
I4
sg11
VPTEN
p15423
sg13
I1
sa(dp15424
g7
I475
sg8
VP38936
p15425
sg10
I4
sg11
VWAF1
p15426
sg13
I1
sa(dp15427
g7
I521
sg8
VP40305
p15428
sg10
I3
sg11
Vp27
p15429
sg13
I1
sa(dp15430
g7
I459
sg8
VP42857
p15431
sg10
I3
sg11
Vp21
p15432
sg13
I1
sa(dp15433
g7
I459
sg8
VP42857
p15434
sg10
I3
sg11
Vp21
p15435
sg13
I1
sa(dp15436
g7
I662
sg8
VP01116
p15437
sg10
I3
sg11
VRas
p15438
sg13
I1
sa(dp15439
g7
I679
sg8
g18
sg10
I6
sg11
VRalGDS
p15440
sg13
I1
sa(dp15441
g7
I260
sg8
VP26358
p15442
sg10
I37
sg11
VDNA (cytosine-5-)-methyltransferase 1
p15443
sg13
I3
sa(dp15444
g7
I464
sg8
VP38936
p15445
sg10
I4
sg11
VCip1
p15446
sg13
I1
sa(dp15447
g7
I537
sg8
VP46527
p15448
sg10
I4
sg11
VKIP1
p15449
sg13
I1
sa(dp15450
g7
I526
sg8
VP46527
p15451
sg10
I4
sg11
VKip1
p15452
sg13
I1
sa(dp15453
g7
I165
sg8
VP12830
p15454
sg10
I10
sg11
Vcadherin 1
p15455
sg13
I2
sa(dp15456
g7
I655
sg8
VP10276
p15457
sg10
I3
sg11
VRAR
p15458
sg13
I1
sa(dp15459
g7
I561
sg8
g18
sg10
I14
sg11
Vtensin homolog
p15460
sg13
I2
sa(dp15461
g7
I185
sg8
VP53355
p15462
sg10
I65
sg11
VE-cadherin (epithelial) (CDH1), death-associated protein kinase 1
p15463
sg13
I7
sasg20
(lp15464
(dp15465
g7
I807
sg23
VC0339515
p15466
sg10
I23
sg11
VSorsby fundus dystrophy
p15467
sg13
I3
sa(dp15468
g7
I606
sg23
VC0006826
p15469
sg10
I7
sg11
Vcancers
p15470
sg13
I1
sa(dp15471
g7
I101
sg23
VC0027651
p15472
sg10
I5
sg11
Vtumor
p15473
sg13
I1
sa(dp15474
g7
I48
sg23
VC0006826
p15475
sg10
I6
sg11
Vcancer
p15476
sg13
I1
sa(dp15477
g7
I127
sg23
VC0678222
p15478
sg10
I13
sg11
Vbreast cancer
p15479
sg13
I2
sa(dp15480
g7
I893
sg23
VC0019562
p15481
sg10
I3
sg11
VVHL
p15482
sg13
I1
sa(dp15483
g7
I307
sg23
VC0025202
p15484
sg10
I8
sg11
Vmelanoma
p15485
sg13
I1
sa(dp15486
g7
I865
sg23
VC0019562
p15487
sg10
I26
sg11
Vvon Hippel-Lindau syndrome
p15488
sg13
I3
sa(dp15489
g7
I101
sg23
VC0027651
p15490
sg10
I5
sg11
Vtumor
p15491
sg13
I1
sasa(dp15492
g2
S'We examined the promoter methylation status of von Hippel-Lindau disease (VHL), retinoic acid receptor beta (RAR-beta), RAS association domain family 1A (RASSF1A), and fragile histidine triad (FHIT) genes in 22 esophageal squamous cell carcinoma cell lines and 47 primary tumors and corresponding noncancerous tissues by a methylation-specific PCR.\n'
p15493
sg4
(lp15494
(dp15495
g7
I80
sg8
VP10826
p15496
sg10
I27
sg11
Vretinoic acid receptor beta
p15497
sg13
I4
sa(dp15498
g7
I120
sg8
g18
sg10
I32
sg11
VRAS association domain family 1A
p15499
sg13
I5
sa(dp15500
g7
I74
sg8
VP40337
p15501
sg10
I3
sg11
VVHL
p15502
sg13
I1
sa(dp15503
g7
I154
sg8
g18
sg10
I7
sg11
VRASSF1A
p15504
sg13
I1
sa(dp15505
g7
I47
sg8
VP40337
p15506
sg10
I25
sg11
Vvon Hippel-Lindau disease
p15507
sg13
I3
sa(dp15508
g7
I109
sg8
VP10826
p15509
sg10
I8
sg11
VRAR-beta
p15510
sg13
I1
sasg20
(lp15511
(dp15512
g7
I47
sg23
VC0019562
p15513
sg10
I25
sg11
Vvon Hippel-Lindau disease
p15514
sg13
I3
sa(dp15515
g7
I74
sg23
VC0019562
p15516
sg10
I3
sg11
VVHL
p15517
sg13
I1
sa(dp15518
g7
I211
sg23
VC0279626
p15519
sg10
I34
sg11
Vesophageal squamous cell carcinoma
p15520
sg13
I4
sa(dp15521
g7
I264
sg23
VC0677930
p15522
sg10
I14
sg11
Vprimary tumors
p15523
sg13
I2
sasa(dp15524
g2
S'In this study, we found that lncRNA HOXC cluster antisense RNA 1 (HOXC-AS1) and homeobox C6 (HOXC6) were downregulated in carotid atherosclerosis by performing microarray analysis.\n'
p15525
sg4
(lp15526
(dp15527
g7
I80
sg8
VP09630
p15528
sg10
I11
sg11
Vhomeobox C6
p15529
sg13
I2
sa(dp15530
g7
I66
sg8
g18
sg10
I8
sg11
VHOXC-AS1
p15531
sg13
I1
sa(dp15532
g7
I93
sg8
VP31260
p15533
sg10
I5
sg11
VHOXC6
p15534
sg13
I1
sa(dp15535
g7
I29
sg8
VP00966
p15536
sg10
I35
sg11
VlncRNA HOXC cluster antisense RNA 1
p15537
sg13
I6
sasg20
(lp15538
(dp15539
g7
I71
sg23
VC1846534
p15540
sg10
I3
sg11
VAS1
p15541
sg13
I1
sa(dp15542
g7
I122
sg23
VC0577631
p15543
sg10
I23
sg11
Vcarotid atherosclerosis
p15544
sg13
I2
sasa(dp15545
g2
S'Both, hyperthyroidism (HpT) and hypothyroidism (HypoT) reduced the peak of CIC but increased EC, in spite of improving PICR.\n'
p15546
sg4
(lp15547
sg20
(lp15548
(dp15549
g7
I6
sg23
VC0020550
p15550
sg10
I15
sg11
Vhyperthyroidism
p15551
sg13
I1
sa(dp15552
g7
I48
sg23
VC0020676
p15553
sg10
I5
sg11
VHypoT
p15554
sg13
I1
sa(dp15555
g7
I23
sg23
VC0020550
p15556
sg10
I3
sg11
VHpT
p15557
sg13
I1
sa(dp15558
g7
I32
sg23
VC0020676
p15559
sg10
I14
sg11
Vhypothyroidism
p15560
sg13
I1
sasa(dp15561
g2
S'One strategy focused on the probability of incidence only and was based on logistic regression (MRS1); the other strategy accounted for the age at diagnosis of diabetes and was based on Cox regression (MRS2).\n'
p15562
sg4
(lp15563
sg20
(lp15564
(dp15565
g7
I160
sg23
VC0011849
p15566
sg10
I8
sg11
Vdiabetes
p15567
sg13
I1
sasa(dp15568
g2
S'MRS2 had a similar performance and was significantly associated with a younger age of onset of type 2 diabetes (Beta = -3.44 years per MRS2 SD in the training population, p = 1.56 x 10(-7); Beta = -4.73 years per MRS2 SD in the validation population, p = 4.04 x 10(-3)).\n'
p15569
sg4
(lp15570
sg20
(lp15571
(dp15572
g7
I95
sg23
VC0011860
p15573
sg10
I15
sg11
Vtype 2 diabetes
p15574
sg13
I3
sasa(dp15575
g2
S'TACO is characterized by respiratory distress and acute pulmonary edema.\n'
p15576
sg4
(lp15577
sg20
(lp15578
(dp15579
g7
I0
sg23
VC2921022
p15580
sg10
I4
sg11
VTACO
p15581
sg13
I1
sa(dp15582
g7
I25
sg23
VC0476273
p15583
sg10
I20
sg11
Vrespiratory distress
p15584
sg13
I2
sa(dp15585
g7
I50
sg23
VC0155919
p15586
sg10
I21
sg11
Vacute pulmonary edema
p15587
sg13
I3
sasa(dp15588
g2
S'Consistent with this, Tctn3 mutant mice exhibit holoprosencephaly and randomized heart looping and lack the floor plate in the neural tube, the phenotypes similar to those of Tctn1 and Tctn2 mutants.\n'
p15589
sg4
(lp15590
(dp15591
g7
I22
sg8
g18
sg10
I12
sg11
VTctn3 mutant
p15592
sg13
I2
sa(dp15593
g7
I185
sg8
g18
sg10
I13
sg11
VTctn2 mutants
p15594
sg13
I2
sa(dp15595
g7
I175
sg8
g18
sg10
I5
sg11
VTctn1
p15596
sg13
I1
sasg20
(lp15597
(dp15598
g7
I28
sg23
VC0596988
p15599
sg10
I6
sg11
Vmutant
p15600
sg13
I1
sa(dp15601
g7
I48
sg23
VC0079541
p15602
sg10
I17
sg11
Vholoprosencephaly
p15603
sg13
I1
sasa(dp15604
g2
S'Similarly, replacement of Tctn3 with Tctn1 or Tctn2 in the Tctn3 gene locus results in reduced ciliogenesis and Hh signaling, holoprosencephaly, and randomized heart looping.\n'
p15605
sg4
(lp15606
(dp15607
g7
I46
sg8
g18
sg10
I5
sg11
VTctn2
p15608
sg13
I1
sa(dp15609
g7
I37
sg8
g18
sg10
I5
sg11
VTctn1
p15610
sg13
I1
sasg20
(lp15611
(dp15612
g7
I126
sg23
VC0079541
p15613
sg10
I17
sg11
Vholoprosencephaly
p15614
sg13
I1
sasa(dp15615
g2
S'Dejerine-Sottas disease (DSD), also called hereditary motor and sensory neuropathy type III (HMSNIII), is a severe, infantile-onset demyelinating polyneuropathy syndrome that may be associated with point mutations in either the PMP22 gene, PO gene, EGR2 gene or the PRX gene (for the recessive form).\n'
p15616
sg4
(lp15617
(dp15618
g7
I228
sg8
g18
sg10
I10
sg11
VPMP22 gene
p15619
sg13
I2
sa(dp15620
g7
I266
sg8
VP30041
p15621
sg10
I8
sg11
VPRX gene
p15622
sg13
I2
sa(dp15623
g7
I249
sg8
VP11161
p15624
sg10
I9
sg11
VEGR2 gene
p15625
sg13
I2
sasg20
(lp15626
(dp15627
g7
I93
sg23
VC0011195
p15628
sg10
I7
sg11
VHMSNIII
p15629
sg13
I1
sa(dp15630
g7
I43
sg23
VC0011195
p15631
sg10
I48
sg11
Vhereditary motor and sensory neuropathy type III
p15632
sg13
I7
sa(dp15633
g7
I0
sg23
VC0011195
p15634
sg10
I23
sg11
VDejerine-Sottas disease
p15635
sg13
I2
sa(dp15636
g7
I25
sg23
VC0011195
p15637
sg10
I3
sg11
VDSD
p15638
sg13
I1
sa(dp15639
g7
I132
sg23
VC0270922
p15640
sg10
I28
sg11
Vdemyelinating polyneuropathy
p15641
sg13
I2
sa(dp15642
g7
I161
sg23
VC0039082
p15643
sg10
I8
sg11
Vsyndrome
p15644
sg13
I1
sasa(dp15645
g2
S'Hereditary motor and sensory neuropathy type Ia (HMSN Ia) is known as a primarily demyelinating peripheral nerve disease.\n'
p15646
sg4
(lp15647
sg20
(lp15648
(dp15649
g7
I0
sg23
VC0270911
p15650
sg10
I47
sg11
VHereditary motor and sensory neuropathy type Ia
p15651
sg13
I7
sa(dp15652
g7
I49
sg23
VC0270911
p15653
sg10
I7
sg11
VHMSN Ia
p15654
sg13
I2
sa(dp15655
g7
I96
sg23
VC0031117
p15656
sg10
I24
sg11
Vperipheral nerve disease
p15657
sg13
I3
sasa(dp15658
g2
S'A 1.4-Mb tandem duplication, including the gene for peripheral myelin protein 22 (PMP22) in chromosome 17p11.2-12 is responsible for 70% of the cases of the demyelinating type 1 of Charcot-Marie-Tooth disease or hereditary motor and sensory neuropathy I (CMT1A/HMSN I).\n'
p15659
sg4
(lp15660
(dp15661
g7
I82
sg8
g18
sg10
I5
sg11
VPMP22
p15662
sg13
I1
sa(dp15663
g7
I52
sg8
g18
sg10
I28
sg11
Vperipheral myelin protein 22
p15664
sg13
I4
sasg20
(lp15665
(dp15666
g7
I261
sg23
VC0270912
p15667
sg10
I6
sg11
VHMSN I
p15668
sg13
I2
sa(dp15669
g7
I181
sg23
VC0007959
p15670
sg10
I27
sg11
VCharcot-Marie-Tooth disease
p15671
sg13
I2
sa(dp15672
g7
I212
sg23
VC0270912
p15673
sg10
I41
sg11
Vhereditary motor and sensory neuropathy I
p15674
sg13
I6
sa(dp15675
g7
I255
sg23
VC0270911
p15676
sg10
I5
sg11
VCMT1A
p15677
sg13
I1
sa(dp15678
g7
I16
sg23
VC1705960
p15679
sg10
I11
sg11
Vduplication
p15680
sg13
I1
sasa(dp15681
g2
S'Dejerine-Sottas disease (DSD), also called hereditary motor and sensory neuropathy type III (HMSNIII), is a severe, infantile-onset, demyelinating polyneuropathy syndrome that may be associated with point mutations in either the PMP22 gene or the P0 gene and shares considerable clinical and pathologic features with CMT1.\n'
p15682
sg4
(lp15683
(dp15684
g7
I229
sg8
g18
sg10
I10
sg11
VPMP22 gene
p15685
sg13
I2
sasg20
(lp15686
(dp15687
g7
I93
sg23
VC0011195
p15688
sg10
I7
sg11
VHMSNIII
p15689
sg13
I1
sa(dp15690
g7
I43
sg23
VC0011195
p15691
sg10
I48
sg11
Vhereditary motor and sensory neuropathy type III
p15692
sg13
I7
sa(dp15693
g7
I25
sg23
VC0011195
p15694
sg10
I3
sg11
VDSD
p15695
sg13
I1
sa(dp15696
g7
I0
sg23
VC0011195
p15697
sg10
I23
sg11
VDejerine-Sottas disease
p15698
sg13
I2
sa(dp15699
g7
I133
sg23
VC0270922
p15700
sg10
I28
sg11
Vdemyelinating polyneuropathy
p15701
sg13
I2
sa(dp15702
g7
I162
sg23
VC0039082
p15703
sg10
I8
sg11
Vsyndrome
p15704
sg13
I1
sasa(dp15705
g2
S'Mutations in genes encoding the myelin proteins peripheral myelin protein 22, myelin protein zero and connection 32 are associated with hereditary motor and sensory neuropathy type I and II and hereditary neuropathy with liability to pressure palsies.\n'
p15706
sg4
(lp15707
sg20
(lp15708
(dp15709
g7
I194
sg23
VC0393814
p15710
sg10
I56
sg11
Vhereditary neuropathy with liability to pressure palsies
p15711
sg13
I7
sa(dp15712
g7
I136
sg23
VC0751036
p15713
sg10
I46
sg11
Vhereditary motor and sensory neuropathy type I
p15714
sg13
I7
sasa(dp15715
g2
S'Three genes responsible for hereditary motor and sensory neuropathy type I (HMSNI) or CMT1 have been identified: peripheral myelin protein 22 (PMP22) and myelin protein zero (MPZ) for the autosomal dominant form and connexin 32 (Cx32) for the X-linked dominant variant.\n'
p15716
sg4
(lp15717
(dp15718
g7
I229
sg8
VP08034
p15719
sg10
I4
sg11
VCx32
p15720
sg13
I1
sa(dp15721
g7
I216
sg8
VP08034
p15722
sg10
I11
sg11
Vconnexin 32
p15723
sg13
I2
sa(dp15724
g7
I143
sg8
g18
sg10
I5
sg11
VPMP22
p15725
sg13
I1
sa(dp15726
g7
I113
sg8
g18
sg10
I28
sg11
Vperipheral myelin protein 22
p15727
sg13
I4
sa(dp15728
g7
I86
sg8
VP08034
p15729
sg10
I4
sg11
VCMT1
p15730
sg13
I1
sasg20
(lp15731
(dp15732
g7
I76
sg23
VC0751036
p15733
sg10
I5
sg11
VHMSNI
p15734
sg13
I1
sa(dp15735
g7
I28
sg23
VC0751036
p15736
sg10
I46
sg11
Vhereditary motor and sensory neuropathy type I
p15737
sg13
I7
sasa(dp15738
g2
S'Posthemorrhoidectomy patients usually opt for a spice-free diet due to fear of pain or anal pruritus induced by spices.\n'
p15739
sg4
(lp15740
sg20
(lp15741
(dp15742
g7
I87
sg23
VC0033775
p15743
sg10
I13
sg11
Vanal pruritus
p15744
sg13
I2
sa(dp15745
g7
I71
sg23
VC0233702
p15746
sg10
I12
sg11
Vfear of pain
p15747
sg13
I3
sasa(dp15748
g2
S'Thus, spice-related paradoxic conservatism in stapled hemorrhoidopexy, which involves no open wound, needed to be studied.\n'
p15749
sg4
(lp15750
sg20
(lp15751
sa(dp15752
g2
S'A prospective open-ended study (July 2008 to August 2009) investigated consecutive candidates for day-care stapled hemorrhoidopexy randomized by the date of birth method into a controlled group (receiving a spices-free diet) and a study group (receiving a spicy diet) after an ethics and informed consent protocol.\n'
p15753
sg4
(lp15754
sg20
(lp15755
sa(dp15756
g2
S'For young patients, especially those with a past hemorrhoidal history, spice or alcohol intake and constipation are risk factors for hemorrhoidal crisis.\n'
p15757
sg4
(lp15758
sg20
(lp15759
(dp15760
g7
I99
sg23
VC0009806
p15761
sg10
I12
sg11
Vconstipation
p15762
sg13
I1
sa(dp15763
g7
I133
sg23
VC2363897
p15764
sg10
I19
sg11
Vhemorrhoidal crisis
p15765
sg13
I2
sasa(dp15766
g2
S'This study explores the effect of COL1A2, COL6A3, and THBS2 gene silencing on proliferation, migration, invasion, and apoptosis of gastric cancer cells through the PI3K-Akt signaling pathway.\n'
p15767
sg4
(lp15768
(dp15769
g7
I164
sg8
VP42336
p15770
sg10
I4
sg11
VPI3K
p15771
sg13
I1
sa(dp15772
g7
I169
sg8
g18
sg10
I3
sg11
VAkt
p15773
sg13
I1
sa(dp15774
g7
I54
sg8
VP35442
p15775
sg10
I10
sg11
VTHBS2 gene
p15776
sg13
I2
sa(dp15777
g7
I42
sg8
VP12111
p15778
sg10
I6
sg11
VCOL6A3
p15779
sg13
I1
sasg20
(lp15780
(dp15781
g7
I131
sg23
VC0024623
p15782
sg10
I14
sg11
Vgastric cancer
p15783
sg13
I2
sa(dp15784
g7
I104
sg23
VC2699153
p15785
sg10
I8
sg11
Vinvasion
p15786
sg13
I1
sa(dp15787
g7
I78
sg23
VC0334094
p15788
sg10
I13
sg11
Vproliferation
p15789
sg13
I1
sasa(dp15790
g2
S'Expressions of COL1A2, COL6A3, and THBS2 in gastric cancer cells transfected with corresponding silencing sequences were evaluated by RT-qPCR and Western blot.\n'
p15791
sg4
(lp15792
(dp15793
g7
I23
sg8
VP12111
p15794
sg10
I6
sg11
VCOL6A3
p15795
sg13
I1
sa(dp15796
g7
I35
sg8
VP35442
p15797
sg10
I5
sg11
VTHBS2
p15798
sg13
I1
sasg20
(lp15799
(dp15800
g7
I44
sg23
VC0024623
p15801
sg10
I14
sg11
Vgastric cancer
p15802
sg13
I2
sasa(dp15803
g2
S'The positive expression of PI3K, Akt, and p-Akt was higher in gastric cancer tissues compared with adjacent normal tissues, and the mRNA expression of COL1A2, COL6A3, and THBS2 was increased in gastric cancer tissues.\n'
p15804
sg4
(lp15805
(dp15806
g7
I159
sg8
VP12111
p15807
sg10
I6
sg11
VCOL6A3
p15808
sg13
I1
sa(dp15809
g7
I42
sg8
g18
sg10
I5
sg11
Vp-Akt
p15810
sg13
I1
sa(dp15811
g7
I33
sg8
g18
sg10
I3
sg11
VAkt
p15812
sg13
I1
sa(dp15813
g7
I171
sg8
VP35442
p15814
sg10
I5
sg11
VTHBS2
p15815
sg13
I1
sa(dp15816
g7
I27
sg8
VP42336
p15817
sg10
I4
sg11
VPI3K
p15818
sg13
I1
sasg20
(lp15819
(dp15820
g7
I62
sg23
VC0024623
p15821
sg10
I14
sg11
Vgastric cancer
p15822
sg13
I2
sa(dp15823
g7
I62
sg23
VC0024623
p15824
sg10
I14
sg11
Vgastric cancer
p15825
sg13
I2
sasa(dp15826
g2
S'This study demonstrates that COL1A2, COL6A3, and THBS2 gene silencing inhibits gastric cancer cell proliferation, migration, and invasion while promoting apoptosis through the PI3K-Akt signaling pathway.\n'
p15827
sg4
(lp15828
(dp15829
g7
I49
sg8
VP35442
p15830
sg10
I10
sg11
VTHBS2 gene
p15831
sg13
I2
sa(dp15832
g7
I176
sg8
VP42336
p15833
sg10
I4
sg11
VPI3K
p15834
sg13
I1
sa(dp15835
g7
I181
sg8
g18
sg10
I3
sg11
VAkt
p15836
sg13
I1
sa(dp15837
g7
I37
sg8
VP12111
p15838
sg10
I6
sg11
VCOL6A3
p15839
sg13
I1
sasg20
(lp15840
(dp15841
g7
I99
sg23
VC0334094
p15842
sg10
I13
sg11
Vproliferation
p15843
sg13
I1
sa(dp15844
g7
I79
sg23
VC0024623
p15845
sg10
I14
sg11
Vgastric cancer
p15846
sg13
I2
sa(dp15847
g7
I129
sg23
VC2699153
p15848
sg10
I8
sg11
Vinvasion
p15849
sg13
I1
sasa(dp15850
g2
S'Methyl-sensitive cut counting analysis (MSCC) showed fold decreases in GBM CpG methylation sites for genes PBK, KIF23, COL6A3, and LOX.\n'
p15851
sg4
(lp15852
(dp15853
g7
I107
sg8
g18
sg10
I3
sg11
VPBK
p15854
sg13
I1
sa(dp15855
g7
I112
sg8
g18
sg10
I5
sg11
VKIF23
p15856
sg13
I1
sa(dp15857
g7
I119
sg8
VP12111
p15858
sg10
I6
sg11
VCOL6A3
p15859
sg13
I1
sasg20
(lp15860
(dp15861
g7
I71
sg23
VC0017636
p15862
sg10
I3
sg11
VGBM
p15863
sg13
I1
sasa(dp15864
g2
S'hZTL1 mediates Zn uptake when expressed in Xenopus laevis oocytes and hZIP4 is mutated in most cases of the inherited Zn deficiency disease acrodermatitis enteropathica.\n'
p15865
sg4
(lp15866
(dp15867
g7
I0
sg8
g18
sg10
I5
sg11
VhZTL1
p15868
sg13
I1
sasg20
(lp15869
(dp15870
g7
I121
sg23
VC0011156
p15871
sg10
I18
sg11
Vdeficiency disease
p15872
sg13
I2
sa(dp15873
g7
I140
sg23
VC0221036
p15874
sg10
I28
sg11
Vacrodermatitis enteropathica
p15875
sg13
I2
sasa(dp15876
g2
S'In the univariable Cox analysis, age, hypertension, albumin, phosphorus levels, and combined elevation of NT-proBNP with Gal-3 above the median (hazard ratio [HR] = 3.65, 95% confidence interval [CI] = 1.45-9.21) were associated with outcomes.\n'
p15877
sg4
(lp15878
(dp15879
g7
I121
sg8
VP16278
p15880
sg10
I5
sg11
VGal-3
p15881
sg13
I1
sa(dp15882
g7
I52
sg8
VP00441
p15883
sg10
I7
sg11
Valbumin
p15884
sg13
I1
sasg20
(lp15885
(dp15886
g7
I38
sg23
VC0020538
p15887
sg10
I12
sg11
Vhypertension
p15888
sg13
I1
sasa(dp15889
g2
S'In the CRS, galectin-3 was significantly higher with older age, black race, female sex, body mass index, hypertension, diabetes mellitus and kidney disease, and also in those who developed incident stroke.\n'
p15890
sg4
(lp15891
(dp15892
g7
I7
sg8
VP22676
p15893
sg10
I3
sg11
VCRS
p15894
sg13
I1
sa(dp15895
g7
I12
sg8
VP17931
p15896
sg10
I10
sg11
Vgalectin-3
p15897
sg13
I1
sasg20
(lp15898
(dp15899
g7
I105
sg23
VC0020538
p15900
sg10
I12
sg11
Vhypertension
p15901
sg13
I1
sa(dp15902
g7
I141
sg23
VC0022658
p15903
sg10
I14
sg11
Vkidney disease
p15904
sg13
I2
sa(dp15905
g7
I7
sg23
VC0010278
p15906
sg10
I3
sg11
VCRS
p15907
sg13
I1
sa(dp15908
g7
I198
sg23
VC0038454
p15909
sg10
I6
sg11
Vstroke
p15910
sg13
I1
sa(dp15911
g7
I119
sg23
VC0011849
p15912
sg10
I17
sg11
Vdiabetes mellitus
p15913
sg13
I2
sasa(dp15914
g2
S'Thus, in this community-based population, higher plasma galectin-3 levels were associated with an elevated risk of developing incident CKD, particularly among those with hypertension.\n'
p15915
sg4
(lp15916
(dp15917
g7
I49
sg8
VP17931
p15918
sg10
I17
sg11
Vplasma galectin-3
p15919
sg13
I2
sasg20
(lp15920
(dp15921
g7
I170
sg23
VC0020538
p15922
sg10
I12
sg11
Vhypertension
p15923
sg13
I1
sasa(dp15924
g2
S'These data suggest that Gal-3 could be a potential therapeutic candidate for the prevention of early renal alterations in hypertension.\n'
p15925
sg4
(lp15926
(dp15927
g7
I24
sg8
VP16278
p15928
sg10
I5
sg11
VGal-3
p15929
sg13
I1
sasg20
(lp15930
(dp15931
g7
I122
sg23
VC0020538
p15932
sg10
I12
sg11
Vhypertension
p15933
sg13
I1
sasa.